PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Klag, MJ; Whelton, PK; Randall, BL; Neaton, JD; Brancati, FL; Ford, CE; Shulman, NB; Stamler, J				Klag, MJ; Whelton, PK; Randall, BL; Neaton, JD; Brancati, FL; Ford, CE; Shulman, NB; Stamler, J			Blood pressure and end-stage renal disease in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; DIABETES-MELLITUS; RISK-FACTORS; PROGRESSION; INSUFFICIENCY; HYPERTENSION; FAILURE; DEATH; RACE	Background, End-stage renal disease in the United States creates a large burden for both individuals and society as a whole, Efforts to prevent the condition require an understanding of modifiable risk factors. Methods. We assessed the development of end-stage renal disease through 1990 in 332,544 men, 35 to 57 years of age, who were screened between 1973 and 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). We used data from the national registry for treated end-stage renal disease of the Health Care Financing Administration and from records on death from renal disease from the National Death Index and the Social Security Administration. Results. During an average of 16 years of follow-up, 814 subjects either died of end-stage renal disease or were treated for that condition (15.6 cases per 100,000 person-years of observation), A strong, graded relation between both systolic and diastolic blood pressure and end-stage renal disease was identified, independent of associations between the disease and age, race, income, use of medication for diabetes mellitus, history of my-ocardial infarction, serum cholesterol concentration, and cigarette smoking. As compared with men with an optimal level of blood pressure (systolic pressure <120 mm Hg and diastolic pressure <80 mm Hg), the relative risk of end-stage renal disease for those with stage 4 hypertension (systolic pressure greater than or equal to 210 mm Hg or diastolic pressure greater than or equal to 120 mm Hg) was 22.1 (P<0.001). These relations were not due to end-stage renal disease that occurred soon after screening and, in the 12,866 screened men who entered the MRFIT study, were not changed by taking into account the base-line serum creatinine concentration and urinary protein excretion, The estimated risk of end-stage renal disease associated with elevations of systolic pressure was greater than that linked with elevations of diastolic pressure when both variables were considered together, Conclusions. Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control of both high-normal and high blood pressure. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA; UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA; EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health Science Center Houston; Emory University; Northwestern University					NHLBI NIH HHS [R01 HL28715] Funding Source: Medline; NIDDK NIH HHS [R01 DK41837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; COX DR, 1972, J R STAT SOC B, V34, P187; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINCAIDSMITH P, 1958, Q J MED, V27, P117; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAMDANI BH, 1974, NEW ENGL J MED, V291, P1343, DOI 10.1056/NEJM197412192912509; MROCZEK WJ, 1969, CIRCULATION, V40, P893, DOI 10.1161/01.CIR.40.6.893; NEATON JD, 1987, CONTROL CLIN TRIALS, V8, pS41; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; PARVING HH, 1983, LANCET, V1, P1175; PERERA G A, 1955, J Chronic Dis, V1, P33, DOI 10.1016/0021-9681(55)90019-9; PERNEGER TV, 1995, AM J EPIDEMIOL, V141, P10, DOI 10.1093/oxfordjournals.aje.a117338; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; PERNEGER TV, 1994, ANN INTERN MED, V121, P912, DOI 10.7326/0003-4819-121-12-199412150-00002; PERRY HM, 1995, HYPERTENSION, V25, P587, DOI 10.1161/01.HYP.25.4.587; PETTINGER WA, 1989, HYPERTENSION, V13, P766, DOI 10.1161/01.HYP.13.6.766; RAVID M, 1992, ARCH INTERN MED, V152, P1225, DOI 10.1001/archinte.152.6.1225; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Statistical design considerations in the multiple risk factor intervention trial (MRFIT), 1977, J CHRON DIS, V30, P261; TIERNEY WM, 1989, AM J KIDNEY DIS, V13, P485, DOI 10.1016/S0272-6386(89)80006-X; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309; 1994, NIH943176 PUBL; 1994, REPORT TASK FORCE RE; 1993, ARCH INTERN MED, V153, P598; 1987, HCFA03274 HLTH CAR F; 1974, DHEW NIH75628 NAT HE; 1980, DHHS PHS801260 DEP H	41	1230	1277	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					13	18		10.1056/NEJM199601043340103	http://dx.doi.org/10.1056/NEJM199601043340103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494564	Bronze			2022-12-01	WOS:A1996TM48200003
J	Vakil, NB; Schwartz, SM; Buggy, BP; Brummitt, CF; Kherellah, M; Letzer, DM; Gilson, IH; Jones, PG				Vakil, NB; Schwartz, SM; Buggy, BP; Brummitt, CF; Kherellah, M; Letzer, DM; Gilson, IH; Jones, PG			Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SCLEROSING CHOLANGITIS; CHOLANGIOPATHY; VIRUS; SPECTRUM; DISEASE	Background. In March 1993, the municipal water supply in Milwaukee became contaminated with cruptosporidium and a widespread outbreak of cryptosporidiosis occurred. Methods. We retrospectively studied the relations among the clinical presentation, CD4 count, and survival in a group of 82 patients infected with the human immunodeficiency virus (HIV) in whom cryptosporidiosis developed during the outbreak. Infection was documented by the finding of cryptosporidium in stool. Results. There was a sharp increase in the number of HIV-infected patients with cryptosporidiosis after the period of water contamination. Four of 24 patients with biliary symptoms (17 percent) and 30 of 58 without biliary symptoms (52 percent) were alive one year after the outbreak (P = 0.003). Twenty-one of the patients with biliary symptoms had CD4 counts less than or equal to 50 per cubic millimeter, as compared with 36 of 57 patients without biliary symptoms (88 percent vs. 63 percent, P = 0.03). The CD4 count was not available for one patient in the latter group, Within one year, 41 of the patients with CD4 counts less than or equal to 50 per cubic millimeter had died, as compared with 6 of those with higher counts (72 percent vs. 25 percent, P < 0.001). After adjustment for the CD4 count, independent predictors of death were older age and the presence of nausea and vomiting. Conclusions, When HIV-infected patients are exposed to cryptosporidium, those with CD4 counts less than or equal to 50 per cubic millimeter are at increased risk for biliary symptoms and for death within one year after the infection. (C) 1996, Massachusetts Medical Society.	MED COLL WISCONSIN,MILWAUKEE,WI 53226	Medical College of Wisconsin	Vakil, NB (corresponding author), UNIV WISCONSIN,SCH MED,SINAI SAMARITAN MED CTR,DEPT MED,MILWAUKEE CAMPUS,945 N 12TH ST,RM A 324,MILWAUKEE,WI 53233, USA.							ARMITAGE P, 1987, STATISTICAL METHODS; BENATOR DA, 1994, ANN INTERN MED, V121, P663, DOI 10.7326/0003-4819-121-9-199411010-00006; BENHAMOU Y, 1993, DIGEST DIS SCI, V38, P1113, DOI 10.1007/BF01295729; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BOUCHE H, 1993, J HEPATOL, V17, P34, DOI 10.1016/S0168-8278(05)80518-5; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHAN MF, 1992, HEPATOLOGY, V16, pA127; COX DR, 1972, J R STAT SOC B, V34, P187; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; FORBES A, 1993, GUT, V34, P116, DOI 10.1136/gut.34.1.116; GODWIN TA, 1991, HUM PATHOL, V22, P1215, DOI 10.1016/0046-8177(91)90103-V; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; KAVIN H, 1986, ANN INTERN MED, V104, P53, DOI 10.7326/0003-4819-104-1-53; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; PETERSEN C, 1992, CLIN INFECT DIS, V15, P903, DOI 10.1093/clind/15.6.903; PITLIK SD, 1983, ARCH INTERN MED, V143, P2269, DOI 10.1001/archinte.143.12.2269; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; RICHARDSON AJ, 1991, EPIDEMIOL INFECT, V107, P485, DOI 10.1017/S0950268800049189; SCHNEIDERMAN DJ, 1987, ANN INTERN MED, V106, P546, DOI 10.7326/0003-4819-106-4-546; SOAVE R, 1984, ANN INTERN MED, V100, P504, DOI 10.7326/0003-4819-100-4-504; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	22	109	117	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					19	23		10.1056/NEJM199601043340104	http://dx.doi.org/10.1056/NEJM199601043340104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494565				2022-12-01	WOS:A1996TM48200004
J	Gardner, P; Eickhoff, T; Poland, GA; Gross, P; Griffin, M; LaForce, M; Schaffner, W; Strikas, R				Gardner, P; Eickhoff, T; Poland, GA; Gross, P; Griffin, M; LaForce, M; Schaffner, W; Strikas, R			Adult immunizations	ANNALS OF INTERNAL MEDICINE			English	Article							ATTENUATED VARICELLA VACCINE; HEPATITIS-A VACCINE; HEALTHY-CHILDREN; UNITED-STATES; SALMONELLA-TYPHI; ZOSTER VIRUS; SUSCEPTIBILITY; INFECTIONS; SEROSURVEY; RECRUITS	New vaccines have been licensed for hepatitis A, varicella, and typhoid. This paper reviews these Vaccines and their recommended uses in adults. Special attention is given to a new national policy establishing age 50 years as a time for review of preventive health measures with emphasis on evaluating risk factors that indicate a need for pneumococcal vaccine and the initiation of annual influenza immunization.	UNIV COLORADO, HLTH SCI CTR, DIV INFECT DIS, DENVER, CO 80262 USA; MAYO CLIN & MAYO FDN, MAYO VACCINE RES GRP, DEPT MED & CLIN PHARMACOL, ROCHESTER, MN 55905 USA; HACKENSACK MED CTR, DEPT INTERNAL MED, HACKENSACK, NJ 07601 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; UNIV ROCHESTER, GENESSEE HOSP, SCH MED & DENT, ROCHESTER, NY 14607 USA; VANDERBILT UNIV, SCH MED, DEPT PREVENT MED, DIV INFECT DIS, NASHVILLE, TN 37232 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM, ATLANTA, GA 30333 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Mayo Clinic; Hackensack University Medical Center; Vanderbilt University; University of Rochester; Vanderbilt University; Centers for Disease Control & Prevention - USA	Gardner, P (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, STONY BROOK, NY 11794 USA.							ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; AKRIVIADIS EA, 1989, ANN INTERN MED, V110, P838, DOI 10.7326/0003-4819-110-10-838; ALTER SJ, 1986, INFECT CONT HOSP EP, V7, P448, DOI 10.1017/S0195941700064936; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P1133, DOI 10.1001/jama.272.14.1133; Gershon A A, 1994, Clin Diagn Virol, V2, P271, DOI 10.1016/0928-0197(94)90051-5; GERSHON AA, 1988, J INFECT DIS, V158, P132, DOI 10.1093/infdis/158.1.132; GERSHON AA, 1989, NEW ENGL J MED, V320, P892, DOI 10.1056/NEJM198904063201403; GREEN MS, 1993, J INFECT DIS, V168, P740, DOI 10.1093/infdis/168.3.740; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; HARRIS RE, 1965, OBSTET GYNECOL, V25, P734; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; JILIG W, 1994, VACCINES, P583; KANE MA, 1992, VACCINE, V10, pS93, DOI 10.1016/0264-410X(92)90555-X; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KLUGMAN KP, 1987, LANCET, V2, P1165; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LEMON SM, 1994, INFECT AGENT DIS, V3, P38; MCMAHON BJ, 1994, 34TH INT C ANT AG CH, pH11; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; RYAN CA, 1989, REV INFECT DIS, V11, P1; SHAPIRO CN, 1992, VACCINE, V10, pS59, DOI 10.1016/0264-410X(92)90545-U; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; TSOLIA M, 1990, J PEDIATR-US, V116, P184, DOI 10.1016/S0022-3476(05)82872-0; USA Adult Vaccine Preventable Disease Br., 1995, Morbidity and Mortality Weekly Report, V44, P506; WAGNER G, 1993, VACCINE, V11, P1027, DOI 10.1016/0264-410X(93)90128-K; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WHITE CJ, 1991, PEDIATRICS, V87, P604; 1995, MMWR-MORBID MORTAL W, V44, P561; 1994, GUIDE ADULT IMMUNIZA	34	46	46	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				35	40		10.7326/0003-4819-124-1_Part_1-199601010-00007	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503476				2022-12-01	WOS:A1996TL94300007
J	Genc, M; Mardh, PA				Genc, M; Mardh, PA			A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women	ANNALS OF INTERNAL MEDICINE			English	Article							PELVIC INFLAMMATORY DISEASE; ECONOMIC-EVALUATION; DECISION-ANALYSIS; ADOLESCENT MALES; SPECIMENS; ASSAY; RISK	Objective: To assess the cost-effectiveness of identifying and treating asymptomatic female carriers of Chlamydia trachomatis. Design: Cost-effectiveness analysis based on previously reported cohort analytic studies and average salaries and costs of medical care in Sweden. Setting: Women attending youth, family planning, and gynecology clinics. Participants: 1000 women and their male sex partners. Intervention: Screening with tissue cell culture, confirmed enzyme immunoassay, and DNA amplification as says based on either polymerase chain reaction or ligase chain reaction was compared with no screening (no treatment and no tracing of sexual contacts). The effect of antibiotic regimens on the outcome of the screening strategies was also evaluated. Results: When the prevalence of chlamydial infection exceeded 6%, screening of women with DNA amplification assay and treatment of positive patients with a single oral dose of azithromycin given under supervision in the clinic was the most cost-effective intervention strategy. At greater prevalences, screening with enzyme immunoassay also generated savings and improved the cure rates compared with no screening, but such screening was less cost-effective than screening with a DNA amplification assay. Compared with no intervention, tissue cell culture is cost-effective only when the prevalence of infection is greater than 14%. Compared with the azithromycin regimen, the standard 7-day, twice-daily doxycycline regimen resulted in significantly lower cure rates because of patients' poor compliance with this regimen. Conclusion: For asymptomatic female carriers of C. trachomatis, screening with a DNA amplification assay combined with the single-dose azithromycin treatment of positive patients is the most cost-effective strategy when the prevalence is 6%. When the prevalence is lower than 6%, the decision to choose a competing strategy depends on the physician's view of the value of preventing an illness caused by untreated chlamydial infection.			Genc, M (corresponding author), UPPSALA UNIV, CTR STD RES, INST CLIN BACTERIOL, BOX 552, S-75122 UPPSALA, SWEDEN.							BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; CHERNESKY M, 1994, CHLAMYDIAL INFECTION, P333; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; GENC M, 1993, JAMA-J AM MED ASSOC, V270, P2057, DOI 10.1001/jama.270.17.2057; GENC M, 1994, JAMA-J AM MED ASSOC, V271, P1741, DOI 10.1001/jama.1994.03510460033017; GENC M, 1991, CHLAMYDIAL INFECTION, P112; HADDIX A, 1994, CHLAMYDIAL INFECTION, P55; HELLBERG D, 1995, GENITOURIN MED, V71, P88; HILLIS SD, 1993, AM J OBSTET GYNECOL, V168, P1503, DOI 10.1016/S0002-9378(11)90790-X; HOOK EW, 1994, JAMA-J AM MED ASSOC, V272, P867, DOI 10.1001/jama.272.11.867; KATZ BP, 1988, SEX TRANSM DIS, V15, P11, DOI 10.1097/00007435-198801000-00003; LANGILLE DB, 1992, CAN J PUBLIC HEALTH, V83, P358; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MAHONY JB, 1992, MOL CELL PROBE, V6, P381, DOI 10.1016/0890-8508(92)90031-R; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MONCADA J, 1990, J CLIN MICROBIOL, V28, P1770, DOI 10.1128/JCM.28.8.1770-1773.1990; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; PIOT P, 1994, CHLAMYDIAL INFECTION, P7; QUINN TC, 1994, CHLAMYDIAL INFECTION, P21; RAMSTEDT K, 1991, SEX TRANSM DIS, V18, P205, DOI 10.1097/00007435-199110000-00002; RAMSTEDT K, 1991, INT J STD AIDS, V2, P428, DOI 10.1177/095646249100200607; RANDOLPH AG, 1990, AM J PUBLIC HEALTH, V80, P545, DOI 10.2105/AJPH.80.5.545; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2056, DOI 10.1001/jama.257.15.2056; WESTROM L, 1993, GENITOURIN MED, V69, P9; Whatley J D, 1991, Int J STD AIDS, V2, P248	28	113	113	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				1	7		10.7326/0003-4819-124-1_Part_1-199601010-00001	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503471				2022-12-01	WOS:A1996TL94300001
J	Murakami, S; Mizobuchi, M; Nakashiro, Y; Doi, T; Hato, N; Yanagihara, N				Murakami, S; Mizobuchi, M; Nakashiro, Y; Doi, T; Hato, N; Yanagihara, N			Bell palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; VARICELLA-ZOSTER VIRUS; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; GENE	Objective: To determine whether herpes simplex virus type 1 (HSV-1) causes Bell palsy. Design: Prospective study. Setting: University inpatient service. Patients: 14 patients with Bell palsy, 9 patients with the Ramsay-Hunt syndrome, and 12 other controls. Measurements: Viral genomes of HSV-1, varicella-zoster virus, and Epstein-Barr virus were analyzed in clinical samples of facial nerve endoneurial fluid and posterior auricular muscle using polymerase chain reaction (PCR) followed by hybridization with Southern blot analysis. Results: Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not in patients with the Ramsay-Hunt syndrome or in other controls. The nucleotide sequences of the PCR fragments were identical to those of the HSV-1 genome. Conclusions: Herpes simplex virus type 1 is the major etiologic agent in Bell palsy.	EHIME UNIV, SCH MED, DEPT NEUROPSYCHIAT, SHIGENOBU, EHIME 79102, JAPAN	Ehime University	Murakami, S (corresponding author), EHIME UNIV, SCH MED, DEPT OTOLARYNGOL, SHIGENOBU, EHIME 79102, JAPAN.							ABRAMSKY O, 1975, J NEUROL SCI, V26, P13, DOI 10.1016/0022-510X(75)90109-4; ADOUR KK, 1975, JAMA-J AM MED ASSOC, V233, P527, DOI 10.1001/jama.233.6.527; Aitken RS, 1933, LANCET, V1, P19; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BURGESS RC, 1994, ANN OTO RHINOL LARYN, V103, P775, DOI 10.1177/000348949410301006; CARTON CA, 1953, J NEUROSURG, V10, P463, DOI 10.3171/jns.1953.10.5.0463; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; DEVRIESE PP, 1974, ACTA OTO-LARYNGOL, V77, P108, DOI 10.3109/00016487409124605; DOWBENKO DJ, 1984, J VIROL, V52, P154, DOI 10.1128/JVI.52.1.154-163.1984; FURUTA Y, 1992, J INFECT DIS, V166, P1157, DOI 10.1093/infdis/166.5.1157; GILDEN DH, 1992, J INFECT DIS, V166, pS30, DOI 10.1093/infdis/166.Supplement_1.S30; HADAR T, 1983, J MED VIROL, V12, P237, DOI 10.1002/jmv.1890120403; LISTON SL, 1989, LARYNGOSCOPE, V99, P23; MCCORMICK DP, 1972, LANCET, V1, P937; MIZOBUCHI M, 1991, MOL ENDOCRINOL, V5, P476, DOI 10.1210/mend-5-4-476; PALVA T, 1978, ACTA OTO-LARYNGOL, V86, P269, DOI 10.3109/00016487809124746; SARTORETTISCHEFER S, 1994, AM J NEURORADIOL, V15, P479; SPRUANCE SL, 1994, ANN INTERN MED, V120, P1045, DOI 10.7326/0003-4819-120-12-199406150-00013; TAKASU T, 1992, ACTA OTO-LARYNGOL, V112, P1004, DOI 10.3109/00016489209137502; TOWNSEND JJ, 1986, J NEUROPATH EXP NEUR, V45, P419, DOI 10.1097/00005072-198607000-00004	20	455	473	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				27	30		10.7326/0003-4819-124-1_Part_1-199601010-00005	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503474				2022-12-01	WOS:A1996TL94300005
J	Salerno, SM; Landry, FJ; Schick, JD; Schoomaker, EB				Salerno, SM; Landry, FJ; Schick, JD; Schoomaker, EB			The effect of multiple neuroimaging studies on classification, treatment, and outcome of acute ischemic stroke	ANNALS OF INTERNAL MEDICINE			English	Article							RESONANCE; INFARCTION	Objective: To examine the effect of serial neuroimaging studies on the diagnosis, therapy, and outcome of patients with acute stroke. Design: Retrospective case series. Setting: Tertiary care teaching hospital. Patients: 206 adult patients (mean age +/- SD, 66.0 +/- 10.8 years) hospitalized with a diagnosis of acute stroke between 1990 and 1993. Measurements: Strokes were retrospectively assigned to five categories (large-vessel, small-vessel, cardioembolic, other, or unknown) using standardized criteria based on the history, physical examination, ancillary test results, and first computed tomographic (CT) or magnetic resonance imaging (MRI) study of the head. Strokes were reclassified after the results of further neuroimaging studies, if any, were reviewed. The type and timing of therapy and the patient outcome at hospital discharge were documented. Results: The additional studies changed stroke classification in only 20.0% of the 140 patients who had two or more neuroimaging studies. All classification changes were from the unknown cause category to a category with a specific cause. In most patients receiving treatment (93.2%), therapy began before an additional CT or MRI study was obtained. In patients who had one neuroimaging study, 70.1% went home, 24.0% went to a skilled nursing facility, and 5.9% died; the corresponding percentages in persons who had multiple studies were 73.3%, 24.4%, and 2.2% (P > 0.1). Conclusions: Serial neuroimaging studies did not alter the classification of strokes for which an initial diagnosis had already been made. However, they were useful in determining the cause of strokes initially classified as having an unknown cause. Therapy was almost always begun immediately after the first CT or MRI study was obtained. Outcome at hospital discharge was not significantly related to the number of neuroimaging studies obtained.	MADIGAN ARMY MED CTR, DEPT MED, TACOMA, WA 98431 USA	Madigan Army Medical Center								ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; HOMMEL M, 1990, STROKE, V21, P546, DOI 10.1161/01.STR.21.4.546; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KERTESZ A, 1987, NEUROLOGY, V37, P1580, DOI 10.1212/WNL.37.10.1580; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; SHUAIB A, 1992, NEUROLOGY, V42, P816, DOI 10.1212/WNL.42.4.816; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; WALL SD, 1982, AM J ROENTGENOL, V138, P307, DOI 10.2214/ajr.138.2.307	10	8	8	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				21	26		10.7326/0003-4819-124-1_Part_1-199601010-00004	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503473				2022-12-01	WOS:A1996TL94300004
J	Zignego, AL; Ferri, C; Giannini, C; Monti, M; LaCivita, L; Careccia, G; Longombardo, G; Lombardini, F; Bombardieri, S; Gentilini, P				Zignego, AL; Ferri, C; Giannini, C; Monti, M; LaCivita, L; Careccia, G; Longombardo, G; Lombardini, F; Bombardieri, S; Gentilini, P			Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; INTERFERON-ALPHA; LIVER-DISEASE; ANTIBODIES; INFECTION; CELLS	Objective: To investigate the possible role of HCV variants in the pathogenesis of mixed cryoglobulinemia. Setting: Medical service (rheumatology and hepatology units) of urban, university-affiliate teaching hospitals. Design: Analysis of vira I genotypes in a cohort of patients with hepatitis C virus (HCV) infection and mixed cryoglobulinemia. Patients: 90 unselected HCV-positive (anti-HCV antibody-positive and HCV RNA-positive) patients consecutively recruited at routine ambulatory visits: 29 with and 61 without (control group) mixed cryoglobulinemia. Measurements: Clinical and histologic data; HCV RNA detection in serum and peripheral blood mononuclear cells by polymerase chain reaction (PCR); HCV genotype determination by two methods based on genotype specific primer PCR and genotype-specific probe hybridization, respectively. Results: Persistent aminotransferase increases were found in 55% of patients with mixed cryoglobulinemia. Peripheral blood mononuclear cells were infected in 80% of cases. In serum samples, HCV genotype 2a/III was detected with a higher prevalence in patients with mixed cryoglobulinemia than in controls (41% compared with 15%). The overall prevalence of genotype 2a/III in mixed cryoglobulinemia increased to 52% when findings in peripheral blood mononuclear cells were also considered. Among patients with mixed cryoglobulinemia, this genotype was more frequent in those without clinical and biochemical signs of liver disease (85%) or with serum autoantibodies (75%). Conclusions: Mixed cryoglobulinemia may be related, at least in part, to the HCV genotype infecting the host.	IST PATOL MED 1, PISA, ITALY		Zignego, AL (corresponding author), UNIV FLORENCE, IST MED INTERNA, V MORGAGNI 85, I-50134 FLORENCE, ITALY.		Zignego, Anna Linda/AAL-8205-2021					BUNN CC, 1982, J CLIN LAB IMMUNOL, V8, P13; FERRI C, 1994, J INTERN MED, V236, P31, DOI 10.1111/j.1365-2796.1994.tb01116.x; FERRI C, 1994, EUR J CLIN INVEST, V24, P781, DOI 10.1111/j.1365-2362.1994.tb01077.x; FERRI C, 1993, BLOOD, V82, P3701; FERRI C, 1993, BLOOD, V81, P1132; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; GIANNINI C, 1995, J HEPATOL, V23, P246, DOI 10.1016/S0168-8278(95)80002-6; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X; ZIGNEGO AL, 1995, J MED VIROL, V47, P58, DOI 10.1002/jmv.1890470112; ZIGNEGO AL, 1994, HEPATOLOGY, V19, P577, DOI 10.1002/hep.1840190306	20	166	170	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				31	34		10.7326/0003-4819-124-1_Part_1-199601010-00006	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503475				2022-12-01	WOS:A1996TL94300006
J	Lackritz, EM; Satten, GA; AberleGrasse, J; Dodd, RY; Raimondi, VP; Janssen, RS; Lewis, WF; Notari, EP; Petersen, LR				Lackritz, EM; Satten, GA; AberleGrasse, J; Dodd, RY; Raimondi, VP; Janssen, RS; Lewis, WF; Notari, EP; Petersen, LR			Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-HIV; TRANSFUSION; INFECTION; DONORS; PREVALENCE; TYPE-1; SAFETY; TESTS	Background. In the United States, transmission of the human immunodeficiency virus (HIV) by blood transfusion occurs almost exclusively when a recently infected blood donor is infectious but before antibodies to HIV become detectable (during the ''window period''). We estimated the risk of HIV transmission caused by transfusion on the basis of the window period associated with the use of current, sensitive enzyme immunosorbent assays and recent data on HIV incidence among blood donors. Methods. We analyzed demographic and laboratory data on more than 4.1 million blood donations obtained in 1992 and 1993 in 19 regions served by the American National Red Cross, as well as the results of HIV-antibody tests of 4.9 million donations obtained in an additional 23 regions. Results. We estimated that, in the 19 study regions, 1 donation in every 360,000 (95 percent confidence interval, 210,000 to 1,140,000) was made during the window period. In addition, it is estimated that 1 in 2,600,000 donations was HIV-seropositive but was not identified as such because of an error in the laboratory. We estimated that 15 to 42 percent of window-period donations were discarded because they were seropositive on laboratory tests other than the HIV-antibody test. When these results were extrapolated to include the additional 23 Red Cross service regions, there was a risk of 1 case of HIV transmission for every 450,000 to 660,000 donations of screened blood. If the Red Cross centers are assumed to be representative of all U.S. blood centers, among the 12 million donations collected nationally each year an estimated 18 to 27 infectious donations are available for transfusion. Conclusions The estimated risk of transmitting HIV by the transfusion of screened blood is very small and nearly half that estimated previously, primarily because the sensitivity of enzyme immunosorbent assays has been improved.	CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,STAT & DATA MANAGEMENT BRANCH,ATLANTA,GA 30333; AMER NATL RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD; ORKAND CORP,ATLANTA,GA	Centers for Disease Control & Prevention - USA; American Red Cross	Lackritz, EM (corresponding author), CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,HIV SEROEPIDEMIOL BRANCH,MAILSTOP E-46,ATLANTA,GA 30333, USA.			Satten, Glen/0000-0001-7275-5371; Lackritz, Eve/0000-0002-5397-7291				BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; BUSCH MP, 1995, 1995 NAT I HLTH CONS, P29; CARSON JL, 1992, AM J MED, V92, P45, DOI 10.1016/0002-9343(92)90014-3; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; COUROUCE AM, 1993, REV FR TRANSFUS HEM, V36, P327, DOI 10.1016/S1140-4639(05)80238-2; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JOHNSON ES, 1994, TRANSFUSION, V34, P769, DOI 10.1046/j.1537-2995.1994.34994378277.x; KALBFLEISCH JD, 1989, TRANSFUSION, V29, P672, DOI 10.1046/j.1537-2995.1989.29890020437.x; KLEINMAN S, 1988, TRANSFUSION, V28, P499, DOI 10.1046/j.1537-2995.1988.28588337347.x; KLEINMAN S, 1990, ARCH PATHOL LAB MED, V114, P298; KLEINMAN SH, 1989, TRANSFUSION, V29, P572, DOI 10.1046/j.1537-2995.1989.29789369672.x; LINDEN JV, 1994, TRANSFUS MED REV, V8, P169, DOI 10.1016/S0887-7963(94)70109-7; LINDEN JV, 1994, TRANSFUSION, V34, P1016, DOI 10.1046/j.1537-2995.1994.341195065028.x; PETERSEN L, 1992, 8TH INT C AIDS 3RD S, V1; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; ROBERTS CR, 1994, ARCH PATHOL LAB MED, V118, P1188; SCHALLA WO, 1995, 2ND NAT C HUM RETR R, P120; SELIK RM, 1994, AM J EPIDEMIOL, V140, P105, DOI 10.1093/oxfordjournals.aje.a117221; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; YOUNG FE, 1990, TRANSFUSION, V30, P4, DOI 10.1046/j.1537-2995.1990.30190117628.x; 1994, NATIONAL HIV SEROSUR, V3	28	270	281	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1721	1725		10.1056/NEJM199512283332601	http://dx.doi.org/10.1056/NEJM199512283332601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491134				2022-12-01	WOS:A1995TM16900001
J	ROBINSON, JC; CASALINO, LP				ROBINSON, JC; CASALINO, LP			THE GROWTH OF MEDICAL GROUPS PAID THROUGH CAPITATION IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNIVERSAL HEALTH-INSURANCE; MANAGED COMPETITION; PROMOTE QUALITY; ECONOMY; 1990S; PLAN	Background. In California, it is common for health maintenance organizations (HMOs) to contract with large medical groups that are paid through capitation and are responsible for managing a full spectrum of medical services. Methods. We studied six large medical groups in California - Bristol Park Medical, Friendly Hills HealthCare Network, HealthCare Partners Medical Group, Mullikin Medical Centers, Palo Alto Medical Foundation, and San Jose Medical Group - that are paid through capitation and that are growing as a result of contracts with managed-care organizations. We conducted interviews and obtained data on factors such as patient enrolment, capitation and other revenue, numbers of days spent by enrollees in the hospital, and numbers of visits to physicians per enrollee. Results Between 1990 and 1994, the number of HMO enrollees whose care was paid for through capitation in the six medical groups increased by 91 percent, from 398,359 to 759,474. In 1994, the mean number of hospital days per 1000 HMO enrollees ranged from 120 to 149 for non-Medicare patients and from 643 to 936 days for Medicare patients. By comparison, in 1993 the mean numbers of hospital days per 1000 HMO enrollees not covered by Medicare were 232 for California and 297 for the United States; for HMO enrollees covered by Medicare, the numbers were 1337 for California and 1698 for the United States. In 1994, the average annual number of visits to physicians for HMO patients in the six groups not covered by Medicare ranged from 3.1 to 3.9; for Medicare patients, it ranged from 6.8 to 9.3; these rates were slightly lower than statewide and national rates. Four of the groups have sold their assets (such as facilities, supplies, equipment, and patients' charts) to outside investors; the physicians remain employed by physician-owned professional corporations. Conclusions. Medical groups paid through capitation offer a model for the status of physicians in managed-care systems that differs from the employee status offered by staff-model HMOs and the subcontractor status offered by HMOs that negotiate directly with individual physicians. Despite their growth, such medical groups in California face substantial challenges, such as obtaining the financial assets necessary to sustain rapid growth.			ROBINSON, JC (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,418 WARREN HALL,BERKELEY,CA 94720, USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; HODAPP TE, 1994, HMOS 1995 RIGHT PLAC; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; MORRISON EM, 1995, CONSOLIDATION PROVID; 1994, MARION MERRELL DOW M; 1994, CAPITATION STRATEGY	8	131	132	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1684	1687		10.1056/NEJM199512213332506	http://dx.doi.org/10.1056/NEJM199512213332506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477222				2022-12-01	WOS:A1995TL40100006
J	BONDY, S				BONDY, S			ALCOHOL AVAILABILITY AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CONSUMPTION; STRIKE				BONDY, S (corresponding author), ADDICT RES FDN,TORONTO,ON M5S 2S1,CANADA.		Bondy, Susan J/C-6737-2014	Bondy, Susan J/0000-0002-6516-4159				BASS K, DEV LOCAL CONTROL AL; BLOSE JO, 1987, J STUD ALCOHOL, V48, P52, DOI 10.15288/jsa.1987.48.52; Bruun K., 1975, ALCOHOL CONTROL POLI; EDWARDS G, 1994, ALCOHOL POLICY PUBLI, pCH6; GODFREY C, 1988, APPL ECON, V20, P1541, DOI 10.1080/00036848800000085; GRUENEWALD PJ, 1993, ALCOHOL CLIN EXP RES, V17, P38, DOI 10.1111/j.1530-0277.1993.tb00723.x; GRUENEWALD PJ, 1993, NIAAA RES MONOGRAPH, V25, P59; HOLDER HD, 1987, CONTROL ISSUES ALCOH; HORVERAK O, 1983, BRIT J ADDICT, V78, P51; Lenke L., 1990, ALCOHOL CRIMINAL VIO; LESTER D, 1988, SOC PSYCH PSYCH EPID, V23, P202, DOI 10.1007/BF01794789; MAKELA K, 1980, J DRUG ISSUES, V10, P131; Mosher J. F., 1994, CONFRONTING SACRAMEN; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V30, P54; OSTERBERG E, 1991, NATURAL EXPT DECREAS; OSTERBERG E, 1993, ALCOHOL HEALTH RES W, V17, P205; ROOM R, 1984, ANNU REV PUBL HEALTH, V5, P293, DOI 10.1146/annurev.pu.05.050184.001453; RUSH BR, 1986, J STUD ALCOHOL, V47, P1; SCHECHTER EJ, 1986, CONT DRUG PROBL, V15, P587; SCRIBNER RA, 1994, J STUD ALCOHOL, V55, P447, DOI 10.15288/jsa.1994.55.447; SKOG OJ, 1980, J DRUG ISSUES, V10, P71, DOI 10.1177/002204268001000105; SONENSHEIM RJ, 1993, BATTLE LIQUOR STORES; WATTS RK, 1983, ALCOHOL CLIN EXP RES, V7, P47, DOI 10.1111/j.1530-0277.1983.tb05410.x; WILKINSON JT, 1987, SOUTHERN ECON J, V54, P322, DOI 10.2307/1059317	24	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1832	1832		10.1001/jama.274.23.1832	http://dx.doi.org/10.1001/jama.274.23.1832			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500522				2022-12-01	WOS:A1995TK14700008
J	JAY, GT; CHOW, MSS				JAY, GT; CHOW, MSS			INTERACTION OF EPINEPHRINE AND BETA-BLOCKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROPRANOLOL; HYPERTENSION; BLOCKADE				JAY, GT (corresponding author), UNIV CONNECTICUT,HARTFORD,CT 06112, USA.							DZUBOW LM, 1986, J AM ACAD DERMATOL, V15, P71, DOI 10.1016/S0190-9622(86)70145-X; FOSTER CA, 1983, PLAST RECONSTR SURG, V72, P74, DOI 10.1097/00006534-198307000-00017; GANDY W, 1989, ANN EMERG MED, V18, P98, DOI 10.1016/S0196-0644(89)80324-5; HANSBROUGH JF, 1980, ANN INTERN MED, V92, P717, DOI 10.7326/0003-4819-92-5-717_2; HOFFMAN B B, 1990, P187; HOUBEN H, 1982, CLIN PHARMACOL THER, V31, P685, DOI 10.1038/clpt.1982.96; MACKIE K, 1991, J CLIN MONITOR, V7, P213, DOI 10.1007/BF01619262; MALTBAEK N, 1984, ACTA MED SCAND S677, V215, P21; REEVES RA, 1984, CLIN PHARMACOL THER, V35, P461, DOI 10.1038/clpt.1984.60; Smith TW, 1988, HEART DIS, P524; VANZWIETEN PA, 1990, CARDIOVASCULAR PHARM, P1; WHELAN TV, 1987, ANN INTERN MED, V106, P327, DOI 10.7326/0003-4819-106-2-327_1	12	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1830	&		10.1001/jama.274.23.1830	http://dx.doi.org/10.1001/jama.274.23.1830			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500521				2022-12-01	WOS:A1995TK14700007
J	LAUNER, LJ; MASAKI, K; PETROVITCH, H; FOLEY, D; HAVLIK, RJ				LAUNER, LJ; MASAKI, K; PETROVITCH, H; FOLEY, D; HAVLIK, RJ			THE ASSOCIATION BETWEEN MIDLIFE BLOOD-PRESSURE LEVELS AND LATE-LIFE COGNITIVE FUNCTION - THE HONOLULU-ASIA AGING STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; WHITE MATTER LESIONS; MINI-MENTAL STATE; JAPANESE MEN; HYPERTENSION; STROKE; HAWAII; CALIFORNIA; MORTALITY; DEMENTIA	Objective.-To assess the long-term relationship of midlife blood pressure levels to late-life cognitive function. Design.-The 4678 surviving cohort members of the prospective Honolulu Heart Program (baseline, 1965-1968) were examined a fourth time in 1991 through 1993 and given a cognitive test. Participants.-The subjects were 3735 Japanese-American men living in Hawaii in the community or in institutions, with an average age of 78 years at the fourth examination. Main Outcome Measures.-Cognitive function, measured by the 100-point Cognitive Abilities Screening Instrument (CASI), was categorized into good (reference: a CASI score of 92 to 100), intermediate (<92 to 82), and poor (<82). Midlife systolic blood pressure (SEP) and diastolic blood pressure (DBP) values were measured in 1965, 1968, and 1971. A respondent was classified into the following categories if two of three measurements fell into the following groups: for SEP, <110, 110 to 139, 140 to 159, and greater than or equal to 160 mm Hg; and for DBP, <80, 80 to 89, 90 to 94, and greater than or equal to 95 mm Hg. Results.-When we controlled for age and education, the risk for intermediate and poor cognitive function increased progressively with increasing level of midlife SEP category (P for trend <.03 and <.001, respectively). for every 10-mm Hg increase in SEP there was an increase in risk for intermediate cognitive function of 7% (95% confidence interval [C], 3% to 11%) and for poor cognitive function of 9% (95% CI, 3% to 16%). Adjustment for prevalent stroke, coronary heart disease, and subclinical atherosclerosis reduced the strength of the relationship between midlife SEP and poor cognitive function to 5% (95% CI, 0% to 12%). The level of cognitive function was not associated with midlife DBP. Conclusions.-Midlife SEP is a significant predictor of reduced cognitive function in later life. Early control of SEP levels may reduce the risk for cognitive impairment in old age.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,BILTHOVEN,NETHERLANDS; UNIV HAWAII,DEPT MED,HONOLULU,HI; KUAKINI MED CTR,HONOLULU,HI 96817; NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892	Erasmus University Rotterdam; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	LAUNER, LJ (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,POB 1,3720 BA BILTHOVEN,NETHERLANDS.				NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-02901] Funding Source: Medline; NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ELIAS MF, 1989, J GERONTOL, V44, pP25, DOI 10.1093/geronj/44.1.P25; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; FARMER ME, 1987, AM J EPIDEMIOL, V126, P1103, DOI 10.1093/oxfordjournals.aje.a114749; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUMTA A, 1991, STROKE, V22, P442; GRAVES AB, 1993, ALZHEIMERS DIS ADV C, P113; Hasegawa K, 1983, AGING 80S, P207; HAVLIK RJ, 1992, NESTLE NUTR WORKSHOP, P7; KANNEL WB, 1985, HDB BIOL AGING, P859; KANNEL WB, 1976, STROKE, V4, P327; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MILLER VT, 1983, ARCH NEUROL-CHICAGO, V40, P129, DOI 10.1001/archneur.1983.04050030023002; NAG S, 1984, ACTA NEUROPATHOL, V62, P178, DOI 10.1007/BF00691850; REED D, 1994, STROKE, V25, P60, DOI 10.1161/01.STR.25.1.60; SALERNO JA, 1992, HYPERTENSION, V20, P340, DOI 10.1161/01.HYP.20.3.340; SANDS LP, 1992, J GERONTOL, V47, pP81, DOI 10.1093/geronj/47.2.P81; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; STAMLER J, 1987, NEW PERSPECTIVES CAR, P13; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TATAMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WALLACE RB, 1985, J CHRON DIS, V38, P475, DOI 10.1016/0021-9681(85)90031-1; WHITE LR, 1992, CURR SCI INDIA, V63, P456; WILKIE F, 1971, SCIENCE, V172, P959, DOI 10.1126/science.172.3986.959; WILKIE F L, 1976, Experimental Aging Research, V2, P3; WINKELSTEIN W, 1975, AM J EPIDEMIOL, V102, P502, DOI 10.1093/oxfordjournals.aje.a112188; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186; YANO K, 1983, J CHRON DIS, V36, P569, DOI 10.1016/0021-9681(83)90145-5; 1987, DIAGNOSTIC STATISTIC; 1993, SAS STAT USERS GUIDE	43	698	727	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1846	1851		10.1001/jama.274.23.1846	http://dx.doi.org/10.1001/jama.274.23.1846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500533				2022-12-01	WOS:A1995TK14700025
J	NEFF, JM; ANDERSON, G				NEFF, JM; ANDERSON, G			CARING FOR THE UNINSURED AND UNDERINSURED - PROTECTING CHILDREN WITH CHRONIC ILLNESS IN A COMPETITIVE MARKETPLACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPITATION RATES	Health care for children with chronic illnesses is significantly more expensive than for the average child. Children with chronic illnesses are especially vulnerable in a competitive health care environment because of the higher ongoing cost associated with treating their illnesses and the inherent pressures to reduce services to manage within the capitated rate. To minimize the adverse impact a competitive market could have on these children, a ''carve-out'' for specific medical conditions is discussed. A capitation pricing system that reflects their higher costs is proposed, as well as a delivery system that is focused on their needs.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; JOHNS HOPKINS MED INST,CTR HOSP FINANCE MANAGEMENT,BALTIMORE,MD 21205	University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Medicine	NEFF, JM (corresponding author), CHILDRENS HOSP & MED CTR,4800 SAND POINT WAY NE,POB 5371,SEATTLE,WA 98105, USA.							ACKERLOFF GA, 1970, Q J ECON, V84, P489; ANDERSON GF, 1990, INQUIRY-J HEALTH CAR, V27, P225; ARROW KJ, 1963, AM ECON REV, V53, P941; Ash A, 1989, Health Care Financ Rev, V10, P17; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BEHRMAN RE, 1992, NELSON TXB PAEDIAT, P1; BOYLE CA, 1994, PEDIATRICS, V93, P399; CONE TE, 1979, HIST AM PEDIATRICS, P159; ELSAS LJ, 1991, RUDOLPHS PEDIATRICS, P281; ELWOOD JM, 1992, EPIDEMIOLOGY CONTROL, P110; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Epstein A M, 1988, Health Care Financ Rev, V10, P51; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FOX HB, 1993, AM J DIS CHILD, V147, P546, DOI 10.1001/archpedi.1993.02160290052025; GILLUM RF, 1994, AM HEART J, V127, P919, DOI 10.1016/0002-8703(94)90562-2; Hahn J A, 1993, Paediatr Perinat Epidemiol, V7, P450, DOI 10.1111/j.1365-3016.1993.tb00426.x; HOWARD WT, 1924, PUBLIC HLTH ADM NATU; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; HUGHES DC, 1995, PEDIATRICS, V95, P591; IANNACCONE ST, 1992, PEDIATR CLIN N AM, V39, P879; MCCLURE W, 1984, INQUIRY-J HEALTH CAR, V21, P205; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; RUDOLPH AM, 1991, RUDOLPHS PEDIATRICS, P1; SAMANEK M, 1992, PEDIATR CARDIOL, V13, P152; Starfield B, 1985, EFFECTIVENESS MED CA; THOMAS JW, 1986, MED CARE, V24, P259, DOI 10.1097/00005650-198603000-00008; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; 1992, CTR FUTURE CHILDREN, P102; 1987, NATIONAL MED EXPENDI, P37; 1994, ANN REPORT C 1994; 1992, VITAL HLTH STAT 10, V189; 1994, WASHINGTON HLTH SERV; 1995, MMWR-MORBID MORTAL W, V43, P952	37	88	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1866	1869		10.1001/jama.274.23.1866	http://dx.doi.org/10.1001/jama.274.23.1866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500537				2022-12-01	WOS:A1995TK14700029
J	GWILT, DJ				GWILT, DJ			CARDIOLOGISTS IN CASUALTY	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; EMERGENCY ROOM; CHEST PAIN				GWILT, DJ (corresponding author), MILTON KEYNES DIST GEN HOSP, MILTON KEYNES, BUCKS, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AUFDERHEIDE TP, 1992, AM J CARDIOL, V69, P991, DOI 10.1016/0002-9149(92)90852-P; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HEDEN B, 1994, AM J CARDIOL, V74, P5, DOI 10.1016/0002-9149(94)90482-0; HIMBERT D, 1993, AM J CARDIOL, V71, P377, DOI 10.1016/0002-9149(93)90435-F; KAUL S, 1994, ANN INTERN MED, V121, P976, DOI 10.7326/0003-4819-121-12-199412150-00013; LEE HS, 1994, BRIT HEART J, V71, P311; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; MCLEOD AA, 1994, BRIT HEART J, V72, P303; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; PEELS CH, 1990, AM J CARDIOL, V65, P687, DOI 10.1016/0002-9149(90)90143-O; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WEISSMAN I, 1995, ANN INTERN MED, V123, P314, DOI 10.7326/0003-4819-123-4-199508150-00013	15	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	1995	346	8990					1571	1572		10.1016/S0140-6736(95)91923-6	http://dx.doi.org/10.1016/S0140-6736(95)91923-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500745	Bronze			2022-12-01	WOS:A1995TK48100004
J	HAY, RJ				HAY, RJ			SICK LIBRARY SYNDROME	LANCET			English	Editorial Material							MYCOTOXINS				HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							BHAT RV, 1977, INDIAN J MED RES, V66, P55; BROOK SJ, 1994, J CLIN EPIDEMIOL, V47, P1171; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; HENDRY KM, 1993, J TOXICOL ENV HEALTH, V38, P183, DOI 10.1080/15287399309531711; HUXLEY A, 1962, ISLAND, P140; LEON FE, 1995, J CLIN EPIDEMIOL, V48, P1183, DOI 10.1016/0895-4356(95)00006-P; NORTHRUP SC, 1978, ENCY HDB, V3, P91; SMORAGIEWICZ W, 1993, INT ARCH OCC ENV HEA, V65, P113, DOI 10.1007/BF00405729	8	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1573	1574		10.1016/S0140-6736(95)91925-2	http://dx.doi.org/10.1016/S0140-6736(95)91925-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500747	Bronze			2022-12-01	WOS:A1995TK48100006
J	JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C				JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C			RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS	LANCET			English	Article							VASCULAR-DISEASE	Concern about the risks of cardiovascular illness in women using combined oral contraceptives (OC) containing the progestagens desogestrel and gestodene prompted two studies of data from the UK General Practice Research Database. We compared the risks of certain cardiovascular illnesses in otherwise healthy women exposed to one of three OCs containing <35 mu g oestrogen plus levonorgestrel, desogestrel, or gestodene. In the first study, based on some 470 general practices, there were 15 cases of unexpected idiopathic cardiovascular death among 303 470 women who were current users of one of the study OCs. The estimated incidence rates were 8/184 536 (4.3 per 100 000) woman-years at risk for users of combined OCs containing levonorgestrel, 2/135 567 (1.5 per 100 000) for desogestrel users, and 5/105 201 (4.8 per 100 000) for gestodene users. The relative risk (RR) estimates were 0.4 (95% CI 0.1-2.1) and 1.4 (CI 0.5-4.5) for desogestrel and gestodene, respectively, compared with levonorgestrel. In the second study, derived from some 370 general practices, there were 80 cases of nonfatal venous thromboembolism (VTE) in a cohort of 238 130 otherwise healthy women. The incidence rates of VTE per 100 000 woman-years at risk were 16.1 for levonorgestrel users, 29.3 for desogestrel, and 28.1 for gestodene. The adjusted RR estimates from the cohort analysis were 1.9 (1.1-3.2) and 1.8 (1.0-3.2) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. In a nested case-control analysis the adjusted matched RR estimates were 2.2 (1.1-4.4) and 2.1 (1.0-4.4) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. The excess risk for nonfatal VTE associated with the new generation of combined OCs containing low-dose oestrogen and the progestagens desogestrel or gestodene compared with levonorgestrel is estimated to be 16 per 100 000 woman-years.	HARVARD UNIV,DEACONESS HOSP,SCH MED,VASC RES LAB,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138	Harvard University; Harvard University	JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				Abenhaim L, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; VANDERVANGE N, 1988, CONTEMP OBSTET GYNEC, P317; 1995, LANCET, V346, P1582	10	622	630	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1589	1593		10.1016/S0140-6736(95)91928-7	http://dx.doi.org/10.1016/S0140-6736(95)91928-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500750	hybrid			2022-12-01	WOS:A1995TK48100009
J	KRISHNAN, SC; SHIVKUMAR, K; GARAN, H; RUSKIN, JN				KRISHNAN, SC; SHIVKUMAR, K; GARAN, H; RUSKIN, JN			INCREASED VULNERABILITY OF THE SUBENDOCARDIUM TO ISCHEMIC-INJURY - AN ELECTROPHYSIOLOGICAL EXPLANATION	LANCET			English	Note							MYOCARDIAL BLOOD-FLOW; CORONARY-ARTERY OCCLUSION; ISCHEMIC CELL-DEATH; INFARCT SIZE; VENTRICULAR WALL; COLLATERAL FLOW; DOG HEART; EPICARDIUM; PRESSURE; TENSION		HENRY FORD HOSP,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	KRISHNAN, SC (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,CARDIAC UNIT,BOSTON,MA 02114, USA.		Shivkumar, Kalyanam/AAI-1085-2019	Shivkumar, Kalyanam/0000-0002-4121-1766				ALLEN DG, 1989, J PHYSIOL-LONDON, V410, P297, DOI 10.1113/jphysiol.1989.sp017534; ANTZELEVITCH C, 1991, CIRC RES, V69, P1427, DOI 10.1161/01.RES.69.6.1427; AUCHAMPACH JA, 1991, J PHARMACOL EXP THER, V259, P961; CAMICI P, 1984, BASIC RES CARDIOL, V79, P454, DOI 10.1007/BF01908146; DIDIEGO JM, 1993, CIRCULATION, V88, P1177, DOI 10.1161/01.CIR.88.3.1177; DOWNAR E, 1977, CIRCULATION, V56, P217, DOI 10.1161/01.CIR.56.2.217; ENG C, 1987, J AM COLL CARDIOL, V9, P374, DOI 10.1016/S0735-1097(87)80391-1; FUKUNAMI M, 1987, Canadian Journal of Cardiology, V3, P94; GAMBLE WJ, 1974, CIRC RES, V34, P672, DOI 10.1161/01.RES.34.5.672; GETTES LS, 1992, HEART CARDIOVASCULAR, P2021; GOLDNER MG, 1971, J AMER MED ASSOC, V218, P1400, DOI 10.1001/jama.218.9.1400; GRIGGS DM, 1972, AM J PHYSIOL, V222, P705; HOMANS DC, 1988, CIRCULATION, V78, P1267, DOI 10.1161/01.CIR.78.5.1267; HORN H, 1950, AM HEART J, V40, P63, DOI 10.1016/0002-8703(50)90150-5; KIMURA S, 1986, CIRCULATION, V74, P401, DOI 10.1161/01.CIR.74.2.401; KIRK ES, 1964, AM J PHYSIOL, V207, P361, DOI 10.1152/ajplegacy.1964.207.2.361; KLEBER AG, 1984, J MOL CELL CARDIOL, V16, P389, DOI 10.1016/S0022-2828(84)80610-0; KRISHNAN SC, 1991, CIRC RES, V69, P277, DOI 10.1161/01.RES.69.2.277; Krishnan Subramaniam, 1993, Journal of the American College of Cardiology, V21, p220A; LANGER GA, 1987, WESTERN J MED, V146, P713; LEE JT, 1981, CIRCULATION, V64, P526, DOI 10.1161/01.CIR.64.3.526; LOWE JE, 1983, CIRCULATION, V68, P190, DOI 10.1161/01.CIR.68.1.190; MARQUIS RM, 1955, BRIT HEART J, V17, P373; MASTER AM, 1950, CIRCULATION, V1, P1302, DOI 10.1161/01.CIR.1.6.1302; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OPIE LH, 1993, CARDIOVASC DRUG THER, V7, P507, DOI 10.1007/BF00877615; PATH G, 1990, CIRC RES, V67, P660, DOI 10.1161/01.RES.67.3.660; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; RIVAS F, 1976, CIRC RES, V38, P439, DOI 10.1161/01.RES.38.5.439; RUBIO R, 1975, PROG CARDIOVASC DIS, V18, P105, DOI 10.1016/0033-0620(75)90001-8; RUFFY R, 1979, CIRC RES, V45, P764, DOI 10.1161/01.RES.45.6.764; SABBAH HN, 1982, AM J PHYSIOL, V242, pH240, DOI 10.1152/ajpheart.1982.242.2.H240; SEDEK G, 1986, BASIC RES CARDIOL, V81, P219; STEIN PD, 1980, AM J PHYSIOL, V238, pH625, DOI 10.1152/ajpheart.1980.238.5.H625; WEINTRAUB WS, 1981, CIRC RES, V48, P430, DOI 10.1161/01.RES.48.3.430; WEISS HR, 1978, CIRC RES, V42, P394, DOI 10.1161/01.RES.42.3.394; WETTWER E, 1994, CIRC RES, V75, P473, DOI 10.1161/01.RES.75.3.473; WHITE FC, 1981, BASIC RES CARDIOL, V76, P189, DOI 10.1007/BF01907957	38	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1612	1614		10.1016/S0140-6736(95)91936-8	http://dx.doi.org/10.1016/S0140-6736(95)91936-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500758				2022-12-01	WOS:A1995TK48100017
J	ALEXIEWICZ, JM; KUMAR, D; SMOGORZEWSKI, M; KLIN, M; MASSRY, SG				ALEXIEWICZ, JM; KUMAR, D; SMOGORZEWSKI, M; KLIN, M; MASSRY, SG			POLYMORPHONUCLEAR LEUKOCYTES IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - ABNORMALITIES IN METABOLISM AND FUNCTION	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NON-INSULIN-DEPENDENT; NEUTROPHILS; PHAGOCYTOSIS; CALCIUM CHANNELS; GLYBURIDE	INCREASES CYTOSOLIC CALCIUM; PROTEIN KINASE-C; PHOSPHATE-DEPLETION; IMPAIRED PHAGOCYTOSIS; PARATHYROID-HORMONE; PANCREATIC-ISLETS; CA-2+ TRANSPORT; RAT ADIPOCYTES; MECHANISM; SODIUM	Objective: To determine basal levels of cytosolic calcium ([Ca2+]i) and phagocytic activity in polymorphonuclear leukocytes (PMNLs) from patients with non-insulin-dependent diabetes (NIDDM). Design: Prospective cohort study. Setting: A university-county hospital. Measurements: Cytosolic calcium levels, adenosine triphosphate (ATP) content, and phagocytosis of PMNLs from patients with NIDDM and from controls. Intervention: In patients with NIDDM, we evaluated the effect of treatment with an oral hypoglycemic agent (glyburide) on [Ca2+]i levels, ATP content, and the phagocytosis of PMNLs. Patients: 22 controls and 34 patients with NIDDM were examined. Fifteen patients were studied before and after 3 months of treatment with glyburide. Results: Polymorphonuclear leukocytes from patients with NIDDM showed significantly elevated basal levels of [Ca2+]i (68 +/- 9.6 compared with 43 +/- 4.9 nmol/L; P < 0.01); reduced ATP content (1.30 +/- 0.58 compared with 2.35 +/- 0.45 nmol/10(6) PMNLs; P < 0.01); and impaired phagocytosis (117 +/- 21.0 compared with 145 +/- 17.4 mu g oil/10(7) PMNLs per minute; P < 0.01) compared with controls. There was a direct and significant correlation (P < 0.01, r = 0.80) between [Ca2+]i levels in PMNLs and serum glucose levels and an inverse correlation between phagocytic ability and [Ca2+]i levels (P < 0.01; r = 0.62) as well as between phagocytic activity and fasting serum glucose levels (P < 0.01, r = 0.54) in patients with NIDDM. Glyburide therapy resulted in significant reduction in fasting serum glucose levels; in PMNLs, this treatment resulted in a significant reduction in [Ca2+]i levels, a significant increase in ATP content, and a significant improvement of phagocytosis. Conclusions: Patients with NIDDM have elevated [Ca2+]i levels in PMNLs. This abnormality is probably induced by hyperglycemia and is primarily responsible for the impaired phagocytosis seen in these patients.	UNIV SO CALIF, SCH MED, DIV NEPHROL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DIV ENDOCRINOL DIABET & HYPERTENS, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California			Kalra, D/H-6661-2019	Kalra, D/0000-0001-5254-4067	NIDDK NIH HHS [DK 29955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK029955, R01DK029955] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXIEWICZ JM, 1991, AM J NEPHROL, V11, P102, DOI 10.1159/000168284; ALEXIEWICZ JM, 1995, AM J KIDNEY DIS, V25, P440, DOI 10.1016/0272-6386(95)90106-X; ALEXIEWICZ JM, 1992, AM J HYPERTENS, V5, P536, DOI 10.1093/ajh/5.8.536; ALLO SN, 1991, AM J PHYSIOL, V260, pC1165, DOI 10.1152/ajpcell.1991.260.6.C1165; BACZYNSKI R, 1985, KIDNEY INT, V27, P718, DOI 10.1038/ki.1985.71; BAGDADE JD, 1974, DIABETES, V23, P9, DOI 10.2337/diab.23.1.9; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHERVU I, 1992, KIDNEY INT, V41, P1501, DOI 10.1038/ki.1992.219; CRADDOCK PR, 1974, NEW ENGL J MED, V290, P1403, DOI 10.1056/NEJM197406202902504; DENTON RM, 1985, AM J PHYSIOL, V249, pE543, DOI 10.1152/ajpendo.1985.249.6.E543; DOWD TL, 1993, J BIOL CHEM, V268, P991; DRAZNIN B, 1989, ENDOCRINOLOGY, V125, P2341, DOI 10.1210/endo-125-5-2341; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ERNE P, 1984, NEW ENGL J MED, V310, P1084, DOI 10.1056/NEJM198404263101705; FADDA GZ, 1990, AM J PHYSIOL, V258, pE975, DOI 10.1152/ajpendo.1990.258.6.E975; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; GREENE DA, 1983, J CLIN INVEST, V72, P1058, DOI 10.1172/JCI111030; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS M, 1979, DIABETES, V28, P1039; KIERSZTEJN M, 1992, J AM SOC NEPHROL, V2, P1484; KLIN M, 1994, AM J PHYSIOL-GASTR L, V267, pG754, DOI 10.1152/ajpgi.1994.267.5.G754; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LUNDIN A, 1986, METHOD ENZYMOL, V133, P27; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; MARHOFFER W, 1992, DIABETES CARE, V15, P256, DOI 10.2337/diacare.15.2.256; MASSRY SG, 1994, SEMIN NEPHROL, V14, P219; MASSRY SG, 1992, MINER ELECTROL METAB, V18, P133; MASSRY SG, 1991, AM J PHYSIOL, V260, pF12, DOI 10.1152/ajprenal.1991.260.1.F12; MAZZANTI L, 1990, DIABETES, V39, P850, DOI 10.2337/diabetes.39.7.850; OHARA T, 1991, DIABETES, V40, P1560, DOI 10.2337/diabetes.40.11.1560; OSHIMA T, 1987, JPN CIRC J, V51, P1184, DOI 10.1253/jcj.51.1184; RESNICK LM, 1991, HYPERTENSION, V17, P951, DOI 10.1161/01.HYP.17.6.951; SOUTHWICK FS, 1986, MANUAL CLIN LABORATO, P326; STOJCEVATANEVA O, 1993, NEPHRON, V64, P592, DOI 10.1159/000187406; STUDER RK, 1989, ENDOCRINOLOGY, V125, P2421, DOI 10.1210/endo-125-5-2421; TRIVELLI LA, 1971, NEW ENGL J MED, V284, P353, DOI 10.1056/NEJM197102182840703; TRUMP BE, 1987, ADV MOD ENV TOXICOL, V14, P27; TSCHOPE D, 1994, AM J MED, V96, P260; ZERNEL MB, 1990, METABOLISM, V39, P704; ZHANG YB, 1994, KIDNEY INT, V45, P1113, DOI 10.1038/ki.1994.148; ZHOU XJ, 1991, KIDNEY INT, V39, P120, DOI 10.1038/ki.1991.15	41	155	161	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					919	+		10.7326/0003-4819-123-12-199512150-00004	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486486				2022-12-01	WOS:A1995TK12000004
J	MULLER, AD; SONNENBERG, A				MULLER, AD; SONNENBERG, A			PREVENTION OF COLORECTAL-CANCER BY FLEXIBLE ENDOSCOPY AND POLYPECTOMY - A CASE-CONTROL STUDY OF 32702 VETERANS	ANNALS OF INTERNAL MEDICINE			English	Article						COLORECTAL NEOPLASMS; ENDOSCOPY, GASTROINTESTINAL; SIGMOIDOSCOPY; COLONOSCOPY; COLONIC POLYPS	RISK; POLYPS; CARCINOMA; ADENOMAS; RECTUM; COLON	Objective: To determine whether patients with colorectal cancer are less likely than unaffected controls to have had one or more endoscopic procedures (flexible sigmoidoscopy, colonoscopy, or polypectomy) before being diagnosed with cancer. Design: Case-control study. Setting: Hospitals of the Department of Veterans Affairs. Patients: 8722 and 7629 case-patients with colon and rectal cancer, respectively, and age-, sex-, race-matched controls who were discharged at the same time as the corresponding case-patients. Measurements: Number and type of endoscopic procedures of the large bowel done from 1981 until the development of colorectal cancer in each case-patient. The influence of endoscopic procedures on the development of colorectal cancer was tested by conditional multiple logistic regression analysis. Results: Compared with controls, patients with colorectal cancer were less likely to have had an endoscopic procedure of the large bowel before being diagnosed with cancer (odds ratio for colon cancer, 0.51 [95% CI, 0.44 to 0.58]; odds ratio for rectal cancer, 0.55 [CI, 0.47 to 0.64]). In patients who had flexible sigmoidoscopy, colonoscopy, and polypectomy, the odds ratios were even smaller. When analyzed by separate 1-year intervals, patients with cancer had significantly fewer procedures during periods of up to 6 years before the onset of their cancer. Similarly, fewer inpatient and outpatient procedures were done in patients than in controls. Conclusions: Endoscopic procedures of the large bowel reduce the risk for developing colon and rectal cancer by 50%, their protective influence lasting 6 years.	VET AFFAIRS MED CTR, GASTROENTEROL SECT, ALBUQUERQUE, NM 87108 USA; MED COLL WISCONSIN, DEPT FAMILY MED, MILWAUKEE, WI 53226 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical College of Wisconsin								AHLQUIST DA, 1993, NEW ENGL J MED, V329, P1351; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; Breslow N, 1980, STAT METHODS CANC RE, P248; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; KEEFFE EB, 1993, GASTROINTEST ENDOSC, V39, P840, DOI 10.1016/S0016-5107(93)70284-9; KIRSCHNER CG, 1994, PHYSICIANS CURRENT P; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MADARA JL, 1983, AM J PATHOL, V110, P230; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; SANDLER RS, 1995, GASTROENTEROLOGY, V109, P302; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMONS BD, 1992, J NATL CANCER I, V84, P962, DOI 10.1093/jnci/84.12.962; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TURNER D, 1993, CAN MED ASSOC J, V149, P595; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1989, DHHS PHS891260; 1992, SAS STAT SOFTWARE CH, P435	23	484	490	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					904	+		10.7326/0003-4819-123-12-199512150-00002	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486484				2022-12-01	WOS:A1995TK12000002
J	SELIK, RM; CHU, SY; WARD, JW				SELIK, RM; CHU, SY; WARD, JW			TRENDS IN INFECTIOUS-DISEASES AND CANCERS AMONG PERSONS DYING OF HIV-INFECTION IN THE UNITED-STATES FROM 1987 TO 1992	ANNALS OF INTERNAL MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS PROPHYLAXIS; AIDS PATIENTS; SURVIVAL	Objective: To determine trends in the relative frequency of infectious diseases and cancers among U.S. residents dying of human immunodeficiency virus (HIV) infection. Data Source: National multiple-cause mortality data for 1987 to 1992 compiled from death certificates. Subjects: Deaths reported with HIV infection as the underlying cause and with nonunderlying causes that could be secondary to HIV infection. Data Analysis: Trends in the annual percentage of deaths associated with each infectious disease or cancer that accounted for at least 1.0% of all HIV-related deaths. Results: From 1987 to 1992, the percentage of HIV-related deaths associated with the following diseases decreased: pneumocystosis, from 32.5% to 13.8%; cryptococcosis, from 7.7% to 5.0%; and candidiasis, from 2.3% to 1.7%. The percentage of deaths associated with the following diseases increased: nontuberculous mycobacteriosis, from 6.7% to 12.2%; cytomegalovirus disease, from 5.2% to 9.9%; bacterial septicemia, from 9.0% to 11.5%; non-Hodgkin lymphoma, from 3.9% to 5.7%; tuberculosis, from 2.9% to 4.1%; progressive multifocal leukoencephalopathy, from 0.8% to 1.9%; bacterial pneumonia, from 1.2% to 2.1%; and cryptosporidiosis or isosporiasis, from 0.7% to 1.2%, The percentages of deaths associated with toxoplasmosis, Kaposi sarcoma, and pneumonia caused by unspecified organisms had no significant linear trends (ranges from 4.9% to 5.5%, 10.4% to 12.1%, and 17.6% to 18.6%, respectively). Conclusions: The percentage of HIV-related deaths associated with pneumocystosis has decreased dramatically, probably because of chemoprophylaxis and improved treatment. Pneumonia caused by unspecified organisms has now become the leading secondary cause of death among persons dying of HIV infection. Decreases in the percentages of HIV-related deaths associated with cryptococcosis and candidiasis may reflect the use of new antifungal agents such as fluconazole.			SELIK, RM (corresponding author), CTR DIS CONTROL & PREVENT, MAIL STOP E47, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							BEAMAN MH, 1992, ANN INTERN MED, V117, P163, DOI 10.7326/0003-4819-117-2-163; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; KOCHANEK KD, 1995, MONTHLY VITAL STATIS, V43, P70; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; NELSON MR, 1994, AIDS, V8, P651, DOI 10.1097/00002030-199405000-00011; PARENTE F, 1994, AM J GASTROENTEROL, V89, P416; SAAH AJ, 1995, JAMA-J AM MED ASSOC, V273, P1197, DOI 10.1001/jama.273.15.1197; SAMET JH, 1994, AM J MED, V97, P347, DOI 10.1016/0002-9343(94)90301-8; SELIK RM, 1987, AIDS, V1, P175; 1989, SAS P243 SAS I INC T, P1351; [No title captured]; 1994, MMWR-MORBID MORTAL W, V43, P826	20	105	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					933	936		10.7326/0003-4819-123-12-199512150-00006	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486488				2022-12-01	WOS:A1995TK12000006
J	STEPHENS, DS; HAJJEH, RA; BAUGHMAN, WS; HARVEY, RC; WENGER, JD; FARLEY, MM				STEPHENS, DS; HAJJEH, RA; BAUGHMAN, WS; HARVEY, RC; WENGER, JD; FARLEY, MM			SPORADIC MENINGOCOCCAL DISEASE IN ADULTS - RESULTS OF A 5-YEAR POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Note							IMMUNODEFICIENCY; MENINGITIS; INFECTION	Objective: To define the incidence, demographics, clinical features, and risk factors for sporadic meningococcal disease in adults (greater than or equal to 18 years) residing in metropolitan Atlanta. Design: Prospective, population-based surveillance, with retrospective review of clinical and laboratory records. Setting: Eight-county metropolitan Atlanta area. Patients: All adult patients in whom Neisseria meningitidis was isolated from normally sterile sites (blood, cerebrospinal fluid) during the period 1 December 1988 to 30 November 1993. Measurements: Incidence, relative risk, clinical and laboratory parameters, and serogroup of meningococcal isolates. Results: For the 5-year period, 44 (33%) of 132 cases of meningococcal disease in Atlanta occurred in adults (annual incidence, 0.50/100 000 adults per year). Twenty-three (52%) of the 44 adults presented without rash or meningitis, the two most obvious signs of meningococcal disease. Pneumonia, sinusitis, or purulent tracheobronchitis, but without rash, were the likely sources of meningococcal bacteremia in 15 (34%) of the 44 adults. Twelve of the 15 patients with meningococcal respiratory infection were older than 50 years of age or were immunocompromised (or both), and three fourths of the 15 patients had disease caused by serogroups B, Y, and W-135. Overall, two thirds of adults older than 24 years of age with meningococcal disease had one or more immunocompromising conditions (for example, low complement 50 level [CH50], corticosteroid use, congestive heart failure, multiple myeloma, human immunodeficiency virus infection). Meningococcemia or meningococcal meningitis, often caused by serogroup C, were the presentations in 14 of 15 adults 18 to 24 years old; only 2 had an identified underlying condition. Conclusions: In this 5-year population-based study, one third of all cases of sporadic meningococcal disease occurred in adults. Over half of the adults presented without rash or meningitis. Pneumonia, sinusitis, and tracheobronchitis are important sources of bacteremic meningococcal disease, especially in immunocompromised patients and elderly persons.	CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	STEPHENS, DS (corresponding author), EMORY UNIV, SCH MED, VET AFFAIRS MED CTR, ATLANTA, GA 30322 USA.		Stephens, David S/A-8788-2012					APICELLA MA, 1995, PRINCIPLES PRACTICE, P1896; BANKS JS, 1948, LANCET, P635; BENOIT FL, 1963, AM J MED, V35, P103, DOI 10.1016/0002-9343(63)90167-0; COHEN MS, 1979, ANN INTERN MED, V91, P7, DOI 10.7326/0003-4819-91-1-7; ELLISON RT, 1983, NEW ENGL J MED, V308, P913, DOI 10.1056/NEJM198304213081601; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; FARLEY MM, 1993, NEW ENGL J MED, V328, P1807, DOI 10.1056/NEJM199306243282503; IRWIN RS, 1975, ANN INTERN MED, V82, P493, DOI 10.7326/0003-4819-82-4-493; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; JURADO RL, 1993, CLIN INFECT DIS, V17, P224, DOI 10.1093/clinids/17.2.224; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; NITTA AT, 1993, AIDS, V7, P87, DOI 10.1097/00002030-199301000-00013; PINNER RW, 1992, J INFECT DIS, V166, P359, DOI 10.1093/infdis/166.2.359; SALTZMAN RL, 1987, REV INFECT DIS, V9, P1127; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; WITT D, 1982, AM REV RESPIR DIS, V125, P255; WOLF RE, 1968, AM J MED, V44, P243, DOI 10.1016/0002-9343(68)90156-3; WOODS CR, 1994, J INFECT DIS, V170, P453, DOI 10.1093/infdis/170.2.453; 1995, MMWR-MORBID MORTAL W, V44, P121	20	83	86	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1995	123	12					937	940		10.7326/0003-4819-123-12-199512150-00007	http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK120	7486489				2022-12-01	WOS:A1995TK12000007
J	ANNAS, GJ				ANNAS, GJ			WOMEN AND CHILDREN FIRST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				KIPLING R, 1940, COMPLETE VERSE DEFIN, P432; KRAUTHAMMER C, 1995, WASHINGTON POST 0203, pA19; MAIER T, 1995, NEWSDAY         0622, P6; NORDHEIMER J, 1995, NY TIMES        0606, pB1; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; ROVNER J, 1995, LANCET, V346, P171, DOI 10.1016/S0140-6736(95)91219-3; SIMPSON AWB, 1984, CANNIBALISM COMMON L, P97; WERTZ RW, 1977, LYING IN HIST CHILDB; 1995, HOSPITAL LENGTH STAY; 1995, AM MED NEWS     0807, P13; 1995, MMWR-MORBID MORTAL W, V44, P335	11	44	45	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1647	1651		10.1056/NEJM199512143332420	http://dx.doi.org/10.1056/NEJM199512143332420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477216				2022-12-01	WOS:A1995TK06500032
J	CARRERA, MRA; ASHLEY, JA; PARSONS, LH; WIRSCHING, P; KOOB, GF; JANDA, KD				CARRERA, MRA; ASHLEY, JA; PARSONS, LH; WIRSCHING, P; KOOB, GF; JANDA, KD			SUPPRESSION OF PSYCHOACTIVE EFFECTS OF COCAINE BY ACTIVE IMMUNIZATION	NATURE			English	Article							AMPHETAMINE; APOMORPHINE; METABOLISM; SEROTONIN; MORPHINE; NEURONS; HUMANS; MICE; RATS	COCAINE is a powerfully addictive substance and new strategies are needed to treat its abuse. Generating an active immunization(1,2) to cocaine offers a means of blocking the actions of the drug by preventing it from entering the central nervous system, and should have fewer side effects than treatments based on manipulation of central neurotransmitter function. The design and preparation of a cocaine immunogen requires special regard for the stability of cocaine both free and as a haptenic determinant. Immunochemistry and a well defined behavioural model were brought together to address the problem of inactivation of the psychostimulant actions of cocaine. We report here that active immunization with a new, stable cocaine conjugate suppressed locomotor activity and stereotyped behaviour in rats induced by cocaine but not by amphetamine, Moreover, following acute injection of cocaine, levels of cocaine in the striatum and cerebellum of the immunized animals were lower than those of control animals, These results suggest that immunopharmacotherapy may be a promising means by which to explore new treatments for cocaine abuse.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute								BAGASRA O, 1992, IMMUNOPHARMACOLOGY, V23, P173, DOI 10.1016/0162-3109(92)90023-6; BENUCK M, 1987, J PHARMACOL EXP THER, V243, P144; BERKOWITZ B, 1972, SCIENCE, V178, P1290, DOI 10.1126/science.178.4067.1290; CUNNINGHAM KA, 1990, NEUROPSYCHOPHARMACOL, V3, P41; EISEN HN, 1964, METHOD MED RES, P106; FISCHMAN MW, 1983, PHARMACOL BIOCHEM BE, V18, P123, DOI 10.1016/0091-3057(83)90261-7; FRAY PJ, 1980, PSYCHOPHARMACOLOGY, V69, P253, DOI 10.1007/BF00433091; GALLACHER G, 1994, IMMUNOPHARMACOLOGY, V27, P79, DOI 10.1016/0162-3109(94)90009-4; GARRETT ER, 1983, J PHARM SCI, V72, P258, DOI 10.1002/jps.2600720314; GOLD LH, 1988, PHARMACOL BIOCHEM BE, V29, P645, DOI 10.1016/0091-3057(88)90034-2; HILL JH, 1973, CLIN EXP IMMUNOL, V15, P213; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KELLY PH, 1976, EUR J PHARMACOL, V40, P45, DOI 10.1016/0014-2999(76)90352-6; KULLBACK S, 1968, INFORMATION THEORY S; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; LYON M, 1975, CURRENT DEV PSYCHOPH, V2, P89; MATSUBARA K, 1984, FORENSIC SCI INT, V26, P169, DOI 10.1016/0379-0738(84)90215-9; MINDEN P, 1967, HDB EXPT IMMUNOLOGY, P463; MISRA AL, 1976, RES COMMUN CHEM PATH, V13, P579; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBBINS TW, 1977, HDB PSYCHOPHARMACOLO, V7, P37; SPECTOR S, 1973, PHARMACOL REV, V25, P281; Steward M.W., 1983, ANTIBODY AFFINITY TH; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; Taussig M J, 1973, Curr Top Microbiol Immunol, V60, P125	26	170	180	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					727	730		10.1038/378727a0	http://dx.doi.org/10.1038/378727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501020				2022-12-01	WOS:A1995TK37900055
J	JONTES, JD; WILSONKUBALEK, EM; MILLIGAN, RA				JONTES, JD; WILSONKUBALEK, EM; MILLIGAN, RA			A 32-DEGREES TAIL SWING IN BRUSH-BORDER MYOSIN-I ON ADP RELEASE	NATURE			English	Article							MUSCLE-CONTRACTION; ACTOMYOSIN ATPASE; EPITHELIAL-CELLS; ACTIN; CALMODULIN; PROTEIN; COMPLEX; ORGANIZATION; CYTOSKELETON; MECHANISM	BRUSH border myosin I (BBMI) is a single-headed, unconventional myosin from intestinal microvilli, composed of a heavy chain of relative molecular mass 119,000 (M(r) 119K) and three calmodulin light chains(1-3). Although believed to have a largely structural role, it exhibits the normal actin-activated ATPase and motility properties of a member of the myosin superfamily(4,5). Here we present three-dimensional maps of BBMI-decorated actin filaments with and without bound MgADP. While the motor domain remains in a state similar to rigor, the light-chain-binding domain swings through similar to 32 degrees, resulting in a similar to 50-Angstrom movement at the end of the region visualized (the second calmodulin light chain). This could correspond to similar to 72-Angstrom movement of the entire domain, Although qualitatively similar to the movement observed in myosin II6, the magnitude of the change is sufficiently different to suggest that structural changes during the actomyosin ATPase cycle differ among myosins, possibly reflecting adaptation for specialized functional demands.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BRENNER B, 1987, ANNU REV PHYSIOL, V49, P655; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DRENCKHAHN D, 1988, J CELL BIOL, V107, P1037, DOI 10.1083/jcb.107.3.1037; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; Hill T.L., 1974, Progress Biophys Molec Biol, V28, P267, DOI 10.1016/0079-6107(74)90020-0; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MC, 1988, J MOL BIOL, V204, P357, DOI 10.1016/0022-2836(88)90582-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; [No title captured]	26	166	167	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					751	753		10.1038/378751a0	http://dx.doi.org/10.1038/378751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501027				2022-12-01	WOS:A1995TK37900062
J	KOEKEMOER, AM; HENKEL, C; GREENHILL, LJ; DEY, A; VANBREUGEL, W; ANTONUCCI, R; CODELLA, C				KOEKEMOER, AM; HENKEL, C; GREENHILL, LJ; DEY, A; VANBREUGEL, W; ANTONUCCI, R; CODELLA, C			A WATER-VAPOR GIGA-MASER IN THE ACTIVE GALAXY TXFS2226-184	NATURE			English	Article							STAR-FORMING REGIONS; GALACTIC NUCLEI; H2O MASERS; EMISSION; NGC-3079	ACTIVE galactic nuclei are thought to be powered by gas falling into a massive black hole; the different types of active galaxy mag arise because we view them through a thick torus of molecular gas at varying angles of inclination(1). One way to determine whether the black hole is surrounded by a torus, which would obscure the accretion disk around the black hole along certain lines of sight, is to search for water masers, as these exist only in regions with plentiful molecular gas. Since the first detection(2) of an extragalactic water maser in 1979, they have come to be associated primarily with active galaxies, and have even been used to probe the mass of the central engine(3). Here we report the detection of a water giga-maser in the radio galaxy TXFS2226-184. The strength of the emission supports a recently proposed theory of maser pumping(4) that allows for even more powerful masers, which might be detectable at cosmological distances. Water masers may accordingly provide a may to determine distances to galaxies outside the usual distance ladder, providing an independent calibration of the Hubble constant(3,5).	MAX PLANCK INST RADIOASTRON,D-53121 BONN,GERMANY; HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; UNIV CALIF BERKELEY,DEPT ASTRON,BERKELEY,CA 94720; LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106	Max Planck Society; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Barbara	KOEKEMOER, AM (corresponding author), MT STROMLO & SIDING SPRING OBSERV,WESTON,ACT 2611,AUSTRALIA.		Koekemoer, Anton M./F-8400-2014; Codella, Claudio/AAB-2539-2021	Koekemoer, Anton M./0000-0002-6610-2048; Codella, Claudio/0000-0003-1514-3074				ANTONUCCI RRJ, 1985, ASTROPHYS J, V297, P621, DOI 10.1086/163559; BAARS JWM, 1977, ASTRON ASTROPHYS, V61, P99; BARTHEL PD, 1989, ASTROPHYS J, V336, P606, DOI 10.1086/167038; BICAY MD, 1990, ASTROPHYS J, V362, P59, DOI 10.1086/169243; BRAATZ JA, 1994, ASTROPHYS J, V437, pL99, DOI 10.1086/187692; BRAATZ JA, 1995, P OXF TOR WORKSH, P77; BURDYUZHA VV, 1990, ASTRON ASTROPHYS, V234, P40; CLAUSSEN MJ, 1984, NATURE, V310, P298, DOI 10.1038/310298a0; CLAUSSEN MJ, 1986, ASTROPHYS J, V308, P592, DOI 10.1086/164529; DOSSANTOS PM, 1979, NATURE, V278, P34, DOI 10.1038/278034a0; ELITZUR M, 1992, ASTROPHYS J, V394, P221, DOI 10.1086/171574; ELITZUR M, 1989, ASTROPHYS J, V346, P983, DOI 10.1086/168080; FALCKE H, 1995, ASTRON ASTROPHYS, V298, P395; GREENHILL LJ, 1995, ASTROPHYS J, V440, P619, DOI 10.1086/175301; GREENHILL LJ, 1993, ASTROPHYS J, V406, P482, DOI 10.1086/172460; GREENHILL LJ, 1990, ASTROPHYS J, V364, P513, DOI 10.1086/169433; GREENHILL LJ, IN PRESS ASTR ASTROP; HASCHICK AD, 1985, NATURE, V314, P144, DOI 10.1038/314144a0; HASCHICK AD, 1994, ASTROPHYS J, V437, pL35, DOI 10.1086/187676; HASCHICK AD, 1990, ASTROPHYS J, V356, P149, DOI 10.1086/168825; Heckman T. M., 1980, Astronomy & Astrophysics Supplement Series, V40, P295; HENKEL C, 1990, ASTRON ASTROPHYS, V229, P431; HENKEL C, 1984, ASTRON ASTROPHYS, V141, pL1; HO PTP, 1987, ASTROPHYS J, V320, P663, DOI 10.1086/165583; MAOZ E, 1995, ASTROPHYS J, V447, pL91, DOI 10.1086/175250; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; NEUFELD DA, 1994, ASTROPHYS J, V436, pL127, DOI 10.1086/187649; NEUFELD DA, 1995, ASTROPHYS J, V447, pL17, DOI 10.1086/309553; OTT M, 1994, ASTRON ASTROPHYS, V284, P331; PADOVANI P, 1991, ASTROPHYS J, V368, P373, DOI 10.1086/169701; SHLOSMAN I, 1990, NATURE, V345, P679, DOI 10.1038/345679a0	31	44	46	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					697	699		10.1038/378697a0	http://dx.doi.org/10.1038/378697a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501016				2022-12-01	WOS:A1995TK37900044
J	LI, M; SENDTNER, M; SMITH, A				LI, M; SENDTNER, M; SMITH, A			ESSENTIAL FUNCTION OF LIF RECEPTOR IN MOTOR-NEURONS	NATURE			English	Article							LEUKEMIA-INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; EMBRYONIC MOTONEURONS; CNTF RECEPTOR; ONCOSTATIN-M; STEM-CELLS; SURVIVAL; RAT; DEGENERATION; EXPRESSION	DEVELOPMENT and maintenance of the mammalian nervous system is dependent upon neurotrophic cytokines. One class of neurotrophic factor acts through receptor complexes involving the low-affinity leukaemia inhibitory factor receptor subunit (LIF-R)(1-3). Members of this family of cytokines, such as ciliary neurotrophic factor (CNTF) and leukaemia inhibitory factor (LIF), have profound effects on the survival and maintenance of motor neurons(4-10). Recently it was reported that mice lacking LIF-R die shortly after birth(11) unlike mice lacking CNTF or LIF which are viable. Here we describe histopathological analyses of lifr mutants that reveal a loss >35% of facial motor neurons, 40% of spinal motor neurons and 50% of neurons in the nucleus ambiguus. These findings point to the existence of a ligand for LIF-R that is required for the normal development of motor neurons in both brainstem nuclei and spinal cord.	UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV WURZBURG,DEPT NEUROL,CLIN RES UNIT NEUROREGENERAT,D-97080 WURZBURG,GERMANY	University of Edinburgh; University of Wurzburg			Sendtner, Michael/M-8137-2014; Li, Meng/I-6941-2013; Sendtner, Michael/J-1542-2012	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Smith, Austin/0000-0002-3029-4682				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; PATON JFR, 1994, PFLUG ARCH EUR J PHY, V428, P250, DOI 10.1007/BF00724504; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; RICHARDS LJ, 1992, J NEUROSCI RES, V33, P476, DOI 10.1002/jnr.490330314; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Smith A., 1991, J TISSUE CULTURE MET, V13, P89, DOI [10.1007/bf01666137, DOI 10.1007/BF01666137]; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; ZURN AD, 1994, DEV BIOL, V163, P309, DOI 10.1006/dbio.1994.1150	26	263	268	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					724	727		10.1038/378724a0	http://dx.doi.org/10.1038/378724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501019	Green Submitted			2022-12-01	WOS:A1995TK37900054
J	LINGUEGLIA, E; CHAMPIGNY, G; LAZDUNSKI, M; BARBRY, P				LINGUEGLIA, E; CHAMPIGNY, G; LAZDUNSKI, M; BARBRY, P			CLONING OF THE AMILORIDE-SENSITIVE FMRFAMIDE PEPTIDE-GATED SODIUM-CHANNEL	NATURE			English	Article							CAENORHABDITIS-ELEGANS; RECEPTOR; BRAIN; NEURODEGENERATION; EXPRESSION	THE peptide Phe-Met-Arg-Phe-NH2 (FMRFamide) and structurally related peptides are present both in invertebrate and vertebrate nervous systems(1,2). Although they constitute a major class of invertebrate peptide neurotransmitters(3), the molecular structure of their receptors has not yet been identified, In neurons of the snail Helix aspersa(4), as well as in Aplysia bursting(5) and motor(6) neurons, FMRFamide induces a fast excitatory depolarizing response due to direct activation of an amiloride-sensitive Na+ channel(4). We have now isolated a complementary DNA from Helix nervous tissue; when expressed in Xenopus oocytes, it encodes an FMRF-amide-activated Na+ channel (FaNaCh) that can be blocked by amiloride. The corresponding protein shares a very low sequence identity with the previously cloned epithelial Na+ channel subunits(7-12) and Caenorhabditis elegans degenerins(13-15), but it displays the same overall structural organization. To our knowledge, this is the first characterization of a peptide-gated ionotropic receptor.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Barbry, Pascal/O-5021-2016; LINGUEGLIA, Eric/F-5509-2013	Barbry, Pascal/0000-0001-9632-6483; LINGUEGLIA, Eric/0000-0003-3902-3405				BELKIN KJ, 1993, J NEUROSCI, V13, P5139, DOI 10.1523/JNEUROSCI.13-12-05139.1993; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; COTTRELL GA, 1993, COMP MOL NEUROBIOL, V63, P279; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARTY H, 1994, FASEB J, V8, P523; GREEN KA, 1994, PFLUG ARCH EUR J PHY, V428, P232, DOI 10.1007/BF00724502; GREENBERG MJ, 1992, PROG BRAIN RES, V92, P25, DOI 10.1016/S0079-6123(08)61162-0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.physiol.54.1.51; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RAFFA RB, 1988, PEPTIDES, V9, P915, DOI 10.1016/0196-9781(88)90141-6; RENARD S, 1994, J BIOL CHEM, V269, P12981; RUBEN P, 1986, J NEUROSCI, V6, P252; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	30	338	344	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					730	733		10.1038/378730a0	http://dx.doi.org/10.1038/378730a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501021				2022-12-01	WOS:A1995TK37900056
J	OLSEN, JH; BOICE, JD; SEERSHOLM, N; BAUTZ, A; FRAUMENI, JF				OLSEN, JH; BOICE, JD; SEERSHOLM, N; BAUTZ, A; FRAUMENI, JF			CANCER IN THE PARENTS OF CHILDREN WITH CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOFT-TISSUE SARCOMA; CHILDHOOD-CANCER; BREAST-CANCER; RETINOBLASTOMA PATIENTS; RELATIVES; RISK; MORTALITY; SURVIVORS; FAMILIES; MOTHERS	Background. Certain types of cancer in children and young adults have been linked with an increased risk of cancer in close relatives. However, the relation between childhood cancer and familial risk remains to be fully assessed in population-based studies. Methods. We conducted a nationwide study in Denmark of 11,380 parents of children with cancer. The children were identified from records in the Danish Cancer Registry; their parents were identified from population registers. The occurrence and rate of cancer in the parents were determined with use of the Cancer Registry's files and compared with national incidence rates for various categories of tumor. Results. Overall, 1445 cancers were diagnosed in the parents, as compared with 1496 expected from national incidence rates, to yield standardized incidence ratios of 1.0 (95 percent confidence interval, 0.9 to 1.0) for all parents, 1.0 for mothers, and 0.9 for fathers. The lower rate of cancer among fathers reflected their lower standardized incidence ratio for lung cancer (0.8; 95 percent confidence interval, 0.6 to 0.9), as calculated from 114 observations. Conclusions. Genetic determinants are important in several types of childhood cancer, but the genetic susceptibility to tumors does not generally extend to the parents of children with cancer, nor do the patterns of incidence point to the influence of shared environmental factors. Thus, cancer in children should not be viewed as a general marker for an increased risk of cancer in the patients' parents.	NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				[Anonymous], 1976, INT CLASSIFICATION D; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BIRCH JM, 1984, BRIT J CANCER, V49, P325, DOI 10.1038/bjc.1984.51; BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; BURKE E, 1991, CANCER-AM CANCER SOC, V67, P1467, DOI 10.1002/1097-0142(19910301)67:5<1467::AID-CNCR2820670535>3.0.CO;2-4; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; GARBER JE, 1991, CANCER RES, V51, P6094; GRUNDY GW, 1973, JNCI-J NATL CANCER I, V51, P767, DOI 10.1093/jnci/51.3.767; HARTLEY AL, 1993, CANCER, V72, P923, DOI 10.1002/1097-0142(19930801)72:3<923::AID-CNCR2820720343>3.0.CO;2-Y; HARTLEY AL, 1986, BRIT J CANCER, V54, P819, DOI 10.1038/bjc.1986.245; HAYASAKA S, 1986, BRIT J OPHTHALMOL, V70, P107, DOI 10.1136/bjo.70.2.107; Jensen O M, 1985, Natl Cancer Inst Monogr, V68, P245; KNUDSON AG, 1985, CANCER RES, V45, P1437; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MATTHIESSEN PC, 1984, GROWTH POPULATION CA; MOUTOU C, 1994, J MED GENET, V31, P429, DOI 10.1136/jmg.31.6.429; OLSEN JH, 1990, HUM GENET, V85, P283; PASTORE G, 1987, CANCER LETT, V37, P17, DOI 10.1016/0304-3835(87)90141-8; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; ROTHMAN K, 1979, DHHS NIH791649 PUBL; SEVERSON RK, 1993, CANCER EPIDEM BIOMAR, V2, P433; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; THOMPSON EN, 1988, BRIT J CANCER, V57, P127, DOI 10.1038/bjc.1988.25; 1957, MANUAL INT STATISTIC	32	77	79	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1594	1599		10.1056/NEJM199512143332403	http://dx.doi.org/10.1056/NEJM199512143332403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477194				2022-12-01	WOS:A1995TK06500003
J	PERILLO, NL; PACE, KE; SEILHAMER, JJ; BAUM, LG				PERILLO, NL; PACE, KE; SEILHAMER, JJ; BAUM, LG			APOPTOSIS OF T-CELLS MEDIATED BY GALECTIN-1	NATURE			English	Article							GALACTOSIDE-BINDING-PROTEIN; DEATH; ADHESION; IDENTIFICATION; GLYCOSYLATION; BIOSYNTHESIS; GALAPTIN; CD45	GALECTIN-1, a member of the family of beta-galactoside binding proteins(1), has growth regulatory and immunomodulatory activities(2-4). We report here that galectin-1, expressed by stromal cells in human thymus and lymph nodes(5,6), is present at sites of cell death by apoptosis during normal T-cell development and maturation, Galectin-1 induced apoptosis of activated human T cells and human T leukaemia cell lines. Resting T cells also bound galectin-1, but did not undergo apoptosis. Human endothelial cells that expressed galectin-1 induced apoptosis of bound T cells. Galectin-1-induced apoptosis required expression of CD45, and was decreased when N-glycan elongation was blocked by treatment of the cells by swainsonine(7), whereas inhibition of O-glycan elongation(8) potentiated the apoptotic effect of galectin-1. Induction of apoptosis by an endogenous mammalian lectin represents a new mechanism for regulating the immune response.	UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90095 USA; INCYTE PHARMACEUT INC, PALO ALTO, CA 94304 USA	University of California System; University of California Los Angeles; Incyte								ALLEN HJ, 1990, J CELL BIOCHEM, V43, P43, DOI 10.1002/jcb.240430105; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; HARRISON FL, 1980, FEBS LETT, V122, P157, DOI 10.1016/0014-5793(80)80428-5; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEVI G, 1983, EUR J IMMUNOL, V13, P500, DOI 10.1002/eji.1830130613; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; ONG CJ, 1994, J IMMUNOL, V152, P3793; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TRAUTH BC, 1994, SCIENCE, V245, P150; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WESSELBORG S, 1993, J IMMUNOL, V150, P4338	30	903	931	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					736	739		10.1038/378736a0	http://dx.doi.org/10.1038/378736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501023				2022-12-01	WOS:A1995TK37900058
J	RAMIREZSOLIS, R; LIU, PT; BRADLEY, A				RAMIREZSOLIS, R; LIU, PT; BRADLEY, A			CHROMOSOME ENGINEERING IN MICE	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; GENE; DROSOPHILA; GENOME; TUMORS	CHROMOSOMAL rearrangements are the major cause of inherited human disease and fetal loss(1). Translocations(2) and loss of heterorygosity(3) are important genetic changes causally involved in neoplasia. Chromosomal variants, such as deficiencies, are commonly exploited in genetic screens in organisms such as Dlosophila because a small portion of the genome is functionally hemizygous(4) In the mouse, deficiencies are not generally available, thus genetic screens for recessive mutations are cumbersome(5). We report here that defined deficiencies, inversions and duplications extending to 3-4 cM can be constructed in embryonic stem cells, This was achieved by consecutive targeting of loxP recombination substrates to thf end points of a genetic interval followed by Cre-induced recombination, This reconstructs a positive selectable marker which facilitates direct selection of clones with a chromosome structure specific to the relative orientation of the loxP sites, Duplication and deletion alleles have been transmitted into the mouse germ line. The availability of mice with defined regions of segmental haploidy will allow their use in genetic screens and enable accurate models of human 'chromosomal' diseases to be generated.	BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839; Ramirez-Solis, Ramiro/0000-0003-4182-173X				CROPP CS, 1994, CANCER RES, V54, P2548; Epstein C.J, 1986, CONSEQUENCES CHROMOS; FULLER PJ, 1987, MOL ENDOCRINOL, V1, P306, DOI 10.1210/mend-1-4-306; GAO X, 1995, CANCER RES, V55, P1002; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MEDBERRY SL, 1995, NUCLEIC ACIDS RES, V23, P485, DOI 10.1093/nar/23.3.485; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORI T, 1994, CANCER RES, V54, P1638; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Rinchik E.M., 1990, GENOME ANAL, P121; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SAITO H, 1993, CANCER RES, V53, P3382; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; ZHANG HB, 1994, MOL CELL BIOL, V14, P2404, DOI 10.1128/MCB.14.4.2404	30	394	437	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					720	724		10.1038/378720a0	http://dx.doi.org/10.1038/378720a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501018				2022-12-01	WOS:A1995TK37900053
J	RAO, ZH; BELYAEV, AS; FRY, E; ROY, P; JONES, IM; STUART, DI				RAO, ZH; BELYAEV, AS; FRY, E; ROY, P; JONES, IM; STUART, DI			CRYSTAL-STRUCTURE OF SIV MATRIX ANTIGEN AND IMPLICATIONS FOR VIRUS ASSEMBLY	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS; PROTEIN	SIMIAN immunodeficiency virus (SIV) is closely related to human immunodeficiency virus (HIV)(1), their matrix antigens (MAs) sharing some 50% sequence identity. MA is a component of Pr55Gag, the sole protein required for assembly of the virion shell(2). MA targets Pr55 to the plasma membrane(3), and facilitates incorporation of the virus envelope protein(4) and assembly of the Pr55Gag shell(5). Cleavage of Pr55 by the viral protease produces the mature protein of relative molecular mass 17-18K, which underlies the host-derived membrane and is important in both virus entry(6) and nuclear localization of the virion core(7). Here we report the crystal structure of SIV MA. The molecule forms a trimer consistent with oligomerization in vitro(8), the observed virion architecture(9), and various biological properties of MA.	UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND; UNIV ALABAMA,SCH PUBL HLTH,BIRMINGHAM,AL 35294; OXFORD CTR MOLEC SCI,OXFORD OX1 3QT,ENGLAND	University of Oxford; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Alabama System; University of Alabama Birmingham; University of Oxford			Rao, Zihe/HCH-6944-2022	Roy, Polly/0000-0001-6535-6911; Fry, Elizabeth/0000-0001-9754-5303; Stuart, David/0000-0002-3426-4210				BELYAEV AS, 1994, J MOL BIOL, V241, P744, DOI 10.1006/jmbi.1994.1550; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DELACHAMBRE M, 1989, EMBO J, V8, P2653; EHRLICH LS, 1994, VIROLOGY, V204, P515, DOI 10.1006/viro.1994.1565; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Fry E, 1990, SEMIN VIROL, V1, P439; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVINE M, 1984, ACTA CRYSTALLOGR A, V40, P600, DOI 10.1107/S0108767384001239; MASSIAH MA, 1994, J MOL BIOL, V244, P194; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORIKAWA Y, 1995, J VIROL, V69, P4519, DOI 10.1128/JVI.69.7.4519-4523.1995; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P1; PRONGAY AJ, 1990, P NATL ACAD SCI USA, V87, P9980, DOI 10.1073/pnas.87.24.9980; SMITH TJ, 1986, SCIENCE, V233, P1233; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993	29	174	174	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					743	747		10.1038/378743a0	http://dx.doi.org/10.1038/378743a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501025				2022-12-01	WOS:A1995TK37900060
J	RENAUD, JP; ROCHEL, N; RUFF, M; VIVAT, V; CHAMBON, P; GRONEMEYER, H; MORAS, D				RENAUD, JP; ROCHEL, N; RUFF, M; VIVAT, V; CHAMBON, P; GRONEMEYER, H; MORAS, D			CRYSTAL-STRUCTURE OF THE RAR-GAMMA LIGAND-BINDING DOMAIN BOUND TO ALL-TRANS-RETINOIC ACID	NATURE			English	Article							NUCLEAR RECEPTOR; IDENTIFICATION; ACTIVATION; DNA	The 2.0-Angstrom crystal structure of the ligand-binding domain (LED) of the human retinoic acid receptor (RAR)-gamma bound to all-trans retinoic acid reveals the ligand-binding interactions and suggests an electrostatic guidance mechanism. The overall fold is similar to that of the human RXR-alpha apo-LBD, except for the carboxy-terminal part which folds back towards the LED core, contributing to the hydrophobic ligand pocket and 'sealing' its entry site. We propose a 'mouse trap' mechanism whereby a ligand-induced conformational transition repositions the amphipathic alpha-helix of the AF-2 activating domain and forms a transcriptionally active receptor.	UNIV STRASBOURG 1,COLL FRANCE,CNRS,INSERM,INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/H-7002-2016; Renaud, Jean-Paul/AAM-4879-2020; Rochel, Natacha/A-5718-2016; ruff, marc/J-3011-2013; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011	Gronemeyer, Hinrich/0000-0001-9454-2449; Renaud, Jean-Paul/0000-0001-9180-5426; Rochel, Natacha/0000-0002-3573-5889; ruff, marc/0000-0001-5451-6377; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				ALLENBY G, 1994, J BIOL CHEM, V269, P16689; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BAUR EV, IN PRESS EMBO J; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; WURTZ JM, IN PRESS NATURE STRU; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	49	987	1003	4	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					681	689		10.1038/378681a0	http://dx.doi.org/10.1038/378681a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501014				2022-12-01	WOS:A1995TK37900042
J	SCHIAVO, G; GMACHL, MJS; STENBECK, G; SOLLNER, TH; ROTHMAN, JE				SCHIAVO, G; GMACHL, MJS; STENBECK, G; SOLLNER, TH; ROTHMAN, JE			A POSSIBLE DOCKING AND FUSION PARTICLE FOR SYNAPTIC TRANSMISSION	NATURE			English	Article							SECRETION; PROTEINS; FAMILY; STEPS	SEVERAL proteins have been implicated in the rapid (millisecond) calcium-controlled release of transmitters at nerve endings(1,2), including soluble N-ethylmaleimide-sensitive fusion protein (NSF3-5) and soluble NSF attachment protein (alpha-SNAP(3,6)), the synaptic SNAP receptor (SNARE)(3,7) and the calcium-binding protein synaptotagmin(2), which may function as a calcium sensor in exocytosis(8). A second SNAP isoform (beta-SNAP), which is 83% identical to alpha-SNAP, is highly expressed in brain(9), but its role is still unclear. Here we show that these proteins assemble cooperatively to form a docking and fusion complex. beta-SNAP (but not alpha-SNAP) binds synaptotagmin and recruits NSF, indicating that the complex may link the process of membrane fusion to calcium entry by attaching a specialized fusion protein (beta-SNAP) to a calcium sensor (synaptotagmin). Polyphosphoinositols that block transmitter release, inositol 1,3,4,5-tetrakisphosphate (InsP(4)), inositol 1,3,4,5,6-pentakisphosphate (InsP(5)) and inositol 1,2,3,4,5,6-hexakisphosphate (InsP(6)), also block the assembly of the particle by preventing beta-SNAP from binding to synaptotagmin.			SCHIAVO, G (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Schiavo, Giampietro/0000-0002-4319-8745				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1993, NEURON, V14, P893; SCHIAVO G, 1994, MOL MICROBIOL, V13, P1; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1994, CELL, V80, P929; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	26	161	163	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					733	736		10.1038/378733a0	http://dx.doi.org/10.1038/378733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501022				2022-12-01	WOS:A1995TK37900057
J	SHIOZAKI, K; RUSSELL, P				SHIOZAKI, K; RUSSELL, P			CELL-CYCLE CONTROL LINKED TO EXTRACELLULAR ENVIRONMENT BY MAP KINASE PATHWAY IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; PROTEIN PHOSPHATASE; MITOSIS	IN fission yeast the onset of mitosis is brought about by Cdc2/Cdc13 kinase, which is inhibited by the Wee1/Mik1 tyrosine kinases and activated by Cdc25 tyrosine phosphatase(1). This control network integrates many signals, including those that monitor DNA replication, DNA damage and cell size, We report here that a fission yeast MAP kinase pathway links the cell-cycle G(2)/M control with changes in the extracellular environment that affect cell physiology. Fission yeast spc1(-) mutants have a G(2) delay that is greatly exacerbated by growth in high osmolarity media and nutrient limitation. A lethal interaction of spc1 and cdc25 mutations shows that Spc1 promotes the onset of mitosis, Spc1 is a MAP kinase homologue that is activated by Wis1 kinase in response to osmotic stress and nutrient limitation, Spc1 is inactivated by Pyp1, a phosphatase previously identified as a mitotic inhibitor(2,3). Pyp1 dephosphorylates only tyrosine-173 of Spc1, unlike the dual-specificity phosphatases that have been shown to regulate other MAP kinases(4).	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Shiozaki, Kazuhiro/K-3440-2019	Shiozaki, Kazuhiro/0000-0002-0395-5457				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNIG G, 1994, P NATL ACAD SCI USA, V91, P10084, DOI 10.1073/pnas.91.21.10084; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	29	393	398	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					739	743		10.1038/378739a0	http://dx.doi.org/10.1038/378739a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501024				2022-12-01	WOS:A1995TK37900059
J	VOGEL, A; RODRIGUEZ, C; WARNKEN, W; BELMONTE, JCI				VOGEL, A; RODRIGUEZ, C; WARNKEN, W; BELMONTE, JCI			DORSAL CELL FATE SPECIFIED BY CHICK LMX1 DURING VERTEBRATE LIMB DEVELOPMENT	NATURE			English	Article							APICAL ECTODERMAL RIDGE; BUD; EMBRYO; DROSOPHILA; MESODERM; GENE	THE positional cues that govern the fate of cells along the dorsoventral axis of the developing vertebrate limb are established in the mesoderm before outgrowth of limb buds. In Drosophila, a LIM/homeodomain gene, apterous, expressed in the dorsal compartment of the wing disc, specifies dorsal cell fate(1,2). Here we report the isolation of a vertebrate LIM-homeodomain containing gene, Chick Lmx1 (C-Lmx1). Transcripts for C-Lmx1 are detected in the presumptive dorsal limb mesoderm and are restricted thereafter to the dorsal mesoderm of the developing chick bud. C-Lmx1 expression is regulated by the overlying ectoderm where Wnt7a messenger RNA is localized(3). Wnt7a, required for normal development of the dorsoventral axis in mouse limbs(4), can induce ectopic expression of C-Lmx1 in ventral mesoderm, Misexpression of C-Lmx1 during limb outgrowth causes ventral to dorsal transformations of limb mesoderm, We propose that C-Lmx1 specifies dorsal cell fate during chick limb development.			VOGEL, A (corresponding author), SALK INST BIOL STUDIES, GENE EXPRESS LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DHOUAILLY D, 1972, DEV BIOL, V28, P162, DOI 10.1016/0012-1606(72)90134-0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MCCABE JA, 1973, DEV BIOL, V31, P323, DOI 10.1016/0012-1606(73)90269-8; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PAUTOU MP, 1973, CR ACAD SCI D NAT, V277, P1225; SAUNDERS JW, 1976, DEV BIOL, V50, P16, DOI 10.1016/0012-1606(76)90063-4; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	23	248	252	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					716	720		10.1038/378716a0	http://dx.doi.org/10.1038/378716a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501017				2022-12-01	WOS:A1995TK37900052
J	WAGNER, RL; APRILETTI, JW; MCGRATH, ME; WEST, BL; BAXTER, JD; FLETTERICK, RJ				WAGNER, RL; APRILETTI, JW; MCGRATH, ME; WEST, BL; BAXTER, JD; FLETTERICK, RJ			A STRUCTURAL ROLE FOR HORMONE IN THE THYROID-HORMONE RECEPTOR	NATURE			English	Article							V-ERBA; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; DNA-BINDING; C-ERBA; SUPERFAMILY; REFINEMENT; ACTIVATION; MODEL	The crystal structure of the rat a, thyroid hormone receptor ligand-binding domain bound with a thyroid hormone agonist reveals that ligand is completely buried within the domain as part of the hydrophobic core. In addition, the carboxy-terminal activation domain forms an amphipathic helix, with its hydrophobic face constituting part of the hormone binding cavity. These observations suggest a structural role for ligand, in establishing the active conformation of the receptor, that is likely to underlie hormonal regulation of gene expression for the nuclear receptors.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; KHEPRI PHARMACEUT INC, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	WAGNER, RL (corresponding author), UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Wood, David W/B-2992-2012	West, Brian/0000-0002-5320-3691				APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; BHAT MK, 1995, BIOCHEM BIOPH RES CO, V210, P464, DOI 10.1006/bbrc.1995.1683; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHATTERJEE VKK, 1994, J CLIN ENDOCR METAB, V78, P990, DOI 10.1210/jcem.78.4.8157732; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen E.C., 1978, Hormonal Proteins and Peptides, V6, P107; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATHAM KR, 1981, J BIOL CHEM, V256, P2088; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MCGRATH ME, 1994, J MOL BIOL, V237, P236, DOI 10.1006/jmbi.1994.1224; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RATINEJAD F, 1995, NATURE, V375, P203; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SELMI S, 1991, J BIOL CHEM, V266, P11589; TONE Y, 1994, J BIOL CHEM, V269, P31157; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	49	771	795	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					690	697		10.1038/378690a0	http://dx.doi.org/10.1038/378690a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501015				2022-12-01	WOS:A1995TK37900043
J	WHITTAKER, M; WILSONKUBALEK, EM; SMITH, JE; FAUST, L; MILLIGAN, RA; SWEENEY, HL				WHITTAKER, M; WILSONKUBALEK, EM; SMITH, JE; FAUST, L; MILLIGAN, RA; SWEENEY, HL			A 35-ANGSTROM MOVEMENT OF SMOOTH-MUSCLE MYOSIN ON ADP RELEASE	NATURE			English	Article							CROSS-BRIDGE KINETICS; ACTOMYOSIN ATPASE; LIGHT CHAIN; CONTRACTION; ACTIN; FIBERS; PHOTOLYSIS; LOCATION; COMPLEX; BINDING	MYOSIN II crossbridges interact with F-actin producing power-strokes of around 100 Angstrom (refs 1, 2), during which the products of ATP hydrolysis are released(3,5). This has been postulated to involve an articulation of the myosin head (S1) on actin, or substantial conformational changes in S1 itself(6-8). Small movements of the regulatory light chain have been detected (see, for example, refs 9, 10), but most data suggest that the bulk of S1 does not move on actin during crossbridge cyclings(8,11). Here we present three-dimensional maps of S1-decorated F-actin in the presence and absence of MgADP. The myosin motor domain is similar in both states but there are major orientational differences in the chain-binding domain, This domain acts as a rigid level arm pivoting about the end of the motor domain and swinging similar to 23 degrees, resulting in a similar to 35-Angstrom step. Small, nucleotide-mediated conformational changes in the motor domain(14-16) may thus be converted by the light-chain domain into large movement steps.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania			Sweeney, H Lee/F-1862-2010					BRENNER B, 1987, ANNU REV PHYSIOL, V49, P655; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; DANTZIG JA, 1991, J PHYSIOL-LONDON, V432, P639, DOI 10.1113/jphysiol.1991.sp018405; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HAMBLY B, 1992, BIOPHYS J, V63, P1306, DOI 10.1016/S0006-3495(92)81717-4; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MILLIGAN RA, IN PRESS P NATN ACAD; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; SWEENEY HL, IN PRESS BIOPHYS J; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; [No title captured]	32	341	342	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					748	751		10.1038/378748a0	http://dx.doi.org/10.1038/378748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501026				2022-12-01	WOS:A1995TK37900061
J	AVORN, J; GURWITZ, JH; BOHN, RL; MOGUN, H; MONANE, M; WALKER, A				AVORN, J; GURWITZ, JH; BOHN, RL; MOGUN, H; MONANE, M; WALKER, A			INCREASED INCIDENCE OF LEVODOPA THERAPY FOLLOWING METOCLOPRAMIDE USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DRUG	Objective.-To determine whether there is an increase in use of antiparkinsonian therapy in older persons taking metoclopramide hydrochloride. Design.-Case-control study. Setting.-New Jersey Medicaid program. Patients.-Medicaid enrollees aged 65 years and older. Cases were patients newly prescribed a levodopa-containing medication (n=1253); a secondary case group were patients newly prescribed an anticholinergic antiparkinsonian drug (n=2377). The control group consisted of 16 435 Medicaid enrollees older than 65 years who were not users of any antiparkinsonian therapy. Main Outcome Measures.-We used logistic regression to determine the odds ratio (OR) for the initiation of antiparkinsonian therapy in patients using metoclopramide relative to nonusers, after adjusting for age, sex, race, nursing home residence, exposure to antipsychotic medication, and days hospitalized. Results.-Metoclopramide users were three times more likely to begin use of a levodopa-containing medication compared with nonusers (OR=3.09; 95% confidence interval [CI], 2.25 to 4.26). Risk increased with increasing daily metoclopramide dose: the OR was 1.19 (95% CI, 0.50 to 2.81) for more than 0 to 10 mg per day, 3.33 (95% CI, 1.98 to 5.58) for more than 10 to 20 mg per day, and 5.25 (95% CI, 1.16 to 8.50) for more than 20 mg per day. The effect persisted after adjustment for demographic, health service utilization, and medication use variables. The OR for initiation of anticholinergic antiparkinsonian drugs was also elevated in metoclopramide users. Conclusion.-Metoclopramide use confers an increased risk for the initiation of treatment generally reserved for the management of idiopathic Parkinson's disease. Such polypharmacy may represent the misdiagnosis of Parkinson's disease in patients with drug-induced parkinsonian symptoms, which should be ruled out before starting dopaminergic therapy for this condition.	HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	AVORN, J (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIA NIH HHS [AG09634] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009634] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avorn J, 1993, J Glaucoma, V2, P158; AVORN J, 1990, JAMA-J AM MED ASSOC, V263, P1823, DOI 10.1001/jama.263.13.1823; AVORN J, 1995, AM J MED, V99, P48, DOI 10.1016/S0002-9343(99)80104-1; AVORN J, 1990, GERIATRIC MED; BERKOW R, 1992, MERCK MANUAL DIAGNOS, P1283; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; DURAZO FA, 1993, AM J GASTROENTEROL, V88, P1657; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; GURWITZ JH, 1994, ARCH INTERN MED, V154, P97, DOI 10.1001/archinte.154.1.97; KALISH SC, 1995, J AM GERIATR SOC, V43, P967, DOI 10.1111/j.1532-5415.1995.tb05559.x; Koller W, 1987, Adv Neurol, V45, P317; MARTTILA RJ, 1976, ACTA NEUROL SCAND, V53, P81; MCEVOY GK, 1995, AHFS 95 DRUG INFORMA, P2042; SNAPE WJ, 1982, ANN INTERN MED, V96, P444, DOI 10.7326/0003-4819-96-4-444; 1993, MED LETT DRUGS THER, V35, P124	16	45	46	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1780	1782		10.1001/jama.274.22.1780	http://dx.doi.org/10.1001/jama.274.22.1780			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500509				2022-12-01	WOS:A1995TJ22500028
J	OBRIEN, LA; GRISSO, JA; MAISLIN, G; LAPANN, K; KROTKI, KP; GRECO, PJ; SIEGERT, EA; EVANS, LK				OBRIEN, LA; GRISSO, JA; MAISLIN, G; LAPANN, K; KROTKI, KP; GRECO, PJ; SIEGERT, EA; EVANS, LK			NURSING-HOME RESIDENTS PREFERENCES FOR LIFE-SUSTAINING TREATMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY-RESUSCITATION; DECISIONS; CARE	Objectives.-To determine life-sustaining treatment preferences among nursing home residents, whether information regarding cardiopulmonary resuscitation (CPR) affected these preferences, and with whom treatment preferences had been discussed, and to identify factors associated with CPR preferences. Design.-In-person survey. Setting.-Forty-nine randomly selected nursing homes. Subjects.-Four hundred twenty-one randomly selected nursing home residents capable of making decisions. Main Outcome Measures.-Preferences regarding CPR, hospitalization, and enteral tube feedings, and individual factors associated with CPR preferences. Results.-Of 1458 randomly selected nursing home residents assessed for the ability to participate in the study, 552 residents (38%) were eligible to participate and 421 agreed to be interviewed. Sixty percent of participants able to participate in the decision reported that they would elect CPR, 89% would choose hospitalization if seriously ill, and 33% would elect enteral tube feedings a no longer able to eat because of permanent brain damage. Individual factors associated with preferences for CPR included the following: African-American ethnicity, high self-reported physical mobility, belief that most important medical care decisions should be made by the doctor, moderate-to-severe impairment in daily decision-making skills, and not having a spouse. Fourteen percent changed their preference from preferring CPR to not preferring CPR after receiving additional information about CPR procedures. Twelve percent reported having discussed preferences with health care providers, and 31% discussed preferences with family members. Conclusions-More than half of nursing home residents capable of making decisions preferred the use of CPR. Few had discussed their preferences with health care providers. Individual preferences should be assessed when considering the use of life-sustaining treatments.	UNIV PENN,SCH NURSING,PHILADELPHIA,PA 19104; TEMPLE UNIV,INST SURVEY RES,PHILADELPHIA,PA 19122; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ 08103	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University Medical Center	OBRIEN, LA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		AHRQ HHS [1-R01-HS-06815] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; FILLENBAUM GG, 1980, J AM GERIATR SOC, V28, P381, DOI 10.1111/j.1532-5415.1980.tb01103.x; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; Hosmer D, 2013, APPL LOGISTIC REGRES; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JONSEN AR, 1986, CLIN ETHICS PRACTICA, P52; KISH L, 1965, SURVEY SAMPLING, P230; KOENIG HG, 1992, INT J PSYCHIAT MED, V22, P183, DOI 10.2190/M1F5-F40P-C4KD-YPA3; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; PFEIFFER E, 1975, J AM GERIATR SOC, V25, P433; SACHS GA, 1992, J AM GERIATR SOC, V42, P269; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; SHADLEN F, 1990, J AM GERIATR SOC, V38, pA55; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SINGER PA, 1991, HASTINGS CTR REP S2, V21, P1; TENO J, 1991, CLIN RES, V39, pA632; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; 1993, SUDAAN VERSION 6 33; 1990, SAS P200 I INC TECHN, P194	23	134	135	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1775	1779		10.1001/jama.274.22.1775	http://dx.doi.org/10.1001/jama.274.22.1775			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ225	7500508				2022-12-01	WOS:A1995TJ22500027
J	RIMELL, FL; THOME, A; STOOL, S; REILLY, JS; RIDER, G; STOOL, D; WILSON, CL				RIMELL, FL; THOME, A; STOOL, S; REILLY, JS; RIDER, G; STOOL, D; WILSON, CL			CHARACTERISTICS OF OBJECTS THAT CAUSE CHOKING IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOREIGN-BODIES; CHILDHOOD ASPHYXIATION; AIRWAY; BODY; INHALATION	Objective.-To characterize the types, shapes, and sizes of objects causing choking or asphyxiation in children and to compare these characteristics to current standards. Design.-To evaluate morbidity, retrospective 5-year medical record survey; to evaluate mortality, data reanalysis. Settings.-Pediatric hospital and consumer product testing laboratory. Patients.-All children (n=165) who underwent endoscopy for foreign body aspiration or ingestion at Children's Hospital of Pittsburgh (Pa) between 1989 and 1993 and children (n=449) whose deaths due to choking on man-made objects were recorded by the Consumer Product Safety Commission (CPSC) between 1972 and 1992. Main Outcome Measures.-Objects removed from children's aerodigestive tracts were characterized by location, procedure for removal, and type. Objects causing death were characterized by type, shape, and consistency. Three-dimensional objects that had caused asphyxiation were analyzed by computer-simulated models. Results.-Of the 165 children treated by endoscopy, 69% were 3 years of age or younger. Foreign bodies most often ingested or aspirated were food (in 36 children) and coins (in 60 children). Of 449 children whose deaths after aspirating foreign bodies were reported to the CPSC, 65% were younger than 3 years. Balloons caused 29% of deaths overall. Conforming objects such as balloons caused a significantly (P<.001) higher proportion of deaths in those aged 3 years or older (60%) vs those younger than 3 years (33%). Of the 101 objects causing deaths that we could analyze, 14 met current standards for use by children younger than 3 years. Conclusions.-Balloons pose a high risk of asphyxiation to children of any age. Changes in regulations regarding products intended for children's use might have prevented up to 14 (14%) of 101 deaths in this study.	CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT OTOLARYNGOL,PITTSBURGH,PA 15213; ALFRED I DUPONT INST,DIV PEDIAT OTOLARYNGOL,WILMINGTON,DE; INCHCAPE TESTING SERV RISK ANAL & MANAGEMENT,MOONACHIE,NJ	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nemours Alfred I. duPont Hospital for Children								AYTAC A, 1977, J THORAC CARDIOV SUR, V74, P145; BAKER SP, 1980, JAMA-J AM MED ASSOC, V244, P1343; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BINDER L, 1984, ANN EMERG MED, V13, P112, DOI 10.1016/S0196-0644(84)80573-9; BLAZER S, 1980, AM J DIS CHILD, V134, P68, DOI 10.1001/archpedi.1980.02130130050015; HARRIS CS, 1984, JAMA-J AM MED ASSOC, V251, P2231, DOI 10.1001/jama.251.17.2231; HAWKINS DB, 1990, ANN OTO RHINOL LARYN, V99, P935, DOI 10.1177/000348949009901201; Kenna M A, 1988, Pediatr Rev, V10, P25, DOI 10.1542/pir.10-1-25; KIM IG, 1973, LARYNGOSCOPE, V83, P347, DOI 10.1288/00005537-197303000-00004; MITTLEMAN RE, 1984, AM J FOREN MED PATH, V5, P201, DOI 10.1097/00000433-198409000-00003; MU LC, 1991, LARYNGOSCOPE, V101, P657; ODELOWO EOO, 1990, INT SURG, V75, P148; RIMELL FL, 1994, DEC SOC RISK AN ANN; WOLACH B, 1994, INT J PEDIATR OTORHI, V30, P1, DOI 10.1016/0165-5876(94)90045-0; 1995, MONTHLY VITAL STAT S, V40; 1979, METHOD IDENTIFYING T; 1994, VITAL HLTH STATISTIC	17	108	110	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1763	1766		10.1001/jama.274.22.1763	http://dx.doi.org/10.1001/jama.274.22.1763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500505				2022-12-01	WOS:A1995TJ22500024
J	SUGARMAN, J; REISNER, EG; KURTZBERG, J				SUGARMAN, J; REISNER, EG; KURTZBERG, J			ETHICAL ASPECTS OF BANKING PLACENTAL BLOOD FOR TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECONSTITUTION; BODY	Transplantation of blood cells harvested from the umbilical cord immediately after birth has been effective in repopulating the bone marrow. These placental blood transplantations may be safer than conventional bone marrow transplantations and may suspend the need to harvest bone marrow, a process fraught with difficulties. Further understanding and advancement of this emerging technology require developing large banks of placental blood. In this article, we examine some of the ethical issues associated with placental blood banking, including (1) questions about ownership of the tissue, (2) the necessity and nature of obtaining informed consent from parents for harvesting placental blood and the information-gathering process associated with it, (3) obligations to notify parents and children of the results of medical testing for infectious diseases and genetic information, (4) matters of privacy and confidentiality related to such information, and (5) the need for fair and equitable harvesting of and access to placental blood.	DUKE UNIV,MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,PEDIAT BONE MARROW TRANSPLANT PROGRAM,DURHAM,NC 27710	Duke University; Duke University; Duke University	SUGARMAN, J (corresponding author), DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DIV GEN INTERNAL MED,PROGRAM MED ETH,BOX 3040,DURHAM,NC 27710, USA.			Sugarman, Jeremy/0000-0001-7022-8332				ANDREWS LB, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3562693; [Anonymous], 1986, HIST THEORY INFORM C; AUERBACH AD, 1994, BLOOD CELLS, V20, P303; Campbell C S, 1993, Second Opin, V19, P69; DULA A, 1994, CAMB Q HEALTHC ETHIC, V3, P347, DOI 10.1017/S0963180100005168; GALE RP, 1995, NEW ENGL J MED, V332, P392, DOI 10.1056/NEJM199502093320612; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; KURTZBERG J, 1994, BLOOD CELLS, V20, P275; MCCULLOUGH J, 1994, BLOOD CELLS, V20, P609; McCullough J, 1989, BONE MARROW TRANSPL, P641; MURRAY TH, 1987, HASTINGS CENT REP, V17, P30, DOI 10.2307/3562041; ROBERTSON JA, 1991, FERTIL STERIL, V55, P681; ROBERTSON JA, 1989, HASTINGS CENT REP, V19, P7, DOI 10.2307/3561979; RUBINSTEIN P, 1993, BLOOD, V81, P1679; RUBINSTEIN P, 1994, BLOOD CELLS, V20, P587; WAGNER JE, 1994, BLOOD CELLS, V20, P227	16	61	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1783	1785		10.1001/jama.274.22.1783	http://dx.doi.org/10.1001/jama.274.22.1783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ225	7500510				2022-12-01	WOS:A1995TJ22500029
J	COHEN, SI				COHEN, SI			OVERDIAGNOSIS OF SCHIZOPHRENIA - ROLE OF ALCOHOL AND DRUG MISUSE	LANCET			English	Editorial Material							PRECEDING 1ST ADMISSIONS; PSYCHOSIS											AZUONYE IO, 1992, PSYCHIATR B, V16, P311; COHEN SI, 1988, BRIT MED J, V297, P1270, DOI 10.1136/bmj.297.6658.1270-c; COHEN SI, 1994, BRIT J PSYCHIAT, V165, P410, DOI 10.1192/bjp.165.3.410; COHEN SI, 1995, J ROY SOC MED, V88, P73; COHEN SI, 1993, BRIT J PSYCHIAT, V163, P547; COHEN SI, 1992, PSYCHIATR B, V16, P513; COHEN SI, 1992, PSYCHIATRIC B, V16, P664; COOPER JE, 1972, MAUDSLEY MONOGRAPHS, V20; DUKE PJ, 1994, BRIT J PSYCHIAT, V164, P630, DOI 10.1192/bjp.164.5.630; EVA J, 1992, PSYCHIAT B, V16, P310; EVANS M, 1992, PSYCHIATR B, V16, P327; HUMPHREYS MS, 1992, BRIT J PSYCHIAT, V161, P501, DOI 10.1192/bjp.161.4.501; MARTINEZAREVALO MJ, 1994, BRIT J PSYCHIAT, V164, P679, DOI 10.1192/bjp.164.5.679; ROTTANBURG D, 1982, LANCET, V2, P1364; Sandford T, 1995, Nurs Stand, V9, P16; SCADDING G, 1993, BRIT J PSYCHIAT, V162, P237, DOI 10.1192/S0007125000180109; SMITH J, 1994, BRIT J PSYCHIAT, V165, P13, DOI 10.1192/bjp.165.1.13; VANPRAAG HM, 1992, BRIT J PSYCHIAT, V160, P266, DOI 10.1192/bjp.160.2.266; WILSON GT, 1988, BEHAV RES THER, V26, P369, DOI 10.1016/0005-7967(88)90070-8	19	12	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1541	1542		10.1016/S0140-6736(95)92058-7	http://dx.doi.org/10.1016/S0140-6736(95)92058-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ291	7491053				2022-12-01	WOS:A1995TJ29100017
J	NELLES, J; HARDING, T				NELLES, J; HARDING, T			PREVENTING HIV TRANSMISSION IN PRISON - A TALE OF MEDICAL DISOBEDIENCE AND SWISS PRAGMATISM	LANCET			English	Editorial Material									INST UNIV MED LEGALE,GENEVA,SWITZERLAND	University of Geneva	NELLES, J (corresponding author), UNIV BERN,PSYCHIAT KLIN,BERN,SWITZERLAND.							[Anonymous], 1991, Lancet, V337, P647; CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; MARTIN V, 1994, TUBERCLE LUNG DIS, V75, P49, DOI 10.1016/0962-8479(94)90102-3; NELLES J, 1995, DROGEN HIV PRAVENTIO; POWER KG, 1992, BRIT J ADDICT, V87, P35; SCHALLER S, 1995, MED SOC PREVEN, V40, P298; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; Turnbull P. J., 1991, PRISON HIV AIDS RISK; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; 1990, HIV DISEASE CORRECTI; 1993, WHO GUIDELINES HIV I	12	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1507	1508		10.1016/S0140-6736(95)92047-1	http://dx.doi.org/10.1016/S0140-6736(95)92047-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491043				2022-12-01	WOS:A1995TJ29100006
J	TOGNONI, G; RONCAGLIONI, MC				TOGNONI, G; RONCAGLIONI, MC			DISSENT - AN ALTERNATIVE INTERPRETATION OF MAST-I	LANCET			English	Note											TOGNONI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,DEPT CARDIOVASC RES,VIA ERITREA 62,I-20157 MILAN,ITALY.		roncaglioni, maria carla/AAB-1875-2020	roncaglioni, maria carla/0000-0002-2029-7847				DONNAN GA, 1995, LANCET, V345, P578; HACKE W, 1995, JAMA-J AM MED ASSOC, V284, P1017; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0	3	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1515	1515		10.1016/S0140-6736(95)92050-1	http://dx.doi.org/10.1016/S0140-6736(95)92050-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491045				2022-12-01	WOS:A1995TJ29100009
J	WARNOCK, DW; DELVES, HT; CAMPELL, CK; CROUDACE, IW; DAVEY, KG; JOHNSON, EM; SIENIAWSKA, C				WARNOCK, DW; DELVES, HT; CAMPELL, CK; CROUDACE, IW; DAVEY, KG; JOHNSON, EM; SIENIAWSKA, C			TOXIC GAS GENERATION FROM PLASTIC MATTRESSES AND SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article								Microbial generation of toxic gases from antimony, arsenic, or phosphorus in compounds used as fire retardants in cot mattresses has been proposed as a cause of sudden infant death. To test this hypothesis, 23 polyvinyl chloride mattress samples from cot death cases were incubated on malt agar plates until good microbial growth was obtained. Silver nitrate and mercuric chloride test papers were then inserted and the colour reactions recorded. The predominant organism, recovered from all mattresses tested, was not, as claimed in earlier work, the fungus Scopulariopsis brevicaulis, but a mix of common environmental Bacillus spp. Test paper colour changes occurred whenever bacterial growth was present, but these reactions also occurred in control tests in which no mattress material was present on the plates. Chemical and instrumental analyses of exposed test papers showed that the colour reactions were not due to deposits of antimony, arsenic, or phosphorus. Our findings do not support the hypothesis that toxic gases derived from antimony, arsenic, or phosphorus are a cause of sudden infant death. More sulphur was found in test papers exposed in plates containing bacterial growth than in those without such growth. This result suggests that the test paper reactions were due to the generation of sulphur-containing compounds during bacterial growth on the agar medium.	SOUTHAMPTON GEN HOSP,DEPT CLIN BIOCHEM,TRACE ELEMENT UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON OCEANOG CTR,DEPT GEOL,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton; NERC National Oceanography Centre; University of Southampton	WARNOCK, DW (corresponding author), PUBL HLTH LAB,PHLS MYCOL REFERENCE LAB,BRISTOL BS2 8EL,AVON,ENGLAND.		Croudace, Ian W/N-7018-2013	Croudace, Ian W/0000-0003-1547-5650				CULLEN WR, 1989, CHEM REV, V89, P713, DOI 10.1021/cr00094a002; GATES PN, 1995, LANCET, V345, P386, DOI 10.1016/S0140-6736(95)90372-0; KELLEY J, 1992, HUM EXP TOXICOL, V11, P247; MORTON FJ, 1963, 86 COMM MYC I MYC PA; ONIONS AHS, 1966, SCOPULARIOPSIS BREVI; RICHARDSON BA, 1994, J FORENSIC SCI SOC, V34, P199, DOI 10.1016/S0015-7368(94)72915-7; RICHARDSON BA, 1990, LANCET, V335, P670, DOI 10.1016/0140-6736(90)90463-F; TURNBULL PCB, 1990, TOPLEY WILSONS PRINC, V2, P187; 1991, SUDDEN INFANT DEATH	9	33	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1516	1520		10.1016/S0140-6736(95)92051-X	http://dx.doi.org/10.1016/S0140-6736(95)92051-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491046				2022-12-01	WOS:A1995TJ29100010
J	BRUSA, R; ZIMMERMANN, F; KOH, DS; FELDMEYER, D; GASS, P; SEEBURG, PH; SPRENGEL, R				BRUSA, R; ZIMMERMANN, F; KOH, DS; FELDMEYER, D; GASS, P; SEEBURG, PH; SPRENGEL, R			EARLY-ONSET EPILEPSY AND POSTNATAL LETHALITY ASSOCIATED WITH AN EDITING-DEFICIENT GLUR-B ALLELE IN MICE	SCIENCE			English	Article							RECEPTOR CHANNELS; DIFFERENTIAL EXPRESSION; ION FLOW; GENE; SUBUNITS; NEURONS; PERMEABILITY; HIPPOCAMPUS; SWITCH; FAMILY	The arginine residue at position 586 of the GluR-B subunit renders heteromeric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-sensitive glutamate receptor channels impermeable to calcium. The codon for this arginine is introduced at the precursor messenger RNA (pre-mRNA) stage by site-selective adenosine editing of a glutamine codon. Heterozygous mice engineered by gene targeting to harbor an editing-incompetent GluR-B allele synthesized unedited GluR-B subunits and, in principal neurons and interneurons, expressed AMPA receptors with increased calcium permeability. These mice developed seizures and died by 3 weeks of age, showing that GluR-B pre-mRNA editing is essential for brain function.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, INST NEUROPATHOL, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	BRUSA, R (corresponding author), UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, NEUENHEIMER FELD 282, D-69120 HEIDELBERG, GERMANY.		Feldmeyer, Dirk/H-5940-2013	Feldmeyer, Dirk/0000-0002-1716-8972				BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/jphysiol.1995.sp020738; DISTREY BD, 1970, HISTOLOGICAL LABORAT; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hauser W, 1990, EPILEPSY FREQUENCY C; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISHII T, 1993, J BIOL CHEM, V268, P2836; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Jonas Peter, 1994, Current Opinion in Neurobiology, V4, P366, DOI 10.1016/0959-4388(94)90098-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NADLER JV, 1981, LIFE SCI, V29, P2031; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	44	457	471	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1677	1680		10.1126/science.270.5242.1677	http://dx.doi.org/10.1126/science.270.5242.1677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502080				2022-12-01	WOS:A1995TJ29300052
J	CHONG, L; VANSTEENSEL, B; BROCCOLI, D; ERDJUMENTBROMAGE, H; HANISH, J; TEMPST, P; DELANGE, T				CHONG, L; VANSTEENSEL, B; BROCCOLI, D; ERDJUMENTBROMAGE, H; HANISH, J; TEMPST, P; DELANGE, T			A HUMAN TELOMERIC PROTEIN	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; DNA-BINDING; RAP1; CENTROMERE; YEAST; IDENTIFICATION; VARIABILITY; STABILITY; REPEATS	Telomeres are multifunctional elements that shield chromosome ends from degradation and end-to-end fusions, prevent activation of DNA damage checkpoints, and modulate the maintenance of telomeric DNA by telomerase. A major protein component of human telomeres has been identified and cloned. This factor, TRF, contains one Myb-type DNA-binding repeat and an amino-terminal acidic domain. Immunofluorescent labeling shows that TRF specifically colocalizes with telomeric DNA in human interphase cells and is located at chromosome ends during metaphase. The presence of TRF along the telomeric TTAGGG repeat army demonstrates that human telomeres form a specialized nucleoprotein complex.	ROCKEFELLER UNIV, CELL BIOL & GENET LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center			de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [P30 CA08748-29] Funding Source: Medline; NIGMS NIH HHS [GM49046] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049046, R01GM049046] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; BAUERLE PA, 1988, CELL, V53, P211; Broccoli D., UNPUB; Chong L. S., UNPUB; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DELANGE T, 1995, TELOMERES, P265; DELANGE T, UNPUB; DELANGE T, IN PRESS SEMIN CELL; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DOHONY KF, 1993, CELL, V73, P761; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FANG G, 1995, TELOMERES, P69; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Rhodes D., COMMUNICATION; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIBON OCM, 1994, HISTOCHEMISTRY, V101, P223, DOI 10.1007/BF00269548; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; STILLMAN B, COMMUNICATION; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; VANSTEENSEL B, UNPUB; ZAKIAN VA, 1995, TELOMERES, P107; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	58	613	661	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1663	1667		10.1126/science.270.5242.1663	http://dx.doi.org/10.1126/science.270.5242.1663			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502076				2022-12-01	WOS:A1995TJ29300048
J	COON, SL; ROSEBOOM, PH; BALER, R; WELLER, JL; NAMBOODIRI, MAA; KOONIN, EV; KLEIN, DC				COON, SL; ROSEBOOM, PH; BALER, R; WELLER, JL; NAMBOODIRI, MAA; KOONIN, EV; KLEIN, DC			PINEAL SEROTONIN N-ACETYLTRANSFERASE - EXPRESSION CLONING AND MOLECULAR ANALYSIS	SCIENCE			English	Article							RAT PINEAL; GLAND; MELATONIN; DECREASE	Pineal serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, or AA-NAT) generates the large circadian rhythm in melatonin, the hormone that coordinates daily and seasonal physiology in some mammals. Complementary DNA encoding ovine AA-NAT was cloned. The abundance of AA-NAT messenger RNA (mRNA) during the day was high in the ovine pineal gland and somewhat lower in retina. AA-NAT mRNA was found unexpectedly in the pituitary gland and in some brain regions. The night-to-day ratio of ovine pineal AA-NAT mRNA is less than 2. In contrast, the ratio exceeds 150 in rats. AA-NAT represents a family within a large superfamily of acetyltransferases.	NICHHD, DEV NEUROBIOL LAB, NEUROBIOL SECT, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, DEPT BIOL, WASHINGTON, DC 20057 USA; NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)				Klein, David/0000-0002-1792-5806				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arendt J., 1995, MELATONIN MAMMALIAN, p[201, 27]; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BALER R, UNPUB; BALER R, IN PRESS J BIOL CHEM; BERNARD M, 1995, BRAIN RES, V696, P37, DOI 10.1016/0006-8993(95)00651-6; DEGUCHI T, 1975, J NEUROCHEM, V24, P1083, DOI 10.1111/j.1471-4159.1975.tb03682.x; DISTRIA M, 1994, GEN COMP ENDOCR, V96, P6, DOI 10.1006/gcen.1994.1153; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; IUVONE PM, 1986, J NEUROCHEM, V46, P82, DOI 10.1111/j.1471-4159.1986.tb12928.x; JANAVS JL, 1991, BRAIN RES, V540, P138, DOI 10.1016/0006-8993(91)90500-U; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; KLEIN DC, 1978, SCIENCE, V199, P309, DOI 10.1126/science.202027; MEFFORD IN, 1983, ENDOCRINOLOGY, V113, P1582, DOI 10.1210/endo-113-5-1582; NAMBOODIRI MAA, 1985, J NEUROCHEM, V45, P832, DOI 10.1111/j.1471-4159.1985.tb04069.x; NAMBOODIRI MAA, 1981, SCIENCE, V213, P571, DOI 10.1126/science.7017937; NAMBOODIRI MAA, 1980, J BIOL CHEM, V255, P6032; NAMBOODIRI MAA, 1984, J COMP BIOCH B, V80, P731; O'Brien PJ, 1986, PINEAL RETINAL RELAT; RIODAN JF, 1972, METHODS ENZYMOL B, V25, P494; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROSEBOOM PH, UNPUB; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SKENE DJ, 1992, BIOCHEM SOC T, V20, P312, DOI 10.1042/bst0200312; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; VOISIN P, 1984, J BIOL CHEM, V259, P913; WATANABE M, 1992, J BIOL CHEM, V267, P8429; YU L, 1993, J NEUROCHEM, V60, P1436, DOI 10.1111/j.1471-4159.1993.tb03306.x; ZATZ M, 1978, BIOCHEM PHARMACOL, V27, P2549, DOI 10.1016/0006-2952(78)90324-6; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P21	37	295	305	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1681	1683		10.1126/science.270.5242.1681	http://dx.doi.org/10.1126/science.270.5242.1681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502081				2022-12-01	WOS:A1995TJ29300053
J	EHRENHOFERMURRAY, AE; GOSSEN, M; PAK, DTS; BOTCHAN, MR; RINE, J				EHRENHOFERMURRAY, AE; GOSSEN, M; PAK, DTS; BOTCHAN, MR; RINE, J			SEPARATION OF ORIGIN RECOGNITION COMPLEX FUNCTIONS BY CROSS-SPECIES COMPLEMENTATION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; TRANSCRIPTIONAL STATES; S-CEREVISIAE; YEAST; GENE; VECTORS	Transcriptional silencing at the HMRa locus of Saccharomyces cerevisiae requires the function of the origin recognition complex (ORC), the replication initiator of yeast. Expression of a Drosophila melanogaster Orc2 complementary DNA in the yeast orc2-1 strain, which is defective for replication and silencing, complemented the silencing defect but not the replication defect; this result indicated that the replication and silencing functions of ORC were separable. The orc2-1 mutation mapped to the region of greatest homology between the Drosophila and yeast proteins. The silent state mediated by DmOrc2 was epigenetic; it was propagated during mitotic divisions in a relatively stable way, whereas the nonsilent state was metastable. In contrast, the silent state was erased during meiosis.	UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,DIV GENET,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031105, R37GM031105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; ZHOU C, 1989, J BIOL CHEM, V264, P9022	22	56	56	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1671	1674		10.1126/science.270.5242.1671	http://dx.doi.org/10.1126/science.270.5242.1671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502078				2022-12-01	WOS:A1995TJ29300050
J	GAVIN, KA; HIDAKA, M; STILLMAN, B				GAVIN, KA; HIDAKA, M; STILLMAN, B			CONSERVED INITIATOR PROTEINS IN EUKARYOTES	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; YEAST; GENES; START; EGGS	The origin recognition complex (ORC), a multisubunit protein identified in Saccharomyces cerevisiae, binds to chromosomal replicators and is required for the initiation of cellular DNA replication. complementary DNAs (cDNAs) encoding proteins related to the two largest subunits of ORC were cloned from various eukaryotes. The cDNAs encoding proteins related to S. cerevisiae Orc1p were cloned from the budding yeast Kluyveromyces lactis, the fission yeast Schizosaccharomyces pombe, and human cells. These proteins show similarity to regulators of the S and M phases of the cell cycle. Genetic analysis of orc1(+) from S. pombe reveals that it is essential for cell viability. The cDNAs encoding proteins related to S. cerevisiae Orc2p were cloned from Arabidopsis thaliana, Caenorhabditis elegans, and human cells. The human ORC-related proteins interact in vivo to form a complex. These studies suggest that ORC subunits are conserved and that the role of ORC is a general feature of eukaryotic DNA replication.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; SUNY STONY BROOK, GENET PROGRAM, STONY BROOK, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook				Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker T, 1991, DNA REPLICATION, V2; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1990, J CELL SCI, V95, P383; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, UNPUB; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445	43	205	216	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1667	1671		10.1126/science.270.5242.1667	http://dx.doi.org/10.1126/science.270.5242.1667			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502077				2022-12-01	WOS:A1995TJ29300049
J	GOSSEN, M; PAK, DTS; HANSEN, SK; ACHARYA, JK; BOTCHAN, MR				GOSSEN, M; PAK, DTS; HANSEN, SK; ACHARYA, JK; BOTCHAN, MR			A DROSOPHILA HOMOLOG OF THE YEAST ORIGIN RECOGNITION COMPLEX	SCIENCE			English	Article							ELECTRON-MICROSCOPIC ANALYSIS; DNA-REPLICATION; MELANOGASTER; EMBRYOS	Genes from Drosophila melanogaster have been identified that encode proteins homologous to Orc2p and Orc5p of the Saccharomyces cerevisiae origin recognition complex (ORC). The abundance of the Drosophila Orc2p homolog DmORC2 is developmentally regulated and is greatest during the earliest stages of embryogenesis, concomitant with the highest rate of DNA replication. Fractionation of embryo nuclear extracts revealed that DmORC2 is found in a tightly associated complex with five additional polypeptides, much like the yeast ORC. These studies will enable direct testing of the initiator-based model of replication in a metazoan.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego			Gossen, Manfred/K-9602-2013	Acharya, Jairaj/0000-0001-7366-4228; Gossen, Manfred/0000-0002-1761-4063	NCI NIH HHS [CA30490] Funding Source: Medline; NIEHS NIH HHS [ES-01896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA030490, R01CA030490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLUMENTH.AB, 1973, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/SQB.1974.038.01.024; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; EHRENHOFERMURRA.AE, 1995, SCIENCE, V270, P1671; FOE VE, 1993, DEV DROSOPHILA MELAN, V1, P149; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HANAHAN D, 1989, RECOMBINANT DNA METH, P267; HANSEN SB, UNPUB; HARLOW E, 1988, ANTIBODIES; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZAKIAN VA, 1976, J MOL BIOL, V108, P305, DOI 10.1016/S0022-2836(76)80123-4	25	125	131	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1674	1677		10.1126/science.270.5242.1674	http://dx.doi.org/10.1126/science.270.5242.1674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502079				2022-12-01	WOS:A1995TJ29300051
J	LI, B; TOM, JYK; OARE, D; YEN, R; FAIRBROTHER, WJ; WELLS, JA; CUNNINGHAM, BC				LI, B; TOM, JYK; OARE, D; YEN, R; FAIRBROTHER, WJ; WELLS, JA; CUNNINGHAM, BC			MINIMIZATION OF A POLYPEPTIDE HORMONE	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; NATRIURETIC PEPTIDE RECEPTORS; EXTRACELLULAR DOMAIN; FUNCTIONAL EPITOPE; CYCLASE ACTIVATION; ANTIBODY; MUTAGENESIS; INHIBITORS; PROTEINS; ANALOGS	A stepwise approach for reducing the size of a polypeptide hormone, atrial natriuretic peptide (ANP), from 28 residues to 15 while retaining high biopotency is described. Systematic structural and functional analysis identified a discontinuous functional epitope for receptor binding and activation, most of which was placed onto a smaller ring (Cys(6) to Cys(17)) that was created by repositioning the ANP native disulfide bond (Cys(7) to Cys(23)). High affinity was subsequently restored by optimizing the remaining noncritical residues by means of phage display. Residues that flanked the mini-ring structure were then deleted in stages, and affinity losses were rectified by additional phage-sorting experiments. Thus, structural and functional data on hormones, coupled with phage display methods, can be used to shrink the hormones to moieties more amenable to small-molecule design.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,BIOORGAN CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOVY PR, 1989, J BIOL CHEM, V264, P20309; BOVY PR, 1992, J MED CHEM, V35, P808; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COREY DR, 1994, P NATL ACAD SCI USA, V91, P4106, DOI 10.1073/pnas.91.10.4106; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRBROTHER WJ, 1994, BIOCHEMISTRY-US, V33, P8897, DOI 10.1021/bi00196a006; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LUNNEY EA, 1994, J MED CHEM, V37, P2664, DOI 10.1021/jm00043a006; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.ph.54.030192.000303; MCDOWELL RS, 1994, J AM CHEM SOC, V116, P5069, DOI 10.1021/ja00091a007; NAVIA MA, 1992, CURR OPIN STRUC BIOL, V2, P202; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; NUTT RF, 1989, SYNTHETIC PEPTIDES A, P267; NUTT RF, 1988, PEPTIDES CHEM BIOL, P444; PRESTA L, 1994, ANNU REP MED CHEM, V29, P317; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; VONGELDERN TW, 1992, J MED CHEM, V35, P808, DOI 10.1021/jm00083a003; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wells J. A., 1992, CURR OPIN STRUC BIOL, V2, P597; WELLS JA, 1994, P NATL ACAD SCI USA, V91, P4110, DOI 10.1073/pnas.91.10.4110; WELLS JA, 1991, METHODS ENZYMOL, V202	36	123	142	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1657	1660		10.1126/science.270.5242.1657	http://dx.doi.org/10.1126/science.270.5242.1657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502074				2022-12-01	WOS:A1995TJ29300046
J	RUBIO, F; GASSMANN, W; SCHROEDER, JI				RUBIO, F; GASSMANN, W; SCHROEDER, JI			SODIUM-DRIVEN POTASSIUM UPTAKE BY THE PLANT POTASSIUM TRANSPORTER HKT1 AND MUTATIONS CONFERRING SALT TOLERANCE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CULTIVARS; MECHANISM; PROTEIN; MUTANT; YEAST	Sodium (Na+) at high millimolar concentrations in soils is toxic to most higher plants and severely reduces agricultural production worldwide. However, the molecular mechanisms for plant Na+ uptake remain unknown. Here, the wheat root high-affinity potassium (K+) uptake transporter HKT1 was shown to function as a high-affinity K+-Na+ cotransporter. High-affinity K+ uptake was activated by micromolar Na+ concentrations; moreover, high-affinity Na+ uptake was activated by K+ (half-activation constant, 2.8 mu M K+). However, at physiologically detrimental concentrations of Na+, K+ accumulation mediated by HKT1 was blocked and low-affinity Na+ uptake occurred (Michaelis constant, similar to 16 mM Na+), which correlated to Na+ toxicity in plants. Point mutations in the sixth putative transmembrane domain of HKT1 that increase Na+ tolerance were isolated with the use of yeast as a screening system. Na+ uptake and Na+ inhibition of K+ accumulation indicate a possible role for HKT1 in physiological Na+ toxicity in plants.					Rubio, Francisco/K-2854-2014; Rubio, Francisco/ABF-8662-2020	Rubio, Francisco/0000-0001-7640-9548; Rubio, Francisco/0000-0001-7640-9548; Gassmann, Walter/0000-0002-7527-0385; Schroeder, Julian/0000-0002-3283-5972				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BARKLA BJ, 1991, P NATL ACAD SCI USA, V88, P11177, DOI 10.1073/pnas.88.24.11177; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; FAN TWM, 1989, P NATL ACAD SCI USA, V86, P9856, DOI 10.1073/pnas.86.24.9856; FLOWERS TJ, 1983, ENCY PLANT PHYSL B, V15, P651; GASSMANN W, UNPUB; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; MAATHUIS FJM, 1994, P NATL ACAD SCI USA, V91, P9272, DOI 10.1073/pnas.91.20.9272; MURGUIA JR, 1995, SCIENCE, V267, P232; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARR.A, 1984, J BACTERIOL, V159, P940; RUBIO F, UNPUB; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHUBERT S, 1990, PLANT SOIL, V123, P205, DOI 10.1007/BF00011269; SERRANO R, 1985, PLASMA MEMBRANE ATPA; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH FA, 1989, J MEMBRANE BIOL, V108, P125, DOI 10.1007/BF01871024; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; WALKER NA, 1991, PLANTA, V185, P443, DOI 10.1007/BF00201070	26	476	536	5	82	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1660	1663		10.1126/science.270.5242.1660	http://dx.doi.org/10.1126/science.270.5242.1660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502075				2022-12-01	WOS:A1995TJ29300047
J	YIN, H; WANG, MD; SVOBODA, K; LANDICK, R; BLOCK, SM; GELLES, J				YIN, H; WANG, MD; SVOBODA, K; LANDICK, R; BLOCK, SM; GELLES, J			TRANSCRIPTION AGAINST AN APPLIED FORCE	SCIENCE			English	Article							RNA-POLYMERASE; ESCHERICHIA-COLI; SINGLE MOLECULES; DNA; TEMPLATE	The force produced by a single molecule of Escherichia coli RNA polymerase during transcription was measured optically. Polymerase immobilized on a surface was used to transcribe a DNA template attached to a polystyrene bead 0.5 micrometer in diameter. The bead position was measured by interferometry while a force opposing translocation of the polymerase along the DNA was applied with an optical trap. At saturating nucleoside triphosphate concentrations, polymerase molecules stalled reversibly at a mean applied force estimated to be 14 piconewtons. This force is substantially larger than those measured for the cytoskeletal motors kinesin and myosin and exceeds mechanical loads that are estimated to oppose transcriptional elongation in vivo. The data are consistent with efficient conversion of the free energy liberated by RNA synthesis into mechanical work.	BRANDEIS UNIV, DEPT BIOCHEM, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; PRINCETON UNIV, PRINCETON MAT INST, PRINCETON, NJ 08544 USA; AT&T BELL LABS, DEPT BIOL COMPUTAT, MURRAY HILL, NJ 07974 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Brandeis University; Brandeis University; Princeton University; Princeton University; AT&T; Nokia Corporation; Nokia Bell Labs; University of Wisconsin System; University of Wisconsin Madison								BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHAMBERLIN M, 1963, J MOL BIOL, V7, P334, DOI 10.1016/S0022-2836(63)80028-5; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; COOK DN, 1994, NUCL ACIDS MOL BIOL, V8, P133; COOK PR, 1994, BIOESSAYS, V16, P425, DOI 10.1002/bies.950160611; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FINER JT, 1995, BIOPHYS J, V68, pS291; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIYATA H, 1995, BIOPHYS J, V68, pS286; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG JC, 1992, TRANSCRIPTIONAL REGU, P1253; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	32	465	490	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1653	1657		10.1126/science.270.5242.1653	http://dx.doi.org/10.1126/science.270.5242.1653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502073				2022-12-01	WOS:A1995TJ29300045
J	SWARTZ, R; HOLMES, C				SWARTZ, R; HOLMES, C			MACROPHAGES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									BAXTER HLTHCARE CORP,MCGAW PK,IL 60085	Baxter International Inc	SWARTZ, R (corresponding author), UNIV MICHIGAN HOSP,ANN ARBOR,MI 48109, USA.								0	1	1	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1546	1546		10.1056/NEJM199512073332306	http://dx.doi.org/10.1056/NEJM199512073332306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477170				2022-12-01	WOS:A1995TH15700006
J	WILCOX, AJ; WEINBERG, CR; BAIRD, DD				WILCOX, AJ; WEINBERG, CR; BAIRD, DD			TIMING OF SEXUAL INTERCOURSE IN RELATION TO OVULATION - EFFECTS ON THE PROBABILITY OF CONCEPTION, SURVIVAL OF THE PREGNANCY, AND SEX OF THE BABY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY ESTROGEN; NORMAL MEN; TEMPERATURE; SPERMATOZOA; SPERM	Background. The timing of sexual intercourse in relation to ovulation strongly influences the chance of conception, although the actual number of fertile days in a woman's menstrual cycle is uncertain. The timing of intercourse may also be associated with the sex of the baby. Methods. We recruited 221 healthy women who were planning to become pregnant. At the same time the women stopped using birth-control methods, they began collecting daily urine specimens and keeping daily records of whether they had sexual intercourse. We measured estrogen and progesterone metabolites in urine to estimate the day of ovulation. Results. In a total of 625 menstrual cycles for which the dates of ovulation could be estimated, 192 pregnancies were initiated, as indicated by increases in the urinary concentration of human chorionic gonadotropin around the expected time of implantation. Two thirds (n=129) ended in live births. Conception occurred only when intercourse took place during a six-day period that ended on the estimated day of ovulation. The probability of conception ranged from 0.10 when intercourse occurred five days before ovulation to 0.33 when it occurred on the day of ovulation itself. There was no evident relation between the age of sperm and the viability of the conceptus, although only 6 percent of the pregnancies could be firmly attributed to sperm that were three or more days old. Cycles producing male and female babies had similar patterns of intercourse in relation to ovulation. Conclusions. Among healthy women trying to conceive, nearly all pregnancies can be attributed to intercourse during a six-day period ending on the day of ovulation. For practical purposes, the timing of sexual intercourse in relation to ovulation has no influence on the sex of the baby.	NIEHS,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	WILCOX, AJ (corresponding author), NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC 27709, USA.		Wilcox, Allen J/C-7723-2019; Baird, Donna D/D-5214-2017	Wilcox, Allen J/0000-0002-3376-1311; Baird, Donna D/0000-0002-5544-2653; Weinberg, Clarice/0000-0002-7713-8556				ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; BAIRD DD, 1991, STAT MED, V10, P255, DOI 10.1002/sim.4780100209; BAIRD DD, 1995, EPIDEMIOLOGY, V6, P547, DOI 10.1097/00001648-199509000-00015; BAKER RJ, 1978, GLIM SYSTEM; BARRETT JC, 1969, POP STUD-J DEMOG, V23, P455, DOI 10.1080/00324728.1969.10405297; Bongaarts J., 1983, DETERMINANTS FERTILI, V1, P103; Campbell K L, 1985, Res Front Fertil Regul, V3, P1; CHECK JH, 1989, AM J OBSTET GYNECOL, V160, P598, DOI 10.1016/S0002-9378(89)80036-5; COHEN J, 1985, FERTIL STERIL, V44, P254; COLLINS WP, 1983, CURRENT TOPICS REPRO, V3, P49; FRANCE JT, 1992, INT J FERTIL, V37, P244; FREUND M, 1962, J REPROD FERTIL, V4, P143; Glezerman M, 1993, INFERTILITY MALE FEM; GUERREROV R, 1975, NEW ENGL J MED, V293, P573; KESNER JS, 1994, STEROIDS, V59, P205, DOI 10.1016/0039-128X(94)90029-9; MACLEOD J, 1952, FERTIL STERIL, V3, P297; PERLOFF WH, 1964, AM J OBSTET GYNECOL, V88, P439; POLAND ML, 1985, FERTIL STERIL, V44, P396; POTTER RG, 1961, MILBANK FUND Q, V39, P132, DOI 10.2307/3348639; ROYSTON JP, 1982, BIOMETRICS, V38, P397, DOI 10.2307/2530453; SARNARAJEEWA P, 1979, J STEROID BIOCHEM, V11, P1165; SCHWARTZ D, 1980, POP STUD-J DEMOG, V34, P397, DOI 10.1080/00324728.1980.10410398; SHETTLES LB, 1984, CHOOSE SEX YOUR BABY; SIMPSON J L, 1988, Advances in Contraception, V4, P247, DOI 10.1007/BF01849266; WEINBERG CR, 1994, BIOMETRICS, V50, P358, DOI 10.2307/2533379; WEINBERG CR, 1995, HUM REPROD, V10, P304, DOI 10.1093/oxfordjournals.humrep.a135932; WEINBERG CR, IN PRESS PONTIFICAL; Wilcox A J, 1990, Epidemiology, V1, P382, DOI 10.1097/00001648-199009000-00008; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WILCOX AJ, 1985, FERTIL STERIL, V44, P366; WRIGHT K, 1978, STEROIDS, V31, P407, DOI 10.1016/0039-128X(78)90053-3; ZARUTSKIE PW, 1989, FERTIL STERIL, V52, P891; 1983, FERTIL STERIL, V40, P773; 1984, FERTIL STERIL, V41, P593	34	720	738	3	65	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 7	1995	333	23					1517	1521		10.1056/NEJM199512073332301	http://dx.doi.org/10.1056/NEJM199512073332301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH157	7477165				2022-12-01	WOS:A1995TH15700001
J	BONE, RC				BONE, RC			ANOTHER TASTE OF LEMONADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1656	1656		10.1001/jama.274.21.1656	http://dx.doi.org/10.1001/jama.274.21.1656			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474255				2022-12-01	WOS:A1995TH15100001
J	DALY, LE; KIRKE, PN; MOLLOY, A; WEIR, DG; SCOTT, JM				DALY, LE; KIRKE, PN; MOLLOY, A; WEIR, DG; SCOTT, JM			FOLATE LEVELS AND NEURAL-TUBE DEFECTS - IMPLICATIONS FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLIC-ACID; VITAMIN SUPPLEMENTATION; TRIAL	Using data from a recent case-control study, a woman's risk of having a child with a neural tube defect (NTD) was found to be associated with early pregnancy red cell folate levels in a continuous dose-response relationship. These findings were used to calculate the reduction in NTD cases that would be expected under two different strategies to raise folate levels. Targeting high-risk individuals has a small effect on the population prevalence but can substantially change an individual's risk. Targeting the population produces a small change in individual risk but has a large effect on the population prevalence. Supplementation of high-risk women would be the most efficient method to implement the high-risk strategy, while food fortification would be preferable for the population approach. The current guidelines for the prevention of NTD are for an increased folio acid intake of 0.4 mg per day. This would result in a 48% reduction in NTDs, which may be near optimal. The two intervention strategies should be considered complementary in prevention of NTDs.	HLTH RES BOARD,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT CLIN MED,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT BIOCHEM,DUBLIN,IRELAND	Health Research Board - Ireland; Trinity College Dublin; Trinity College Dublin	DALY, LE (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT EPIDEMIOL & PUBL HLTH MED,EARLSFORT TERRACE,DUBLIN 2,IRELAND.			Molloy, Anne/0000-0002-1688-9049				BERESFORD SAA, 1994, AM J PUBLIC HEALTH, V84, P348, DOI 10.2105/AJPH.84.3.348; CLARK NAC, 1994, BRIT J OBSTET GYNAEC, V101, P709, DOI 10.1111/j.1471-0528.1994.tb13190.x; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; HESEKER H, 1987, J NUTR SCI VITAMINOL, V33, P163, DOI 10.3177/jnsv.33.163; HUBER AM, 1988, J AM DIET ASSOC, V88, P791; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; OAKLEY GP, 1993, JAMA-J AM MED ASSOC, V269, P1292, DOI 10.1001/jama.269.10.1292; SCOTT J, 1994, Q J MED, V87, P705, DOI 10.1093/oxfordjournals.qjmed.a068887; SMITHELLS RW, 1983, LANCET, V1, P1027; TSUI JC, 1990, J AM DIET ASSOC, V90, P1551; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WOTEKI CE, 1988, AM J CLIN NUTR, V47, P320, DOI 10.1093/ajcn/47.2.320; 1993, POSITION PAPER FOLIC; 1992, FOLIC ACID PREVENTIO	16	564	583	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1698	1702		10.1001/jama.274.21.1698	http://dx.doi.org/10.1001/jama.274.21.1698			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474275				2022-12-01	WOS:A1995TH15100027
J	FINKELHOR, D; WOLAK, J				FINKELHOR, D; WOLAK, J			NONSEXUAL ASSAULTS TO THE GENITALS IN THE YOUTH POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACE-TO-FACE; CHILD SEXUAL ABUSE; TELEPHONE; RELIABILITY; TRAUMA; BOYS	Objective.-To assess the frequency with which youth suffer nonsexual assaults to the genitals and their context and consequences. Design.-Telephone survey with follow-up interview 1 year later. Setting.-General population of the United States living in households with telephones. Participants.-Random sample of 1042 boys and 958 girls aged 10 through 16 years. Results.-A nonsexual assault to the genitals was experienced by 9.2% of the boys and 1.0% of the girls in the year prior to the initial interview and 9.1% of the boys and 2.2% of the girls in the year prior to the follow-up interview. Among the boys, about a quarter of the assaults involved some injury, but only one in 50 needed medical attention. The most common assailants were same-aged peers. The assaults occurred in a variety of contexts including gang attacks, peer fighting, bullying, and some situations in which girls retaliated against the genitals of harassing boys. Boy victims of nonsexual genital assault had significantly higher levels of posttraumatic and depression symptomatology than boys without such assaults. Conclusions.-Nonsexual genital violence needs additional clinical and research attention. Youth should be educated about its possible consequences. Clinicians should ask about nonsexual genital violence when taking a history, particularly with youth who have experienced other kinds of assaults.			FINKELHOR, D (corresponding author), UNIV NEW HAMPSHIRE,FAMILY RES LAB,126 HORTON SOCIAL SCI CTR,DURHAM,NH 03824, USA.							BAJOS N, 1992, AIDS, V6, P315; BAYS J, 1990, AM J DIS CHILD, V144, P1319, DOI 10.1001/archpedi.1990.02150360043017; BAYS J, 1993, CHILD ABUSE NEGLECT, V17, P91, DOI 10.1016/0145-2134(93)90011-S; BERMACK E, 1989, PSYCHOL REP, V65, P259, DOI 10.2466/pr0.1989.65.1.259; BONEYMCCOY S, 1995, J CONSULT CLIN PSYCH, V63, P726, DOI 10.1037/0022-006X.63.5.726; Czaja R, 1987, Int Q Community Health Educ, V8, P23, DOI 10.2190/XT6W-31CX-TD87-E643; EVANS C, 1993, J CONTEMP ETHNOGR, V22, P139, DOI 10.1177/089124193022002001; FINE GA, 1987, LITTLE LEAGUE BASEBA; FINKEL MA, 1989, PEDIATRICS, V84, P317; FINKELHOR D, 1994, PEDIATRICS, V94, P413; Finkelhor D, 1994, Future Child, V4, P31, DOI 10.2307/1602522; FINKELHOR D, 1995, CHILD ABUSE NEGL, V19, P137; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; GROTH N, 1979, MEN RAPE; HARLEY J, 1995, JAN SAN DIEG C RESP; HAUSMAN AJ, 1992, J ADOLESCENT HEALTH, V13, P668, DOI 10.1016/1054-139X(92)90061-F; HERMANGIDDENS ME, 1987, PEDIATRICS, V80, P203; HERMANGIDDENS ME, 1989, JAMA-J AM MED ASSOC, V261, P577; HOBBS CJ, 1989, CHILD ABUSE NEGLECT, V13, P195, DOI 10.1016/0145-2134(89)90006-9; JOHNSON CF, 1985, CHILD ABUSE NEGLECT, V9, P207, DOI 10.1016/0145-2134(85)90013-4; KERNS DL, 1992, AM J DIS CHILD, V146, P494; MARIN G, 1989, HISPANIC J BEHAV SCI, V11, P330, DOI 10.1177/07399863890114003; MCCANN J, 1992, PEDIATRICS, V89, P307; MERRITT KA, 1994, PEDIATRICS, V94, P17; MORRISON L J, 1988, Journal of Emergency Medicine, V6, P521, DOI 10.1016/0736-4679(88)90412-X; MURAM D, 1989, CHILD ABUSE NEGLECT, V13, P211, DOI 10.1016/0145-2134(89)90007-0; POTTS MK, 1990, J PSYCHIATR RES, V24, P335, DOI 10.1016/0022-3956(90)90005-B; RIMZA ME, 1982, PEDIATRICS, V69, P8; SHAFFER D, 1992, NATIONAL I MENTAL HL; SLOSBERG EJ, 1978, AM J DIS CHILD, V132, P719, DOI 10.1001/archpedi.1978.02120320079019; SPENCER MJ, 1986, PEDIATRICS, V78, P133; STEWART WF, 1989, PSYCHOSOM MED, V51, P559, DOI 10.1097/00006842-198909000-00007; WEEKS MF, 1983, AM J PUBLIC HEALTH, V73, P1389, DOI 10.2105/AJPH.73.12.1389; WELLS KB, 1988, J PSYCHIAT RES, V22, P207, DOI 10.1016/0022-3956(88)90006-4; 1994, CRIMINAL VICTIMIZATI	35	17	17	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1692	1697		10.1001/jama.274.21.1692	http://dx.doi.org/10.1001/jama.274.21.1692			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TH151	7474274				2022-12-01	WOS:A1995TH15100026
J	GLOTH, FM; GUNDBERG, CM; HOLLIS, BW; HADDAD, JG; TOBIN, JD				GLOTH, FM; GUNDBERG, CM; HOLLIS, BW; HADDAD, JG; TOBIN, JD			VITAMIN-D DEFICIENCY IN HOMEBOUND ELDERLY PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; POPULATION; SERUM; OSTEOCALCIN; CALCIUM	Objective.-To assess the vitamin D status in homebound, community-dwelling elderly persons; sunlight-deprived elderly nursing home residents; and healthy, ambulatory elderly persons. Design.-A cohort analytic study. Participants.-Of 244 subjects at least 65 years old, 116 subjects (85 women and 31 men) had been confined indoors for at least 6 months, either in private dwellings in the community (the Hopkins Elder Housecall Program) or in a teaching nursing home (The Johns Hopkins Geriatrics Center). The 128 control subjects, a healthy ambulatory group, came from the Baltimore Longitudinal Study on Aging. All subjects were free of diseases or medications that might interfere with their vitamin D status. Main Outcome measures.-Serum levels of 25-hydroxyvitamin D (25-OHD) and 1,25-dihydroxyvitamin D (1,25-[OH]D-2) were measured in all subjects. In a subgroup of 80 subjects, serum levels of intact parathyroid hormone (PTH), ionized calcium, and osteocalcin and intake of vitamin D (through 3-day food records) were assessed. A randomly selected cohort of sunlight-deprived subjects also had serum levels of vitamin D binding protein measured. Results.-In sunlight-deprived subjects overall, the mean 25-OHD level was 30 nmol/L (12 ng/mL) (range, <10 to 77 nmol/L [<4 to 31 ng/mL]) and the mean 1,25(OH)(2)D level was 52 pmol/L (20 pg/mL) (range, 18 to 122 pmol/L [7 to 47 pg/mL]). In the sunlight-deprived subjects, 54% of community dwellers and 38% of nursing home residents had serum levels of 25-OHD below 25 nmol/L (10 ng/mL) (normal range, 25 to 137 nmol/L [10 to 55 ng/mL]). A significant inverse relationship existed between 25-OHD (ie, Log [25-OHD]) and PTH when they were analyzed together (r=-0.42; R(2)=0.18; P<.001) and for each cohort separately. All other parameters measured, except ionized calcium, differed significantly from the Baltimore Longitudinal Study Group means. The mean (SD) daily intakes of vitamin D (121 [132] IU) and calcium (583 [322] mg) were below the recommended dietary allowance only in the community-dwelling homebound population. The mean vitamin D binding protein level in the sunlight-deprived subgroup was in the normal range. Conclusions.-Despite a relatively high degree of vitamin supplementation in the United States, homebound elderly persons are likely to suffer from vitamin D deficiency.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV GERIATR MED & GERONTOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS BAYVIEW MED CTR, BALTIMORE, MD USA; YALE UNIV, SCH MED, DEPT ORTHOPED, NEW HAVEN, CT USA; MED UNIV S CAROLINA, CHILDRENS HOSP, DEPT PEDIAT, CHARLESTON, SC 29425 USA; UNIV PENN, DIV ENDOCRINOL, PHILADELPHIA, PA 19104 USA; NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yale University; Medical University of South Carolina; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	GLOTH, FM (corresponding author), UNION MEM HOSP, DEPT MED, DIV GERIATR, 201 E UNIV PKWY, BALTIMORE, MD 21218 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000120] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR02719] Funding Source: Medline; NIAMS NIH HHS [AR 38460] Funding Source: Medline; NIA NIH HHS [5 T32 AG00120-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUILLON R, 1977, J CLIN ENDOCR METAB, V45, P225, DOI 10.1210/jcem-45-2-225; Chalmers J, 1967, J Bone Joint Surg Br, V49, P403; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; GLOTH FM, 1991, J AM GERIATR SOC, V39, P137, DOI 10.1111/j.1532-5415.1991.tb01615.x; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GLOTH FM, 1995, AM J PHYS MED REHAB, V74, P45, DOI 10.1097/00002060-199501000-00008; GLOTH FM, 1991, ARCH INTERN MED, V151, P1662, DOI 10.1001/archinte.151.8.1662; GLOTH FM, 1995, J AM GERIATR SOC, V43, P1269, DOI 10.1111/j.1532-5415.1995.tb07404.x; GLOTH FM, 1993, J BONE MINER RES, V8, pS216; GLOTH FM, 1990, J BONE MINER RES S2, V5, pS268; GLOTH FM, IN PRESS J AM DIET A; GUILLEMANT S, 1989, J STEROID BIOCHEM, V33, P1155, DOI 10.1016/0022-4731(89)90424-X; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HOLLIS BW, 1986, CLIN CHEM, V32, P2060; HOLLIS BW, 1993, CLIN CHEM, V39, P529; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; OOMS ME, 1995, J BONE MINER RES, V10, P1177; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; SKARIA J, 1975, ACTA NEUROL SCAND, V51, P37; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075; YASUMURA S, 1987, J CLIN ENDOCR METAB, V64, P681, DOI 10.1210/jcem-64-4-681; [No title captured]; 1989, NATIONAL ACADEMY SCI	26	359	375	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1683	1686		10.1001/jama.274.21.1683	http://dx.doi.org/10.1001/jama.274.21.1683			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474272				2022-12-01	WOS:A1995TH15100024
J	WEISS, M; LOPRINZI, CL; CREAGAN, ET; DALTON, RJ; NOVOTNY, P; OFALLON, JR				WEISS, M; LOPRINZI, CL; CREAGAN, ET; DALTON, RJ; NOVOTNY, P; OFALLON, JR			UTILITY OF FOLLOW-UP TESTS FOR DETECTING RECURRENT DISEASE IN PATIENTS WITH MALIGNANT MELANOMAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BREAST-CANCER; GUIDELINES; POLICY	Objective.-To determine the effectiveness of follow-up tests for signaling recurrences in patients with intermediate- and high-risk malignant melanomas treated with curative intention. Design.-Retrospective analysis of prospectively collected data. Setting.-North Central Cancer Treatment Group. Patients.-A total of 261 patients with resected local (greater than or equal to 1.69 mm) and regional nodal malignant melanomas who were enrolled in a single prospective adjuvant trial were studied. All patients were scheduled to be followed up monthly for 2 months, then every 2 months for the first year, every 4 months the second year, every 6 months the next 3 years, and annually thereafter, with each visit consisting of a history, physical examination, complete blood cell count, blood chemistry panel, and a chest x-ray. Results.-Of the 145 evaluable patients who developed recurrent melanomas, 99 patients (68%) developed symptoms that signaled the diagnosis of recurrent disease. Physical examination of asymptomatic patients led to the diagnosis of recurrent disease in 37 patients (26%). The other nine patients (6%) with recurrent disease had abnormal chest x-rays. Laboratory results were never a sole indicator of recurrent disease. Conclusion.-The majority of recurrences following resection of primary melanomas are discovered by history and/or physical examination despite the frequent use of other follow-up tests. The present data indicate that routine blood analyses and chest x-rays have limited value in the postoperative follow-up of patients with resected intermediate- and high-risk melanomas.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; DULUTH COMMUNITY CLIN ONCOL PROGRAM, DULUTH, MN USA	Mayo Clinic					NCI NIH HHS [CA-37404, CA-25224, CA-15083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037404, U10CA025224, P30CA015083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baughan C A, 1993, Clin Oncol (R Coll Radiol), V5, P174, DOI 10.1016/S0936-6555(05)80321-8; BRANDT SE, 1990, J SURG ONCOL, V43, P157, DOI 10.1002/jso.2930430307; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; BROYN T, 1982, ACTA CHIR SCAND, V148, P401; COLLINS CD, 1993, BRIT J RADIOL, V66, P117, DOI 10.1259/0007-1285-66-782-117; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEMBROW VD, 1986, FUNDAMENTALS SURGICA, P141; DRAKE LA, 1993, J AM ACAD DERMATOL, V28, P638, DOI 10.1016/S0190-9622(08)81784-7; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; JILLELLA A, 1995, P AN M AM SOC CLIN, V14, P413; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KAUFMANN P M, 1992, Aktuelle Radiologie, V2, P81; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P881, DOI 10.1200/JCO.1994.12.5.881; MARTINI L, 1994, TUMORI, V80, P188, DOI 10.1177/030089169408000305; MCCARTHY WH, 1988, SURG GYNECOL OBSTET, V166, P497; MCEWAN L, 1990, PLAST RECONSTR SURG, V86, P527, DOI 10.1097/00006534-199009000-00024; PANDYA KJ, 1985, CANCER, V55, P202, DOI 10.1002/1097-0142(19850101)55:1<202::AID-CNCR2820550132>3.0.CO;2-X; PEARLMAN NW, 1992, AM J SURG, V164, P458, DOI 10.1016/S0002-9610(05)81180-8; ROMERO JB, 1994, J DERMATOL SURG ONC, V20, P175, DOI 10.1111/j.1524-4725.1994.tb00462.x; SCANLON EF, 1980, CANCER, V46, P977, DOI 10.1002/1097-0142(19800815)46:4+<977::AID-CNCR2820461320>3.0.CO;2-0; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V265, P380, DOI 10.1001/jama.265.3.380; SLINGLUFF CL, 1992, CANCER-AM CANCER SOC, V70, P1917, DOI 10.1002/1097-0142(19921001)70:7<1917::AID-CNCR2820700719>3.0.CO;2-5; TAHERY DP, 1992, INT J DERMATOL, V31, P629, DOI 10.1111/j.1365-4362.1992.tb03980.x; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; ZWAVELING A, 1987, J SURG ONCOL, V34, P194, DOI 10.1002/jso.2930340314; 1994, JAMA-J AM MED ASSOC, V271, P1587	27	119	119	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1703	1705		10.1001/jama.274.21.1703	http://dx.doi.org/10.1001/jama.274.21.1703			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474276				2022-12-01	WOS:A1995TH15100028
J	WEN, SW; HERNANDEZ, R; NAYLOR, CD				WEN, SW; HERNANDEZ, R; NAYLOR, CD			PITFALLS IN NONRANDOMIZED OUTCOMES STUDIES - THE CASE OF INCIDENTAL APPENDECTOMY WITH OPEN CHOLECYSTECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; PROSTATECTOMY; COMORBIDITY; DATABASES; RESECTION; MORBIDITY	Objectives.-To assess the short-term outcomes of incidental appendectomy through analysis of hospital administrative data and determine the consistency and plausibility of the observed results. Design.-Population-based historical cohort study. Setting.-All general hospitals in Ontario between 1981 and 1990. Patients.-Patients undergoing open primary cholecystectomy with (7846 exposed) and without (191 599 unexposed) incidental appendectomy. Main Outcome Measures.-In-hospital fatality rates, complication rates, and lengths of hospital stay. Results.-Crude comparisons showed a striking and paradoxical reduction in mortality after cholecystectomy when incidental appendectomy was performed (odds ratio [OR], 0.37; 95% confidence interval [CI], 0.23 to 0.57; P<.001); mean length of stay was also lower by -0.46 day (P<.001). After adjustment for confounding differences, such as comorbidity and nonelective surgery, mortality and lengths of stay were similar for exposed and unexposed patients; but exposed patients showed a significant increase in nonfatal complications (OR, 1.53; 95% CI, 1.39 to 1.68; P<.001). Adverse effects from incidental appendectomy emerged consistently for all three outcomes only after restricting the analysis to subgroups of patients at low surgical risk. The increased mortality for exposed patients was largest among low-risk groups; for example, among those younger than 70 years undergoing elective surgery, the OR was 2.65 (95% CI, 1.25 to 5.64; P<.001). Conclusion.-These findings suggest that incidental appendectomy is associated with a small but definite increase in adverse postoperative outcomes. However, plausible and consistent findings were only obtained after restricting the analysis to low-risk subgroups in which unmeasured differences in patients' baseline characteristics were less likely to confound adjusted outcome comparisons. This exercise highlights the potential pitfalls in nonrandomized outcomes comparisons using data sources with limited clinical detail, such as hospital discharge abstracts,	SUNNYBROOK HLTH SCI CTR,CLIN EPIDEMIOL UNIT,N YORK,ON M4N 3M5,CANADA; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT MED & SURG,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto								ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; ANDERSEN TF, 1990, MED CARE, V28, P870, DOI 10.1097/00005650-199010000-00002; BOGART J N, 1969, American Surgeon, V35, P650; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; DALEY J, 1994, RISK ADJUSTMENT MEAS, P199; DANS PE, 1993, ANN INTERN MED, V119, P855, DOI 10.7326/0003-4819-119-8-199310150-00014; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DONALDSON DR, 1989, BRIT J CLIN PRACT, V43, P15; ELSEFI TAM, 1989, INT SURG, V74, P32; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; LOWERY CH, 1962, ARCH SURG-CHICAGO, V85, P476; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PASS HI, 1988, HARDYS TXB SURG, P574; POLLOCK AV, 1977, BRIT MED J, V1, P20, DOI 10.1136/bmj.1.6052.20; RILEY G, 1993, MED CARE, V31, P921, DOI 10.1097/00005650-199310000-00005; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; ROOS NP, 1992, JAMA-J AM MED ASSOC, V268, P1269, DOI 10.1001/jama.1992.03490100063027; SHUMAKE L B, 1971, American Surgeon, V37, P310; STROM PR, 1983, AM J SURG, V145, P819, DOI 10.1016/0002-9610(83)90150-2; SUGIMOTO T, 1987, AM J PUBLIC HEALTH, V77, P471, DOI 10.2105/AJPH.77.4.471; TUNGPHAISAL S, 1989, Journal of the Medical Association of Thailand, V72, P633; WATERS EG, 1977, OBSTET GYNECOL, V50, P511; WEN SW, 1994, PATTERNS HLTH CARE O, V95, P98; WENNBERG JE, 1994, SCIENCE, V264, P758, DOI 10.1126/science.7513442; WILSON EA, 1973, AM J OBSTET GYNECOL, V116, P76, DOI 10.1016/0002-9378(73)90887-9; 1990, INT CLASSIFICATION D, V1; 1991, CANADIAN HOSPITAL DI; 1986, CANADIAN CLASSIFICAT	32	51	52	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 6	1995	274	21					1687	1691		10.1001/jama.274.21.1687	http://dx.doi.org/10.1001/jama.274.21.1687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH151	7474273				2022-12-01	WOS:A1995TH15100025
J	BARRETT, TG; BUNDEY, SE; MACLEOD, AF				BARRETT, TG; BUNDEY, SE; MACLEOD, AF			NEURODEGENERATION AND DIABETES - UK NATIONWIDE STUDY OF WOLFRAM (DIDMOAD) SYNDROME	LANCET			English	Article							OPTIC ATROPHY; MELLITUS; INSIPIDUS	Wolfram syndrome is the association of diabetes mellitus and optic atrophy, and is sometimes called DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). Incomplete characterisation of this autosomal recessive syndrome has relied on case-reports, and there is confusion with mitochondrial genome disorders. We therefore undertook a UK nationwide cross-sectional case-finding study to describe the natural history, complications, prevalence, and inheritance of the syndrome. We identified 45 patients with Wolfram syndrome-a prevalence of one per 770000. Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years). Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal;tract abnormalities (26, 58%) presented in the third decade followed by neurological complications (cerebellar ataxia, myoclonus [28, 62%]) in the fourth decade. Other abnormalities included gastrointestinal dysmotility in 11 (24%), and primary gonadal atrophy in seven of ten males investigated. Median age at death (commonly central respiratory failure with brain-stem atrophy) was 30 years (range 25-49). The natural history of Wolfram syndrome suggests that most patients will eventually develop most complications of this progressive, neurodegenerative disorder. Family studies indicate autosomal recessive inheritance with a carrier frequency of one in 354, an absence of a maternal history of diabetes or deafness, and an absence of the mitochondrial tRNA Leu (3243) mutation. Juvenile-onset diabetes mellitus and optic atrophy are the best available diagnostic criteria for Wolfram syndrome, the differential diagnosis of which includes other causes of neurodegeneration.	UNIV BIRMINGHAM, DEPT PAEDIAT & CHILD HLTH, CLIN GENET UNIT, BIRMINGHAM, W MIDLANDS, ENGLAND; ROYAL SHREWSBURY HOSP NHS TRUST, SHREWSBURY, SALOP, ENGLAND	University of Birmingham			Barrett, Timothy/F-1682-2010	Barrett, Timothy/0000-0002-6873-0750				BARRETT TG, 1995, J INHERIT METAB DIS, V18, P218, DOI 10.1007/BF00711771; BLASI C, 1986, DIABETES CARE, V9, P521, DOI 10.2337/diacare.9.5.521; BORNAPIGNATTI C, 1989, J PEDIATR, V114, P405; BU XD, 1993, LANCET, V342, P598, DOI 10.1016/0140-6736(93)91416-J; BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965; CARSON MJ, 1977, AM J DIS CHILD, V131, P1382, DOI 10.1001/archpedi.1977.02120250064010; CREMERS C W R J, 1977, Acta Paediatrica Scandinavica Supplement, P1; DIDMOAD, 1986, LANCET, V1, P1075; EMERY AEH, 1986, METHODOLOGY MED GENE; FRASER FC, 1977, J MED GENET, V14, P190, DOI 10.1136/jmg.14.3.190; GARCIALUNA PP, 1988, ACTA PAEDIATR SCAND, V77, P413, DOI 10.1111/j.1651-2227.1988.tb10669.x; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GUNN T, 1976, J PEDIATR-US, V89, P565, DOI 10.1016/S0022-3476(76)80387-3; HAGOPIAN WA, 1993, DIABETES, V42, P631, DOI 10.2337/diabetes.42.4.631; HAMPTON SM, 1988, CLIN ENDOCRINOL, V29, P9, DOI 10.1111/j.1365-2265.1988.tb00244.x; JACKSON MJ, 1994, DIABETES CARE, V17, P728, DOI 10.2337/diacare.17.7.728; MCCARTY DJ, 1993, INT J EPIDEMIOL, V22, P559, DOI 10.1093/ije/22.3.559; MONSON JP, 1983, LANCET, V1, P1286; PAGE MM, 1976, Q J MED, V45, P505; PEDEN NR, 1986, Q J MED, V58, P167; PILZ D, 1994, J MED GENET, V31, P328, DOI 10.1136/jmg.31.4.328; POLYMEROPOULOS MH, 1994, NAT GENET, V8, P95, DOI 10.1038/ng0994-95; RANDO TA, 1992, NEUROLOGY, V42, P1220, DOI 10.1212/WNL.42.6.1220; ROSE FC, 1966, Q J MED, V35, P385; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; Wolfram D.J., 1938, MAYO CLIN PROC, V13, P715	28	402	423	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1458	1463		10.1016/S0140-6736(95)92473-6	http://dx.doi.org/10.1016/S0140-6736(95)92473-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490992				2022-12-01	WOS:A1995TH15600010
J	CAIRNCROSS, S				CAIRNCROSS, S			VICTORY OVER GUINEAWORM DISEASE - PARTIAL OR PYRRHIC	LANCET			English	Editorial Material							ERADICATION				CAIRNCROSS, S (corresponding author), LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1,ENGLAND.							EDUNGBOLA LD, 1992, AM J TROP MED HYG, V47, P529, DOI 10.4269/ajtmh.1992.47.529; GARETT L, 1995, COMING PLAGUE NEWLY, P47; GREER G, 1994, AM J TROP MED HYG, V50, P393, DOI 10.4269/ajtmh.1994.50.393; HOPKINS DR, 1990, AM J TROP MED HYG, V43, P296, DOI 10.4269/ajtmh.1990.43.296; HOURS M, 1994, T ROY SOC TROP MED H, V88, P559, DOI 10.1016/0035-9203(94)90163-5; RUIZTIBEN E, 1995, EMERG INFECT DIS, V1, P58, DOI 10.3201/eid0102.950205; 1995, GUINEA WORM WRAP UP, V48, P1; 1995, WKLY EPIDEMIOL REC, V70, P29; 1994, WKLY EPIDEMIOL REC, V69, P121; 1995, WKLY EPIDEMIOL REC, V70, P77	10	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1440	1440		10.1016/S0140-6736(95)92465-5	http://dx.doi.org/10.1016/S0140-6736(95)92465-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490984				2022-12-01	WOS:A1995TH15600002
J	GAETJE, R; KOTZIAN, S; HERRMANN, G; BAUMANN, R; STARZINSKIPOWITZ, A				GAETJE, R; KOTZIAN, S; HERRMANN, G; BAUMANN, R; STARZINSKIPOWITZ, A			INVASIVENESS OF ENDOMETRIOTIC CELLS IN-VITRO	LANCET			English	Note								The pathogenesis of endometriosis is not known. The currently favoured theory is that viable endometrial cells, shed from the endometrium into the pelvic cavity by retrograde menstruation, reattach and invade other tissues. We used a collagen gel invasion assay to assess invasive potential of endometriotic cells. The invasion indices of cells from peritoneal endometriotic lesions and a metastatic bladder carcinoma cell line (EJ28) were similar (2.2-15.6 vs 8.4-11.6) whereas cells from normal endometrium and non-metastatic carcinoma cells (RT112) were non-invasive (indices <1). Invasiveness of endometriotic cells might contribute to the pathogenesis of endometriosis.	UNIV FRANKFURT,D-60054 FRANKFURT,GERMANY; UNIV FRANKFURT KLINIKUM,ZENTRUM FRAUENHEILKUNDE & GEBURTSCHILFE,W-6000 FRANKFURT,GERMANY; UNIV FRANKFURT KLINIKUM,ZENTRUM SENCKENBERG PATHOL,W-6000 FRANKFURT,GERMANY	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital								BATTISTA G, 1991, OBSTET GYNECOL SURV, V46, P374; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GLDMANN MB, 1990, CURRENT CONCEPTS END, P15; HANEY AF, 1990, CURRENT CONCEPTS END, P1; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; LANFRANCONE L, 1994, CURR OPIN GENET DEV, V4, P109, DOI 10.1016/0959-437X(94)90099-X; MACKINNON WB, 1992, INVAS METAST, V12, P241; OSTEEN KG, 1989, FERTIL STERIL, V52, P965; RAMEY JW, 1993, FERTIL STERIL, V60, P1	9	126	137	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1463	1464		10.1016/S0140-6736(95)92474-4	http://dx.doi.org/10.1016/S0140-6736(95)92474-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490993				2022-12-01	WOS:A1995TH15600011
J	HAQ, IU; JACKSON, PR; YEO, WW; RAMSAY, LE				HAQ, IU; JACKSON, PR; YEO, WW; RAMSAY, LE			SHEFFIELD RISK AND TREATMENT TABLE FOR CHOLESTEROL-LOWERING FOR PRIMARY PREVENTION OF CORONARY HEART-DISEASE	LANCET			English	Article							SERUM-CHOLESTEROL; MORTALITY; MANAGEMENT; FRAMINGHAM; REDUCTION; TRIALS	When used for the secondary prevention of coronary heart disease, treatment with an inhibitor of hydroxymethylglutaryl-coenzyme-A reductase results in worthwhile benefit that clearly exceeds any risk in patients whose risk of coronary death is 1.5% or more per year. This evidence can be extrapolated logically to primary prevention of coronary disease provided that treatment is targeted at those with similar or higher risk. We present a table that refines previously proposed methods of risk prediction. The table identifies subjects who have the specified degree of coronary risk; shows the serum cholesterol concentration that confers that degree of risk in the individual; and identifies subjects who will not have this degree of risk, irrespective of their cholesterol concentration. It is simple enough for use in ordinary practice. The table highlights the predominant effect of age on coronary risk; a person who is free of vascular disease and younger than 52 years is unlikely to have the specified degree of risk. Even in older people (60-70 years) several risk factors are generally required to attain this degree of risk. Some people are candidates for lipid-lowering drug treatment with serum cholesterol as low as 5.5 mmol/L, whereas others with cholesterol as high as 9.0 mmol/L are not. Although cholesterol lowering is a powerful method for preventing coronary events in people at high risk, cholesterol measurement by itself is not a good way to identify those with high coronary risk. The method can be adapted readily to target a different level of coronary-risk as new evidence on the benefit and risk of treatment becomes available.	ROYAL HALLAMSHIRE HOSP, DEPT MED & PHARMACOL, CLIN PHARMACOL & THERAPEUT SECT, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND	University of Sheffield				Yeo, Wilfred/0000-0001-9554-5203				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; [Anonymous], 1988, BRIT MED J, V296, P316; ASSMANN G, 1986, PROCAM TRIAL; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; EVANS P, 1994, BRIT MED J, V309, P509, DOI 10.1136/bmj.309.6953.509; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GROVER SA, 1995, BRIT MED J, V310, P975, DOI 10.1136/bmj.310.6985.975; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; National Cholesterol Education Program, 1994, CIRCULATION, V89, P1333, DOI [10.1161/01.CIR.89.3.1333, DOI 10.1161/01.CIR.89.3.1333]; OLIVER M, 1995, BMJ-BRIT MED J, V310, P1280, DOI 10.1136/bmj.310.6990.1280; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHAPER AG, 1986, BRIT MED J, V293, P474, DOI 10.1136/bmj.293.6545.474; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; TURNER RC, 1993, J HYPERTENS, V11, P309; WHINCUP PH, 1994, TXB HYPERTENSION, P38; 1989, WORLD HLTH STATISTIC	30	126	127	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1467	1471		10.1016/S0140-6736(95)92477-9	http://dx.doi.org/10.1016/S0140-6736(95)92477-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490996				2022-12-01	WOS:A1995TH15600014
J	LAFONT, A; GUEROT, C; LEMARCHAND, P				LAFONT, A; GUEROT, C; LEMARCHAND, P			WHICH GENE FOR WHICH RESTENOSIS	LANCET			English	Editorial Material									INSERM,U25,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	LAFONT, A (corresponding author), FAC NECKER ENFANTS MALAD,PARIS,FRANCE.		lemarchand, patricia/C-3247-2011	lemarchand, patricia/0000-0002-5330-2008				CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; ISNER JM, 1994, LANCET, V344, P1653, DOI 10.1016/S0140-6736(94)90454-5; KAKUTA T, 1994, CIRCULATION, V89, P2809, DOI 10.1161/01.CIR.89.6.2809; LAFONT A, 1995, CIRC RES, V76, P996, DOI 10.1161/01.RES.76.6.996; MINTZ GS, 1994, CIRCULATION, V90, P1; NUNES GL, 1995, ARTERIOSCL THROM VAS, V15, P156, DOI 10.1161/01.ATV.15.1.156; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; POST MJ, 1994, CIRCULATION, V89, P2816, DOI 10.1161/01.CIR.89.6.2816; STRAUSS BH, 1994, CIRC RES, V75, P650, DOI 10.1161/01.RES.75.4.650; TANAKA H, 1995, ANN NY ACAD SCI, V748, P526; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WALLER BF, 1991, CIRCULATION S2, V83, P128	14	19	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1442	1443		10.1016/S0140-6736(95)92467-1	http://dx.doi.org/10.1016/S0140-6736(95)92467-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490986				2022-12-01	WOS:A1995TH15600004
J	MURPHY, DJ; SELLERS, S; MACKENZIE, IZ; YUDKIN, PL; JOHNSON, AM				MURPHY, DJ; SELLERS, S; MACKENZIE, IZ; YUDKIN, PL; JOHNSON, AM			CASE-CONTROL STUDY OF ANTENATAL AND INTRAPARTUM RISK-FACTORS FOR CEREBRAL-PALSY IN VERY PRETERM SINGLETON BABIES	LANCET			English	Article							GERMINAL MATRIX HEMORRHAGE; LOW-BIRTH-WEIGHT; MATERNAL TOXEMIA; INFANTS; DELIVERY; CHORIOAMNIONITIS; INFECTION; NEWBORN; EVENTS; LABOR	The increase in survival of very preterm babies during the 1980s was accompanied by a sharp increase in the rate of cerebral palsy in this group. The relation between antenatal and intrapartum factors and cerebral palsy in such babies has not been well defined. To identify adverse and protective antenatal and intrapartum factors we undertook a case-control study of 59 very preterm babies who developed cerebral palsy, identified from a population-based register, and 234 randomly selected controls. The frequency of cerebral palsy decreased with increasing gestational age and birthweight. Antenatal complications occurred in 215 (73%) of the women with preterm deliveries. Factors associated with an increased risk of cerebral palsy after adjustment for gestational age were chorioamnionitis (odds ratio 4.2 [95% CI 1.4-12.0]) rupture of membranes (2.3 [1.2-4.2]), and infection (2.3 [1.2-4.5]). Pre-eclampsia was associated with a reduced risk of cerebral palsy (0.4 [0.2-0.9]), as was delivery without labour (0.3 [0.2-0.7]). There was no increased risk of cerebral palsy with intrauterine growth retardation (1.0 [0.9-1.1]). The effect of rigorous management of adverse antenatal factors on the frequency of cerebral palsy in very preterm babies should be tested in randomised controlled trials.	RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND; JOHN RADCLIFFE NHS TRUST,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND	Radcliffe Infirmary; University of Oxford				Murphy, Deirdre/0000-0001-6074-6718				AMON E, 1987, AM J OBSTET GYNECOL, V156, P1143, DOI 10.1016/0002-9378(87)90128-1; BERNAL AL, 1989, BRIT J OBSTET GYNAEC, V96, P1133, DOI 10.1111/j.1471-0528.1989.tb03187.x; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; CHENG LC, 1992, BRIT J OBSTET GYNAEC, V99, P817, DOI 10.1111/j.1471-0528.1992.tb14413.x; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; JOHNSON A, 1989, COMMUNITY MED, V11, P352; KITCHEN W, 1985, OBSTET GYNECOL, V66, P149; KUBAN KCK, 1992, J CHILD NEUROL, V7, P70, DOI 10.1177/088307389200700113; LEVITON A, 1988, OBSTET GYNECOL, V72, P571; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P549; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; O'Shea M, 1992, Paediatr Perinat Epidemiol, V6, P352, DOI 10.1111/j.1365-3016.1992.tb00775.x; OSHEA TM, 1991, PEDIATRICS; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P336, DOI 10.1016/0002-9378(89)90515-2; SINHA SK, 1990, ARCH DIS CHILD-FETAL, V65, P1017, DOI 10.1136/adc.65.10_Spec_No.1017; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; TROUNCE JQ, 1988, ARCH DIS CHILD, V63, P17, DOI 10.1136/adc.63.1.17; VOHR B, 1992, J PEDIATR-US, V121, P280, DOI 10.1016/S0022-3476(05)81204-1; WEINDLING AM, 1985, BRIT J OBSTET GYNAEC, V92, P1218, DOI 10.1111/j.1471-0528.1985.tb04865.x; YU VYH, 1984, BRIT J OBSTET GYNAEC, V91, P633, DOI 10.1111/j.1471-0528.1984.tb04822.x; 1995, LANCET, V345, P1455	30	331	337	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1449	1454		10.1016/S0140-6736(95)92471-X	http://dx.doi.org/10.1016/S0140-6736(95)92471-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490990				2022-12-01	WOS:A1995TH15600008
J	SAINSBURY, R				SAINSBURY, R			UPPER-LIMB DISEASE IN WOMEN TREATED FOR BREAST-CANCER	LANCET			English	Editorial Material											SAINSBURY, R (corresponding author), ROYAL INFIRM,HUDDERSFIELD,W YORKSHIRE,ENGLAND.							ADAM A, 1995, BRIT MED J, V311, P341, DOI 10.1136/bmj.311.7001.341; Janse A J, 1995, Eur J Surg Oncol, V21, P155, DOI 10.1016/S0748-7983(95)90270-8; TAYLOR PJ, 1995, BRIT J SURG, V82, P1089, DOI 10.1002/bjs.1800820827; 1995, MANAGEMENT ADVERSE E	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1444	1444		10.1016/S0140-6736(95)92469-8	http://dx.doi.org/10.1016/S0140-6736(95)92469-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490988				2022-12-01	WOS:A1995TH15600006
J	AUGENBRAUN, M; FELDMAN, J; CHIRGWIN, K; ZENILMAN, J; CLARKE, L; DEHOVITZ, J; LANDESMAN, S; MINKOFF, H				AUGENBRAUN, M; FELDMAN, J; CHIRGWIN, K; ZENILMAN, J; CLARKE, L; DEHOVITZ, J; LANDESMAN, S; MINKOFF, H			INCREASED GENITAL SHEDDING OF HERPES-SIMPLEX VIRUS TYPE-2 IN HIV-SEROPOSITIVE WOMEN	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED IMMUNODEFICIENCY; RISK-FACTORS; INFECTION; TRANSMISSION; ACQUISITION; FREQUENCY; PARTNER; HISTORY	Objective: To compare the prevalence of genital herpes simplex virus type 2 (HSV-2) shedding in human immunodeficiency virus (HIV)-seropositive women and HIV-seronegative women. Design: Cross-sectional study Setting: A major inner-city medical center. Patients: 106 women who were HIV-seropositive and HSV-2-seropositive and 70 women who were HIV-seronegative and HSV-2-seropositive were enrolled from various primary care settings. Measurements: Herpes simplex virus type 2 antibody determinations were done for all patients. Regardless of symptoms, vulvar and cervical HSV cultures were obtained from all HIV-seropositive women and from a randomly selected subgroup of HIV-seronegative women. Results: The prevalence of HSV-2 shedding was nearly four times greater in HIV-seropositive than in HIV-seronegative women (13.2% compared with 3.6%; P = 0.04; odds ratio, 4.1 [95% CI, 1.0 to 27.4]) when the serum antibody for HSV-2 was present. Seventy-nine percent of viral shedding among HIV-seropositive women was asymptomatic. Overall viral shedding increased significantly as the CD4 cell count decreased. Conclusions: Women with HIV infection, particularly those with low CD4 cell counts, shed HSV-2 from the vulva and cervix more commonly than women not infected with HIV. Most of this shedding is asymptomatic.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University	AUGENBRAUN, M (corresponding author), SUNY HLTH SCI CTR, 450 CLARKSON AVE, BOX 56, BROOKLYN, NY 11203 USA.			DeHovitz, Jack/0000-0001-7307-0614	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095014, R01AI031834, U01AI031834] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31834-03, N01-AI-95014] Funding Source: Medline; BHP HRSA HHS [CSA-92-100] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BHP HRSA HHS		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1985, AM J OBSTET GYNECOL, V153, P24, DOI 10.1016/0002-9378(85)90584-8; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; CONE RW, 1994, JAMA-J AM MED ASSOC, V272, P792, DOI 10.1001/jama.272.10.792; DEHOVITZ JA, 1994, AM J EPIDEMIOL, V140, P1125, DOI 10.1093/oxfordjournals.aje.a117212; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; RATTRAY MC, 1978, BRIT J VENER DIS, V54, P262; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; SAFRIN S, 1991, AIDS, V5, P1107, DOI 10.1097/00002030-199109000-00008; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; STENZELPOORE MP, 1987, SEX TRANSM DIS, V14, P17, DOI 10.1097/00007435-198701000-00004; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; YEAGER AS, 1984, PEDIATRICS, V73, P188; 1987, MMWR-MORBID M      S, V36, P1	18	162	165	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					845	847		10.7326/0003-4819-123-11-199512010-00006	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486467				2022-12-01	WOS:A1995TG20900006
J	BECKMANN, H; CHEN, JL; OBRIEN, T; TJIAN, R				BECKMANN, H; CHEN, JL; OBRIEN, T; TJIAN, R			COACTIVATOR AND PROMOTER-SELECTIVE PROPERTIES OF RNA-POLYMERASE-I TAFS	SCIENCE			English	Article							TRANSCRIPTION FACTOR; BINDING	Human ribosomal RNA synthesis by RNA polymerase I requires the activator UBF and the promoter selectivity factor SL1, which consists of the TATA binding protein (TBP) and three associated subunits, TAF(I) 110, TAF(I)63, and TAF(I)48. Here it is shown that both TAF(I)110 and TAF(I)63 contact the promoter, whereas TAF(l)48 serves as a target for interaction with UBF and is required to form a transcriptionally active SL1 complex responsive to UBF in vitro. TAF(I)48 also alters the ability of TBP to interact with TATA box elements, and the resulting complex fails to support transcription by RNA polymerase II. Thus, TAF(I)48 may function both as a target to mediate UBF activation and as a class-specific promoter selectivity factor.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				O'Brien, Thomas/0000-0002-9161-8070				BECKMANN H, UNPUB; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KWON H, 1994, J BIOL CHEM, V269, P30140; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OBRIEN T, 1995, GENE DEV, V9, P1098, DOI 10.1101/gad.9.9.1098; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; RUPPERT S, IN PRESS GENES DEV; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	30	82	85	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	1995	270	5241					1506	1509		10.1126/science.270.5241.1506	http://dx.doi.org/10.1126/science.270.5241.1506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491500				2022-12-01	WOS:A1995TH37500043
J	DELEON, M; WANG, Y; JONES, L; PEREZREYES, E; WEI, XY; SOONG, TW; SNUTCH, TP; YUE, DT				DELEON, M; WANG, Y; JONES, L; PEREZREYES, E; WEI, XY; SOONG, TW; SNUTCH, TP; YUE, DT			ESSENTIAL CA2+-BINDING MOTIF FOR CA2+-SENSITIVE INACTIVATION OF L-TYPE CA2+ CHANNELS	SCIENCE			English	Article							CALCIUM-DEPENDENT INACTIVATION; FUNCTIONAL EXPRESSION; ALPHA-1 SUBUNIT; BETA-SUBUNIT; BINDING; NEURONS; CLONING; PHOSPHORYLATION; BRAIN; CELLS	Intracellular calcium (Ca2+) inhibits the opening of L-type (alpha(1C)) Ca2+ channels, providing physiological control of Ca2+ entry into a wide variety of cells. A structural determinant of this Ca2+-sensitive inactivation was revealed by chimeric Ca2+ channels derived from parental alpha(1C) and alpha(1E) channels, the latter of which is a neuronal channel lacking Ca2+ inactivation. A consensus Ca2+-binding motif (an EF hand), located on the alpha(1C) subunit, was required for Ca2+ inactivation. Donation of the alpha(1C) EF-hand region to the alpha(1E) channel conferred the Ca2+-inactivating phenotype. These results strongly suggest that Ca2+ binding to the alpha(1C) subunit initiates Ca2+ inactivation.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOMED ENGN,PROGRAM MOLEC & CELLULAR SYST PHYSIOL,BALTIMORE,MD 21205; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153; MED COLL GEORGIA,INST MOLEC MED & GENET,AUGUSTA,GA 30912; UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER,BC V6T 1Z3,CANADA	Johns Hopkins University; Loyola University Chicago; University System of Georgia; Augusta University; University of British Columbia			Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Soong, Tuck Wah/0000-0002-0876-0325				ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; BRODIN P, 1990, J BIOL CHEM, V265, P11125; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; GUTNICK MJ, 1989, J PHYSIOL-LONDON, V412, P197, DOI 10.1113/jphysiol.1989.sp017611; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; IMREDY JP, 1992, NEURON, V9, P197, DOI 10.1016/0896-6273(92)90159-B; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KRETSINGER RH, 1972, NATURE-NEW BIOL, V240, P85, DOI 10.1038/newbio240085a0; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; NOBLE D, 1979, INITIATION HEARTBEAT, P1; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Reuter H, 1973, Prog Biophys Mol Biol, V26, P1, DOI 10.1016/0079-6107(73)90016-3; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHERUBL H, 1993, AM J PHYSIOL, V264, pE354, DOI 10.1152/ajpendo.1993.264.3.E354; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHERMAN A, 1990, BIOPHYS J, V58, P985, DOI 10.1016/S0006-3495(90)82443-7; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; WANG Q, 1995, CELL, V80, P1; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1991, J BIOL CHEM, V266, P21943; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	38	226	227	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1502	1506		10.1126/science.270.5241.1502	http://dx.doi.org/10.1126/science.270.5241.1502			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491499				2022-12-01	WOS:A1995TH37500042
J	FRIEDLANDER, M; BROOKS, PC; SHAFFER, RW; KINCAID, CM; VARNER, JA; CHERESH, DA				FRIEDLANDER, M; BROOKS, PC; SHAFFER, RW; KINCAID, CM; VARNER, JA; CHERESH, DA			DEFINITION OF 2 ANGIOGENIC PATHWAYS BY DISTINCT ALPHA(V) INTEGRINS	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; MECHANISMS; FIBRINOGEN	Angiogenesis depends on cytokines and vascular cell adhesion events, Two cytokine-dependent pathways of angiogenesis were shown to exist and were defined by their dependency on distinct vascular cell integrins. In vivo angiogenesis in corneal or chorioallantoic membrane models induced by basic fibroblast growth factor or by tumor necrosis factor-alpha depended on alpha(V) beta(3), whereas angiogenesis initiated by vascular endothelial growth factor, transforming growth factor-alpha, or phorbol ester depended on alpha(V) beta(5). Antibody to each integrin selectively blocked one of these pathways, and a cyclic peptide antagonist of both integrins blocked angiogenesis stimulated by each cytokine tested. These pathways are further distinguished by their sensitivity to calphostin C, an inhibitor of protein kinase C that blocked angiogenesis potentiated by alpha(V) beta(5) but not by alpha(V) beta(3).	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego	FRIEDLANDER, M (corresponding author), Scripps Res Inst, DEPT CELL BIOL, ROBERT MEALEY LAB STUDY MASCULAR DEGENERAT, LA JOLLA, CA 92037 USA.			Varner, Judith/0000-0002-9251-0600				AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROOKS PM, UNPUB; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DRAKE CJ, 1995, J CELL SCI, V108, P2655; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SEP RET SOC M SANT F; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER JW, 1994, AM J PATHOL, V145, P574; PFAFF M, 1994, J BIOL CHEM, V269, P20233; SHAFFER R, IN PRESS NATO ASI MO; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	22	1139	1256	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1500	1502		10.1126/science.270.5241.1500	http://dx.doi.org/10.1126/science.270.5241.1500			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491498				2022-12-01	WOS:A1995TH37500041
J	JEON, YH; NEGISHI, T; SHIRAKAWA, M; YAMAZAKI, T; FUJITA, N; ISHIHAMA, A; KYOGOKU, Y				JEON, YH; NEGISHI, T; SHIRAKAWA, M; YAMAZAKI, T; FUJITA, N; ISHIHAMA, A; KYOGOKU, Y			SOLUTION STRUCTURE OF THE ACTIVATOR CONTACT DOMAIN OF THE RNA-POLYMERASE ALPHA-SUBUNIT	SCIENCE			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION ACTIVATION; FUNCTIONAL MAP; PROTEINS; RECOGNITION; OCT-1	The structure of the carboxyl-terminal domain of the Escherichia coli RNA polymerase oc subunit (alpha CTD), which is regarded as the contact site for transcription activator proteins and for the promoter UP element, was determined by nuclear magnetic resonance spectroscopy, Its compact structure of four helices and two long arms enclosing its hydrophobic core shows a folding topology distinct from those of other DNA-binding proteins, The UP element binding site was found on the surface comprising helix 1, the amino-terminal end of helix 4, and the preceding loop, Mutation experiments indicated that the contact sites for transcription activator proteins are also on the same surface.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; NARA INST SCI & TECHNOL,GRAD SCH BIOSCI,NARA 63001,JAPAN	Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Nara Institute of Science & Technology			Jeon, Young Ho/F-4483-2011					ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; Bax A., 1993, NMR PROTEINS, P33; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1992, VERSION 3 1; Burgess RR, 1976, RNA POLYMERASE, P69; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P946; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HELLMAN J, 1988, ANNU REV BIOCHEM, V57, P839; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyogoku Y, 1995, METHOD ENZYMOL, V261, P524; MAJUMDAR A, 1993, J BIOMOL NMR, V3, P387; MATSUO Y, 1994, PROTEIN SCI, V3, P2055, DOI 10.1002/pro.5560031118; MURAKAMI K, UNPUB; NEGISHI T, 1995, J MOL BIOL, V248, P723, DOI 10.1006/jmbi.1995.0254; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TAO K, IN PRESS J BACTERIOL; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	29	153	156	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1495	1497		10.1126/science.270.5241.1495	http://dx.doi.org/10.1126/science.270.5241.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491496				2022-12-01	WOS:A1995TH37500039
J	KATO, S; ENDOH, H; MASUHIRO, Y; KITAMOTO, T; UCHIYAMA, S; SASAKI, H; MASUSHIGE, S; GOTOH, Y; NISHIDA, E; KAWASHIMA, H; METZGER, D; CHAMBON, P				KATO, S; ENDOH, H; MASUHIRO, Y; KITAMOTO, T; UCHIYAMA, S; SASAKI, H; MASUSHIGE, S; GOTOH, Y; NISHIDA, E; KAWASHIMA, H; METZGER, D; CHAMBON, P			ACTIVATION OF THE ESTROGEN-RECEPTOR THROUGH PHOSPHORYLATION BY MITOGEN-ACTIVATED PROTEIN-KINASE	SCIENCE			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVATION; HUMAN-BREAST-CANCER; DOMAINS; IDENTIFICATION; BINDING; GROWTH; 4-HYDROXYTAMOXIFEN; TAMOXIFEN; ONCOGENE; ELEMENT	The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1). This Ser(118) is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and in cells treated with epidermal growth factor (EGF) and insulin-like growth factor (IGF) in vivo. Overexpression of MAPK kinase (MAPKK) or of the guanine nucleotide binding protein Ras, both of which activate MAPK, enhanced estrogen-induced and antiestrogen (tamoxifen);induced transcriptional activity of wild-type ER, but not that of a mutant ER with an alanine in place of Ser(118). Thus, the activity of the amino-terminal AF-1 of the ER is modulated by the phosphorylation of Ser(118) through the Ras-MAPK cascade of the growth factor signaling pathways.	UNIV STRASBOURG 1, INSERM, CNRS, INST GENET BIOL MOLEC & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; TOKYO UNIV AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN; YAMANOUCHI INST DRUG DISCOVERY RES CO LTD, MOLEC MED RES LAB 2, TSUKUBA, IBARAKI 305, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tokyo University of Agriculture; Kyoto University				Kitamoto, Takuya/0000-0002-4008-5497; Metzger, Daniel/0000-0002-5555-046X				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARNOLD SF, 1995, J STEROID BIOCHEM, V52, P159, DOI 10.1016/0960-0760(94)00166-J; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRUNNER N, 1993, CANCER RES, V53, P3229; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DENTON RR, 1992, J BIOL CHEM, V267, P7263; Efremidis AP, 1989, CANCER J, V2, P288; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6; HARRIS AL, 1988, BREAST CANCER CELLUL, P93; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JANES PW, 1994, ONCOGENE, V9, P3601; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; JORDAN VC, 1987, BREAST CANCER RES TR, V10, P31, DOI 10.1007/BF01806132; Kastner P., 1994, Vitamin A in health and disease., P189; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KATO S, UNPUB; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; MANGELSDORF DJ, 1994, RETINOIDS, pCH8; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON S, 1995, BREAST, V4, P11, DOI 10.1016/0960-9776(95)90022-5; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P157; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Murphy L C, 1990, Semin Cancer Biol, V1, P305; PETECH SL, 1992, SCIENCE, V257, P1355; ROCHLITZ CF, 1989, CANCER RES, V49, P357; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WASBURN T, 1991, MOL ENDOCRINOL, V5, P235; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	47	1604	1668	0	92	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1491	1494		10.1126/science.270.5241.1491	http://dx.doi.org/10.1126/science.270.5241.1491			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491495				2022-12-01	WOS:A1995TH37500038
J	KAULA, WM				KAULA, WM			VENUS RECONSIDERED	SCIENCE			English	Article							THERMAL EVOLUTION; PHASE-TRANSITION; MAGELLAN DATA; TECTONICS; MODEL; CONSTRAINTS; MANTLE; EARTH; WATER	The Magellan imagery shows that Venus has a crater abundance equivalent to a surface age of 300 million to 500 million years and a crater distribution close to random. Hence, the tectonics of Venus must be quiescent compared to those of Earth in the last few 100 million years. The main debate is whether the decline in tectonic activity on Venus is closer to monotonic or episodic, with enhanced tectonism and volcanism yet to come. The former hypothesis implies that most radioactive heat sources have been differentiated upward; the latter, that they have remained at depth. The low level of activity in the last few 100 million years inferred from imagery favors the monotonic hypothesis; some chemical evidence, particularly the low abundance of radiogenic argon, favors the episodic. A problem for both hypotheses is the rapid decline of thermal and tectonic activity some 300 million to 500 million years ago. The nature of the convective instabilities that caused the decline, and their propagation, are unclear.			KAULA, WM (corresponding author), UNIV CALIF LOS ANGELES, DEPT EARTH & SPACE SCI, LOS ANGELES, CA 90095 USA.							ARKANIHAMED J, 1994, J GEOPHYS RES-PLANET, V99, P2019, DOI 10.1029/93JE03172; ARKANIHAMED J, 1993, J GEOPHYS RES-PLANET, V98, P5309, DOI 10.1029/93JE00052; ARKANIHAMED J, 1993, PHYS EARTH PLANET IN, V76, P75, DOI 10.1016/0031-9201(93)90056-F; BAKER VR, 1992, J GEOPHYS RES-PLANET, V97, P13421, DOI 10.1029/92JE00927; BIRD GP, 1995, REV GEOPHYS S, V33, P379; BRACKETT RA, 1995, J GEOPHYS RES-PLANET, V100, P1553, DOI 10.1029/94JE02708; Burnham C. W., 1979, EVOLUTION IGNEOUS RO, P439, DOI DOI 10.2307/J.CTT13X1DKM.19; CARLSON RW, 1994, REV GEOPHYS, V32, P337, DOI 10.1029/94RG01874; FORSYTH DW, 1985, J GEOPHYS RES-SOLID, V90, P2623, DOI 10.1029/JB090iB14p12623; FREED AM, 1995, LUNAR PLANET SCI C, V26, P421; GREEN DH, 1973, EARTH PLANET SC LETT, V19, P37, DOI 10.1016/0012-821X(73)90176-3; GRIMM RE, 1988, J GEOPHYS RES-SOLID, V93, P11911, DOI 10.1029/JB093iB10p11911; GRIMM RE, 1994, J GEOPHYS RES-PLANET, V99, P23163, DOI 10.1029/94JE02196; HERRICK RR, 1994, GEOLOGY, V22, P703, DOI 10.1130/0091-7613(1994)022<0703:RHOV>2.3.CO;2; Herzog S. G., 1995, LUNAR PLANET SCI C, P591; IVANOV MA, 1993, GEOPHYS RES LETT, V20, P2579, DOI 10.1029/93GL02692; JULL MG, 1995, PHYS EARTH PLANET IN, V89, P163, DOI 10.1016/0031-9201(95)03015-O; KARATO SI, 1986, J GEOPHYS RES-SOLID, V91, P8151, DOI 10.1029/JB091iB08p08151; KARGEL JS, 1993, ICARUS, V103, P253, DOI 10.1006/icar.1993.1069; KAULA WM, 1993, GEOPHYS RES LETT, V20, P2583, DOI 10.1029/93GL03086; KAULA WM, 1981, GEOPHYS RES LETT, V8, P1187, DOI 10.1029/GL008i012p01187; KAULA WM, 1992, J GEOPHYS RES-PLANET, V97, P16085, DOI 10.1029/92JE01643; KAULA WM, 1990, SCIENCE, V247, P1191, DOI 10.1126/science.247.4947.1191; KAULA WM, 1993, LUNAR PLANET SCI C, V24, P767; KAULA WM, UNPUB; KIEFER WS, 1986, GEOPHYS RES LETT, V13, P14, DOI 10.1029/GL013i001p00014; KLOSE KB, 1992, J GEOPHYS RES-PLANET, V97, P16353, DOI 10.1029/92JE01865; KONOPLIV AS, UNPUB; LACHENBRUCH AH, 1970, J GEOPHYS RES, V75, P3291, DOI 10.1029/JB075i017p03291; LITHGOWBERTELLONI C, 1993, GEOPHYS RES LETT, V20, P375, DOI 10.1029/93GL00168; MACKWELL SJ, 1995, ROCK MECHANICS - PROCEEDINGS OF THE 35TH U.S. SYMPOSIUM, P207; NAMIKI N, 1994, SCIENCE, V265, P929, DOI 10.1126/science.265.5174.929; NAMIKI N, 1993, J GEOPHYS RES-PLANET, V98, P15025, DOI 10.1029/93JE01626; NAMIKI N, 1995, LUNAR PLANET SCI, V26, P1029; NIKOLAYEVA OV, 1995, LUNAR PLANET SCI C, V26, P1049; PARMENTIER EM, 1992, GEOPHYS RES LETT, V19, P2015, DOI 10.1029/92GL01862; PHILLIPS RJ, 1995, GEOPHYS RES LETT, V22, P1517, DOI 10.1029/95GL01412; PHILLIPS RJ, 1992, J GEOPHYS RES-PLANET, V97, P15923, DOI 10.1029/92JE01696; PHILLIPS RJ, 1994, ANNU REV EARTH PL SC, V22, P597, DOI 10.1146/annurev.ea.22.050194.003121; PHILLIPS RJ, 1991, SCIENCE, V252, P651, DOI 10.1126/science.252.5006.651; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P1301, DOI 10.1029/JB095iB02p01301; PHILLIPS RJ, 1990, LUNAR PLANET SCI, V21, P1065; POLLACK JB, 1992, ICARUS, V51, P169; PRICE M, 1994, NATURE, V372, P756, DOI 10.1038/372756a0; SANDWELL DT, 1992, SCIENCE, V257, P766, DOI 10.1126/science.257.5071.766; SCHABER GG, 1992, J GEOPHYS RES-PLANET, V97, P13257, DOI 10.1029/92JE01246; SCHATZ JF, 1972, J GEOPHYS RES, V77, P6966, DOI 10.1029/JB077i035p06966; SOLOMON SC, 1993, LUNAR PLANET SCI, V24, P1331; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; STROM RG, 1994, J GEOPHYS RES-PLANET, V99, P10899, DOI 10.1029/94JE00388; SURKOV YA, 1987, J GEOPHYS RES-SOLID, V92, pE537, DOI 10.1029/JB092iB04p0E537; SURKOV YA, 1984, J GEOPHYS RES S, V89, pB383; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; TURCOTTE DL, 1993, J GEOPHYS RES-PLANET, V98, P17061, DOI 10.1029/93JE01775; ZUBER MT, 1987, J GEOPHYS RES-SOLID, V92, pE541, DOI 10.1029/JB092iB04p0E541	55	28	28	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1460	1464		10.1126/science.270.5241.1460	http://dx.doi.org/10.1126/science.270.5241.1460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491490				2022-12-01	WOS:A1995TH37500029
J	LYDALL, D; WEINERT, T				LYDALL, D; WEINERT, T			YEAST CHECKPOINT GENES IN DNA-DAMAGE PROCESSING - IMPLICATIONS FOR REPAIR AND ARREST	SCIENCE			English	Article							EXONUCLEASE ACTIVE-SITE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; REPLICATION; MITOSIS; POLYMERASES; P34CDC28; PROTEIN; MUTANTS	Yeast checkpoint control genes were found to affect processing of DNA damage as well as cell cycle arrest. An assay that measures DNA damage processing in vivo showed that the checkpoint genes RAD17, RAD24, and MEC3 activated an exonuclease that degrades DNA. The degradation is probably a direct consequence of checkpoint protein function, because RAD17 encodes a putative 3'-5' DNA exonuclease. Another checkpoint gene, RAD9, had a different role: It inhibited the degradation by RA17, RAD24, and MEC3. A model of how processing of DNA damage may be linked to both DNA repair and cell cycle arrest is proposed.			LYDALL, D (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045276] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45276-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HOLLIDAY R, 1976, GENET RES, V27, P413, DOI 10.1017/S0016672300016621; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V689, P7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LYDALL D, UNPUB; NASIM A, 1975, GENETICS, V79, P573; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NOWAK R, 1995, SCIENCE, V268, P1700, DOI 10.1126/science.7792589; ONEL K, 1995, MOL CELL BIOL, V15, P5329; ONEL K, UNPUB; RILES L, 1993, GENETICS, V134, P81; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; THELEN MP, 1994, J BIOL CHEM, V269, P747; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8	29	352	356	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1488	1491		10.1126/science.270.5241.1488	http://dx.doi.org/10.1126/science.270.5241.1488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491494				2022-12-01	WOS:A1995TH37500037
J	MANABE, YC; VINETZ, JM; MOORE, RD; MERZ, C; CHARACHE, P; BARTLETT, JG				MANABE, YC; VINETZ, JM; MOORE, RD; MERZ, C; CHARACHE, P; BARTLETT, JG			CLOSTRIDIUM DIFICILE COLITIS - AN EFFICIENT CLINICAL APPROACH TO DIAGNOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; DIARRHEA; TOXINS; FECES	DIFFICILE-ASSOCIATED DIARRHEA; RISK-FACTORS; HOSPITALIZED-PATIENTS; TOXIN; INFECTION; COHORT	Objective: To define clinical and laboratory variables that suggest the presence of Clostridium difficile colitis and to establish the number of stool specimens needed to reasonably exclude the diagnosis of C. difficile colitis. Design: Prospective study of consecutive inpatients whose stool specimens were sent to be evaluated for the presence of C. difficile toxin. Setting: University teaching hospital. Patients: 268 hospital inpatients in medical, surgical, and gynecology units. Measurements: Structured history and physical examination; detection of C. difficile toxin by cytotoxin tissue-culture assay with anti-C. difficile antiserum neutralization and by enzyme-linked immunoassay (EIA) for C. difficile toxins A and B; and detection of fecal leukocytes by microscopic examination and by latex agglutination lactoferrin assay. Results: 43 of 268 consecutive inpatients were positive for C. difficile toxin by EIA or tissue-culture assay. Although toxin was detected by EIA alone in 39 of the 43 patients, it was detected in an additional 4 patients (10%) by tissue-culture assay alone. Univariate and multivariate logistic regression analysis showed that the following clinical and laboratory features were associated with C. difficile toxin positivity: the onset of diarrhea 6 or more days after the administration of antibiotics (odds ratio, 1.38 [95% CI, 1.10 to 3.79]); hospital stay longer than 15 days (odds ratio, 1.33 [CI, 1.09 to 3.95]); the presence of fecal leukocytes determined by microscopy (odds ratio, 2.39 [CI, 1.05 to 5.42]) or lactoferrin assay (odds ratio, 3.74 [CI, 1.80 to 7.76]); the presence of semiformed (as opposed to watery) stools (odds ratio, 2.33 [CI, 1.10 to 4.90]); and cephalosporin use (odds ratio, 2.36 [CI, 1.10 to 5.09]). Toxin-positive patients were no more likely than controls to have had fever, abdominal pain or cramps, leukocytosis, green-colored diarrhea, or blood in the stool or to have received clindamycin or penicillin derivatives. Of the 43 patients with C. difficile toxin, 34 (79%) had positive results for the toxin on the first stool specimen, 5 (cumulative, 91%) had positive results on the second specimen, and 4 had positive results on the third specimen. Overall, the negative predictive value of the first stool specimen was 97%. All patients who had two or more clinical or laboratory predictors were diagnosed with C. difficile disease when either the first or the second stool specimen was positive for toxin. Conclusions: Clinicians at the bedside can use readily available clinical and laboratory information to decide which patients are likely to have C. difficile disease and when it is appropriate and useful to order specific diagnostic tests for C. difficile toxin. Such data are also useful in determining the number of stool samples that reasonably excludes the diagnosis of C. difficile colitis.	JOHNS HOPKINS UNIV, SCH MED, DIV INFECT DIS, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV INTERNAL MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, CLIN MICROBIOL LAB, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University				Vinetz, Joseph/0000-0001-8344-2004				ANAND A, 1994, AM J GASTROENTEROL, V89, P519; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BORRIELLO SP, 1992, EUR J CLIN MICROBIOL, V11, P360, DOI 10.1007/BF01962079; BOWMAN RA, 1986, FEMS MICROBIOL LETT, V34, P31, DOI 10.1016/0378-1097(86)90265-X; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; FEKETY R, 1993, JAMA-J AM MED ASSOC, V269, P71, DOI 10.1001/jama.269.1.71; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; GUERRANT RL, 1992, J CLIN MICROBIOL, V30, P1238, DOI 10.1128/JCM.30.5.1238-1242.1992; MCFARLAND LV, 1991, INFECT IMMUN, V59, P2456, DOI 10.1128/IAI.59.7.2456-2462.1991; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MERZ CS, 1994, J CLIN MICROBIOL, V32, P1142, DOI 10.1128/JCM.32.5.1142-1147.1994; MOGG GAG, 1979, BRIT J SURG, V66, P738, DOI 10.1002/bjs.1800661017; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; VISCIDI R, 1981, GASTROENTEROLOGY, V81, P5; YONG WH, 1994, J CLIN MICROBIOL, V32, P1360, DOI 10.1128/JCM.32.5.1360-1361.1994	18	133	137	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					835	+		10.7326/0003-4819-123-11-199512010-00004	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486465				2022-12-01	WOS:A1995TG20900004
J	MANNING, WJ; WEINTRAUB, RM; WAKSMONSKI, CA; HAERING, JM; ROONEY, PS; MASLOW, AD; JOHNSON, RG; DOUGLAS, PS				MANNING, WJ; WEINTRAUB, RM; WAKSMONSKI, CA; HAERING, JM; ROONEY, PS; MASLOW, AD; JOHNSON, RG; DOUGLAS, PS			ACCURACY OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY FOR IDENTIFYING LEFT ATRIAL THROMBI - A PROSPECTIVE, INTRAOPERATIVE STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; HEART ATRIUM; THROMBOSIS, CORONARY; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS	RHEUMATIC HEART-DISEASE; MITRAL-VALVE; DIMENSIONAL ECHOCARDIOGRAPHY; FIBRILLATION; CARDIOVERSION; DIAGNOSIS; CONTRAST	Objective: To determine the ability of transesophageal echocardiography to accurately identify or exclude left atrial thrombi. Design: Prospective cohort study. Setting: University hospital. Patients: 231 consecutive patients having transesophageal echocardiography before elective repair or replacement of the mitral valve or excision of a left atrial tumor. Fifty-six percent of patients had a history of atrial fibrillation, and 17% had a history of thromboembolism. Measurement: Identification of left atrial thrombi during transesophageal echocardiographic examination and comparison with direct near-simultaneous visualization during cardiac surgery. Results: Transesophageal echocardiography identified 14 left atrial thrombi in 14 patients (6%). Thrombus size ranged from 3 to 80 mm. Surgery confirmed 12 of 14 thrombi (86%), including 9 thrombi confined to the left appendage. No additional thrombi were found on direct inspection of the atria (sensitivity, 100% [95% CI, 74% to 100%]; specificity, 99% [CI, 97% to 99.9%]; positive predictive value, 86% [12/14]; negative predictive value, 100% [217/217]; for a population that had a 5.2% prevalence of thrombi). All 12 surgically confirmed thrombi were identified by two independent observers. Neither thrombus seen by only a single observer on transesophageal echocardiography was confirmed during direct inspection of the atria at surgery. Conclusion: Transesophageal echocardiography is highly accurate for identifying left atrial thrombi and can be used clinically to exclude left atrial thrombi.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	MANNING, WJ (corresponding author), BETH ISRAEL HOSP, DIV CARDIOVASC, CHARLES A DANA & HARVARD THORNDIKE LAB, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049				ABERG H, 1969, ACTA MED SCAND, V185, P373; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; BLACKSHEAR JL, 1993, AM J CARDIOL, V72, P840, DOI 10.1016/0002-9149(93)91079-W; CASTELLO R, 1990, AM J CARDIOL, V65, P1149, DOI 10.1016/0002-9149(90)90330-4; DEPACE NL, 1981, AM J CARDIOL, V48, P954, DOI 10.1016/0002-9149(81)90364-7; GUIRAUDON GM, 1991, ANN THORAC SURG, V52, P1058, DOI 10.1016/0003-4975(91)91281-Y; HERZOG CA, 1984, J AM COLL CARDIOL, V3, P1340, DOI 10.1016/S0735-1097(84)80195-3; HWANG JJ, 1993, AM J CARDIOL, V72, P677; KRONZON I, 1990, J AM COLL CARDIOL, V16, P1320, DOI 10.1016/0735-1097(90)90572-7; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MANNING WJ, 1992, BRIT HEART J, V67, P170; MUGGE A, 1990, American Journal of Cardiac Imaging, V4, P173; Olson J D, 1992, J Am Soc Echocardiogr, V5, P52; ORSINELLI DA, 1993, AM J CARDIOL, V72, P1337, DOI 10.1016/0002-9149(93)90315-4; Pearlman A S, 1992, J Am Soc Echocardiogr, V5, P187; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SCHWEIZER P, 1981, BRIT HEART J, V45, P148; Seward J B, 1992, J Am Soc Echocardiogr, V5, P288; SHRESTHA NK, 1983, CIRCULATION, V67, P341, DOI 10.1161/01.CIR.67.2.341; STARLING MR, 1983, AM HEART J, V106, P1143, DOI 10.1016/0002-8703(83)90664-6; TARDIF JC, 1994, AM HEART J, V128, P156, DOI 10.1016/0002-8703(94)90022-1; VISSER CA, 1983, CHEST, V83, P228, DOI 10.1378/chest.83.2.228	24	301	311	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					817	+		10.7326/0003-4819-123-11-199512010-00001	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486462				2022-12-01	WOS:A1995TG20900001
J	MEISSNER, RS; REBEK, J; DEMENDOZA, J				MEISSNER, RS; REBEK, J; DEMENDOZA, J			AUTOENCAPSULATION THROUGH INTERMOLECULAR FORCES - A SYNTHETIC SELF-ASSEMBLING SPHERICAL COMPLEX	SCIENCE			English	Article								The synthesis and characterization of a system for the study of molecular recognition phenomena are described. The system involves a tetraurea molecule that is capable of assembly into various associated states through hydrogen bonding. In organic solvents, the dynamic transition between a low-ordered (aggregate) state and a highly ordered dimeric assembly can be induced by the introduction of smaller molecules of appropriate size and shape. These smaller molecules, such as benzene, adamantanes, and ferrocenes, act as guests that occupy the pseudospherical capsule formed by the dimeric host, Among various guests, those that best fill the cavity and offer chemical complementarity to the host are preferentially encapsulated.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV AUTONOMA MADRID,DEPT QUIM,E-28049 MADRID,SPAIN	Massachusetts Institute of Technology (MIT); Autonomous University of Madrid								BAXTER P, 1993, ANGEW CHEM INT EDIT, V32, P69, DOI 10.1002/anie.199300691; BEERLI R, 1995, TETRAHEDRON LETT, V36, P1813, DOI 10.1016/0040-4039(95)00150-B; BONARLAW RP, 1993, TETRAHEDRON LETT, V34, P1677, DOI 10.1016/0040-4039(93)85039-Y; BRANDA N, 1994, SCIENCE, V263, P1267, DOI 10.1126/science.8122107; CARPINO LA, 1963, J AM CHEM SOC, V85, P2144, DOI 10.1021/ja00897a024; CRAM DJ, 1992, NATURE, V356, P29, DOI 10.1038/356029a0; CRAM DJ, 1993, J AM CHEM SOC, V115, P10111, DOI 10.1021/ja00075a029; DUGAS H, 1989, BIOORG CHEM, P20; FUJITA M, 1995, J AM CHEM SOC, V117, P1649, DOI 10.1021/ja00110a026; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931; Israelachvili J., 1992, INTERMOLECULAR SURFA; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; MATTIAS JP, 1994, J AM CHEM SOC, V116, P1725; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; SETO CT, 1991, J AM CHEM SOC, V113, P712, DOI 10.1021/ja00002a071; SIMARD M, 1991, J AM CHEM SOC, P4696; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991; YANG J, 1993, J AM CHEM SOC, V115, P5314, DOI 10.1021/ja00065a061	19	201	201	1	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1485	1488		10.1126/science.270.5241.1485	http://dx.doi.org/10.1126/science.270.5241.1485			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491493				2022-12-01	WOS:A1995TH37500036
J	NISSEN, P; KJELDGAARD, M; THIRUP, S; POLEKHINA, G; RESHETNIKOVA, L; CLARK, BFC; NYBORG, J				NISSEN, P; KJELDGAARD, M; THIRUP, S; POLEKHINA, G; RESHETNIKOVA, L; CLARK, BFC; NYBORG, J			CRYSTAL-STRUCTURE OF THE TERNARY COMPLEX OF PHE-TRNA(PHE), EF-TU, AND A GTP ANALOG	SCIENCE			English	Article							ELONGATION-FACTOR-TU; AMINOACYL-TRANSFER-RNA; PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTALLOGRAPHIC REFINEMENT; BINDING-SITE; PROTEIN; YEAST; RESOLUTION; RIBOSOME	The structure of the ternary complex consisting of yeast phenylalanyl-transfer RNA (Phe-tRNA(Phe)), Thermus aquaticus elongation factor Tu (EF-Tu), and the guanosine triphosphate (GTP) analog GDPNP was determined by x-ray crystallography at 2.7 angstrom resolution. The ternary complex participates in placing the amino acids in their correct order when messenger RNA is translated into a protein sequence on the ribosome. The EF-Tu-GDPNP component binds to one side of the acceptor helix of Phe-tRNA(Phe) involving all three domains of EF-Tu. Binding sites for the phenylalanylated CCA end and the phosphorylated 5' end are located at domain interfaces, whereas the T stem interacts with the surface of the beta-barrel domain 3. The binding involves many conserved residues in EF-Tu. The overall shape of the ternary complex is similar to that of the translocation factor, EF-G-GDP, and this suggests a novel mechanism involving ''molecular mimicry'' in the translational apparatus.	AARHUS UNIV, INST CHEM, DEPT BIOSTRUCT CHEM, DK-8000 AARHUS C, DENMARK; RUSSIAN ACAD SCI, VA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, RUSSIA	Aarhus University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS			Nissen, Poul/D-5774-2014	Thirup, Soren/0000-0002-0061-7137; Nissen, Poul/0000-0003-0948-6628				Abrahams Jan Pieter, 1992, Spectroscopy (Amsterdam), V10, P1; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMOR JC, 1994, NATURE, V372, P704; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; ANTONSSON B, 1984, EUR J BIOCHEM, V141, P483, DOI 10.1111/j.1432-1033.1984.tb08218.x; ANTONSSON B, 1986, BIOCHEMISTRY-US, V25, P3655, DOI 10.1021/bi00360a027; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CANTOR CR, 1979, TRANSFER RNA STRUCTU, P363; Clark Brian F. C., 1995, P423; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; DINCBAS V, 1995, FEBS LETT, V357, P19, DOI 10.1016/0014-5793(94)01318-U; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAULHAMMER HG, 1987, FEBS LETT, V217, P203, DOI 10.1016/0014-5793(87)80664-6; FORSTER C, 1994, P NATL ACAD SCI USA, V91, P4254, DOI 10.1073/pnas.91.10.4254; FORSTER C, 1993, BIOCHIMIE, V75, P1159, DOI 10.1016/0300-9084(93)90015-K; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; JONAK J, 1994, FEBS LETT, V343, P94, DOI 10.1016/0014-5793(94)80614-4; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIESEWETTER S, 1990, NUCLEIC ACIDS RES, V18, P4677, DOI 10.1093/nar/18.16.4677; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; LEBERMAN R, 1995, FEBS LETT, V358, P71, DOI 10.1016/0014-5793(94)01398-K; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LOUIE A, 1984, J BIOL CHEM, V259, P5010; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIERHAUS KH, 1993, TRANSLATIONAL APPARATUS, P263; NISSEN P, 1994, FEBS LETT, V356, P165, DOI 10.1016/0014-5793(94)01254-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSTERBERG R, 1981, EUR J BIOCHEM, V117, P155; OTT G, 1990, BIOCHIM BIOPHYS ACTA, V1050, P222, DOI 10.1016/0167-4781(90)90170-7; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PINGOUD A, 1982, J BIOL CHEM, V257, P1261; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCOBLE J, 1994, BIOCHIMIE, V76, P59, DOI 10.1016/0300-9084(94)90063-9; SHULMAN RG, 1974, J MOL BIOL, V90, P601, DOI 10.1016/0022-2836(74)90237-X; SPURIO R, 1993, TRANSLATIONAL APPARATUS, P241; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; THIRUP S, 1990, PROTEINS, V7, P291, DOI 10.1002/prot.340070310; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VANNOORT JM, 1985, P NATL ACAD SCI USA, V82, P3212, DOI 10.1073/pnas.82.10.3212; VANNOORT JM, 1984, P NATL ACAD SCI-BIOL, V81, P3969; VOSS RH, 1992, EUR J BIOCHEM, V207, P839, DOI 10.1111/j.1432-1033.1992.tb17115.x; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WIKMAN FP, 1982, EMBO J, V1, P1095, DOI 10.1002/j.1460-2075.1982.tb01302.x; Yarus Michael, 1995, P443; 1979, CCP4 DAR LAB	77	787	803	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	1995	270	5241					1464	1472		10.1126/science.270.5241.1464	http://dx.doi.org/10.1126/science.270.5241.1464			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491491				2022-12-01	WOS:A1995TH37500030
J	OPPENHEIMER, BR; KULKARNI, SR; MATTHEWS, K; NAKAJIMA, T				OPPENHEIMER, BR; KULKARNI, SR; MATTHEWS, K; NAKAJIMA, T			INFRARED SPECTRUM OF THE COOL BROWN DWARF-GL-229B	SCIENCE			English	Article								Spectroscopic measurements of a cool brown dwarf, Gl 229B, reveal absorption features attributable to methane in the near infrared much like those of Jupiter, These features are not seen in any star. The presence of methane indicates that the surface temperature of Gl 229B is below 1000 kelvin. Features attributed to water vapor also indicate that Gl 229B is much cooler than any known star.	CALTECH,PALOMAR OBSERV 10524,PASADENA,CA 91125	California Institute of Technology				Oppenheimer, Rebecca/0000-0001-7130-7681				Allard F., 1995, Bottom of the Main Sequence - and Beyond. Proceedings of the ESO Workshop, P32; BURROWS A, 1993, REV MOD PHYS, V65, P301, DOI 10.1103/RevModPhys.65.301; DANIELSON RE, 1966, ASTROPHYS J, V143, P949, DOI 10.1086/148570; JONES HRA, 1994, MON NOT R ASTRON SOC, V267, P413, DOI 10.1093/mnras/267.2.413; KUMAR SS, 1963, ASTROPHYS J, V137, P1121, DOI 10.1086/147589; NAKAJIMA T, IN PRESS NATURE; Stevenson D.J., 1986, ASTROPHYSICS BROWN D, P218; STEVENSON DJ, 1991, ANNU REV ASTRON ASTR, V29, P163; Tsuji T., 1964, Annals of the Tokyo Astronomical Observatory, V9, P1; Tsuji T., 1995, Bottom of the Main Sequence - and Beyond. Proceedings of the ESO Workshop, P45; ZUCKERMAN B, 1992, ASTROPHYS J, V386, P260, DOI 10.1086/171012	11	259	259	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1478	1479		10.1126/science.270.5241.1478	http://dx.doi.org/10.1126/science.270.5241.1478			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491492				2022-12-01	WOS:A1995TH37500033
J	SNOW, TP; WITT, AN				SNOW, TP; WITT, AN			THE INTERSTELLAR CARBON BUDGET AND THE ROLE OF CARBON IN DUST AND LARGE MOLECULES	SCIENCE			English	Article							AROMATIC HYDROCARBON MOLECULES; HYDROGENATED AMORPHOUS-CARBON; B-TYPE STARS; CHEMICAL EVOLUTION; GALACTIC DISK; SOLAR NEIGHBORHOOD; ORION NEBULA; ELEMENTAL ABUNDANCES; EXTINCTION CURVE; ZETA-OPHIUCHI	Published data on stellar composition show that carbon in the sun is substantially more abundant than in other stars. A carbon abundance of 225 carbon atoms per 10(6) hydrogen atoms is representative of galactic stars, whereas Published values for the sun range from 350 to 470 carbon atoms per 10(6) hydrogen atoms. Other elements are also present in enhanced quantities in the solar system, consistent with suggestions that a supernova event was closely associated with the formation of the solar system. The overabundance of carbon in the solar system has many important implications, including new constraints on nucleosynthesis models for supernovae and substantial modification of the so-called ''cosmic'' composition normally adopted in discussions of galactic and interstellar abundances. A reduction in the galactic carbon budget, as suggested by the stellar composition data, strongly constrains the quantity of carbon that is available for the formation of interstellar dust, and some dust models now appear implausible because they require more carbon than is available.	UNIV TOLEDO,RITTER OBSERV,TOLEDO,OH 43606	University System of Ohio; University of Toledo	SNOW, TP (corresponding author), UNIV COLORADO,CTR ASTROPHYS & SPACE ASTRON,BOULDER,CO 80309, USA.		Witt, Adolf N./AAX-6976-2021					AANNESTAD PA, 1995, ASTROPHYS J, V443, P653, DOI 10.1086/175557; ADAMSON AJ, 1990, MON NOT R ASTRON SOC, V243, P400; ADELMAN SJ, 1993, PUBL ASTRON SOC PAC, V105, P327, DOI 10.1086/133158; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; AMARI S, 1995, ASTROPHYS J, V447, pL147, DOI 10.1086/309573; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BALDWIN JA, 1991, ASTROPHYS J, V374, P580, DOI 10.1086/170146; BOESGAARD AM, 1989, ASTROPHYS J, V336, P798, DOI 10.1086/167050; BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; BUCHMANN L, 1993, PHYS REV LETT, V70, P726, DOI 10.1103/PhysRevLett.70.726; BUSOLETTI E, 1987, APJ, V321, pL87; CAMERON AGW, 1995, ASTROPHYS J, V447, pL53, DOI 10.1086/309554; CAMERON AGW, 1973, SPACE SCI REV, V15, P121; CARDELLI JA, 1993, ASTROPHYS J, V402, pL17, DOI 10.1086/186689; CARDELLI JA, 1991, ASTROPHYS J, V377, pL57, DOI 10.1086/186116; CARDELLI JA, IN PRESS ASTROPHYS J; CARIGI L, 1994, ASTROPHYS J, V424, P181, DOI 10.1086/173881; CARLBERG RG, 1985, ASTROPHYS J, V294, P674, DOI 10.1086/163337; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CUNHA K, 1994, ASTROPHYS J, V426, P170, DOI 10.1086/174053; DESERT FX, 1990, ASTRON ASTROPHYS, V237, P215; Draine B, 1989, INTERSTELLAR DUST, P313; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; DULEY WW, 1990, ASTROPHYS J, V351, pL49, DOI 10.1086/185677; DULEY WW, 1987, MON NOT R ASTRON SOC, V229, P203, DOI 10.1093/mnras/229.2.203; DULEY WW, 1985, MON NOT R ASTRON SOC, V215, P259, DOI 10.1093/mnras/215.2.259; DULEY WW, 1989, MON NOT R ASTRON SOC, V236, P709, DOI 10.1093/mnras/236.4.709; DULEY WW, 1995, DIFFUSE INTERSTELLAR, V359; EDVARDSSON B, 1993, ASTRON ASTROPHYS, V275, P101; FANG Z, 1993, PHYS REV A, V48, P1114, DOI 10.1103/PhysRevA.48.1114; FOING BH, 1994, NATURE, V369, P296, DOI 10.1038/369296a0; FURTON DG, 1993, ASTROPHYS J, V415, pL51, DOI 10.1086/187030; GIES DR, 1992, ASTROPHYS J, V387, P673, DOI 10.1086/171116; GREVESSE N, 1991, ASTRON ASTROPHYS, V242, P488; GREVESSE N, 1992, INFRARED SOLAR PHYSI, P539; Grevesse N., 1993, ORIGIN EVOLUTION ELE, P15; HOBBS LM, 1982, ASTROPHYS J, V252, pL21, DOI 10.1086/183711; HOLWEGER H, 1974, SOL PHYS, V39, P19, DOI 10.1007/BF00154968; HONG SS, 1980, ASTRON ASTROPHYS, V88, P194; JENKINS EB, 1979, ASTROPHYS J, V231, P55, DOI 10.1086/157163; JENKINS EB, 1983, ASTROPHYS J, V270, P88, DOI 10.1086/161100; JOBLIN C, 1992, ASTROPHYS J, V393, pL79, DOI 10.1086/186456; JONES AP, 1990, MON NOT R ASTRON SOC, V247, P305; KILIAN J, 1994, ASTRON ASTROPHYS, V284, P437; KILIAN J, 1992, ASTRON ASTROPHYS, V262, P171; KILIANMONTENBRU.J, 1994, ASTRON ASTROPHYS, V291, P757; LAMBERT DL, 1978, MON NOT R ASTRON SOC, V182, P249, DOI 10.1093/mnras/182.2.249; LEGER A, 1995, ASTRON ASTROPHYS, V293, pL53; LENNON DJ, 1985, ASTROPHYS J, V294, P200, DOI 10.1086/163287; LUCK RE, 1994, ASTROPHYS J SUPPL S, V91, P309, DOI 10.1086/191940; MALINIE G, 1993, ASTROPHYS J, V413, P633, DOI 10.1086/173032; MATHIS JS, 1977, ASTROPHYS J, V217, P425, DOI 10.1086/155591; MATHIS JS, 1989, ASTROPHYS J, V341, P808, DOI 10.1086/167538; MATTEUCCI F, 1983, ASTRON ASTROPHYS, V123, P121; MEYER DM, 1994, ASTROPHYS J, V437, pL59, DOI 10.1086/187682; MORTON DC, 1975, ASTROPHYS J, V197, P85, DOI 10.1086/153490; OLIVE KA, 1982, ASTROPHYS J, V257, P276, DOI 10.1086/159986; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; PAGEL BEJ, 1989, EVOLUTIONARY PHENOMENA IN GALAXIES, P201; PAGEL BEJ, 1975, MON NOT R ASTRON SOC, V172, P13, DOI 10.1093/mnras/172.1.13; PAPOULAR R, 1993, ASTRON ASTROPHYS, V270, pL5; PEIMBERT M, 1993, ASTROPHYS J, V414, P626, DOI 10.1086/173108; PENDLETON YJ, 1994, ASTROPHYS J, V437, P683, DOI 10.1086/175031; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; REEVES H, 1978, PROTOSTARS PLANETS, P399; ROLLESTON WRJ, 1994, ASTRON ASTROPHYS, V284, P72; ROY JR, 1995, ASTRON ASTROPHYS, V294, P432; RUBIN RH, 1991, ASTROPHYS J, V374, P564, DOI 10.1086/170145; RUBIN RH, 1993, ASTROPHYS J, V413, P242, DOI 10.1086/172992; SALAMA F, 1992, ASTROPHYS J, V395, P301, DOI 10.1086/171652; SALAMA F, 1992, NATURE, V358, P42, DOI 10.1038/358042a0; SANCISI R, 1974, GALACTIC RADIO ASTRO, P115; SANDFORD SA, 1991, ASTROPHYS J, V371, P607, DOI 10.1086/169925; SCHUSTER WJ, 1989, ASTRON ASTROPHYS, V222, P69; SEARLE L, 1972, ASTROPHYS J, V173, P25, DOI 10.1086/151398; Snow T., UNPUB; SNOW TP, 1976, ASTROPHYS J, V204, P759, DOI 10.1086/154223; SNOW TP, IN PRESS ASTROPHYS J; SOFIA UJ, 1994, ASTROPHYS J, V430, P650, DOI 10.1086/174438; SORRELL WH, 1990, MON NOT R ASTRON SOC, V243, P570; Tielens A.G.G.M., 1995, DIFFUSE INTERSTELLAR; Tielens A.G.G.M., 1987, INTERSTELLAR PROCESS, P397; TINSLEY BM, 1980, FUNDAM COSMIC PHYS, V5, P587; TOMKIN J, 1995, ASTRON J, V109, P2204, DOI 10.1086/117446; TWAROG BA, 1980, ASTROPHYS J, V242, P242, DOI 10.1086/158460; TWAROG BA, 1982, ASTROPHYS J, V261, P636, DOI 10.1086/160375; WELTY DE, 1986, PUBL ASTRON SOC PAC, V98, P857, DOI 10.1086/131834; WHITTET DCB, 1989, MON NOT R ASTRON SOC, V241, P707, DOI 10.1093/mnras/241.4.707; WHITTET DCB, 1984, MON NOT R ASTRON SOC, V210, P479, DOI 10.1093/mnras/210.2.479; Williams, 1993, DUST CHEM ASTRONOMY, P9; ZHAO Z, 1993, PHYS REV LETT, V70, P2066, DOI 10.1103/PhysRevLett.70.2066; [No title captured]	94	164	164	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1455	1460		10.1126/science.270.5241.1455	http://dx.doi.org/10.1126/science.270.5241.1455			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491489				2022-12-01	WOS:A1995TH37500028
J	TAYLOR, MFJ; SHEN, Y; KREITMAN, ME				TAYLOR, MFJ; SHEN, Y; KREITMAN, ME			A POPULATION GENETIC TEST OF SELECTION AT THE MOLECULAR-LEVEL	SCIENCE			English	Article							INSECTICIDE RESISTANCE; HELIOTHIS-VIRESCENS; DROSOPHILA-MELANOGASTER; TOBACCO BUDWORM; LEPIDOPTERA; NOCTUIDAE; POLYMORPHISMS; PATTERNS; LOCUS	The role of natural selection in molecular evolution has been inferred primarily by rejection of null hypotheses based on neutral theory, rather than by acceptance of specific predictions based on selection. In this report, a population genetic lest of a specific prediction for selection on DNA polymorphism is presented. Pyrethroid insecticide use constitutes an experiment for which form of selection and molecular target (voltage-gated sodium channels) are both known. As predicted, differential pyrethroid selection on tobacco budworm populations generated significant geographic heterogeneity in sodium channel marker allele frequencies, compared with arbitrary loci.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago	TAYLOR, MFJ (corresponding author), UNIV ARIZONA,CTR INSECT SCI,DEPT ENTOMOL,TUCSON,AZ 85721, USA.							BERRY A, 1993, GENETICS, V134, P869; CHRISTIANSEN FB, 1974, GENETICS, V77, P765; FFRENCHCONSTANT RH, 1993, P NATL ACAD SCI USA, V90, P1957, DOI 10.1073/pnas.90.5.1957; HANZLIK TN, 1989, J BIOL CHEM, V264, P12419; HARSHMAN LG, 1994, INSECT BIOCHEM MOLEC, V24, P671, DOI 10.1016/0965-1748(94)90054-X; HEAD RB, 1990, P BELTWIDE COTTON PR, P157; KARL SA, 1992, SCIENCE, V256, P100, DOI 10.1126/science.1348870; KING EG, 1990, P BELTWIDE COTTON C, P140; KORMAN AK, 1993, ANN ENTOMOL SOC AM, V86, P182, DOI 10.1093/aesa/86.2.182; KREITMAN M, 1991, GENETICS, V127, P565; LESSA EP, 1993, MOL ECOL, V2, P119, DOI 10.1111/j.1365-294X.1993.tb00006.x; LEWONTIN RC, 1973, GENETICS, V74, P175; MCCAFFERY AR, 1991, SOUTHWEST ENTOMOL S, V15, P143; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NARAHASHI T, 1986, NEUROPHARMACOLOGY PE, P37; NEI M, 1983, ANN HUM GENET, V47, P253, DOI 10.1111/j.1469-1809.1983.tb00993.x; NEI M, 1975, GENETICS, V80, P395; NEUNZIG HH, 1963, J ECON ENTOMOL, V56, P135, DOI 10.1093/jee/56.2.135; PLAPP FW, 1990, J ECON ENTOMOL, V83, P335, DOI 10.1093/jee/83.2.335; RAYMOND M, 1991, NATURE, V350, P151, DOI 10.1038/350151a0; ROBERTSON A, 1975, GENETICS, V80, P396; ROEHRDANZ RL, 1994, ANN ENTOMOL SOC AM, V87, P856, DOI 10.1093/aesa/87.6.856; ROSENHEIM JA, 1986, J ECON ENTOMOL, V79, P1161, DOI 10.1093/jee/79.5.1161; SATTELLE DB, 1988, ADV INSECT PHYSL, V20, P145; SOKAL R, 1981, BIOMETRY, pCH18; STADELBACHER E A, 1972, Environmental Entomology, V1, P318; STAETZ CA, 1985, J ECON ENTOMOL, V78, P505, DOI 10.1093/jee/78.3.505; TABASHNIK BE, 1987, J ECON ENTOMOL, V80, P1091, DOI 10.1093/jee/80.6.1091; TAYLOR MFJ, 1993, INSECT BIOCHEM MOLEC, V23, P763, DOI 10.1016/0965-1748(93)90064-Y	29	62	65	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1497	1499		10.1126/science.270.5241.1497	http://dx.doi.org/10.1126/science.270.5241.1497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491497				2022-12-01	WOS:A1995TH37500040
J	TRIEMSTRA, M; ROSENDAAL, FR; SMIT, C; VANDERPLOEG, HM; BRIET, E				TRIEMSTRA, M; ROSENDAAL, FR; SMIT, C; VANDERPLOEG, HM; BRIET, E			MORTALITY IN PATIENTS WITH HEMOPHILIA - CHANGES IN A DUTCH POPULATION FROM 1986 TO 1992 AND 1973 TO 1986	ANNALS OF INTERNAL MEDICINE			English	Article						HEMOPHILIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; LIFE EXPECTANCY; HEPATITIS; NETHERLANDS	UNITED-STATES; DEATH	Objective: To determine causes of death and mortality rates in patients with hemophilia over a period of 20 years, to assess changes in mortality, and to distinguish between hemophilia-related death and recent death induced by viral infections. Design: Cohort study of 919 patients followed from January 1986 to June 1992. Results were compared with outcomes of previous follow-up from 1973 to 1986. Setting: Consecutive national questionnaire surveys on hemophilia, using patient registries of the Netherlands Hemophilia Society and Dutch hemophilia centers. Patients: 919 males with hemophilia A or B who participated in a national questionnaire survey on hemophilia in 1985. Median duration of follow-up was 6.4 years, which yielded 5753 person-years of follow-up. The mean age at study entry was 30 years (range, 1 to 85 years). Measurements: Standardized mortality ratios, causes of death, median life expectancy, age-adjusted relative risks associated with the type or severity of hemophilia, presence of inhibitors, prophylaxis, and human immunodeficiency virus infection. Results: 45 patients (5%) died between January 1986 and June 1992; 22.6 patients had been expected to die. Thus, the overall standardized mortality ratio was 2.0. The overall median life expectancy was 66 years for the cohort studied from 1973 to 1986 and 68 years for the cohort studied from 1986 to 1992. When deaths related to viral infection were excluded, the life expectancy almost equaled that of the general male population. Between 1986 and 1992, 1 patient died of ischemic heart disease compared with the 5.2 who were expected to die of this disease. Infection with HIV was the strongest independent predictor of death (relative risk, 27.5 [95% CI, 5.7 to 132.8]). After adjustment for HIV infection, no other hemophilia-related risk factors were associated with the risk for death. Conclusions: The acquired immunodeficiency syndrome and hepatitis strongly influence mortality in patients with hemophilia. In the absence of viral infections, the life expectancy of patients with hemophilia would almost equal that of the general male population.	LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2300 RC LEIDEN, NETHERLANDS; VRIJE UNIV AMSTERDAM, DEPT MED PSYCHOL, 1081 BT AMSTERDAM, NETHERLANDS; NETHERLANDS HEMOPHILIA SOC, 1171 GN BADHOEVEDORP, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Vrije Universiteit Amsterdam				Triemstra, Mattanja/0000-0001-7133-6028				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ARONSON DL, 1988, AM J HEMATOL, V27, P7, DOI 10.1002/ajh.2830270103; CHORBA TL, 1994, AM J HEMATOL, V45, P112, DOI 10.1002/ajh.2830450204; Cox DR., 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438/ANALYSIS-SURVIVAL-DATA-COX-OAKES; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; IKKALA E, 1982, BRIT J HAEMATOL, V52, P7, DOI 10.1111/j.1365-2141.1982.tb03856.x; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JONES PK, 1991, ANN INTERN MED, V114, P641, DOI 10.7326/0003-4819-114-8-641; LARSSON SA, 1983, ACTA MED SCAND, V214, P199; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; MANN JM, 1992, AIDS WORLD 1992; MEADE TW, 1994, BRIT MED BULL, V50, P755, DOI 10.1093/oxfordjournals.bmb.a072924; PHILLIPS AN, 1994, BRIT MED J, V309, P309, DOI 10.1136/bmj.309.6950.309; RAMGREN O, 1962, ACTA MED SCAND, V171, P37; ROSENDAAL FR, 1990, BRIT J HAEMATOL, V75, P525, DOI 10.1111/j.1365-2141.1990.tb07793.x; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SMIT C, 1989, BRIT MED J, V298, P235, DOI 10.1136/bmj.298.6668.235; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; 1994, ETHICAL ASPECTS BIOM, P17; [No title captured]	20	149	152	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1995	123	11					823	+		10.7326/0003-4819-123-11-199512010-00002	http://dx.doi.org/10.7326/0003-4819-123-11-199512010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG209	7486463				2022-12-01	WOS:A1995TG20900002
J	BARONE, MV; COURTNEIDGE, S				BARONE, MV; COURTNEIDGE, S			MYC BUT NOT FOS RESCUE OF PDGF SIGNALING BLOCK CAUSED BY KINASE INACTIVE SRC	NATURE			English	Article							C-MYC; GROWTH-FACTOR; CELL-PROLIFERATION; PROTO-ONCOGENE; 3T3 CELLS; TYROSINE KINASES; ANTISENSE RNA; MESSENGER-RNA; GENE; EXPRESSION	GROWTH factors such as platelet-derived growth factor (PDGF) elicit the transcriptional activation of a large number of immediate early genes (many of which encode transcription factors), and ultimately DNA synthesis(1). Both AP1 and Myc are activated in fibroblasts in response to growth factor stimulation(2-5), and various experiments suggest their importance in proliferation(6-10). Src family kinases are required for PDGF (and other growth factors) to induce DNA synthesis(11,12). We have examined which transcription factors, when constitutively expressed, 'rescue' the block elicited by dominant negative Src. We report here that Myc, but not Fos and/or Jun, was able to rescue the block. In contrast, Fos and Jun, but not Myc, rescued the block induced by dominant negative Ras. Our data suggest that Src kinases control the transcriptional activation of Myc.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063	European Molecular Biology Laboratory (EMBL)				BARONE, Maria Vittoria/0000-0001-6190-4917				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARONE MV, 1989, EMBO J, V8, P1079, DOI 10.1002/j.1460-2075.1989.tb03476.x; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUCHINO Y, 1985, JPN J CANCER RES, V76, P75; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOVOVA V, 1993, INT J CANCER, V53, P983; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WELHAM MJ, 1990, ONCOGENE, V5, P161; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581	30	290	292	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					509	512		10.1038/378509a0	http://dx.doi.org/10.1038/378509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477410				2022-12-01	WOS:A1995TH05400076
J	BREGMAN, BS; KUNKELBAGDEN, E; SCHNELL, L; DAI, HN; GAO, D; SCHWAB, ME				BREGMAN, BS; KUNKELBAGDEN, E; SCHNELL, L; DAI, HN; GAO, D; SCHWAB, ME			RECOVERY FROM SPINAL-CORD INJURY MEDIATED BY ANTIBODIES TO NEURITE GROWTH-INHIBITORS	NATURE			English	Article							LOCOMOTOR FUNCTION; ADULT-RATS; NEWBORN; REGENERATION; PLASTICITY; DAMAGE; AXONS; CATS; LESIONS	THERE is little axonal growth after central nervous system (CNS) injury in adult mammals. The administration of antibodies (IN-1) to neutralize the myelin-associated neurite growth inhibitory proteins leads to long-distance regrowth of a proportion of CNS axons after injury(1-5). Our aim was: to determine if spinal cord lesion in adult rats, followed by treatment with antibodies to neurite growth inhibitors, can lead to regeneration and anatomical plasticity of other spinally projecting pathways; to determine if the anatomical projections persist at long survival intervals; and to determine whether this fibre growth is associated with recovery of function. We report here that brain stem-spinal as well as corticospinal axons undergo regeneration and anatomical plasticity after application of IN-1 antibodies. There is a recovery of specific reflex and locomotor functions after spinal cord injury in these adult rats. Removal of the sensorimotor cortex in IN-1-treated rats 2-3 months later abolished the recovered contact-placing responses, suggesting that the recovery was dependent upon the regrowth of these pathways.	UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND	University of Zurich	BREGMAN, BS (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT CELL BIOL,DIV NEUROBIOL,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.		Schwab, Martin E/B-6818-2016					ALSTERMARK B, 1987, NEUROSCI RES, V5, P66; AMASSIAN VE, 1978, J PHYSIOL-PARIS, V74, P165; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BREGMAN BS, 1983, DEV BRAIN RES, V9, P137, DOI 10.1016/0165-3806(83)90047-0; BREGMAN BS, 1989, J COMP NEUROL, V282, P355, DOI 10.1002/cne.902820304; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; BREGMAN BS, 1986, J COMP NEUROL, V244, P86, DOI 10.1002/cne.902440107; BREGMAN BS, 1983, DEV BRAIN RES, V9, P119, DOI 10.1016/0165-3806(83)90046-9; BREGMAN BS, 1982, SCIENCE, V217, P553, DOI 10.1126/science.7089581; BREGMAN BS, 1987, DEV BRAIN RES, V34, P245, DOI 10.1016/0165-3806(87)90213-6; BREGMAN BS, 1987, DEV BRAIN RES, V34, P265, DOI 10.1016/0165-3806(87)90214-8; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; EIDELBERG E, 1977, EXP NEUROL, V56, P312, DOI 10.1016/0014-4886(77)90350-8; GOLDBERGER ME, 1990, EXP NEUROL, V107, P113, DOI 10.1016/0014-4886(90)90149-M; KUNKELBAGDEN E, 1990, EXP BRAIN RES, V81, P25; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; VILENSKY JA, 1992, J MOTOR BEHAV, V24, P288, DOI 10.1080/00222895.1992.9941624; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x	25	599	643	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					498	501		10.1038/378498a0	http://dx.doi.org/10.1038/378498a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477407				2022-12-01	WOS:A1995TH05400073
J	CHAPMAN, LE; FOLKS, TM; SALOMON, DR; PATTERSON, AP; EGGERMAN, TE; NOGUCHI, PD				CHAPMAN, LE; FOLKS, TM; SALOMON, DR; PATTERSON, AP; EGGERMAN, TE; NOGUCHI, PD			XENOTRANSPLANTATION AND XENOGENEIC INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SIMIAN IMMUNODEFICIENCY VIRUS; CRIMEAN HEMORRHAGIC-FEVER; OUTBREAK; RETROVIRUSES; EVOLUTION; PHYLOGENY; DISEASE; AFRICA; HIV-2		SCRIPPS RES INST, LA JOLLA, CA 92037 USA; US FDA, BETHESDA, MD 20892 USA	Scripps Research Institute; US Food & Drug Administration (FDA)	CHAPMAN, LE (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV AIDS STD & TB LAB RES, RETROVIRUS DIS BRANCH, ATLANTA, GA 30333 USA.		Salomon, Daniel/E-9380-2012					ALDHOUS P, 1990, NATURE, V347, P321, DOI 10.1038/347321c0; Allan Jonathan S., 1995, ILAR J, V37, P37; Beran GW., 1994, HDB ZOONOSES; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CHAPMAN LE, 1994, INFECT AGENT DIS, V3, P234; CHARI RS, 1994, NEW ENGL J MED, V331, P234, DOI 10.1056/NEJM199407283310404; CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271; COURGNAUD V, 1992, J VIROL, V66, P414, DOI 10.1128/JVI.66.1.414-419.1992; DEINHARDT F, 1980, VIRAL ONCOLOGY, P357; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DOOLITTLE RF, 1990, CURR TOP MICROBIOL, V157, P1; DOOLITTLE RF, 1989, NATURE, V339, P338, DOI 10.1038/339338a0; DUNNING JJ, 1994, PATHOL BIOL, V42, P231; EASTLUND T, 1995, CELL TRANSPLANT, V4, P455, DOI 10.1016/0963-6897(95)00035-V; Fishman Jay A., 1994, Xenotransplantation, V1, P47, DOI 10.1111/j.1399-3089.1994.tb00049.x; FLUGEL RM, 1991, J ACQ IMMUN DEF SYND, V4, P739; FRANCHINI G, 1989, ANN NY ACAD SCI, V554, P81, DOI 10.1111/j.1749-6632.1989.tb22412.x; FRANCHINI G, 1994, AIDS RES HUM RETROV, V10, P1047, DOI 10.1089/aid.1994.10.1047; FRAZIER ME, 1985, ARCH VIROL, V83, P83, DOI 10.1007/BF01310966; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; HOLMES GP, 1995, CLIN INFECT DIS, V20, P421, DOI 10.1093/clinids/20.2.421; JIN MJ, 1994, J VIROL, V68, P8454, DOI 10.1128/JVI.68.12.8454-8460.1994; KALTER SS, 1976, HDB LABORATORY ANIMA, V3, P655; KANKI PJ, 1988, VET MICROBIOL, V17, P309, DOI 10.1016/0378-1135(88)90072-7; KHABBAZ RF, 1994, NEW ENGL J MED, V330, P172, DOI 10.1056/NEJM199401203300304; MARTINI GA, 1969, T ROY SOC TROP MED H, V63, P295, DOI 10.1016/0035-9203(69)90001-7; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MOORE C, 1992, VET CLIN N AM-FOOD A, V8, P461, DOI 10.1016/S0749-0720(15)30698-8; MYERS G, 1992, RETROVIRIDAE, V1, P57; Nalesnik M A, 1994, Transplant Sci, V4, P61; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; NOWAK R, 1994, SCIENCE, V266, P1148, DOI 10.1126/science.7973690; PEETERS M, 1992, AIDS, V6, P447, DOI 10.1097/00002030-199205000-00002; PRUSINER SB, 1995, SCI AM, V272, P48, DOI 10.1038/scientificamerican0195-48; SHIIGI S, 1989, J MED PRIMATOL, V18, P185; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SIMONDS RJ, 1993, AIDS, V7, pS35, DOI 10.1097/00002030-199311002-00008; SMITH DM, 1993, NEW ENGL J MED, V328, P142, DOI 10.1056/NEJM199301143280218; SULEIMAN MNEH, 1980, LANCET, V2, P939; SWANEPOEL R, 1987, AM J TROP MED HYG, V36, P120, DOI 10.4269/ajtmh.1987.36.120; VANIN EF, 1994, J VIROL, V68, P4241, DOI 10.1128/JVI.68.7.4241-4250.1994; WILSON ME, 1994, ANN NY ACAD SCI, V740, P1, DOI 10.1111/j.1749-6632.1994.tb19849.x; 1978, WHO ORG 1978, V56, P271; 1992, MMWR-MORBID MORTAL W, V41, P814	46	140	145	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	1995	333	22					1498	1501		10.1056/NEJM199511303332211	http://dx.doi.org/10.1056/NEJM199511303332211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG445	7477153				2022-12-01	WOS:A1995TG44500011
J	COLEMAN, MJ; MEYRAND, P; NUSBAUM, MP				COLEMAN, MJ; MEYRAND, P; NUSBAUM, MP			A SWITCH BETWEEN 2 MODES OF SYNAPTIC TRANSMISSION MEDIATED BY PRESYNAPTIC INHIBITION	NATURE			English	Article							SENSORY AFFERENTS; MODULATION; MECHANISM; TERMINALS; GANGLION; NEURONS; SYSTEM; CRAB	PRESYNAPTIC inhibition reduces chemical synaptic transmission in the central nervous system between pairs of neurons(1-4), but its role(s) in shaping the multisynaptic interactions underlying neural network activity are not well studied. We therefore used the crustacean stomatogastric nervous system to study how presynaptic inhibition of the identified projection neuron, modulatory commissural neuron 1 (MCN1), influences the MCN1 synaptic effects on the gastric mill neural network. Tonic MCN1 discharge excites gastric mill network neurons and activates the gastric mill rhythm(5,6). One network neuron, the lateral gastric (LG) neuron, presynaptically inhibits MCN1 and is electrically coupled to its terminals(5,6). We show here that this presynaptic inhibition selectively reduces or eliminates transmitter-mediated excitation from MCN1 without reducing its electrically mediated excitatory effects, thereby switching the network neurons excited by MCN1. By switching the type of synaptic output from MCN1 and, hence, the activated network neurons, this presynaptic inhibition is pivotal to motor pattern generation.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,NEUROBIOL RES CTR,BIRMINGHAM,AL 35294; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV BORDEAUX 1,NEUROBIOL & PHYSIOL COMPAREES LAB,F-33120 ARCACHON,FRANCE; CNRS,F-33120 ARCACHON,FRANCE	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS)			Nusbaum, Michael/GWC-1917-2022	Nusbaum, Michael/0000-0001-5935-0046				ALFORD S, 1991, EUR J NEUROSCI, V3, P107, DOI 10.1111/j.1460-9568.1991.tb00071.x; Bennett M V, 1992, Semin Cell Biol, V3, P29; CATTAERT D, 1992, J NEUROPHYSIOL, V67, P610, DOI 10.1152/jn.1992.67.3.610; Clarac F, 1992, Curr Opin Neurobiol, V2, P764, DOI 10.1016/0959-4388(92)90131-4; COLEMAN MJ, 1992, J COMP NEUROL, V325, P581, DOI 10.1002/cne.903250410; COLEMAN MJ, 1994, J NEUROSCI, V14, P6544; COLEMAN MJ, 1995, THESIS U ALABAMA BIR; DIXON DB, 1993, NEURON, V11, P267, DOI 10.1016/0896-6273(93)90183-R; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; Harris -Warrick R.M., 1992, DYNAMIC BIOL NETWORK; Harris-Warrick Ronald M., 1992, P87; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; HAYDON PG, 1991, J NEUROSCI, V11, P3851; KATZ PS, 1995, J NEUROSCI, V15, P6035; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; NORRIS BJ, 1994, J NEUROPHYSIOL, V72, P1451, DOI 10.1152/jn.1994.72.4.1451; Nusbaum Michael P., 1994, Current Opinion in Neurobiology, V4, P909, DOI 10.1016/0959-4388(94)90141-4; NUSBAUM MP, 1992, J NEUROSCI, V12, P2706; Rossignol Serge, 1994, Current Opinion in Neurobiology, V4, P894, DOI 10.1016/0959-4388(94)90139-2; Rudomin P, 1993, Curr Opin Neurobiol, V3, P997, DOI 10.1016/0959-4388(93)90173-V; SEGEV I, 1990, J NEUROPHYSIOL, V63, P987, DOI 10.1152/jn.1990.63.5.987; Selverston A.I., 1987, CRUSTACEAN STOMATOGA; SILLAR KT, 1994, J NEUROSCI, V14, P2636; SMALL SA, 1992, J NEUROSCI, V12, P1616; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; WATSON AHD, 1992, COMP BIOCHEM PHYS A, V103, P227, DOI 10.1016/0300-9629(92)90573-9; WEIMANN JM, 1991, J NEUROPHYSIOL, V65, P111, DOI 10.1152/jn.1991.65.1.111; WEIMANN JM, 1994, CURR BIOL, V4, P896, DOI 10.1016/S0960-9822(00)00199-8; [No title captured]	30	125	125	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					502	505		10.1038/378502a0	http://dx.doi.org/10.1038/378502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477408				2022-12-01	WOS:A1995TH05400074
J	COLLURA, RV; STEWART, CB				COLLURA, RV; STEWART, CB			INSERTIONS AND DUPLICATIONS OF MTDNA IN THE NUCLEAR GENOMES OF OLD-WORLD MONKEYS AND HOMINOIDS	NATURE			English	Article							MITOCHONDRIAL-DNA; EVOLUTION; SEQUENCES; AMPLIFICATION; PRIMATES	USING oligonucleotide primers designed to match conserved regions of mammalian mitochondrial DNA (mtDNA)(1), we have amplified and sequenced two divergent cytochrome b nuclear pseudogenes from orangutan cellular DNA. Evolutionary analysis suggests that a nuclear transfer occurred about 30 million years ago on the lineage leading to the catarrhines (Old World monkeys and hominoids), and involved a long (at least 3 kilobases), probably damaged, piece of mtDNA. After this transfer, the pseudogene duplicated, giving rise to the two copies that are probably present in all hominoids, including humans. More recent transfers involving the entire cytochrome b gene have also occurred in the Old World monkeys. Such nuclear copies of mtDNA can confound phylogenetic and population genetic studies(2-4), and be an insidious source of DNA contamination of 'ancient'(3,5) and forensic DNA. Indeed, contamination with these anciently transferred human pseudogenes(5) is almost certainly the source of the cytochrome b sequences recently reported from 'dinosaur bone DNA'(6).	SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; COHEN J, 1995, SCIENCE, V268, P22, DOI 10.1126/science.7701333; FELSENSTEIN J, 1994, PHYLIP PHYLOGENY INF; FUKUDA M, 1985, J MOL BIOL, V186, P257, DOI 10.1016/0022-2836(85)90102-0; GINGERICH PD, 1986, MOL BIOL EVOL, V3, P205; GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; HEDGES SB, 1995, SCIENCE, V268, P1191, DOI 10.1126/science.7761839; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HU GX, 1994, GENE, V147, P197, DOI 10.1016/0378-1119(94)90065-5; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LI WH, IN PRESS MOL PHYLOGE; LOPEZ JV, 1994, J MOL EVOL, V39, P174; MADDISON WP, 1994, ANAL PHYLOGENY CHARA; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Quinn TW, 1992, MOL ECOL, V1, P105, DOI 10.1111/j.1365-294X.1992.tb00162.x; SAITOU N, 1994, MOL BIOL EVOL, V11, P504; SHAY JW, 1992, MUTAT RES, V275, P227, DOI 10.1016/0921-8734(92)90026-L; SMITH MF, 1992, MOL BIOL EVOL, V9, P204; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; VANDERKUYL AC, 1995, J MOL EVOL, V40, P652, DOI 10.1007/BF00160513; VANDERKUYL AC, 1995, J MOL EVOL, V40, P173, DOI 10.1007/BF00167111; WOODWARD SR, 1995, SCIENCE, V268, P1194, DOI 10.1126/science.268.5214.1194; WOODWARD SR, 1994, SCIENCE, V266, P1229; WRISCHNIK LA, 1987, NUCLEIC ACIDS RES, V15, P529, DOI 10.1093/nar/15.2.529; ZISCHLER H, 1995, SCIENCE, V268, P1192, DOI 10.1126/science.7605504; ZULLO S, 1991, J MOL BIOL, V221, P1223	29	168	176	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					485	489		10.1038/378485a0	http://dx.doi.org/10.1038/378485a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477403				2022-12-01	WOS:A1995TH05400069
J	DEGRAAF, RM; VISSCHER, J; SCHWARTZ, AW				DEGRAAF, RM; VISSCHER, J; SCHWARTZ, AW			A PLAUSIBLY PREBIOTIC SYNTHESIS OF PHOSPHONIC-ACIDS	NATURE			English	Article							AQUEOUS FORMALDEHYDE; ELEMENT	THE insolubility of calcium phosphate in water is a significant stumbling block in the chemistry required for the origin of life(1). The discovery of alkyl phosphonic acids in the Murchison meteorite(2) suggests the possibility of delivery of these water-soluble, phosphorus-containing molecules by meteorites or comets to the early Earth. This could have provided a supply of organic phosphorus for the earliest stages of chemical evolution; although probably not components of early genetic systems, phosphonic acids may have been precursors to the first nucleic acids(3). Here we report the synthesis of several phosphonic acids, including the most abundant found in the Murchison meteorite, by ultraviolet irradiation of orthophosphorous acid in the presence of formaldehyde, primary alcohols, or acetone, We argue that similar reactions might explain the presence of phosphonic acids in Murchison, and could also have occurred on the prebiotic Earth.	CATHOLIC UNIV NIJMEGEN,FAC SCI,EVOLUT BIOL RES GRP,6525 ED NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			de Graaf, Rob/E-7665-2012	de Graaf, Rob/0000-0001-9143-8961				BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; Calvert J. G., 1966, PHOTOCHEMISTRY; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COOPER GW, 1992, GEOCHIM COSMOCHIM AC, V56, P4109, DOI 10.1016/0016-7037(92)90023-C; ENGEL R, 1977, CHEM REV, V77, P349, DOI 10.1021/cr60307a003; FEGLEY B, 1980, ICARUS, V41, P439, DOI 10.1016/0019-1035(80)90228-6; FREEDMAN LD, 1957, CHEM REV, V57, P479, DOI 10.1021/cr50015a003; GULICK A, 1955, AM SCI, V43, P479; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; MATSUURA N, 1971, B CHEM SOC JPN, V44, P1027, DOI 10.1246/bcsj.44.1027; MILLER SL, 1959, SCIENCE, V130, P245, DOI 10.1126/science.130.3370.245; PARK HR, 1988, J PHOTOCH PHOTOBIO A, V43, P155, DOI 10.1016/1010-6030(88)80015-7; SCHWARTZ AW, 1993, J MOL EVOL, V36, P101, DOI 10.1007/BF00166245; SCHWARTZ AW, 1973, INORG NUCL CHEM LETT, V9, P39, DOI 10.1016/0020-1650(73)80083-2; SCHWARTZ AW, 1993, TETRAHEDRON LETT, V34, P2201, DOI 10.1016/S0040-4039(00)60382-9; SEIFERT KG, 1973, ANGEW CHEM INT EDIT, V12, P763, DOI 10.1002/anie.197307631; VANDERLINDE HJ, 1971, PHOTOCHEM PHOTOBIOL, V13, P147; Walker J. F., 1964, FORMALDEHYDE	18	63	64	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					474	477		10.1038/378474a0	http://dx.doi.org/10.1038/378474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477402				2022-12-01	WOS:A1995TH05400065
J	GHOSH, P; AMAYA, M; MELLINS, E; WILEY, DC				GHOSH, P; AMAYA, M; MELLINS, E; WILEY, DC			THE STRUCTURE OF AN INTERMEDIATE IN CLASS-II MHC MATURATION - CLIP BOUND TO HLA-DR3	NATURE			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; HLA-DR MOLECULES; CELL LINE; ASSOCIATION; BINDING	A complex between HLA-DR3 and a fragment of invariant chain called CLIP was isolated from a human cell line defective in antigen presentation and its X-ray crystal structure determined. Previous data indicate that this complex is an intermediate in class II histocompatibility maturation, occurring between invariant chain-DR3 and antigenic peptide-DR3 complexes. The structure shows that the CLIP fragment binds to DR3 in a way almost identical to that in which antigenic peptides bind class II histocompatibility glycoproteins. The structure is the substrate for the loading of antigenic peptides by an exchange process catalysed by DM.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104; CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104	Harvard University; Harvard University; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia								AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BROWN JH, 1993, NATURE, V368, P33; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GAUTAM AM, 1995, P NATL ACAD SCI USA, V92, P335, DOI 10.1073/pnas.92.1.335; GELUK A, 1995, MOL IMMUNOL, V32, P975, DOI 10.1016/0161-5890(95)00058-M; GELUK A, 1994, J IMMUNOL, V152, P5742; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KROPSHOFER H, 1995, P NATL ACAD SCI USA, V92, P8313, DOI 10.1073/pnas.92.18.8313; LEE C, 1995, P NATL ACAD SCI USA, V92, P8269, DOI 10.1073/pnas.92.18.8269; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MALCHEREK G, 1993, INT IMMUNOL, V5, P1229, DOI 10.1093/intimm/5.10.1229; MAURER D, 1991, J IMMUNOL, V146, P621; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONJI T, 1994, J IMMUNOL, V153, P4468; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARK SJ, 1995, P NATL ACAD SCI USA, V92, P11289, DOI 10.1073/pnas.92.24.11289; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; URBAN RG, 1994, J EXP MED, V180, P751, DOI 10.1084/jem.180.2.751; XU MZ, 1994, MOL IMMUNOL, V31, P723, DOI 10.1016/0161-5890(94)90146-5	50	523	537	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					457	462		10.1038/378457a0	http://dx.doi.org/10.1038/378457a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477400				2022-12-01	WOS:A1995TH05400059
J	KOSSLYN, SM; THOMPSON, WL; KIM, IJ; ALPERT, NM				KOSSLYN, SM; THOMPSON, WL; KIM, IJ; ALPERT, NM			TOPOGRAPHICAL REPRESENTATIONS OF MENTAL IMAGES IN PRIMARY VISUAL-CORTEX	NATURE			English	Article								WE report here the use of positron emission tomography (PET) to reveal that the primary visual cortex is activated when subjects close their eyes and visualize objects. The size of the image is systematically related to the location of maximal activity, which is as expected because the earliest visual areas are spatially organized(1-5). These results were only evident, however, when imagery conditions were compared to a non-imagery baseline in which the same auditory cues were presented (and hence the stimuli were controlled); when a resting baseline was used (and hence brain activation was uncontrolled), imagery activation was obscured because of activation in visual cortex during the baseline condition. These findings resolve a debate in the literature about whether imagery activates early visual cortex(6-11) and indicate that visual mental imagery involves 'depictive' representations, not solely language-like descriptions(12-14). Moreover, the fact that stored visual information can affect processing in even the earliest visual areas suggests that knowledge can fundamentally bias what one sees.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	KOSSLYN, SM (corresponding author), HARVARD UNIV,DEPT PSYCHOL,33 KIRKLAND ST,CAMBRIDGE,MA 02138, USA.		Park, Irene J. K./D-1798-2010					[Anonymous], 1993, BRAIN ACTIVATION; CHARLOT V, 1992, NEUROPSYCHOLOGIA, V30, P565, DOI 10.1016/0028-3932(92)90059-U; Damasio H., 1993, Society for Neuroscience Abstracts, V19, P1603; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; Douglas K. L., 1992, Society for Neuroscience Abstracts, V18, P390; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; KOPS ER, 1990, J COMPUT ASSIST TOMO, V14, P437, DOI 10.1097/00004728-199005000-00022; Kosslyn S.M., 1994, IMAGE BRAIN RESOLUTI; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KOSSLYN SM, 1977, COGNITIVE PSYCHOL, V9, P52, DOI 10.1016/0010-0285(77)90004-4; LEBIHAN D, 1993, P NATL ACAD SCI USA, V5, P11802; MENON R, 1993, FUNCTIONAL MRI BRAIN; PYLYSHYN ZW, 1973, PSYCHOL BULL, V80, P1, DOI 10.1037/h0034650; ROLAND PE, 1995, CEREB CORTEX, V5, P79, DOI 10.1093/cercor/5.1.79; ROLAND PE, 1985, J NEUROPHYSIOL, V53, P1219, DOI 10.1152/jn.1985.53.5.1219; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; TALAIRACH J, 1988, COOPLANAR STREOTAXIC; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981	20	480	494	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					496	498		10.1038/378496a0	http://dx.doi.org/10.1038/378496a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477406				2022-12-01	WOS:A1995TH05400072
J	LUECKE, H; CHANG, BT; MAILLIARD, WS; SCHLAEPFER, DD; HAIGLER, HT				LUECKE, H; CHANG, BT; MAILLIARD, WS; SCHLAEPFER, DD; HAIGLER, HT			CRYSTAL-STRUCTURE OF THE ANNEXIN-XII HEXAMER AND IMPLICATIONS FOR BILAYER INSERTION	NATURE			English	Article							SELF-ASSOCIATION; CALCIUM; SYNEXIN; IDENTIFICATION; RESOLUTION; MEMBRANES; CHANNELS	ANNEXINS are a family of calcium- and phospholipid-binding proteins(1,2) implicated in a number of biological processes including membrane fusion(3) and ion channel formation(4-7). The crystal structure of the annexin XII hexamer, refined at 2.8 Angstrom resolution, forms a concave disk with 3-2 symmetry, about 100 Angstrom in diameter and 70 Angstrom thick with a central hydrophilic pore. Six intermolecular Ca2+ ions are involved in hexamer formation. An additional 18 Ca2+ ions are located on the perimeter of the disk, accessible only from the side of the hexameric disk. On the basis of the hexamer structure we propose here a new mode of protein-phospholipid bilayer interaction that is distinct from the hydrophobic insertion of typical membrane proteins. This speculative model postulates the Ca2+-dependent insertion of the hydrophilic annexin XII hexamer into phospholipid bilayers with local reorientation of the bilayer phospholipids.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	University of California System; University of California Irvine	LUECKE, H (corresponding author), STANFORD SYNCHROTRON RADIAT LAB,MS 69,STANFORD,CA 94305, USA.		Luecke, Hartmut/F-4712-2012; Haigler, Harry/C-3788-2011	Luecke, Hartmut/0000-0002-4938-0775; 				AHN NG, 1988, J BIOL CHEM, V262, P18657; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BURGER A, 1994, J MOL BIOL, V237, P479, DOI 10.1006/jmbi.1994.1249; CONCHA NO, 1992, FEBS LETT, V314, P159, DOI 10.1016/0014-5793(92)80964-I; CREUTZ CE, 1979, J BIOL CHEM, V254, P553; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEMANGE P, 1994, TRENDS BIOCHEM SCI, V19, P272, DOI 10.1016/0968-0004(94)90002-7; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V99, P3867; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; Leslie A. G., 1992, JOINT CCP4 ESF EACMB, V26; Moss S. E, 1992, ANNEXINS; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; NEUMANN JM, 1994, EUR J BIOCHEM, V225, P819, DOI 10.1111/j.1432-1033.1994.0819b.x; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHLAEPFER DD, 1992, J BIOL CHEM, V267, P9529; SMART OS, 1994, BIOCHEM SOC T, V22, pS146, DOI 10.1042/bst022146s; SWAIRJO MA, 1994, REV BIOPHYS BIOMOLEC, V23, P193; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WEAVER JC, 1993, ANN NY ACAD SCI, V720, P141; WENG XW, 1993, PROTEIN SCI, V2, P448; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	30	125	128	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					512	515		10.1038/378512a0	http://dx.doi.org/10.1038/378512a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477411				2022-12-01	WOS:A1995TH05400077
J	SILLITO, AM; GRIEVE, KL; JONES, HE; CUDEIRO, J; DAVIS, J				SILLITO, AM; GRIEVE, KL; JONES, HE; CUDEIRO, J; DAVIS, J			VISUAL CORTICAL MECHANISMS DETECTING FOCAL ORIENTATION DISCONTINUITIES	NATURE			English	Article							DEPENDENT NEURONAL OSCILLATIONS; CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; RECEPTIVE-FIELDS; HYPERCOMPLEX CELLS; PATTERNS; RESPONSES; DISCRIMINATION; INHIBITION	NEURONS in the primary visual cortex (V1) respond in well defined ways to stimuli within their classical receptive field, but these responses can be modified by stimuli overlying the surrounding area(1-7). For example patch-suppressed cells respond to gratings of a specific orientation within their classical receptive field, but the response diminishes if the grating is expanded to cover the surrounding area(1-7). We report here more complex effects in many such cells. When stimulated at their optimal orientation, introducing a surrounding field at a significantly different (for example, orthogonal) orientation enhanced their output by both a disinhibitory mechanism and an active facilitatory mechanism producing 'supra-optimal' responses. Importantly, some cells responded well if the orientations of centre and surround stimuli were swapped. The output reflected the discontinuity because neither stimulus component alone was effective. Under these stimulus conditions simultaneously recorded cells with orthogonally oriented receptive fields showed correlated firing consistent with neuronal binding to the configuration. We propose a mechanism integrating orientation-dependent information over adjacent areas of visual space to represent focal orientation discontinuities such as junctions or corners.	UNIV LA CORUNA,HOSP JUAN CANALEJO,UNIDAD CIRUGAI,DEPT CIENCAS SALUD 1,EL FERROL,SPAIN	Complejo Hospitalario Universitario A Coruna; Universidade da Coruna	SILLITO, AM (corresponding author), INST OPHTHALMOL,DEPT VISUAL SCI,BATH ST,LONDON EC1V 9EL,ENGLAND.			Cudeiro, Javier/0000-0002-6597-6077				ABELES M, 1988, J NEUROPHYSIOL, V60, P909, DOI 10.1152/jn.1988.60.3.909; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; BERGEN JR, 1983, IEEE T SYST MAN CYB, V13, P857, DOI 10.1109/TSMC.1983.6313080; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7071, DOI 10.1073/pnas.88.16.7071; DEANGELIS GC, 1992, J NEUROPHYSIOL, V68, P144, DOI 10.1152/jn.1992.68.1.144; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FRIES W, 1977, VISION RES, V17, P1001, DOI 10.1016/0042-6989(77)90002-5; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; KEEBLE DRT, 1995, VISION RES, V35, P1991, DOI 10.1016/0042-6989(94)00284-S; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; ORBAN GA, 1979, J NEUROPHYSIOL, V42, P818, DOI 10.1152/jn.1979.42.3.818; ORBAN GA, 1979, J NEUROPHYSIOL, V42, P833, DOI 10.1152/jn.1979.42.3.833; PALM G, 1988, BIOL CYBERN, V59, P1, DOI 10.1007/BF00336885; SILLITO AM, 1993, EXP BRAIN RES, V93, P6; SILLITO AM, 1977, J PHYSIOL-LONDON, V273, P791, DOI 10.1113/jphysiol.1977.sp012124; TSO DY, 1986, J NEUROSCI, V6, P1160	24	474	487	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					492	496		10.1038/378492a0	http://dx.doi.org/10.1038/378492a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477405				2022-12-01	WOS:A1995TH05400071
J	STAYTON, PS; SHIMOBOJI, T; LONG, C; CHILKOTI, A; CHEN, GH; HARRIS, JM; HOFFMAN, AS				STAYTON, PS; SHIMOBOJI, T; LONG, C; CHILKOTI, A; CHEN, GH; HARRIS, JM; HOFFMAN, AS			CONTROL OF PROTEIN-LIGAND RECOGNITION USING A STIMULI-RESPONSIVE POLYMER	NATURE			English	Article							POLY(N-ISOPROPYLACRYLAMIDE); IMMUNOASSAY; MEMBRANE; RELEASE; GELS	STIMULI-responsive polymers exhibit reversible phase changes in response to changes in environmental factors such as pH or temperature(1-14). Conjugating such polymers to antibodies and proteins provides molecular systems for applications such as affinity separations, immunoassays and enzyme recovery and recycling(15-25). Here we show that conjugating a temperature-sensitive polymer to a genetically engineered site on a protein allows the protein's ligand binding affinity to be controlled. We synthesized a mutant of the protein streptavidin to enable site-specific conjugation of the responsive polymer near the protein's binding site. Normal binding of biotin to the modified protein occurs below 32 degrees C, whereas above this temperature the polymer collapses and blocks binding. The collapse of the polymer and thus the enabling and disabling of binding, is reversible. Such environmentally triggered control of binding may find many applications in biotechnology and biomedicine, such as the control of enzyme reaction rates and of biosensor activity, and the controlled release of drugs.	UNIV ALABAMA,DEPT CHEM,HUNTSVILLE,AL 35899	University of Alabama System; University of Alabama Huntsville	STAYTON, PS (corresponding author), UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195, USA.		Stayton, Patrick/C-1975-2018	Stayton, Patrick/0000-0001-6939-6371				BRANNONPEPPAS L, 1989, J CONTROL RELEASE, V8, P267, DOI 10.1016/0168-3659(89)90048-5; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; Chen G.H., 1992, POLYM PREPR-ACS, V33, P468; CHEN GH, 1994, J BIOMAT SCI-POLYM E, V5, P371; CHEN GH, 1993, BIOCONJUGATE CHEM, V4, P509, DOI 10.1021/bc00024a013; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; CHEN GH, 1995, MACROMOL CHEM PHYS, V196, P1251, DOI 10.1002/macp.1995.021960424; CHEN JP, 1990, BIOMATERIALS, V11, P625, DOI 10.1016/0142-9612(90)90019-M; CHIIKOTI A, 1994, BIOCONJ CHEM, V5, P504; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; CUSSLER EL, 1984, AICHE J, V30, P578, DOI 10.1002/aic.690300408; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI [DOI 10.1080/10601326808051910, 10.1080/10601326808051910]; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOFFMAN AS, 1995, ARTIF ORGANS, V19, P458, DOI 10.1111/j.1525-1594.1995.tb02359.x; IRIE M, 1990, ADV POLYM SCI, V94, P28; ISHIHARA K, 1984, POLYM J, V16, P625, DOI 10.1295/polymj.16.625; KABRA BG, 1991, POLYM COMMUN, V32, P322; KOKUFUTA E, 1994, J BIOMAT SCI-POLYM E, V6, P35, DOI 10.1163/156856295X00733; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; MONJI N, 1994, J BIOMAT SCI-POLYM E, V5, P407, DOI 10.1163/156856294X00112; MONJI N, 1990, BIOCHEM BIOPH RES CO, V172, P652, DOI 10.1016/0006-291X(90)90724-2; OKUZAKI H, 1994, J BIOMAT SCI-POLYM E, V5, P485, DOI 10.1163/156856294X00167; STAYTON PS, 1988, J BIOL CHEM, V267, P13544; TAKEI YG, 1993, BIOCONJUGATE CHEM, V4, P42, DOI 10.1021/bc00019a006; TANAKA T, 1981, SCI AM, V244, P124, DOI 10.1038/scientificamerican0181-124; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; YANG HJ, 1990, J POLYM SCI POL CHEM, V28, P219, DOI 10.1002/pola.1990.080280116; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	30	581	600	2	222	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					472	474		10.1038/378472a0	http://dx.doi.org/10.1038/378472a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477401				2022-12-01	WOS:A1995TH05400064
J	YU, BD; HESS, JL; HORNING, SE; BROWN, GAJ; KORSMEYER, SJ				YU, BD; HESS, JL; HORNING, SE; BROWN, GAJ; KORSMEYER, SJ			ALTERED HOX EXPRESSION AND SEGMENTAL IDENTITY IN MLL-MUTANT MICE	NATURE			English	Article							DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; MOUSE; TRANSFORMATIONS; REGULATOR; MUTATION; DOMAINS; MOTIF	THE mixed-lineage leukaemia gene (MLL/HRX/ALL-1) is disrupted by chromosomal translocation in human acute leukaemias that often display mixed lymphoid-myeloid phenotypes and present in infancy(1-4). MLL possesses a highly conserved SET domain also found in Drosophila trithorax (trx) and Polycomb group (Pc-G) genes, which are known to regulate homeotic genes (HOM-C) in a positive or negative fashion, respectively(5). Mll was targeted in mice by homologous recombination in embryonic stem (ES) cells to assess its role in pattern development. MII heterozygous (+/-) mice had retarded growth, displayed haematopoietic abnormalities, and demonstrated bidirectional homeotic transformations of the axial skeleton as well as sternal malformations. Mll deficiency (-/-) was embryonic lethal. Anterior boundaries of Hoxa-7 and Noxc-9 expression were shifted posteriorly in Mll +/- embryos, but their expression was abolished in Mll -/- embryos. Thus Mll is required for proper segment identity in mammals, displays haplo-insufficiency, and positively regulates Hox gene expression.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,DIV MOLEC ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,DIV MOLEC ONCOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)				Yu, Benjamin/0000-0001-6663-6616				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; BREEN TR, 1991, MECH DEVELOP, V35, P113, DOI 10.1016/0925-4773(91)90062-B; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; DUBOULE D, 1994, DEVELOPMENT, P135; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hogan B., 1994, MANIPULATING MOUSE E; INGHAM P, 1980, MOL GEN GENET, V179, P607, DOI 10.1007/BF00271751; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; Kaufman M.H, 1992, ATLAS MOUSE DEV; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PoPeSKo P, 1992, COLOUR ATLAS ANATOMY, V2; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SEDKOV Y, 1994, DEVELOPMENT, V120, P1907; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SINGH PB, 1994, J CELL SCI, V107, P2653; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	29	688	709	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					505	508		10.1038/378505a0	http://dx.doi.org/10.1038/378505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477409				2022-12-01	WOS:A1995TH05400075
J	ZISCHLER, H; GEISERT, H; VONHAESELER, A; PAABO, S				ZISCHLER, H; GEISERT, H; VONHAESELER, A; PAABO, S			A NUCLEAR FOSSIL OF THE MITOCHONDRIAL D-LOOP AND THE ORIGIN OF MODERN HUMANS	NATURE			English	Article							DNA SEQUENCES; EVOLUTION	MAMMALIAN mitochondrial DNA sequences evolve more rapidly than nuclear sequences(1). Although the rapid rate of evolution is an advantage for the study of closely related species and populations, it presents a problem in situations where related species, used as outgroups in phylogenetic analyses, have accumulated so much change that multiple substitutions obliterate the phylogenetic information(2). However, mitochondrial DNA sequences are frequently inserted into the nuclear genome(3), where they presumably evolve as nuclear pseudogene sequences and therefore more slowly than their mitochondrial counterparts. Such sequences thus represent molecular 'fossils' that could shed light on the evolution of the mitochondrial genome and could be used as outgroups in situations where no appropriate outgroup species exist. Here we show that human chromosome 11 carries a recent integration of the mitochondrial control region that can be used to gain further insight into the origin of the human mitochondrial gene pool.			ZISCHLER, H (corresponding author), UNIV MUNICH,INST ZOOL,POB 202136,LUISENSTR 14,D-80021 MUNICH,GERMANY.		von Haeseler, Arndt/HCI-9958-2022	von Haeseler, Arndt/0000-0002-3366-4458; Zischler, Hans/0000-0002-3440-8376				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; DODA JN, 1981, P NATL ACAD SCI-BIOL, V78, P6116, DOI 10.1073/pnas.78.10.6116; FELSENSTEIN J, 1994, PHYLIP VERSION 3 5P; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; LUNDSTROM R, 1992, P NATL ACAD SCI USA, V89, P5961, DOI 10.1073/pnas.89.13.5961; MADDISON DR, 1991, SYST ZOOL, V40, P355, DOI 10.2307/2992327; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; Nei M., 1987, MOL EVOLUTIONARY GEN, DOI 10.7312/nei-92038; PENA SDJ, 1994, P NATL ACAD SCI USA, V91, P1946, DOI 10.1073/pnas.91.5.1946; PULT I, 1994, BIOL CHEM H-S, V375, P837; RUVOLO M, 1991, P NATL ACAD SCI USA, V88, P1570, DOI 10.1073/pnas.88.4.1570; Sambrook J., 1989, MOL CLONING LAB MANU; TAPPER DP, 1981, J BIOL CHEM, V256, P5106; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WARD RH, 1991, P NATL ACAD SCI USA, V88, P8720, DOI 10.1073/pnas.88.19.8720; ZULLO S, 1991, J MOL BIOL, V221, P1123	21	175	180	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 30	1995	378	6556					489	492		10.1038/378489a0	http://dx.doi.org/10.1038/378489a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH054	7477404				2022-12-01	WOS:A1995TH05400070
J	DASGUPTA, B; BOWLES, J				DASGUPTA, B; BOWLES, J			SCINTIGRAPHIC LOCALIZATION OF STEROID INJECTION SITE IN PLANTAR FASCIITIS	LANCET			English	Note								Plantar fasciitis is a common cause of heel pain. We evaluated scintigraphic localisation of the inflammatory focus in 15 patients with this condition. Technetium-labelled bone scans precisely localised abnormal discrete areas of tracer uptake in 12 (80%) of patients in the medial and posterior aspect below the inferior surface of the calcaneum. Steroid injection at the inflammatory site abolished local tenderness and reduced pain in all 12. Our findings support an injection approach through the medial heel border posterior to the point of heel tenderness. Technetium scintigraphy may be a useful investigation to localise the steroid injection site in resistant cases of plantar fasciitis.			DASGUPTA, B (corresponding author), SOUTHEND HLTH CARE TRUST,WESTCLIFF ON SEA SS0 0RY,ESSEX,ENGLAND.		Bowles, Josephine/AAG-4903-2020	Bowles, Josephine/0000-0003-2867-7438				BEIKOWITZ JF, 1991, RADIOLOGY, V179, P665; INTENZO CM, 1991, CLIN NUCL MED, V16, P325, DOI 10.1097/00003072-199105000-00006; MAPP PI, 1993, OXFORD TXB RHEUMATOL; SCHEPSIS AA, 1991, CLIN ORTHOPAEDICS, V266, P185; SELMAN JR, 1994, FOOT ANKLE INT, V15, P376; Wall J R, 1993, Foot Ankle, V14, P465	6	29	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1400	1401		10.1016/S0140-6736(95)92409-4	http://dx.doi.org/10.1016/S0140-6736(95)92409-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475824				2022-12-01	WOS:A1995TG20700012
J	GJERTSEN, MK; BAKKA, A; BREIVIK, J; SAETERDAL, I; SOLHEIM, BG; SOREIDE, O; THORSBY, E; GAUDERNACK, G				GJERTSEN, MK; BAKKA, A; BREIVIK, J; SAETERDAL, I; SOLHEIM, BG; SOREIDE, O; THORSBY, E; GAUDERNACK, G			VACCINATION WITH MUTANT RAS PEPTIDES AND INDUCTION OF T-CELL RESPONSIVENESS IN PANCREATIC-CARCINOMA PATIENTS CARRYING THE CORRESPONDING RAS MUTATION	LANCET			English	Note							REJECTION	Mutations in codon 12 of K-RAS are frequently found in pancreatic adenocarcinomas. T-cell responses specific for individual RAS mutations can be elicited in vitro by stimulation of peripheral blood mononuclear cells with synthetic peptides. Mutant ras peptides are therefore a candidate vaccine for specific immunotherapy in pancreatic carcinoma patients. When vaccinated with a synthetic ras peptide representing the K-RAS mutation in their tumours, a transient ras-specific T-cell response was induced in two of five patients treated. The vaccination protocol involved multiple in fusions of large amounts of peptide-pulsed antigen-presenting-cells obtained by leucapheresis. These results indicate that specific T-cell responses against mutations uniquely harboured in tumour cells can be induced in cancer patients by vaccination.	NATL HOSP,INST TRANSPLANTAT IMMUNOL,OSLO,NORWAY; NATL HOSP,DEPT SURG B,OSLO,NORWAY; RED CROSS & NATL HOSP BLOOD CTR,OSLO,NORWAY	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway			Klemp, Marianne/AAQ-5652-2021	Klemp, Marianne/0000-0002-9530-8344				BECKER JC, 1993, INT IMMUNOL, V5, P1501, DOI 10.1093/intimm/5.12.1501; FOSSUM B, 1994, INT J CANCER, V56, P40, DOI 10.1002/ijc.2910560108; FOSSUM B, 1995, CANCER IMMUNOL IMMUN, V40, P165; GEDDEDAHL T, 1992, INT IMMUNOL, V4, P1331, DOI 10.1093/intimm/4.11.1331; GEDDEDAHL T, 1993, EUR J IMMUNOL, V23, P754, DOI 10.1002/eji.1830230328; JUNG S, 1991, J EXP MED, V73, P273; KAHN SM, 1991, ONCOGENE, V6, P1079; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VAESSEN LMB, 1992, CLIN EXP IMMUNOL, V88, P213	10	164	173	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1399	1400		10.1016/S0140-6736(95)92408-6	http://dx.doi.org/10.1016/S0140-6736(95)92408-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475823	Bronze			2022-12-01	WOS:A1995TG20700011
J	HENDERSON, AS; EASTEAL, S; JORM, AF; MACKINNON, AJ; KORTEN, AE; CHRISTENSEN, H; CROFT, L; JACOMB, PA				HENDERSON, AS; EASTEAL, S; JORM, AF; MACKINNON, AJ; KORTEN, AE; CHRISTENSEN, H; CROFT, L; JACOMB, PA			APOLIPOPROTEIN-E ALLELE EPSILON-4, DEMENTIA, AND COGNITIVE DECLINE IN A POPULATION-SAMPLE	LANCET			English	Article							ALZHEIMERS-DISEASE; TYPE-4 ALLELE	From clinically based series it has been proposed that, in homozygotes for the apolipoprotein E epsilon 4 (apoE epsilon 4) allele, Alzheimer's disease is almost inevitable by the age of 80. A population sample of persons aged 70 years and over was interviewed in 1990-91 to ascertain the presence of dementia or cognitive impairment. The sample was re-interviewed in 1994, when the apoE genotype was also determined. Prevalence data for the 638 persons who completed the second examination revealed a linear association between having an apoE epsilon 4 allele and both dementia and cognitive impairment (for heterozygotes, odds ratio for dementia 1.89, 95% confidence interval 1.04-3.44 and for homozygotes OR 3.58, 95% CI 1.82-11.82; both adjusted for age). However, even in subjects homozygous for epsilon 4 the estimated prevalence of dementia by age 90 was only about 50%. Persons with one or two epsilon 4 alleles were more likely to have a family history of dementia than those with none. This study confirms in a population sample that the epsilon 4 allele is a risk factor for dementia, but refutes the suggestion that homozygosity for the epsilon 4 allele is sufficient for the development of Alzheimer's disease: persons with either one or two epsilon 4 alleles may reach late old age without cognitive impairment.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,HUMAN GENET GRP,CANBERRA,ACT 2601,AUSTRALIA; MENTAL HLTH RES INST,BIOSTAT & PSYCHOMETR UNIT,PARKVILLE,VIC,AUSTRALIA	Australian National University; John Curtin School of Medical Research; Florey Institute of Neuroscience & Mental Health	HENDERSON, AS (corresponding author), AUSTRALIAN NATL UNIV,NATL HLTH & MED RES COUNCIL,SOCIAL PSYCHIAT RES UNIT,GPO BOX 4,CANBERRA,ACT 0200,AUSTRALIA.		Christensen, Helen/F-5053-2012; Jorm, Anthony F/B-5555-2009	Christensen, Helen/0000-0003-0435-2065; Jorm, Anthony F/0000-0002-1424-4116; Easteal, Simon/0000-0002-0462-502X; Mackinnon, Andrew/0000-0003-0831-9801				[Anonymous], 1993, ICD 10 CLASSIFICATIO; BENJAMIN R, 1994, LANCET, V343, P1564; BROUSSEAU T, 1994, NEUROLOGY, V44, P342, DOI 10.1212/WNL.44.2.342; CHRISTENSEN H, 1994, AGE AGEING, V23, P204, DOI 10.1093/ageing/23.3.204; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FESKENS EJM, 1994, BRIT MED J, V309, P1202, DOI 10.1136/bmj.309.6963.1202; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HENDERSON AS, 1994, PSYCHOL MED, V24, P473, DOI 10.1017/S0033291700027446; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; Jorm AF, 1992, MEMORY FUNCTIONING D, P267, DOI DOI 10.1016/S0166-4115(08)60939-5; JORM AF, 1993, PROBLEM DEMENTIA AUS; KERVINEN K, 1994, ATHEROSCLEROSIS, V105, P89, DOI 10.1016/0021-9150(94)90011-6; KUUSISTO J, 1995, BRIT MED J, V309, P636; MACKINNON A, 1993, ACTA PSYCHIAT SCAND, V87, P146, DOI 10.1111/j.1600-0447.1993.tb03346.x; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; Nelson H.E., 1982, WIND UK NFER NELSON; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; RICHARDS B, 1992, HUM MOL GENET, V2, P159; RIGGS JE, 1994, ARCH NEUROL-CHICAGO, V51, P750, DOI 10.1001/archneur.1994.00540200024011; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; ROYCHOUDHURY AK, 1958, HUMAN POLYMORPHIC GE; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT J, 1993, LANCET, V342, P696, DOI 10.1016/0140-6736(93)91704-P; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; 1992, ACTA PSYCHIAT SCAND, V85, P105; 1987, DIAGNOSTIC STATISTIC	30	250	254	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1387	1390		10.1016/S0140-6736(95)92405-1	http://dx.doi.org/10.1016/S0140-6736(95)92405-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475820				2022-12-01	WOS:A1995TG20700008
J	NICHOLLS, MG; RICHARDS, AM; LEWIS, LK; YANDLE, TG				NICHOLLS, MG; RICHARDS, AM; LEWIS, LK; YANDLE, TG			OUABAIN - A NEW STEROID-HORMONE	LANCET			English	Editorial Material							DIGITALIS-LIKE-FACTOR; HUMAN PLASMA		CHRISTCHURCH HOSP,DEPT ENDOCRINOL,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand	NICHOLLS, MG (corresponding author), CHRISTCHURCH HOSP,DEPT MED,CHRISTCHURCH,NEW ZEALAND.							BOULANGER BR, 1993, AM J PHYSIOL, V264, pE413, DOI 10.1152/ajpendo.1993.264.3.E413; CAPPUCCIO FP, 1986, POSTGRAD MED J, V62, P265, DOI 10.1136/pgmj.62.726.265; DORIS PA, 1994, HYPERTENSION, V23, P632, DOI 10.1161/01.HYP.23.5.632; GOMEZSANCHEZ EP, 1994, AM J HYPERTENS, V7, P647, DOI 10.1093/ajh/7.7.647; HAMLYN JM, 1992, J HYPERTENS S7, V10, P99; HINSON JP, 1995, J ENDOCRINOL, V146, P369, DOI 10.1677/joe.0.1460369; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LEWIS LK, 1994, HYPERTENSION, V24, P549, DOI 10.1161/01.HYP.24.5.549; LUDENS JH, 1992, HYPERTENSION, V19, P721, DOI 10.1161/01.HYP.19.6.721; LUDENS JH, 1991, HYPERTENSION, V17, P923, DOI 10.1161/01.HYP.17.6.923; MATHEWS WR, 1991, HYPERTENSION, V17, P930, DOI 10.1161/01.HYP.17.6.930; NARUSE K, 1994, HYPERTENSION S1, V23, P102; ROSSI GP, 1995, 7TH EUR M HYP MIL; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; WOOLFSON RG, 1994, KIDNEY INT, V46, P297, DOI 10.1038/ki.1994.275	15	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1381	1382		10.1016/S0140-6736(95)92402-7	http://dx.doi.org/10.1016/S0140-6736(95)92402-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475817				2022-12-01	WOS:A1995TG20700005
J	OLIVER, MF				OLIVER, MF			STATINS PREVENT CORONARY HEART-DISEASE	LANCET			English	Editorial Material											OLIVER, MF (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON, ENGLAND.							BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; DAYTON S, 1969, CIRCULATION S2, V39, P63; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; LORD I, 1992, J CLIN EPIDEMIOL, V45, P849, DOI 10.1016/0895-4356(92)90068-X; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1994, LANCET, V344, P633; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; 1993, MORTALITY STATIS DH2	16	26	26	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	1995	346	8987					1378	1379		10.1016/S0140-6736(95)92399-3	http://dx.doi.org/10.1016/S0140-6736(95)92399-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475814	Bronze			2022-12-01	WOS:A1995TG20700002
J	PERRY, IJ; REFSUM, H; MORRIS, RW; EBRAHIM, SB; UELAND, PM; SHAPER, AG				PERRY, IJ; REFSUM, H; MORRIS, RW; EBRAHIM, SB; UELAND, PM; SHAPER, AG			PROSPECTIVE-STUDY OF SERUM TOTAL HOMOCYSTEINE CONCENTRATION AND RISK OF STROKE IN MIDDLE-AGED BRITISH MEN	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; PLASMA HOMOCYST(E)INE	Moderate hyperhomocysteinaemia is common in the general population and has been linked with cardiovascular disease. However, there are no data from prospective, population-based studies. We examined the association between serum total homocysteine (tHcy) concentration and stroke in a nested case-control study within the British Regional Heart Study cohort. Between 1978 and 1980 serum was saved from 5661 men, aged 40-59 years, randomly selected from the population of one general practice in each of 18 towns in the UK. During follow-up to December, 1991, there were 141 incident cases of stroke among men with no history of stroke at screening. Serum tHcy was measured in 107 cases and 118 control men (matched for age-group and town, without a history of stroke at screening, who did not develop a stroke or myocardial infarction during follow-up). tHcy concentrations were significantly higher in cases than controls (geometric mean 13.7 [95% CI 12.7-14.8] vs 11.9 [11.3-12.6] mu mol/L; p=0004). There was a graded increase in the relative risk of stroke in the second, third, and fourth quarters of the tHcy distribution (odds ratios 1.3, 1.9, 2.8; trend p=0.005) relative to the first. Adjustment for age-group, town, social class, body-mass index, hypertensive status, cigarette smoking, expiratory volume, packed-cell volume, alcohol diabetes, high-density-lipoprotein cholesterol, and serum creatinine did not attenuate the association. These findings suggest that tHcy is a strong and independent risk factor for stroke.	UNIV BERGEN,DEPT BIOL CLIN,DIV PHARMACOL,BERGEN,NORWAY	University of Bergen	PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Refsum, Helga/A-4073-2010; Ueland, Per M/C-7340-2013	Morris, Richard/0000-0001-7240-4563; Ueland, Per Magne/0000-0002-1903-0571; Perry, Ivan/0000-0002-4965-9792				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; ISRAELSSON B, 1993, SCAND J CLIN LAB INV, V39, P263; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MASSER PE, 1995, J IR COLL PHYS SURG, V24, P25; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; POCOCK SJ, 1989, J CLIN PATHOL, V42, P172, DOI 10.1136/jcp.42.2.172; REFSUM H, 1989, CLIN CHEM, V35, P1921; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; SHAPER AG, 1988, LANCET, V2, P1268; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; THELLE DS, 1984, BRIT HEART J, V49, P205; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; WALKER M, 1984, J R COLL GEN PRACT, V34, P197; WANNAMETHEE G, 1994, J INTERN MED, V235, P163, DOI 10.1111/j.1365-2796.1994.tb01050.x	30	714	744	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1395	1398		10.1016/S0140-6736(95)92407-8	http://dx.doi.org/10.1016/S0140-6736(95)92407-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475822				2022-12-01	WOS:A1995TG20700010
J	STEWART, T; STEWART, N				STEWART, T; STEWART, N			BREAST-CANCER IN FEMALE FLIGHT ATTENDANTS	LANCET			English	Editorial Material									UNIV OTTAWA,OTTAWA,ON,CANADA	University of Ottawa	STEWART, T (corresponding author), OTTAWA GEN HOSP,OTTAWA,ON K1H 8L6,CANADA.			Stewart, Nicolas/0000-0002-8969-4242				COHEN BL, 1994, INT ARCH OCC ENV HEA, V66, P71, DOI 10.1007/BF00383360; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; LEVY JA, 1995, LANCET, V346, P786, DOI 10.1016/S0140-6736(95)91611-3; LIU SZ, 1985, CHINESE J RADIOL MED, V5, P124; LIU SZ, 1987, HLTH PHYS, V52, P579; Luckey TD, 1991, RAD HORMESIS; PUKKALA E, 1995, BRIT MED J, V311, P649, DOI 10.1136/bmj.311.7006.649; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; TUSCHL H, 1980, RADIAT RES, V81, P1, DOI 10.2307/3575358	9	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1379	1379		10.1016/S0140-6736(95)92400-0	http://dx.doi.org/10.1016/S0140-6736(95)92400-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475815				2022-12-01	WOS:A1995TG20700003
J	THOMPSON, JN				THOMPSON, JN			PREVENTING ADHESIONS	LANCET			English	Editorial Material											THOMPSON, JN (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT SURG, LONDON, ENGLAND.							BECKER JM, 1995, SODIUM HYALURONATE B; DIZEREGA GS, 1994, FERTIL STERIL, V61, P219; SEKIBA K, 1992, OBSTET GYNECOL, V79, P518; THOMPSON JN, 1995, BRIT J SURG, V82, P3, DOI 10.1002/bjs.1800820103; VIPOND MN, 1990, LANCET, V335, P1120, DOI 10.1016/0140-6736(90)91125-T; WHAWELL SA, 1995, EUR J SURG, V161, P315; WISEMAN DM, 1994, POLYM SITE SPECIFIC, P369	7	4	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 25	1995	346	8987					1382	1382		10.1016/S0140-6736(95)92403-5	http://dx.doi.org/10.1016/S0140-6736(95)92403-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475818				2022-12-01	WOS:A1995TG20700006
J	WINSTON, DJ				WINSTON, DJ			PREVENTION OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; IMMUNE GLOBULIN; GANCICLOVIR PROPHYLAXIS; VIRUS INFECTION; DOUBLE-BLIND; TRIAL				WINSTON, DJ (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024, USA.							BOECKH M, 1994, 34TH INT C ANT AG CH, V7; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; HIBBERD PL, 1995, ANN INTERN MED, V123, P18, DOI 10.7326/0003-4819-123-1-199507010-00002; MARTIN M, 1994, TRANSPLANTATION, V58, P225; PRENTICE HG, 1994, LANCET, V343, P749, DOI 10.1016/S0140-6736(94)91835-X; SINGH N, 1994, ANN INTERN MED, V120, P375, DOI 10.7326/0003-4819-120-5-199403010-00004; SNYDMAN DR, 1993, ANN INTERN MED, V119, P984, DOI 10.7326/0003-4819-119-10-199311150-00004; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9; WINSTON DJ, IN PRESS TRANSPLANTA	13	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1380	1381		10.1016/S0140-6736(95)92401-9	http://dx.doi.org/10.1016/S0140-6736(95)92401-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475816	Bronze			2022-12-01	WOS:A1995TG20700004
J	DALY, MJ; MINTON, KW				DALY, MJ; MINTON, KW			RESISTANCE TO RADIATION	SCIENCE			English	Editorial Material											DALY, MJ (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.							DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; DALY MJ, 1995, J BACTERIOL, V177, P7506; MATTIMORE V, IN PRESS J BACTERIOL; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MINTON KW, 1995, BIOESSAYS, V17, P457, DOI 10.1002/bies.950170514	5	29	32	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1318	1318		10.1126/science.270.5240.1318	http://dx.doi.org/10.1126/science.270.5240.1318			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481818				2022-12-01	WOS:A1995TF89900027
J	DAVIDSON, EH; PETERSON, KJ; CAMERON, RA				DAVIDSON, EH; PETERSON, KJ; CAMERON, RA			ORIGIN OF BILATERIAN BODY PLANS - EVOLUTION OF DEVELOPMENTAL REGULATORY MECHANISMS	SCIENCE			English	Article							MARINE-INVERTEBRATES; LARVAL DEVELOPMENT; PATTERN-FORMATION; HOX CODE; DROSOPHILA; HINDBRAIN; PHYLOGENY; EMBRYOS; GENES; EXPRESSION	An argument is proposed to explain the origin of large metazoans, based on the regulatory processes that underlie the morphogenetic organization of pattern in modern animals. Genetic regulatory systems similar to those used in modern, indirectly developing marine invertebrates are considered to indicate the Precambrian regulatory platform on which were erected innovations that underlie the development of macroscopic body plans. Those systems are genetic regulatory programs that produce groups of unspecified ''set-aside cells'' and hierarchical regulatory programs that initially define regions of morphogenetic space in terms of domains of transcription factor expression, These ideas affect interpretation of the development of arthropods and chordates as well as interpretation of the role of the genes of the homeotic complex in embryogenesis.	UNIV CALIF LOS ANGELES,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	DAVIDSON, EH (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Peterson, Kevin J/A-2188-2009	Cameron, R. Andrew/0000-0003-3947-6041	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005753, R37HD005753] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006591] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-06591] Funding Source: Medline; NICHD NIH HHS [HD-05753] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; BALSER EJ, 1990, ACTA ZOOL-STOCKHOLM, V71, P235, DOI 10.1111/j.1463-6395.1990.tb01082.x; BENGTSON S., 1986, PROBLEMATIC FOSSIL T, P3; Berrill N.J., 1955, ORIGIN VERTEBRATES; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; BRITTEN RJ, 1971, QUART REV BIOL, V46, P111; Brusca R.C., 1990, INVERTEBRATES; CAMERON R A, 1989, Molecular Reproduction and Development, V1, P149, DOI 10.1002/mrd.1080010302; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; CAMERON RA, 1989, DEVELOPMENT, V113, P1085; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CARROLL SB, 1994, DEVELOPMENT, P217; Coffman JA, 1992, CURR OPIN GENET DEV, V2, P260, DOI 10.1016/S0959-437X(05)80283-7; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; CZIHAK G, 1965, ROUX ARCH ENTW MECH, V155, P709; DAMEN P, 1994, DEV BIOL, V162, P364, DOI 10.1006/dbio.1994.1094; Dan, 1968, INVERTEBRATE EMBRYOL; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1993, DEVELOPMENT, V118, P665; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DAVIDSON EH, 1994, BIOESSAYS, V16, P603, DOI 10.1002/bies.950160903; DAVIDSON EH, 1986, GENE ACTIVITY EARLY, pCH3; EDGAR LG, 1994, DEVELOPMENT, V120, P443; EMLET RB, 1995, DEV BIOL, V167, P405, DOI 10.1006/dbio.1995.1037; FEDONKIN MA, 1994, NOBEL S, V84, P370; GARCIABELLIDO A, 1994, P NATL ACAD SCI USA, V91, P10222, DOI 10.1073/pnas.91.21.10222; GEHLING JG, 1991, MEMOIRS GEOLOGICAL S, V20, P181; GONZALEZGAITAN M, 1994, MECH DEVELOP, V40, P183; Gould S.J., 1989, WONDERFUL LIFE BURGE; GOULD SJ, 1992, ORIGIN EARLY EVOLUTI; Hadfield M.G., 1975, P185; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HASZPRUNAR G, 1995, ACTA ZOOL-STOCKHOLM, V76, P141, DOI 10.1111/j.1463-6395.1995.tb00988.x; HOLLAND LZ, 1989, MAR BIOL, V101, P83, DOI 10.1007/BF00393481; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; Hyman L. H., 1959, INVERTEBRATES SMALLE, VV; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; Jagersten G, 1972, EVOLUTION METAZOAN L; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEAHY PS, 1994, MECH DEVELOP, V45, P255, DOI 10.1016/0925-4773(94)90012-4; MacBride EW, 1903, PHILOS T R SOC LON B, V195, P285, DOI 10.1098/rstb.1903.0006; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MILEIKOVSKY SA, 1971, MAR BIOL, V10, P193, DOI 10.1007/BF00352809; MOLVEN A, 1990, DEVELOPMENT, V109, P279; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORGAN BA, 1994, DEVELOPMENT, P181; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; MORRIS SC, 1993, PALAEONTOLOGY, V36, P593; MORRIS SC, 1994, DEVELOPMENT S, V1; NIELSEN C, 1985, BIOL J LINN SOC, V25, P243, DOI 10.1111/j.1095-8312.1985.tb00396.x; Pearse JS, 1991, REPRODUCTION MARINE, P514; PETERSON KJ, 1995, LETHAIA, V28, P25, DOI 10.1111/j.1502-3931.1995.tb01591.x; QUIRING R, 1994, SCIENCE, V265, P85; RAFF RA, 1987, DEV BIOL, V119, P6, DOI 10.1016/0012-1606(87)90201-6; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; RAFF RA, 1994, NOB S, V84, P489; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1994, DEVELOPMENT, V120, P1123; RUNNEGAR B, 1982, ALCHERINGA, V6, P223, DOI 10.1080/03115518208565415; RUNNEGAR B, 1982, J GEOL SOC AUST, V29, P395, DOI 10.1080/00167618208729222; Runnegar Bruce, 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V195, P303; SCHELTEMA AH, 1993, BIOL BULL, V171, P57; SCHNEIDERMAUNOU.S, 1993, CELL, V0075; Sepkoski J.J. Jr, 1992, P1171; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; STRATHMANN RR, 1978, EVOLUTION, V32, P894, DOI 10.1111/j.1558-5646.1978.tb04642.x; STRATHMANN RR, 1985, ANNU REV ECOL SYST, V16, P339, DOI 10.1146/annurev.es.16.110185.002011; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORSON G, 1950, BIOL REV, V25, P1, DOI 10.1111/j.1469-185X.1950.tb00585.x; VALENTINE JW, 1994, NOBEL S, V84, P401; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; WEIGUO S, 1994, NOBLE S, V84, P358; WHEELER WC, 1993, CLADISTICS, V9, P1, DOI 10.1111/j.1096-0031.1993.tb00207.x; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; WRAY GA, 1994, DEVELOPMENT, P97; WRAY GA, 1994, AM ZOOL, V34, P353; [No title captured]	83	308	315	1	44	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1319	1325		10.1126/science.270.5240.1319	http://dx.doi.org/10.1126/science.270.5240.1319			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481819				2022-12-01	WOS:A1995TF89900028
J	ECONOMIDES, AN; RAVETCH, JV; YANCOPOULOS, GD; STAHL, N				ECONOMIDES, AN; RAVETCH, JV; YANCOPOULOS, GD; STAHL, N			DESIGNER CYTOKINES - TARGETING ACTIONS TO CELLS OF CHOICE	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; CNTF RECEPTOR; SIGNAL TRANSDUCER; ALPHA COMPONENT; ONCOSTATIN-M; EXPRESSION; GP-130; GP130	Some growth factors are therapeutically useful partly because restricted expression of their receptors limits their action to particular cell types. However, no unique stimulatory factor is known for many clinically relevant cell types, such as CD34(+) hematopoietic stem cells. Here, soluble alpha receptor (R alpha) components for interleukin-6 (IL-6) and ciliary neurotrophic factor (CNTF) were targeted in an active form to cells expressing surface markers such as CD34 or CD45, thereby rendering those cells responsive to IL-6 or CNTF. The targeting of R alpha components may provide the means to create ''designer'' cytokines that activate a desired cell type expressing a specific cell surface marker.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; SLOAN KETTERING INST,BIOCHEM GENET LAB,NEW YORK,NY 10021	Regeneron; Memorial Sloan Kettering Cancer Center			Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041; Economides, Aris/0000-0002-6508-8942				ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; ECONOMIDES A, UNPUB; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; HAAKFRENDSCHO M, 1994, J IMMUNOL, V152, P1347; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; METCALF D, 1994, STEM CELLS, V1, P259; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PANAYOTATOS N, 1994, BIOCHEMISTRY-US, V33, P5813, DOI 10.1021/bi00185a020; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; ROWE JM, 1992, J CLIN PHARMACOL, V32, P486, DOI 10.1177/009127009203200602; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZAULI G, 1994, BLOOD, V83, P167	26	22	35	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1351	1353		10.1126/science.270.5240.1351	http://dx.doi.org/10.1126/science.270.5240.1351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481821				2022-12-01	WOS:A1995TF89900036
J	ITOH, K; STEVENS, B; SCHACHNER, M; FIELDS, RD				ITOH, K; STEVENS, B; SCHACHNER, M; FIELDS, RD			REGULATED EXPRESSION OF THE NEURAL CELL-ADHESION MOLECULE L1 BY SPECIFIC PATTERNS OF NEURAL IMPULSES	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; NERVOUS-SYSTEM; SCHWANN-CELLS; SURFACE; GROWTH; NEURONS; STEP; ACID	Development of the mammalian nervous system is regulated by neural impulse activity, but the molecular mechanisms are not well understood. If cell recognition molecules [for example, L1 and the neural cell adhesion molecule (NCAM)] were influenced by specific patterns of impulse activity, cell-cell interactions controlling nervous system structure could be regulated by nervous system function at critical stages of development. Low frequency electrical pulses delivered to mouse sensory neurons in culture (0.1 hertz for 5 days) down-regulated expression of L1 messenger RNA and protein (but not NCAM). Fasciculation of neurites, adhesion of neuroblastoma cells, and the number of Schwann cells on neurites was reduced after 0.1-hertz stimulation, but higher frequencies or stimulation after synaptogenesis were without effect.	NICHHD,NEUROCYTOL & PHYSIOL UNIT,BETHESDA,MD 20892; ETH HONGGERBERG,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Swiss Federal Institutes of Technology Domain; ETH Zurich								BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BOCK E, 1985, EMBO J, V4, P2765, DOI 10.1002/j.1460-2075.1985.tb04001.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fields R. Douglas, 1992, P67; FIELDS RD, 1991, J NEUROSCI, V11, P134; FIELDS RD, 1992, INT REV NEUROBIOL, V34, P133, DOI 10.1016/S0074-7742(08)60098-7; FITZGERALD M, 1987, NATURE, V326, P603, DOI 10.1038/326603a0; Fitzgerald M, 1992, SENSORY NEURONS DIVE, P287; ITOH K, 1995, J NEUROSCI, V15, P2504, DOI 10.1523/JNEUROSCI.15-03-02504.1995; LAWSON SN, 1984, J COMP NEUROL, V228, P263, DOI 10.1002/cne.902280211; MOOS M, 1989, NATURE, V334, P701; MOSCOSO LM, 1995, J COMP NEUROL, V352, P321, DOI 10.1002/cne.903520302; RATHJEN FG, 1984, EMBO J, V3, P1; RUTISHAUSER U, 1991, TRENDS NEUROSCI, V14, P528, DOI 10.1016/0166-2236(91)90006-G; SCHACHNER M, 1990, MORPHOREGULATORY MOL, P443; SEILHEIMER B, 1988, J CELL BIOL, V107, P341, DOI 10.1083/jcb.107.1.341; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SPRINKLE TJ, 1987, BRAIN RES, V426, P349, DOI 10.1016/0006-8993(87)90888-2; SWEADNER KJ, 1983, J NEUROSCI, V3, P2504; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; WOOD P, 1990, ANN NY ACAD SCI, V605, P1, DOI 10.1111/j.1749-6632.1990.tb42376.x; XIAONAN G, 1995, NATURE, V375, P784	22	151	152	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1369	1372		10.1126/science.270.5240.1369	http://dx.doi.org/10.1126/science.270.5240.1369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481827				2022-12-01	WOS:A1995TF89900042
J	KROPSHOFER, H; VOGT, AB; STERN, LJ; HAMMERLING, GJ				KROPSHOFER, H; VOGT, AB; STERN, LJ; HAMMERLING, GJ			SELF-RELEASE OF CLIP IN PEPTIDE LOADING OF HLA-DR MOLECULES	SCIENCE			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; CELL LINE; ASSOCIATION; CONTAINS; BINDING	The assembly and transport of major histocompatibility complex (MHC) class II molecules require interaction with the invariant chain. A fragment of the invariant chain, CLIP, occupies the peptide-binding groove of the class II molecule. At endosomal pH, the binding of CLIP to human MHC class II HLA-DR molecules was counteracted by its amino-terminal segment (residues 81 to 89), which facilitated rapid release. The CLIP(81-89) fragment also catalyzed the release of CLIP(90-105) and a subset of other self-peptides, probably by transient interaction with an effector site outside the groove. Thus, CLIP may facilitate peptide loading through an allosteric release mechanism.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KROPSHOFER, H (corresponding author), GERMAN CANC RES CTR,DEPT MOLEC IMMUNOL,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.							ADAMS S, 1995, EUR J IMMUNOL, V25, P1693, DOI 10.1002/eji.1830250632; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARNES KA, 1995, J EXP MED, V181, P1715, DOI 10.1084/jem.181.5.1715; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GELUK A, 1992, J IMMUNOL, V149, P2864; Ghosh P., COMMUNICATION; GORGA JC, 1987, J BIOL CHEM, V262, P16087; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; KROPSHOFER H, 1993, P NATL ACAD SCI USA, V90, P403, DOI 10.1073/pnas.90.2.403; KROPSHOFER H, 1995, P NATL ACAD SCI USA, V92, P8313, DOI 10.1073/pnas.92.18.8313; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; LEE C, 1995, P NATL ACAD SCI USA, V92, P8269, DOI 10.1073/pnas.92.18.8269; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SETTE A, 1995, J EXP MED, V181, P677, DOI 10.1084/jem.181.2.677; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; URBAN RG, 1994, J EXP MED, V180, P751, DOI 10.1084/jem.180.2.751	40	93	98	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1357	1359		10.1126/science.270.5240.1357	http://dx.doi.org/10.1126/science.270.5240.1357			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481823				2022-12-01	WOS:A1995TF89900038
J	MEIER, UC; KLENERMAN, P; GRIFFIN, P; JAMES, W; KOPPE, B; LARDER, B; MCMICHAEL, A; PHILLIPS, R				MEIER, UC; KLENERMAN, P; GRIFFIN, P; JAMES, W; KOPPE, B; LARDER, B; MCMICHAEL, A; PHILLIPS, R			CYTOTOXIC T-LYMPHOCYTE LYSIS INHIBITED BY VIABLE HIV MUTANTS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GENETIC-VARIATION; RECOGNITION; RETROVIRUS; CELLS	Immune evasion by the human immunodeficiency virus (HIV) is unexplained but may involve the mutation of viral antigens. When cytotoxic T lymphocytes engaged CD4-positive cells that were acutely infected with HIV bearing natural variant epitopes in reverse transcriptase, substantial inhibition of specific antiviral lysis was observed. Mutant viruses capable of these transactive effects could facilitate the persistence of a broad range of HIV variants in the face of an active and specific immune response.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Oxford; University of Oxford; University of Oxford; GlaxoSmithKline; Wellcome Research Laboratories			james, william/H-4289-2013; Meier, Ute Christiane/N-6891-2018; Larder, Brendan/AAB-3106-2020	james, william/0000-0002-2506-1198; Meier, Ute Christiane/0000-0002-8838-5464; klenerman, paul/0000-0003-4307-9161	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BEVAN MJ, 1975, J EXP MED, V142, P1349, DOI 10.1084/jem.142.6.1349; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; COFFIN JM, 1995, NATURE, V375, P534, DOI 10.1038/375534a0; COLLIN M, 1994, J GEN VIROL, V75, P1597, DOI 10.1099/0022-1317-75-7-1597; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; EBERLE J, 1992, J VIROL METHODS, V40, P347, DOI 10.1016/0166-0934(92)90092-R; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, UNPUB; KLENERMAN P, 1994, NATURE, V269, P403; KOUP RA, 1995, J EXP MED, V180, P779; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MCADAM S, 1995, J IMMUNOL, V155, P2729; MDRENAS J, 1995, SCIENCE, V267, P515; MEIER UE, UNPUB; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; REID S, UNPUB; SHIMOTOHNO K, 1982, J VIROL, V41, P163, DOI 10.1128/JVI.41.1.163-171.1982; SIMON JHM, 1993, J EXP MED, V177, P949, DOI 10.1084/jem.177.4.949; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	33	93	94	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1360	1362		10.1126/science.270.5240.1360	http://dx.doi.org/10.1126/science.270.5240.1360			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481824				2022-12-01	WOS:A1995TF89900039
J	ONATE, SA; TSAI, SY; TSAI, MJ; OMALLEY, BW				ONATE, SA; TSAI, SY; TSAI, MJ; OMALLEY, BW			SEQUENCE AND CHARACTERIZATION OF A COACTIVATOR FOR THE STEROID-HORMONE RECEPTOR SUPERFAMILY	SCIENCE			English	Article							HUMAN PROGESTERONE-RECEPTOR; THYROID-HORMONE; RETINOIC ACID; RETINOBLASTOMA PROTEIN; RESPONSE ELEMENTS; ESTROGEN-RECEPTOR; ACTIVATION; TRANSCRIPTION; TRANSACTIVATION; ANTIHORMONE	A yeast two-hybrid system was used to identify a protein that interacts with and enhances the human progesterone receptor (hPR) transcriptional activity without altering the basal activity of the promoter. Because the protein stimulated transactivation of all the steroid receptors tested, it has been termed steroid receptor coactivator-1 (SRC-1). Coexpression of SRC-1 reversed the ability of the estrogen receptor to squelch activation by hPR. Also, the amino terminal truncated form of SRC-1 acted as a dominant-negative repressor. Together, these results indicate that SRC-1 encodes a coactivator that is required for full transcriptional activity of the steroid receptor superfamily.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine					NICHD NIH HHS [HD08188] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Ausubel FM, 1992, SHORT PROTOCOLS MOL; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conneely OM, 1989, GENE REGULATION STER, V4, P220; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LENG XH, 1994, J BIOL CHEM, V269, P31436; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; ONATE SA, UNPUB; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4	30	1941	1990	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	1995	270	5240					1354	1357						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481822				2022-12-01	WOS:A1995TF89900037
J	PANGANIBAN, G; SEBRING, A; NAGY, L; CARROLL, S				PANGANIBAN, G; SEBRING, A; NAGY, L; CARROLL, S			THE DEVELOPMENT OF CRUSTACEAN LIMBS AND THE EVOLUTION OF ARTHROPODS	SCIENCE			English	Article							DISTAL-LESS; DEVELOPING FOREBRAIN; RESTRICTED EXPRESSION; DROSOPHILA EMBRYO; HOMEOBOX GENES; HOMEODOMAIN	Arthropods exhibit great diversity in the position, number, morphology, and function of their limbs. The evolutionary relations among limb types and among the arthropod groups that bear them (insects, crustaceans, myriapods, and chelicerates) are controversial. Here, the use of molecular probes, including an antibody to proteins encoded by arthropod and vertebrate Distal-less (Dll and Dlx) genes, provided evidence that common genetic mechanisms underlie the development of all arthropod limbs and their branches and that all arthropods derive from a common ancestor. However, differences between crustacean and insect body plans were found to correlate with differences in the deployment of particular homeotic genes and in the ways that these genes regulate limb development.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison			Boekhoff-Falk, Grace E/B-2240-2008	Boekhoff-Falk, Grace E/0000-0002-9877-8309				AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Anderson D. T., 1973, EMBRYOLOGY PHYLOGENY; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; BEAUCHEMIN M, 1992, DEV BIOL, V154, P55, DOI 10.1016/0012-1606(92)90047-K; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOUDREAUX HB, 1987, ANTHR PHYLOGENY SPEC; BUDD G, COMMUNICATION; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; COHEN B, 1993, DEVELOPMENT, V117, P597; Cohen S. M., 1993, DEV DROSOPHILA MELAN, P747; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIRKSEN ML, 1993, MECH DEVELOP, V41, P121, DOI 10.1016/0925-4773(93)90042-V; EKKER M, 1992, NEURON, V9, P27, DOI 10.1016/0896-6273(92)90217-2; EMERSON MJ, 1990, SCIENCE, V250, P667, DOI 10.1126/science.250.4981.667; FRENCH V, 1994, CURR BIOL, V4, P34, DOI 10.1016/S0960-9822(00)00006-3; HELD LI, 1995, BIOESSAYS, V17, P721, DOI 10.1002/bies.950170809; HESSLER R R, 1975, Fossils and Strata, V4, P437; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANTON SM, 1964, MANDIBULAR MECHANISM, V247; PANGANIBAN G, UNPUB; PANGANIBAN G, 1994, CURR BIOL, V4, P67; PAPALOPULU N, 1993, DEVELOPMENT, V117, P961; PATEL NH, COMMUNICATION; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; ROBINSON GW, 1991, NEW BIOL, V3, P1183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schrehardt A, 1987, ARTEMIA RES ITS APPL, V1, P5; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; Snodgrass RE, 1935, PRINCIPLES INSECT MO; SNODGRASS RE, 1938, SMITHSONIAN MISCELLA, V97; SNODGRASS RE, 1958, SMITHSONIAN MISCELLA, V138; STRUHL G, 1981, NATURE, V292, P635, DOI 10.1038/292635a0; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; Williams JA, 1995, DNA CLONING, P15; ZRZAVY J, 1994, J EVOLUTION BIOL, V7, P743, DOI 10.1046/j.1420-9101.1994.7060743.x	42	290	300	2	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1363	1366		10.1126/science.270.5240.1363	http://dx.doi.org/10.1126/science.270.5240.1363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481825				2022-12-01	WOS:A1995TF89900040
J	ROSENBERG, PS				ROSENBERG, PS			SCOPE OF THE AIDS EPIDEMIC IN THE UNITED-STATES	SCIENCE			English	Article							INCUBATION PERIOD; HOMOSEXUAL MEN; HIV-INFECTION; SAN-FRANCISCO; COHORT; PREVALENCE; THERAPY; AGE	Two-dimensional deconvolution techniques are used here to reconstruct age-specific human immunodeficiency virus(HIV) infection rates in the United States from surveillance data on acquired immunodeficiency syndrome (AIDS). This approach suggests that 630,000 to 897,000 adults and adolescents in the United States were living with HIV infection as of January 1993, including 107,000 to 150,000 women. The estimated incidence of HIV infection declined markedly over time among white males, especially those older than 30 years. In contrast, HIV incidence appears to have remained relatively constant among women and minorities. As of January 1993, prevalence was highest among young adults in their late twenties and thirties and among minorities. An estimated 3 percent of black men and 1 percent of black women in their thirties were living with HIV infection as of that date. If infection rates remain at these levels, HIV must be considered as endemic in the United States.			ROSENBERG, PS (corresponding author), NCI,ROCKVILLE,MD 20852, USA.			Rosenberg, Philip/0000-0001-6349-9126				BECKER NG, 1993, BIOMETRIKA, V80, P165, DOI 10.1093/biomet/80.1.165; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; KARON JM, COMMUNICATION; LANG W, 1993, J ACQ IMMUN DEF SYND, V6, P191; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; MCQUILLAN GM, 1994, J ACQ IMMUN DEF SYND, V7, P1195; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG PS, 1992, STAT MED, V11, P1633, DOI 10.1002/sim.4780111302; ROSENBERG PS, 1994, STAT MED, V13, P1975, DOI 10.1002/sim.4780131909; VERDECCHIA A, 1994, INT J EPIDEMIOL, V23, P1027, DOI 10.1093/ije/23.5.1027; 1994, LANCET, V343, P871; 1987, MORB MORTAL WKLY S1, V36; 1992, MORB MORTAL WKLY REP, V41; 1990, MMWR-MORBID MORTAL W, V39, P110; 1994, MMWR-MORBID MORTAL W, V43, P826	24	150	152	1	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1372	1375		10.1126/science.270.5240.1372	http://dx.doi.org/10.1126/science.270.5240.1372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481828				2022-12-01	WOS:A1995TF89900043
J	TADDESE, A; NAH, SY; MCCLESKEY, EW				TADDESE, A; NAH, SY; MCCLESKEY, EW			SELECTIVE OPIOID INHIBITION OF SMALL NOCICEPTIVE NEURONS	SCIENCE			English	Article							CONDUCTION-VELOCITY; GANGLION-CELLS; NERVE ACTIVITY; CAT; PAIN; SUBSTANCE; RECEPTORS; MORPHINE; CURRENTS; RELEASE	Opioid analgesia, the selective suppression of pain without effects on other sensations, also distinguishes between different types of pain: severe, persistent pain is potently inhibited by opioids, but they fail to conceal the sensation of a pinprick. The cellular basis for this specificity was analyzed by means of patch-clamp experiments performed on fluorescently labeled nociceptive neurons (nociceptors) that innervate rat tooth pulp. Activation of the mu opioid receptor inhibited calcium channels on almost all small nociceptors but had minimal effect on large nociceptors. Somatostatin had the opposite specificity, preferentially inhibiting calcium channels on the large cells. Because persistent pain is mediated by slow-conducting, small nociceptors, opioids are thus likely to inhibit neurotransmitter release only at those primary synapses specialized for persistent pain.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University								AHLQUIST ML, 1984, PAIN, V19, P353, DOI 10.1016/0304-3959(84)90081-2; AHLQUIST ML, 1985, ADV PAIN RES THER, V9, P352; AKINS PT, 1993, NEUROSCIENCE, V56, P759, DOI 10.1016/0306-4522(93)90372-M; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7; COOPER BY, 1986, PAIN, V24, P93, DOI 10.1016/0304-3959(86)90030-8; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DONG WK, 1985, BRAIN RES, V334, P389, DOI 10.1016/0006-8993(85)90239-2; EDWALL L, 1977, PAIN, V3, P121, DOI 10.1016/0304-3959(77)90075-6; FORS UGH, 1988, PAIN, V33, P253, DOI 10.1016/0304-3959(88)90097-8; GO VLW, 1987, J PHYSIOL-LONDON, V391, P141, DOI 10.1113/jphysiol.1987.sp016731; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; GRUDT TJ, 1994, J NEUROSCI, V14, P1646, DOI 10.1523/JNEUROSCI.14-03-01646.1994; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; JUMA I, 1978, BRAIN RES, V171, P573; JYVASJARVI E, 1987, J PHYSIOL-LONDON, V391, P193, DOI 10.1113/jphysiol.1987.sp016733; LEE KH, 1986, J COMP NEUROL, V243, P335, DOI 10.1002/cne.902430305; Lewis T, 1937, CLIN SCI, V3, P67; MARFURT CF, 1984, J COMP NEUROL, V223, P353; MOISES HC, 1994, J NEUROSCI, V14, P5903; NARHI M, 1994, ARCH ORAL BIOL, V39, pS23, DOI 10.1016/0003-9969(94)90184-8; RANG HP, 1994, TXB PAIN, pCH1; SANDKUHLER J, 1990, NEUROSCIENCE, V34, P565, DOI 10.1016/0306-4522(90)90165-Z; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SEWARD E, 1991, P ROY SOC B-BIOL SCI, V244, P129, DOI 10.1098/rspb.1991.0061; SHEFNER SA, 1981, BRAIN RES, V221, P109, DOI 10.1016/0006-8993(81)91066-0; STEPHENSON JL, 1995, EXP NEUROL, V131, P11, DOI 10.1016/0014-4886(95)90003-9; TOREBJORK H, 1972, EXP BRAIN RES, V16, P321; WALL PD, 1994, PAIN, pCH1; WILDING TJ, 1995, J NEUROSCI, V15, P4124; WILLIAMS J, 1981, NEUROSCI LETT, V21, P211, DOI 10.1016/0304-3940(81)90384-0	34	130	133	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1366	1369		10.1126/science.270.5240.1366	http://dx.doi.org/10.1126/science.270.5240.1366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481826				2022-12-01	WOS:A1995TF89900041
J	XIA, ZG; DICKENS, M; RAINGEAUD, J; DAVIS, RJ; GREENBERG, ME				XIA, ZG; DICKENS, M; RAINGEAUD, J; DAVIS, RJ; GREENBERG, ME			OPPOSING EFFECTS OF ERK AND JNK-P38 MAP KINASES ON APOPTOSIS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROGRAMMED CELL-DEATH; MICROTUBULE-ASSOCIATED PROTEIN-2; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; FACTOR DEPRIVATION; FACTOR WITHDRAWAL; PROTO-ONCOGENE	Apoptosis plays an important role during neuronal development, and defects in apoptosis may underlie various neurodegenerative disorders, To characterize molecular mechanisms that regulate neuronal apoptosis, the contributions to cell death of mitogen-activated protein (MAP) kinase family members, including ERK (extracellular signal-regulated kinase), JNK (c-JUN NH2-terminal protein kinase), and p38, were examined after withdrawal of nerve growth factor (NGF) from rat PC-12 pheochromocytoma cells. NGF withdrawal led to sustained activation of the JNK and p38 enzymes and inhibition of ERKs, The effects of dominant-interfering or constitutively activated forms of various components of the JNK-p38 and ERK signaling pathways demonstrated that activation of JNK and p38 and concurrent inhibition of ERK are critical for induction of apoptosis in these cells. Therefore, the dynamic balance between growth factor-activated ERK and stress-activated JNK-p38 pathways may be important in determining whether a cell survives or undergoes apoptosis.	CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA43855, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA043855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1993, MOL CELL BIOCHEM, V127, P201; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BUCKMASTER EA, 1994, EUR J NEUROSCI, V6, P1316, DOI 10.1111/j.1460-9568.1994.tb00322.x; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FERRARI G, 1993, J NEUROSCI, V13, P1879; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1982, DEV BIOL, V91, P305, DOI 10.1016/0012-1606(82)90037-9; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOIKE T, 1992, PROG NEUROPSYCHOPHAR, V16, P65; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAINGEAUD J, UNPUB; RAPP UR, 1994, ONCOGENE, V9, P3493; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SIUSS HK, 1994, MOL CELL BIOL, V14, P8376; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TENG KK, 1993, J NEUROSCI, V13, P3124; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZY, UNPUB; YAN MH, 1994, NATURE, V372, P798; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	81	4906	5108	8	390	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 24	1995	270	5240					1326	1331		10.1126/science.270.5240.1326	http://dx.doi.org/10.1126/science.270.5240.1326			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF899	7481820				2022-12-01	WOS:A1995TF89900029
J	BALDINI, N; SCOTLANDI, K; BARBANTIBRODANO, G; MANARA, MC; MAURICI, D; BACCI, G; BERTONI, F; PICCI, P; SOTTILI, S; CAMPANACCI, M; SERRA, M				BALDINI, N; SCOTLANDI, K; BARBANTIBRODANO, G; MANARA, MC; MAURICI, D; BACCI, G; BERTONI, F; PICCI, P; SOTTILI, S; CAMPANACCI, M; SERRA, M			EXPRESSION OF P-GLYCOPROTEIN IN HIGH-GRADE OSTEOSARCOMAS IN RELATION TO CLINICAL OUTCOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODIES; DRUG-RESISTANCE; OSTEO-SARCOMA; IMMUNOHISTOCHEMICAL DETECTION; MULTIPLE-MYELOMA; HUMAN CANCERS; CELL-LINES; CHEMOTHERAPY; VERAPAMIL	Background. Increased levels of P-glycoprotein occur in some osteosarcomas. In this study we determined the relation between P-glycoprotein status and outcome in patients with high-grade osteosarcoma. Methods. P-glycoprotein status was determined immunohistochemically in specimens of osteosarcoma of the extremities (stage II) from 92 patients who were treated with surgery and chemotherapy. The P-glycoprotein status was analyzed in relation to the length of event-free survival. Results. The presence of increased levels of P-glycoprotein in the osteosarcoma was significantly associated with a decreased probability of remaining event-free after diagnosis (P=0.002). In a multivariate analysis, P-glycoprotein status (P=0.001) and the extent of tumor necrosis after preoperative chemotherapy (P=0.04) were independent predictors of clinical outcome. The risk of adverse events was increased substantially (rate ratio, 3.37; 95 percent confidence interval, 1.60 to 7.10) among patients with increased levels of P-glycoprotein in tumor cells, as compared with patients who did not have increased levels of P-glycoprotein in tumor cells. Conclusions. In patients with high-grade osteosarcoma treated with surgery and chemotherapy, the presence of increased levels of P-glycoprotein in tumor cells is associated with a significantly increased risk of adverse events and is independent of the extent of necrosis after preoperative chemotherapy.			BALDINI, N (corresponding author), IST ORTOPED RIZZOLI,DIPARTIMENTO ONCOL,RIC ONCOL LAB,VIA BARBIANO 1-10,I-40136 BOLOGNA,ITALY.		Serra, Massimo/J-4878-2016; Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018; Baldini, Nicola/J-4806-2016; Picci, Piero/J-5979-2016	Serra, Massimo/0000-0003-0742-1177; Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; Baldini, Nicola/0000-0003-2228-3833; Barbanti Brodano, Giovanni/0000-0002-7075-7020; Picci, Piero/0000-0002-8519-4101				BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C; BALDINI N, IN PRESS EUR J CELL; Blaney S M, 1993, Cancer Treat Res, V62, P55; BOIOCCHI M, 1992, EUR J CANCER, V28A, P1099, DOI 10.1016/0959-8049(92)90465-E; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CAMPANACCI M, 1981, CANCER, V48, P1569, DOI 10.1002/1097-0142(19811001)48:7<1569::AID-CNCR2820480717>3.0.CO;2-X; CHAN HSL, 1990, J CLIN ONCOL, V8, P689, DOI 10.1200/JCO.1990.8.4.689; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLIN DC, 1977, AM J SURG PATHOL, V1, P61, DOI 10.1097/00000478-197701010-00007; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, V153, P106; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P8; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROGAN T, 1990, LAB INVEST, V63, P815; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LINK MP, 1991, CLIN ORTHOP RELAT R, V270, P8; MILLER RG, 1981, SURVIVAL ANAL, P44; OMEARA A, 1992, ONCOLOGY, V49, P203; PICCI P, 1985, CANCER, V56, P1515, DOI 10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6; SALMON SE, 1991, BLOOD, V78, P44; SAMUELS BL, 1991, CANCER RES, V51, P521; SCHEPER RJ, 1988, INT J CANCER, V42, P389, DOI 10.1002/ijc.2910420314; SCHLAIFER D, 1991, BRIT J CANCER, V63, P164; SCHLAIFER D, 1990, BRIT J CANCER, V62, P177, DOI 10.1038/bjc.1990.256; SERRA M, 1993, ANTICANCER RES, V13, P323; SERRA M, IN PRESS EUR J CANCE; SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; SONNEVELD P, 1994, J CLIN ONCOL, V12, P1584, DOI 10.1200/JCO.1994.12.8.1584; STEIN U, 1993, EUR J CANCER, V29A, P1979, DOI 10.1016/0959-8049(93)90457-Q; TAWA A, 1990, CANCER, V66, P1980, DOI 10.1002/1097-0142(19901101)66:9<1980::AID-CNCR2820660922>3.0.CO;2-E; TOFFOLI G, 1992, ANN ONCOL, V3, P63, DOI 10.1093/oxfordjournals.annonc.a058073; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; VANDERVALK P, 1990, ANN ONCOL, V1, P56; VERGIER B, 1993, BRIT J CANCER, V68, P1221, DOI 10.1038/bjc.1993.508; WUNDER JS, 1993, J ORTHOPAED RES, V11, P396, DOI 10.1002/jor.1100110311; YUEN AR, 1994, J CLIN ONCOL, V12, P2453, DOI 10.1200/JCO.1994.12.11.2453; YUSA K, 1989, CANCER RES, V49, P5002; Zelterman D., 1992, MED USES STAT, P293	49	345	357	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1380	1385		10.1056/NEJM199511233332103	http://dx.doi.org/10.1056/NEJM199511233332103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477118				2022-12-01	WOS:A1995TF52100003
J	BEZRUKOV, SM; VODYANOY, I				BEZRUKOV, SM; VODYANOY, I			NOISE-INDUCED ENHANCEMENT OF SIGNAL-TRANSDUCTION ACROSS VOLTAGE-DEPENDENT ION CHANNELS	NATURE			English	Article							ALAMETHICIN; CONDUCTANCE	THE presence of noise in a signal transduction system usually interferes with its ability to transfer information reliably. But many nonlinear systems can use noise to enhance performance(1), and this phenomenon, called stochastic resonance, may underlie the extraordinary ability of some biological systems to detect and amplify small signals in noisy environments(2-5). Previous work has demonstrated the occurrence of stochastic resonance in a complex system of biological transducers and neural signal pathways(6), but the possibility that it could occur at the sub-cellular level has remained open. Here we report the observation of stochastic resonance in a system of voltage-dependent ion channels formed by the peptide alamethicin. A hundred-fold increase in signal transduction induced by external noise is accompanied by a growth in the output signal-to-noise ratio. The system of ion channels considered here represents the simplest biological system yet known to exhibit stochastic resonance.	OFF NAVAL RES, LONDON NW1 5TH, ENGLAND; ST PETERSBURG NUCL PHYS INST, GATCHINA 188350, RUSSIA; UCL, LONDON, ENGLAND	National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; University of London; University College London	BEZRUKOV, SM (corresponding author), NIH, DIV COMP RES & TECHNOL, BETHESDA, MD 20892 USA.			Vodyanoy, Vitaly/0000-0003-3092-6245				BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BLOCK SM, 1992, SOC GEN PHY, V47, P1; BULSARA AR, 1994, PHYS REV E, V49, P4989, DOI 10.1103/PhysRevE.49.4989; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; EISENBERG M, 1973, J MEMBRANE BIOL, V14, P143, DOI 10.1007/BF01868075; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; Hille B., 1992, IONIC CHANNELS EXCIT; KALMIJN AJ, 1982, SCIENCE, V218, P916, DOI 10.1126/science.7134985; Makeyev V. M., 1993, Biophysics (English Translation of Biofizika), V38, P189; PANTAZELOU E, 1995, INT J BIFURCAT CHAOS, V5, P101, DOI 10.1142/S0218127495000089; PETRACCHI D, 1994, BIOPHYS J, V66, P1844, DOI 10.1016/S0006-3495(94)80978-6; POLK C, 13TH P A M NAT COUNC; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	14	338	341	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					362	364		10.1038/378362a0	http://dx.doi.org/10.1038/378362a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477370				2022-12-01	WOS:A1995TF89300049
J	BRANNIGAN, JA; DODSON, G; DUGGLEBY, HJ; MOODY, PCE; SMITH, JL; TOMCHICK, DR; MURZIN, AG				BRANNIGAN, JA; DODSON, G; DUGGLEBY, HJ; MOODY, PCE; SMITH, JL; TOMCHICK, DR; MURZIN, AG			A PROTEIN CATALYTIC FRAMEWORK WITH AN N-TERMINAL NUCLEOPHILE IS CAPABLE OF SELF-ACTIVATION	NATURE			English	Article							GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; ESCHERICHIA-COLI K-12; PENICILLIN ACYLASE; TRANSPEPTIDASE; CYSTEINE; GENE	THE crystal structures of three amidohydrolases have been determined recently(1-3): glutamine PRPP amidotransferase (GAT), penicillin acylase, and the proteasome. These enzymes use the side chain of the amino-terminal residue, incorporated in a beta-sheet, as the nucleophile in the catalytic attack at the carbonyl carbon. The nucleophile is cysteine in GAT, serine in penicillin acylase, and threonine in the proteasome. Here we show that all three enzymes share an unusual fold in which the nucleophile and other catalytic groups occupy equivalent sites. This fold provides both the capacity for nucleophilic attack and the possibility of autocatalytic processing. We suggest the name Ntn (N-terminal nucleophile) hydrolases for this structural superfamily of enzymes which appear to be evolutionarily related but which have diverged beyond any recognizable sequence similarity.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	MRC National Institute for Medical Research; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Cambridge	BRANNIGAN, JA (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238; Tomchick, Diana/0000-0002-7529-4643	NIDDK NIH HHS [R37 DK042303] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042303] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGRAWAL AK, 1995, CURR OPINION STRUCT, V5, P11; BRUNS W, 1985, J MOL APPL GENET, V3, P36; CHOTHIA C, 1981, P NATL ACAD SCI-BIOL, V78, P4146, DOI 10.1073/pnas.78.7.4146; COLSTON MJ, 1994, MOL MICROBIOL, V12, P359, DOI 10.1111/j.1365-2958.1994.tb01025.x; DODSON GG, 1992, FARADAY DISCUSS, V93, P95, DOI 10.1039/fd9929300095; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KUMAGAI H, 1993, J MOL BIOL, V234, P1259, DOI 10.1006/jmbi.1993.1677; LOUGH TJ, 1992, PLANT MOL BIOL, V19, P391, DOI 10.1007/BF00023386; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MATSUDA A, 1987, J BACTERIOL, V169, P5821, DOI 10.1128/jb.169.12.5821-5826.1987; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; OINONEN C, IN PRESS NATURE STRU; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; SIZMANN D, 1990, EUR J BIOCHEM, V192, P143, DOI 10.1111/j.1432-1033.1990.tb19207.x; Smith JL, 1995, BIOCHEM SOC T, V23, P894, DOI 10.1042/bst0230894; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; SMITH TK, 1995, P NATL ACAD SCI USA, V92, P2360, DOI 10.1073/pnas.92.6.2360; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TATE SS, 1985, METHOD ENZYMOL, V113, P400; WALLACE CJA, 1993, PROTEIN SCI, V2, P697, DOI 10.1002/pro.5560020501; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZHOU G, 1992, J BIOL CHEM, V267, P7936; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	31	545	552	2	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					416	419		10.1038/378416a0	http://dx.doi.org/10.1038/378416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477383				2022-12-01	WOS:A1995TF89300067
J	DINCHUK, JE; CAR, BD; FOCHT, RJ; JOHNSTON, JJ; JAFFEE, BD; COVINGTON, MB; CONTEL, NR; ENG, VM; COLLINS, RJ; CZERNIAK, PM; GORRY, SA; TRZASKOS, JM				DINCHUK, JE; CAR, BD; FOCHT, RJ; JOHNSTON, JJ; JAFFEE, BD; COVINGTON, MB; CONTEL, NR; ENG, VM; COLLINS, RJ; CZERNIAK, PM; GORRY, SA; TRZASKOS, JM			RENAL ABNORMALITIES AND AN ALTERED INFLAMMATORY RESPONSE IN MICE LACKING CYCLOOXYGENASE-II	NATURE			English	Article							RAT PREOVULATORY FOLLICLES; PROSTAGLANDIN SYNTHASE; HORMONAL-REGULATION; ARACHIDONIC-ACID; MESSENGER-RNA; H SYNTHASE; CELLS; MOUSE; EXPRESSION; INDUCTION	PROSTAGLANDINS have wide-ranging effects in the body and are thought to be important mediators of inflammation. Cyclooxygenase (COX) plays a keg regulatory role in prostaglandin synthesis, and occurs in both constitutive (COX-1) and inducible (COX-2) isoforms(1,2). COX-1 is thought to provide cytoprotective effects(3), whereas COX-2 is both inducible and the major isoform of inflammatory cells(4), Reduction of prostaglandin production by inhibition of cyclooxygenases appears to be the main mechanism of action of most non-steroidal anti-inflammatory drugs (NSAIDS)(5), Here we present an animal model of COX-2 deficiency that was generated by gene targeting. Defects in null mice correlating with reduced viability included renal alterations, characteristic of renal dysplasia (100% penetrance), and cardiac fibrosis (50% penetrance). Female Cox-2 -/- mice were infertile, COX-2 deficiency failed to alter inflammatory responses in several standard models, but striking mitigation of endotoxin-induced hepatocellular cytotoxicity was observed.	UNIV PENN, ANIM RESOURCES LAB, PHILADELPHIA, PA 19104 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA	University of Pennsylvania; DuPont	DINCHUK, JE (corresponding author), DUPONT MERCK PHARMACEUT CO, GLENOLDEN, PA 19036 USA.							ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378; CALHOUN W, 1987, AGENTS ACTIONS, V21, P306, DOI 10.1007/BF01966499; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; DEWITT DL, 1993, AM J MED S, V40, pS40; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; GANS KR, 1990, J PHARMACOL EXP THER, V254, P180; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KINKAIDSMITH P, 1993, DISEASES KIDNEY, P1099; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN M, 1994, KIDNEY INT, V45, P150, DOI 10.1038/ki.1994.18; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PETERS T, 1990, EUR J BIOCHEM, V191, P583, DOI 10.1111/j.1432-1033.1990.tb19161.x; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; Robertson E. J, 1987, TERATOCARCINOMAS EMB, P71; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1993, J BIOL CHEM, V268, P12199; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TIEGS G, 1988, BIOCHEM PHARMACOL, V37, P2569, DOI 10.1016/0006-2952(88)90248-1; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOUNG JM, 1984, J INVEST DERMATOL, V82, P367, DOI 10.1111/1523-1747.ep12260709	30	844	858	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					406	409		10.1038/378406a0	http://dx.doi.org/10.1038/378406a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477380				2022-12-01	WOS:A1995TF89300064
J	GASSMANN, M; CASAGRANDA, F; ORIOLI, D; SIMON, H; LAI, C; KLEIN, R; LEMKE, G				GASSMANN, M; CASAGRANDA, F; ORIOLI, D; SIMON, H; LAI, C; KLEIN, R; LEMKE, G			ABERRANT NEURAL AND CARDIAC DEVELOPMENT IN MICE LACKING THE ERBB4 NEUREGULIN RECEPTOR	NATURE			English	Article							GLIAL GROWTH-FACTOR; NERVOUS-SYSTEM; PROTEIN; FAMILY; HINDBRAIN; MEMBER; HER4/P180(ERBB4); IDENTIFICATION; PURIFICATION; DISRUPTION	VARIOUS in vitro studies have suggested that ErbB4 (HER4) is a receptor for the neuregulins, a family of closely related proteins implicated as regulators of neural and muscle development, and of the differentiation and oncogenic transformation of mammary epithelia(1-3). Here we demonstrate that ErbB4 is an essential in vivo regulator of both cardiac muscle differentiation and axon guidance in the central nervous system (CNS). Mice lacking ErbB4 die during mid-embryogenesis from the aborted development of myocardial trabeculae in the heart ventricle. They also display striking alterations in innervation of the hindbrain in the CNS that are consistent with the restricted expression of the ErbB4 gene in rhombomeres 3 and 5. Similarities in the cardiac phenotype of ErbB4 and neuregulin gene mutants suggest that ErbB4 functions as a neuregulin receptor in the heart; however, differences in the hindbrain phenotypes of these mutants are consistent with the action of a new ErbB4 ligand in the CNS.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	European Molecular Biology Laboratory (EMBL); Scripps Research Institute	GASSMANN, M (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Gassmann, Martin/0000-0001-6201-3032; ORIOLI, DONATA/0000-0002-3830-3408				CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHALLICE CE, 1974, TISSUE CELL, V6, P447, DOI 10.1016/0040-8166(74)90037-8; Chang H., 1994, Society for Neuroscience Abstracts, V20, P1694; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; COVELL DA, 1989, J COMP NEUROL, V286, P488, DOI 10.1002/cne.902860407; DENT JA, 1989, DEVELOPMENT, V105, P61; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOODY SA, 1989, J COMP NEUROL, V279, P567, DOI 10.1002/cne.902790406; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIETO MA, 1991, DEVELOPMENT, P59; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SWLATEK PJ, 1993, GENE DEV, V7, P2071; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361	32	891	918	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	1995	378	6555					390	394		10.1038/378390a0	http://dx.doi.org/10.1038/378390a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477376				2022-12-01	WOS:A1995TF89300060
J	GIBBS, CS; COUTRE, SE; TSIANG, M; LI, WX; JAIN, AK; DUNN, KE; LAW, VS; MAO, CT; MATSUMURA, SY; MEJZA, SJ; PABORSKY, LR; LEUNG, LLK				GIBBS, CS; COUTRE, SE; TSIANG, M; LI, WX; JAIN, AK; DUNN, KE; LAW, VS; MAO, CT; MATSUMURA, SY; MEJZA, SJ; PABORSKY, LR; LEUNG, LLK			CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING	NATURE			English	Article							BLOOD-COAGULATION; STRUCTURAL BASIS; HUMAN-FIBRINOGEN; ACTIVATION; COFACTOR; PRIMATES; DOMAINS; INVIVO; CHAIN	AT sites of vascular injury, thrombin interacts with multiple procoagulant substrates(1-6) to mediate both fibrin clotting and platelet aggregation. But upon binding to thrombomodulin on the vascular endothelium, thrombin instead activates protein C, thereby functioning as an anticoagulant and attenuating clot formation(7). Upon infusion in vivo, both the procoagulant and anticoagulant effects of thrombin were observed(8,9). Preliminary studies indicating that thrombin's protein C activating and fibrinogen clotting activities could be dissociated by mutagenesis(10) suggested to us that a thrombin variant that lacked procoagulant activity while retaining anticoagulant function might be an attractive antithrombotic agent. Using protein engineering, we introduced a single substitution, E229A, that substantially shifted thrombin's specificity in favour of the anticoagulant substrate, protein C. In monkeys, this modified thrombin functioned as an endogenous protein C activator demonstrating dose-dependent, reversible anticoagulation without any indication of procoagulant activity. Notably, template bleeding times were not prolonged, suggesting a reduced potential for bleeding complications.	GILEAD SCI,FOSTER CITY,CA 94404	Gilead Sciences				Coutre, Steven/0000-0001-8420-5748				BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; COMP PC, 1982, J CLIN INVEST, V70, P127, DOI 10.1172/JCI110584; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GRAYCAR TP, 1987, J CELL BIOCHEM     S, V11, P234; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LORAND L, 1992, THROMBIN STRUCTURE F, P257; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; ORTHNER CL, 1993, THROMB HAEMOSTASIS, V69, P441; OWEN WG, 1981, J BIOL CHEM, V256, P5532; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; TSIANG M, 1995, J BIOL CHEM, V270, P19370, DOI 10.1074/jbc.270.33.19370; TSIANG M, 1992, J BIOL CHEM, V267, P6164; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WU Q, 1991, P NATL ACAD SCI USA, V88, P6675; YE J, 1994, J BIOL CHEM, V269, P17965; 1985, GUIDE CARE USE LABOR, V8523	27	126	133	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					413	416		10.1038/378413a0	http://dx.doi.org/10.1038/378413a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477382				2022-12-01	WOS:A1995TF89300066
J	HAMMER, MF				HAMMER, MF			A RECENT COMMON ANCESTRY FOR HUMAN-Y-CHROMOSOMES	NATURE			English	Article							EVOLUTION; POLYMORPHISM; POPULATIONS; SEQUENCES	THE male-specific portion of the Y chromosome is especially useful for studies of human origins. Patterns of nucleotide variation that are neutral with respect to fitness should permit estimates of when and where ancestral Y chromosomes existed(1). However, variation on the human Y chromosome has been observed to be greatly reduced relative to the autosomes and the X chromosome(2-5). One explanation is that selection for a favourable mutation on the nonrecombining portion of the Y chromosome has resulted in the recent fixation of a single Y haplotype(5,6). A 2.6-kilobase fragment encompassing a polymorphic Alu insertion was sequenced from 16 human and four chimpanzee Y chromosomes. Patterns of nucleotide sequence diversity and divergence provide no evidence for a recent, strong selective sweep on the human Y chromosome. The time back to a common ancestral human Y chromosome is estimated to be 188,000 years, with a 95% confidence interval from 51,000 to 411,000 years. These results are consistent with autosomal and mitochondrial DNA studies that suggest a long-term human effective population size of 10,000 and a sex ratio of 1 (ref. 7). These inferences contradict predictions of the multiregional hypothesis(8) positing a widespread transformation of Homo erectus populations into Homo sapiens.			HAMMER, MF (corresponding author), UNIV ARIZONA,MOLEC SYSTEMAT & EVOLUT LAB,BIOSCI W,TUCSON,AZ 85721, USA.		Klein, Richard G/B-5910-2009					DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; ELLIS N, 1990, CELL, V63, P977, DOI 10.1016/0092-8674(90)90501-5; FULLERTON SM, 1994, P NATL ACAD SCI USA, V91, P1805, DOI 10.1073/pnas.91.5.1805; GOLDMAN N, 1992, NATURE, V367, P440; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; HAMMER MF, 1995, AM J HUM GENET, V56, P951; HARPENDING HC, 1993, CURR ANTHROPOL, V34, P483, DOI 10.1086/204195; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; HUDSON RR, 1987, GENETICS, V116, P153; JAKUBICZKA S, 1989, HUM GENET, V84, P86, DOI 10.1007/BF00210680; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KREITMAN M, 1991, GENETICS, V127, P565; LI WH, 1991, GENETICS, V129, P513; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; MAYNARDSMITH J, 1990, NATURE, V344, P591; Nei M., 1987, MOL EVOLUTIONARY GEN, DOI 10.7312/nei-92038; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROGERS AR, 1992, MOL BIOL EVOL, V9, P552; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; STONEKING M, 1993, EVOLUTIONARY ANTHR, V2, P60; STRINGER CB, 1988, SCIENCE, V158, P1263; TAJIMA F, 1983, GENETICS, V105, P437; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WOLPOFF MH, 1989, HUMAN REVOLUTIONS BE, P123	26	297	304	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					376	378		10.1038/378376a0	http://dx.doi.org/10.1038/378376a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477371				2022-12-01	WOS:A1995TF89300055
J	JIANG, H; LUO, JQ; URANO, T; FRANKEL, P; LU, ZM; FOSTER, DA; FEIG, LA				JIANG, H; LUO, JQ; URANO, T; FRANKEL, P; LU, ZM; FOSTER, DA; FEIG, LA			INVOLVEMENT OF RAL GTPASE IN V-SRC-INDUCED PHOSPHOLIPASE-D ACTIVATION	NATURE			English	Article							BINDING PROTEIN; KINASE; FAMILY	AN early response to the tyrosine kinase activity of v-Src is an increase in phospholipase D (PLD) activity(1), which leads to the generation of biologically active lipid second messengers, including phosphatidic acid, lysophosphatidic acid and diacylglycerol(2). We have recently demonstrated that v-Src-induced PLD activity is mediated by Ras(3), although Ras involvement was indirect, requiring a cytosolic factor for PLD activation(3). Ras interacts with(4-6) and activates Ral-GDS(13), the exchange factor responsible for the activation of Ral GTPases. Here we report that this newly identified Ras/Ral signalling pathway mediates PLD activation by v-Src. PLD activity could be precipitated from v-Src-transformed cell lysates with immobilized RalA protein and with an anti-Ral antibody. A mutation to the region of RalA analogous to the 'effector domain' of Ras did not reduce the ability of RalA to complex with PLD, although deletion of a Ral-specific amino-terminal region did. Overexpression of RalA potentiated PLD activation by v-Src, and expression of dominant negative RalA mutants inhibited both v-Src- and v-Ras-induced PLD activity. Thus RalA is involved in the tyrosine kinase activation of PLD through its unique N terminus, and that PLD is a downstream target of a Ras/Ral GTPase cascade.	CUNY HUNTER COLL,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021; CUNY HUNTER COLL,DEPT SCI BIOL,NEW YORK,NY 10021; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Tufts University			Urano, Tomohiko/AFS-9574-2022					BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAMERO A, 1994, ONCOGENE, V9, P1387; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; URANO T, IN PRESS EMBO J; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	25	252	254	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					409	412		10.1038/378409a0	http://dx.doi.org/10.1038/378409a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477381				2022-12-01	WOS:A1995TF89300065
J	LEE, KF; SIMON, H; CHEN, H; BATES, B; HUNG, MC; HAUSER, C				LEE, KF; SIMON, H; CHEN, H; BATES, B; HUNG, MC; HAUSER, C			REQUIREMENT FOR NEUREGULIN RECEPTOR ERBB2 IN NEURAL AND CARDIAC DEVELOPMENT	NATURE			English	Article							NERVOUS-SYSTEM; TRIGEMINAL MOTONEURONS; CHICK-EMBRYOS; CREST CELLS; EXPRESSION; MIGRATION; GANGLIA; DIFFERENTIATION; HINDBRAIN; PROTEIN	THE receptor erbB2/neu is a member of the epidermal growth factor receptor (EGFR or erbB) family that also includes erbB3 and erbB4(1). Amplification of the erbB2/neu gene is found in many cancer types and its overexpression is correlated with a poor prognosis for breast and ovarian cancer patients(2). Investigation of the biology of erbB2 led to the identification of a family of ligands termed neuregulins which included the neu-differentiation factors(3,4), the heregulins(5), a ligand with acctylcholine-receptor-inducing activity(6) and glial growth factor(7). Several lines of evidence suggest that heterodimerization of erbB2 with other erbB receptors is required for neuregulin signalling(1). Here we investigate the developmental role of erbB2 in mammalian development in mice carrying an erbB2 null allele. We find that mutant embryos die before E11, probably as a result of dysfunctions associated with a lack of cardiac trabeculae. Development of cranial neural-crest-derived sensory ganglia was markedly affected, DiI retrograde tracing revealed that the development of motor nerves was also compromised. Our results demonstrate the importance of erbB2 in neural and cardiac development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; WHITEHEAD INST,CAMBRIDGE,MA 02142	University of Texas System; UTMD Anderson Cancer Center; Massachusetts Institute of Technology (MIT); Whitehead Institute	LEE, KF (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P1; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DENT JA, 1989, DEVELOPMENT, V105, P61; DONG Z, 1995, NEURON, V15, P589; EASTER SS, 1993, J NEUROSCI, V13, P285; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LEDOUARIN NM, 1988, ANNU REV CELL BIOL, V4, P375, DOI 10.1146/annurev.cellbio.4.1.375; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P394; MEYER D, 1994, P NATL ACAD SCI USA, V94, P1064; MOODY SA, 1983, J COMP NEUROL, V213, P344, DOI 10.1002/cne.902130309; MOODY SA, 1983, J COMP NEUROL, V213, P327, DOI 10.1002/cne.902130308; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PRESS MF, 1990, ONCOGENE, V5, P953; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTON JA, 1966, DEV BIOL, V14, P246, DOI 10.1016/0012-1606(66)90015-7; WHITE MRA, 1992, ONCOGENE, V7, P677	32	1000	1036	2	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					394	398		10.1038/378394a0	http://dx.doi.org/10.1038/378394a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477377				2022-12-01	WOS:A1995TF89300061
J	LI, XJ; LI, SH; SHARP, AH; NUCIFORA, FC; SCHILLING, G; LANAHAN, A; WORLEY, P; SNYDER, SH; ROSS, CA				LI, XJ; LI, SH; SHARP, AH; NUCIFORA, FC; SCHILLING, G; LANAHAN, A; WORLEY, P; SNYDER, SH; ROSS, CA			A HUNTINGTIN-ASSOCIATED PROTEIN ENRICHED IN BRAIN WITH IMPLICATIONS FOR PATHOLOGY	NATURE			English	Article							TRINUCLEOTIDE REPEAT; DISEASE GENE; LENGTH; EXPRESSION; TISSUES; CLONING; IT-15; ONSET; YEAST; AGE	HUNTINGTON'S disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanding polyglutamine repeat in the IT15 or huntingtin gene(1). Although this gene is widely expressed(2-9) and is required for normal development(10-12), the pathology of HD is restricted to the brain, for reasons that remain poorly understood. The huntingtin gene product is expressed at similar levels in patients and controls, and the genetics of the disorder(13,14) suggest that the expansion of the polyglutamine repeat induces a toxic gain of function, perhaps through interactions with other cellular proteins(15-18). Here we report the identification of a protein (huntingtin-associated protein (HAP)-1) that binds to huntingtin. This binding is enhanced by an expanded polyglutamine repeat, the length of which is also known to correlate with the age of disease onset(19-21). The HAP-1 protein is enriched in the brain, suggesting a possible basis for the selective brain pathology of HD.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	LI, XJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,MOLEC NEUROBIOL LAB,BALTIMORE,MD 21205, USA.		NUCIFORA, FREDERICK/X-2364-2019; Ross, Christopher A/H-8395-2013					ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; AMBROSE CM, 1995, SOMAT CELL MOLEC GEN, V20, P27; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUSELLA JF, 1993, ARCH NEUROL-CHICAGO, V50, P1157, DOI 10.1001/archneur.1993.00540110037003; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; MARGOLIS RL, IN PRESS MOL BRAIN R; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; 1993, CELL, V72, P971	31	520	547	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					398	402		10.1038/378398a0	http://dx.doi.org/10.1038/378398a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477378				2022-12-01	WOS:A1995TF89300062
J	MEYER, D; BIRCHMEIER, C				MEYER, D; BIRCHMEIER, C			MULTIPLE ESSENTIAL FUNCTIONS OF NEUREGULIN IN DEVELOPMENT	NATURE			English	Article							SEGMENT-SPECIFIC EXPRESSION; ZINC-FINGER GENE; NERVOUS-SYSTEM; MOUSE; HINDBRAIN; CELLS	NEUREGULIN (also called NDF, heregulin, GGF and ARIA) is a member of the EGF family which induces growth and differentiation of epithelial, glial and muscle cells in culture(1-4). The biological effects of the factor are mediated by tyrosine kinase receptors. Neuregulin can bind directly to erbB3 and erbB4 and receptor heterodimerization allows neuregulin-dependent activation of erbB2 (refs 1, 2, 5), A targeted mutation in mice reveals multiple essential roles of neuregulin in development, Here we show that neuregulin -/- embryos die during embryogenesis and display heart malformations. In addition, Schwann cell precursors and cranial ganglia fail to develop normally. The phenotype demonstrates that in vivo neuregulin acts locally and frequently in a paracrine manner. All cell types affected by the mutation express either erbB3 or erbB4, indicating that either of these tyrosine kinase receptors can be a component in recognition and transmission of essential neuregulin signals.						Meyer, Dirk/0000-0002-4020-4484				BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRONNERFRASER M, 1995, EXP CELL RES, V118, P405; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOSSLER A, 1993, GENE TARGETING PRACT, P207; HAMBURGER V, 1961, J EXP ZOOL, V148, P91, DOI 10.1002/jez.1401480202; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; ICARDO JM, 1987, ACTA ANAT, V130, P264; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEDOUARIN NM, 1986, TRENDS NEUROSCI, V9, P175, DOI 10.1016/0166-2236(86)90055-X; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	30	983	1015	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					386	390		10.1038/378386a0	http://dx.doi.org/10.1038/378386a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477375				2022-12-01	WOS:A1995TF89300059
J	NELSON, RJ; DEMAS, GE; HUANG, PL; FISHMAN, MC; DAWSON, VL; DAWSON, TM; SNYDER, SH				NELSON, RJ; DEMAS, GE; HUANG, PL; FISHMAN, MC; DAWSON, VL; DAWSON, TM; SNYDER, SH			BEHAVIORAL ABNORMALITIES IN MALE-MICE LACKING NEURONAL NITRIC-OXIDE SYNTHASE	NATURE			English	Article								Is addition to its role in blood vessel(1,2) and macrophage(3,4) function, nitric oxide (NO) is a neurotransmitter(5) found in high densities in emotion-regulating brain regions(6-8). Mice with targeted disruption of neuronal NO synthase (nNOS) display grossly normal appearance, locomotor activity, breeding(9), long-term potentiation and long-term depression(11). The nNOS(-) mice are resistant to neural stroke damage following middle cerebral artery ligation(12). Although CO2-induced cerebral vasodilatation in wild-type mice is NO-dependent, in nNOS(-) mice this vasodilation is unaffected by NOS inhibitors(13). Establishing a behavioural role for NO has, until now, not been feasible, as NOS inhibitor drugs can only be administered acutely and because their pronounced effects on blood pressure and other body functions obfuscate behavioural interpretations. We now report a large increase in aggressive behaviour and excess, inappropriate sexual behaviour in nNOS(-) mice.	JOHNS HOPKINS UNIV,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PSYCHOL,BEHAV NEUROENDOCRINOL GRP,BALTIMORE,MD 21218; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02129	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Massachusetts General Hospital			Dawson, Valina/Y-9757-2019; Demas, Gregory/Y-1783-2019	Demas, Gregory/0000-0003-3914-0900; Nelson, Randy/0000-0002-8194-4016; Dawson, Valina/0000-0002-2915-3970				ALBERT DJ, 1984, NEUROSCI BIOBEHAV R, V8, P5, DOI 10.1016/0149-7634(84)90017-4; BRAIN PF, 1992, PSYCHONEUROENDOCRINO, V17, P537, DOI 10.1016/0306-4530(92)90014-X; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; DAWSON TM, 1994, J NEUROSCI, V14, P5147; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; OGAWA S, 1995, END SOC ABSTR; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; REZUANI AH, 1995, PHARM BIOCH BEHAV, V50, P265; RODRIGO J, 1994, PHILOS T R SOC B, V345, P175, DOI 10.1098/rstb.1994.0096; SALIS PJ, 1971, NATURE, V232, P400, DOI 10.1038/232400a0; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SQUADRITO F, 1994, EUR J PHARMACOL, V255, P51, DOI 10.1016/0014-2999(94)90081-7; VINCENT SR, 1992, NEUROSCIENCE, V4, P755	24	524	535	1	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					383	386		10.1038/378383a0	http://dx.doi.org/10.1038/378383a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477374				2022-12-01	WOS:A1995TF89300058
J	REES, JH; SOUDAIN, SE; GREGSON, NA; HUGHES, RAC				REES, JH; SOUDAIN, SE; GREGSON, NA; HUGHES, RAC			CAMPYLOBACTER-JEJUNI INFECTION AND GUILLAIN-BARRE-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROPATHY	Background. Although infection with Campylobacter jejuni is recognized as a common antecedent of the Guillain-Barre syndrome, the clinical and epidemiologic features of this association are not well understood. Methods. We performed a prospective case-control study in a cohort of patients with Guillajn-Barre syndrome (96 patients) or Miller Fisher syndrome (7 patients) who were admitted to hospitals throughout England and Wales between November 1992 and April 1994. Bacteriologic and serologic techniques were used to diagnose preceding C. jejuni infection. Results. There was evidence of recent C. jejuni infection in 26 percent of the patients with Guillain-Barre or Miller Fisher syndrome, as compared with 2 percent of household controls and 1 percent of age-matched hospital controls (P<0.001). Of the 27 patients with C. jejuni infection, 19 (70 percent) reported having had a diarrheal illness within 12 weeks before the onset of the neurologic illness. No specific serotypes were associated with Guillain-Barre syndrome. C. jejuni infection was slightly more common in men (P=0.14) and was more likely to be associated with a pure motor syndrome and a slower recovery (P=0.03). The patients with preceding C. jejuni infection were more likely to have acute axonal neuropathy or axonal degeneration in association with acute inflammatory demyelinating polyradiculoneuropathy, and they had greater disability after one year (P=0.02). C. jejuni infection was significantly associated with a poor outcome even after correction for other factors associated with a poor prognosis. Conclusions. Infection with C. jejuni often precedes the Guillain-Barre syndrome and is associated with axonal degeneration, slow recovery, and severe residual disability.	UNITED MED & DENT SCH,GUYS HOSP,DEPT NEUROL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Rees, Jeremy/AAH-4382-2019					ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; DYCK PJ, 1993, NEUROLOGY, V43, P1277, DOI 10.1212/WNL.43.7.1277; ENDERS U, 1993, ANN NEUROL, V34, P136, DOI 10.1002/ana.410340208; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; GREGSON NA, 1993, Q J MED, V86, P111; KALDOR J, 1984, BRIT MED J, V288, P1867, DOI 10.1136/bmj.288.6434.1867; KUROKI S, 1993, ANN NEUROL, V33, P243, DOI 10.1002/ana.410330304; MCKHANN GM, 1993, ANN NEUROL, V33, P333, DOI 10.1002/ana.410330402; MISHU B, 1993, ANN INTERN MED, V118, P947, DOI 10.7326/0003-4819-118-12-199306150-00006; Palace J A, 1994, Eur J Neurol, V1, P21, DOI 10.1111/j.1468-1331.1994.tb00046.x; REES JH, 1993, Q J MED, V86, P623, DOI 10.1093/qjmed/86.10.623; ROBERTS T, 1987, J NEUROL NEUROSUR PS, V50, P1557, DOI 10.1136/jnnp.50.11.1557; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SKIRROW MB, 1987, EPIDEMIOL INFECT, V99, P647, DOI 10.1017/S0950268800066504; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; WROE SJ, 1985, J NEUROL NEUROSUR PS, V48, P593, DOI 10.1136/jnnp.48.6.593; YUKI N, 1993, J EXP MED, V178, P1771, DOI 10.1084/jem.178.5.1771	19	532	545	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1374	1379		10.1056/NEJM199511233332102	http://dx.doi.org/10.1056/NEJM199511233332102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477117				2022-12-01	WOS:A1995TF52100002
J	ROTHMAN, KJ; MOORE, LL; SINGER, MR; NGUYEN, USDT; MANNINO, S; MILUNSKY, A				ROTHMAN, KJ; MOORE, LL; SINGER, MR; NGUYEN, USDT; MANNINO, S; MILUNSKY, A			TERATOGENICITY OF HIGH VITAMIN-A INTAKE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERVITAMINOSIS-A; SUPPLEMENTATION; CONGENERS; DEFECTS	Background. Studies in animals indicate that natural forms of vitamin A are teratogenic. Synthetic retinoids chemically similar to vitamin A cause birth defects in humans; as in animals, the defects appear to affect tissues derived from the cranial neural crest. Methods. Between October 1984 and June 1987, we identified 22,748 pregnant women when they underwent screening either by measurement of maternal serum alpha-fetoprotein or by amniocentesis. Nurse interviewers obtained information on the women's diet, medications, and illnesses during the first trimester of pregnancy, as well as information on their family and medical history and exposure to environmental agents. We obtained information on the outcomes of pregnancy from the obstetricians who delivered the babies or from the women themselves. Of the 22,748 women, 339 had babies with birth defects; 121 of these babies had defects occurring in sites that originated in the cranial neural crest. Results. For defects associated with cranial-neural-crest tissue, the ratio of the prevalence among the babies born to women who consumed more than 15,000 IU of preformed vitamin A per day from food and supplements to the prevalence among the babies whose mothers consumed 5000 IU or less per day was 3.5 (95 percent confidence interval, 1.7 to 7.3). For vitamin A from supplements alone, the ratio of the prevalence among the babies born to women who consumed more than 10,000 IU per day to that among the babies whose mothers consumed 5000 IU or less per day was 4.8 (95 percent confidence interval, 2.2 to 10.5). Using a smoothed regression curve, we found an apparent threshold near 10,000 IU per day of supplemental vitamin A. The increased frequency of defects was concentrated among the babies born to women who had consumed high levels of vitamin A before the seventh week of gestation. Conclusions. High dietary intake of preformed vitamin A appears to be teratogenic. Among the babies born to women who took more than 10,000 IU of preformed vitamin A per day in the form of supplements, we estimate that about 1 infant in 57 had a malformation attributable to the supplement.	BOSTON UNIV,SCH MED,CTR HUMAN GENET,BOSTON,MA 02118; UNIV G DANNUNZIO,INST HUMAN PATHOL & SOCIAL MED,CHAIR HYG,CHIETI,ITALY	Boston University; G d'Annunzio University of Chieti-Pescara	ROTHMAN, KJ (corresponding author), BOSTON UNIV,SCH MED,EVANS DEPT MED,PREVENT MED & EPIDEMIOL SECT,B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.			Singer, Martha/0000-0003-4048-7987; Rothman, Kenneth/0000-0003-2398-1705; Nguyen, Uyen-Sa/0000-0003-2715-9073; Milunsky, Aubrey/0000-0003-2114-4823; Moore, Lynn/0000-0002-1028-919X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019561] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19561] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1987, Teratology, V35, P269; BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; BOCKMAN DE, 1984, SCIENCE, V223, P498, DOI 10.1126/science.6606851; COHLAN SQ, 1954, PEDIATRICS, V13, P556; DENCKER L, 1991, J CRAN GENET DEV BIO, V11, P303; ECKHOFF C, 1990, ARCH TOXICOL, V64, P502, DOI 10.1007/BF01977634; EVANS K, 1991, BRIT J OPHTHALMOL, V75, P691, DOI 10.1136/bjo.75.11.691; GEELEN JAG, 1979, CRC CR REV TOXICOL, V6, P351, DOI 10.3109/10408447909043651; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; KIRBY ML, 1987, PEDIATR RES, V21, P219, DOI 10.1203/00006450-198703000-00001; KIZER KW, 1990, WESTERN J MED, V152, P78; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARTINEZFRIAS ML, 1990, EUR J EPIDEMIOL, V6, P118, DOI 10.1007/BF00145783; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; PINNOCK CB, 1992, MED J AUSTRALIA, V157, P804; ROSA FW, 1986, TERATOLOGY, V33, P355, DOI 10.1002/tera.1420330315; ROSA FW, 1983, LANCET, V2, P513; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; STUDER M, 1994, SCIENCE, V265, P1728, DOI 10.1126/science.7916164; WERLER MM, 1990, TERATOLOGY, V42, P497, DOI 10.1002/tera.1420420506; 1985, 0025M CTR DIS CONTR; 1987, MMWR-MORBID MORTAL W, V36, P80; 1989, RECOMMENDED DIETARY, P84	25	460	475	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	1995	333	21					1369	1373		10.1056/NEJM199511233332101	http://dx.doi.org/10.1056/NEJM199511233332101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF521	7477116				2022-12-01	WOS:A1995TF52100001
J	TROTTIER, Y; LUTZ, Y; STEVANIN, G; IMBERT, G; DEVYS, D; CANCEL, G; SAUDOU, F; WEBER, C; DAVID, G; TORA, L; AGID, Y; BRICE, A; MANDEL, JL				TROTTIER, Y; LUTZ, Y; STEVANIN, G; IMBERT, G; DEVYS, D; CANCEL, G; SAUDOU, F; WEBER, C; DAVID, G; TORA, L; AGID, Y; BRICE, A; MANDEL, JL			POLYGLUTAMINE EXPANSION AS A PATHOLOGICAL EPITOPE IN HUNTINGTONS-DISEASE AND 4 DOMINANT CEREBELLAR ATAXIAS	NATURE			English	Article							LOCUS	A POLYGLUTAMINE expansion (encoded by a CAG repeat) in specific proteins causes neurodegeneration in Huntington's disease (HD) and four other disorders(1-6), by an unknown mechanism thought to involve gain of function or toxicity of the mutated protein(7,8). The pathological threshold is 37-40 glutamines in three of these diseases, whereas the corresponding normal proteins contain polymorphic repeats of up to about 35 glutamines(1-3). The age of onset of clinical manifestations is inversely correlated to the length of the polyglutamine expansion. Here we report the characterization of a monoclonal antibody that selectively recognizes polyglutamine expansion in the proteins implicated in HD and in spinocerebellar ataxia (SCA) 1 and 3. The intensity of signal depends on the length of the polyglutamine expansion, and the antibody also detects specific pathological proteins expected to contain such expansion, in SCA2 and in autosomal dominant cerebellar ataxia with retinal degeneration, whose genes have not yet been identified(9-13).	ULP,CNRS,INSERM,INST GENET & BIOL MOLEC CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; HOP LA PITIE SALPETRIERE,INSERM,U289,F-75651 PARIS 13,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			SAUDOU, Frédéric/L-3454-2014; brice, alexis/AAE-8275-2019; Tora, Laszlo/E-9999-2018; Brice, Alexis/A-2170-2009; Stevanin, Giovanni/E-5038-2016; Trottier, Yvon/H-8852-2016	SAUDOU, Frédéric/0000-0001-6107-1046; brice, alexis/0000-0002-0941-3990; Tora, Laszlo/0000-0001-7398-2250; Stevanin, Giovanni/0000-0001-9368-8657; Devys, Didier/0000-0001-9655-3512; Trottier, Yvon/0000-0001-7230-4810; Cancel-Tassin, Geraldine/0000-0002-9583-6382				ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; BELAL S, 1994, NEUROLOGY, V44, P1423, DOI 10.1212/WNL.44.8.1423; BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84; DURR A, IN PRESS BRAIN; GARDNER K, 1994, NEUROLOGY, V44, pA361; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; GISPERT S, 1995, AM J HUM GENET, V56, P183; GOSTOUT B, 1995, AM J HUM GENET, V52, P1182; GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HOUSMAN D, 1995, NAT GENET, V10, P3, DOI 10.1038/ng0595-3; IMBERT G, 1994, GENOMICS, V21, P667, DOI 10.1006/geno.1994.1335; KAWAGUCHI Y, 1995, NAT GENET, V8, P221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LEZIN A, IN PRESS HUM GENET; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PULST SM, 1993, NAT GENET, V5, P8, DOI 10.1038/ng0993-8c; RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SITTLER A, IN PRESS HUM MOL GEN; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; 1993, CELL, V72, P971	31	566	588	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 23	1995	378	6555					403	406		10.1038/378403a0	http://dx.doi.org/10.1038/378403a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477379				2022-12-01	WOS:A1995TF89300063
J	WHITFIELD, LS; SULSTON, JE; GOODFELLOW, PN				WHITFIELD, LS; SULSTON, JE; GOODFELLOW, PN			SEQUENCE VARIATION OF THE HUMAN Y-CHROMOSOME	NATURE			English	Article							DNA POLYMORPHISM	WE have generated over 100 kilobases of sequence from the nonrecombining portion of the Y chromosomes from five humans and one common chimpanzee. The human subjects were chosen to match the earliest branches of the human mitochondrial tree. The survey of 18.3 kilobases from each human detected only three sites at which substitutions were present, whereas the human and chimpanzee sequences showed 1.3% divergence. The coalescence time estimated from our Y chromosome sample is more recent than that of the mitochondrial genome. A recent coalescence time for the Y chromosome could have been caused by the selected sweep of an advantageous Y chromosome or extensive migration of human males.	SANGER CTR, HINXTON CB10 1RQ, CAMBS, ENGLAND	Wellcome Trust Sanger Institute	WHITFIELD, LS (corresponding author), UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 3EH, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1993, MEGA MOL EVOLUTIONAR; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; CLARK AG, 1987, GENETICS, V115, P569; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; JAKUBICZKA S, 1989, HUM GENET, V84, P86, DOI 10.1007/BF00210680; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; WHITFIELD LS, 1995, GENOMICS, V27, P306, DOI 10.1006/geno.1995.1047; YANG Z, 1995, SYST BIOL, V44, P384, DOI 10.2307/2413599; Yang Z., 1995, PAML PHYLOGENETIC AN; YANG ZB, 1994, J MOL EVOL, V39, P105; YANG ZH, 1995, J MOL EVOL, V40, P689, DOI 10.1007/BF00160518	16	210	212	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 23	1995	378	6555					379	380		10.1038/378379a0	http://dx.doi.org/10.1038/378379a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TF893	7477372				2022-12-01	WOS:A1995TF89300056
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL FOR EMERGENCY USE RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REGISTER, V60, P49086	1	6	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1578	1578		10.1001/jama.274.20.1578	http://dx.doi.org/10.1001/jama.274.20.1578			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474231				2022-12-01	WOS:A1995TE73800004
J	OPTENBERG, SA; THOMPSON, IM; FRIEDRICHS, P; WOJCIK, B; STEIN, CR; KRAMER, B				OPTENBERG, SA; THOMPSON, IM; FRIEDRICHS, P; WOJCIK, B; STEIN, CR; KRAMER, B			RACE, TREATMENT, AND LONG-TERM SURVIVAL FROM PROSTATE-CANCER IN AN EQUAL-ACCESS MEDICAL-CARE DELIVERY SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RACIAL-DIFFERENCES; UNITED-STATES; BLACK; ADENOCARCINOMA; MORTALITY; STAGE; POPULATIONS; CARCINOMA; DIAGNOSIS; PATTERNS	Objective.-To evaluate long-term survival of black and white prostate cancer patients in an equal-access medical care system to help distinguish biological from medical and social explanations of mortality differences. Design and Setting.-Retrospective study of US Department of Defense tumor registry patients with prostate cancer. Ethnicity, age, diagnosis, staging, risk factors, treatment, and survival end points were extracted. Patients.-Prostate cancer patients (N=1606; 7.5% black, 92.5% white) who were active-duty personnel, dependents, or retirees eligible for care in the military medical system. Main Outcome Measuress-Racial differences in tumor stage and grade, risk factors, recurrence, and treatment wait time (time between initial diagnosis and initial treatment); influence of stage, grade, treatment, wait time, age, and race on survival. Results.-No differences were found in behavioral risk factors or tumor grade or size, but blacks entered active treatment (P<.001) and exhibited a higher relative risk of cancer (P=.01) in younger age groups, presented with higher stage (P<.001), and demonstrated increased progression in distant metastatic disease (P=.01). No significant differences were detected in overall wait time. When adjusted for stage, no difference was found in type of treatment. Overall, stage, grade, and age were found to affect survival (P=.04 to P<.001), but race did not, When analyzed by stage, blacks demonstrated a clear trend of longer survival for distant metastatic disease (P=.04 to P=.06). This trend was confirmed using Kaplan-Meier estimates (P=.04, likelihood ratio), Conclusions.-This analysis suggests that in an equal-access medical care system there are no stage-specific differences in treatment between black and white prostate cancer patients, Survival among blacks is similar to that among whites and may surpass it for high-stage disease.	USA,MED DEPT CTR & SCH,CTR HLTHCARE EDUC & STUDIES,SAN ANTONIO,TX; BROOKE ARMY MED CTR,UROL SERV,SAN ANTONIO,TX; NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD	San Antonio Military Medical Center; United States Department of Defense; United States Army; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								APRIKIAN AG, 1994, CANCER, V74, P1768, DOI 10.1002/1097-0142(19940915)74:6<1768::AID-CNCR2820740620>3.0.CO;2-9; AUSTIN JP, 1990, AM J CLIN ONCOL-CANC, V13, P465, DOI 10.1097/00000421-199012000-00002; AUSTIN JP, 1993, AM J CLIN ONCOL-CANC, V16, P140, DOI 10.1097/00000421-199304000-00012; AZIZ H, 1988, AM J CLIN ONCOL-CANC, V11, P166, DOI 10.1097/00000421-198804000-00015; BALLWEG JA, 1989, PUBLIC HEALTH REP, V104, P498; BANG KM, 1988, CANCER, V61, P1255, DOI 10.1002/1097-0142(19880315)61:6<1255::AID-CNCR2820610634>3.0.CO;2-7; BEAHRS OH, 1992, MANUAL STAGING CANCE; BLAIR A, 1978, J NATL CANCER I, V61, P1379; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BRAWN PN, 1994, CANCER, V74, P1607, DOI 10.1002/1097-0142(19940901)74:5<1607::AID-CNCR2820740518>3.0.CO;2-F; DAYAL HH, 1982, J CHRON DIS, V35, P553, DOI 10.1016/0021-9681(82)90074-1; DEMARKWAHNEFRIED W, 1993, UROLOGY, V42, P269, DOI 10.1016/0090-4295(93)90615-H; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; ELEY JW, 1994, JAMA-J AM MED ASSOC, V242, P947; FLEISS JL, 1981, STATISTICAL METHODS, V23, P26; HARLAN L, 1995, J CLIN ONCOL, V13, P93, DOI 10.1200/JCO.1995.13.1.93; HUSSAIN F, 1992, INT J RADIAT ONCOL, V24, P451, DOI 10.1016/0360-3016(92)91059-V; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; LAWTON CA, 1994, RADIOLOGY, V92, P37; LEE JY, 1990, SOUTHERN MED J, V83, P185, DOI 10.1097/00007611-199002000-00012; LEVINE RL, 1979, J UROLOGY, V121, P761, DOI 10.1016/S0022-5347(17)56981-5; LIFF JM, 1991, CANCER, V67, P1454, DOI 10.1002/1097-0142(19910301)67:5<1454::AID-CNCR2820670533>3.0.CO;2-K; MEBANE C, 1990, J NATL MED ASSOC, V82, P782; METTLIN C, 1987, CANCER, V60, P474, DOI 10.1002/1097-0142(19870801)60:3+<474::AID-CNCR2820601508>3.0.CO;2-5; METTLIN CJ, 1994, CANCER, V74, P1640, DOI 10.1002/1097-0142(19940901)74:5<1640::AID-CNCR2820740525>3.0.CO;2-3; MYERS RE, 1994, UROLOGY, V43, P480, DOI 10.1016/0090-4295(94)90235-6; NATARAJAN N, 1989, J SURG ONCOL, V40, P232, DOI 10.1002/jso.2930400406; PAMIES RJ, 1992, PRIMARY CARE, V19, P443; POLEDNAK AP, 1990, CANCER-AM CANCER SOC, V66, P1654, DOI 10.1002/1097-0142(19901001)66:7<1654::AID-CNCR2820660734>3.0.CO;2-I; POLEDNAK AP, 1992, CANCER, V70, P2152, DOI 10.1002/1097-0142(19921015)70:8<2152::AID-CNCR2820700824>3.0.CO;2-#; RIES LAG, 1994, SEER CANCER STATISTI; ROACH M, 1992, INT J RADIAT ONCOL, V24, P441, DOI 10.1016/0360-3016(92)91058-U; RUFFER J E, 1991, International Journal of Radiation Oncology, Biology, Physics, V21, P212, DOI 10.1016/0360-3016(91)90609-8; TANARI N, 1993, CANCER, V71, P1289; TARGONSKI PV, 1991, J NATL MED ASSOC, V83, P1094; WHITMORE WF, 1984, UROL CLIN N AM, V11, P205; 1994, PHS951101 US DHEW PU, V2; 1992, SAS P229 SAS I INC R, P433; 1993, DEFENSE ENROLLMENT E; 1989, SAS STATOR USERS GUI; 1974, US DHEW HRA751101 PH, V2; 1994, DEFENSE MED INFORMAT; 1985, PHS851101 US DHEW PU, V2	43	198	201	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1599	1605		10.1001/jama.274.20.1599	http://dx.doi.org/10.1001/jama.274.20.1599			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474244				2022-12-01	WOS:A1995TE73800024
J	SCHOENENBERGER, RA; TANASIJEVIC, MJ; JHA, A; BATES, DW				SCHOENENBERGER, RA; TANASIJEVIC, MJ; JHA, A; BATES, DW			APPROPRIATENESS OF ANTIEPILEPTIC DRUG LEVEL MONITORING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHENYTOIN; EPILEPSY; MANAGEMENT; PHYSICIAN; IMPACT	Objectives.-To develop explicit, reliable appropriateness criteria for antiepileptic drug level monitoring and to assess the appropriateness of monitoring in one tertiary care institution. Design.-Appropriateness criteria derived from the literature and through expert opinion were used to evaluate a stratified random sample of antiepileptic drug level determinations obtained from chart review. Setting.-Tertiary care center performing more than 10 000 antiepileptic drug level determinations per year. Patients.-A total of 330 inpatients in whom antiepileptic drug levels were measured a total of 855 times. Methods.-Drug levels were assessed at least 200 times for each of four antiepileptic drugs (phenytoin, carbamazepine, phenobarbital, and valproic acid). Main Outcome Measures.-The proportion of antiepileptic drug levels with an appropriate indication and, of those, the proportion sampled appropriately. Results.-Overall, 27% (95% confidence interval, 24% to 30%) of levels had an appropriate indication. Interrater agreement for appropriateness was substantial (kappa=0.61). There was no significant difference in the appropriateness rate among the four drugs (range, 25% to 29%), Of the 624 antiepileptic drug level determinations considered inappropriate (73%), only four (0.6%) were more than 20% higher than the upper limit of normal, and none of the four patients had clinical signs of drug toxicity, A median of six levels (range, one through 69) was determined per patient, and the median interval between level determinations was 24 hours. Of the 27% of level determinations with an appropriate indication, 51% were sampled correctly, resulting in an overall appropriateness rate of 14%. Conclusions.-Only 27% of antiepileptic drug level determinations had an appropriate indication, and half of these were not sampled correctly. Routine daily monitoring without pharmacological justification accounted for most of the inappropriate drug level determinations. Efforts to decrease inappropriate monitoring may result in substantial cost reductions without missing important clinical results.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV CLIN EPIDEMIOL,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates D W, 1994, Qual Manag Health Care, V2, P18; BEARDSLEY RS, 1983, EPILEPSIA, V24, P330, DOI 10.1111/j.1528-1157.1983.tb04896.x; BRODIE MJ, 1988, BRIT MED J, V296, P1110, DOI 10.1136/bmj.296.6629.1110; BUSSEY HI, 1983, THER DRUG MONIT, V5, P245, DOI 10.1097/00007691-198309000-00002; CHADWICK DW, 1987, BRIT MED J, V294, P723, DOI 10.1136/bmj.294.6574.723; CHOONARA IA, 1990, CLIN PHARMACOKINET, V18, P318, DOI 10.2165/00003088-199018040-00004; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; FINEBERG HV, 1979, DHEW PHS793216 PUBL, P144; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FROESCHER W, 1981, J NEUROL, V224, P193; FROESCHER W, 1992, WIEN KLIN WOCHEN S15, V19, P15; GARDNER MJ, 1989, BRIT MED J; HOLFORD NHG, 1987, AVERYS DRUG TREATMEN, P195; JOHANNESSEN SI, 1991, COMPREHENSIVE EPILEP, P505; KNOTT C, 1990, CLIN PHARMACOKINET, V19, P425, DOI 10.2165/00003088-199019060-00002; KUTT H, 1985, RECENT ADV EPILEPSY, P183; LEVIN B, 1981, AM J HOSP PHARM, V38, P845, DOI 10.1093/ajhp/38.6.845; LEVINE M, 1988, THER DRUG MONIT, V10, P50, DOI 10.1097/00007691-198801000-00009; LOTT R, 1988, APPL THER, P1371; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V249, P639, DOI 10.1001/jama.249.5.639; MALONEY TW, 1979, NEW ENGL J MED, V301, P1413; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCINNES GT, 1989, BRIT J CLIN PHARMACO, V27, P281, DOI 10.1111/j.1365-2125.1989.tb05365.x; MCKEE PJW, 1993, THER DRUG MONIT, V15, P83, DOI 10.1097/00007691-199304000-00003; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; PANZER RJ, 1987, J GEN INTERN MED, V2, P365, DOI 10.1007/BF02596179; PATSALOS PN, 1987, LANCET, V2, P39; PEARCE GA, 1990, THER DRUG MONIT, V12, P250, DOI 10.1097/00007691-199005000-00007; PITTERLE ME, 1985, AM J HOSP PHARM, V42, P1547, DOI 10.1093/ajhp/42.7.1547; PORTER RJ, 1989, ANTIEPILEPTIC DRUGS, P117; RICHENS A, 1992, TXB EPILEPSY, P535; RIED LD, 1989, AM J HOSP PHARM, V46, P945, DOI 10.1093/ajhp/46.5.945; RUBENSTEIN KE, 1972, BIOCHEM BIOPH RES CO, V47, P846, DOI 10.1016/0006-291X(72)90570-0; SPECTOR R, 1988, CLIN PHARMACOL THER, V43, P345, DOI 10.1038/clpt.1988.42; THEODORE WH, 1992, PHARMACOL THERAPEUT, V54, P297, DOI 10.1016/0163-7258(92)90004-J; TOMSON T, 1994, EPILEPSIA, V35, P122, DOI 10.1111/j.1528-1157.1994.tb02921.x; TRISOLINI MG, 1987, MED CARE, V25, P286, DOI 10.1097/00005650-198704000-00003; TROUPIN AS, 1984, ANN INTERN MED, V100, P854, DOI 10.7326/0003-4819-100-6-854; VOZEH S, 1980, EUR J CLIN PHARMACOL, V17, P33, DOI 10.1007/BF00561674; VOZEH S, 1987, CLIN PHARMACOKINET, V13, P131; WING DS, 1989, THER DRUG MONIT, V11, P32, DOI 10.1097/00007691-198901000-00007; 1993, EPILEPSIA, V34, P585; 1989, LANCET, V2, P1190	43	76	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1622	1626		10.1001/jama.274.20.1622	http://dx.doi.org/10.1001/jama.274.20.1622			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474249				2022-12-01	WOS:A1995TE73800029
J	SILVERS, SM; HAMPSON, NB				SILVERS, SM; HAMPSON, NB			CARBON-MONOXIDE POISONING AMONG RECREATIONAL BOATERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To describe the case characteristics of a series of patients poisoned with carbon monoxide (CO) while boating for recreation. Design.-Cases of patients referred for treatment of CO poisoning with hyperbaric oxygen were reviewed. Those cases that occurred during recreational boating were selected for analysis. Setting.-A private, urban, tertiary care center studied from July 1984 to June 1994. Patients.-Thirty-nine patients ranging in age from 6 months to 69 years who were poisoned in 27 separate incidents. Main Outcome Measures.-Characteristics of the poisoning incidents were assessed at initial patient presentation, immediately following treatment, and with follow-up telephone interviews. Results.-Of 512 patients treated for acute unintentional CO poisoning, 39 cases (8%) occurred in 27 incidents related to recreational boating activities. Individuals typically lost consciousness as a result of the poisoning. Most cases occurred aboard a boat that was older than 10 years, had an enclosable cabin, was longer than 22 feet, was powered by a gasoline engine, and was without a CO detector on board. Conclusions.-Carbon monoxide poisoning is a serious hazard associated with recreational boating. The installation of CO detectors aboard boat types typically associated with this syndrome st-could be strongly encouraged.	VIRGINIA MASON CLIN,DEPT MED,SEATTLE,WA 98111; VIRGINIA MASON MED CTR,DEPT HYPERBAR,SEATTLE,WA; UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14627	Virginia Mason Medical Center; Virginia Mason Medical Center; University of Rochester			Silvers, Scott/AAM-1234-2021		NIEHS NIH HHS [ESO-0220] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		COBB N, 1991, JAMA-J AM MED ASSOC, V226, P659; GOMEZ GA, 1991, SURG CLIN N AM, V71, P419; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; HAMPSON NB, 1992, JAMA-J AM MED ASSOC, V267, P538, DOI 10.1001/jama.267.4.538; HAMPSON NB, 1994, JAMA-J AM MED ASSOC, V271, P52, DOI 10.1001/jama.271.1.52; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; RADFORD EP, 1982, PHS821250 PUBL; Tan E S, 1993, Ned Tijdschr Geneeskd, V137, P2266; 1994, BOATING 1994; 1994, BOATING STATISTICS 1; 1982, MMWR-MORBID MORTAL W, V31, P529	12	26	26	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	1995	274	20					1614	1616						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE738	7474247				2022-12-01	WOS:A1995TE73800027
J	DILLNER, J; KNEKT, P; SCHILLER, JT; HAKULINEN, T				DILLNER, J; KNEKT, P; SCHILLER, JT; HAKULINEN, T			PROSPECTIVE SEROEPIDEMIOLOGICAL EVIDENCE THAT HUMAN PAPILLOMAVIRUS TYPE-16 INFECTION IS A RISK FACTOR FOR ESOPHAGEAL SQUAMOUS-CELL CARCINOMA	BRITISH MEDICAL JOURNAL			English	Article							CANCER		NATL PUBL HLTH INST,HELSINKI,FINLAND; FINNISH SOCIAL INSURANCE INST,HELSINKI,FINLAND; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; KAROLINSKA INST,DEPT CANC EPIDEMIOL,STOCKHOLM,SWEDEN; FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; Finnish Cancer Registry	DILLNER, J (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Schiller, John/ABK-8287-2022					CHANG FJ, 1992, GASTROENTEROLOGY, V103, P1336, DOI 10.1016/0016-5085(92)91526-A; HEINO P, 1995, J NATL CANCER I, V87, P437, DOI 10.1093/jnci/87.6.437; KIRNBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494, DOI 10.1093/jnci/86.7.494; KNEKT P, 1988, AM J EPIDEMIOL, V127, P28, DOI 10.1093/oxfordjournals.aje.a114788; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958	5	70	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1346	1346		10.1136/bmj.311.7016.1346	http://dx.doi.org/10.1136/bmj.311.7016.1346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496288	Green Published			2022-12-01	WOS:A1995TF90100026
J	GOOD, MF				GOOD, MF			WHAT CAN A WORM TEACH US ABOUT AUTOIMMUNITY	LANCET			English	Editorial Material							T-CELLS; TOLERANCE; EPITOPES				GOOD, MF (corresponding author), QUEENSLAND INST MED RES,BRISBANE,QLD 4006,AUSTRALIA.							BRAUN G, 1991, J EXP MED, V174, P169, DOI 10.1084/jem.174.1.169; BRONZE MS, 1988, J EXP MED, V167, P1849, DOI 10.1084/jem.167.6.1849; GALLIN MY, 1995, J EXP MED, V182, P41, DOI 10.1084/jem.182.1.41; GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1; LANZAVECCHIA A, 1995, J EXP MED, V181, P1945, DOI 10.1084/jem.181.6.1945; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; POMBO D, 1988, J IMMUNOL, V140, P3594; PRUKSAKORN S, 1994, INT IMMUNOL, V6, P1235, DOI 10.1093/intimm/6.8.1235; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430	12	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1311	1312		10.1016/S0140-6736(95)92337-3	http://dx.doi.org/10.1016/S0140-6736(95)92337-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475765				2022-12-01	WOS:A1995TE91600003
J	HELLER, RF; STEELE, PL; FISHER, JD; ALEXANDER, HM; DOBSON, AJ				HELLER, RF; STEELE, PL; FISHER, JD; ALEXANDER, HM; DOBSON, AJ			SUCCESS OF CARDIOPULMONARY-RESUSCITATION AFTER HEART-ATTACK IN-HOSPITAL AND OUTSIDE HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; SURVIVAL	Objectives-To determine factors associated with cardiopulmonary resuscitation being attempted after cardiac arrest from myocardial infarction, in or outside hospital, and estimate short term and long term survival rates. Design-Descriptive cross sectional and cohort study. Setting-Community based register of all suspected heart attacks and sudden cardiac deaths in Lower Hunter region of New South Wales, Australia. Subject-4924 men and women aged 25-69. Main outcome measures-Rates of attempted cardiopulmonary resuscitation and survival after successful resuscitation. Results-Cardiopulmonary resuscitation was attempted in 41% of cases of cardiac arrest after myocardial infarction outside hospital and 63% of cases in hospital, Survival rates at 28 days were 12% and 39% respectively, Among the survivors, although 41% had another myocardial infarction (or coronary death), 81% of both groups were still alive two years later. Younger and better educated people were more likely to receive cardiopulmonary resuscitation in either setting, and being married predicted cardiopulmonary resuscitation being attempted outside hospital. Younger age predicted better survival rates after attempted resuscitation in hospital. Conclusions-The reasons for better education to predict cardiopulmonary resuscitation being attempted need explanation. The higher survival rate after cardiopulmonary resuscitation in hospital compared with outside hospital and the good long term prognosis for survivors in both settings suggest that attempts to improve success of cardiopulmonary resuscitation outside hospital may be worth while.	UNIV NEWCASTLE,FAC MED & HLTH SCI,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle			Dobson, Annette J/B-5273-2008	Heller, Richard/0000-0003-3161-5967				BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BEURET P, 1993, RESUSCITATION, V25, P171, DOI 10.1016/0300-9572(93)90093-6; DOBSON AJ, 1988, ACTA MED SCAND S, V728, P84; EBELL MH, 1992, J FAM PRACTICE, V34, P551; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; JOSLYN SA, 1993, AM J EMERG MED, V11, P200, DOI 10.1016/0735-6757(93)90124-T; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; SOLOMON NA, 1993, ARCH INTERN MED, V153, P1218, DOI 10.1001/archinte.153.10.1218; TRESCH DD, 1993, AM J MED, V95, P123, DOI 10.1016/0002-9343(93)90252-K; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583	12	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1332	1336		10.1136/bmj.311.7016.1332	http://dx.doi.org/10.1136/bmj.311.7016.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496282	Green Published			2022-12-01	WOS:A1995TF90100019
J	IMPALLOMENI, M; GALLETLY, NP; WORT, SJ; STARR, JM; ROGERS, TR				IMPALLOMENI, M; GALLETLY, NP; WORT, SJ; STARR, JM; ROGERS, TR			INCREASED RISK OF DIARRHEA CAUSED BY CLOSTRIDIUM-DIFFICILE IN ELDERLY PATIENTS RECEIVING CEFOTAXIME	BRITISH MEDICAL JOURNAL			English	Article									ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND	Imperial College London	IMPALLOMENI, M (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DIV GERIATR MED,LONDON W12 0HS,ENGLAND.		Starr, John/C-8951-2011	Rogers, Thomas/0000-0003-4336-7729				GOLLEDGE CL, 1989, J ANTIMICROB CHEMOTH, V23, P929, DOI 10.1093/jac/23.6.929; GREEN ST, 1985, ULSTER MED J, V54, P80; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; 1994, CLOSTRIDIUM DIFFICIL; 1993, BR J HOSP MED, V49, P346	5	85	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1345	1346		10.1136/bmj.311.7016.1345	http://dx.doi.org/10.1136/bmj.311.7016.1345			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496287	Green Published			2022-12-01	WOS:A1995TF90100025
J	MACARTHUR, A; MACARTHUR, C; WEEKS, S				MACARTHUR, A; MACARTHUR, C; WEEKS, S			EPIDURAL-ANESTHESIA AND LOW-BACK-PAIN AFTER DELIVERY - A PROSPECTIVE COHORT STUDY	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM BACKACHE; CHILDBIRTH	Objective-To determine whether epidural anaesthesia during labour and delivery is a risk factor for postpartum back pain. Design-Prospective cohort study with follow up at one day, seven days, and six weeks after delivery. Setting-Teaching hospital in Montreal. Subjects-329 women who delivered a live infant(s) during the study period, Exclusion criteria were back pain before pregnancy and delivery by elective caesarean section. Intervention-Epidural anaesthesia during labour and delivery. Main outcome measures and results-The primary outcome variable was development of postpartum low back pain, Back pain was quantified with self reports (yes/no), a pain score (numeric rating scale), and degree of interference with daily activities. Of the 329 women, 164 received epidural anaesthesia during labour and 165 did not. The incidence of low back pain in epidural v non-epidural group was 53% v 43% on day one; 21% v 23% on day seven; and 14% v 7% at six weeks, The relative risk for low back pain (epidural v non-epidural) adjusted for parity, delivery, ethnicity, and weight was 1.76 (95% confidence interval 1.06 to 2.92) on day one; 1.00 (0.54 to 1.86) on day seven; and 2.22 (0.89 to 5.53) at six weeks. There were no differences between the two groups in pain scores or the frequency of interference with daily activities. Similar results were obtained in the subgroup of women with low back pain of new onset-that is, those women with no back pain during their pregnancy, Conclusions-Postpartum low back pain was common but decreased considerably over the short term, The association between epidural anaesthesia and postpartum low back pain was inconsistent over time with a significantly increased risk of low back pain (epidural v non-epidural) noted only on the first day after delivery.	ROYAL VICTORIA HOSP,DEPT ANAESTHESIA,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA	McGill University; Royal Victoria Hospital; McGill University			MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				Alexander J T, 1993, Neurosurg Clin N Am, V4, P153; BREEN TW, 1994, ANESTHESIOLOGY, V81, P29, DOI 10.1097/00000542-199407000-00006; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; KITZINGER S, 1987, SOME WOMENS EXPERIEN; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P165; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299	11	52	54	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1336	1339		10.1136/bmj.311.7016.1336	http://dx.doi.org/10.1136/bmj.311.7016.1336			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496283	Green Published			2022-12-01	WOS:A1995TF90100020
J	MCCULLOCH, P; CHOY, A; MARTIN, L				MCCULLOCH, P; CHOY, A; MARTIN, L			ASSOCIATION BETWEEN TUMOR ANGIOGENESIS AND TUMOR-CELL SHEDDING INTO EFFLUENT VENOUS-BLOOD DURING BREAST-CANCER SURGERY	LANCET			English	Note							CARCINOMA; INDICATOR	Tumour angiogenesis is a powerful prognostic indicator in breast cancer. Shedding of tumour cells into the bloodstream is essential for haematogenous metastasis. The relation between cell shedding and angiogenesis in human cancer is not known. We studied vascular density and cell shedding in 16 women undergoing breast cancer surgery. Circulating cells were found in one patient before, in six during, acid none after operation. Vascular density was related to detection of circulating tumour cells during surgery (correlation coefficient for first intraoperative sampling=0.56, p=0.024, 95% CI 0.08 to 0.83). Tumour cell shedding during surgery is related to vascular density; the relevance of this relation to the prognostic significance of vascular density in breast cancer merits further study.			MCCULLOCH, P (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT SURG,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND.			McCulloch, Peter/0000-0002-3210-8273				FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; LIOTTA LA, 1976, CANCER RES, V36, P889; MCCULLOCH P, 1994, LANCET, V344, P402; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	6	90	91	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1334	1335		10.1016/S0140-6736(95)92345-4	http://dx.doi.org/10.1016/S0140-6736(95)92345-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475773				2022-12-01	WOS:A1995TE91600011
J	PARKES, C; WALD, NJ; MURPHY, P; GEORGE, L; WATT, HC; KIRBY, R; KNEKT, P; HELZLSOUER, KJ; TUOMILEHTO, J				PARKES, C; WALD, NJ; MURPHY, P; GEORGE, L; WATT, HC; KIRBY, R; KNEKT, P; HELZLSOUER, KJ; TUOMILEHTO, J			PROSPECTIVE OBSERVATIONAL STUDY TO ASSESS VALUE OF PROSTATE-SPECIFIC ANTIGEN AS SCREENING-TEST FOR PROSTATE-CANCER	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM VITAMIN-E; RISK; SELENIUM; MEN	Objective-To evaluate measurement of serum prostate specific antigen as a potential screening test for future clinical prostate cancer among healthy men. Design-Nested case-control study with stored serum samples collected from 49261 men with follow up using national death and cancer registration systems. Subjects-265 asymptomatic men who subsequently developed clinical prostate cancer and 1055 controls matched for age, study centre, and duration of storage of samples. Main outcome measures-Distribution of concentrations of the antigen in men who developed prostate cancer and in controls. Results-Prostate specific antigen concentrations were significantly higher in men who subsequently developed prostate cancer than in controls. In the first three years after blood collection the median concentration was 23 times greater in cases than in controls of the same age at the same centre (that is, 23 multiples of the median). A smaller difference persisted thereafter; 4.0 multiples of the median 3-6 years after blood collection, 3.6 6-10 years, and 1.8 after 10 years. In the first three years the proportion of men who developed prostate cancer and had raised levels of the antigen (greater than or equal to 12 multiples of the median) (detection rate or sensitivity) was 81% (95% confidence interval 54% to 96%). The proportion of men who did not develop prostate cancer but had levels this high (false positive rate) was only 0.5%. Conclusion-Prostate specific antigen measurement is a highly discriminatory screening test for prostate cancer among healthy men. In the general population, 60-74 year old men who had greater than or equal to 12 times the normal median level would have about a 50% chance of developing clinical prostate cancer in the next three years. Measurement of this antigen is a good enough screening test to justify a randomised controlled trial to determine any reduction in mortality from prostate cancer.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, DEPT UROL, LONDON EC1A 7BE, ENGLAND; NATL PUBL HLTH INST, DEPT HLTH & DISABIL, HELSINKI, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, HELSINKI, FINLAND; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, TRAINING CTR PUBL HLTH RES, BALTIMORE, MD 21742 USA; NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, HELSINKI, FINLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; Finland National Institute for Health & Welfare; Johns Hopkins University; Finland National Institute for Health & Welfare			Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					AXTELL LM, 1976, US DHEW5 REP; BRESLOW N, 1977, INT J CANCER, V20, P680, DOI 10.1002/ijc.2910200506; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; HELZLSOUER KJ, 1989, CANCER RES, V49, P6144; HELZLSOUER KJ, 1992, CANCER EPIDEM BIOMAR, V1, P537; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; KILLIAN CS, 1990, CANCER INVEST, V8, P27, DOI 10.3109/07357909009017544; KNEKT P, 1988, INT J CANCER, V42, P846, DOI 10.1002/ijc.2910420609; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; PALKEN M, 1990, J UROLOGY, V143, P1155, DOI 10.1016/S0022-5347(17)40213-8; PUSKA P, 1979, BRIT MED J, V2, P1173, DOI 10.1136/bmj.2.6199.1173; STAMEY TA, 1989, J UROLOGY, V141, P1070; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; WALD NJ, 1987, BRIT J CANCER, V56, P69, DOI 10.1038/bjc.1987.156; WHITTEMORE AS, 1995, J NATL CANCER I, V87, P354, DOI 10.1093/jnci/87.5.354; 1994, CANCER STATISTICS RE; 1990, 3813BE HYBR EUR CAT; 1993, MORTALITY STATIS DH2	23	53	53	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	1995	311	7016					1340	1343		10.1136/bmj.311.7016.1340	http://dx.doi.org/10.1136/bmj.311.7016.1340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496284	Green Published			2022-12-01	WOS:A1995TF90100022
J	SCHOUTEN, EJ; BORGDORFF, MW				SCHOUTEN, EJ; BORGDORFF, MW			INCREASED MORTALITY AMONG DUTCH DEVELOPMENT WORKERS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL TROP INST,1092 AD AMSTERDAM,NETHERLANDS		SCHOUTEN, EJ (corresponding author), HEALTHNET INT,1017 MB AMSTERDAM,NETHERLANDS.							FRAME JD, 1992, AM J TROP MED HYG, V46, P686, DOI 10.4269/ajtmh.1992.46.686; HARGARTEN SW, 1985, JAMA-J AM MED ASSOC, V10, P1326; Houweling H, 1991, Int J STD AIDS, V2, P252; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; 1975, INT CLASSIFICATION D	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1343	1344		10.1136/bmj.311.7016.1343	http://dx.doi.org/10.1136/bmj.311.7016.1343			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TF901	7496285	Green Published			2022-12-01	WOS:A1995TF90100023
J	SMITH, JD; ROSE, ML; POMERANCE, A; BURKE, M; YACOUB, MH				SMITH, JD; ROSE, ML; POMERANCE, A; BURKE, M; YACOUB, MH			REDUCTION OF CELLULAR REJECTION AND INCREASE IN LONGER-TERM SURVIVAL AFTER HEART-TRANSPLANTATION AFTER HLA-DR MATCHING	LANCET			English	Article							CARDIAC ALLOGRAFT RECIPIENTS; RISK-FACTORS; ANTIGENS; HISTOCOMPATIBILITY	HLA matching in cardiac transplants is perceived as being logistically difficult. We studied 1135 consecutive primary cardiac allografts between 1980 and 1994 to assess the effect of HLA mismatching on long-term graft survival acid cellular rejection episodes within 3 months of transplantation. We found a significant association between HLA-DR mismatching and the number of episodes of rejection (no mismatch 0.80 [SE 0.13], one mismatch 1.22 [0.06], two mismatches 1.42 [0.06], p<0.05). We found a similar correlation between the total number of biopsy specimens showing evidence of cellular rejection and HLA-DR mismatch. The time between operation and the first rejection episode shortened with increasing HLA-DR mismatch (no mismatch 85.5 [37.3] days, one mismatch 43.1 [8.1], two mismatches 24.1 [2.9], p<0.05). Furthermore, the proportion of patients with no evidence of rejection correlated with HLA-DR incompatibility. A significant association between improved graft survival and HLA-DR mismatching was found over 1, 5, and 10 years after transplantation (no mismatch 1 year 92%, 5 years 83%, 10 years 76%, one mismatch 1 year 81%, 5 years 73%, 10 years 59%, and two mismatches 78% 1 year, 5 years 70%, and 10 years 52%, p=0.02). Increased efforts to prospectively HLA match patients has resulted in 25% of patients transplanted between January and May 1995 (n=13/52) receiving grafts matched for HLA-DR. HLA matching reduces the frequency and severity of acute cardiac allograft rejection and improves graft survival for up to 10 years. Our preliminary results suggest that it is possible to use HLA matching prospectively for our selection of recipients.	HAREFIELD HOSP,IMPERIAL COLL SCI & TECHNOL,NATL HEART & LUNG INST,DEPT CARDIOTHORAC SURG,HAREFIELD UB9 6JH,MIDDX,ENGLAND; HAREFIELD HOSP,ROYAL BROMPTON & NATL HEART HOSP,CTR HEART SCI,HAREFIELD UB9 6JH,MIDDX,ENGLAND	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital								Billingham M E, 1990, J Heart Transplant, V9, P587; BRAND DL, 1970, HISTOCOMPATIBILITY T, P357; BUYSE I, 1993, TISSUE ANTIGENS, V41, P1, DOI 10.1111/j.1399-0039.1993.tb01970.x; COCHRANE A, 1992, TRANSPLANT P, V24, P169; DISESA VJ, 1990, ANN THORAC SURG, V49, P220, DOI 10.1016/0003-4975(90)90141-R; FESTENSTEIN H, 1989, IMMUNOBIOLOGY HLA II, P526; FRIST WH, 1987, ANN THORAC SURG, V44, P242, DOI 10.1016/S0003-4975(10)62062-0; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KHAGHANI A, 1989, TRANSPLANT P, V21, P799; LAUFER G, 1989, J THORAC CARDIOV SUR, V98, P1113; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFEFFER PF, 1988, TRANSPLANT P, V20, P367; POLLACK MS, 1990, CLIN TRANSPLANT, V4, P269; RAFFOUX C, 1987, TRANSPLANT P, V19, P3559; ROSE M, 1988, HUM IMMUNOL, V23, P179, DOI 10.1016/0198-8859(88)90056-0; ROSE ML, 1986, TRANSPLANTATION, V41, P776, DOI 10.1097/00007890-198606000-00021; SHEIL AGR, 1993, TRANSPLANT P, V25, P1383; SHELDON S, 1994, TRANSPLANTATION, V6, P719; VALERI M, 1990, TRANSPLANT P, V4, P1906; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0; YACOUB M, 1987, TRANSPLANT P, V1, P2487; ZERBE TR, 1991, TRANSPLANTATION, V52, P485, DOI 10.1097/00007890-199109000-00019	24	64	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1318	1322		10.1016/S0140-6736(95)92341-1	http://dx.doi.org/10.1016/S0140-6736(95)92341-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475769				2022-12-01	WOS:A1995TE91600007
J	VONKONIG, CHW; POSTELSMULTANI, S; BOCK, HL; SCHMITT, HJ				VONKONIG, CHW; POSTELSMULTANI, S; BOCK, HL; SCHMITT, HJ			PERTUSSIS IN ADULTS - FREQUENCY OF TRANSMISSION AFTER HOUSEHOLD EXPOSURE	LANCET			English	Article							WHOOPING-COUGH; INFECTION; ERYTHROMYCIN; PREVENTION; EFFICACY	Although pertussis in adults is well documented, opinions differ about incidence of adult disease and about the role of adults as reservoirs of infection. We made use of a prospective household contact study of an acellular pertussis vaccine to collect data about pertussis in adults. All members of families with an index case of pertussis were monitored for respiratory symptoms, and pertussis was confirmed by laboratory tests. In 122 households, 104 children (85%) and 18 adults (15%) were the source of pertussis. These households consisted of 265 adults (aged 19-83 years), in 84 of whom (31%) pertussis was confirmed. Of these 84, 81% had respiratory symptoms for 21 days or more. The spread of pertussis was independent of whether a child (74/104) or an adult (14/18) was the index case. Most adult index cases had no pertussis recall (odds ratio 11.8). The overall attack rate in adult contacts was 0.267 and was independent of the social status and the size of the family and of a pertussis recall, although it differed significantly between women and men (p<0.05). Erythromycin treatment of the index case reduced the attack rate significantly (p<0.05). Patients whose first pertussis episode dated back more than 20 years had similar symptoms and attack rates to patients without a recall. We conclude that adults are often involved in the spread of pertussis, and that they can be susceptible to reinfection 20 years after a first pertussis episode.	UNIV MAINZ,KINDERKLIN,W-6500 MAINZ,GERMANY; SMITHKLINE BEECHAM PHARMA,CLIN RES,MUNICH,GERMANY	Johannes Gutenberg University of Mainz; GlaxoSmithKline	VONKONIG, CHW (corresponding author), STADT KRANKENANSTALTEN,INST HYG & LAB MED,LUTHERPL 40,D-47805 KREFELD,GERMANY.							AOYAMA T, 1992, AM J DIS CHILD, V146, P163, DOI 10.1001/archpedi.1992.02160140029015; BASS JW, 1986, PEDIATR INFECT DIS J, V5, P154, DOI 10.1097/00006454-198601000-00051; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; FEER E, 1914, MED KLIN, V10, P837; GIAMMANCO A, 1991, REV INFECT DIS, V13, P1216; GORDON JE, 1951, AM J MED SCI, V222, P333, DOI 10.1097/00000441-195109000-00011; GROB PR, 1981, LANCET, V1, P772; HE QS, 1994, J INFECT DIS, V170, P705, DOI 10.1093/infdis/170.3.705; ISACSON J, 1993, PEDIATR INFECT DIS J, V12, P284, DOI 10.1097/00006454-199304000-00005; MacLean D W, 1982, J R Coll Gen Pract, V32, P298; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MINK CM, 1994, ARCH PEDIAT ADOL MED, V148, P153, DOI 10.1001/archpedi.1994.02170020039006; MORSE SI, 1968, ANN INTERN MED, V68, P953, DOI 10.7326/0003-4819-68-4-953; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; SCHMITT HJ, IN PRESS JAMA; SCHMITZ M, 1994, MONATSSCHR KINDERH, V142, P41; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; STORSAETER J, 1992, AM J DIS CHILD, V146, P167, DOI 10.1001/archpedi.1992.02160140033016; TROLLFORS B, 1981, BRIT MED J, V283, P696, DOI 10.1136/bmj.283.6293.696; VONKONIG CHW, 1991, DEUT MED WOCHENSCHR, V116, P649, DOI 10.1055/s-2008-1063661; VONKONIG CHW, 1992, METHODEN MIKROBIOLOG; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; Ziegler R, 1988, Offentl Gesundheitswes, V50, P25; 1992, LANCET, V339, P526	26	150	155	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1326	1329						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475771				2022-12-01	WOS:A1995TE91600009
J	WILSON, RPH; BUCHAN, I; WALLEY, T				WILSON, RPH; BUCHAN, I; WALLEY, T			ALTERATIONS IN PRESCRIBING BY GENERAL-PRACTITIONER FUNDHOLDERS - AN OBSERVATIONAL STUDY	BRITISH MEDICAL JOURNAL			English	Article							COSTS	Objectives-To compare prescribing in general practices before and after they become fundholders to assess whether this affected prescribing patterns. Design-Analysis of prescribing data (PACT) for one year before and one year after practices become first, second, or third wave fundholders and comparison with practices that were not fundholders during any part of the study. Main outcome measures-Prescribing costs (net ingredient cost per prescribing unit), prescribing volume (items per 1000 prescribing units), net ingredient cost per item, and percentage of generic prescribing. Setting-Former Mersey Regional Health Authority. Subjects-100 fundholders (20 first wave, 31 second wave, 49 third wave) and 312 non-fundholders. Results-Prescribing costs and volume rose throughout the study in all groups. In all three fundholding waves the rate of increase of prescribing costs was significantly lower than for non-fundholders. Both cost per item and prescribing volume tended to decrease, the former probably because of a significant increase in generic prescribing: Fundholding and non-fundholding practices differed in several respects. Conclusion-Fundholding has altered practice prescribing patterns compared with those of non-fundholders, increasing generic prescribing and reducing the rate of increase of prescribing costs.	UNIV LIVERPOOL,DEPT THERAPEUT & PHARMACOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; University of Liverpool			Buchan, Iain E/H-5767-2013	Buchan, Iain E/0000-0003-3392-1650				BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRITTEN N, 1995, BRIT MED J, V310, P1067, DOI 10.1136/bmj.310.6986.1067c; CHEW R, 1995, OHE COMPENDIUM HLTH; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; GILLIGAN JD, 1991, 54 ROYAL COLL GEN PR; GLENNERSTER H, 1994, EVALUATING NHS REFOR; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; WALLEY T, 1995, PHARMACOECONOMICS, V7, P320, DOI 10.2165/00019053-199507040-00006; 1994, PRESCRIPTION IMPROVE; 1994, PRIORITY SETTING NHS; 1995, BRIEFING GP FUNDHOLD; [No title captured]	17	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1347	1350		10.1136/bmj.311.7016.1347	http://dx.doi.org/10.1136/bmj.311.7016.1347			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496289	Green Published			2022-12-01	WOS:A1995TF90100027
J	BACH, EA; SZABO, SJ; DIGHE, AS; ASHKENAZI, A; AGUET, M; MURPHY, KM; SCHREIBER, RD				BACH, EA; SZABO, SJ; DIGHE, AS; ASHKENAZI, A; AGUET, M; MURPHY, KM; SCHREIBER, RD			LIGAND-INDUCED AUTOREGULATION OF IFN-GAMMA RECEPTOR-BETA CHAIN EXPRESSION IN T-HELPER CELL SUBSETS	SCIENCE			English	Article							INTERFERON-GAMMA; IDENTIFICATION; ANTIBODIES	Interferon gamma (IFN-gamma) responsiveness in certain cells depends on the state of cellular differentiation or activation. Here an in vitro developmental system was used to show that IFN-gamma produced during generation of the CD4(+) T helper cell type 1 (T(H)1) subset extinguishes expression of the IFN-gamma receptor beta subunit, resulting in T(H)1 cells that are unresponsive to IFN-gamma. This beta chain loss also occurred in IFN-gamma-treated T(H)2 cells and thus represents a specific response of CD4(+) T cells to IFN-gamma rather than a T(H)1-specific differentiation event. These results define a mechanism of cellular desensitization where a cytokine down-regulates expression of a receptor subunit required primarily for signaling and not ligand binding.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Genentech			Schreiber, Robert/Q-7550-2019; Ashkenazi, Avi/ABG-2712-2020; Dighe, Anand/AAP-9640-2020; Schreiber, Robert D/A-1276-2013	Ashkenazi, Avi/0000-0002-6890-4589; Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341; Bach, Erika/0000-0002-5997-4489; Dighe, Anand/0000-0003-4130-0758				BACH E, UNPUB; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P5401; PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; SCHREIBER RD, 1994, GUIDEBOOK CYTOKINES, P120; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SOH J, 1994, CELL, P796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X	18	193	194	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1215	1218		10.1126/science.270.5239.1215	http://dx.doi.org/10.1126/science.270.5239.1215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502050				2022-12-01	WOS:A1995TE90500062
J	BELL, SP; MITCHELL, J; LEBER, J; KOBAYASHI, R; STILLMAN, B				BELL, SP; MITCHELL, J; LEBER, J; KOBAYASHI, R; STILLMAN, B			THE MULTIDOMAIN STRUCTURE OF ORC1P REVEALS SIMILARITY TO REGULATORS OF DNA-REPLICATION AND TRANSCRIPTIONAL SILENCING	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST; LOCI; REPRESSION; DIVISION; MUTANTS; MITOSIS; CDC6	The origin recognition complex (ORC) is a six protein assembly that binds S. cerevisiae origins of replication and directs DNA replication throughout the genome and transcriptional silencing at the yeast mating-type loci. Here we report the cloning of the genes encoding the 120 kDa (ORC1), 62 kDa (ORC3), and 56 kDa (ORC4) subunits of ORC and the reconstitution of the complete complex after expression of all six subunits in insect cells. Orc1p is related to Cdc6p and Cdc18p, which regulate DNA replication and mitosis, and to Sir3p, a regulator of transcriptional silencing. The N-terminal region of Orc1p is highly related to Sir3p, and studies of Orc1p/Sir3p chimeric proteins indicate that this domain is dedicated to the transcriptional silencing function of ORC.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	BELL, SP (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Stillman, Bruce/0000-0002-9453-4091; Bell, Stephen/0000-0002-2876-610X	PHS HHS [A120460] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NEWTON CS, 1993, CURR OPIN GENE DEV, V3, P752; PLATTI S, 1995, EMBO J, V14, P3788; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	28	216	221	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					563	568		10.1016/0092-8674(95)90096-9	http://dx.doi.org/10.1016/0092-8674(95)90096-9			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585959	Bronze			2022-12-01	WOS:A1995TF24800009
J	DEVORE, DL; HORVITZ, HR; STERN, MJ				DEVORE, DL; HORVITZ, HR; STERN, MJ			AN FGF RECEPTOR SIGNALING PATHWAY IS REQUIRED FOR THE NORMAL-CELL MIGRATIONS OF THE SEX MYOBLASTS IN C-ELEGANS HERMAPHRODITES	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; VULVAR INDUCTION; POINT MUTATION; GENE SEM-5; MESODERM; PROTEIN; MITOGENESIS; NEMATODE; ENCODES	The sex myoblasts (SMs) in C. elegans hermaphrodites undergo anteriorly directed cell migrations that allow for the proper localization of the egg-laying muscles. These migrations are controlled in part by a signal emanating from gonadal cells that allows the SMs to be attracted to their precise final positions flanking the center of the go nad. Mutations in egl-15 alter the nature of the interaction between the gonad and the SMs, resulting in the posterior displacement of the SMs. Here we show that egl-15 encodes a receptor tyrosine kinase of the fibroblast growth factor receptor (FGFR) subfamily with multiple roles in development. Three genes were identified that behave genetically as activators or mediators of egl-15 activity. One of these genes, sem-5, encodes an adaptor molecule that transduces signals from a variety of receptor tyrosine kinases. Like egl-15 and sem-5, the other two genes may similarly act in FGFR signaling pathways in C, elegans.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	DEVORE, DL (corresponding author), YALE UNIV,SCH MED,DEPT GENET,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							ADNANE J, 1991, ONCOGENE, V6, P659; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1991, GENETICS, V128, P251; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLIFFORD RJ, 1989, GENETICS, V123, P771; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fodor A., 1985, Journal of Genetics, V64, P143, DOI 10.1007/BF02931143; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; HODGKIN J, 1979, GENETICS, V91, P67; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LABONNE C, 1994, DEVELOPMENT, V120, P463; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSBAUM C, 1989, GENETICS, V122, P579; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 1989, MOL CLONING LAB MANU; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; STERN MJ, 1991, DEVELOPMENT, V113, P797; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Wood WB, 1988, NEMATODE CAENORHABDI	43	147	156	3	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					611	620		10.1016/0092-8674(95)90101-9	http://dx.doi.org/10.1016/0092-8674(95)90101-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585964	hybrid			2022-12-01	WOS:A1995TF24800014
J	ELLIS, NA; GRODEN, J; YE, TZ; STRAUGHEN, J; LENNON, DJ; CIOCCI, S; PROYTCHEVA, M; GERMAN, J				ELLIS, NA; GRODEN, J; YE, TZ; STRAUGHEN, J; LENNON, DJ; CIOCCI, S; PROYTCHEVA, M; GERMAN, J			THE BLOOMS-SYNDROME GENE-PRODUCT IS HOMOLOGOUS TO RECQ HELICASES	CELL			English	Article							SYNDROME FIBROBLASTS; SYNDROME CELLS; ADENOMATOUS POLYPOSIS; PUTATIVE HELICASES; DNA GLYCOSYLASE; RECOMBINATION; REPAIR; IDENTIFICATION; REPLICATION; SENSITIVITY	The Bloom's syndrome (BS) gene, BLM, plays an important role in the maintenance of genomic stability in somatic cells. A candidate for BLM was identified by direct selection of a cDNA derived from a 250 kb segment of the genome to which BLM had been assigned by somatic crossover point mapping. In this novel mapping method, cells were used from persons with BS that had undergone intragenic recombination within BLM. cDNA analysis of the candidate gene identified a 4437 bp cDNA that encodes a 1417 amino acid peptide with homology to the RecQ helicases, a subfamily of DExH box-containing DNA and RNA helicases. The presence of chain-terminating mutations in the candidate gene in persons with BS proved that it was BLM.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati	ELLIS, NA (corresponding author), NEW YORK BLOOD CTR, HUMAN GENET LAB, NEW YORK, NY 10021 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD004134] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA050897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50897] Funding Source: Medline; NICHD NIH HHS [HD-04134] Funding Source: Medline; NIEHS NIH HHS [ES-06096] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKMANN JS, 1993, HUM MOL GENET, V2, P2019, DOI 10.1093/hmg/2.12.2019; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEHAZYA P, 1986, CANCER RES, V46, P3756; ELLIS NA, 1994, AM J HUM GENET, V55, P453; ELLIS NA, 1994, NAT GENET, V6, P394, DOI 10.1038/ng0494-394; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; FREJTER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRIEDBERG EC, 1979, ADV RADIAT BIOL, V8, P85; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1989, CLIN GENET, V35, P57; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GERMAN J, IN PRESS CLIN GENET; GERMAN J, 1980, GENETIC ENV FACTORS, P175; GLANNELLI F, 1977, NATURE, V265, P466; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; Heddle J.A., 1983, CHROMOSOME MUTATION, P203; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIM S, 1986, MUTAT RES, V173, P141, DOI 10.1016/0165-7992(86)90092-8; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; LEHESJOKI AE, 1993, HUM MOL GENET, V2, P1229, DOI 10.1093/hmg/2.8.1229; LONN U, 1990, CANCER RES, V50, P3141; LUISIDELUCA C, 1989, GENETICS, V122, P269; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MATHEW S, 1993, CYTOGENET CELL GENET, V63, P33, DOI 10.1159/000133496; MCDANIEL LD, 1992, P NATL ACAD SCI USA, V89, P7968, DOI 10.1073/pnas.89.17.7968; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NICOTERA TM, 1989, CANCER RES, V49, P5239; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEAL G, 1988, P NATL ACAD SCI USA, V85, P2339, DOI 10.1073/pnas.85.7.2339; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SHIRAISHI Y, 1989, MUTAT RES, V211, P273, DOI 10.1016/0027-5107(89)90010-9; SIRUGO G, 1992, AM J HUM GENET, V50, P559; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SURDEJ P, 1994, ANNU REV GENET, V28, P263; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSENG YC, 1994, MUTAT RES, V315, P1; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WARBURTON D, 1990, GENOMICS, V6, P358, DOI 10.1016/0888-7543(90)90577-H; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0	61	1152	1185	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 17	1995	83	4					655	666		10.1016/0092-8674(95)90105-1	http://dx.doi.org/10.1016/0092-8674(95)90105-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585968	Bronze			2022-12-01	WOS:A1995TF24800018
J	GALLAY, P; SWINGLER, S; SONG, JP; BUSHMAN, F; TRONO, D				GALLAY, P; SWINGLER, S; SONG, JP; BUSHMAN, F; TRONO, D			HIV NUCLEAR IMPORT IS GOVERNED BY THE PHOSPHOTYROSINE-MEDIATED BINDING OF MATRIX TO THE CORE DOMAIN OF INTEGRASE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA-MEMBRANE; CELL-CYCLE; PROTEIN; INFECTION; DNA; REGION; RNA	The karyophilic properties of the viral matrix (MA) protein govern HIV nuclear import in nondividing cells such as macrophages. A critical regulator of this process is the C-terminal tyrosine phosphorylation of MA during virus maturation. Here, we reveal the mechanism of this phenomenon, by demonstrating that tyrosine phosphorylation induces the binding of MA to integrase (IN). This leads to the incorporation of MA molecules into virus cores, and subsequently into uncoated viral nucleoprotein complexes. A direct interaction between tyrosine-phosphorylated MA and the central domain of IN can be demonstrated in vitro. It is blocked by phosphotyrosine, indicating that IN recognizes the phosphorylated C-terminal residue of MA. These results explain how the karyophilic potential of MA is conferred to the HIV nucleoprotein complex.			GALLAY, P (corresponding author), SALK INST BIOL STUDIES,INFECT DIS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NIAID NIH HHS [AI34786, AI37510] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034786, R01AI037510] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; HUMPHRIES EH, 1974, J VIROL, V14, P531, DOI 10.1128/JVI.14.3.531-546.1974; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MYERS G, 1992, HUMAN RETROVIRUSES A; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SHAROVA N, 1991, AIDS RES HUM RETROV, V7, P303, DOI 10.1089/aid.1991.7.303; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	33	319	323	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					569	576		10.1016/0092-8674(95)90097-7	http://dx.doi.org/10.1016/0092-8674(95)90097-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585960	Bronze			2022-12-01	WOS:A1995TF24800010
J	GRIFFITH, TS; BRUNNER, T; FLETCHER, SM; GREEN, DR; FERGUSON, TA				GRIFFITH, TS; BRUNNER, T; FLETCHER, SM; GREEN, DR; FERGUSON, TA			FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE	SCIENCE			English	Article							CELL-DEATH	The eye is a privileged site that cannot tolerate destructive inflammatory responses. inflammatory cells entering the anterior chamber of the eye in response to viral infection underwent apoptosis that was dependent on Fas (CD95)-Fas ligand (FasL) and produced no tissue damage. In contrast, viral infection in gld mice, which lack functional Fast, resulted in an inflammation and invasion of ocular tissue without apoptosis. Fas-positive but not Fas-negative tumor cells were killed by apoptosis when placed within isolated anterior segments of the eyes of normal but not Fast-negative mice. Fast messenger RNA and protein were detectable in the eye. Thus, Fas-FasL interactions appear to be:an important mechanism for the maintenance of immune privilege.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92037	Washington University (WUSTL); Washington University (WUSTL); La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NEI NIH HHS [EY06765, EY02687] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATHERTON SS, 1987, INVEST OPHTH VIS SCI, V28, P859; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASPI RR, 1986, J IMMUNOL, V136, P928; FERGUSON TA, 1995, J IMMUNOL, V155, P1746; GAO EK, UNPUB; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENE HSN, 1949, CANCER RES, V9, P728; GRIFFITH TS, UNPUB; HOOPER P, 1991, CURR EYE RES, V10, P363, DOI 10.3109/02713689108996342; IWAI K, 1994, BLOOD, V4, P1201; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; MOGIL RJ, 1995, INT IMMUNOL, V7, P1451, DOI 10.1093/intimm/7.9.1451; NIEDERKORN JY, 1983, J IMMUNOL, V131, P2587; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPANGRUDE GJ, 1994, CURRENT PROTOCOLS IM, V1; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; van Dooremaal J. C., 1873, A VONGRAEFES ARCH OP, V19, P359; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125	26	1735	1810	1	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1189	1192		10.1126/science.270.5239.1189	http://dx.doi.org/10.1126/science.270.5239.1189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502042	Green Submitted			2022-12-01	WOS:A1995TE90500053
J	HEALE, SM; PETES, TD				HEALE, SM; PETES, TD			THE STABILIZATION OF REPETITIVE TRACTS OF DNA BY VARIANT REPEATS REQUIRES A FUNCTIONAL DNA MISMATCH REPAIR SYSTEM	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CAG REPEAT; YEAST; INSTABILITY; GENE; SEQUENCE; MUTANTS; RECOMBINATION; MUTATIONS	Simple repetitive tracts of DNA are unstable in all organisms thus far examined. In the yeast S. cerevisiae, we show that a 51 bp poly(GT) tract alters length at a rate of about 10(-5) per cell division. Insertion of a single variant repeat (either AT or CT) into the middle of the poly(GT) tract results in 100-fold stabilization. This stabilization requires the DNA mismatch repair system. Alterations within tracts with variant repeats occur more frequently on one side of the interruption than on the other. The stabilizing effects of variant repeats and polarity of repeat alterations have also been observed in trinucleotide repeats associated with certain human diseases.			HEALE, SM (corresponding author), UNIV N CAROLINA,DEPT BIOL,CB 3280,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM50892] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1987, GENETICS, V117, P5; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BICHARA M, 1992, GENETICS, V140, P897; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DETLOFF P, 1992, MOL CELL BIOL, V12, P1805, DOI 10.1128/MCB.12.4.1805; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FARBER RA, 1994, HUM MOL GENET, V3, P253, DOI 10.1093/hmg/3.2.253; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GACY AM, 1995, CELL, V81, P533; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; Sambrook J., 1989, MOL CLONING LAB MANU; SELVA EM, 1995, GENETICS, V139, P1175; Sherman F., 1983, METHODS YEAST GENETI; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAND MK, 1995, IN PRESS P NATL ACAD; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5345; WILLIAMSON MS, 1985, GENETICS, V110, P609; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	47	59	74	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					539	545		10.1016/0092-8674(95)90093-4	http://dx.doi.org/10.1016/0092-8674(95)90093-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585956	Bronze, Green Submitted			2022-12-01	WOS:A1995TF24800006
J	HERMISTON, ML; GORDON, JI				HERMISTON, ML; GORDON, JI			INFLAMMATORY BOWEL-DISEASE AND ADENOMAS IN MICE EXPRESSING A DOMINANT-NEGATIVE N-CADHERIN	SCIENCE			English	Article							TRANSGENIC MICE; CELL LINEAGE; APC GENE; DIFFERENTIATION; ASSOCIATION; MUTATION; PROTEIN	Cadherins mediate cell adhesion and are essential for normal development. Embryonic stem cells were transfected with a dominant negative N-cadherin mutant (NCAD Delta) under the control of promoters active in small intestinal epithelial cells and then introduced into C57BL/6 mouse blastocysts. Analysis of adult chimeric mice revealed that expression of NCAD Delta along the entire crypt-villus axis, but not in the villus epithelium alone, produced an inflammatory bowel disease resembling Crohn's disease. NCAD Delta perturbed proliferation, migration, and death programs in crypts, which lead to adenomas. This model provides insights about cadherin function in an adult organ and the factors underlying inflammatory bowel disease and intestinal neoplasia.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIDDK NIH HHS [DK39760, DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNEN DJ, 1994, J PATHOL, V173, P317, DOI 10.1002/path.1711730406; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, UNPUB; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KEMIER R, 1993, TRENDS GENET, V9, P317; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEVIN B, 1995, INFLAMM BOWEL DIS, P461; LEVINE E, 1994, DEVELOPMENT, V120, P901; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; RIDDELL RH, 1995, INFLAMM BOWEL DIS, P517; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0	32	561	578	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	1995	270	5239					1203	1207		10.1126/science.270.5239.1203	http://dx.doi.org/10.1126/science.270.5239.1203			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502046				2022-12-01	WOS:A1995TE90500058
J	HOHFELD, J; MINAMI, Y; HARTL, FU				HOHFELD, J; MINAMI, Y; HARTL, FU			HIP, A NOVEL COCHAPERONE INVOLVED IN THE EUKARYOTIC HSC70/HSP40 REACTION CYCLE	CELL			English	Article							HEAT-SHOCK PROTEINS; BINDING-SPECIFICITY; ATPASE; CLONING; HSP90; HSP70; DNAK; IDENTIFICATION; EXPRESSION; FRAGMENT	The Hsc70-interacting protein Hip, a tetratricopeptide repeat protein, participates in the regulation of the eukaryotic 70 kDa heat shock cognate Hsc70. One Hip oligomer binds the ATPase domains of at least two Hsc70 molecules dependent on activation of the Hsc70 ATPase by Hsp40. While hydrolysis remains the rate-limiting step in the ATPase cycle, Hip stabilizes the ADP state of Hsc70 that has a high affinity for substrate protein. Through its own chaperone activity, Hip may contribute to the interaction of Hsc70 with various target proteins. We propose a mechanism for the regulation of eukaryotic Hsc70 that is distinct from that of bacterial Hsp70. The Hsc70/Hsp40/Hip system is apparently independent of a GrpE-like nucleotide exchange factor.	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019		NIGMS NIH HHS [GM 48742] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048742] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHAPPEL TG, 1987, J BIOL CHEM, V252, P746; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HARLOW W, 1988, ANTIBODIES LABORATOR; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIN B, 1990, GENES, V4, P120; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9407; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; UPARANUKRAW P, 1993, MOL BIOCHEM PARASIT, V33, P101; WANG TF, 1993, J BIOL CHEM, V268, P26049; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; [No title captured]	46	352	365	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 17	1995	83	4					589	598						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585962				2022-12-01	WOS:A1995TF24800012
J	HORN, D; CROSS, GAM				HORN, D; CROSS, GAM			A DEVELOPMENTALLY-REGULATED POSITION EFFECT AT A TELOMERIC LOCUS IN TRYPANOSOMA-BRUCEI	CELL			English	Article							GENE-EXPRESSION SITE; BLOOD-STREAM FORMS; TRANSCRIPTION UNIT; ANTIGENIC VARIATION; REPETITIVE PROTEIN; II TRANSCRIPTION; SURFACE-ANTIGEN; VSG GENE; PROMOTER; DNA	Trypanosoma brucei undergoes antigenic variation in the mammalian host. This can be achieved by activation and inactivation of telomeric variant-specific surface glycoprotein genes (vsg). In procyclic (insect midgut stage) cells, Vsg is not expressed. The mechanisms that regulate transcription of vsg expression sites (ESs) are unknown. Here we demonstrate that transcription from three different promoters was repressed when they were inserted at a transcriptionally silent telomere-proximal locus in bloodstream-form cells. This position effect was stable and heritable. Only transcription from an ES promoter was repressed in procyclic cells. The observed position effect and the promoter-specific developmental regulation suggest that these phenomena reflect the mechanisms that regulate vsg expression.			HORN, D (corresponding author), ROCKEFELLER UNIV,MOLEC PARASITOL LAB,NEW YORK,NY 10021, USA.		Cross, George A M/B-7444-2011	Cross, George A M/0000-0003-1374-6955; Horn, David/0000-0001-5173-9284	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021729, R01AI021729] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21729] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; BORST P, 1993, COLD SPRING HARB SYM, V58, P105, DOI 10.1101/SQB.1993.058.01.014; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DROCOURT D, 1990, NUCLEIC ACIDS RES, V18, P4009, DOI 10.1093/nar/18.13.4009; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAJDUK SL, 1981, PARASITOLOGY, V83, P609, DOI 10.1017/S0031182000080574; HARTREE D, 1995, MOL BIOCHEM PARASIT, V71, P27, DOI 10.1016/0166-6851(95)00034-X; HEHL A, 1994, PARASITOL TODAY, V10, P442, DOI 10.1016/0169-4758(94)90180-5; HIRUMI H, 1994, PARASITOL TODAY, V10, P80, DOI 10.1016/0169-4758(94)90402-2; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JEFFERIES D, 1993, NUCLEIC ACIDS RES, V21, P191, DOI 10.1093/nar/21.2.191; JOHNSON JG, 1979, BIOCHEM J, V178, P689, DOI 10.1042/bj1780689; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEE MGS, 1995, MOL BIOCHEM PARASIT, V69, P223, DOI 10.1016/0166-6851(94)00186-Q; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; PATNAIK PK, 1993, EMBO J, V12, P2529, DOI 10.1002/j.1460-2075.1993.tb05908.x; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLIMME W, 1993, PARASITOLOGY, V107, P237, DOI 10.1017/S003118200007921X; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; URMENYI TP, 1995, NUCLEIC ACIDS RES, V23, P1010, DOI 10.1093/nar/23.6.1010; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VIJAYASARATHY S, 1990, NUCLEIC ACIDS RES, V18, P2967, DOI 10.1093/nar/18.10.2967; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1993, MOL BIOCHEM PARASIT, V57, P295, DOI 10.1016/0166-6851(93)90205-C; ZOMERDIJK JCBM, 1992, NUCLEIC ACIDS RES, V20, P2725, DOI 10.1093/nar/20.11.2725; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	43	123	123	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					555	561		10.1016/0092-8674(95)90095-0	http://dx.doi.org/10.1016/0092-8674(95)90095-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585958	Bronze			2022-12-01	WOS:A1995TF24800008
J	INAGAKI, N; GONOI, T; CLEMENT, JP; NAMBA, N; INAZAWA, J; GONZALEZ, G; AGUILARBRYAN, L; SEINO, S; BRYAN, J				INAGAKI, N; GONOI, T; CLEMENT, JP; NAMBA, N; INAZAWA, J; GONZALEZ, G; AGUILARBRYAN, L; SEINO, S; BRYAN, J			RECONSTITUTION OF I-KATP - AN INWARD RECTIFIER SUBUNIT PLUS THE SULFONYLUREA RECEPTOR	SCIENCE			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC BETA-CELLS; REGULATED POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; INTRACELLULAR ATP; B-CELLS; DIAZOXIDE; CLONING	A member of the inwardly rectifying potassium channel family was cloned here. The channel, called BIR (Kir6.2), was expressed in large amounts in rat pancreatic islets and glucose-responsive insulin-secreting cell lines. Coexpression with the sulfonylurea receptor SUR reconstituted an inwardly rectifying potassium conductance of 76 picosiemens that was sensitive to adenosine triphosphate (ATP) (I-KATP) and was inhibited by sulfonylureas and activated by diazoxide. The data indicate that these pancreatic beta cell potassium channels are a complex composed of at least two subunits-BIR, a member of the inward rectifier potassium channel family, and SUR, a member of the ATP-binding cassette superfamily. Gene mapping data show that these two potassium channel subunit genes are clustered on human chromosome 11 at position 11p15.1.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC MED,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR,CHUO KU,CHIBA 260,JAPAN; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN	Chiba University; Chiba University; Baylor College of Medicine; Baylor College of Medicine; Kyoto Prefectural University of Medicine			, gonoi/GRS-0648-2022; gonoi, tohru/AAC-5181-2021	, gonoi/0000-0003-3655-7911; gonoi, tohru/0000-0003-3655-7911; Inagaki, Nobuya/0000-0001-8261-2593	NIDDK NIH HHS [DK44311] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FINDLAY I, 1985, J MEMBRANE BIOL, V88, P165, DOI 10.1007/BF01868430; GONOI T, UNPUB; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; INAGAKI N, UNPUB; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KERR ID, 1995, NATURE, V372, P112; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; NAMBA N, UNPUB; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; RORSMAN P, 1985, PFLUG ARCH EUR J PHY, V405, P305, DOI 10.1007/BF00595682; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STURGESS NC, 1988, BRIT J PHARMACOL, V95, P83, DOI 10.1111/j.1476-5381.1988.tb16551.x; SUTCLIFFE MJ, 1994, NATURE, V369, P616, DOI 10.1038/369616b0; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSUURA Y, 1992, DIABETES, V42, P861; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WIBRAND F, 1992, P NATL ACAD SCI USA, V89, P5133, DOI 10.1073/pnas.89.11.5133; YAMASHITA H, 1992, ANAL SCI, V8, P251, DOI 10.2116/analsci.8.251	35	1491	1551	1	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1166	1170		10.1126/science.270.5239.1166	http://dx.doi.org/10.1126/science.270.5239.1166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502040				2022-12-01	WOS:A1995TE90500046
J	KINOSHITA, N; MINSHULL, J; KIRSCHNER, MW				KINOSHITA, N; MINSHULL, J; KIRSCHNER, MW			THE IDENTIFICATION OF 2 NOVEL LIGANDS OF THE FGF RECEPTOR BY A YEAST SCREENING METHOD AND THEIR ACTIVITY IN XENOPUS DEVELOPMENT	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; PANCREATIC RIBONUCLEASE; MIDBLASTULA TRANSITION; MESODERM INDUCTION; BINDING-PROTEIN; FACTOR-II; GENE; EXPRESSION	We have developed a functional screen in yeast to identify ligands for receptor tyrosine kinases, Using this method, we cloned two Xenopus genes that activate the fibroblast growth factor (FGF) receptor. These encode novel secreted proteins, designated FRL1 and FRL2, distantly related to the epidermal growth factor and angiogenin/ribonuclease families, respectively. Both genes activate the FGF receptor in Xenopus oocytes as well as in yeast. Overexpression induces mesoderm and neural-specific genes in Xenopus explants; induction Is blocked by a dominant negative inhibitor of the FGF receptor. FRL1 is broadly expressed during gastrulation and neurulation, while FRL2 is expressed principally in the axial mesoderm and brain at later stages. Our results indicate that despite their lack of similarity with FGF, FRL1 and FRL2 are ligands for the FGF receptor that play distinct roles in development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KINOSHITA, N (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Kinoshita, Noriyuki/0000-0002-1362-4045				AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BOND MD, 1993, BIOCHIM BIOPHYS ACTA, V1162, P177, DOI 10.1016/0167-4838(93)90145-H; BOND MD, 1990, BIOCHEM BIOPH RES CO, V171, P988, DOI 10.1016/0006-291X(90)90781-H; BRANDLI AW, 1995, DEV DYNAM, V203, P119; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DONO R, 1993, DEVELOPMENT, V118, P1157; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GALLWITZ D, 1981, NUCLEIC ACIDS RES, V9, P6339, DOI 10.1093/nar/9.23.6339; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HOPP TP, 1986, BIOTECHNOLOGY, V6, P1205; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABONNE C, 1994, DEVELOPMENT, V120, P463; LUSTIG KD, 1995, P NATL ACAD SCI USA, V92, P6234, DOI 10.1073/pnas.92.14.6234; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYONS S, 1984, P NATL ACAD SCI-BIOL, V81, P7426, DOI 10.1073/pnas.81.23.7426; MAES P, 1988, FEBS LETT, V241, P41, DOI 10.1016/0014-5793(88)81027-5; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; RECHLER MM, 1980, ENDOCRINOLOGY, V107, P1451, DOI 10.1210/endo-107-5-1451; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHULLER C, 1990, MOL BIOL EVOL, V7, P29; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMYTH DG, 1963, J BIOL CHEM, V238, P227; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WESTERMARK B, 1991, CANCER RES, V51, P2087; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	56	131	133	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					621	630		10.1016/0092-8674(95)90102-7	http://dx.doi.org/10.1016/0092-8674(95)90102-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585965	Bronze			2022-12-01	WOS:A1995TF24800015
J	LEEUW, T; FOURESTLIEUVIN, A; WU, CL; CHENEVERT, J; CLARK, K; WHITEWAY, M; THOMAS, DY; LEBERER, E				LEEUW, T; FOURESTLIEUVIN, A; WU, CL; CHENEVERT, J; CLARK, K; WHITEWAY, M; THOMAS, DY; LEBERER, E			PHEROMONE RESPONSE IN YEAST - ASSOCIATION OF BEM1P WITH PROTEINS OF THE MAP KINASE CASCADE AND ACTIN	SCIENCE			English	Article							BUD SITE SELECTION; SACCHAROMYCES-CEREVISIAE; CELLULAR MORPHOGENESIS; GENE BEM1; GROWTH; POLARITY; DICTYOSTELIUM; POLARIZATION; INTERACTS; IDENTIFY	Haploid cells of the yeast Saccharomyces cerevisiae respond to mating pheromones with polarized growth toward the mating partner. This morphological response requires the function of the cell polarity establishment protein Bem1p. Immunochemical and two-hybrid protein interaction assays revealed that Bem1p interacts with two components of the pheromone-responsive mitogen-activated protein (MAP) kinase cascade, Ste20p and Ste5p, as well as with actin. Mutants of Bem1p that are associated with defective pheromone-induced polarized morphogenesis interacted with Ste5p and actin but not with Ste20p. Thus, the association of Bem1p with Ste20p and Ste5p may contribute to the conveyance of spatial information that regulates polarized rearrangement of the actin cytoskeleton during yeast mating.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL,PQ H4P 2R2,CANADA; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	National Research Council Canada; University of California System; University of California San Francisco			Fourest-Lieuvin, Anne/AGA-6504-2022; Thomas, David/M-7661-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; Thomas, David/0000-0002-8854-762X				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cellbio.4.1.43; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHENEVERT J, 1994, GENETICS, V136, P1287; CHENEVERT J, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEBERER E, UNPUB; LEEUW T, UNPUB; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROSE MD, 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	52	178	178	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1210	1213		10.1126/science.270.5239.1210	http://dx.doi.org/10.1126/science.270.5239.1210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502048				2022-12-01	WOS:A1995TE90500060
J	LIN, RL; THOMPSON, S; PRIESS, JR				LIN, RL; THOMPSON, S; PRIESS, JR			POP-1 ENCODES AN HMG BOX PROTEIN REQUIRED FOR THE SPECIFICATION OF A MESODERM PRECURSOR IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							SEX-DETERMINING REGION; DNA-BINDING MOTIF; CAENORHABDITIS-ELEGANS; CELLULAR INTERACTIONS; TRANSCRIPTION FACTOR; ALPHA-ENHANCER; MESSENGER-RNA; GENE; GUT; EXPRESSION	In C. elegans embryogenesis, the MS blastomere produces predominantly mesodermal cell types, while its sister E generates only endodermal tissue. We show that a maternal gene, pop-1, is essential for the specification of MS fate and that a mutation in pop-1 results in MS adopting an E fate. Previous studies have shown that the maternal gene skn-1 is required for both MS and E development and that skn-1 encodes a transcription factor. We show here that the pop-1 gene encodes a protein with an HMG box similar to the HMG boxes in the vertebrate lymphoid-specific transcriptional regulators TCF-1 and LEF-1. We propose that POP-1 and SKN-1 function together in the early embryo to allow MS-specific differentiation.			LIN, RL (corresponding author), HOWARD HUGHES MED INST,FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98109, USA.							AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GRANATO M, 1994, DEVELOPMENT, V120, P3005; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HO IC, 1990, MOL CELL BIOL, V10, P4720, DOI 10.1128/MCB.10.9.4720; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JUNKERSDORF B, 1992, ROUX ARCH DEV BIOL, V202, P17, DOI 10.1007/BF00364593; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROBINSON PA, 1988, J IMMUNOL METHODS, V108, P115, DOI 10.1016/0022-1759(88)90409-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL H, 1990, SCIENCE, V250, P686, DOI 10.1126/science.250.4981.686; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1; XIE W, 1991, BIOTECHNIQUES, V11, P325; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	51	255	261	1	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					599	609		10.1016/0092-8674(95)90100-0	http://dx.doi.org/10.1016/0092-8674(95)90100-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585963	Bronze			2022-12-01	WOS:A1995TF24800013
J	MEISTER, M; LAGNADO, L; BAYLOR, DA				MEISTER, M; LAGNADO, L; BAYLOR, DA			CONCERTED SIGNALING BY RETINAL GANGLION-CELLS	SCIENCE			English	Article							ROD OUTER SEGMENTS; TIGER SALAMANDER; X-CELL; Y-CELL; GOLDFISH; NEURONS; NOISE; INPUTS	To analyze the rules that govern communication between eye and brain, visual responses were recorded from an intact salamander retina. Parallel observation of many retinal ganglion cells with a microelectrode array showed that nearby neurons often fired synchronously, with spike delays of less than 10 milliseconds. The frequency of such synchronous spikes exceeded the correlation expected from a shared visual stimulus up to 20-fold. Synchronous firing persisted under a variety of visual stimuli and accounted for the majority of action potentials recorded. Analysis of receptive fields showed that concerted spikes encoded information not carried by individual cells; they may represent symbols in a multineuronal code for vision.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University	MEISTER, M (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.			Meister, Markus/0000-0003-2136-6506	NATIONAL EYE INSTITUTE [R01EY010020, R37EY001543, R01EY001543] Funding Source: NIH RePORTER; NEI NIH HHS [EY10020, EY01543, EY05750] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHO AC, 1988, NATURE, V334, P348, DOI 10.1038/334348a0; ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812; ARNETT DW, 1978, EXP BRAIN RES, V32, P49; Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI 10.3109/0954898X.2011.638888; Barlow H B, 1971, Vision Res, VSuppl 3, P87; Barlow H.B., 1961, SENSORY COMMUNICATIO; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BUCHSBAUM G, 1983, PROC R SOC SER B-BIO, V220, P89, DOI 10.1098/rspb.1983.0090; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; GHOSE GM, 1994, J NEUROPHYSIOL, V71, P330, DOI 10.1152/jn.1994.71.1.330; GINSBURG KS, 1984, J PHYSIOL-LONDON, V351, P433, DOI 10.1113/jphysiol.1984.sp015254; GLICKMAN RD, 1982, BRAIN RES, V234, P81, DOI 10.1016/0006-8993(82)90474-7; GUILOFF GD, 1992, VISION RES, V32, P2023, DOI 10.1016/0042-6989(92)90063-O; JOHNSEN JA, 1983, J PHYSIOL-LONDON, V345, P439, DOI 10.1113/jphysiol.1983.sp014987; MAPLE BR, 1994, VISION RES, V34, P2357, DOI 10.1016/0042-6989(94)90281-X; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P121, DOI 10.1098/rspb.1984.0086; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P303, DOI 10.1152/jn.1983.49.2.303; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P325, DOI 10.1152/jn.1983.49.2.325; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P350, DOI 10.1152/jn.1983.49.2.350; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MEISTER M, IN PRESS P NATL ACAD; MILLAR T, 1985, NEUROSCI LETT, V61, P311, DOI 10.1016/0304-3940(85)90482-3; MOORE GP, 1970, BIOPHYS J, V10, P876, DOI 10.1016/S0006-3495(70)86341-X; SAKAI HM, 1990, J NEUROPHYSIOL, V63, P105, DOI 10.1152/jn.1990.63.1.105; SCHNITZER MJ, UNPUB; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WERBLIN F, 1988, VISUAL NEUROSCI, V1, P317, DOI 10.1017/S0952523800001978; WUNK DF, 1979, J GEN PHYSIOL, V73, P265, DOI 10.1085/jgp.73.3.265	29	286	292	1	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1207	1210		10.1126/science.270.5239.1207	http://dx.doi.org/10.1126/science.270.5239.1207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502047				2022-12-01	WOS:A1995TE90500059
J	MORISHITA, T; MITSUZAWA, H; NAKAFUKU, M; NAKAMURA, S; HATTORI, S; ANRAKU, Y				MORISHITA, T; MITSUZAWA, H; NAKAFUKU, M; NAKAMURA, S; HATTORI, S; ANRAKU, Y			REQUIREMENT OF SACCHAROMYCES-CEREVISIAE RAS FOR COMPLETION OF MITOSIS	SCIENCE			English	Article							PROTEIN-KINASE; ADENYLATE-CYCLASE; SHUTTLE VECTORS; YEAST; GENE; INTERACTS; ENCODES; RSR1	In the yeast Saccharomyces cerevisiae, Ras regulates adenylate cyclase, which is essential for progression through the G(1) phase of the cell cycle. However, even when the adenosine 3',5'-monophosph (cAMP) pathway was bypassed, the double disruption of RAS1 and RAS2 resulted in defects in growth at both low and high temperatures. Furthermore, the simultaneous disruption of RAS1, RAS2, and the RAS-related gene RSR1 was lethal at any temperature. The triple-disrupted cells were arrested late in the mitotic (M) phase, which was accompanied by an accumulation of cells with divided chromosomes and sustained histone H1 kinase activity. The lethality of the triple disruption was suppressed by the multicopies of CDC5, CDC15, DBF2, SPO12, and TEM1, all of which function in the completion of the M phase. Mammalian ras also suppressed the lethality, which suggests that a similar signaling pathway exists in higher eukaryotes. These results demonstrate that S. cerevisiae Ras functions in the completion of the M phase in a manner independent of the Ras-cAMP pathway.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo			Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; MORISHITA T, UNPUB; POWERS S, 1991, CELL, V65, P1231; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TODA T, 1987, ONCOGENES CANCER, P253; TOYN JH, 1993, GENETICS, V135, P963; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074	31	57	58	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1213	1215		10.1126/science.270.5239.1213	http://dx.doi.org/10.1126/science.270.5239.1213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502049				2022-12-01	WOS:A1995TE90500061
J	PUGLISI, JD; CHEN, L; BLANCHARD, S; FRANKEL, AD				PUGLISI, JD; CHEN, L; BLANCHARD, S; FRANKEL, AD			SOLUTION STRUCTURE OF A BOVINE IMMUNODEFICIENCY VIRUS TAT-TAR PEPTIDE-RNA COMPLEX	SCIENCE			English	Article							LONG TERMINAL REPEAT; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; MINOR-GROOVE; RECOGNITION; SYNTHETASE; DNA; CONFORMATION; SPECIFICITY; RESOLUTION	The Tat protein of bovine immunodeficiency virus (BIV) binds to its target RNA, TAR, and activates transcription. A 14-amino acid arginine-rich peptide corresponding to the RNA-binding domain of BIV Tat binds specifically to BIV TAR, and biochemical and in vivo experiments have identified the amino acids and nucleotides required for binding, The solution structure of the RNA-peptide complex has now been determined by nuclear magnetic resonance spectroscopy. TAR forms a virtually continuous A-form helix with two unstacked bulged nucleotides. The peptide adopts a beta-turn conformation and sits in the major groove of the RNA. Specific contacts are apparent between critical amino acids in the peptide and bases and phosphates in the RNA. The structure is consistent with ail biochemical data and demonstrates ways in which proteins can recognize the major groove of RNA.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	PUGLISI, JD (corresponding author), UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064, USA.		Blanchard, Scott C./A-5804-2009	Blanchard, Scott C./0000-0003-2717-9365	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135, F32AI008591] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08591, AI29135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CARPENTER S, 1993, J VIROL, V67, P4399, DOI 10.1128/JVI.67.7.4399-4403.1993; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; Creighton TE, 1993, PROTEINS STRUCTURES; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PALLANSCH LA, 1992, J VIROL, V66, P2647, DOI 10.1128/JVI.66.5.2647-2652.1992; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SHUMACHER MA, 1994, SCIENCE, V266, P763; SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9	36	317	328	1	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1200	1203		10.1126/science.270.5239.1200	http://dx.doi.org/10.1126/science.270.5239.1200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502045				2022-12-01	WOS:A1995TE90500057
J	RICE, WG; SUPKO, JG; MALSPEIS, L; BUCKHEIT, RW; CLANTON, D; BU, M; GRAHAM, L; SCHAEFFER, CA; TURPIN, JA; DOMAGALA, J; GOGLIOTTI, R; BADER, JP; HALLIDAY, SM; COREN, L; SOWDER, RC; ARTHUR, LO; HENDERSON, LE				RICE, WG; SUPKO, JG; MALSPEIS, L; BUCKHEIT, RW; CLANTON, D; BU, M; GRAHAM, L; SCHAEFFER, CA; TURPIN, JA; DOMAGALA, J; GOGLIOTTI, R; BADER, JP; HALLIDAY, SM; COREN, L; SOWDER, RC; ARTHUR, LO; HENDERSON, LE			INHIBITORS OF HIV NUCLEOCAPSID PROTEIN ZINC FINGERS AS CANDIDATES FOR THE TREATMENT OF AIDS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; TYPE-1; RETROVIRUSES; INFECTIVITY; SEQUENCES; CLONE; RNA	Strategies for the treatment of human immunodeficiency virus-type 1 (HIV-1) infection must contend with the obstacle of drug resistance. HIV-1 nucleocapsid protein zinc fingers are prime antiviral targets because they are mutationally into lerant and are required both for acute infection and virion assembly. Nontoxic disulfide-substituted benzamides were identified that attack the zinc fingers, inactivate cell-free virions, inhibit acute and chronic infections, and exhibit broad antiretroviral activity. The compounds were highly synergistic with other antiviral agents, and resistant mutants have not been detected. Zinc finger-reactive compounds may offer an anti-HIV strategy that restricts drug-resistance development.	NCI,DIV CANC TREATMENT,PHARMACEUT CHEM LAB,DEV THERAPEUT PROGRAM,FREDERICK,MD 21701; SO RES INST FREDERICK RES CTR,VIROL RES GRP,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,ANTI AIDS VIRUS DRUG SCREENING LAB,FREDERICK,MD 21702; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CHEM,ANN ARBOR,MI 48105; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,ANTIVIRAL EVALUAT BRANCH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	RICE, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702, USA.							ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BUCKHEIT RW, 1995, ANTIVIR RES, V26, P117, DOI 10.1016/0166-3542(94)00069-K; BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2; BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10124; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CUSHMAN M, 1994, J MED CHEM, V37, P3040, DOI 10.1021/jm00045a008; FOLKS TM, 1988, J IMMUNOL, V140, P1117; GIBALDI M, 1982, PHARMACOKINETICS, P410; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; KAGEYAMA S, 1994, ANTIMICROB AGENTS CH, V38, P1107, DOI 10.1128/AAC.38.5.1107; Mellors J. W., 1995, International Antiviral News, V3, P8; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Rice W. G., 1995, International Antiviral News, V3, P87; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RICE WG, 1995, ANTIVIR RES, V26, pA235; RICE WG, UNPUB; South T L, 1990, Adv Inorg Biochem, V8, P199; SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P; STAAL FTJ, 1993, AIDS RES HUM RETROV, V9, P4299; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577	30	234	280	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1194	1197		10.1126/science.270.5239.1194	http://dx.doi.org/10.1126/science.270.5239.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502043				2022-12-01	WOS:A1995TE90500055
J	RIDDLE, RD; ENSINI, M; NELSON, C; TSUCHIDA, T; JESSELL, TM; TABIN, C				RIDDLE, RD; ENSINI, M; NELSON, C; TSUCHIDA, T; JESSELL, TM; TABIN, C			INDUCTION OF THE LIM HOMEOBOX GENE LMX1 BY WNT7A ESTABLISHES DORSOVENTRAL PATTERN IN THE VERTEBRATE LIMB	CELL			English	Article							ECTODERMAL CONTROL; WINGLESS PROTEIN; IMAGINAL DISKS; INSULIN GENE; CHICK-EMBRYO; DROSOPHILA; EXPRESSION; BUD; DIFFERENTIATION; HOMEODOMAIN	During vertebrate limb development, the ectoderm directs the dorsoventral patterning of the underlying mesoderm. To define the molecular events involved in this process, we have analyzed the function of WNT7a, a secreted factor expressed in the dorsal ectoderm, and LMX1, a LIM homeodomain transcription factor expressed in the dorsal mesenchyme. Ectopic expression of Wnt7a is sufficient to induce and maintain Lmx1 expression in limb mesenchyme, both in vivo and in vitro. Ectopic expression of Lmx1 in the ventral mesenchyme is sufficient to generate double-dorsal limbs. Thus, the dorsalization of limb mesoderm appears to involve the WNT7a-mediated induction of Lmx1 in limb mesenchymal cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	RIDDLE, RD (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; CHUONG CM, 1993, BIOESSAYS, V15, P513, DOI 10.1002/bies.950150804; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DENT JA, 1989, DEVELOPMENT, V105, P61; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GAVIN BJ, 1991, GENE DEV, V4, P2319; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUMASON GL, 1972, ANIMAL TISSUE TECHNI, P173; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSE R, 1992, CELL, V75, P1073; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PAUTOU MP, 1977, J EMBRYOL EXP MORPH, V42, P177; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SAUNDERS J. W., 1968, EPITHELIAL MESENCHYM, P78; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0	49	386	397	1	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					631	640		10.1016/0092-8674(95)90103-5	http://dx.doi.org/10.1016/0092-8674(95)90103-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585966	Bronze			2022-12-01	WOS:A1995TF24800016
J	ROMAO, MJ; ARCHER, M; MOURA, I; MOURA, JJG; LEGALL, J; ENGH, R; SCHNEIDER, M; HOF, P; HUBER, R				ROMAO, MJ; ARCHER, M; MOURA, I; MOURA, JJG; LEGALL, J; ENGH, R; SCHNEIDER, M; HOF, P; HUBER, R			CRYSTAL-STRUCTURE OF THE XANTHINE OXIDASE-RELATED ALDEHYDE OXIDOREDUCTASE FROM D-GIGAS	SCIENCE			English	Article							DESULFOVIBRIO-GIGAS; ELECTRON-TRANSFER; MOLYBDENUM COFACTOR; PULSE-RADIOLYSIS; DEHYDROGENASE; PROTEIN; MECHANISM; OXIDOREDUCTASE; EXAFS; CRYSTALLIZATION	The crystal structure of the aldehyde oxido-reductase (Mop) from the sulfate reducing anaerobic Gram-negative bacterium Desulfovibrio gigas has been determined at 2.25 Angstrom resolution by multiple isomorphous replacement and refined. The protein, a homodimer of 907 amino acid residues subunits, is a member of the xanthine oxidase family. The protein contains a molybdopterin cofactor (Mo-co) and two different [2Fe-2S] centers. It is folded into four domains of which the first two bind the iron sulfur centers and the last two are involved in Mo-co binding, Mo-co is a molybdenum molybdopterin cytosine dinucleotide. Molybdopterin forms a tricyclic system with the pterin bicycle annealed to a pyran ring. The molybdopterin dinucleotide is deeply buried in the protein, The cis-dithiolene group of the pyran ring binds the molybdenum, which is coordinated by three more (oxygen) ligands.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; INST TECNOL QUIM & BIOQUIM, P-2780 OEIRAS, PORTUGAL; DEPT QUIM, P-1096 LISBON, PORTUGAL; UNIV NOVA LISBOA, DEPT QUIM, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV NOVA LISBOA, FAC CIENCIAS & TECNOL, CQFB, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	Max Planck Society; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University System of Georgia; University of Georgia			Romao, Maria J/A-4115-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017; Moura, José J G/D-6426-2013; Moura, Isabel/D-6339-2013	Romao, Maria J/0000-0002-3004-0543; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Moura, José J G/0000-0002-4726-2388; Moura, Isabel/0000-0003-0971-4977; Engh, Richard/0000-0002-6207-0560; Archer, Margarida/0000-0001-8419-5420				BARATA BAS, 1992, EUR J BIOCHEM, V204, P773, DOI 10.1111/j.1432-1033.1992.tb16693.x; BARATA BAS, 1993, BIOCHEMISTRY-US, V32, P11559, DOI 10.1021/bi00094a012; Bray R. C., 1980, BIOL MAGN RESON, V2, P45; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; CALDEIRA J, 1995, J INORG BIOCHEM, V59, P739; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRAMER SP, 1984, J INORG BIOCHEM, V20, P275, DOI 10.1016/0162-0134(84)85026-6; DUGGAN DE, 1975, J MED CHEM, V18, P900, DOI 10.1021/jm00243a008; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; HABER R, 1994, ACTA CRYSTALLOGR D, V50, P760; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1993, ACS SYM SER, V535, P22; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1982, J BIOL CHEM, V257, P8898; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEITH TP, 1987, GENETICS, V116, P67; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MEYER O, 1993, ACS SYM SER, V535, P50; MOURA JJG, 1978, BIOCHEM J, V173, P419, DOI 10.1042/bj1730419; NISHINO T, 1989, J BIOL CHEM, V264, P5468; OERTLING WA, 1990, J BIOL CHEM, V265, P17446; RAJAGOPALAN KV, 1993, ACS SYM SER, V535, P38; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; ROMAO MJ, 1993, EUR J BIOCHEM, V215, P729, DOI 10.1111/j.1432-1033.1993.tb18085.x; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SPENCE JT, 1982, BIOCHEMISTRY-US, V21, P1656, DOI 10.1021/bi00536a028; Steigemann W., 1974, THESIS TU MUNCHEN GE; STIEFEL EI, 1993, ACS SYM SER, V535, P1; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; Turk D., 1992, THESIS TU MUNCHEN GE; TURNER N, 1987, BIOCHEM J, V243, P755, DOI 10.1042/bj2430755; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; ZHIGUONG X, 1992, J AM CHEM SOC, V114, P9194; 1994, 4 COLL COMP PROJ	49	456	460	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	1995	270	5239					1170	1176						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502041				2022-12-01	WOS:A1995TE90500047
J	RUDENKO, G; BLUNDELL, PA; DIRKSMULDER, A; KIEFT, R; BORST, P				RUDENKO, G; BLUNDELL, PA; DIRKSMULDER, A; KIEFT, R; BORST, P			A RIBOSOMAL DNA PROMOTER REPLACING THE PROMOTER OF A TELOMERIC VSG GENE-EXPRESSION SITE CAN BE EFFICIENTLY SWITCHED ON AND OFF IN TRYPANOSOMA-BRUCEI	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; RNA POLYMERASE-I; PROTOZOAN TRYPANOSOMA-BRUCEI; BLOOD-STREAM-FORM; ANTIGENIC VARIATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION UNITS; INACTIVATION; SEQUENCES; PROTEIN	Trypanosoma brucei survives in the mammalian bloodstream by regularly changing its variant surface glycoprotein (VSG) coat. The active VSG gene is located in a telomeric expression site, and coat switching occurs either by replacing the transcribed VSG gene or by changing the expression site that is active, To determine whether VSG expression site control requires promoter-specific sequences, we replaced the active VSG expression site promoter in bloodstream-form T. brucei with a ribosomal DNA (rDNA) promoter. These transformants were fully infective in laboratory animals, and the rDNA promoter, which is normally constitutively active, was efficiently inactivated and reactivated in the context of the VSG gene expression site. As there is no sequence similarity between the VSG expression site promoter and the rDNA promoter, VSG expression site control does not involve sequences specific to the VSG expression site promoter. We conclude that an epigenetic mechanism, such as telomeric silencing, is involved in VSG expression site control in bloodstream-form T. brucei.			RUDENKO, G (corresponding author), NETHERLANDS CANC INST,DEPT BIOL MOLEC,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BERNARDS A, 1984, CELL, V36, P163, DOI 10.1016/0092-8674(84)90085-0; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTESDIENER K, 1990, MOL CELL BIOL, V10, P6079, DOI 10.1128/MCB.10.11.6079; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LAMONT GS, 1986, PARASITOLOGY, V92, P355, DOI 10.1017/S003118200006412X; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; MICHELS PAM, 1984, EMBO J, V3, P1345, DOI 10.1002/j.1460-2075.1984.tb01975.x; PALLADINO F, 1994, CURR OPIN CELL BIOL, V6, P373, DOI 10.1016/0955-0674(94)90029-9; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PAYS E, 1989, MOL CELL BIOL, V9, P4018, DOI 10.1128/MCB.9.9.4018; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RICEFICHT AC, 1981, NATURE, V294, P53, DOI 10.1038/294053a0; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1991, NEW BIOL, V3, P324; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	41	124	125	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					547	553		10.1016/0092-8674(95)90094-2	http://dx.doi.org/10.1016/0092-8674(95)90094-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585957	Bronze			2022-12-01	WOS:A1995TF24800007
J	SUBRAMANIAN, V; MEYER, BI; GRUSS, P				SUBRAMANIAN, V; MEYER, BI; GRUSS, P			DISRUPTION OF THE MURINE HOMEOBOX GENE CDX1 AFFECTS AXIAL SKELETAL IDENTITIES BY ALTERING THE MESODERMAL EXPRESSION DOMAINS OF HOX GENES	CELL			English	Article							EMBRYONIC STEM-CELLS; CAUDAL GENE; C-ELEGANS; HOMEOTIC TRANSFORMATION; CERVICAL-VERTEBRAE; ECTOPIC EXPRESSION; DROSOPHILA; MOUSE; MICE; GRADIENT	Cdx1 is expressed along the embryonic axis from day 7.5 postcoitum until day 12, by which time the anterior limit of expression has regressed from the hindbrain level to the forelimb bud region. To assign a functional role for Cdx1 in murine embryonic development, we have inactivated the gene via homologous recombination. Viable fertile homozygous mutant mice were obtained that show anterior homeotic transformations of vertebrae. These abnormalities were concomitant with posterior shifts of Hox gene expression domains in the semitic mesoderm. The presence of putative Cdx1-binding sites in Hox gene control regions as well as in vitro transactivation of Hoxa-7 indicates a direct regulation.	UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath	SUBRAMANIAN, V (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT MOLEC CELL BIOL,D-37077 GOTTINGEN,GERMANY.							BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BREIER G, 1986, EMBO J, V5, P2209, DOI 10.1002/j.1460-2075.1986.tb04486.x; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; CONDIE BG, 1993, DEVELOPMENT, V119, P579; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DAWES B, 1930, PHILOS T ROY SOC B, V218, P155; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FLINT OP, 1977, CELL INTERACTIONS DE; FRUMKIN A, 1991, DEVELOPMENT, V112, P207; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cellbio.8.1.227; JAMES R, 1991, J BIOL CHEM, V266, P3246; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; Joyner AL, 1993, GENE TARGETING PRACT; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIENY M, 1972, DEV BIOL, V28, P142, DOI 10.1016/0012-1606(72)90133-9; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEYER BI, 1993, DEVELOPMENT, V117, P191; Miller JH., 1972, EXPT MOL GENETICS; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NORTHROP JL, 1994, DEV BIOL, V161, P490, DOI 10.1006/dbio.1994.1047; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; PUSCHEL AW, 1990, DEVELOPMENT, V106, P435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; SERRANO J, 1993, BIOCHEM BIOPH RES CO, V190, P270, DOI 10.1006/bbrc.1993.1041; SHARPE PT, 1988, DEVELOPMENT, V102, P397; SUH E, 1995, MOL CELL BIOL, V14, P7340; TAM PPL, 1986, SOMITES DEV EMBRYOS, P17; TREMBLAY P, 1995, IN PRESS DEV BIOL; VANDERLUGT N, 1994, THESIS U AMSTERDAM A; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; XU X, 1994, DEVELOPMENT, V120, P277	61	289	295	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					641	653		10.1016/0092-8674(95)90104-3	http://dx.doi.org/10.1016/0092-8674(95)90104-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585967	Bronze			2022-12-01	WOS:A1995TF24800017
J	TSAI, CC; FOLLIS, KE; SABO, A; BECK, TW; GRANT, RF; BISCHOFBERGER, N; BENVENISTE, RE; BLACK, R				TSAI, CC; FOLLIS, KE; SABO, A; BECK, TW; GRANT, RF; BISCHOFBERGER, N; BENVENISTE, RE; BLACK, R			PREVENTION OF SIV INFECTION IN MACAQUES BY (R)-9-(2-PHOSPHONYLMETHOXYPROPYL)ADENINE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ACYCLIC NUCLEOSIDE PHOSPHONATES; RHESUS-MONKEYS; ANTIRETROVIRAL AGENTS; INVITRO; PROPHYLAXIS; RESISTANCE; ZIDOVUDINE; LENTIVIRUS; METABOLISM	The efficacy of pre- and postexposure treatment with the antiviral compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV). PMPA was administered subcutaneously once daily beginning either 48 hours before, 4 hours after, or 24 hours after virus inoculation. Treatment continued for 4 weeks and the virologic, immunologic, and clinical status of the macaques was monitored for up to 56 weeks. PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected. These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.	GILEAD SCI INC,FOSTER CITY,CA 94404; NCI,FREDERICK,MD 21701; NIAID,DIV AIDS,BETHESDA,MD 20852	Gilead Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	TSAI, CC (corresponding author), UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195, USA.				NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [N01-AI-15120] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015120] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; CALIENDO AM, 1994, CLIN INFECT DIS, V18, P516, DOI 10.1093/clinids/18.4.516; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; Follis Kathryn E., 1994, Journal of Medical Primatology, V23, P255; GARDNER MB, 1991, ANTIVIR RES, V15, P267, DOI 10.1016/0166-3542(91)90009-G; HO HT, 1992, MOL PHARMACOL, V41, P197; LEGRAND R, 1994, AIDS RES HUM RETROV, V10, P1279, DOI 10.1089/aid.1994.10.1279; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MCCLURE HM, 1990, ANN NY ACAD SCI, V616, P287; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; MONTANER JSG, 1995, LANCET, V345, P377, DOI 10.1016/S0140-6736(95)90356-9; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; RICHMANN DD, 1994, AIDS, V7, P135; SRINIVAS RV, 1993, ANTIMICROB AGENTS CH, V37, P2247, DOI 10.1128/AAC.37.10.2247; TOKARS JI, 1993, ANN INTERN MED, V118, P193; Tsai C.-E., UNPUB; TSAI CC, 1993, J ACQ IMMUN DEF SYND, V6, P1086; TSAI CC, 1990, ANTIVIR RES, V14, P87, DOI 10.1016/0166-3542(90)90046-A; TSAI CC, 1994, J INFECT DIS, V169, P260, DOI 10.1093/infdis/169.2.260; TSAI CC, 1994, J MED PRIMATOL, V23, P175, DOI 10.1111/j.1600-0684.1994.tb00119.x; TSAI CC, 1995, J INFECT DIS, V171, P1338, DOI 10.1093/infdis/171.5.1338; TSAI CC, 1993, LAB ANIM SCI, V43, P441; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; VELLA S, 1994, AIDS, V8, pS25, DOI 10.1097/00002030-199409001-00006; WYAND MS, 1992, AIDS RES HUM RETROV, V8, P349, DOI 10.1089/aid.1992.8.349	30	461	481	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1197	1199		10.1126/science.270.5239.1197	http://dx.doi.org/10.1126/science.270.5239.1197			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502044				2022-12-01	WOS:A1995TE90500056
J	WEISSMAN, JS; HOHL, CM; KOVALENKO, O; KASHI, Y; CHEN, SX; BRAIG, K; SAIBIL, HR; FENTON, WA; HORWICH, AL				WEISSMAN, JS; HOHL, CM; KOVALENKO, O; KASHI, Y; CHEN, SX; BRAIG, K; SAIBIL, HR; FENTON, WA; HORWICH, AL			MECHANISM OF GROEL ACTION - PRODUCTIVE RELEASE OF POLYPEPTIDE FROM A SEQUESTERED POSITION UNDER GROES	CELL			English	Article							ESCHERICHIA-COLI; ORNITHINE TRANSCARBAMYLASE; MOLECULAR CHAPERONE; CENTRAL CAVITY; COOPERATIVITY; HYDROLYSIS; SURFACE; BINDING; CYCLE	The chaperonin GroEL is a large, double-ring structure that, together with ATP and the cochaperonin GroES, assists protein folding in vivo. GroES forms an asymmetric complex with GroEL in which a single GroES ring binds one end of the GroEL cylinder. Cross-linking studies reveal that polypeptide binding occurs exclusively to the GroEL ring not occupied by GroES (trans). During the folding reaction, however, released GroES can rebind to the GroEL ring containing polypeptide (cis). The polypeptide is held tightly in a proteolytically protected environment in cis complexes, in the presence of ADP. Single turnover experiments with ornithine transcarbamylase reveal that polypeptide is productively released from the cis but not the trans complex. These observations suggest a two-step mechanism for GroEL-mediated folding. First, GroES displaces the polypeptide from its initial binding sites, sequestering it in the GroEL central cavity. Second, ATP hydrolysis induces release of GroES and productive release of polypeptide.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND	Howard Hughes Medical Institute; Yale University; University of London; Birkbeck University London	WEISSMAN, JS (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.		Kashi, Yechezkel/D-5433-2013					AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHMIDT M, 1994, J BIOL CHEM, V14, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	43	372	376	0	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					577	587		10.1016/0092-8674(95)90098-5	http://dx.doi.org/10.1016/0092-8674(95)90098-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585961	hybrid			2022-12-01	WOS:A1995TF24800011
J	ZIMMERLY, S; GUO, HT; ESKES, R; YANG, J; PERLMAN, PS; LAMBOWITZ, AM				ZIMMERLY, S; GUO, HT; ESKES, R; YANG, J; PERLMAN, PS; LAMBOWITZ, AM			A GROUP-II INTRON RNA IS A CATALYTIC COMPONENT OF A DNA ENDONUCLEASE INVOLVED IN INTRON MOBILITY	CELL			English	Article							YEAST MITOCHONDRIA; INVITRO; TRANSPOSITION; PROTEINS	The mobility (homing) of the yeast mitochondrial DNA group II intron al2 occurs via target DNA-primed reverse transcription at a double-strand break in the recipient DNA. Here, we show that the site-specific DNA endonuclease that makes the double-strand break is a ribonucleoprotein complex containing the al2-encoded reverse transcriptase protein and excised al2 RNA. Remarkably, the al2 RNA catalyzes cleavage of the sense strand of the recipient DNA, while the al2 protein appears to cleave the antisense strand. The RNA-catalyzed sense strand cleavage occurs via a partial reverse splicing reaction in which the protein component stabilizes the active intron structure and appears to confer preference for DNA substrates. Our results demonstrate a biologically relevant ribozyme reaction with a substrate other than RNA.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZIMMERLY, S (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480, GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MOHR G, 1993, NUCLEIC ACIDS RES, V21, P4991, DOI 10.1093/nar/21.22.4991; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT WM, 1994, J MOL BIOL, V243, P157, DOI 10.1006/jmbi.1994.1642; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	23	156	179	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 17	1995	83	4					529	538		10.1016/0092-8674(95)90092-6	http://dx.doi.org/10.1016/0092-8674(95)90092-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TF248	7585955	Bronze			2022-12-01	WOS:A1995TF24800005
J	BEHAN, DP; HEINRICHS, SC; TRONCOSO, JC; LIU, XJ; KAWAS, CH; LING, N; DESOUZA, EB				BEHAN, DP; HEINRICHS, SC; TRONCOSO, JC; LIU, XJ; KAWAS, CH; LING, N; DESOUZA, EB			DISPLACEMENT OF CORTICOTROPIN-RELEASING FACTOR FROM ITS BINDING-PROTEIN AS A POSSIBLE TREATMENT FOR ALZHEIMERS-DISEASE	NATURE			English	Article							FACTOR-LIKE IMMUNOREACTIVITY; CENTRAL NERVOUS-SYSTEM; FACTOR RECEPTORS; HUMAN-PLASMA; RAT; CRF; DIAGNOSIS; DISORDERS; DEMENTIA; BEHAVIOR	In Alzheimer's disease (AD) there are dramatic reductions in the content of corticotropin releasing factor (CRF)(1-4), reciprocal increases in CRF receptors(1,2), and morphological abnormalities in CRF neurons(5) in affected brain areas. Cognitive impairment in AD patients is associated with a lower cerebrospinal fluid concentration of CRF(6), which is known to induce increases in learning and memory in rodents(7-9). This suggests that CRF deficits contribute to cognitive impairment. The identification in post-mortem brain of CRF-binding protein (CRF-BP)(10,11), a high-affinity binding protein that inactivates CRF, and the differential distribution of CRF-BP12 and CRF receptors(13), provides the potential for improving learning and memory without stress effects of CRF receptor agonists(14). Here we show that ligands that dissociate CRF from CRF-BP increase brain levels of 'free CRF' in AD to control levels and show cognition-enhancing properties in models of learning and memory in animals without the characteristic stress effects of CRF receptor agonists.	JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	BEHAN, DP (corresponding author), NEUROCRINE BIOSCI INC, 3050 SCI PK RD, SAN DIEGO, CA 92121 USA.			Heinrichs, Stephen/0000-0002-8395-6096; Kawas, Claudia/0000-0001-9577-230X				BEHAN DP, 1993, ANN NY ACAD SCI, V697, P1, DOI 10.1111/j.1749-6632.1993.tb49918.x; BISSETTE G, 1985, JAMA-J AM MED ASSOC, V254, P3067, DOI 10.1001/jama.254.21.3067; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; DESOUZA EB, 1987, J NEUROSCI, V7, P88; DESOUZA EB, 1988, HOSP PRACT, V23, P59; DESOUZA EB, 1985, J NEUROSCI, V5, P3189; DESOUZA EB, 1986, NATURE, V319, P591; DESOUZA EB, 1990, ANNU REP MED CHEM, V25, P215; DIAMANT M, 1993, NEUROENDOCRINOLOGY, V57, P1071, DOI 10.1159/000126473; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KOOB GF, 1985, FED PROC, V44, P259; KOOB GF, 1993, CIBA F SYMP, V172, P277; LIANG KC, 1988, PSYCHOPHARMACOLOGY, V96, P232; LINTON EA, 1988, CLIN ENDOCRINOL, V28, P315, DOI 10.1111/j.1365-2265.1988.tb01218.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; ORTH DN, 1987, BIOCHEM BIOPH RES CO, V143, P411, DOI 10.1016/0006-291X(87)91369-6; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; POMARA N, 1989, BIOL PSYCHIAT, V26, P500, DOI 10.1016/0006-3223(89)90071-1; POTTER E, 1991, NATURE, V349, P423, DOI 10.1038/349423a0; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; POWERS RE, 1987, SYNAPSE, V1, P405, DOI 10.1002/syn.890010504; STEWART CA, 1993, BEHAV NEUROSCIENCE P, P107; SUDA T, 1988, J CLIN ENDOCR METAB, V67, P1278, DOI 10.1210/jcem-67-6-1278; SUTTON SW, 1995, ENDOCRINOLOGY, V136, P1097, DOI 10.1210/en.136.3.1097; WHITEHOUSE PJ, 1987, NEUROLOGY, V37, P905, DOI 10.1212/WNL.37.6.905	26	203	215	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					284	287		10.1038/378284a0	http://dx.doi.org/10.1038/378284a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477348	Green Published			2022-12-01	WOS:A1995TE85800050
J	BERGLUND, J; EITREM, R; ORNSTEIN, K; LINDBERG, A; RINGNER, A; ELMRUD, H; CARLSSON, M; RUNEHAGEN, A; SVANBORG, C; NORRBY, R				BERGLUND, J; EITREM, R; ORNSTEIN, K; LINDBERG, A; RINGNER, A; ELMRUD, H; CARLSSON, M; RUNEHAGEN, A; SVANBORG, C; NORRBY, R			AN EPIDEMIOLOGIC-STUDY OF LYME-DISEASE IN SOUTHERN SWEDEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LATE CUTANEOUS MANIFESTATIONS; TICK-BORNE ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; BORRELIA-BURGDORFERI; FORESTRY WORKERS; PREVALENCE; SERODIAGNOSIS; ANTIBODIES; POPULATION; ARTHRITIS	Background. Lyme disease is the most common vector-borne infection in some temperate regions of the Northern Hemisphere, However, for most areas of endemic disease reliable epidemiologic data are sparse. Methods. Over a one-year period, we conducted a prospective, population-based survey of cases of Lyme disease in southern Sweden. The diagnosis was made on the basis of the presence of erythema migrans at least 5 cm in diameter or characteristic clinical manifestations such as arthritis, neuroborreliosis, and carditis. Results. We identified 1471 patients with Lyme disease, for an overall annual incidence of 69 cases per 100,000 inhabitants. The incidence varied markedly according to geographic region, and there were several areas where disease was widely prevalent. The incidence varied according to age, with the highest rates among people 5 to 9 and 60 to 74 years of age, but not according to sex. The most frequent clinical manifestation was erythema migrans (seen in 77 percent of all cases), followed by neuroborreliosis (16 percent) and arthritis (7 percent). Carditis was rare. A preceding tick bite was reported by 79 percent of the patients. Bites in the head and neck region were more common among children than among adults and were associated with an increased risk of neuroborreliosis. Conclusions. Lyme disease is very common in southern Sweden, with a relatively high frequency of neurologic complications and arthritis. With the exception of the low incidence of carditis, the pattern of disease we found in Sweden was similar to that reported in the United States.	LUND UNIV, DEPT COMMUNITY HLTH SCI, LUND, SWEDEN; LUND UNIV, DEPT INFECT DIS, LUND, SWEDEN; LUND UNIV, DEPT MED MICROBIOL, LUND, SWEDEN; DEPT INFECT DIS CONTROL BLEKINGE CTY, KARLSKRONA, SWEDEN; DEPT INFECT DIS CONTROL HALLAND CTY, HALMSTAD, SWEDEN; DEPT INFECT DIS CONTROL KALMAR CTY, KALMAR, SWEDEN; DEPT INFECT DIS CONTROL KRISTIANSTAD CTY, KRISTIANSTAD, SWEDEN; DEPT INFECT DIS CONTROL JONKOPING CTY, JONKOPING, SWEDEN; DEPT INFECT DIS CONTROL KRONOBERG CTY, VAXJO, SWEDEN	Lund University; Lund University; Lund University			Sanmartin Berglund, Johan/HGB-0471-2022					AESCHLIMANN A, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P450; AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; AGUEROROSENFELD ME, 1994, J CLIN MICROBIOL, V32, P860; ANANJEVA LP, 1995, ARTHRITIS RHHEUM, V22, P689; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASBRINK E, 1984, ACTA DERM-VENEREOL, V64, P506; BERGLUND J, 1993, SCAND J INFECT DIS, V25, P67, DOI 10.3109/00365549309169672; BERGLUND J, 1995, J RHEUMATOL, V22, P695; BLAAUW I, 1991, J RHEUMATOL, V18, P1819; CANICA MM, 1993, SCAND J INFECT DIS, V25, P441, DOI 10.3109/00365549309008525; CHRISTEN HJ, 1993, ACTA PAEDIATR, V82, P1, DOI 10.1111/j.1651-2227.1993.tb18082.x; DEKONENKO EJ, 1988, J INFECT DIS, V158, P748, DOI 10.1093/infdis/158.4.748; DENNIS DT, 1993, LYME DISEASE, V27, P37; DRESSLER F, 1994, CLIN EXP RHEUMATOL, V12, pS49; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; GARCIAMONCO JC, 1990, J INFECT DIS, V161, P1187, DOI 10.1093/infdis/161.6.1187; GUSTAFSON R, 1993, SCAND J INFECT DIS, V25, P605, DOI 10.3109/00365549309008549; Gustafson R, 1994, Scand J Infect Dis Suppl, V92, P1; HAMMERSBERGGREN S, 1993, STROKE, V24, P1393, DOI 10.1161/01.STR.24.9.1393; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HORST H, 1990, NIEDERSACHSISCH ARZT, V63, P32; KRYGER P, 1990, SCAND J RHEUMATOL, V19, P77, DOI 10.3109/03009749009092625; KUIPER H, 1993, EUR J CLIN MICROBIOL, V12, P413, DOI 10.1007/BF01967434; LEY C, 1994, WESTERN J MED, V160, P534; Linde M. R. van der, 1993, Aspects of Lyme borreliosis., P131; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V268, P873, DOI 10.1001/jama.1992.03490070050034; MITCHELL PD, 1994, J CLIN MICROBIOL, V32, P1958, DOI 10.1128/JCM.32.8.1958-1962.1994; MITCHELL PD, 1994, J CLIN MICROBIOL, V32, P2343; NADAL D, 1989, EUR J CLIN MICROBIOL, V8, P992, DOI 10.1007/BF01967572; SCHMID GP, 1985, REV INFECT DIS, V7, P41; SCHMUTZHARD E, 1988, INFECTION, V16, P269, DOI 10.1007/BF01645068; SCHWARTZ BS, 1994, AM J EPIDEMIOL, V139, P504, DOI 10.1093/oxfordjournals.aje.a117033; STANEK G, 1988, ANN NY ACAD SCI, V539, P274, DOI 10.1111/j.1749-6632.1988.tb31861.x; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; WILSKE B, 1988, ANN NY ACAD SCI, V539, P126, DOI 10.1111/j.1749-6632.1988.tb31846.x; 1990, MMWR-MORBID MORTAL W, V39, P19; 1995, MMWR MORTAL WKLY REP, V44, P459; 1994, MMWR MORTAL WKLY REP, V43, P564	43	294	302	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	1995	333	20					1319	1324		10.1056/NEJM199511163332004	http://dx.doi.org/10.1056/NEJM199511163332004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE365	7566023				2022-12-01	WOS:A1995TE36500004
J	BRUNET, M; BEAUVILAIN, A; COPPENS, Y; HEINTZ, E; MOUTAYE, AHE; PILBEAM, D				BRUNET, M; BEAUVILAIN, A; COPPENS, Y; HEINTZ, E; MOUTAYE, AHE; PILBEAM, D			THE FIRST AUSTRALOPITHECINE 2,500 KILOMETERS WEST OF THE RIFT-VALLEY (CHAD)	NATURE			English	Article								The first sites with Pliocene and Pleistocene mammals west of the Rift Valley in Central Africa in northern Chad mere reported in 1959 (ref. 1), and documented the presence of mixed savannah and woodland habitats. Further sites(2) and a probable Homo erectus cranio-facial fragment(3) mere subsequently discovered. In 1993 a survey of Pliocene and Pleistocene formations in the Borkou-Ennedi-Tibesti Province of Chad (B.E.T.) led to the discovery of 17 new sites in the region of Bahr el Ghazal (classical Arabic for River of the Gazelles) near Koro Toro. One site, KT 12 (15 degrees 58'10'' N, 18 degrees 52'46'' E) yielded an australopithecine mandible associated with a fauna biochronologically estimated to be 3.0-3.5 Myr old. Australopithecine species described since 1925 are known from southern Africa and from sites spread along the eastern Rift Valley from Tanzania to Ethiopia (Fig. 1). This new find from Chad, which is most similar in morphology to Australopithecus afarensis(4), documents the presence of an early hominid a considerable distance, 2,500 km, west of the Rift Valley.	CNAR, NDJAMENA, CHAD; COLL FRANCE, CHAIRE PALEOANTHROPOL & PREHIST, F-75005 PARIS, FRANCE; CNRS, F-75794 PARIS 16, FRANCE; DRGM, NDJAMENA, CHAD; HARVARD UNIV, DEPT ANTHROPOL, CAMBRIDGE, MA 02138 USA	UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Harvard University	BRUNET, M (corresponding author), UNIV POITIERS, FAC SCI JE 273 MST, GEOBIOL BIOCHRONOL & PALEONTOL HUMAINE, 40 AVE RECTEUR PINEAU, F-86022 POITIERS, FRANCE.		Klein, Richard G/B-5910-2009; Lund, Laura/H-7335-2012					ABADLE J, 1959, CR HEBD ACAD SCI, V248, P3329; Beden M, 1985, ENV HOMINIDES PLIO P, P21; BRAGA JC, 1995, THESIS U BORDEAUX; COOKE HBS, 1985, ENV HOMINIDES PLIO P, P101; COPPENS Y, 1965, CR HEBD ACAD SCI, V260, P2869; COPPENS Y, 1983, SINGE AFRIQUE HOMME, P1; COPPENS YVES, 1967, P89; EISENMANN U, 1993, KOOBI FORA PROJECT, P156; EISENMANN V, 1976, Geobios (Villeurbanne), V9, P577, DOI 10.1016/S0016-6995(76)80025-3; GEZE R, 1980, THESIS U PARIS; Geze R., 1985, ENV HOMINIDES PLIO P, P81; Groves C.P., 1986, P187; GRUPP P, 1993, PIGS PECCARIES HIPPO, P66; Guerin C., 1979, Bulletin de la Societe Geologique de France, V21, P283; HARRIS JM, 1979, T AM PHILOS SOC, V69, P5; HARRIS JM, 1983, KOOBI FORA RES PROJE, V2, P215; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P545, DOI 10.1002/ajpa.1330570406; Jolly Clifford J., 1993, P67; KORTLANDT A, 1972, NEW PERSPECTIVES APE, P9; LEAKEY MD, 1976, NATURE, V262, P460, DOI 10.1038/262460a0; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; Pickford M., 1990, Human Evolution, V5, P1, DOI 10.1007/BF02436472; RUVOLO M, 1994, P NATL ACAD SCI USA, V91, P8900, DOI 10.1073/pnas.91.19.8900; SCHNEIDER JL, 1989, THESIS U AVIGNON; SCHNEIDER JL, 1992, DOCUMENT BRGM, V209; UCHIDA A, 1993, AM J PHYS ANTHR S, V16, P198; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; WOOD BA, 1992, CAMBRIDGE ENCY HUMAN, P231	28	178	185	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					273	275		10.1038/378273a0	http://dx.doi.org/10.1038/378273a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477344				2022-12-01	WOS:A1995TE85800046
J	CAO, WX; TYKODI, SS; ESSER, MT; BRACIALE, VL; BRACIALE, TJ				CAO, WX; TYKODI, SS; ESSER, MT; BRACIALE, VL; BRACIALE, TJ			PARTIAL ACTIVATION OF CD8(+) T-CELLS BY A SELF-DERIVED PEPTIDE	NATURE			English	Article							LIGAND	T cells are normally activated when the peptide for which they are specific is presented to them in the context of the appropriate major histocompatibility complex (MHC) (class I and Class II for CD8(+) and CD4(+) T cells, respectively). An increasing body of evidence indicates that structural homologues of the immunogenic peptide can partially activate or antagonize CD4(+) T cells(1-3). CD8(+) T cells may also be partially antagonized by such peptides(4,5), and self-derived peptides of this type may play a role in CD8(+) T cell selection in the thymus(6-8). Activated CD8(+) T cells lyse their targets by perforin-dependent granule exocytosis(9,10) and by inducing apoptosis mediated bs CD95 (also known as Fas or APO1) with its ligand (CD95L)(11-15). Here we show that a clone of K-d-restricted CD8(+) T cells specific for influenza haemagglutinin, which can also be activated in a crossreactive manner by a peptide derived from a myeloma tumour immunoglobulin heavy-chain variable region (IgVH) to kill by both routes(16), kills only by the CD95-CD95L pathway when stimulated by the corresponding germline IgVH peptide. As this germline IgVH peptide differs from the tumour peptide only at a single position buried in the MHC-binding be triggered independently of the perforin-mediated pathway, and can be selectively affected by changes in MHC conformation.	UNIV VIRGINIA,HLTH SCI CTR,BELRNE B CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; WASHINGTON UNIV,SCH MED,DIV BIOL & BIOMED SCI,PROGRAM IMMUNOL,ST LOUIS,MO 63110	University of Virginia; University of Virginia; University of Virginia; Washington University (WUSTL)								BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; CAO WX, 1994, J EXP MED, V179, P195, DOI 10.1084/jem.179.1.195; CHATTOPADHYAY S, 1993, J EXP MED, V179, P213; CRISPE IN, 1994, IMMUNITY, V1, P347; EVAVOLD BD, 1992, J IMMUNOL, V148, P347; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ITO N, 1991, CELL, V66, P233; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.iy.11.040193.002125; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SPAIN LM, 1994, J IMMUNOL, V152, P1709; STAIDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WALSH CM, 1994, J IMMUNOL, V153, P2506	29	90	90	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					295	298		10.1038/378295a0	http://dx.doi.org/10.1038/378295a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477351				2022-12-01	WOS:A1995TE85800053
J	CHENG, AM; ROWLEY, B; PAO, W; HAYDAY, A; BOLEN, JB; PAWSON, T				CHENG, AM; ROWLEY, B; PAO, W; HAYDAY, A; BOLEN, JB; PAWSON, T			SYK TYROSINE KINASE REQUIRED FOR MOUSE VIABILITY AND B-CELL DEVELOPMENT	NATURE			English	Article							BONE-MARROW; PROTEIN; CHAIN; REARRANGEMENT; SELECTION; RECEPTOR; GENES	The Syk cytoplasmic protein-tyrosine kinase has two amino-terminal SH2 domains and a carboxy-terminal catalytic domain(1). Syk, and its close relative ZAP-70 (ref. 2), are apparently pivotal in coupling antigen- and Fc-receptors to downstream signalling events(3,4). Syk associates with activated Fc receptors(5), the T cell receptor complex(6) and the B-cell antigen-receptor complex (BCR) in immature and mature B lymphocytes(7). On receptor activation, the tandem SH2 domains of Syk bind dual phosphotyrosine sites in the conserved ITAM motifs of receptor signalling chains, such as the immunoglobulin alpha and beta-chains of the BCR, leading to Syk activation(3,4,8). Here we have investigated Syk function in vivo by generating a mouse strain with a targeted mutation in the syk gene. Homozygous syk mutants suffered severe haemorrhaging as embryos and died perinatally, indicating that Syk has a critical role in maintaining vascular integrity or in wound healing during embryogenesis. Analysis of syk(-/-) lymphoid cells showed that the syk mutation impaired the differentiation of B-lineage cells, apparently by disrupting signalling from the pre-BCR complex and thereby preventing the clonal expansion, and further maturation, of pre-B cells.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOLEC BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL,PRINCETON,NJ 08453; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Bristol-Myers Squibb; Yale University			Pawson, Tony J/E-4578-2013					ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CARLSSON L, 1992, EUR J IMMUNOL, V22, P71, DOI 10.1002/eji.1830220112; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHUKWUOCHA RU, 1994, J IMMUNOGENET, V40, P76; CLARK EA, 1994, J BIOL CHEM, V269, P28859; DECKER DJ, 1991, J IMMUNOL, V146, P350; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DURDEN DL, 1994, BLOOD, V84, P2102; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAASNER D, 1994, INT IMMUNOL, V6, P21, DOI 10.1093/intimm/6.1.21; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Joyner AL, 1993, GENE TARGETING PRACT; KARASUYAMA H, 1992, J EXP MED, V172, P969; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; REZAUL K, 1995, FIBROSIS HEMOSTAS, V72, P937; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	31	543	573	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					303	306		10.1038/378303a0	http://dx.doi.org/10.1038/378303a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477353				2022-12-01	WOS:A1995TE85800055
J	DESPOSITO, M; DETRE, JA; ALSOP, DC; SHIN, RK; ATLAS, S; GROSSMAN, M				DESPOSITO, M; DETRE, JA; ALSOP, DC; SHIN, RK; ATLAS, S; GROSSMAN, M			THE NEURAL BASIS OF THE CENTRAL EXECUTIVE SYSTEM OF WORKING-MEMORY	NATURE			English	Article							HUMAN BRAIN; CORTEX; ATTENTION; ANATOMY	Working memory refers to a system for temporary storage and manipulation of information in the brain, a function critical for a wide range of cognitive operations. It has been proposed that working memory includes a central executive system (CES) to control attention and information flow to and from verbal and spatial short-term memory buffers(1). Although the prefrontal cortex is activated during both verbal and spatial passive working memory tasks(2-8), the brain regions involved in the CES component of working memory have not been identified. We have used functional magnetic resonance imaging (fMRI) to examine brain activation during the concurrent performance of two tasks, which is expected to engage the CES. Activation of the prefrontal cortex was observed when both tasks are performed together, but not when they are performed separately. These results support the view that the prefrontal cortex is involved in human working memory.	UNIV PENN,MED CTR,DEPT RADIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	DESPOSITO, M (corresponding author), UNIV PENN,MED CTR,DEPT NEUROL,PHILADELPHIA,PA 19104, USA.		Alsop, David C/J-5764-2013	Alsop, David C/0000-0002-8206-1995				BADDLEY AD, 1986, WORKING MEMORY; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DESPOSITO M, IN PRESS NEUROPSYCHO; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.ne.11.030188.001033; GOLDMANRAKIC PS, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P445; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SWARTZ BE, 1995, CEREB CORTEX, V3, P205; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063	22	1097	1108	6	110	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					279	281		10.1038/378279a0	http://dx.doi.org/10.1038/378279a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477346				2022-12-01	WOS:A1995TE85800048
J	DOUHAL, A; KIM, SK; ZEWAIL, AH				DOUHAL, A; KIM, SK; ZEWAIL, AH			FEMTOSECOND MOLECULAR-DYNAMICS OF TAUTOMERIZATION IN MODEL BASE-PAIRS	NATURE			English	Article							DOUBLE-PROTON-TRANSFER; TEMPERATURE	Hydrogen bonds commonly lend robustness and directionality to molecular recognition processes and supramolecular structures(1,2). In particular, the two or three hydrogen bonds in Watson-Crick base pairs bind the double-stranded DNA helix and determine the complementarity of the pairing. Watson and Crick pointed out(3), however, that the possible tautomers of base pairs, in which hydrogen atoms become attached to the donor atom of the hydrogen bond, might disturb the genetic code, as the tautomer is capable of pairing with different partners. But the dynamics of hydrogen bonds in general, and of this tautomerization process in particular, are not well understood. Here we report observations of the femtosecond dynamics of tautomerization in model base pairs (7-azaindole dimers) containing two hydrogen bonds. Because of the femtosecond resolution of proton motions, we are able to examine the cooperativity of formation of the tautomer (in which the protons on each base are shifted sequentially to the other base), and to determine the characteristic timescales of the motions in a solvent-free environment. We find that the first step occurs on a timescale of a few hundred femtoseconds, whereas the second step, to form the full tautomer, is much slower, taking place within several picoseconds; the timescales are changed significantly by replacing hydrogen with deuterium. These results establish the molecular basis of the dynamics and the role of quantum tunnelling.			DOUHAL, A (corresponding author), CALTECH, ARTHUR AMOS NOYES LAB CHEM PHYS, PASADENA, CA 91125 USA.		Kim, Sang Kyu/C-1613-2011; Douhal, Abderrazzak/L-4940-2014	Douhal, Abderrazzak/0000-0003-2247-7566				Ball P., 1994, DESIGNING MOL WORLD; BENDERSKII VA, 1992, INT REV PHYS CHEM, V11, P1, DOI 10.1080/01442359209353265; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; FUKE K, 1989, J PHYS CHEM-US, V93, P614, DOI 10.1021/j100339a023; HEREK JL, 1992, J CHEM PHYS, V97, P9046, DOI 10.1063/1.463331; HETHERINGTON WM, 1979, CHEM PHYS LETT, V66, P230, DOI 10.1016/0009-2614(79)85004-6; INGHAM KC, 1974, J AM CHEM SOC, V96, P1674, DOI 10.1021/ja00813a006; KIM SK, 1995, J PHYS CHEM-US, V99, P7421, DOI 10.1021/j100019a027; Lowdin P-O., 1966, ADV QUANTUM CHEM, P213, DOI DOI 10.1016/S0065-3276(08)60076-3; REIN R, 1965, J CHEM PHYS, V42, P2177, DOI 10.1063/1.1696263; SHARE P, 1991, J LUMIN, V48-9, P204, DOI 10.1016/0022-2313(91)90105-5; STRYER L, 1988, BIOCHEMISTRY; TAYLOR CA, 1969, P NATL ACAD SCI USA, V63, P253, DOI 10.1073/pnas.63.2.253; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; YU HT, 1992, J AM CHEM SOC, V114, P8449, DOI 10.1021/ja00048a015; Zewail A., 1992, CHEM BOND STRUCTURE; Zewail A.H., 1994, FEMTOCHEMISTRY ULTRA	17	425	427	1	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					260	263		10.1038/378260a0	http://dx.doi.org/10.1038/378260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477342				2022-12-01	WOS:A1995TE85800042
J	HUANG, MX; GU, GQ; FERGUSON, EL; CHALFIE, M				HUANG, MX; GU, GQ; FERGUSON, EL; CHALFIE, M			A STOMATIN-LIKE PROTEIN NECESSARY FOR MECHANOSENSATION IN C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; MICROTUBULE-ASSOCIATED PROTEINS; NEURONAL MICROTUBULES; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; MEMBRANE-PROTEIN; GENE; EXPRESSION; PRODUCT; TUBULIN	The mec-2 gene is required for the function of a set of six touch receptor neurons in the nematode Caenorhabditis elegans; mec-2 mutants, which are touch-insensitive, have touch cells that appear morphologically normal(1,2). Gene interaction studies suggest that mec-2 positively regulates the activity of the putative mechanosensory transduction channel (ref. 3 and the present paper), comprised in part of proteins encoded by the two degenerin genes mec-4 and mec-10 (refs 3-5). The central region of the mec-2 protein (MEC-2) is very similar to stomatin, an integral membrane protein (band 7.2b) in human red blood cells that is thought to regulate cation conductance(6). MEC-2-LacZ fusions are distributed along the touch receptor axons. This axonal distribution, which is mediated by the mec-2-specific amino terminus, is disrupted by mutations in mec-12, an alpha-tubulin gene needed for touch cell function. Our results indicate that MEC-2 links the mechanosensory channel and the microtubule cytoskeleton of the touch receptor neurons. Such linkage provides the basis for a mechanism of mechanosensation whereby microtubule displacement leads to channel opening.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Ferguson, Edwin/0000-0003-4125-4253				BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; CHALFIE M, 1982, J CELL BIOL, V93, P15, DOI 10.1083/jcb.93.1.15; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1979, J CELL BIOL, V82, P278, DOI 10.1083/jcb.82.1.278; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITANI S, 1993, DEVELOPMENT, V119, P773; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RIVAS CI, 1988, P NATL ACAD SCI USA, V85, P6092, DOI 10.1073/pnas.85.16.6092; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SALZER U, 1993, BIOCHIM BIOPHYS ACTA, V1151, P149, DOI 10.1016/0005-2736(93)90098-K; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SAVAGE C, 1994, J CELL SCI, V107, P2165; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; STEWART GW, 1992, BLOOD, V79, P1593, DOI 10.1182/blood.V79.6.1593.bloodjournal7961593; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823	33	193	209	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					292	295		10.1038/378292a0	http://dx.doi.org/10.1038/378292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477350				2022-12-01	WOS:A1995TE85800052
J	HUANG, WP; CIOCHON, R; GU, YM; LARICK, R; FANG, QR; SCHWARCZ, H; YONGE, C; DEVOS, J; RINK, W				HUANG, WP; CIOCHON, R; GU, YM; LARICK, R; FANG, QR; SCHWARCZ, H; YONGE, C; DEVOS, J; RINK, W			EARLY HOMO AND ASSOCIATED ARTIFACTS FROM ASIA	NATURE			English	Article							ORIGIN	The site of Longgupo Cave was discovered in 1984 and excavated in 1985-1988 by the Institute of Vertebrate Paleontology and Paleoanthropology (Beijing) and the Chongqing National Museum (Sichuan Province). Important finds include very archaic hominid dental fragments, Gigantopithecus teeth and primitive stone tools. Palaeomagnetic analysis and the presence of Ailuropoda microta (pygmy giant panda) suggested that the hominid-bearing levels dated to the earliest Pleistocene(1). In 1992, joint Chinese-American-Canadian geochronological research corroborated the age using electron spin resonance (ESR) analysis. We report here that the hominid dentition and stone tools from Longgupo Cave are comparable in age and morphology with early representives of the genus Homo (H. habilis and H. ergaster) and the Oldowan technology in East Africa. The Longgupo dentition is demonstrably more primitive than that seen in Asian Homo erectus. Longgupo's diverse and well preserved Plio-Pleistocene fauna of 116 species provide a sensitive contextual base for interpreting the early arrival of the genus Homo in Asia.	UNIV MASSACHUSETTS,DEPT ANTHROPOL,AMHERST,MA 01003; CHONGOING MUSEUM NAT HIST,CHONGQING 630013,PEOPLES R CHINA; UNIV CALGARY,DEPT PHYS & ASTRON,HAMILTON,ON L85 4M1,CANADA; NATL MUSEUM NAT HIST,2300 RA LEIDEN,NETHERLANDS; UNIV IOWA,DEPT PEDIAT DENT,IOWA CITY,IA 52242; ACAD SINICA,INST VERTEBRATE PALEONTOL & PALEOANTHROPOL,BEIJING 100044,PEOPLES R CHINA	University of Massachusetts System; University of Massachusetts Amherst; University of Calgary; University of Iowa; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	HUANG, WP (corresponding author), UNIV IOWA,DEPT ANTHROPOL,IOWA CITY,IA 52242, USA.							Brown Barbara, 1993, P161; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P13917, DOI 10.1029/92JB01202; CIOCHON R, IN PRESS P NATN ACAD; CLARKE RJ, 1990, J HUM EVOL, V19, P699, DOI 10.1016/0047-2484(90)90004-U; CLARKE RJ, 1988, WORLD ARCHAEOL, V21, P1; COLBERT EH, 1953, B AM MUS NAT HIST, V102, P1; Gao Jian, 1975, Vertebrata Palasiatica, V13, P81; GRUN R, 1987, CAN J EARTH SCI, V24, P1022, DOI 10.1139/e87-099; Harris J.W.K., 1983, AFR ARCHAEOL REV, V1, P3, DOI DOI 10.1007/BF01116770; HOWELL FC, 1994, ORIGINS ANATOMICALLY, P253; Huang W.B., 1991, WUSHAN HOMINID SITE; Huang Wanpo, 1993, Vertebrata Palasiatica, V31, P191; Leakey M.D., 1971, OLDUVAI GORGE, V3, P1960; Luo H., 1989, ACTA ANTHROPOL SIN, V8, P172; MATTHEW WD, 1923, B AM MUS NAT HIST, V46, P563; MCDOUGALL I, 1992, GEOPHYS RES LETT, V19, P2349, DOI 10.1029/92GL02714; Rightmire, 1990, EVOLUTION HOMO ERECT; SCHWARCZ HP, 1994, J HUM EVOL, V26, P175, DOI 10.1006/jhev.1994.1010; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TOBIAS PV, 1991, OLDUVAL GORGE, V4; WANG L, 1982, VERTEBRAT PALASIATIC, V20, P255; WELDENREICH F, 1937, PALEONTOL SINICA D, V1, P1; Woo J. K., 1962, Palaeontologia Sinica New Ser D, V11, P1; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B., 1991, HOMINID CRANIAL REMA, V4; Wood Bernard, 1993, P485; ZHANG YY, 1982, AM J PHYS ANTHROPOL, V59, P21; ZHENG SH, 1986, VERTEBRAT PALASIATIC, V24, P81; Zheng SH., 1993, QUATERNARY RODENTS S	29	176	212	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					275	278						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TE858	7477345				2022-12-01	WOS:A1995TE85800047
J	PIEPER, R; LUO, GL; CANE, DE; KHOSLA, C				PIEPER, R; LUO, GL; CANE, DE; KHOSLA, C			CELL-FREE SYNTHESIS OF POLYKETIDES BY RECOMBINANT ERYTHROMYCIN POLYKETIDE SYNTHASES	NATURE			English	Article							MACROLIDE BIOSYNTHESIS; CHAIN-ELONGATION; SACCHAROPOLYSPORA-ERYTHRAEA; STREPTOMYCES-ERYTHREUS; COENZYME-A; ACID; IDENTIFICATION; ORGANIZATION; INTERMEDIATE	Modular polyketide synthases (PKSs) are complex multi-enzyme proteins that catalyse the bacterial biosynthesis of many pharmaceutically useful polyketides. The PKSs are organized into a series of modules, each containing the active catalytic sites required for one step in the synthesis process(1,4). Here we report a method for cell-free enzymatic synthesis of 6-deoxyerythronolide B (6-dEB), the parent molecule of the antibiotic erythromycin A, using recombinant 6-deoxyerythronolide B synthase (DEBS), a modular PKS with at least 28 distinct active sites. We have also synthesized in vitro a triketide lactone by using a truncated mutant of DEBS. The availability of such cell-free synthetic routes will allow direct investigation of the structural and mechanistic basis for the unusual combination of high substrate specificity(5-10) and tolerance to genetic reprogramming(2,11-15) found in this enzyme family.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; BROWN UNIV,DEPT CHEM,PROVIDENCE,RI 02912	Stanford University; Brown University				Khosla, Chaitan/0000-0001-6529-495X				BROWN MJB, 1995, J CHEM SOC CHEM COMM, P1517, DOI 10.1039/c39950001517; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1995, J ANTIBIOT, V48, P647, DOI 10.7164/antibiotics.48.647; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1991, TETRAHEDRON LETT, V32, P5457, DOI 10.1016/0040-4039(91)80057-D; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CANE DE, 1995, J AM CHEM SOC, V117, P6633, DOI 10.1021/ja00129a044; CORCORAN JW, 1981, ANTIBIOTICS, V4, P146; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V288, P1487; DAGNOLO G, 1973, BIOCHIM BIOPHYS ACTA, V326, P155, DOI 10.1016/0005-2760(73)90241-5; DIMROTH P, 1970, EUR J BIOCHEM, V13, P98, DOI 10.1111/j.1432-1033.1970.tb00904.x; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DULTON CJ, 1994, TETRAHEDRON LETT, V35, P327; HUNAITI AA, 1984, ANTIMICROB AGENTS CH, V25, P173, DOI 10.1128/AAC.25.2.173; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.micro.47.1.875; LANZ T, 1991, J BIOL CHEM, V266, P9971; LEADLAY PF, 1993, BIOCHEM SOC T, V21, P218, DOI 10.1042/bst0210218; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; O'Hagan D., 1991, POLYKETIDE METABOLIT; OFFENZELLER M, 1993, J BIOL CHEM, V268, P26127; PIEPER R, IN PRESS J AM CHEM S; PLATE CA, 1970, J BIOL CHEM, V245, P2868; ROBERTS G, 1984, BIOCHEM SOC T, V12, P642, DOI 10.1042/bst0120642; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; WALDT SJ, 1989, BIOCHEMISTRY-US, V28, P4523; WAWSZKIEWICZ EJ, 1964, BIOCHEM Z, V340, P213; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	35	95	105	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					263	266		10.1038/378263a0	http://dx.doi.org/10.1038/378263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477343				2022-12-01	WOS:A1995TE85800043
J	REID, RC; ALONSO, JM				REID, RC; ALONSO, JM			SPECIFICITY OF MONOSYNAPTIC CONNECTIONS FROM THALAMUS TO VISUAL-CORTEX	NATURE			English	Article							SIMPLE RECEPTIVE-FIELDS; CAT STRIATE CORTEX; SPATIAL STRUCTURE; INPUTS; CELLS	In cortical area 17 of the cat, simple receptive fields are arranged in elongated subregions that respond best to bright (on) or dark (off) oriented contours, whereas the receptive fields of their thalamic inputs have a concentric on and off organization(1). This dramatic transformation suggests that there are specific rules governing the connections made between thalamic and cortical neurons(1-3) (see ref. 4). Here we report a study of these rules in which we recorded from thalamic (lateral geniculate nucleus; LGN) and cortical neurons simultaneously and related their receptive fields to their connectivity, as measured by cross-correlation analysis(5,6). The probability of finding a monosynaptic connection was high when a geniculate receptive field was superimposed anywhere over an elongated simple-cell subregion of the same signature (on or off). However, 'inappropriate' connections from geniculate cells of the opposite receptive field signature were extremely rare. Together, these findings imply that the outline of the elongated, simple receptive field, and thus of cortical orientation selectivity, is laid down at the level of the first synapse from the thalamic afferents.			REID, RC (corresponding author), ROCKEFELLER UNIV, NEUROBIOL LAB, NEW YORK, NY 10021 USA.							Alonso Jose-Manuel, 1993, Society for Neuroscience Abstracts, V19, P425; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; FERSTER D, 1987, J NEUROSCI, V7, P1780; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; REID RC, 1994, SOC NEUR ABSTR, V20, P425; RODLECK RW, 1965, VISION RES, V5, P583; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303; TANAKA K, 1985, VISION RES, V25, P357, DOI 10.1016/0042-6989(85)90060-4; Usrey W. Martin, 1995, Society for Neuroscience Abstracts, V21, P21	15	540	545	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 16	1995	378	6554					281	284						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477347				2022-12-01	WOS:A1995TE85800049
J	TURNER, M; MEE, PJ; COSTELLO, PS; WILLIAMS, O; PRICE, AA; DUDDY, LP; FURLONG, MT; GEAHLEN, RL; TYBULEWICZ, VLJ				TURNER, M; MEE, PJ; COSTELLO, PS; WILLIAMS, O; PRICE, AA; DUDDY, LP; FURLONG, MT; GEAHLEN, RL; TYBULEWICZ, VLJ			PERINATAL LETHALITY AND BLOCKED B-CELL DEVELOPMENT IN MICE LACKING THE TYROSINE KINASE SYK	NATURE			English	Article							PRECURSORS; DISRUPTION; CULTURE; PROTEIN	The tyrosine kinase Syk (relative molecular mass 72,000), which is widely expressed in haematopoietic cells, becomes associated with and activated by engagement of the B-cell antigen receptor(1,2). Furthermore, it has been implicated in signalling through the receptors for interleukin-2 (IL-2)(3), granulocyte colony-stimulating factor (G-CSF)(4) and Fc(5), the T cell receptor, as well as through receptors for several platelet agonists(7). A homologous kinase, ZAP-70, is crucial in signalling through the T-cell receptor and in T-cell development(8,9). Using homologous recombination in embryonic stem cells, we created mice null for the syk gene which showed petechiae in utero and died shortly after birth. Irradiated mice reconstituted with Syk-deficient fetal liver showed a block in B-cell development at the pro-B to pre-B cell transition, consistent with a key role for Syk in pre-B-cell receptor signalling. Despite the production of small numbers of immature B cells, Syk-deficient radiation chimaeras failed to accumulate mature B cells, indicating a possible role for this protein in the production or maintenance of mature B cells. In addition, whereas the development of alpha beta T cells proceeded normally, Syk-deficient mice showed impaired development of thymocytes using the V gamma 3 variable region gene (V gamma 3(+) thymocytes). Finally, we show that Syk is not required for signalling through the IL-2 and G-CSF receptors.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	MRC National Institute for Medical Research; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Turner, Martin/N-9976-2014; Williams, Owen/B-5003-2013	Turner, Martin/0000-0002-3801-9896; Williams, Owen/0000-0002-1760-6880; Tybulewicz, Victor/0000-0003-2439-0798; Geahlen, Robert/0000-0001-8400-2924				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHEN JZ, 1994, INT IMMUNOL, V6, P1265, DOI 10.1093/intimm/6.8.1265; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HERBERTSON B M, 1964, J Med Genet, V1, P10, DOI 10.1136/jmg.1.1.10; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; PAIGE CJ, 1984, EUR J IMMUNOL, V14, P979, DOI 10.1002/eji.1830141104; RAMSDEN DA, 1994, J IMMUNOL, V153, P1150; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONFREEDENJEFFR.U, 1995, J EXP MED, V181, P1518	30	628	655	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					298	302		10.1038/378298a0	http://dx.doi.org/10.1038/378298a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477352				2022-12-01	WOS:A1995TE85800054
J	VAUGHAN, J; DONALDSON, C; BITTENCOURT, J; PERRIN, MH; LEWIS, K; SUTTON, S; CHAN, R; TURNBULL, AV; LOVEJOY, D; RIVIER, C; RIVIER, J; SAWCHENKO, PE; VALE, W				VAUGHAN, J; DONALDSON, C; BITTENCOURT, J; PERRIN, MH; LEWIS, K; SUTTON, S; CHAN, R; TURNBULL, AV; LOVEJOY, D; RIVIER, C; RIVIER, J; SAWCHENKO, PE; VALE, W			UROCORTIN, A MAMMALIAN NEUROPEPTIDE RELATED TO FISH UROTENSIN-I AND TO CORTICOTROPIN-RELEASING FACTOR	NATURE			English	Article							EDINGER-WESTPHAL NUCLEUS; RAT; EXPRESSION; CLONING; CRF; SEQUENCE; RECEPTOR; SYSTEM; GENE	Corticotropin-releasing factor (CRF), a peptide first isolated from mammalian brain(1), is critical in the regulation of the pituitary-adrenal axis, and in complementary stress-related endocrine, autonomic and behavioural responses(2). Fish urotensin I and amphibian sauvagine were considered to be homologues(3) of CRF until peptides even more closely related to CRF were identified in these same vertebrate classes(4,5). We have characterized another mammalian member of the CRF family and have localized its urotensin-like immunoreactivity to, and cloned related complementary DNAs from, a discrete rat midbrain region. The deduced protein encodes a peptide that we name urocortin, which is related to urotensin (63% sequence identity) and CRF (45% sequence identity). Synthetic urocortin evokes secretion of adrenocorticotropic hormone (ACTH) both in vitro and in vivo and binds and activates transfected type-1 CRF receptors(6,9), the subtype expressed by pituitary corticotropes. The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors(10-13) in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.	SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,NEURONAL STRUCT & FUNCT LAB,LA JOLLA,CA 92037	Salk Institute; Salk Institute			Bittencourt, Jackson/I-9187-2014; Bittencourt, Jackson Cioni/AAF-6896-2021; Bittencourt, Jackson/B-4696-2011	Bittencourt, Jackson/0000-0002-8908-6474; Bittencourt, Jackson Cioni/0000-0002-8908-6474; Bittencourt, Jackson/0000-0002-8908-6474	NIDDK NIH HHS [DK-26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN RKW, 1993, J NEUROSCI, V13, P5125; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHUNG RY, 1987, NEUROSCI LETT, V83, P13, DOI 10.1016/0304-3940(87)90208-4; IMAKI J, 1991, BRAIN RES, V547, P28; ISHIDA I, 1986, P NATL ACAD SCI USA, V83, P803; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Lederis K., 1985, Recent Progress in Hormone Research, V41, P553; Lederis K., 1994, P67; LOEWY AD, 1978, BRAIN RES, V141, P153, DOI 10.1016/0006-8993(78)90624-8; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; LOVENBERG TW, 1995, ENDOCRINOLOGY, V136, P3351; McDougal D. H., 2014, COMPR PHYSIOL, DOI [10.1002/cphy.c140014, DOI 10.1002/CPHY.C140014]; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; OKAWARA Y, 1988, P NATL ACAD SCI USA, V85, P8439, DOI 10.1073/pnas.85.22.8439; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; PERRIN MH, 1993, ENDOCRINOLOGY, V133, P3058, DOI 10.1210/en.133.6.3058; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777; SAPER CB, 1979, J COMP NEUROL, V183, P689, DOI 10.1002/cne.901830402; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; STENZELPOORE MP, 1992, MOL ENDOCRINOL, V6, P1716, DOI 10.1210/me.6.10.1716; SUTTON SW, 1995, ENDOCRINOLOGY, V136, P1097, DOI 10.1210/en.136.3.1097; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; VALE W, 1983, METHOD ENZYMOL, V103, P565; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VALE W, 1983, RECENT PROG HORM RES, V39, P245; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Webster William R., 1995, P797	30	1333	1368	0	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					287	292		10.1038/378287a0	http://dx.doi.org/10.1038/378287a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477349				2022-12-01	WOS:A1995TE85800051
J	YAO, B; ZHANG, YH; DELIKAT, S; MATHIAS, S; BASU, S; KOLESNICK, R				YAO, B; ZHANG, YH; DELIKAT, S; MATHIAS, S; BASU, S; KOLESNICK, R			PHOSPHORYLATION OF RAF BY CERAMIDE-ACTIVATED PROTEIN-KINASE	NATURE			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR; SERINE; C-RAF-1; INSULIN; CELLS	The sphingomyelin pathway, initiated by hydrolysis of sphingomyelin to ceramide and stimulation of a Ser/Thr ceramide-activated protein (CAP) kinase, mediates tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta action(1-4). CAP kinase is membrane-bound and proline-directed, recognizing the minimal substrate motif Thr-Leu-Pro (ref. 5). TNF may use the sphingomyelin pathway to signal Raf1 to activate the MAP kinase cascade(6-8). Evidence shows that cytoplasmic Raf1 binds to GTP-ras upon cellular stimulation, is recruited to the plasma membrane, and activated(9,11). How membrane-bound Raf1 is activated is uncertain, but regulation of its kinase activity may involve its phosphorylation(12,19). Specific Raf kinases, however, have not hitherto been identified. Here we report that CAP kinase phosphorylates Raf1 on Thr 269, increasing its activity towards MEK (MAP kinase or ERK kinase). Moreover, in intact HL-60 cells, CAP kinase complexes with Raf1 and, in response to TNF and ceramide analogues, phosphorylates and activates Raf1, implicating CAP kinase as a link between the TNF receptor and Raf1.	MEM SLOAN KETTERING CANC CTR,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center								APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GUILBINS E, 1995, IMMUNITY, V2, P341; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JOSEPH CK, 1993, J BIOL CHEM, V268, P2002; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU J, 1994, J BIOL CHEM, V269, P3047; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MOORE DJ, 1994, METHOD ENZYMOL, V226, P448; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; RAINES MA, 1993, J BIOL CHEM, V268, P14572; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WANG HG, 1994, ONCOGENE, V9, P2751; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	306	315	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 16	1995	378	6554					307	310		10.1038/378307a0	http://dx.doi.org/10.1038/378307a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE858	7477354				2022-12-01	WOS:A1995TE85800056
J	FERMO, I; DANGELO, SV; PARONI, R; MAZZOLA, G; CALORI, G; DANGELO, A				FERMO, I; DANGELO, SV; PARONI, R; MAZZOLA, G; CALORI, G; DANGELO, A			PREVALENCE OF MODERATE HYPERHOMOCYSTEINEMIA IN PATIENTS WITH EARLY-ONSET VENOUS AND ARTERIAL OCCLUSIVE DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERHOMOCYSTEINEMIA; HOMOCYSTEINE; ARTERIAL OCCLUSIVE DISEASES; THROMBOPHLEBITIS; THROMBOEMBOLISM	POOR ANTICOAGULANT RESPONSE; PROTEIN-C ACTIVATION; PLASMA HOMOCYSTEINE; ENDOTHELIAL-CELLS; VASCULAR-DISEASE; ORAL ANTICOAGULATION; THROMBOGENIC AGENT; RISK FACTOR; THROMBOSIS; HOMOCYST(E)INE	Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional e-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 +/- 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 +/- 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L-methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% Cl, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements done after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (Cl, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (Cl, 1.19 to 2.42; P < 0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 +/- 11.2 years compared with 25.2 +/- 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 +/- 11.1 years compared with 31.0 +/- 12.3; P < 0.005). Patients with mild hyperhomocysteineria had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [Cl, 51% to 95%]) in patients with defects than in patients without defects (41% [Cl, 26% to 57%] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.			FERMO, I (corresponding author), IRCCS, IST SCI HS RAFFAELE, ANAL LAB, VIA OLGETTINA 60, I-20132 MILAN, ITALY.		PARONI, RITA/AAC-6265-2020; fermo, isabella/AAN-3999-2020; PARONI, RITA/C-2955-2012; D'Angelo, Armando/K-2583-2018	PARONI, RITA/0000-0002-3186-8860; fermo, isabella/0000-0003-2947-1933; PARONI, RITA/0000-0002-3186-8860; D'Angelo, Armando/0000-0002-9857-4509				BANDELLO F, 1994, THROMB HAEMOSTASIS, V72, P39; BERTINA RM, 1994, NATURE, V64, P369; BLANN AD, 1992, ATHEROSCLEROSIS, V94, P89, DOI 10.1016/0021-9150(92)90192-J; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; CADROY Y, 1994, BLOOD, V83, P2008; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; CUSHMAN M, 1994, THROMB HAEMOSTASIS, V72, P647; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; DANGELO SV, 1995, THROMB RES, V77, P375; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FERMO I, 1992, J CHROMATOGR, V593, P171, DOI 10.1016/0021-9673(92)80283-Z; FERMO I, 1993, AMINO ACIDS, V5, P17, DOI 10.1007/BF00806188; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GRIFFIN JH, 1993, BLOOD, V82, P1989; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1543; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1983, METABOLIC BASIS INHE, P522; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PATHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WANG J, 1993, THROMB HAEMOSTASIS, V70, P1047	46	217	222	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1995	123	10					747	+		10.7326/0003-4819-123-10-199511150-00002	http://dx.doi.org/10.7326/0003-4819-123-10-199511150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE172	7574192				2022-12-01	WOS:A1995TE17200002
J	GORMAN, JM				GORMAN, JM			RESPIRATION DISORDERS IN PANIC ATTACKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GORMAN, JM (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.							Barlow D.H., 2002, ANXIETY ITS DISORDER; KLEIN DF, 1993, ARCH GEN PSYCHIAT, V50, P306; PAPP LA, 1993, AM J PSYCHIAT, V150, P1149	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474206				2022-12-01	WOS:A1995TD57100010
J	JAMPEL, HD				JAMPEL, HD			PATCHING FOR CORNEAL ABRASIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CONTACT				JAMPEL, HD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218, USA.							ANDERSON C, 1991, CORNEA, V10, P478, DOI 10.1097/00003226-199111000-00003; ASWAD MI, 1989, ARCH OPHTHALMOL-CHIC, V107, P1667, DOI 10.1001/archopht.1989.01070020745040; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; SCHEIN OD, 1993, AM J EMERG MED, V11, P606, DOI 10.1016/0735-6757(93)90012-Z	4	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474205				2022-12-01	WOS:A1995TD57100009
J	KLEIN, DF				KLEIN, DF			RESPIRATION DISORDERS IN PANIC ATTACKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KLEIN, DF (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474207				2022-12-01	WOS:A1995TD57100011
J	NYGARD, O; VOLLSET, SE; REFSUM, H; STENSVOLD, I; TVERDAL, A; NORDREHAUG, JE; UELAND, PM; KVALE, G				NYGARD, O; VOLLSET, SE; REFSUM, H; STENSVOLD, I; TVERDAL, A; NORDREHAUG, JE; UELAND, PM; KVALE, G			TOTAL PLASMA HOMOCYSTEINE AND CARDIOVASCULAR RISK PROFILE - THE HORDALAND HOMOCYSTEINE STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CORONARY-ARTERY DISEASE; VASCULAR-DISEASE; METHIONINE METABOLISM; LIPOPROTEIN LEVELS; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY; UNITED-STATES; HEART-DISEASE; FOLATE LEVELS	Objective.-To estimate the relations between established cardiovascular risk factors and total homocysteine (tHcy) in plasma. Design.-Health examination survey by the Norwegian Health Screening Service in 1992 and 1993. Setting.-General community, Hordaland County of Western Norway. Participants.-A total of 7591 men and 8585 women, 40 to 67 years of age, with no history of hypertension, diabetes, coronary heart disease, or cerebrovascular disease were included. Main Outcome Measure.-Plasma tHcy level. Results.-The level of plasma tHcy was higher in men than in women and increased with age. In subjects 40 to 42 years old, geometric means were 10.8 mu mol/L for 5918 men and 9.1 mu mol/L for 6348 women. At age 65 to 67 years, the corresponding tHcy values were 12.3 mu mol/L (1386 men) and 11.0 mu mol/L (1932 women). Plasma tHcy level increased markedly with the daily number of cigarettes smoked in all age groups. Its relation to smoking was particularly strong in women. The combined effect of age, sex, and smoking was striking. Heavy-smoking men aged 65 to 67 years had a mean tHcy level 4.8 mu mol/L higher than never-smoking women aged 40 to 42 years. Plasma tHcy level also was positively related to total cholesterol level, blood pressure, and heart rate and inversely related to physical activity. The relations were not substantially changed by multivariate adjustment, including intake of vitamin supplements, fruits, and vegetables. Conclusions.-Elevated plasma tHcy level was associated with major components of the cardiovascular risk profile, ie, male sex, old age, smoking, high blood pressure, elevated cholesterol level, and lack of exercise. These findings should influence future studies on the etiology and pathogenesis of cardiovascular disease.	UNIV BERGEN, DEPT BIOL CLIN, DIV PHARMACOL, BERGEN, NORWAY; UNIV BERGEN, CTR INT HLTH, BERGEN, NORWAY; HAUKELAND UNIV HOSP, DEPT HEART DIS, BERGEN, NORWAY; NATL HLTH SCREENING SERV, OSLO, NORWAY	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital			Ueland, Per M/C-7340-2013; Refsum, Helga/A-4073-2010	Ueland, Per Magne/0000-0002-1903-0571; Tverdal, Aage/0000-0002-2909-5678				ANDERSSON A, 1992, EUR J CLIN CHEM CLIN, V30, P377; ANDERSSON A, 1992, EUR J CLIN INVEST, V22, P79, DOI 10.1111/j.1365-2362.1992.tb01940.x; ANKER G, 1995, INT J CANCER, V60, P365; ARAKI A, 1993, ATHEROSCLEROSIS, V103, P149, DOI 10.1016/0021-9150(93)90258-V; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BERG K, 1992, CLIN GENET, V41, P315; BERGMARK C, 1993, EUR J VASCULAR SURG, V7, P391, DOI 10.1016/S0950-821X(05)80255-5; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOERS GH, 1983, J CLIN INVEST, V72, P1971, DOI 10.1172/JCI111161; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1992, SCAND J CLIN LAB INV, V52, P283, DOI 10.3109/00365519209088360; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4; CHEN ATL, 1989, ENVIRON MOL MUTAGEN, V13, P319, DOI 10.1002/em.2850130407; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; D'Avanzo B, 1993, Ann Epidemiol, V3, P645; DASTUR DK, 1972, BMJ-BRIT MED J, V3, P260, DOI 10.1136/bmj.3.5821.260; DECESARIS R, 1992, CARDIOLOGY, V81, P233, DOI 10.1159/000175809; DIXON WJ, 1992, BMDP STATISTICAL SOF, V1; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; GOLDBERG L, 1985, MED CLIN N AM, V69, P41; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1986, METABOLISM, V35, P889, DOI 10.1016/0026-0495(86)90049-1; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LINNELL JC, 1968, BRIT MED J, V2, P215, DOI 10.1136/bmj.2.5599.215; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MALINOW MR, 1994, CLIN CHEM, V40, P857; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; MCPHILLIPS JB, 1994, J AM DIET ASSOC, V94, P287, DOI 10.1016/0002-8223(94)90370-0; MOLGAARD J, 1992, J INTERN MED, V231, P273; MORRIS JN, 1980, LANCET, V2, P1207; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PIYATHILAKE CJ, 1994, AM J CLIN NUTR, V60, P559, DOI 10.1093/ajcn/60.4.559; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; REFSUM H, 1989, CLIN CHEM, V35, P1921; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SUBAR AF, 1990, AM J PUBLIC HEALTH, V80, P1323, DOI 10.2105/AJPH.80.11.1323; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; UELAND PM, 1995, CLIN CHEM, V41, P340; UELAND PM, 1993, CLIN CHEM, V39, P1764; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VANDERMOOREN MJ, 1994, EUR J CLIN INVEST, V24, P733; VERMAAK WJH, 1990, AM J CLIN NUTR, V51, P1058, DOI 10.1093/ajcn/51.6.1058; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549; WEINTRAUB MS, 1989, CIRCULATION, V79, P1007, DOI 10.1161/01.CIR.79.5.1007; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; WONG PWK, 1988, AM J MED, V84, P1093, DOI 10.1016/0002-9343(88)90328-2; WU LL, 1994, CLIN CHEM, V40, P552; 1991, S PLUS USERS MANUAL, V1	62	896	932	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1526	1533		10.1001/jama.274.19.1526	http://dx.doi.org/10.1001/jama.274.19.1526			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD571	7474221				2022-12-01	WOS:A1995TD57100029
J	REINISCH, JM; SANDERS, SA; MORTENSEN, EL; RUBIN, DB				REINISCH, JM; SANDERS, SA; MORTENSEN, EL; RUBIN, DB			IN-UTERO EXPOSURE TO PHENOBARBITAL AND INTELLIGENCE DEFICITS IN ADULT MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; CENTRAL-NERVOUS-SYSTEM; MATERNAL ALCOHOL-USE; EDUCATIONAL-LEVEL; FEBRILE SEIZURES; BEHAVIOR; CHILDREN; PREGNANCY; INFANTS; DRUGS	Objective.-To test whether exposure to phenobarbital in utero is associated with deficits in intelligence scores in adult men and whether the magnitude of the postnatal effect is mediated by exposure parameters and/or postnatal environmental factors. Design.-Two double-blind studies were conducted on independent samples of adult men prenatally exposed to phenobarbital and matched control samples using different measures of general intelligence, Based on data from control subjects, regression models were built relating intelligence scores to relevant pre-exposure matching variables and age at testing, Models generated predicted scores for each exposed subject, Group mean differences between the individually predicted and observed scores estimated exposure effects. Setting.-Copenhagen, Denmark. Participants.-Exposed subjects were adult men born at the largest hospital in Copenhagen between 1959 and 1961 who were exposed to phenobarbital during gestation via maternal medical treatment and whose mothers had no history of a central nervous system disorder and no treatment during pregnancy with any other psychopharmacological drug. Study 1 included 33 men and study 2, 81 men. Controls were unexposed members of the same birth cohort matched on a wide spectrum of maternal variables recorded prenatally and perinatally. Controls for studies 1 and 2 included 52 and 101 men, respectively. Main Outcome Measures.-In study 1: Wechsler Adult intelligence Scale (Danish version); in study 2: Danish Military Draft Board Intelligence Test (Borge Priens Prove). Result.-Men exposed prenatally to phenobarbital had significantly lower verbal intelligence scores (approximately 0.5 SD) than predicted, Lower socioeconomic status and being the offspring of an ''unwanted'' pregnancy increased the magnitude of the negative effects; Exposure that included the last trimester was the most detrimental. Conclusion.-Phenobarbital exposure during early development can have long-term deleterious effects on cognitive performance. Detrimental environmental conditions can interact with prenatal biological insult to magnify negative outcomes, Physicians are urged to use increased caution in prescribing such medications during pregnancy.	INST PREVENT MED, HOSP CORP, COPENHAGEN, DENMARK; HARVARD UNIV, DEPT STAT, CAMBRIDGE, MA USA	Harvard University	REINISCH, JM (corresponding author), INDIANA UNIV, KINSEY INST RES SEX GENDER & REPROD, MORRISON HALL, 3RD FLOOR, BLOOMINGTON, IN 47405 USA.				NICHD NIH HHS [HD 20263, HD 17655] Funding Source: Medline; NIDA NIH HHS [DA 05056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017655, R01HD020263] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARAI Y, 1968, ENDOCRINOLOGY, V82, P1005, DOI 10.1210/endo-82-5-1005; ARAI Y, 1968, ENDOCRINOLOGY, V82, P1010, DOI 10.1210/endo-82-5-1010; ARMITAGE SG, 1952, J COMP PHYSIOL PSYCH, V45, P146, DOI 10.1037/h0062268; BRENT DA, 1990, PEDIATRICS, V85, P1086; CAMFIELD CS, 1979, J PEDIATR-US, V95, P361, DOI 10.1016/S0022-3476(79)80507-7; COCHRAN WG, 1973, SANKHYA SER A, V35, P417; DEVASCONCELOS AP, 1990, EXP NEUROL, V108, P176, DOI 10.1016/0014-4886(90)90025-N; DODSON WE, 1989, CLIN PERINATOL, V16, P339, DOI 10.1016/S0095-5108(18)30636-5; FARWELL JR, 1990, NEW ENGL J MED, V323, P485; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; Feingold C, 1994, J Pediatr Nurs, V9, P91; FISHMAN RHB, 1983, NEUROSCI BIOBEHAV R, V7, P19, DOI 10.1016/0149-7634(83)90004-0; FRIIS B, 1977, ARCH DIS CHILD, V52, P239, DOI 10.1136/adc.52.3.239; GAILY E, 1990, DEV MED CHILD NEUROL, V32, P403; Graffar M., 1960, MOD PROBL PADIAT, V5, P30; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; HESS G, 1974, WAIS ANVENDT PA 698; HILL TD, 1985, CLIN PSYCHOL REV, V5, P287, DOI 10.1016/0272-7358(85)90009-1; HIRTZ DG, 1986, AM J DIS CHILD, V140, P909, DOI 10.1001/archpedi.1986.02140230079037; JONES DC, 1992, IND LABOR RELAT REV, V45, P452, DOI 10.2307/2524272; KALTENBACH K, 1986, NEUROTOXICOL TERATOL, V8, P353; KILBEY MM, 1991, DHHSNIDA114 NAT I DR; KLIPSTEIN FA, 1964, BLOOD, V23, P68, DOI 10.1182/blood.V23.1.68.68; LIEWENDAHL K, 1978, CLIN ENDOCRINOL, V8, P185, DOI 10.1111/j.1365-2265.1978.tb01493.x; LITTLE R, 1987, STATISTICAL ANAL MIS; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; Martin J C, 1979, Neurobehav Toxicol, V1, P49; MARTIN JC, 1986, NEUROTOXICOL TERATOL, V8, P335; MIDDAUGH LD, 1986, NEUROTOXICOLOGY, V7, P287; MORALES WJ, 1986, OBSTET GYNECOL, V68, P295, DOI 10.1097/00006250-198609000-00001; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; PFEIFFER SI, 1990, PERCEPT MOTOR SKILL, V70, P1367, DOI 10.2466/PMS.70.3.1367-1378; Rayburn W, 1989, J Perinatol, V9, P268; RAYBURN W, 1988, AM J OBSTET GYNECOL, V159, P1491, DOI 10.1016/0002-9378(88)90580-7; REINISCH JM, 1982, NEUROSCI BIOBEHAV R, V6, P311, DOI 10.1016/0149-7634(82)90043-4; REINISCH JM, 1993, ACTA PSYCHIAT SCAND, V87, P54, DOI 10.1111/j.1600-0447.1993.tb05361.x; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; ROSENBAUM PR, 1985, BIOMETRICS, V41, P103, DOI 10.2307/2530647; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; ROSENTHAL R, 1982, J EDUC PSYCHOL, V74, P708, DOI 10.1037/0022-0663.74.5.708; ROSENTHAL R, 1982, J EDUC PSYCHOL, V74, P166, DOI 10.1037/0022-0663.74.2.166; Rubin DB, 1984, WG COCHRANS IMPACT S, P37; RUSSELL M, 1991, ALCOHOL CLIN EXP RES, V15, P991, DOI 10.1111/j.1530-0277.1991.tb05200.x; Scarr S., 1981, RACE SOCIAL CLASS IN; SCHAIE KW, 1983, DEV PSYCHOL, V19, P531, DOI 10.1037/0012-1649.19.4.531; SCHRAEDER BD, 1986, NURS RES, V35, P237; SMITH I, 1991, ARCH DIS CHILD, V66, P311, DOI 10.1136/adc.66.3.311; Sobczyk W, 1977, Neurol Neurochir Pol, V11, P59; STREISSGUTH AP, 1989, DEV PSYCHOL, V25, P3, DOI 10.1037/0012-1649.25.1.3; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0; TEASDALE TW, 1988, BRIT J EDUC PSYCHOL, V58, P307, DOI 10.1111/j.2044-8279.1988.tb00906.x; TEASDALE TW, 1991, HUM BIOL, V63, P19; VALAES T, 1980, PEDIATR RES, V14, P947, DOI 10.1203/00006450-198008000-00011; VANDERPOL MC, 1991, AM J OBSTET GYNECOL, V164, P121, DOI 10.1016/0002-9378(91)90640-D; VILLUMSEN AL, 1970, ENV FACTORS CONGENIT, P124; VINING EPG, 1987, PEDIATRICS, V80, P165; WALLIN A, 1984, ACTA PAEDIATR SCAND, V73, P488, DOI 10.1111/j.1651-2227.1984.tb09960.x; Wechsler, 2012, WECHSLER ADULT INTEL, DOI 10.1037/t15169-000; Wesson D. R, 1977, BARBITURATES THEIR U; WILSON JT, 1971, CLIN PEDIATR, V10, P684, DOI 10.1177/000992287101001202; WITKIN HA, 1976, SCIENCE, V193, P547, DOI 10.1126/science.959813; Yaffe S J, 1980, Prog Clin Biol Res, V36, P157; YAFFE SJ, 1990, DEV PHARMACOL THERAP, V15, P215, DOI 10.1159/000457649; YANAI J, 1989, NEUROTOXICOLOGY, V10, P543; YANAI J, 1981, EXP NEUROL, V73, P199, DOI 10.1016/0014-4886(81)90055-8; ZACHAUCHRISTIAN.B, 1975, BABIES HUMAN DEV 1ST; ZEMP JW, 1975, ADDICT DIS, V2, P307; 1951, CLASSIFICATION OCCUP, P3	68	214	217	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	1995	274	19					1518	1525		10.1001/jama.274.19.1518	http://dx.doi.org/10.1001/jama.274.19.1518			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD571	7474220				2022-12-01	WOS:A1995TD57100028
J	BOONE, KE; WATTERS, DAK				BOONE, KE; WATTERS, DAK			THE INCIDENCE OF MALARIA AFTER SPLENECTOMY IN PAPUA-NEW-GUINEA	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	In the tropics, as in the developed world, the spleen is the commonest intra-abdominal organ to be injured. Splenic enlargement due to chronic malaria predisposes to splenic injury, particularly in low velocity blunt trauma due to domestic violence or assault, both of which are common in Papua New Guinea. In developed countries the risk of sepsis after splenectomy has resulted in a more conservative approach to splenic trauma. In the tropics death from malaria after splenectomy has been reported, but no formal study has been undertaken. We studied the sequelae of splenic trauma and splenectomy in patients living in an area of Papua New Guinea where malaria is endemic.	DIV SURG,BOROKO,PAPUA N GUINEA				Watters, David Allan/AAI-1022-2020	Watters, David Allan/0000-0002-5742-8417				CULLINGFORD GL, 1991, BRIT J SURG, V78, P716, DOI 10.1002/bjs.1800780626; DEODHAR HA, 1993, BRIT MED J, V307, P1408, DOI 10.1136/bmj.307.6916.1408; HAMILTON DR, 1982, AUST NZ J SURG, V52, P310, DOI 10.1111/j.1445-2197.1982.tb05407.x; LOOAREESUWAN S, 1993, CLIN INFECT DIS, V16, P361, DOI 10.1093/clind/16.3.361; WILSON RH, 1992, INJURY, V23, P5, DOI 10.1016/0020-1383(92)90116-A	5	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1273	1273		10.1136/bmj.311.7015.1273	http://dx.doi.org/10.1136/bmj.311.7015.1273			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496237	Green Published			2022-12-01	WOS:A1995TE85900023
J	CROFT, NM; MARSHALL, TG; FERGUSON, A				CROFT, NM; MARSHALL, TG; FERGUSON, A			GUT INFLAMMATION IN CHILDREN WITH CYSTIC-FIBROSIS ON HIGH-DOSE ENZYME SUPPLEMENTS	LANCET			English	Note							LAVAGE FLUID; DISEASE	We used a whole-gut perfusion technique to study subclinical gut inflammation in children with cystic fibrosis (18 elective tests, three lavages to treat distal intestinal obstruction syndrome); and in 12 control children with constipation or pre-colonoscopy. We assayed for haemoglobin, IgG, albumin, alpha-1-antitrypsin, granulocyte elastase, interleukin-1 beta (IL-1 beta) and IL-8 concentrations in whole-gut ravage fluid. Results for two children with distal intestinal obstruction syndrome, the only children in the series taking Nutrizym 22, were strikingly abnormal. This new test has revealed subclinical gut mucosal inflammation in a minority of CF children, for which distal intestinal obstruction syndrome, Nutrizym 22 treatment, or both, may be risk factors.	ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND		CROFT, NM (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BRYDON WG, 1993, EUR J GASTROEN HEPAT, V5, P269, DOI 10.1097/00042737-199304000-00013; BRYDON WG, 1992, LANCET, V340, P1381, DOI 10.1016/0140-6736(92)92562-T; FERGUSON A, 1994, SCAND J GASTROENTERO, V29, P15, DOI 10.3109/00365529409091390; FERGUSON A, IN PRESS ADV DRUG DE; HODGES M, 1994, J PEDIATR GASTR NUTR, V19, P65, DOI 10.1097/00005176-199407000-00010; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; SMYTH RL, 1995, LANCET, V346, P1247, DOI 10.1016/S0140-6736(95)91860-4; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6	8	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1265	1267						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475719				2022-12-01	WOS:A1995TE14500012
J	DOWSE, GK; GAREEBOO, H; ALBERTI, KGMM; ZIMMET, P; TUOMILEHTO, J; PURRAN, A; FAREED, D; CHITSON, P; COLLINS, VR; HEMRAJ, F				DOWSE, GK; GAREEBOO, H; ALBERTI, KGMM; ZIMMET, P; TUOMILEHTO, J; PURRAN, A; FAREED, D; CHITSON, P; COLLINS, VR; HEMRAJ, F			CHANGES IN POPULATION CHOLESTEROL CONCENTRATIONS AND OTHER CARDIOVASCULAR RISK FACTOR LEVELS AFTER 5 YEARS OF THE NONCOMMUNICABLE DISEASE INTERVENTION PROGRAM IN MAURITIUS	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; STANFORD 5-CITY PROJECT; CORONARY HEART-DISEASE; HYPERTENSION-CONTROL; CHINESE MAURITIANS; PLASMA-CHOLESTEROL; HEALTH EDUCATION; BLOOD-PRESSURE; PREVALENCE; NIDDM	Objective-To study changes in the prevalence of risk factors for cardiovascular disease after a five year population-wide intervention programme promoting a healthy lifestyle in a developing country. Design-Cross sectional cluster surveys in 1987 and 1992. Methodology included a two hour 75 g oral glucose tolerance test, measurement of body mass index, waist:hip ratio, basal Lipid concentrations, and blood pressure; and a lifestyle questionnaire. Setting-Mauritius, in the Indian Ocean. Subjects-All adults aged 25-74 years residing in geographically defined clusters. Main outcome measures-Age standardised prevalence of categorical disease and risk factor conditions and mean levels and frequency distributions of continuous variables. Results-Response rates were 86.2% (5080/5892) in 1987 and 89.5% (5162/5770) in 1992. Significant decreases were found in the prevalence of hypertension (15.0% to 12.1% in men and 12.4% to 10.9% in women); cigarette smoking (58.2% to 47.2% and 6.9% to 3.7% respectively); and heavy alcohol consumption (38.2% to 14.4% and 2 6% to 0.6% respectively). Moderate leisure physical activity increased from 16.9% to 22.1% in men and from 1.3% to 2.7% in women. Mean population serum total cholesterol concentration fell appreciably from 5.5 mmol/l to 4.7 mmol/l (P < 0.001). The prevalence of overweight or obesity increased, and the rates of glucose intolerance changed little. The population frequency distributions of blood pressure, serum lipid concentration, and a composite risk factor score shifted advantageously. Conclusions-Lifestyle intervention projects can be implemented and have positive effects in developing countries. A pronounced improvement in the population lipid profile in Mauritius was probably related to a change in the saturated fat content of a widely used cooking oil.	INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MINIST HLTH,PORT LOUIS,MAURITIUS; UNIV NEWCASTLE UPON TYNE,CTR HUMAN DIABET & METAB RES,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,HELSINKI,FINLAND; WHO,PORT LOUIS,MAURITIUS	Newcastle University - UK; Finland National Institute for Health & Welfare; World Health Organization			Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776	NIDDK NIH HHS [DK-25446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALROOMI KA, 1989, AM J EPIDEMIOL, V129, P503, DOI 10.1093/oxfordjournals.aje.a115161; ARMITAGE P, 1987, STATISTICAL METHODS; BENNETT SA, 1994, MED J AUSTRALIA, V161, P519, DOI 10.5694/j.1326-5377.1994.tb127594.x; BONANOME A, 1988, NEW ENGL J MED, V318, P1244, DOI 10.1056/NEJM198805123181905; COLLINS VR, 1994, DIABETES CARE, V17, P288, DOI 10.2337/diacare.17.4.288; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; DOWSE GK, 1991, DIABETES CARE, V14, P968, DOI 10.2337/diacare.14.11.968; DOWSE GK, 1994, MED J AUSTRALIA, V160, P767, DOI 10.5694/j.1326-5377.1994.tb125945.x; EPSTEIN FH, 1989, INT J EPIDEMIOL, V18, pS203; FORTMANN SP, 1993, AM J EPIDEMIOL, V137, P1039, DOI 10.1093/oxfordjournals.aje.a116608; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HODGE AM, 1994, INT J OBESITY, V18, P419; LI N, 1991, J HYPERTENS, V9, P859; MATTSON FH, 1985, J LIPID RES, V26, P194; NISSINEN A, 1988, AM J EPIDEMIOL, V127, P488, DOI 10.1093/oxfordjournals.aje.a114825; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; ROSSOUW JE, 1993, INT J EPIDEMIOL, V22, P428, DOI 10.1093/ije/22.3.428; SHIGAN E N, 1988, World Health Statistics Quarterly, V41, P267; TUOMILEHTO J, 1986, ADDICT BEHAV, V11, P1, DOI 10.1016/0306-4603(86)90002-X; TUOMILEHTO J, 1993, J INTERN MED, V233, P187, DOI 10.1111/j.1365-2796.1993.tb00672.x; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; WILHELMSEN L, 1989, INT J EPIDEMIOL, V18, pS101; ZIMMET PZ, 1991, AM J EPIDEMIOL, V134, P862, DOI 10.1093/oxfordjournals.aje.a116161; 1993, 1993 WORLD BANK DEV; 1978, WHO TECHNICAL REPORT, V628; 1988, WORLD HLTH STATISTIC; 1990, STATISTICAL PACKAGE	31	161	169	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1255	1259		10.1136/bmj.311.7015.1255	http://dx.doi.org/10.1136/bmj.311.7015.1255			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496233	Green Published			2022-12-01	WOS:A1995TE85900018
J	EPSTEIN, PR; PENA, OC; RACEDO, JB				EPSTEIN, PR; PENA, OC; RACEDO, JB			CLIMATE AND DISEASE IN COLOMBIA	LANCET			English	Editorial Material									UNIV MAGDALENA,SANTA MARTA,COLOMBIA; UNIV JORGE TADEO LOZANO,BOGOTA,COLOMBIA	Universidad del Magdalena; Universidad de Bogota Jorge Tadeo Lozano	EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH PUBL HLTH,NEW DIS GRP,CAMBRIDGE,MA, USA.							DOBSON A, 1993, LANCET, V342, P1096, DOI 10.1016/0140-6736(93)92069-6; EPSTEIN PR, 1993, LANCET, V341, P1404, DOI 10.1016/0140-6736(93)90962-G; Mancera P. Jose Ernesto, 1994, Anales del Instituto de Investigaciones Marinas de Punta de Betin, V23, P103; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; 1995, MMWR-MORBID MORTAL W, V44, P775; 1995, MMWR-MORBID MORTAL W, V44, P721	6	24	30	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1243	1244		10.1016/S0140-6736(95)91856-6	http://dx.doi.org/10.1016/S0140-6736(95)91856-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475711				2022-12-01	WOS:A1995TE14500004
J	KATAN, MB				KATAN, MB			EXIT TRANS-FATTY-ACIDS	LANCET			English	Editorial Material											KATAN, MB (corresponding author), AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,WAGENINGEN,NETHERLANDS.							ALMENDINGEN K, 1995, J LIPID RES, V36, P1370; ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; GILLMAN MW, 1995, CIRCULATION, V91, P925; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI [10.1146/annurev.nu.15.070195.002353, 10.1146/annurev.nutr.15.1.473]; Kris-Etherton P. M., 1995, American Journal of Clinical Nutrition, V62, p655S; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; SENTI FRE, 1988, HLTH ASPECTS DIETARY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; ZOCK PL, 1995, AM J CLIN NUTR, V61, P617, DOI 10.1093/ajcn/61.3.617; 1995, TRANS FATTY ACIDS	11	32	34	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1245	1246		10.1016/S0140-6736(95)91858-2	http://dx.doi.org/10.1016/S0140-6736(95)91858-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475713	Green Accepted			2022-12-01	WOS:A1995TE14500006
J	KLONOFFCOHEN, H; EDELSTEIN, SL				KLONOFFCOHEN, H; EDELSTEIN, SL			BED SHARING AND THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HONG-KONG; SLEEP	Objective-To determine whether infants who died of the sudden infant death syndrome routinely shared their parents' bed more commonly than control infants. Design-Case-control study. Setting-Southern California. Subjects-200 white, African-American, Latin American, and Asian infants who died and 200 living controls, matched by birth hospital, date of birth, sex, and race. Main outcome measures-Routine bedding (for example, crib, cradle), day and night time sleeping arrangement (for example, alone or sharing a bed); for cases only, sleeping arrangement at death. Differences in bed sharing practices among races. Results-Of the infants who died of the syndrome, 45 (22.4%) were sharing a bed. Daytime bed sharing was more common in African-American (P<0.001) and Latin American families (P < 0.001) than in white families. The overall adjusted odds ratio for the syndrome and routine bed sharing in the daytime was 1 38 (95% confidence interval 0.59 to 3.22) and for night was 1.21 (0.59 to 2.48). These odds ratios were adjusted for routine sleep position, passive smoking, breast feeding, intercom use, infant birth weight, medical conditions at birth, and maternal age and education. There was no interaction between bed sharing and passive smoking or alcohol use by either parent. Conclusions-Although there was a significant difference between bed sharing among African-American and Latin American parents compared with white parents, there was no significant relation between routine bed sharing and the sudden infant death syndrome.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, ROCKVILLE, MD 20852 USA	George Washington University	KLONOFFCOHEN, H (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, LA JOLLA, CA 92037 USA.							BOURNE AJ, 1994, BRIT MED J, V308, P537, DOI 10.1136/bmj.308.6927.537c; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; FAROOQI I, 1994, BMJ-BRIT MED J, V308, P204, DOI 10.1136/bmj.308.6922.204b; GUNTHEROTH WG, 1989, CRIB DEATH SUDDEN IN; HOPPENBROUWERS T, 1982, SLEEP, V5, P131; KONNER M, 1987, ROLE CLTURE DEV DISO; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MCKENNA JJ, 1993, ACTA PAEDIATR, V82, P31, DOI 10.1111/j.1651-2227.1993.tb12871.x; MCKENNA JJ, 1990, AM J PHYS ANTHROPOL, V83, P331, DOI 10.1002/ajpa.1330830307; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1993, SLEEP, V16, P387; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; Mitchell EA, 1992, J PAEDIAT CHILD HL S, V28, P3; MOSKO S, 1993, J BEHAV MED, V16, P589, DOI 10.1007/BF00844721; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; TASAKI H, 1992, J PAEDIATRIC ASS JAP, P364; 1989, MONTHLY VITAL STATIS; 1990, SAS USERS GUIDE STAT; 1993, EGRET EPIDEMIOLOGICA	21	56	56	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1269	1272		10.1136/bmj.311.7015.1269	http://dx.doi.org/10.1136/bmj.311.7015.1269			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496236	Green Published			2022-12-01	WOS:A1995TE85900021
J	LANGFORD, LA; PIATYSZEK, MA; XU, RS; SCHOLD, SC; SHAY, JW				LANGFORD, LA; PIATYSZEK, MA; XU, RS; SCHOLD, SC; SHAY, JW			TELOMERASE ACTIVITY IN HUMAN BRAIN-TUMORS	LANCET			English	Note								Malignant gliomas are invasive into surrounding brain and are refractory to therapy. Telomerase stabilises telomere length and may immortalise cells to allow unlimited proliferation. Our analysis of telomerase activity in 90 human gliomas showed that 19 of 19 oligodendrogliomas and 38 of 51 glioblastoma multiformes have detectable telomerase activity. The absence of telomerase activity in anaplastic astrocytomas (2/20 positive)and in one-quarter (13/51) of the glioblastomas suggests that these tumours follow different pathways of neoplastic progression. Thus we have found that a distinct subgroup of brain tumour consists of transformed yet pre-immortal cells.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL NEUROPATHOL,HOUSTON,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center			Piatyszek, Mieczyslaw A./F-9365-2015; Shay, Jerry W/F-7878-2011	Piatyszek, Mieczyslaw A./0000-0003-0502-3239; 				COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; NURNBERG P, 1993, HUM GENET, V91, P190; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Shay Jerry W., 1994, Molecular and Cellular Differentiation, V2, P1; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; WRIGHT WE, IN PRESS DEV GENET	10	215	224	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1267	1268		10.1016/S0140-6736(95)91865-5	http://dx.doi.org/10.1016/S0140-6736(95)91865-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475720				2022-12-01	WOS:A1995TE14500013
J	MALIN, AS; GWANZURA, LKZ; KLEIN, S; ROBERTSON, VJ; MUSVAIRE, P; MASON, PR				MALIN, AS; GWANZURA, LKZ; KLEIN, S; ROBERTSON, VJ; MUSVAIRE, P; MASON, PR			PNEUMOCYSTIS-CARINII PNEUMONIA IN ZIMBABWE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; CENTRAL-AFRICA; LUSAKA; ZAMBIA; AIDS	Pneumocystis carinii pneumonia (PCP) is said to be rare in Africa, with reported rates of 0-22% in human-immunodeficiency-virus (HIV) infected individuals with respiratory symptoms. Over one year in a central hospital in southern Africa, 64 HIV-infected patients with acute diffuse pneumonia unresponsive to penicillin and sputum smear-negative for acid-fast bacilli underwent fibreoptic bronchoscopy. Bronchoalveolar lavage fluid was assessed for bacteria, fungi, Pneumocystis carinii, and mycobacteria. 21 patients (33%) had PCP and 24 (39%) had tuberculosis; 6 of these had both infections. 5 patients had Kaposi's sarcoma (KS) associated with PCP, tuberculosis, or another infection, in 1 patient KS was the only finding, and in 21 no pathogen was identified. A logistic regression model was used to assess clinical, radiographic, and arterial blood gas predictors of PCP and tuberculosis, Fine reticulonodular shadowing on the chest radiograph (nodular component <1 mm) was the strongest independent predictor of PCP (odds ratio 8.5 [95% CI 6.1-10.9]). A respiratory rate of more than 40/min was the best clinical predictor of PCP (odds ratio 11.2 [95% CI 8.8-13.6]). Median CD4(+) T cell count for all cases of PCP was 134/mu L (range 5-355) and for tuberculosis without PCP 206/mu L (range 61-787). In resource-limited countries, a regionally appropriate management algorithm is required.	UNIV ZIMBABWE,DEPT CLIN PHARMACOL,HARARE,ZIMBABWE; UNIV ZIMBABWE,DEPT MED MICROBIOL,HARARE,ZIMBABWE; UNIV ZIMBABWE,DEPT PATHOL,HARARE,ZIMBABWE	University of Zimbabwe; University of Zimbabwe; University of Zimbabwe								ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; AFOLABI OA, 1993, 9 P INT C AIDS BERL; ALTMAN DG, 1991, PRACTICAL STAT MED R, P457; ATZORI C, 1993, T ROY SOC TROP MED H, V87, P55, DOI 10.1016/0035-9203(93)90418-P; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; CARME B, 1991, T ROY SOC TROP MED H, V85, P80, DOI 10.1016/0035-9203(91)90167-W; ELVIN KM, 1989, T ROY SOC TROP MED H, V83, P553, DOI 10.1016/0035-9203(89)90290-3; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; KAMANFU G, 1993, AM REV RESPIR DIS, V147, P658, DOI 10.1164/ajrccm/147.3.658; Lucas S., 1988, AIDS and associated cancers in Africa., P124; LUCAS SB, 1991, AIDS, V5, pS143; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MACHIELS G, 1992, T ROY SOC TROP MED H, V86, P399, DOI 10.1016/0035-9203(92)90237-7; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MILLAR AB, 1990, THORAX, V45, P57, DOI 10.1136/thx.45.1.57; MILLER RF, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90650-R; MILLER RF, 1989, THORAX, V44, P559, DOI 10.1136/thx.44.7.559; MUFSON MA, 1994, CURR OPIN INFECT DIS, V7, P178, DOI 10.1097/00001432-199404000-00006; PIOT P, 1992, AIDS AFRICA MANUAL P; SERWADDA D, 1989, AIDS, V3, P47; WAKEFIELD AE, 1990, T ROY SOC TROP MED H, V84, P800, DOI 10.1016/0035-9203(90)90087-U; WAKEFIELD AE, 1994, J CLIN MICROBIOL, V32, P2959, DOI 10.1128/JCM.32.12.2959-2961.1994; 1991, RRESPIRATORY CONDITI; 1986, WEEKLY EPIDEMIOL REC, V10, P72; 1994, ESSENTIAL DRUGS LIST, P95	25	89	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1258	1261		10.1016/S0140-6736(95)91862-0	http://dx.doi.org/10.1016/S0140-6736(95)91862-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475717				2022-12-01	WOS:A1995TE14500010
J	PORTEGIES, P				PORTEGIES, P			HIV-1, THE BRAIN, AND COMBINATION THERAPY	LANCET			English	Editorial Material							AIDS DEMENTIA COMPLEX; ZIDOVUDINE TREATMENT; CEREBROSPINAL-FLUID				PORTEGIES, P (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT NEUROL,1105 AZ AMSTERDAM,NETHERLANDS.							BREW BJ, 1992, AIDS, V6, P461, DOI 10.1097/00002030-199205000-00004; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; CHOO V, 1995, LANCET, V346, P895, DOI 10.1016/S0140-6736(95)92725-5; DEGANS J, 1988, AIDS, V2, P37, DOI 10.1097/00002030-198802000-00006; DISTEFANO M, 1993, LANCET, V342, P865, DOI 10.1016/0140-6736(93)92724-8; GRAY F, 1994, AIDS, V8, P489, DOI 10.1097/00002030-199404000-00011; MAEHLEN J, 1995, AIDS, V9, P1165, DOI 10.1097/00002030-199510000-00008; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PORTEGIES P, 1989, BRIT MED J, V299, P819, DOI 10.1136/bmj.299.6703.819; PORTEGIES P, 1994, J ACQ IMMUN DEF SYND, V7, pS38; PORTEGIES P, 1993, AIDS, V7, P669, DOI 10.1097/00002030-199305000-00010; PORTEGIES P, 1994, LANCET, V344, P759, DOI 10.1016/S0140-6736(94)92252-7; Price R W, 1995, AIDS, V9 Suppl A, pS221; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; VAGO L, 1993, J ACQ IMMUN DEF SYND, V6, P42; WILDEMANN B, 1993, NEUROLOGY, V43, P2659, DOI 10.1212/WNL.43.12.2659	16	30	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1244	1245		10.1016/S0140-6736(95)91857-4	http://dx.doi.org/10.1016/S0140-6736(95)91857-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475712	Bronze			2022-12-01	WOS:A1995TE14500005
J	SMYTH, RL; ASHBY, D; OHEA, U; BURROWS, E; LEWIS, P; VANVELZEN, D; DODGE, JA				SMYTH, RL; ASHBY, D; OHEA, U; BURROWS, E; LEWIS, P; VANVELZEN, D; DODGE, JA			FIBROSING COLONOPATHY IN CYSTIC-FIBROSIS - RESULTS OF A CASE-CONTROL STUDY	LANCET			English	Article								Fibrosing colonopathy was first described in cystic fibrosis (CF) children in 1994. We have done a nested case-control study to identify possible associations with this condition. A case ascertainment within the UK CF population to identify any cases that occurred between January, 1984, and April, 1994, found 14 cases, all under 14 years and confirmed by independent histopathological review. All had presented since April, 1993; 12 were boys and six had received some or all of their care in Liverpool. Each case was matched, by date of birth, with four controls from the UK CF Registry. Information was obtained about cases and controls from their case records and by a structured interview with the families. In the 12 months before surgery, there was an association between the occurrence of fibrosing colonopathy and use of high-strength pancreatic enzyme preparations. This association was dose related. Odds ratio per extra 1000 high-strength capsules was 1.45 (95% CI 1.14-1.84), For use of protease, the odds ratio per million extra units per kg was 1.55 (1.19-2.03). For usage of individual high-strength products at any time during the 12 months before surgery some differences were observed; for Creon 25000 the odds ratio was 0.38 (0.10-1.42), for Nutrizym 22 43.4 (2.51-751), and for Pancrease HL 8.4 (1.95-36.1). These last two confidence intervals are extremely wide and compatible with these two products having the same odds ratios. Laxative use was independently predictive (odds ratio 2.42 [1.20-4.94]). We conclude that there is a dose-related association between high-strength pancreatic enzyme preparations and fibrosing colonopathy.	UNIV LIVERPOOL,DEPT STAT & COMPUTAT MATH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV WALES COLL CARDIFF,COLL MED,DEPT MED COMP & STAT,CARDIFF,S GLAM,WALES; ROYAL CHILDRENS HOSP,DEPT FETAL & INFANT PATHOL,LIVERPOOL,MERSEYSIDE,ENGLAND; QUEENS UNIV BELFAST,DEPT CHILD HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	University of Liverpool; Cardiff University; Queens University Belfast	SMYTH, RL (corresponding author), ROYAL LIVERPOOL CHILDRENS HOSP ALDER HEY,RESP UNIT,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.							BRESLOW N, INT AGENCY RES CANCE, V32; CAMPBELL CA, 1994, LANCET, V343, P109; Dodge J A, 1993, Paediatr Perinat Epidemiol, V7, P157, DOI 10.1111/j.1365-3016.1993.tb00390.x; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; MACSWEENEY EJ, 1995, LANCET, V345, P752; MAHONY MJ, 1994, LANCET, V343, P599; OADES PJ, 1994, LANCET, V343, P109, DOI 10.1016/S0140-6736(94)90836-2; OHARE MMT, 1995, J PEDIATR GASTR NUTR, V21, P59, DOI 10.1097/00005176-199507000-00010; PETTEI MJ, 1994, J PEDIATR-US, V125, P587, DOI 10.1016/S0022-3476(94)70014-1; ROSENSTEIN BJ, 1983, J PEDIATR GASTR NUTR, V2, P299, DOI 10.1097/00005176-198305000-00014; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470; 1993, GUIDELINES CO SPONSO; ABPI DATA SHEET COMP	14	108	112	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1247	1251		10.1016/S0140-6736(95)91860-4	http://dx.doi.org/10.1016/S0140-6736(95)91860-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475715				2022-12-01	WOS:A1995TE14500008
J	VANHERWERDEN, L; HARRAP, SB; WONG, ZYH; ABRAMSON, MJ; KUTIN, JJ; FORBES, AB; RAVEN, J; LANIGAN, A; WALTERS, EH				VANHERWERDEN, L; HARRAP, SB; WONG, ZYH; ABRAMSON, MJ; KUTIN, JJ; FORBES, AB; RAVEN, J; LANIGAN, A; WALTERS, EH			LINKAGE OF HIGH-AFFINITY IGE RECEPTOR GENE WITH BRONCHIAL HYPERREACTIVITY, EVEN IN ABSENCE OF ATOPY	LANCET			English	Article							CHROMOSOME-11Q; HYPERRESPONSIVENESS; ASTHMA	Asthma is a manifestation of bronchial hyperreactivity (BHR) and forms part of the spectrum of atopic diease. Some pedigree studies of atopy have suggested linkage with the high-affinity IgE receptor (Fc epsilon RI beta) gene on chromosome 11q13, but others find no linkage. The molecular genetics of asthma and BHR have not been studied in the general population. We examined the genetic linkage of the Fc epsilon RI beta gene with clinical asthma and the underlying phenotypes of BHR (to methacholine) and atopy (defined by skinprick testing) in 123 affected sibling-pairs recruited from the general population. We found evidence of significant linkage of a highly polymorphic microsatellite marker in the fifth intron of the Fc epsilon RI beta gene to a diagnosis of asthma (18.0% excess of shared alleles, p=0.002) and to SHR (21.7% excess of shared alleles, p=0.001). Significant linkage was also observed in siblings sharing BHR when those with atopy were excluded (32.8% excess of shared alleles, p=0.004). Atopy in the absence of BHR did not show significant linkage to the Fc epsilon RI beta gene (7.2% excess of shared alleles, p=0.124). These findings suggest that mutations in the Fc epsilon RI beta gene or a closely linked gene influence the BHR underlying asthma, even in the absence of atopy.	MONASH UNIV SCH MED,DEPT SOCIAL & PREVENT MED,PRAHRAN,VIC,AUSTRALIA; ALFRED HOSP,DEPT RESP MED,PRAHRAN,VIC,AUSTRALIA	Monash University; Florey Institute of Neuroscience & Mental Health			WALTERS, Eugene/AAL-2264-2021; van Herwerden, Lynne/I-1087-2012; Abramson, Michael/AAQ-2671-2020	van Herwerden, Lynne/0000-0001-6717-8995; Abramson, Michael/0000-0002-9954-0538; Kutin, Jozica Johanna/0000-0002-3812-0417; Forbes, Andrew/0000-0003-4269-914X; Harrap, Stephen/0000-0003-2907-6714				ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; BRERETON HM, 1994, CLIN EXP ALLERGY, V24, P868, DOI 10.1111/j.1365-2222.1994.tb01809.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; DANIELS SE, 1994, HUM MOL GENET, V3, P213, DOI 10.1093/hmg/3.1.213; HIZAWA N, 1992, CLIN EXP ALLERGY, V22, P1065, DOI 10.1111/j.1365-2222.1992.tb00131.x; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOLMANS P, 1993, AM J HUM GENET, V52, P362; JEANPIERRE M, 1987, NUCLEIC ACIDS RES, V15, P961; LANGE K, 1986, ANN HUM GENET, V50, P283, DOI 10.1111/j.1469-1809.1986.tb01049.x; LYMPANY P, 1992, CLIN EXP ALLERGY, V22, P1085, DOI 10.1111/j.1365-2222.1992.tb00134.x; LYMPANY P, 1992, J ALLERGY CLIN IMMUN, V89, P619, DOI 10.1016/0091-6749(92)90330-5; MARSH DG, 1992, NAT GENET, V2, P252, DOI 10.1038/ng1292-252; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MORTON NE, 1992, CLIN EXP ALLERGY, V22, P1041, DOI 10.1111/j.1365-2222.1992.tb00126.x; NEELY JD, 1994, J ALLERGY CLIN IMMUN, V93, P220; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; RAVETCH JV, 1994, NAT GENET, V7, P117, DOI 10.1038/ng0694-117; RICH SS, 1992, CLIN EXP ALLERGY, V22, P1070, DOI 10.1111/j.1365-2222.1992.tb00132.x; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SHIRAKAWA T, 1991, CYTOGENET CELL GENET, V58, P1070; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671	26	121	122	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1262	1265		10.1016/S0140-6736(95)91863-9	http://dx.doi.org/10.1016/S0140-6736(95)91863-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475718				2022-12-01	WOS:A1995TE14500011
J	ZUREIK, M; DUCIMETIERE, P; WARNET, JM; ORSSAUD, G				ZUREIK, M; DUCIMETIERE, P; WARNET, JM; ORSSAUD, G			FATTY-ACID PROPORTIONS IN CHOLESTEROL ESTERS AND RISK OF PREMATURE DEATH FROM CANCER IN MIDDLE-AGED FRENCH MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ESTERIFYING SERUM-CHOLESTEROL; LUNG-CANCER; DIETARY-CHOLESTEROL; ASSOCIATION; MORTALITY; CONSUMPTION; PREVENTION; LIPIDS; PLASMA	Objective-To assess the association of proportions of fatty acids in cholesterol esters with the risk of premature death ti om cancer in middle aged men. Design-Prospective cohort study. Setting-Paris, France. Subjects-3277 working men aged 36-52 in 1981-5. Main outcome measures-Cancer mortality during an average of 9.3 years of follow up. Results-59 men died of cancer during follow up. The age adjusted relative risks for men in the highest thirds of the distribution of the proportions of linoleic, palmitoleic, and oleic acid in cholesterol esters as compared with those in the corresponding lowest thirds were 0.16 (95% confidence interval 0.05 to 0.51), 3.39 (1.63 to 7.05), and 4.22 (1.95 to 9.12), respectively. Adjustment for and stratification by smoking, alcohol consumption, serum cholesterol concentration, and body mass index did not alter the results. At the time of examination subjects with cancer had a lower intake of polyunsaturated fats, assessed by 24 hour recall, than those without cancer (13.2 v 17.4 g/day, P< 0.01). Conclusions-Monounsaturated and polyunsaturated fatty acids of cholesterol esters are strong biological markers that predict premature death from cancer in French men. Consistently, intake of polyunsaturated fats did not seem to increase the risk of death from cancer. The association of biological markers of dietary fat intake with incidence of and mortality from cancer should be investigated prospectively in other populations.	CTR MEDICOSOCIAL, DIRECT ACT SOCIALE ENFANCE & SANTE LAB, F-75013 PARIS, FRANCE		ZUREIK, M (corresponding author), HOP BROUSSAIS, INSERM, U258, F-75014 PARIS, FRANCE.		Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217				AITCHISON J, 1986, MONOGRAPHS STATISTIC; AUSTOKER J, 1994, BRIT MED J, V308, P1610, DOI 10.1136/bmj.308.6944.1610; BLOCK G, 1982, AM J EPIDEMIOL, V115, P492, DOI 10.1093/oxfordjournals.aje.a113331; BYERS TE, 1987, AM J EPIDEMIOL, V125, P351, DOI 10.1093/oxfordjournals.aje.a114542; CAMBIEN F, 1988, AM J EPIDEMIOL, V127, P75, DOI 10.1093/oxfordjournals.aje.a114793; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CAROLL KK, 1986, PROG CLIN BIOL RES, V206, P237; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; DEBACKER G, 1989, ATHEROSCLEROSIS, V78, P237, DOI 10.1016/0021-9150(89)90229-3; Ducimetiere P., 1992, Nutrition Metabolism and Cardiovascular Diseases, V2, P195; ETIENNE G, 1963, ANN BIOL CLIN, V21, P851; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREUDENHEIM JL, 1989, EPIDEMIOL REV, V11, P229, DOI 10.1093/oxfordjournals.epirev.a036039; GOODMAN MT, 1988, AM J EPIDEMIOL, V128, P1241, DOI 10.1093/oxfordjournals.aje.a115078; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; Karmali R A, 1986, Prog Clin Biol Res, V222, P687; KNEKT P, 1991, NUTR CANCER, V16, P267, DOI 10.1080/01635589109514165; KOLONEL LN, 1988, AM J EPIDEMIOL, V127, P999, DOI 10.1093/oxfordjournals.aje.a114903; KRITCHEVSKY SB, 1992, AM J EPIDEMIOL, V135, P509, DOI 10.1093/oxfordjournals.aje.a116318; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; MOILANEN T, 1985, AM J CLIN NUTR, V42, P708, DOI 10.1093/ajcn/42.4.708; NIKKARI T, 1983, AM J CLIN NUTR, V37, P848, DOI 10.1093/ajcn/37.5.848; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; RENAUD S, 1979, TABLE COMPOSITION AL, P63; RICHARD JL, 1981, NOUV PRESSE MED, V10, P1111; ROSSENEU M, 1994, ATHEROSCLEROSIS, V108, P127, DOI 10.1016/0021-9150(94)90107-4; SANTOS MT, 1984, ATHEROSCLEROSIS, V50, P53, DOI 10.1016/0021-9150(84)90007-8; SARKKINEN ES, 1994, AM J CLIN NUTR, V59, P364, DOI 10.1093/ajcn/59.2.364; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; SHEKELLE RB, 1981, LANCET, V2, P1185; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; TUCKEY RC, 1979, ANAL BIOCHEM, V94, P402, DOI 10.1016/0003-2697(79)90381-6; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; URSIN G, 1993, AM J EPIDEMIOL, V137, P916, DOI 10.1093/oxfordjournals.aje.a116753; WARNET JM, 1985, BRIT MED J, V290, P1859, DOI 10.1136/bmj.290.6485.1859; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0	41	28	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1251	1254		10.1136/bmj.311.7015.1251	http://dx.doi.org/10.1136/bmj.311.7015.1251			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496232	Green Published			2022-12-01	WOS:A1995TE85900017
J	DEACON, NJ; TSYKIN, A; SOLOMON, A; SMITH, K; LUDFORDMENTING, M; HOOKER, DJ; MCPHEE, DA; GREENWAY, AL; ELLETT, A; CHATFIELD, C; LAWSON, VA; CROWE, S; MAERZ, A; SONZA, S; LEARMONT, J; SULLIVAN, JS; CUNNINGHAM, A; DWYER, D; DOWTON, D; MILLS, J				DEACON, NJ; TSYKIN, A; SOLOMON, A; SMITH, K; LUDFORDMENTING, M; HOOKER, DJ; MCPHEE, DA; GREENWAY, AL; ELLETT, A; CHATFIELD, C; LAWSON, VA; CROWE, S; MAERZ, A; SONZA, S; LEARMONT, J; SULLIVAN, JS; CUNNINGHAM, A; DWYER, D; DOWTON, D; MILLS, J			GENOMIC STRUCTURE OF AN ATTENUATED QUASI-SPECIES OF HIV-1 FROM A BLOOD-TRANSFUSION DONOR AND RECIPIENTS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEF GENE; FOLLOW-UP; AIDS; INFECTION; PROGRESSION; DISEASE; CELLS; MEN; DNA	A blood donor infected with human immunodeficiency virus-type 1 (HIV-1) and a cohort of six blood or blood product recipients infected from this donor remain free of HIV-1-related disease with stable and normal CD4 lymphocyte counts 10 to 14 years after infection. HIV-1 sequences from either virus isolates or patient peripheral blood mononuclear cells had similar deletions in the nef gene and in the region of overlap of nef and the U3 region of the long terminal repeat (LTR). Full-length sequencing of one isolate genome and amplification of selected HIV-1 genome regions from other cohort members revealed no other abnormalities of obvious functional significance. These data show that survival after HIV infection can be determined by the HIV genome and support the importance of nef or the U3 region of the LTR in determining the pathogenicity of HIV-1.	MACFARLANE BURNET CTR MED RES,NATL CTR HIV VIROL RES,AIDS CELLULAR BIOL UNIT,FAIRFIELD,VIC 3078,AUSTRALIA; MACFARLANE BURNET CTR MED RES,NATL CTR HIV VIROL RES,AIDS PATHOGENESIS UNIT,FAIRFIELD,VIC 3078,AUSTRALIA; NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY 2000,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT VIROL,WESTMEAD,NSW 2145,AUSTRALIA; WESTMEAD HOSP,NATL CTR HIV VIROL RES,INST CLIN PATHOL & MED RES,WESTMEAD,NSW 2145,AUSTRALIA	Australian Red Cross Blood Service; University of Sydney; University of Sydney	DEACON, NJ (corresponding author), MACFARLANE BURNET CTR MED RES,NATL CTR HIV VIROL RES,AIDS MOLEC BIOL UNIT,YARRA BEND RD,FAIRFIELD,VIC 3078,AUSTRALIA.		McPhee, Dale A/D-1825-2011; Lawson, Victoria/AAJ-7392-2021	Cunningham, Anthony/0000-0002-6744-5667; Tsykin, Anna/0000-0001-5965-6803; Greenway, Alison/0000-0001-8908-2708; Lawson, Victoria/0000-0002-7362-7176				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARCHER G, 1988, 4TH INT C AIDS STOCK; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; FERRE F, 1993, AIDS, V7, pS21, DOI 10.1097/00002030-199311002-00006; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GOODALL J, 1994, THESIS U MELBOURNE; GOU LH, 1982, NUCLEIC ACIDS RES, V10, P2065; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; GREENWAY AL, UNPUB; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; KAPLAN JE, 1992, J ACQ IMMUN DEF SYND, V5, P565; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1994, J VIROL, V68, P2031, DOI 10.1128/JVI.68.3.2031-2037.1994; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEAMONT J, 1995, AIDS RES HUM RETROV, V11, P1; LEAMONT J, 1992, LANCET, V340, P863; LEARMONT J, UNPUB; LEARMONT J, 1994, 10TH INT C AIDS YOK; LEE TH, 1991, AIDS, V5, P683, DOI 10.1097/00002030-199106000-00007; MCPHEE DJ, UNPUB; MEYERS G, 1994, HUMAN RETROVIRUSES A; NEATE EV, 1987, AUST NZ J MED, V17, P461, DOI 10.1111/j.1445-5994.1987.tb00096.x; NOWAK M, 1993, AIDS, V7, pS3, DOI 10.1097/00002030-199301001-00002; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SANGER F, 1977, P NATL ACAD SCI USA, V84, P5463; SCHRAGER LK, 1994, AIDS, V8, P895; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SEMPLE MG, 1993, J VIROL METHODS, V41, P176; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SMITH J, 1992, J GEN VIROL, V73, P1825, DOI 10.1099/0022-1317-73-7-1825; SOLOMON AI, UNPUB; TYSKIN A, UNPUB; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; 1992, MMWR-MORBID MORTAL W, V41, P961	40	1005	1020	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					988	991		10.1126/science.270.5238.988	http://dx.doi.org/10.1126/science.270.5238.988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481804				2022-12-01	WOS:A1995TD87800049
J	DENOOIJ, JC; HARIHARAN, IK				DENOOIJ, JC; HARIHARAN, IK			UNCOUPLING CELL FATE DETERMINATION FROM PATTERNED CELL-DIVISION IN THE DROSOPHILA EYE	SCIENCE			English	Article							C-ELEGANS EMBRYOS; COMPOUND EYE; CYCLIN-A; EXPRESSION; PROTEIN; HOMOLOG; MELANOGASTER; INHIBITOR; MUTANTS; KINASES	Cell proliferation and cell fate specification are under strict spatiotemporal control in the developing Drosophila eye. Cells excluded from five-cell preclusters synchronously enter a single additional cell cycle, the second mitotic wave, after which the remaining cells are sequentially recruited. When the second mitotic wave was blocked with the human cyclin-dependent kinase inhibitor p21(CIP1/WAF1), each cell type was still specified. Hence, cell fate determination is regulated independently of the division pattern of precursor cells. However, the second mitotic wave is needed to generate appropriate numbers of each cell type. Moreover, p21 can arrest precursor cell proliferation and allow appropriate fate choice in vivo.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; Campos-Ortega J A, 1980, Curr Top Dev Biol, V15 Pt 1, P347; DENOOIJ JC, UNPUB; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FOE VE, 1989, DEVELOPMENT, V107, P1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HARPER JW, 1993, CELL, V75, P805; HAY BA, 1994, DEVELOPMENT, V120, P2121; JIANG HP, 1994, ONCOGENE, V9, P3397; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1987, DEV BIOL, V120, P336; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WOLFF T, 1991, DEVELOPMENT, V113, P841; WOLFF T, 1991, DEVELOPMENT, V113, P825; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	117	118	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					983	985		10.1126/science.270.5238.983	http://dx.doi.org/10.1126/science.270.5238.983			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481802				2022-12-01	WOS:A1995TD87800047
J	HAN, S; ELTIS, LD; TIMMIS, KN; MUCHMORE, SW; BOLIN, JT				HAN, S; ELTIS, LD; TIMMIS, KN; MUCHMORE, SW; BOLIN, JT			CRYSTAL-STRUCTURE OF THE BIPHENYL-CLEAVING EXTRADIOL DIOXYGENASE FROM A PCB-DEGRADING PSEUDOMONAD	SCIENCE			English	Article							PROTEIN; DEGRADATION; MECHANISM; PATHWAY	Polychlorinated biphenyls (PCBs) typify a class of stable aromatic pollutants that are targeted by bioremediation strategies. In the aerobic degradation of biphenyl by bacteria, the key step of ring cleavage is catalyzed by an Fe(II)-dependent extradiol dioxygenase. The crystal structure of 2,3-dihydroxybiphenyl 1,2-dioxygenase from a PCB-degrading strain of Pseudomonas cepacia has been determined at 1.9 angstrom resolution, The monomer comprises amino- and carboxyl-terminal domains, Structural homology between and within the domains reveals evolutionary relationships within the extradiol dioxygenase family. The iron atom has five ligands in square pyramidal geometry: one glutamate and two histidine side chains, and two water molecules.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV LAVAL,DEPT BIOCHEM,ST FOY,PQ G1K 7P4,CANADA; GESELL BIOTECHNOL FORSCH MBH,BEREICH MIKROBIOL,D-38124 BRAUNSCHWEIG,GERMANY	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Laval University; Gesellschaft fur Biotechnologische Forschung mbH			Eltis, Lindsay D/J-8272-2015	Eltis, Lindsay D/0000-0002-6774-8158	NIGMS NIH HHS [GM 52831] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052831] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; ARCIERO DM, 1985, J BIOL CHEM, V260, P2170; ASTURIAS JA, 1994, J BIOL CHEM, V269, P7807; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERTINI I, 1994, BIOCHEMISTRY-US, V33, P10777, DOI 10.1021/bi00201a027; BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; BOLIN JT, UNPUB; BOLIN JT, 1993, MAY ANN M AM CRYST A; BOPP LH, 1986, J IND MICROBIOL, V1, P23, DOI 10.1007/BF01569413; BRUNGER AT, 1992, X PLOR; CCP4, 1979, CCP4 SUITE PROGRAMS; CERDAN P, 1994, J BACTERIOL, V176, P6074, DOI 10.1128/jb.176.19.6074-6081.1994; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; ELTIS LD, 1993, J BIOL CHEM, V268, P2727; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.mi.46.100192.003025; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOFER B, 1993, GENE, V130, P47, DOI 10.1016/0378-1119(93)90345-4; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; HORI K, 1973, J BIOCHEM, V74, P375; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; MINOR W, 1993, XDIS PLAYF; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; OHLENDORF DH, 1994, J MOL BIOL, V244, P586, DOI 10.1006/jmbi.1994.1754; OTWINOWSKI Z, 1991, P CCP4 STUDY WEEKEND, P56; RAMOS JL, 1987, SCIENCE, V235, P593, DOI 10.1126/science.3468623; SCARROW RC, 1994, BIOCHEMISTRY-US, V33, P15023, DOI 10.1021/bi00254a011; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; SINGH J, 1992, ATLAS PROTEIN SIDECH; SUGIYAMA K, 1995, P JPN ACAD B-PHYS, V71, P32, DOI 10.2183/pjab.71.32; TIMMIS KN, 1994, ANNU REV MICROBIOL, V48, P525, DOI 10.1146/annurev.mi.48.100194.002521; WASSERFALLEN A, 1991, BIO-TECHNOL, V9, P296, DOI 10.1038/nbt0391-296	39	309	313	3	44	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					976	980		10.1126/science.270.5238.976	http://dx.doi.org/10.1126/science.270.5238.976			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481800				2022-12-01	WOS:A1995TD87800045
J	HYRIEN, O; MARIC, C; MECHALI, M				HYRIEN, O; MARIC, C; MECHALI, M			TRANSITION IN SPECIFICATION OF EMBRYONIC METAZOAN DNA-REPLICATION ORIGINS	SCIENCE			English	Article							RIBOSOMAL-RNA GENES; SACCHAROMYCES-CEREVISIAE; EGG EXTRACTS; 3' END; INITIATION; SITES; DOMAIN; SPACER	In early Xenopus embryos, in which ribosomal RNA genes (rDNA) are not transcribed, rDNA replication initiates and terminates at 9- to 12-kilobase pair intervals, with no detectable dependence on specific DNA sequences. Resumption of ribosomal RNA (rRNA) synthesis at late blastula and early gastrula is accompanied by a specific repression of replication initiation within transcription units; the frequency of initiation within intergenic spacers remains as high as in early blastula, These results demonstrate that for rRNA genes, circumscribed zones of replication initiation emerge in intergenic DNA during the time in metazoan development when the chromatin is remodeled to allow gene transcription.			HYRIEN, O (corresponding author), INST JACQUES MONOD, F-75251 PARIS 05, FRANCE.		Hyrien, Olivier/R-5108-2017	Hyrien, Olivier/0000-0001-8879-675X				BENARD M, 1995, NUCLEIC ACIDS RES, V23, P1447, DOI 10.1093/nar/23.9.1447; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CALLAN HG, 1972, PROC R SOC SER B-BIO, V181, P19, DOI 10.1098/rspb.1972.0039; Depamphilis Melvin L., 1993, Trends in Cell Biology, V3, P161, DOI 10.1016/0962-8924(93)90137-P; DEWINTER RFJ, 1986, NUCLEIC ACIDS RES, V14, P6041, DOI 10.1093/nar/14.15.6041; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; HAASE SB, 1994, MOL CELL BIOL, V14, P2516, DOI 10.1128/MCB.14.4.2516; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; PAN WJ, 1995, MOL CELL BIOL, V15, P3372; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; SHIOKAWA K, 1981, DEV GROWTH DIFFER, V23, P579; SNYDER M, 1988, MOL CELL BIOL, V8, P2184, DOI 10.1128/MCB.8.5.2184; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P258, DOI 10.1016/0167-4781(93)90194-I; YOON Y, 1995, MOL CELL BIOL, V15, P2482	34	265	266	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	1995	270	5238					994	997		10.1126/science.270.5238.994	http://dx.doi.org/10.1126/science.270.5238.994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481806				2022-12-01	WOS:A1995TD87800051
J	MIXON, MB; LEE, E; COLEMAN, DE; BERGHUIS, AM; GILMAN, AG; SPRANG, SR				MIXON, MB; LEE, E; COLEMAN, DE; BERGHUIS, AM; GILMAN, AG; SPRANG, SR			TERTIARY AND QUATERNARY STRUCTURAL-CHANGES IN G(I-ALPHA-1) INDUCED BY GTP HYDROLYSIS	SCIENCE			English	Article							GAMMA-SUBUNIT COMPLEX; BETA-GAMMA; G-PROTEIN; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; BINDING; DISAGGREGATION	Crystallographic analysis of 2.2 angstrom resolution shows that guanosine triphosphate (GTP) hydrolysis triggers conformational changes in the heterotrimeric G-protein alpha subunit, G(i alpha 1). The switch II and switch III segments become disordered, and linker II connecting the Ras and alpha helical domains moves, thus altering the structures of potential effector and beta gamma binding regions. Contacts between the alpha-helical and Ras domains are weakened, possibly facilitating the release of guanosine diphosphate (GDP). The amino and carboxyl termini, which contain receptor and beta gamma binding determinants, are disordered in the complex with GTP, but are organized into a compact microdomain on GDP hydrolysis. The amino terminus also forms extensive quaternary contacts with neighboring alpha subunits in the lattice, suggesting that multimers of alpha subunits or heterotrimers may play a role in signal transduction.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X	NIDDK NIH HHS [DK 46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR JC, 1994, NATURE, V372, P704; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BERGHUIS A, UNPUB; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAKRABARTI P, 1993, J MOL BIOL, V234, P463, DOI 10.1006/jmbi.1993.1599; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DC, UNPUB; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COPLEY RR, 1994, J MOL BIOL, V242, P321; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GRAF R, 1992, J BIOL CHEM, V267, P24307; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1990, UNPUB O VERSION 5 6; KLEUSS C, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1992, J BIOL CHEM, V267, P1212; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAKAMURA S, 1990, P NATL ACAD SCI USA, V87, P6413, DOI 10.1073/pnas.87.16.6413; NAKAMURA SI, 1991, P NATL ACAD SCI USA, V88, P7150, DOI 10.1073/pnas.88.16.7150; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1992, GRASP GRAPHIC REPRES; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	58	259	260	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	1995	270	5238					954	960		10.1126/science.270.5238.954	http://dx.doi.org/10.1126/science.270.5238.954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481799				2022-12-01	WOS:A1995TD87800038
J	RAETZ, CRH; RODERICK, SL				RAETZ, CRH; RODERICK, SL			A LEFT-HANDED PARALLEL BETA-HELIX IN THE STRUCTURE OF UDP-N-ACETYLGLUCOSAMINE ACYLTRANSFERASE	SCIENCE			English	Article							LIPID-A BIOSYNTHESIS; ESCHERICHIA-COLI; ENDOTOXIN BIOSYNTHESIS; 1ST STEP; PROTEIN; GENE; CONFORMATION; REFINEMENT; SHEETS; LPXA	UDP-N-acetylglucosamine 3-O-acyltransferase (LpxA) catalyzes the transfer of (R)-3-hydroxymyristic acid from its acyl carrier protein thioester to UDP-N-acetylglucosamine. LpxA is the first enzyme in the lipid A biosynthetic pathway and is a target for the design of antibiotics. The x-ray crystal structure of LpxA has been determined to 2.6 angstrom resolution and reveals a domain motif composed of parallel beta strands, termed a left-handed parallel beta helix (L beta H). This unusual fold displays repeated violations of the protein folding constraint requiring right-handed crossover connections between strands of parallel beta sheets and may be present in other enzymes that share amino acid sequence homology to the repeated hexapeptide motif of LpxA.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Yeshiva University; Albert Einstein College of Medicine; Duke University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38328] Funding Source: Medline; NIGMS NIH HHS [GM51310] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIGNET J, 1995, ANTIMICROB AGENTS CH, V39, P2027, DOI 10.1128/AAC.39.9.2027; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; CHOU KC, 1987, J MOL BIOL, V205, P241; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; DICKER IB, 1992, MOL MICROBIOL, V6, P817, DOI 10.1111/j.1365-2958.1992.tb01532.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1995, AM CRYSTALLOGRAPHIC, P73; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KELLY TM, 1993, J BIOL CHEM, V268, P19866; NAGANO K, 1977, J MOL BIOL, V109, P235, DOI 10.1016/S0022-2836(77)80032-6; PARENT R, 1992, J BACTERIOL, V174, P2891, DOI 10.1128/JB.174.9.2891-2897.1992; PFITZNER U, 1995, PROTEINS, V22, P191, DOI 10.1002/prot.340220212; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, UNPUB; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STERNBERG MJE, 1977, J MOL BIOL, V110, P269, DOI 10.1016/S0022-2836(77)80072-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VUORIO R, 1992, ANTIMICROB AGENTS CH, V36, P826, DOI 10.1128/AAC.36.4.826; VUORIO R, 1991, FEBS LETT, V292, P90, DOI 10.1016/0014-5793(91)80841-P; VUORIO R, 1994, FEBS LETT, V337, P289, DOI 10.1016/0014-5793(94)80211-4; YODER MD, 1995, FASEB J, V9, P335, DOI 10.1096/fasebj.9.5.7896002; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991; YOUNG K, 1993, FED PROC, V7, P1252	33	297	303	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					997	1000		10.1126/science.270.5238.997	http://dx.doi.org/10.1126/science.270.5238.997			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481807				2022-12-01	WOS:A1995TD87800052
J	SMITH, CK; REGAN, L				SMITH, CK; REGAN, L			GUIDELINES FOR PROTEIN DESIGN - THE ENERGETICS OF BETA-SHEET SIDE-CHAIN INTERACTIONS	SCIENCE			English	Article							HELIX-FORMING TENDENCIES; TERTIARY STRUCTURE; AMINO-ACIDS; STABILITY; PEPTIDES	To determine the interaction energy between cross-strand pairs of side chains on an antiparallel beta sheet, pairwise amino acid substitutions were made on the solvent-exposed face of the B1 domain of streptococcal protein G, The measured interaction energies were substantial (1.8 kilocalories per mole) and comparable to the magnitude of the beta sheet propensities. The experimental results paralleled the statistical frequency with which the residue pairs are found in beta sheets of known structure.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Yale University								BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CHAKRABARTTY A, 1993, P NATL ACAD SCI USA, V90, P11337; CHOU PY, 1973, BIOCHEMISTRY-US, V13, P211; GARRATT RC, 1991, FEBS LETT, V280, P141, DOI 10.1016/0014-5793(91)80223-P; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; LIFSON S, 1980, J MOL BIOL, V139, P627, DOI 10.1016/0022-2836(80)90052-2; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1994, J MOL BIOL, V241, P706, DOI 10.1006/jmbi.1994.1545; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PADMANABHAN S, 1995, PROTEIN SCI, V3, P1992; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; von Heijne G, 1977, J Mol Biol, V117, P821, DOI 10.1016/0022-2836(77)90073-0; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205	23	235	254	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					980	982		10.1126/science.270.5238.980	http://dx.doi.org/10.1126/science.270.5238.980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481801				2022-12-01	WOS:A1995TD87800046
J	WANG, JT; SYED, A; HSIEH, ML; GRALLA, JD				WANG, JT; SYED, A; HSIEH, ML; GRALLA, JD			CONVERTING ESCHERICHIA-COLI RNA-POLYMERASE INTO AN ENHANCER-RESPONSIVE ENZYME - ROLE OF AN NH2-TERMINAL LEUCINE PATCH IN SIGMA(54)	SCIENCE			English	Article							TRANSCRIPTIONAL ENHANCERS; BINDING PROTEINS; PROMOTER; ACTIVATOR; NTRC; INITIATION; SIGMA-54; GLNA	The protein sigma(54) associates with Escherichia coli core RNA polymerase to form a holoenzyme that binds promoters but is inactive in the absence of enhancer activation, Here, mutants of sigma(54) enabled polymerases to transcribe without enhancer protein and adenosine triphosphate. The mutations are in leucines within the NH2-terminal glutamine-rich domain of sigma(54). Multiple leucine substitutions mimicked the effect of enhancer protein, which suggests that the enhancer protein functions to disrupt a leucine patch. The results indicate that sigma(54) acts both as an inhibitor of polymerase activity and as a receptor that interacts with enhancer protein to overcome this inhibition, and that these two activities jointly confer enhancer responsiveness.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM35754] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HSIEH ML, 1994, J MOL BIOL, V239, P15, DOI 10.1006/jmbi.1994.1347; HSIEH ML, 1994, J BIOL CHEM, V269, P373; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAY L, 1990, J BACTERIOL, V172, P818, DOI 10.1128/jb.172.2.818-823.1990; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; SYED A, UNPUB; TINTUT Y, 1994, P NATL ACAD SCI USA, V91, P2120, DOI 10.1073/pnas.91.6.2120; TINTUT Y, 1995, GENE DEV, V9, P2305, DOI 10.1101/gad.9.18.2305; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; WANG TW, UNPUB; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	25	82	82	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 10	1995	270	5238					992	994		10.1126/science.270.5238.992	http://dx.doi.org/10.1126/science.270.5238.992			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD878	7481805				2022-12-01	WOS:A1995TD87800050
J	BANNERMAN, DM; GOOD, MA; BUTCHER, SP; RAMSAY, M; MORRIS, RGM				BANNERMAN, DM; GOOD, MA; BUTCHER, SP; RAMSAY, M; MORRIS, RGM			DISTINCT COMPONENTS OF SPATIAL-LEARNING REVEALED BY PRIOR TRAINING AND NMDA RECEPTOR BLOCKADE	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-FORMATION; SELECTIVE IMPAIRMENT; MEMORY; CORTEX; RATS; AP5; ANTAGONIST; ACID; TRANSMISSION	SYNAPTIC plasticity dependent on N-methyl-D-aspartate (NMDA) receptors is thought to underlie certain types of learning and memory(1 3). In support of this, both hippocampal long-term potentiation and spatial learning in a watermaze are impaired by blocking NMDA receptors with a selective antagonist D(-)-2-amino-5-phosphonovaleric acid (AP5)(4) or by a mutation in one of the receptor subunits(5). Here we report, however, that the AP5-induced learning deficit can be almost completely prevented if rats are pretrained in a different watermaze before administration of the drug. This is not because of stimulus generalization, and occurs despite learning of the second task remaining hippocampus dependent. An APS-induced learning deficit is, however, still seen if the animals are pretrained using a non-spatial task. Thus, despite its procedural simplicity, the watermaze may involve multiple cognitive processes with distinct pharmacological properties; although required for some component of spatial learning, NMDA receptors may not be required for encoding the spatial representation of a specific environment.	UNIV EDINBURGH,SCH MED,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PHARMACOL,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,FUJISAWA INST NEUROSCI,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh			Morris, Richard G M/C-9982-2013	Bannerman, David/0000-0002-3024-7595				ALFORD S, 1994, NMDA RECEPTOR, P277; [Anonymous], 1983, MENTAL MODELS; BARNES CA, 1994, J NEUROSCI, V14, P5793; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; BUTCHER SP, 1991, EXP BRAIN RES, V83, P521; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIS S, 1992, J NEUROSCI, V12, P21; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; FOX K, 1990, J NEUROPHYSIOL, V64, P1413, DOI 10.1152/jn.1990.64.5.1413; HEALE V, 1990, PHARMACOL BIOCHEM BE, V36, P145, DOI 10.1016/0091-3057(90)90140-D; JARRARD LE, 1989, J NEUROSCI METH, V29, P251, DOI 10.1016/0165-0270(89)90149-0; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORRIS RGM, 1988, EXCITATORY AMINO ACI, P297; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SALT TE, 1986, NATURE, V322, P263, DOI 10.1038/322263a0; SILLITO AM, 1990, NEUROSCIENCE, V34, P273, DOI 10.1016/0306-4522(90)90137-S; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND NS, 1970, MECHANISMS ANIMAL DI; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	27	476	485	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					182	186		10.1038/378182a0	http://dx.doi.org/10.1038/378182a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477320				2022-12-01	WOS:A1995TD75900053
J	COHENCORY, S; FRASER, SE				COHENCORY, S; FRASER, SE			EFFECTS OF BRAIN-DERIVED NEUROTROPHIC FACTOR ON OPTIC AXON BRANCHING AND REMODELING IN-VIVO	NATURE			English	Article							NERVE GROWTH-FACTOR; RETINAL GANGLION-CELLS; RECEPTOR; TRKB; RAT; EXPRESSION; SURVIVAL; BDNF; NGF	NEUROTROPHINS are thought to be important for the survival and differentiation of vertebrate neurons(1). Roles have been suggested for target-derived neurotrophins, based both on their expression in target tissues at the time of neuron innervation(2,3), and on their effects on axonal sprouting(4-6). However, direct in vivo evidence of their involvement in axon arborization has remained elusive. We have used in vivo microscopy to follow individual optic axons over time, and have examined the role of the neurotrophin brain-derived neurotrophic factor (BDNF) in their development. Here we show that injection of BDNF into the optic tectum of live Xenopus laevis tadpoles increased the branching and complexity of optic axon terminal arbors. In contrast, injection of specific neutralizing antibodies to BDNF reduced axon arborization and complexity. The onset of these effects was rapid (within 2 hours) and persisted throughout the 24-hour observation period. Other neurotrophins had little or no significant effects. These results demonstrate the involvement of neurotrophins in the dynamic elaboration of axon terminals, and suggest a direct role for target-derived BDNF during synaptic patterning in the developing central nervous system.			COHENCORY, S (corresponding author), CALTECH, CTR BIOL IMAGING, DIV BIOL 139-74, PASADENA, CA 91125 USA.		Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COHENCORY S, 1994, NEURON, V12, P747, DOI 10.1016/0896-6273(94)90328-X; COHENCORY S, 1993, EXP NEUROL, V119, P165, DOI 10.1006/exnr.1993.1018; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DUGICHDJORDJEVIC MM, 1992, NEURON, V8, P1127, DOI 10.1016/0896-6273(92)90133-X; EMFORS P, 1992, EUR J NEUROSCI, V4, P1140; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1987, DEVELOPMENT, V101, P123; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; NAWA H, 1994, J NEUROSCI, V14, P3751; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; OROURKE NA, 1994, NEURON, V12, P921, DOI 10.1016/0896-6273(94)90343-3; RODRIGUEZTEBAR A, 1989, DEV BIOL, V136, P296, DOI 10.1016/0012-1606(89)90256-X; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SIMON DK, 1994, DEV BIOL, V162, P384, DOI 10.1006/dbio.1994.1095; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F	30	505	513	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					192	196		10.1038/378192a0	http://dx.doi.org/10.1038/378192a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477323				2022-12-01	WOS:A1995TD75900056
J	DOLAN, RJ; FLETCHER, P; FRITH, CD; FRISTON, KJ; FRACKOWIAK, RSJ; GRASBY, PM				DOLAN, RJ; FLETCHER, P; FRITH, CD; FRISTON, KJ; FRACKOWIAK, RSJ; GRASBY, PM			DOPAMINERGIC MODULATION OF IMPAIRED COGNITIVE ACTIVATION IN THE ANTERIOR CINGULATE CORTEX IN SCHIZOPHRENIA	NATURE			English	Article							MONKEY PREFRONTAL CORTEX; DELAYED-RESPONSE TASK; CEREBRAL BLOOD-FLOW; RECEPTOR-BINDING; APOMORPHINE; TOMOGRAPHY; RELEASE; GABA	DOPAMINERGIC dysregulation remains an empirical cornerstone for theories concerning the causation of schizophrenia. Evidence for a dopamine system dysfunction in schizophrenia includes the psychosis-inducing effects of dopaminergic agonists(1,2) and the antipsychotic potency of dopaminergic antagonists(3'4). Here we use positron emission tomography (PET) to examine the regulatory role of dopamine on cortical function in normal subjects and unmedicated schizophrenic patients. Using a factorial experimental design, we compared the effect of dopaminergic manipulation with apomorphine on a neural response to a cognitive task. In the schizophrenic patients, relative to controls, an impaired cognitive activation of the anterior cingulate cortex was significantly modulated by a manipulation of dopaminergic neurotransmission. Thus, after apomorphine, the schizophrenic subjects displayed a significantly enhanced cognitive activation of the anterior cingulate cortex relative to the controls. These data provide in vivo evidence that an impaired cognitive-task-induced activation of the anterior cingulate cortex in schizophrenic patients can be significantly modulated by a dopaminergic manipulation.	ROYAL FREE HOSP, SCH MED, LONDON NW3, ENGLAND; UCL, DEPT PSYCHOL, LONDON WC1E 6BT, ENGLAND; HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, LONDON W12 0HS, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Imperial College London	DOLAN, RJ (corresponding author), INST NEUROL, WELLCOME DEPT COGNIT NEUROL, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Frith, Chris D/A-2171-2009; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; Friston, Karl/D-9230-2011; Fletcher, Paul/F-5380-2011	Frith, Chris D/0000-0002-8665-0690; Frackowiak, Richard/0000-0002-3151-822X; Friston, Karl/0000-0001-7984-8909; Fletcher, Paul/0000-0001-8257-1517; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; BENES FM, 1992, J NEUROSCI, V12, P924; BENES FM, 1986, ARCH GEN PSYCHIAT, V43, P31; Bleuler E., 1950, DEMENTIA PRAECOX; CLEGHORN JM, 1991, PSYCHIAT RES-NEUROIM, V40, P135, DOI 10.1016/0165-1781(91)90153-G; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; DAVIDSON M, 1987, AM J PSYCHIAT, V144, P934; Fallon JH, 1987, CEREB CORTEX, V6, P41; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K.J., 1994, HUMAN BRAIN MAPPING, V1, P214; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, IN PRESS HUM BRAIN M; FRISTON KJ, 1995, HUM BRAIN MAPP, V2, P198; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; FRITH CD, 1995, BRIT J PSYCHIAT, V167, P343, DOI 10.1192/bjp.167.3.343; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRASBY PM, 1993, PSYCHOL MED, V23, P605, DOI 10.1017/S0033291700025381; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; LIEBERMAN JA, 1984, AM J PSYCHIAT, V141, P633; MCGHIE A, 1961, BRIT J MED PSYCHOL, V34, P103, DOI 10.1111/j.2044-8341.1961.tb00936.x; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; RETAUX S, 1991, NEUROSCIENCE, V42, P61, DOI 10.1016/0306-4522(91)90150-M; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; TAMMINGA CA, 1992, ARCH GEN PSYCHIAT, V49, P522; WEINBERGER DR, 1988, TRENDS NEUROSCI, V11, P367, DOI 10.1016/0166-2236(88)90060-4; [No title captured]	30	321	326	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					180	182		10.1038/378180a0	http://dx.doi.org/10.1038/378180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TD759	7477319	Green Submitted			2022-12-01	WOS:A1995TD75900052
J	HALL, TMT; PORTER, JA; BEACHY, PA; LEAHY, DJ				HALL, TMT; PORTER, JA; BEACHY, PA; LEAHY, DJ			A POTENTIAL CATALYTIC SITE REVEALED BY THE 1.7-ANGSTROM CRYSTAL-STRUCTURE OF THE AMINO-TERMINAL SIGNALING DOMAIN OF SONIC HEDGEHOG	NATURE			English	Article							ANOMALOUS DIFFRACTION; RESOLUTION	WITHIN the past few years, members of the hedgehog (hh) family of secreted signalling proteins have emerged as the primary signals generated by certain embryonic patterning centres. In vertebrate embryos, for example, sonic hedgehog expression in the notochord appears to be responsible for the local and long-range induction of ventral cell types within the neural tube and somites (reviewed in refs 1, 2). Protein products encoded by hh family members are synthesized as precursors that undergo autoprocessing to generate an amino-terminal domain that appears to be responsible for both local and long-range signalling activities, and a carboxy-terminal domain that contains the autoprocessing activity(3'4). As part of an effort to understand how hit family members participate in cell-to-cell signalling, we have determined and report here the crystal structure at 1.7 Angstrom of the amino-terminal domain of murine Sonic hedgehog (Shh-N)(5-9). The structure revealed a tetrahedrally coordinated zinc ion that appears to be structurally analogous to the zinc coordination sites of zinc hydrolases, such as thermolysin and carboxypeptidase A. This previously unsuspected catalytic site represents a distinct activity from the autoprocessing activity that resides in the carboxy-terminal domain.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University			Hall, Traci/F-5849-2019	Hall, Traci/0000-0001-6166-3009				Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONCORDET JP, 1995, NATURE, V375, P279, DOI 10.1038/375279a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P1; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; OTINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P56; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZECCA M, 1995, DEVELOPMENT, V121, P2265; 1979, SERC4 DAR LAB COLL C	30	163	174	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					212	216		10.1038/378212a0	http://dx.doi.org/10.1038/378212a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477329				2022-12-01	WOS:A1995TD75900062
J	HILLMEN, P; LEWIS, SM; BESSLER, M; LUZZATTO, L; DACIE, JV				HILLMEN, P; LEWIS, SM; BESSLER, M; LUZZATTO, L; DACIE, JV			NATURAL-HISTORY OF PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-LINES; MARROW TRANSPLANTATION; ANCHOR BIOSYNTHESIS; APLASTIC-ANEMIA; RED-CELLS; PIG-A; PHOSPHATIDYLINOSITOL; DEFICIENCY; DEFECT; PROTEIN	Background. Paroxysmal nocturnal hemoglobinuria (PNH), which is characterized by intravascular hemolysis and venous thrombosis, is an acquired clonal disorder associated with a somatic mutation in a totipotent hematopoietic stem cell, An understanding of the natural history of PNH is essential to improve therapy. Methods. We have followed a group of 80 consecutive patients with PNH who were referred to Hammersmith Hospital, London, between 1940 and 1970. They were treated with supportive measures, such as oral anticoagulant therapy after established thromboses, and transfusions. Results. The median age of the patients at the time of diagnosis was 42 years (range, 16 to 75), and the median survival after diagnosis was 10 years, with 22 patients (28 percent) surviving for 25 years. Sixty patients have died; 28 of the 48 patients for whom the cause of death is known died from either venous thrombosis or hemorrhage. Thirty-one patients (39 percent) had one or more episodes of venous thrombosis during their illness. Of the 35 patients who survived for 10 years or more, 12 had a spontaneous clinical recovery, No PNH-affected cells were found among the erythrocytes or neutrophils of the patients in prolonged remission, but a few PNH-affected lymphocytes were detectable in three of the four patients tested. Leukemia did not develop in any of the patients. Conclusions. PNH is a chronic disorder that curtails life, A spontaneous long-term remission can occur, which must be taken into account when considering potentially dangerous treatments, such as bone marrow transplantation. Platelet transfusions should be given, as appropriate, and long-term anticoagulation therapy should be considered for all patients.	ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,LONDON,ENGLAND; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021	Imperial College London; Imperial College London; Memorial Sloan Kettering Cancer Center	HILLMEN, P (corresponding author), GEN INFIRM,INST PATHOL,HAEMATOL MALIGNANCY DIAGNOST SERV,GREAT GEORGE ST,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; BESSLER M, 1994, LANCET, V343, P951, DOI 10.1016/S0140-6736(94)90068-X; CHARACHE S, 1969, BLOOD-J HEMATOL, V33, P877, DOI 10.1182/blood.V33.6.877.877; CROSBY WH, 1951, BLOOD, V6, P270, DOI 10.1182/blood.V6.3.270.270; CROSBY WH, 1953, BLOOD, V8, P769, DOI 10.1182/blood.V8.9.769.769; Dacie J, 1980, Sangre (Barc), V25, P890; DACIE J V, 1972, Series Haematologica, V5, P3; Dacie J V, 1944, Arch Dis Child, V19, P155; DACIE JV, 1961, BRIT J HAEMATOL, V7, P442, DOI 10.1111/j.1365-2141.1961.tb00354.x; DACIE JV, 1963, P ROY SOC MED, V56, P587, DOI 10.1177/003591576305600723; DACIE JV, 1954, HAEMOLYTIC ANAEMIA, P412; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; FERGUSON MAJ, 1992, BIOCHEM SOC T, V20, P243, DOI 10.1042/bst0200243; HILLMEN P, 1993, BLOOD, V81, P193; HILLMEN P, 1993, P NATL ACAD SCI USA, V90, P5272, DOI 10.1073/pnas.90.11.5272; HILLMEN P, 1992, BRIT J HAEMATOL, V80, P399, DOI 10.1111/j.1365-2141.1992.tb08151.x; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; KAWAHARA K, 1992, AM J HEMATOL, V39, P283, DOI 10.1002/ajh.2830390409; KURNICK JE, 1971, P SOC EXP BIOL MED, V137, P917; LETMAN H, 1952, BLOOD, V7, P842, DOI 10.1182/blood.V7.8.842.842; LONGO L, 1994, BRIT J HAEMATOL, V87, P401, DOI 10.1111/j.1365-2141.1994.tb04930.x; LUZZATTO L, 1995, PRACTICAL HAEMATOLOG, P287; MCMULLIN MF, 1994, J INTERN MED, V235, P85, DOI 10.1111/j.1365-2796.1994.tb01037.x; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOORE JG, 1986, EXP HEMATOL, V14, P222; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; ROSSE WF, 1990, BLOOD, V75, P1595; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; ROTOLI B, 1982, BLOOD, V60, P157; STORB R, 1973, BRIT J HAEMATOL, V24, P743, DOI 10.1111/j.1365-2141.1973.tb01701.x; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; VANKAMP H, 1994, BRIT J HAEMATOL, V87, P399, DOI 10.1111/j.1365-2141.1994.tb04929.x; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	40	601	630	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1253	1258		10.1056/NEJM199511093331904	http://dx.doi.org/10.1056/NEJM199511093331904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566002				2022-12-01	WOS:A1995TC71500004
J	JONES, SN; ROE, AE; DONEHOWER, LA; BRADLEY, A				JONES, SN; ROE, AE; DONEHOWER, LA; BRADLEY, A			RESCUE OF EMBRYONIC LETHALITY IN MDM2-DEFICIENT MICE BY ABSENCE OF P53	NATURE			English	Article							WILD-TYPE P53; MDM-2 ONCOGENE; PROTEIN; MOUSE; GROWTH; GENE; TRANSACTIVATION; LINE	THE Mdm2 proto-oncogene was originally identified as one of several genes contained on a mouse double minute chromosome present in a transformed derivative of 3T3 cells(1). Overexpression of Mdm2 can immortalize primary cultures of rodent fibroblasts(2). Human MDM2 is amplified in 30-40% of sarcomas, and is overexpressed in leukaemic cells(3,4). The Mdm2 oncoprotein forms a complex with the p53 tumour-suppressor protein and inhibits p53-mediated transregulation of gene expression(5,6) Because Mdm2 expression increases in response to p53, Mdm2-p53 binding may autoregulate Mdm2 expression and modulate the activity of p53 in the cell(7,8). We have created Mdm2-null and Mdm2/p53-null mice to determine whether Mdm2 possesses developmental functions in addition to the ability to complex with p53, and to investigate the biological role of Mdm2-p53 complex formation in development. Mice deficient for Mdm2 die early in development. In contrast, mice deficient for both Mdm2 and p53 develop normally and are viable. These results suggest that a critical role of Mdm2 in development is the regulation of p53 function.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	JONES, SN (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839				BAKER SJ, 1990, SCIENCE, V253, P49; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN J, 1995, J MOL MED, V1, P142; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; SCHMID P, 1991, DEVELOPMENT, V113, P857; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	23	1040	1060	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					206	208		10.1038/378206a0	http://dx.doi.org/10.1038/378206a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477327				2022-12-01	WOS:A1995TD75900060
J	JORGENSEN, EM; HARTWIEG, E; SCHUSKE, K; NONET, ML; JIN, YS; HORVITZ, HR				JORGENSEN, EM; HARTWIEG, E; SCHUSKE, K; NONET, ML; JIN, YS; HORVITZ, HR			DEFECTIVE RECYCLING OF SYNAPTIC VESICLES IN SYNAPTOTAGMIN MUTANTS OF CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; MEMBRANE-PROTEIN; DOCKING; UNC-104; TISSUE	SYNAPTOTAGMIN, an integral membrane protein of the synaptic vesicle(1,2), binds calcium and interacts with proteins of the plasma membrane(4-6). These observations suggest several possible functions for synaptotagmin in synaptic vesicle dynamics: it could facilitate exocytosis by promoting calcium-dependent fusion(3), inhibit exocytosis by preventing fusion(7), or facilitate endocytosis of synaptic vesicles from the plasma membrane by acting as a receptor for the endocytotic proteins of the clathrin AP2 complex(8). Here we show that synaptic vesicles are depleted at synaptic terminals in synaptotagmin mutants of the nematode Caenorhabditis elegans. This depletion is not caused by a defect in transport or by increased synaptic vesicle release, but rather by a defect in retrieval of synaptic vesicles from the plasma membrane. Thus we propose that, as well as being involved in exocytosis, synaptotagmin functions in vesicular recycling.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL)	JORGENSEN, EM (corresponding author), UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112, USA.			Jin, Yishi/0000-0002-9371-9860				AVERY L, 1993, GENETICS, V133, P897; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1994, GENETICS, V137, P987; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; RAND JB, 1985, PSYCHOPHARMACOL BULL, V21, P623; RAND JB, 1984, GENETICS, V106, P227; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	263	273	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					196	199		10.1038/378196a0	http://dx.doi.org/10.1038/378196a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477324				2022-12-01	WOS:A1995TD75900057
J	LUNA, RMD; WAGNER, DS; LOZANO, G				LUNA, RMD; WAGNER, DS; LOZANO, G			RESCUE OF EARLY EMBRYONIC LETHALITY IN MDM2-DEFICIENT MICE BY DELETION OF P53	NATURE			English	Article							WILD-TYPE P53; MDM-2 ONCOGENE; PROTEIN; APOPTOSIS; PROTOONCOGENE; IRRADIATION; ACTIVATION; DISRUPTION; RADIATION; CELLS	THE gene p53 encodes a transcriptional activator(1,2) of genes involved in growth arrest(3,4), DNA repair(5) and apoptosis(6-8). Loss p53 function contributes to tumor development in vivo(9-11). The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product(11-14). Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumor development(15). To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 null alleles. Rescue of the mdm2(-/-) lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Wagner, Daniel S/C-9379-2009	Wagner, Daniel S/0000-0002-0595-2436				CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARPER JW, 1993, CELL, V75, P805; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	27	1099	1116	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					203	206						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477326				2022-12-01	WOS:A1995TD75900059
J	MOLLOY, JE; BURNS, JE; KENDRICKJONES, J; TREGEAR, RT; WHITE, DCS				MOLLOY, JE; BURNS, JE; KENDRICKJONES, J; TREGEAR, RT; WHITE, DCS			MOVEMENT AND FORCE PRODUCED BY A SINGLE MYOSIN HEAD	NATURE			English	Article							SLIDING MOVEMENT; ACTIN-FILAMENTS; SUBFRAGMENT-1	MUSCLE contraction is driven by the cyclical interaction of myosin with actin, coupled to the breakdown of ATP. Studies of the interaction of filamentous myosin(1) and of a double-headed proteolytic fragment, heavy meromyosin (HMM)(2,3), with actin have demonstrated discrete mechanical events, arising from stochastic interaction of single myosin molecules with actin. Here we show, using an optical-tweezers transducer(2,4), that a single myosin subfragment-1 (S1), which is a single myosin head, can act as an independent generator of force and movement. Our analysis accounts for the broad distribution of displacement amplitudes observed, and indicates that the underlying: movement (working stroke) produced by a single acto-S1 interaction is similar to 4 nm, considerably shorter than previous estimates(1-3,5) but consistent with structural data(6). We measure the average force generated by S1 or HMM to be at least 1.7 pN under isometric conditions.	MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology	MOLLOY, JE (corresponding author), UNIV YORK, DEPT BIOL, YORK YO1 5DW, N YORKSHIRE, ENGLAND.			Molloy, Justin/0000-0002-8307-2450; Burns, Julie/0000-0003-1238-8826				ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Einstein A., 1956, THEORY BROWNIAN MOVE; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, BIOPHYS J, V68, pS298; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0	14	492	513	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					209	212		10.1038/378209a0	http://dx.doi.org/10.1038/378209a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477328				2022-12-01	WOS:A1995TD75900061
J	POLVIKOSKI, T; SULKAVA, R; HALTIA, M; KAINULAINEN, K; VUORIO, A; VERKKONIEMI, A; NIINISTO, L; HALONEN, P; KONTULA, K				POLVIKOSKI, T; SULKAVA, R; HALTIA, M; KAINULAINEN, K; VUORIO, A; VERKKONIEMI, A; NIINISTO, L; HALONEN, P; KONTULA, K			APOLIPOPROTEIN-E, DEMENTIA, AND CORTICAL DEPOSITION OF BETA-AMYLOID PROTEIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPORADIC ALZHEIMERS-DISEASE; SENILE PLAQUES; E POLYMORPHISM; TYPE-4 ALLELE; E GENOTYPE; BINDING; METHENAMINE; DIAGNOSIS; PEPTIDE; HEALTH	Background. The epsilon 4 allele of apolipoprotein E has been associated with an increased risk of late-onset Alzheimer's disease. In a cohort of elderly subjects we prospectively investigated the relation between the apolipoprotein E genotype, dementia, and the accumulation of beta-amyloid protein in the cerebral cortex. Methods. Autopsy involving neuropathological analysis and DNA analysis of frozen blood samples was performed in 92 of 271 persons who were at least 85 years of age, who had been living in Vantaa, Finland, on April 1, 1991, and who had died between that time and the end of 1993. All subjects had been tested for dementia, Apolipoprotein E genotyping was done with a solid-phase minisequencing technique. The percentage of the cortex occupied by methenamine silver-stained plaques was used as an estimate of the extent of beta-amyloid protein deposition. Results. The frequency of the epsilon 4 allele was significantly higher in the subjects with Alzheimer's disease than in the subjects without dementia (30 percent vs, 8 percent, P<0.001), There was a greater accumulation of beta-amyloid protein in the brain and more neurofibrillary tangles in the subjects with the epsilon 4 allele than in those without it (P<0.001), The deposition of beta-amyloid protein varied according to the genotype in both the subjects with dementia and those without dementia: it was lowest in those with the epsilon 2/epsilon 3 genotype, intermediate in those with the epsilon 3/epsilon 3 genotype, and highest in those with the epsilon 3/epsilon 4 genotype. A single subject had the epsilon 4/epsilon 4 genotype and had dementia. Conclusions. The epsilon 4 allele of apolipoprotein E is significantly associated with Alzheimer's disease. Even in elderly subjects without dementia, the apolipoprotein E genotype is related to the degree of deposition of beta-amyloid protein in the cerebral cortex.	HELSINKI UNIV,DEPT NEUROL,HELSINKI,FINLAND; KUOPIO UNIV,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND; KATARIINA GERIATR HOSP,VANTAA,FINLAND	University of Helsinki; University of Eastern Finland	POLVIKOSKI, T (corresponding author), HELSINKI UNIV,DEPT PATHOL,POB 21,HAARTMANINKATU 3,SF-00014 HELSINKI,FINLAND.		Vuorio, Alpo/I-3116-2019					ALLSOP D, 1989, NEUROPATH APPL NEURO, V15, P531, DOI 10.1111/j.1365-2990.1989.tb01252.x; ANWAR N, 1993, LANCET, V342, P1308, DOI 10.1016/0140-6736(93)92404-H; BORGAONKAR DS, 1993, LANCET, V342, P625, DOI 10.1016/0140-6736(93)91458-X; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HOULDEN H, 1994, NEUROSCI LETT, V174, P222, DOI 10.1016/0304-3940(94)90026-4; KONDOH H, 1993, BIOTECH HISTOCHEM, V68, P113, DOI 10.3109/10520299309104677; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LOUHIJA J, 1994, ARTERIOSCLER THROMB, V14, P1084, DOI 10.1161/01.ATV.14.7.1084; LUCOTTE G, 1993, LANCET, V342, P1309; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIETTINEN HE, 1994, HUM GENET, V94, P189; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; PAYAMI H, 1994, JAMA-J AM MED ASSOC, V271, P1316, DOI 10.1001/jama.271.17.1316; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REBECK GW, 1993, NEURON, V11, P575; RICHEY PL, 1995, BIOCHEM BIOPH RES CO, V208, P657, DOI 10.1006/bbrc.1995.1389; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SOBEL E, 1995, NEUROLOGY, V45, P903, DOI 10.1212/WNL.45.5.903; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P904; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; SYVANEN AC, 1993, AM J HUM GENET, V52, P46; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMAGUCHI H, 1990, ACTA NEUROPATHOL, V79, P569, DOI 10.1007/BF00296119; 1987, DIAGNOSTIC STATISTIC	41	421	433	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	1995	333	19					1242	1247		10.1056/NEJM199511093331902	http://dx.doi.org/10.1056/NEJM199511093331902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC715	7566000				2022-12-01	WOS:A1995TC71500002
J	RIDDLE, DR; LO, DC; KATZ, LC				RIDDLE, DR; LO, DC; KATZ, LC			NT-4-MEDIATED RESCUE OF LATERAL GENICULATE NEURONS FROM EFFECTS OF MONOCULAR DEPRIVATION	NATURE			English	Article							NERVE GROWTH-FACTOR; RAT VISUAL-CORTEX; FACTOR NGF; GENE-EXPRESSION; STRIATE CORTEX; MESSENGER-RNA; NUCLEUS; ORGANIZATION; MICROSPHERES; PLASTICITY	ALTERING the balance of activity between the two eyes during the critical period for visual-system development profoundly affects competitive interactions among neurons in the lateral geniculate nucleus and primary visual cortex(1-6). Neurons in the lateral geniculate nucleus that are deprived of activity by closing or silencing one eye atrophy as a result of competition with non-deprived neurons for some critical factor(s) presumed to be present in the cortex. Based on their actions in the developing visual system(7-12) neurotrophins are attractive candidates for such factors. We tested whether neurotrophins mediate intracortical competition of afferents from the lateral geniculate nucleus by using monocular deprivation and a new method for highly localized, in vivo delivery of neurotrophins. This method allowed unambiguous identification of neurons that were exposed to neurotrophin. Here we report that only one neurotrophin, the TrkB ligand NT-4, rescued neurons in the lateral geniculate nucleus from the dystrophic effects of monocular deprivation.			RIDDLE, DR (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710, USA.							ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BERARDI N, 1993, P ROY SOC B-BIOL SCI, V251, P17, DOI 10.1098/rspb.1993.0003; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; DOMENICI L, 1994, VISUAL NEUROSCI, V11, P1093, DOI 10.1017/S095252380000691X; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; DOMENICI L, 1993, P ROY SOC B-BIOL SCI, V251, P25, DOI 10.1098/rspb.1993.0004; GUILLERY RW, 1970, J COMP NEUROL, V139, P413, DOI 10.1002/cne.901390403; GUILLERY RW, 1973, J COMP NEUROL, V144, P117; HAYASHI M, 1990, NEUROSCIENCE, V36, P683, DOI 10.1016/0306-4522(90)90011-R; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LAW MI, 1988, J COMP NEUROL, V278, P157, DOI 10.1002/cne.902780202; LIN CS, 1978, J COMP NEUROL, V181, P809, DOI 10.1002/cne.901810408; LIU X, 1995, NATURE, V375, P238, DOI 10.1038/375238a0; Lo D. C., 1995, Society for Neuroscience Abstracts, V21, P537; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0	29	191	193	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					189	191		10.1038/378189a0	http://dx.doi.org/10.1038/378189a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477322				2022-12-01	WOS:A1995TD75900055
J	SAKAI, H; MEDRANO, LJ; MEYEROWITZ, EM				SAKAI, H; MEDRANO, LJ; MEYEROWITZ, EM			ROLE OF SUPERMAN IN MAINTAINING ARABIDOPSIS FLORAL WHORL BOUNDARIES	NATURE			English	Article							TRANSCRIPTION FACTOR-IIIA; HOMEOTIC GENES; PROTEIN; THALIANA; PRODUCT; DOMAIN; PLANTS; PETALS	THE Arabidopsis gene SUPERMAN (SUP) is necessary for the proper spatial development of reproductive floral tissues(1-3) Recessive mutations cause extra stamens to form interior to the normal third whorl stamens, at the expense of fourth whorl carpel development(1-3). The mutant phenotype is associated with the ectopic expression of the B function genes, AP3 and PI, in the altered floral region, closer to the centre of the flower than in the wild type(3), and ap3 sup and pi sup double mutants exhibit a phenotype similar to ap3 and pi single mutants. These findings led to SUP being interpreted as an upstream negative regulator of the B function organ-identity genes, acting in the fourth whorl(2,3), to establish a boundary between stamen and carpel whorls. Here we show, using molecular cloning and analysis, that it is expressed in the third whorl and acts to maintain this boundary in developing flowers. The putative SUPERMAN protein contains one zinc-finger and a region resembling a basic leucine zipper motif, suggesting a function in transcriptional regulation.			SAKAI, H (corresponding author), CALTECH, DIV BIOL, 156-29, PASADENA, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009					BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GAISER JC, 1995, PLANT CELL, V7, P333, DOI 10.1105/tpc.7.3.333; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; KRIZEK BA, IN PRESS DEVELOPMENT; MEYEROWITZ EM, 1991, DEVELOPMENT S1, V112, P157; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TAGUE BW, 1995, PLANT MOL BIOL, V28, P267, DOI 10.1007/BF00020246; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; TAKATSUJI H, 1994, PLANT CELL, V6, P947, DOI 10.1105/tpc.6.7.947; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	29	334	375	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					199	203		10.1038/378199a0	http://dx.doi.org/10.1038/378199a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477325				2022-12-01	WOS:A1995TD75900058
J	SAUCIER, D; CAIN, DP				SAUCIER, D; CAIN, DP			SPATIAL-LEARNING WITHOUT NMDA RECEPTOR-DEPENDENT LONG-TERM POTENTIATION	NATURE			English	Article							WATER-MAZE; SELECTIVE IMPAIRMENT; SYNAPTIC PLASTICITY; ANTAGONIST; MEMORY; RAT; BLOCKADE; ACQUISITION; MECHANISMS; NPC-17742	HIPPOCAMPAL lesions impair spatial learning in the watermaze(1). Drugs that antagonize N-methyl-D-aspartate (NMDA)-receptor activity, which is required for long-term potentiation (LTP) at various hippocampal synapses(2-4), block LTP and impair watermaze learning(4-6). This has led to the hypothesis that NMDA receptors, through their involvement in LTP, may be necessary for spatial(4-11) and other forms of learning(12,13). We examined this hypothesis using NPC17742 (2R,4R,5S-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptano acid), a potent and specific antagonist of NMDA receptors(14-17). Here we report that NPC17742 completely blocked dentate gyrus LTP but did not prevent normal spatial learning in rats that had been made familiar with the general task requirements by non-spatial pretraining. Although these results do not rule out a contribution of NMDA-mediated dentate LTP to spatial learning, they indicate that this form of LTP is not required for normal spatial learning in the watermaze.	UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON,ON N6A 5C2,CANADA	Western University (University of Western Ontario)	SAUCIER, D (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON,ON N6A 5C2,CANADA.							BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BAUDRY M, 1988, LONG TERM POTENTIATI; BOBELIS DJ, 1993, J PHARMACOL EXP THER, V264, P845; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; CAIN DP, IN PRESS BEHAV NEURO; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; DAVIS S, 1992, J NEUROSCI, V12, P21; FERKANY JW, 1993, J PHARMACOL EXP THER, V264, P256; HARGREAVES EL, 1990, J NEUROSCI, V10, P1472; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KOROL DL, 1993, HIPPOCAMPUS, V3, P127, DOI 10.1002/hipo.450030204; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OLNEY J, 1993, NEUROBIOLOGY CINGULA; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; SAUCIER D, IN PRESS BEHAV NEURO; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; SUTHERLAND RJ, 1993, HIPPOCAMPUS, V3, P141, DOI 10.1002/hipo.450030206; WILEY JL, 1994, PSYCHOPHARMACOLOGY, V116, P266, DOI 10.1007/BF02245327; WILLETTS J, 1993, J PHARMACOL EXP THER, V265, P1055	28	280	289	1	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					186	189		10.1038/378186a0	http://dx.doi.org/10.1038/378186a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477321				2022-12-01	WOS:A1995TD75900054
J	SILBERSWEIG, DA; STERN, E; FRITH, C; CAHILL, C; HOLMES, A; GROOTOONK, S; SEAWARD, J; MCKENNA, P; CHUA, SE; SCHNORR, L; JONES, T; FRACKOWIAK, RSJ				SILBERSWEIG, DA; STERN, E; FRITH, C; CAHILL, C; HOLMES, A; GROOTOONK, S; SEAWARD, J; MCKENNA, P; CHUA, SE; SCHNORR, L; JONES, T; FRACKOWIAK, RSJ			A FUNCTIONAL NEUROANATOMY OF HALLUCINATIONS IN SCHIZOPHRENIA	NATURE			English	Article							CEREBRAL BLOOD-FLOW; AUDITORY HALLUCINATIONS; AREA; PET	HALLUCINATIONS, perceptions in the absence of external stimuli, are prominent among the core symptoms of schizophrenia. The neural correlates of these brief, involuntary experiences are not well understood, and have not been imaged selectively. We have used new positron emission tomography (PET) methods(1,2) to study the brain state associated with the occurrence of hallucinations in six schizophrenic patients. Here we present a group study of five patients with classic auditory verbal hallucinations despite medication, demonstrating activations in subcortical nuclei (thalamic, striatal), limbic structures (especially hippocampus), and paralimbic regions (parahippocampal and cingulate gyri, as well as orbito-frontal cortex). We also present a case study of a unique, drug-naive patient with visual as well as auditory verbal hallucinations, demonstrating activations in visual and auditory/linguistic association cortices as part of a distributed cortical-subcortical network. Activity in deep brain structures, identified with group analysis, may generate or modulate hallucinations, and the particular neocortical regions entrained in individual patients may affect their specific perceptual content. The interaction of these distributed neural systems provides a biological basis for the bizarre reports of schizophrenic patients.	HAMMERSMITH HOSP, INST NEUROL, WELLCOME DEPT COGNIT NEUROL, LONDON W12 0NN, ENGLAND; NEW YORK HOSP, CORNELL MED CTR, FUNCT NEUROIMAGING LAB, NEW YORK, NY 10021 USA; FULBOURNE HOSP, FULBOURN CB1 5EF, ENGLAND	Imperial College London; University of London; University College London; Cornell University; NewYork-Presbyterian Hospital	SILBERSWEIG, DA (corresponding author), HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, DUCANE RD, LONDON W12 0NN, ENGLAND.		Frackowiak, Richard S/I-1809-2013; Frith, Chris D/A-2171-2009; Stern, Emily/E-6035-2011; Frackowiak, Richard/H-4383-2011	Frith, Chris D/0000-0002-8665-0690; Frackowiak, Richard/0000-0002-3151-822X; McKenna, Peter/0000-0001-5474-1144				ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BOGERTS B, 1993, SCHIZOPHRENIA BULL, V19, P431, DOI 10.1093/schbul/19.2.431; CLEGHORN JM, 1992, AM J PSYCHIAT, V149, P1062; CLEGHORN JM, 1990, BRIT J PSYCHIAT, V157, P562, DOI 10.1192/bjp.157.4.562; CSERNANSKY JG, 1991, BIOL PSYCHIAT, V30, P383, DOI 10.1016/0006-3223(91)90295-W; DELISI LE, 1989, BIOL PSYCHIAT, V25, P835, DOI 10.1016/0006-3223(89)90263-1; DOLAN RJ, 1995, HUMAN BRAIN MAPPIN S, V1, P417; FARAH MJ, 1989, TRENDS NEUROSCI, V12, P395, DOI 10.1016/0166-2236(89)90079-9; FRISTON KJ, 1992, BRAIN, V115, P367, DOI 10.1093/brain/115.2.367; FRISTON KJ, IN PRESS BIOL SCHIZO; Friston KJ., 1994, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; KURACHI M, 1985, EUR NEUROL, V24, P176, DOI 10.1159/000115791; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MARSH L, 1994, SCHIZOPHR RES, V11, P225, DOI 10.1016/0920-9964(94)90016-7; MATSUDA H, 1988, CLIN NUCL MED, V13, P53, DOI 10.1097/00003072-198801000-00015; MCGUIRE PK, 1993, LANCET, V342, P703, DOI 10.1016/0140-6736(93)91707-S; MCGUIRE PK, IN PRESS PSYCHOL MED; Mesulam MM, 1985, PRINCIPLES BEHAVIORA, P1; MUSALEK M, 1989, COMPR PSYCHIAT, V30, P99, DOI 10.1016/0010-440X(89)90123-5; NOTARDONATO H, 1989, CLIN NUCL MED, V14, P319, DOI 10.1097/00003072-198905000-00001; OLNEY JW, 1995, BIOL PSYCHIAT, V37, P667, DOI 10.1016/0006-3223(95)94677-O; SILBERSWEIG DA, 1994, J CEREBR BLOOD F MET, V14, P771, DOI 10.1038/jcbfm.1994.98; SILBERSWEIG DA, 1993, J CEREBR BLOOD F MET, V13, P617, DOI 10.1038/jcbfm.1993.80; TALAIRACH J, 1989, CO PLANAR STEREOTAXI; Trimble MR, 1991, PSYCHOSES EPILEPSY; VOLKOW ND, 1987, AM J PSYCHIAT, V144, P151; WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; ZEKI S, 1991, J NEUROSCI, V11, P641	30	717	729	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	1995	378	6553					176	179		10.1038/378176a0	http://dx.doi.org/10.1038/378176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477318				2022-12-01	WOS:A1995TD75900051
J	TALBOT, WS; TREVARROW, B; HALPERN, ME; MELBY, AE; FARR, G; POSTLETHWAIT, JH; JOWETT, T; KIMMEL, CB; KIMELMAN, D				TALBOT, WS; TREVARROW, B; HALPERN, ME; MELBY, AE; FARR, G; POSTLETHWAIT, JH; JOWETT, T; KIMMEL, CB; KIMELMAN, D			A HEMEOBOX GENE ESSENTIAL FOR ZEBRAFISH NOTOCHORD DEVELOPMENT	NATURE			English	Article							HOMEO-BOX GENE; MOUSE T-GENE; FLOOR PLATE; MESODERM FORMATION; EMPTY SPIRACLES; XENOPUS-LAEVIS; NEURAL-TUBE; EMBRYO; EXPRESSION; INDUCTION	The notochord is a midline mesodermal structure with an essential patterning function in all vertebrate embryos. Zebrafish floating head (flh) mutants lack a notochord, but develop with prechordal plate and other mesodermal derivatives, indicating that flh functions specifically in notochord development. We show that floating head Is the zebrafish homologue of Xnot, a homeobox gene expressed In the amphibian organizer and notochord. We propose that flh regulates notochord precursor cell fate.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403; UNIV NEWCASTLE UPON TYNE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	University of Washington; University of Washington Seattle; University of Oregon; Newcastle University - UK					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GONT LK, 1993, DEVELOPMENT, V119, P991; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/S0092-8674(05)80087-X; Halpern ME, 1995, DEVELOPMENT, V121, P4257; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HELDE KA, 1993, DEV BIOL, V159, P418, DOI 10.1006/dbio.1993.1252; HENION PD, IN PRESS DEV GENET; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; Ho R.K., 1992, Seminars in Developmental Biology, V3, P53; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KESSAIN S, 1993, ADV DEV BIOL, V2, P1; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; OPPENHEIMER JM, 1959, J EXP ZOOL, V140, P247, DOI 10.1002/jez.1401400205; PIKE SH, 1992, DEVELOPMENT, V144, P825; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THISSE C, 1993, DEVELOPMENT, V119, P1203; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAN YL, 1995, DEV DYNAM, V203, P363, DOI 10.1002/aja.1002030308	51	403	407	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 9	1995	378	6553					150	157		10.1038/378150a0	http://dx.doi.org/10.1038/378150a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TD759	7477317				2022-12-01	WOS:A1995TD75900043
J	GREENFIELD, S; ROGERS, W; MANGOTICH, M; CARNEY, MF; TARLOV, AR				GREENFIELD, S; ROGERS, W; MANGOTICH, M; CARNEY, MF; TARLOV, AR			OUTCOMES OF PATIENTS WITH HYPERTENSION AND NON-INSULIN-DEPENDENT DIABETES-MELLITUS TREATED BY DIFFERENT SYSTEMS AND SPECIALTIES - RESULTS FROM THE MEDICAL OUTCOMES STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL STATUS; CARE; QUALITY; THERAPY; LIFE; MEN	Objective.-To compare the outcomes of patients with hypertension and non-insulin-dependent diabetes mellitus (NIDDM) who were cared for in three different systems of care and by generalist and subspecialist physicians. Design.-An observational study with follow-up at three periods: (1) a 2-year study of 532 patients with hypertension and 170 patients with NIDDM who had entrance and exit histories, physical examinations, and laboratory tests; (2) a 4-year follow-up of 1044 patients with hypertension and 317 patients with NIDDM based on patient-reported functional status; and (3) 7-year mortality for 1296 patients with hypertension and 424 patients with NIDDM. Setting and Participants.-Patients sampled from health maintenance organizations, large multispecialty groups, and solo or single-specialty group practices in Boston, Mass, Los Angeles, Calif, and Chicago, III. Patients were designated as belonging to one of three systems of care: fee for service; prepaid patients in solo or small single-specialty groups or in large multispecialty group practices, referred to as independent practice associations; and staff-model health maintenance organizations. The principal providers were family practitioners, general internists, cardiologists, or endocrinologists. Main Outcome Measures.-Physiological, functional, and mortality. For hypertension, we measured blood pressure and stroke incidence. For NIDDM, we measured blood pressure, glycosylated hemoglobin level, visual function, vibration sense, ulcers and infections in the feet, and albumin excretion rate. Functional outcomes were assessed using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Mortality was assessed for the 7 years following the entrance examination. Results.-We found no evidence that any one system of care or physician specialty achieved consistently better e-year or 4-year outcomes than others for patients with NIDDM or hypertension, Endocrinologists appeared to achieve better foot-ulcer and infection outcomes for patients with NIDDM, particularly when compared with family practitioners, However, no other specialist differences were found in any individual measures for either condition. Moreover, no adjusted mortality differences among systems or among physician specialties were observed in the 7-year follow-up period. Conclusion.-No meaningful differences were found in the mean health outcomes for patients with hypertension or NIDDM, whether they were treated by different care systems or by different physician specialists. Although prepaid medicine relies more heavily on generalist physicians than does fee for service, there is no evidence from these analyses that the quality of care of moderately ill patients with these two common diseases was adversely affected, These findings must be viewed in light of the historically higher costs of fee-for-service medicine and of subspecialty physician practice.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; VALUE HLTH SCI, SANTA MONICA, CA USA; RAND CORP, SANTA MONICA, CA USA	Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; RAND Corporation	GREENFIELD, S (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, INST HLTH, 750 WASHINGTON ST, BOX 345, BOSTON, MA 02111 USA.			Greenfield, Sheldon/0000-0003-4628-1998				[Anonymous], 1992, Am J Hypertens, V5, P207; BLOOM S, 1984, BRIT MED J, V288, P1793, DOI 10.1136/bmj.288.6433.1793; CAPUTO GM, 1994, NEW ENGL J MED, V331, P854, DOI 10.1056/NEJM199409293311307; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; GEFFNER DL, 1992, DIABETES CARE, V15, P44, DOI 10.2337/diacare.15.1.S44; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LOGERFO JP, 1978, MED CARE, V16, P488, DOI 10.1097/00005650-197806000-00005; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MOLITCH ME, 1994, DIABETES CARE, V17, P756, DOI 10.2337/diacare.17.7.756; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; NEWHOUSE JP, 1993, HLTH INSURANCE MED C; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; ROGERS W, 1992, MEASURING FUNCTIONAL, P27; ROST KM, 1991, DIABETES CARE, V14, P881, DOI 10.2337/diacare.14.10.881; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERWIN RS, 1988, JAMA-J AM MED ASSOC, V260, P37; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Stewart AL, 1992, MEASURING FUNCTIONIN, P67; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; TIU SC, 1993, DIABETES CARE, V16, P616, DOI 10.2337/diacare.16.4.616; Ware J.E., 1993, SCORING SF 36 SF 36, DOI DOI 10.6-10.7; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WARE JE, 1992, MEASURING FUNCTIONIN, P3; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006	35	308	310	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1436	1444						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474189				2022-12-01	WOS:A1995TC47700025
J	JACOBSEN, SJ; KATUSIC, SK; BERGSTRALH, EJ; OESTERLING, JE; OHRT, D; KLEE, GG; CHUTE, CG; LIEBER, MM				JACOBSEN, SJ; KATUSIC, SK; BERGSTRALH, EJ; OESTERLING, JE; OHRT, D; KLEE, GG; CHUTE, CG; LIEBER, MM			INCIDENCE OF PROSTATE-CANCER DIAGNOSIS IN THE ERAS BEFORE AND AFTER SERUM PROSTATE-SPECIFIC ANTIGEN TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1999 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987. Design.-Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time. Study Setting.-Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes. Subjects.-All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis. Results.-The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50% of the older population in 1992. Conclusion.-These results support the premise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying more early stage (smaller) cancers.	MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, DIV METAB & HEMATOL BIOCHEM, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT UROL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, ROCHESTER, MN 55905 USA; BLUE CROSS BLUE SHIELD MINNESOTA, ST PAUL, MN USA; MAYO CLIN & MAYO FDN, HLTH SERV EVALUAT SECT, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, MED INFORMAT RESOURCES SECT, ROCHESTER, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	JACOBSEN, SJ (corresponding author), MAYO CLIN & MAYO FDN, CLIN EPIDEMIOL SECT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Jacobsen, Steven/0000-0002-8174-8533	NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENDER AP, 1993, MINN CANCER SURVEILL, V6, P1; BENOIT RM, 1994, UROLOGY, V44, P795, DOI 10.1016/S0090-4295(94)80160-6; BERGSTRALH EJ, 1992, MAYO CLIN TECHNICAL, V49; BETSILL WL, 1975, CANCER, V36, P305, DOI 10.1002/1097-0142(197508)36:2<305::AID-CNCR2820360202>3.0.CO;2-D; BOSTWICK DG, 1994, SEMIN SURG ONCOL, V10, P60, DOI 10.1002/ssu.2980100110; BRAWLEY OW, 1994, UROLOGY, V43, P594, DOI 10.1016/0090-4295(94)90169-4; Breslow N. E., 1987, STATISTICAL METHODS, VII; Burks D A, 1992, Henry Ford Hosp Med J, V40, P89; CATALONA WJ, 1993, UROLOGY, V42, P113, DOI 10.1016/0090-4295(93)90632-K; CHISHOLM GD, 1993, BRIT J UROL, V71, P375, DOI 10.1111/j.1464-410X.1993.tb15975.x; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHODAK GW, 1993, UROLOGY, V42, P116, DOI 10.1016/0090-4295(93)90633-L; CORDER EH, 1994, CANCER CAUSE CONTROL, V5, P207, DOI 10.1007/BF01830238; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; DENIS LJ, 1992, PROSTATE, P63; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GERBER GS, 1991, J NATL CANCER I, V83, P329, DOI 10.1093/jnci/83.5.329; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; GILLILAND FD, 1994, CANCER, V73, P2192, DOI 10.1002/1097-0142(19940415)73:8<2192::AID-CNCR2820730826>3.0.CO;2-Y; GOHAGAN JK, 1994, AM J PREV MED, V10, P245, DOI 10.1016/S0749-3797(18)30600-7; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; JONLER M, 1994, UROLOGY, V44, P876, DOI 10.1016/S0090-4295(94)80174-6; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; LANGE PH, 1995, JAMA-J AM MED ASSOC, V273, P336, DOI 10.1001/jama.273.4.336; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; LYON JL, 1977, AM J EPIDEMIOL, V105, P439, DOI 10.1093/oxfordjournals.aje.a112402; METTLIN C, 1994, J UROLOGY, V152, P1737, DOI 10.1016/S0022-5347(17)32373-X; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MILLER BA, 1993, NIH932789 PUBL; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; MORRISON AS, 1982, INT J EPIDEMIOL, V11, P261, DOI 10.1093/ije/11.3.261; MORTON RA, 1994, UROLOGY, V44, P637, DOI 10.1016/S0090-4295(94)80196-7; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; SOX HC, 1994, AM J PREV MED, V10, P187, DOI 10.1016/S0749-3797(18)30589-0; TAYLOR JD, 1994, CANCER-AM CANCER SOC, V73, P1704, DOI 10.1002/1097-0142(19940315)73:6<1704::AID-CNCR2820730625>3.0.CO;2-Y; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; 1992, 1992 AM UR ASS POL S, V4, P20	39	185	193	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1445	1449		10.1001/jama.274.18.1445	http://dx.doi.org/10.1001/jama.274.18.1445			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474190				2022-12-01	WOS:A1995TC47700026
J	KOGAN, MD; ALEXANDER, GR; TEITELBAUM, MA; JACK, BW; KOTELCHUCK, M; PAPPAS, G				KOGAN, MD; ALEXANDER, GR; TEITELBAUM, MA; JACK, BW; KOTELCHUCK, M; PAPPAS, G			THE EFFECT OF GAPS IN HEALTH-INSURANCE ON CONTINUITY OF A REGULAR SOURCE OF CARE AMONG PRESCHOOL-AGED CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; AMERICAN CHILDREN; ACCESS; TERMINATION; SERVICES; POOR	Objective.-To estimate the prevalence and length of gaps in health insurance coverage and their effect on having a regular source of care in a national sample of preschool-aged children. Design.-Follow-up survey of a nationally representative sample of 3-year-old children in the US population by phone or personal interview. Participants.-A total of 8129 children whose mothers were interviewed for the 1991 Longitudinal Follow-up to the National Maternal and Infant Health Survey. Main Outcome Measures.-Report of any gap in health insurance for the children, the length of the gap, and the number of different sites where the children were taken for medical care as a measure of continuity of a regular source of care. Results.-About one quarter of US children were without health insurance for at least 1 month during their first 3 years of life, Over half of these children had a health insurance gap of more than 6 months. Less than half of US children had only one site of care during their first 3 years. Children with health insurance gaps of longer than 6 months were at increased risk of having more than one care site (odds ratio = 1.52; 95% confidence interval, 1.19 to 1.96). This risk further increased when an emergency treatment was discounted as a multiple site of care. Conclusions.-Having a gap in health insurance coverage is an important determinant for not having a regular source of care for preschool-aged children. This finding is of concern, given the sizable percentage of children in the United States who lacked continuous health care coverage during a critical period of development.	CHILDRENS DEF FUND,WASHINGTON,DC; BROWN UNIV,SCH MED,DEPT FAMILY MED,PROVIDENCE,RI 02912; UNIV N CAROLINA,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC; UNIV ALABAMA,DEPT MATERNAL & CHILD HLTH,BIRMINGHAM,AL	Brown University; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,6525 BELCREST RD,ROOM 840,HYATTSVILLE,MD 20782, USA.			Jack, Brian/0000-0002-6497-2437				ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; ALPERT JJ, 1976, PEDIATRICS, V57, P917; [Anonymous], 1994, CURRENT POPULATION S; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.me.43.020192.002315; BENNIFIELD RL, 1994, DYNAMICS EC WELL BEI, P70; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BUTLER JA, 1985, PEDIATRICS, V76, P495; CORNELIUS LJ, 1993, J NATL MED ASSOC, V85, P281; Cunningham P J, 1994, Future Child, V4, P24, DOI 10.2307/1602433; CUNNINGHAM PJ, 1990, HLTH AFF MILLWOOD, V90, P76; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HUBBELL FA, 1989, AM J MED, V87, P127; Johansen A. S, 1994, ANAL CONCEPT PRIMARY; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARQUIS MS, 1992, JAMA-J AM MED ASSOC, V268, P3473; MAURER HM, 1993, AM J DIS CHILD, V147, P529, DOI 10.1001/archpedi.1993.02160290035015; MCDANIEL DB, 1975, PEDIATRICS, V56, P504; MONHEIT AC, 1984, FUTURE CHILD, V74, P1331; MOSCOVICE I, 1987, MED CARE, V25, P413, DOI 10.1097/00005650-198705000-00005; NEWACHECK PW, 1994, MATERNAL CHILD HLTH; ORR ST, 1991, MED CARE, V29, P283, DOI 10.1097/00005650-199103000-00009; PETER G, 1994, 1994 REDBOOK; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; REICHEL W, 1981, JAMA-J AM MED ASSOC, V246, P2065, DOI 10.1001/jama.246.18.2065; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; Starfield B., 1992, PRIMARY CARE CONCEPT; SWARTZ K, 1990, INQUIRY-J HEALTH CAR, V27, P281; SWARTZ K, 1993, INQUIRY, V80, P64; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; 1993, 1991 LONGITUDINAL FO; 1993, SURVEY DATA ANAL VER; 1994, MMWR MORB MORTAL WKL, V43; 1991, JAMA-J AM MED ASSOC, V266, P1547	38	129	129	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1429	1435		10.1001/jama.274.18.1429	http://dx.doi.org/10.1001/jama.274.18.1429			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474188				2022-12-01	WOS:A1995TC47700024
J	NAKASHIMA, K; IKEMATSU, H; HAYASHI, J; KISHIHARA, Y; MITSUTAKE, A; KASHIWAGI, S				NAKASHIMA, K; IKEMATSU, H; HAYASHI, J; KISHIHARA, Y; MITSUTAKE, A; KASHIWAGI, S			INTRAFAMILIAL TRANSMISSION OF HEPATITIS-C VIRUS AMONG THE POPULATION OF AN ENDEMIC AREA OF JAPAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; GENOME; SEQUENCE; PRIMERS; RNA	Objectives.-To assess the role of intrafamilial transmission of hepatitis C virus (HCV) among general populations. Design and Setting.-Cross-sectional study in an HCV-endemic area of Japan. Participants.-A total of 1122 residents (mean age, 41.7 years; range, 0 to 80 years), including 359 mother-child pairs and 234 pairs of spouses. Main Outcome Measures.-Antibody to HCV (anti-HCV) was examined using second-generation anti-HCV testing by passive hemagglutination assay. Hepatitis C virus RNA was detected by polymerase chain reaction with primers deduced from the 5'-noncoding region and HCV genotypes by reaction with type-specific primers deduced from the HCV core gene. Results.-Prevalence of anti-HCV was 14.1% (158/1122), and HCV RNA was detected in 82.9% of those who tested positive for anti-HCV. Prevalence of anti-HCV increased with advancing age, but no anti-HCV was found among 312 persons younger than 20 years. Of the 53 children with anti-HCV-positive mothers, three were positive for anti-HCV, all were older than 20 years, and all had a history of surgical treatment. Hepatitis C virus RNA was found in one mother-child pair but with different HCV genotypes. Both spouses were positive for anti-HCV in 17 of 234 pairs. Of the 11 pairs of spouses in whom the HCV genotypes of both were determined, five had different HCV genotypes. Conclusions.-While HCV is highly endemic in this area, neither vertical nor horizontal transmission between spouses seems to play an important role in its spread. The incidence of intrafamilial transmission of HCV seems to be low.			NAKASHIMA, K (corresponding author), KYUSHU UNIV HOSP 71,DEPT GEN MED,HIGASHI KU,FUKUOKA 812,JAPAN.							CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; HAYASHI J, 1995, AM J GASTROENTEROL, V90, P794; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; NAKASHIMA K, 1992, AM J EPIDEMIOL, V136, P1132, DOI 10.1093/oxfordjournals.aje.a116579; NAKASHIMA K, 1994, J EPIDEMIOL, V4, P14; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; TAJIMA K, 1991, LANCET, V337, P1410, DOI 10.1016/0140-6736(91)93089-R	12	62	65	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1459	1461		10.1001/jama.274.18.1459	http://dx.doi.org/10.1001/jama.274.18.1459			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC477	7474193				2022-12-01	WOS:A1995TC47700029
J	ARTENSTEIN, AW; COPPOLA, J; BROWN, AE; CARR, JK; SANDERSBUELL, E; GALBARINI, E; MASCOLA, JR; VANCOTT, TC; SCHONBROOD, P; MCCUTCHAN, FE; BURKE, DS				ARTENSTEIN, AW; COPPOLA, J; BROWN, AE; CARR, JK; SANDERSBUELL, E; GALBARINI, E; MASCOLA, JR; VANCOTT, TC; SCHONBROOD, P; MCCUTCHAN, FE; BURKE, DS			MULTIPLE INTRODUCTIONS OF HIV-1 SUBTYPE-E INTO THE WESTERN-HEMISPHERE	LANCET			English	Note								There are nine recognised genetic subtypes of HIV-1, and the epidemic in Southeast Asia is largely due to subtype E. We have investigated HIV-1 viral subtypes in 11 Uruguayan military personnel, six with infection acquired during a United Nations deployment to Cambodia and five with infection acquired in South America. We found subtype E in five of the six infections acquired in Southeast Asia, and subtype B in all five of the domestically acquired cases. These findings document multiple introductions of HIV-1 subtype E into the western hemisphere and mean that the genetic diversity of the global HIV-1 pandemic must be considered in strategies for epidemic control.	NATL HLTH DIRECTORATE ARMED FORCES,MONTEVIDEO,URUGUAY; HENRY M JACKSON FDN,ROCKVILLE,MD	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	ARTENSTEIN, AW (corresponding author), WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD 20850, USA.		Mascola, John/AAI-7193-2021	/0000-0002-5704-8094				ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; BERRIOLO R, 1992, AIDS, V6, P884; GAO F, 1994, AIDS RES HUM RETROV, V10, P625, DOI 10.1089/aid.1994.10.625; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569; MYERS G, 1994, HUMAN RETROVIRUSES A; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407	10	76	76	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1197	1198		10.1016/S0140-6736(95)92900-2	http://dx.doi.org/10.1016/S0140-6736(95)92900-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475660	Bronze			2022-12-01	WOS:A1995TC97600010
J	BARKER, DJP; OSMOND, C; RODIN, I; FALL, CHD; WINTER, PD				BARKER, DJP; OSMOND, C; RODIN, I; FALL, CHD; WINTER, PD			LOW-WEIGHT GAIN IN INFANCY AND SUICIDE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article									UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PSYCHIAT,SOUTHAMPTON SO14 0YG,HANTS,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1995, LANCET, V345, P1087, DOI 10.1016/S0140-6736(95)90821-8; BARRACLOUGH BM, 1974, BR J PSYCH, V74, P443; CHECKLEY S, 1992, HDB AFFECTIVE DISORD; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; VANKNORRING AL, 1982, ACTA PSYCHIAT SCAND, V65, P283	5	92	96	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1203	1203		10.1136/bmj.311.7014.1203	http://dx.doi.org/10.1136/bmj.311.7014.1203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD768	7488897	Green Published			2022-12-01	WOS:A1995TD76800021
J	BARRETTCONNOR, E; GOODMANGRUEN, D				BARRETTCONNOR, E; GOODMANGRUEN, D			PROSPECTIVE-STUDY OF ENDOGENOUS SEX-HORMONES AND FATAL CARDIOVASCULAR-DISEASE IN POSTMENOPAUSAL WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; STEROIDS; THERAPY; HEALTH; PLASMA	Objectives-To examine the association between androstenedione, total and bioavailable testosterone, oestrone, and total and bioavailable oestradiol concentrations and the risk of death from cardiovascular and ischaemic heart disease. Design-19 year old population based prospective study with 99.9% follow up. Setting-Rancho Bernardo, California. Subjects-651 postmenopausal women, none taking oestrogen. Main outcome measures-Concentrations of plasma sex hormones measured by radioimmunoassay in an endocrinology research laboratory. Cardiovascular and ischaemic heart disease deaths assessed by death certificate; 85% of 30% sample validated by record review. Results-Age adjusted concentrations of sex hormones did not differ significantly in women with and without a history of heart disease at baseline and did not predict cardiovascular death or death from ischaemic heart disease. Most 95% confidence intervals for the age adjusted relative risk of cardiovascular death or death from ischaemic heart disease were narrow, and all included one. Endogenous oestrogen concentrations were not associated with significantly more favourable risk factors for heart disease, and testosterone was not associated with less favourable risk factors. Conclusion-These prospective data do not support a causal or preventive role for endogenous oestrogens or androgens and cardiovascular mortality in older women.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NIDDK NIH HHS [2RO1 DK31 801-0942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DC, 1976, STEROIDS, V28, P179, DOI 10.1016/0039-128X(76)90108-2; BUSH TL, 1990, P S MENOPAUSE, P211; CAULEY JA, 1994, ARTERIOSCLER THROMB, V14, P14, DOI 10.1161/01.ATV.14.1.14; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CAULEY JA, 1991, AM J EPIDEMIOL, V133, P50, DOI 10.1093/oxfordjournals.aje.a115801; CAULEY JA, 1991, AM J EPIDEMIOL, V132, P884; COX DR, 1972, J R STAT SOC B, V34, P187; MELDRUM DR, 1981, OBSTET GYNECOL, V57, P624; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; TRACY R, 1976, J CHRON DIS, V19, P1245; TREMBLAY RR, 1974, CONTRACEPTION, V10, P599, DOI 10.1016/0010-7824(74)90099-7; TUNSTALLPEDOE H, 1991, BMJ-BRIT MED J, V303, P701, DOI 10.1136/bmj.303.6804.701; VERMEULEN A, 1979, CLIN ENDOCRINOL, V9, P59; WINGARD DL, 1984, ANNU REV PUBL HEALTH, V5, P433, DOI 10.1146/annurev.pu.05.050184.002245; ZUMOFF B, 1982, ARTERIOSCLEROSIS, V2, P58, DOI 10.1161/01.ATV.2.1.58; 1985, SAS USERS GUIDE	17	138	145	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1193	1196		10.1136/bmj.311.7014.1193	http://dx.doi.org/10.1136/bmj.311.7014.1193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488894	Green Published			2022-12-01	WOS:A1995TD76800017
J	BRODINE, SK; MASCOLA, JR; WEISS, PJ; ITO, SI; PORTER, KR; ARTENSTEIN, AW; GARLAND, FC; MCCUTCHAN, FE; BURKE, DS				BRODINE, SK; MASCOLA, JR; WEISS, PJ; ITO, SI; PORTER, KR; ARTENSTEIN, AW; GARLAND, FC; MCCUTCHAN, FE; BURKE, DS			DETECTION OF DIVERSE HIV-1 GENETIC SUBTYPES IN THE USA	LANCET			English	Note								Of the nine genetic subtypes of HIV-1 that exist world wide, subtype B predominates in North America and Europe. Thus, most knowledge about HIV-1 and most vaccine development efforts are based on subtype B viruses. We document here the detection of HIV-1 subtypes A, D, and E in five US servicemen who acquired these non-subtype-B infections during overseas deployments. The dispersal of diverse HIV-1 subtypes into regions of the world with previously restricted genetic diversity may have important implications for the epidemiology of the epidemic and for the design and implementation of vaccine trials.	USN,MED RES INST,DEPT INFECT DIS,BETHESDA,MD; WALTER REED ARMY INST RES,DIV RETROVIROL,ROCKVILLE,MD; USN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA 92152; HENRY M JACKSON FDN,ROCKVILLE,MD	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Navy; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	BRODINE, SK (corresponding author), USN,HLTH RES CTR,DIV CLIN EPIDEMIOL,DEPT HLTH SCI & EPIDEMIOL,SAN DIEGO,CA 92186, USA.		Mascola, John/AAI-7193-2021	/0000-0002-5704-8094				ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; GAO F, 1993, AIDS RES HUM RETROV, V10, P625; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HAWKES S, 1994, AIDS, V8, P247, DOI 10.1097/00002030-199402000-00013; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; MASCOLA JR, 1994, J INFECT DIS, V169, P48, DOI 10.1093/infdis/169.1.48; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MYERS G, 1994, HUMAN RETROVIRUSES A; SALMINEN M, 1993, VIROLOGY, V195, P185, DOI 10.1006/viro.1993.1359	10	125	125	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1198	1199		10.1016/S0140-6736(95)92901-0	http://dx.doi.org/10.1016/S0140-6736(95)92901-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475661				2022-12-01	WOS:A1995TC97600011
J	GROSHEIDE, PM; KLOKMANHOUWELING, JM; CONYNVANSPAENDONCK, MAE; VERBRUGGE, HP; LATUPERISA, R; MAZEL, JA; LEMS, AA; YPMA, TD; GERARDS, LJ; AARTS, GJ; BOLSCHER, DJA; DUFFELS, GJJ; KOPPENAAL, A; ENGEL, B; VANDERVOORN, JG; KOSTER, EH; VANDERSTEUR, JB				GROSHEIDE, PM; KLOKMANHOUWELING, JM; CONYNVANSPAENDONCK, MAE; VERBRUGGE, HP; LATUPERISA, R; MAZEL, JA; LEMS, AA; YPMA, TD; GERARDS, LJ; AARTS, GJ; BOLSCHER, DJA; DUFFELS, GJJ; KOPPENAAL, A; ENGEL, B; VANDERVOORN, JG; KOSTER, EH; VANDERSTEUR, JB			PROGRAM FOR PREVENTING PERINATAL HEPATITIS-B INFECTION THROUGH SCREENING OF PREGNANT-WOMEN AND IMMUNIZATION OF INFANTS OF INFECTED MOTHERS IN THE NETHERLANDS, 1989-92	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PASSIVE-ACTIVE IMMUNIZATION; ANTIGEN-CARRIER MOTHERS; VACCINATION PROGRAM; SURFACE-ANTIGEN; IMMUNE GLOBULIN; VIRUS-INFECTION; TRANSMISSION	Objectives-To launch a programme for the prevention of perinatal infection with hepatitis B in the Netherlands. Design-Routine antenatal screening and intervention programme. Setting-Community antenatal programme, the Netherlands. Subjects-Infants of mothers who were carriers of hepatitis B detected by routine screening. Interventions-Infants of infected mothers received hepatitis B immunoglobulin at birth and four doses of hepatitis B vaccine in conjunction with routine immunisation at 3, 4, 5, and 11 months of age. Main outcome measures-Results of screening and immunisation from 1989-92. Results-The coverage of screening increased from 46% in 1989 to 84% in 1992. Hepatitis B surface antigen was detected in 2145 women (0.44%). The coverage of postnatal immunoprophylaxis in 1645 neonates born to mothers who were carriers of hepatitis B was 85% (1398); in 3% (42) there was a delay in administration of immunoglobulin of over 24 hours. In 1991, 96% (537), 95% (532), 94% (525), and 87% (489) of the infants received the first, second, third, and fourth dose of vaccine, respectively. There was considerable variation in the timing of vaccination; 17% (258) of the infants received their first dose more than two weeks late. Of the 59% (583) of infants who received the fourth dose more than two weeks beyond target age, 14% (141) also received their first dose too late. Conclusions-A prevention programme for perinatal hepatitis B in an area of low prevalence, when incorporated into existing health care, is feasible and achieves satisfactory coverage rates. Intensive follow up is needed to improve adherence to the immunisation schedule.	NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT INFECT DIS & EPIDEMIOL, 3720 BA BILTHOVEN, NETHERLANDS; MUNICIPAL PUBL HLTH SERV, HAARLEM, NETHERLANDS; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, AMSTERDAM, NETHERLANDS	Netherlands National Institute for Public Health & the Environment								BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BEASLEY RP, 1983, LANCET, V2, P1099; CHEN D-S, 1987, Journal of the American Medical Association, V257, P2597, DOI 10.1001/jama.257.19.2597; GROSHEIDE PM, 1993, AM J DIS CHILD, V147, P1316, DOI 10.1001/archpedi.1993.02160360058019; GROSHEIDE PM, IN PRESS BMJ; HENNING KJ, 1992, AM J PUBLIC HEALTH, V82, P885, DOI 10.2105/AJPH.82.6.885; INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764; JONAS MM, 1990, AM J GASTROENTEROL, V85, P277; MAZEL JA, 1984, BRIT MED J, V288, P513, DOI 10.1136/bmj.288.6416.513; NIU MT, 1992, AM J DIS CHILD, V146, P793, DOI 10.1001/archpedi.1992.02160190025012; SCHALM SW, 1989, PEDIATRICS, V83, P1041; STEVENS CE, 1985, JAMA-J AM MED ASSOC, V253, P1740, DOI 10.1001/jama.253.12.1740; STROFFOLINI T, 1989, VACCINE, V7, P152, DOI 10.1016/0264-410X(89)90056-X; VERBRUGGE HP, 1990, PEDIATRICS, V86, P1060; WEST DJ, 1993, VACCINE, V11, pS21, DOI 10.1016/0264-410X(93)90154-P	15	18	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	1995	311	7014					1200	1202		10.1136/bmj.311.7014.1200	http://dx.doi.org/10.1136/bmj.311.7014.1200			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488896	Green Published			2022-12-01	WOS:A1995TD76800020
J	GROSHEIDE, PM; WLADIMIROFF, JW; HEIJTINK, RA; MAZEL, JA; CHRISTIAENS, GCML; NUIJTEN, ASM; SCHALM, SW; DUERLOOVOLLAARD, A; ZWIJNENBERG, J; VANDERLAAR, T; BANFFER, JRJ; BAKKERBENDIK, M; BORRIAN, MJ; RIBBERTSMEENK, H; DEGAST, GG; GERARDS, LJ; VANDIJK, H; FETTER, WPF; BAERTS, W				GROSHEIDE, PM; WLADIMIROFF, JW; HEIJTINK, RA; MAZEL, JA; CHRISTIAENS, GCML; NUIJTEN, ASM; SCHALM, SW; DUERLOOVOLLAARD, A; ZWIJNENBERG, J; VANDERLAAR, T; BANFFER, JRJ; BAKKERBENDIK, M; BORRIAN, MJ; RIBBERTSMEENK, H; DEGAST, GG; GERARDS, LJ; VANDIJK, H; FETTER, WPF; BAERTS, W			PROPOSAL FOR ROUTINE ANTENATAL SCREENING AT 14 WEEKS FOR HEPATITIS-B SURFACE-ANTIGEN	BRITISH MEDICAL JOURNAL			English	Article							VIRUS CARRIER STATE; PERINATAL TRANSMISSION; ACTIVE IMMUNIZATION; CONTROLLED TRIAL; PREVENTION; INFECTION; EFFICACY; VACCINE; MOTHERS; INFANTS	Objective-To develop a low cost, high compliance screening programme for identification of carriers of hepatitis B surface antigen in the obstetric population of the Netherlands. Design-A seven year open, descriptive study of screening for hepatitis B surface antigen as part of routine prenatal laboratory testing at 14 weeks of gestation. Compliance with programme evaluated by checking delivery records (hospitals) or registration of births in the 30 participating municipalities (rural area). Setting-Three large city hospitals (two tertiary referral centres) and one rural area with a large number of home deliveries. Subjects-99 706 pregnant women applying for prenatal care for the first time. Main outcome measures-Proportion of pregnant women routinely screened; prevalence of hepatitis B surface antigen in large cities and rural area. Results-Uptake of screening reached 97% in the hospitals after inclusion of 10% screened at delivery; the estimated uptake in the rural area was >95%. Prevalence of hepatitis B surface antigen was 1.6% in the large cities and 0.3% in the rural area. For screening at delivery the prevalence was 2.5 times higher (4%, P < 0.01) than for screening at week 14 of gestation. Conclusion-Incorporation of universal testing for hepatitis B surface antigen into routine prenatal laboratory testing is practical; high compliance is achieved when screening is supplemented with rapid screening at delivery for those who escaped routine prenatal care.	UNIV HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS; UNIV HOSP DIJKZIGT,DEPT OBSTET,3015 GD ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT VIROL,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP,DEPT OBSTET & GYNAECOL,UTRECHT,NETHERLANDS; STATE SCH TRAINING MIDWIVES,ROTTERDAM,NETHERLANDS; RUWAARD VAN PUTTEN HOSP,DEPT PAEDIAT,SPIJKERVISSE,NETHERLANDS; REG PUBL HLTH LAB,ROTTERDAM,NETHERLANDS; ACAD HOSP ROTTERDAM DIJKZIGT,DEPT INTERNAL MED,3000 DR ROTTERDAM,NETHERLANDS; REG LAB PATHOL & MICROBIOL,ENSCHEDE,NETHERLANDS; BLOOD TRANSFUS LAB,UTRECHT,NETHERLANDS; WILHELMINA CHILDRENS HOSP,UTRECHT,NETHERLANDS; SOPHIA HOSP,DEPT PAEDIAT,ZWOLLA,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Wilhelmina Kinderziekenhuis								AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; DELCANHO R, 1994, J HEPATOL, V20, P483, DOI 10.1016/S0168-8278(05)80494-5; FRANCIS DP, 1985, PEDIATRICS, V76, P851; GREENSPOON JS, 1989, J REPROD MED, V34, P655; GROSHEIDE PM, 1993, AM J DIS CHILD, V147, P1316, DOI 10.1001/archpedi.1993.02160360058019; IP HMH, 1989, LANCET, V1, P406; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; MAUPAS P, 1981, LANCET, V1, P289; MAYNARD JE, 1983, INT J EPIDEMIOL, V61, P731; MAZEL JA, 1984, BRIT MED J, V288, P513, DOI 10.1136/bmj.288.6416.513; SCHALM SW, 1989, PEDIATRICS, V83, P1041; SILVERMAN NS, 1991, JAMA-J AM MED ASSOC, V20, P2852; TADA H, 1982, PEDIATRICS, V70, P613; WAINWRIGHT RB, 1986, INT J EPIDEMIOL, V15, P567, DOI 10.1093/ije/15.4.567; 1984, MMWR-MORBID MORTAL W, V33, P285; 1983, B WORLD HEALTH ORGAN, V61, P731	17	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1197	1199		10.1136/bmj.311.7014.1197	http://dx.doi.org/10.1136/bmj.311.7014.1197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488895	Green Published			2022-12-01	WOS:A1995TD76800019
J	HIRSCHL, RB; PRANIKOFF, T; GAUGER, P; SCHREINER, RJ; DECHERT, R; BARTLETT, RH				HIRSCHL, RB; PRANIKOFF, T; GAUGER, P; SCHREINER, RJ; DECHERT, R; BARTLETT, RH			LIQUID VENTILATION IN ADULTS, CHILDREN, AND FULL-TERM NEONATES	LANCET			English	Note								We evaluated the safety and efficacy of partial liquid ventilation in a series of 19 adults, children, and neonates who were in respiratory failure and on extracorporeal life support. During partial liquid ventilation, the alveolar-arterial oxygen difference decreased from 590 (SE 25) to 471 (42) mm Hg (p=0 . 0002) and static pulmonary compliance increased from 0 . 18 (0 . 04) to 0 . 29 (0 . 04) mL cm H2O-1 kg(-1) (p=0 . 0002). 11 patients (58%) survived. These preliminary data suggest that partial liquid ventilation can be safely used in patients with severe respiratory failure and may improve lung function.	UNIV MICHIGAN, DEPT SURG, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			Gauger, Paul/W-8176-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD15434] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT RH, 1990, CURR PROB SURG, V27, P623; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; HIRSCHL RB, 1994, SURGERY, V116, P159; HIRSCHL RB, 1995, CHEST, V108, P500, DOI 10.1378/chest.108.2.500; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; SHAFFER TH, 1992, PEDIATR PULM, V14, P102, DOI 10.1002/ppul.1950140208	8	157	162	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1201	1202		10.1016/S0140-6736(95)92903-7	http://dx.doi.org/10.1016/S0140-6736(95)92903-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475663				2022-12-01	WOS:A1995TC97600013
J	JASS, JR; COTTIER, DS; JEEVARATNAM, P; POKOS, V; HOLDAWAY, KM; BOWDEN, ML; VANDEWATER, NS; BROWETT, PJ				JASS, JR; COTTIER, DS; JEEVARATNAM, P; POKOS, V; HOLDAWAY, KM; BOWDEN, ML; VANDEWATER, NS; BROWETT, PJ			DIAGNOSTIC USE OF MICROSATELLITE INSTABILITY IN HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER	LANCET			English	Note							DINUCLEOTIDE REPEAT POLYMORPHISMS	50 families with a history of colorectal cancer were divided according to whether criteria for hereditary non-polyposis colorectal cancer (HNPCC) were fulfilled totally (A, n=19) or partly (B, n=31) and stratified by the demonstration that at least half the cancers tested per family were positive for DNA replication errors (RER+). Accepted clinical and pathological characteristics of HNPCC were found to cluster within 12 A/RER+ families in which the mean number of affected individuals per family was 10 . 1. Reliance upon clinical data alone may result in over-diagnosis of HNPCC, in small families who just meet the minimum criteria, whereas underdiagnosis is rare. The criteria could be refined by inclusion of RER status.	UNIV AUCKLAND,SCH MED,DEPT MOLEC MED,AUCKLAND,NEW ZEALAND	University of Auckland	JASS, JR (corresponding author), UNIV AUCKLAND,SCH MED,DEPT PATHOL,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.				NICHD NIH HHS [R01HD15434] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AALTONEN LA, 1994, CANCER RES, V54, P1645; EASTON DF, 1993, AM J HUM GENET, V52, P678; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; KIM HG, 1994, AM J PATHOL, V145, P148; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; NYSTROMLAHTI M, 1994, P NATL ACAD SCI USA, V91, P6054, DOI 10.1073/pnas.91.13.6054; RISINGER JI, 1991, HUM MOL GENET, V1, P657; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	11	87	87	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1200	1201		10.1016/S0140-6736(95)92902-9	http://dx.doi.org/10.1016/S0140-6736(95)92902-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475662				2022-12-01	WOS:A1995TC97600012
J	KIECOLTGLASER, JK; MARUCHA, PT; MALARKEY, WB; MERCADO, AM; GLASER, R				KIECOLTGLASER, JK; MARUCHA, PT; MALARKEY, WB; MERCADO, AM; GLASER, R			SLOWING OF WOUND-HEALING BY PSYCHOLOGICAL STRESS	LANCET			English	Article							EXPRESSION; HEALTH	There is evidence that psychological stress adversely affects the immune system. We have investigated the effects of such stress, caused by caring for a relative with Alzheimer's disease, on wound healing. We studied 13 women caring for demented relatives (mean age 62 . 3 [SE 2 . 3] years) and 13 controls matched for age (60 . 4 [2 . 8] years) and family income. All subjects underwent a 3 . 5 mm punch biopsy wound. Healing was assessed by photography of the wound and the response to hydrogen peroxide (healing was defined as no foaming). Wound healing took significantly longer in caregivers than in controls (48 . 7 [2 . 9] vs 39 . 3 [3 . 0] days, p<0 . 05). Peripheral-blood leucocytes from caregivers produced significantly less interleukin-1 beta mRNA in response to lipopolysaccharide stimulation than did controls' cells. Stress-related defects in wound repair could have important clinical implications, for instance for recovery from surgery.	OHIO STATE UNIV,COLL DENT,DEPT PSYCHIAT,PERIODONTOL SECT,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT MED,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT MED MICROBIOL & IMMUNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Kiecolt-Glaser, Janice K/A-3236-2009; Mercado, Ana/ABB-5559-2021; Glaser, Ronald/E-3124-2011	Kiecolt-Glaser, Janice K/0000-0003-4900-9578; 	NCRR NIH HHS [M01 RR0034] Funding Source: Medline; NIMH NIH HHS [R37 MH42096, R01 MH50538] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH042096, R01MH050538] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; BARBUL A, 1990, CLIN PLAST SURG, V17, P433; BURNS EA, 1990, GERIATRIC MED, P312; Cohen S, 1988, SOCIAL PSYCHOL HLTH; ESTERLING BA, 1994, HEALTH PSYCHOL, V13, P291, DOI 10.1037/0278-6133.13.4.291; GIASER R, 1994, HDB HUMAN STRESS IMM; GROVE GL, 1982, ARCH DERMATOL RES, V272, P381, DOI 10.1007/BF00509069; GRUBER RP, 1975, PLAST RECONSTR SURG, V55, P472, DOI 10.1097/00006534-197555040-00013; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; LIGHT E, 1994, STRESS EFFECTS FAMIL; LOWRY SF, 1993, ARCH SURG-CHICAGO, V28, P1235; MARUCHA PT, 1990, J IMMUNOL, V145, P2932; MCCANN JJ, 1991, THESIS RUSH U COLLEG; NEMETH AJ, 1991, ARCH DERMATOL, V127, P1679, DOI 10.1001/archderm.127.11.1679; SHERIDAN JF, 1991, J NEUROIMMUNOL, V31, P245, DOI 10.1016/0165-5728(91)90046-A; STRIETER RM, 1990, J LEUKOCYTE BIOL, V47, P366, DOI 10.1002/jlb.47.4.366; THOMPSON R, 1990, PHYS WORLD, V3, P18, DOI 10.1088/2058-7058/3/12/16	18	654	664	0	58	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 4	1995	346	8984					1194	1196		10.1016/S0140-6736(95)92899-5	http://dx.doi.org/10.1016/S0140-6736(95)92899-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC976	7475659	Bronze			2022-12-01	WOS:A1995TC97600009
J	OBRIEN, J; LONG, H				OBRIEN, J; LONG, H			URINARY-INCONTINENCE - LONG-TERM EFFECTIVENESS OF NURSING INTERVENTION IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article											OBRIEN, J (corresponding author), SOMERSET HLTH COMMISS,DEPT PUBL HLTH MED,TAUNTON TA1 7PQ,SOMERSET,ENGLAND.							HAHN I, 1993, BRIT J UROL, V72, P421, DOI 10.1111/j.1464-410X.1993.tb16170.x; LARGOJANSSEN TLM, 1992, FAM PRACT, V9, P284; MOURITSEN L, 1991, BRIT J UROL, V68, P32, DOI 10.1111/j.1464-410X.1991.tb15252.x; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; 1991, AGENDA ACTION CONTIN	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1208	1208		10.1136/bmj.311.7014.1208	http://dx.doi.org/10.1136/bmj.311.7014.1208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488903	Green Published			2022-12-01	WOS:A1995TD76800027
J	STEVENS, MCG; HOCKLEY, AD; SPOONER, D; WALSH, AR				STEVENS, MCG; HOCKLEY, AD; SPOONER, D; WALSH, AR			TREATMENT FOR CHILDREN WITH BRAIN-TUMORS	BRITISH MEDICAL JOURNAL			English	Article								The overall survival for children with malignant brain tumours has not greatly improved in recent years, so that apparently innovative treatments may seem attractive, especially in cases with a poor prognosis. Problems associated with treating such children include balancing the need to provide optimum treatment for individual patients with the need to properly evaluate advances in treatment in clinical trials and determining who should be responsible for decisions about funding such treatments. Treatment abroad is rarely justified when judged on the basis of whether the treatment is available in Britain (or European Community) and whether there is accepted evidence for its clinical benefit. However, referral to specialist paediatric centres is essential. The range of daily experience in such centres allows an educated choice between established and new treatments. Close collaboration these centres is essential for clinical trials.			STEVENS, MCG (corresponding author), BIRMINGHAM CHILDRENS HOSP NHS TRUST,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.			Stevens, Michael/0000-0001-6466-551X				LUKENS JN, 1994, CANCER-AM CANCER SOC, V74, P2710, DOI 10.1002/1097-0142(19941101)74:9+<2710::AID-CNCR2820741821>3.0.CO;2-G; MAGRATH I, 1995, LANCET, V345, P601, DOI 10.1016/S0140-6736(95)90516-2; SMYTH JF, 1994, BRIT MED J, V309, P457, DOI 10.1136/bmj.309.6952.457; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1994, BRIT MED J, V309, P1612, DOI 10.1136/bmj.309.6969.1612; 1993, SAFE NEUROSURGERY MA; 1992, ASSESSING EFFECTS HL; [No title captured]	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1213	1214		10.1136/bmj.311.7014.1213	http://dx.doi.org/10.1136/bmj.311.7014.1213			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488906	Green Published			2022-12-01	WOS:A1995TD76800030
J	SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H; BROWN, SS				SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H; BROWN, SS			PROSPECTIVE-STUDY OF TRENDS IN REFERRAL PATTERNS IN FUNDHOLDING AND NON-FUNDHOLDING PRACTICES IN THE OXFORD REGION, 1990-4	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare outpatient referral patterns in fundholding and non-fundholding practices before and after the NHS reforms in April 1991. Design-Prospective collection of data on general practitioners' referrals to specialist outpatient clinics between June 1990 and January 1994 and detailed comparisons of three phases-October 1990 to March 1991 (phase 1), October 1991 to March 1992 (phase 2), and October 1993 to January 1994 (phase 3). Setting-10 first wave fundholding practices and six non-fundholding practices in the Oxford region. Subjects-Patients referred to consultant outpatient clinics. Results-NHS referral rates increased in fundholding practices in phase 2 and phase 3 of the study by 8.1/1000 patients a year (95% confidence interval 5.7 to 10.5), an increase of 7.5% from phase 1 (107.3/1000) to phase 3 (115.4/1000). Non-fundholders' rates increased significantly, by 25.3/1000 patients (22.5-28.1), an increase of 26.6% from phase 1 (95.0/1000) to phase 3 (120.3/1000). The fundholders' referral rates to private clinics decreased by 8.8%, whereas those from non-fundholding practices increased by 12.2%. The proportion of referrals going outside district boundaries did not change significantly. Three of the four practices entering the third and fourth wave of fundholding increased their referral rates significantly in the year before becoming fundholders. Conclusions-No evidence existed that budgetary pressures caused first wave fundholders to reduce referral rates, although the method of budget allocation may have encouraged general practitioners to inflate their referral rates in the preparatory year. Despite investment in new practice based facilities, no evidence yet exists that fundholding encourages a shift away from specialist care.	KINGS FUND DEV CTR,LONDON W1M 0AN,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	Radcliffe Infirmary; University of Oxford; University of Oxford			Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BRADLOW J, 1992, PATTERNS REFERRAL; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, IN PRESS EUR J PUBLI; GARDINER M, 1990, BMJ; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; Roland M, 1992, HOSPITAL REFERRALS; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059	7	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1205	1208		10.1136/bmj.311.7014.1205	http://dx.doi.org/10.1136/bmj.311.7014.1205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488902	Green Published			2022-12-01	WOS:A1995TD76800026
J	WAXMAN, J; SHEER, D				WAXMAN, J; SHEER, D			IS PROSTATE-CANCER WORTH DIAGNOSING	LANCET			English	Editorial Material							POPULATION		IMPERIAL CANC RES FUND, HYMAN CYTOGENET LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	WAXMAN, J (corresponding author), HAMMERSMITH HOSP, DEPT ONCOL, LONDON, ENGLAND.		Sheer, Denise/C-6705-2011	Sheer, Denise/0000-0001-9067-1796	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		BANDYK MG, 1994, GENE CHROMOSOME CANC, V9, P19, DOI 10.1002/gcc.2870090105; BOOKSTEIN R, 1994, J CELL BIOCHEM, P217; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; HANKS GE, 1987, INT J RADIAT ONCOL, V13, P499, DOI 10.1016/0360-3016(87)90063-0; JOHANSSON JE, 1989, LANCET, V1, P799; NAROD SA, 1995, NAT MED, V1, P99, DOI 10.1038/nm0295-99; PEDERSEN KV, 1990, BRIT MED J, V300, P1041, DOI 10.1136/bmj.300.6731.1041; SMITH DS, 1995, UROLOGY, V45, P70, DOI 10.1016/S0090-4295(95)96812-1; TAKAHASHI S, 1994, CANCER RES, V54, P3574; UMBAS R, 1994, CANCER RES, V54, P3929; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254	15	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1177	1178		10.1016/S0140-6736(95)92895-2	http://dx.doi.org/10.1016/S0140-6736(95)92895-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475655				2022-12-01	WOS:A1995TC97600005
J	ALADJEM, MI; GROUDINE, M; BRODY, LL; DIEKEN, ES; FOURNIER, REK; WAHL, GM; EPNER, EM				ALADJEM, MI; GROUDINE, M; BRODY, LL; DIEKEN, ES; FOURNIER, REK; WAHL, GM; EPNER, EM			PARTICIPATION OF THE HUMAN BETA-GLOBIN LOCUS-CONTROL REGION IN INITIATION OF DNA-REPLICATION	SCIENCE			English	Article							ACTIVATION REGION; CHROMATIN STRUCTURE; GENE DOMAIN; ORIGIN; CELLS; CHROMOSOMES; TRANSCRIPTION; EXPRESSION; HYBRIDS	The human beta-globin locus control region (LCR) controls the transcription, chromatin structure, and replication timing of the entire locus. DNA replication was found to initiate in a transcription-independent manner within a region located 50 kilobases downstream of the LCR in human, mouse, and chicken cells containing the entire human beta-globin locus. However, DNA replication did not initiate within a deletion mutant locus lacking the sequences that encompass the LCR. This mutant locus replicated in the 3' to 5' direction. Thus, interactions between distantly separated sequences can be required for replication initiation, and factors mediating this interaction appear to be conserved in evolution.	SALK INST,GENE EXPRESS LAB,SAN DIEGO,CA 92037; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195; UNIV WASHINGTON,SEATTLE,WA 98195	Salk Institute; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle			Aladjem, Mirit/G-2169-2010	Aladjem, Mirit/0000-0002-1875-3110				ALADJEM MI, UNPUB; BABA T, 1989, VIROLOGY, V144, P139; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BREAM GL, 1992, J VIROL, V66, P7319, DOI 10.1128/JVI.66.12.7319-7327.1992; BREWER BJ, 1994, CURR OPIN GENET DEV, V4, P196, DOI 10.1016/S0959-437X(05)80045-0; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CADDLE MS, 1992, NUCLEIC ACIDS RES, V20, P5971, DOI 10.1093/nar/20.22.5971; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; Depamphilis Melvin L., 1993, Trends in Cell Biology, V3, P161, DOI 10.1016/0962-8924(93)90137-P; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; EPNER E, 1992, TRENDS GENET, V2, P262; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GILBERT DM, 1993, COLD SPRING HARB SYM, V58, P475, DOI 10.1101/SQB.1993.058.01.054; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; TRASK BJ, 1993, COLD SPRING HARB SYM, V58, P767, DOI 10.1101/SQB.1993.058.01.084; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; YOON Y, 1995, MOL CELL BIOL, V15, P2482	37	188	191	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					815	819		10.1126/science.270.5237.815	http://dx.doi.org/10.1126/science.270.5237.815			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481774				2022-12-01	WOS:A1995TC71200046
J	CHEN, YM; CHEN, CF; RILEY, DJ; ALLRED, DC; CHEN, PL; VONHOFF, D; OSBORNE, CK; LEE, WH				CHEN, YM; CHEN, CF; RILEY, DJ; ALLRED, DC; CHEN, PL; VONHOFF, D; OSBORNE, CK; LEE, WH			ABERRANT SUBCELLULAR-LOCALIZATION OF BRCA1 IN BREAST-CANCER	SCIENCE			English	Article							GLUCOCORTICOID RECEPTOR; NUCLEAR-LOCALIZATION; CELL-CYCLE; HORMONE; PROTEIN; PHOSPHORYLATION; EXPRESSION; CLONING; GENE	The BRCA1 gene product was identified as a 220-kilodalton nuclear phosphoprotein in normal cells, including breast ductal epithelial cells, and in 18 of 20 tumor cell lines derived from tissues other than breast and ovary. In 16 of 17 breast and ovarian cancer lines and 17 of 17 samples of cells obtained from malignant effusions, however, BRCA1 localized mainly in cytoplasm. Absence of BRCA1 or aberrant subcellular location was also observed to a variable extent in histological sections of many breast cancer biopsies. These findings suggest that BRCA1 abnormalities may be involved in the pathogenesis of many breast cancers, sporadic as well as familial.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV MED ONCOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio				Chen, Chi-Fen/0000-0002-6391-821X	NATIONAL CANCER INSTITUTE [P50CA058183] Funding Source: NIH RePORTER; NCI NIH HHS [CA58318, P50CA58183] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen Y, UNPUB; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jensen E V, 1991, Curr Top Pathol, V83, P365; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SCHNEIDER J, 1988, CELL, V54, P117, DOI 10.1016/0092-8674(88)90185-7; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X	29	285	303	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					789	791		10.1126/science.270.5237.789	http://dx.doi.org/10.1126/science.270.5237.789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481765				2022-12-01	WOS:A1995TC71200037
J	CORBETTA, M; SHULMAN, GL; MIEZIN, FM; PETERSEN, SE				CORBETTA, M; SHULMAN, GL; MIEZIN, FM; PETERSEN, SE			SUPERIOR PARIETAL CORTEX ACTIVATION DURING SPATIAL ATTENTION SHIFTS AND VISUAL FEATURE CONJUNCTION	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; BRAIN; RESPONSES; SEARCH; PET	Positron emission tomography was used to measure changes in the regional cerebral blood flow of normal people while they searched visual displays for targets defined by color, by motion, or by a conjunction of color and motion. A region in the superior parietal cortex was activated only during the conjunction task, at a location that had previously been shown to be engaged by successive shifts of spatial attention. Correspondingly, the time needed to detect a conjunction target increased with the number of items in the display, which is consistent with the use of a mechanism that successively analyzes each item in the visual field.	WASHINGTON UNIV,SCH MED,MCDONNELL CTR STUDY HIGHER BRAIN FUNCT,ST LOUIS,MO 63110	Washington University (WUSTL)	CORBETTA, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL & NEUROL SURG,ST LOUIS,MO 63110, USA.		Petersen, Steve/ABF-1368-2020; Corbetta, Maurizio/AAZ-5219-2020	CORBETTA, MAURIZIO/0000-0001-8295-3304	NEI NIH HHS [EY08775] Funding Source: Medline; NINDS NIH HHS [NS06833, NS2533] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006833, P01NS006833] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUCKNER RL, 1995, J NEUROSCI, V15, P12; BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CORBETTA M, 1991, J NEUROSCI, V8, P2383; De Renzi E., 1982, DISORDERS SPACE EXPL; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; HEINZE HJ, 1995, NATURE, V372, P543; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HUNTON DE, UNPUB; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; POSNER MI, 1984, J NEUROSCI, V4, P1863; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TOWNSEND JT, 1972, BRIT J MATH STAT PSY, V25, P168, DOI 10.1111/j.2044-8317.1972.tb00490.x; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; WOLFE JM, 1989, J EXP PSYCHOL HUMAN, V15, P419, DOI 10.1037/0096-1523.15.3.419; YAMAMOTO M, 1982, IEEE T NUCL SCI, V29, P529, DOI 10.1109/TNS.1982.4335901	20	565	576	0	29	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					802	805		10.1126/science.270.5237.802	http://dx.doi.org/10.1126/science.270.5237.802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC712	7481770				2022-12-01	WOS:A1995TC71200042
J	GEKAKIS, N; SAEZ, L; DELAHAYEBROWN, AM; MYERS, MP; SEHGAL, A; YOUNG, MW; WEITZ, CJ				GEKAKIS, N; SAEZ, L; DELAHAYEBROWN, AM; MYERS, MP; SEHGAL, A; YOUNG, MW; WEITZ, CJ			ISOLATION OF TIMELESS BY PER PROTEIN-INTERACTION - DEFECTIVE INTERACTION BETWEEN TIMELESS PROTEIN AND LONG-PERIOD MUTANT PER(L)	SCIENCE			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; DROSOPHILA CLOCK; GENE-PRODUCT; MOSAIC ANALYSIS; TRANSFORMATION; MELANOGASTER; EXPRESSION; SYSTEM; DNA; ELEMENT	The period (per) gene likely encodes a component of the Drosophila circadian clock. Circadian oscillations in the abundance of per messenger RNA and per protein (PER) are thought to arise from negative feedback control of per gene transcription by PER. A recently identified second clock locus, timeless (tim), apparently regulates entry of PER into the nucleus. Reported here are the cloning of complementary DNAs derived from the tim gene in a two-hybrid screen for PER-interacting proteins and the demonstration of a physical interaction between the tim protein (TIM) and PER in vitro. A restricted segment of TIM binds directly to a part of the PER dimerization domain PAS. PER(L), a mutation that causes a temperature-sensitive lengthening of circadian period and a temperature-sensitive delay in PER nuclear entry, exhibits a temperature-sensitive defect in binding to TIM. These results suggest that the interaction between TIM and PER determines the timing of PER nuclear entry and therefore the duration of part of the circadian cycle.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; ROCKEFELLER UNIV,CTR BIOL TIMING,HOWARD HUGHES MED INST,NATL SCI FDN SCI & TECHNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021; UNIV PENN,MED CTR,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; Rockefeller University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine			, 机智的马小跳和机智的羊不愁/ABC-5169-2020					ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUCE VG, 1972, GENETICS, V70, P537; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUA KL, UNPUB; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.ph.55.030193.003343; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Edmunds LN, 1988, CELLULAR MOL BASES B; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIESEN WO, 1993, ANNU REV PHYSIOL, V55, P661, DOI 10.1146/annurev.ph.55.030193.003305; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, UUNPUB; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HILL J, 1991, NUCLEIC ACIDS RES, V19, P57911; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN K, 1976, P DAHLEM WORKSHOP, V20, P63; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Moore-Ede MC., 1982, CLOCKS TIME US; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; ROTHENFLUHHILFI.A, UNPUB; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZEHRING WA, 1984, CELL, V39, P369, DOI 10.1016/0092-8674(84)90015-1; ZENG H, 1994, EMBO J, V3, P3590; ZWEIBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882	49	298	312	2	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					811	815		10.1126/science.270.5237.811	http://dx.doi.org/10.1126/science.270.5237.811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481773				2022-12-01	WOS:A1995TC71200045
J	MYERS, MP; WAGERSMITH, K; WESLEY, CS; YOUNG, MW; SEHGAL, A				MYERS, MP; WAGERSMITH, K; WESLEY, CS; YOUNG, MW; SEHGAL, A			POSITIONAL CLONING AND SEQUENCE-ANALYSIS OF THE DROSOPHILA CLOCK GENE, TIMELESS	SCIENCE			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE; AH-RECEPTOR; NUCLEAR-PROTEIN; VISUAL-SYSTEM; NOTCH LOCUS; MELANOGASTER; PRODUCT; MUTATIONS; MUTANTS	The Drosophila genes timeless (tim) and period (per) interact, and both are required for production of circadian rhythms. Here the positional cloning and sequencing of tim are reported. The tim gene encodes a previously uncharacterized protein of 1389 amino acids, and possibly another protein of 1122 amino acids. The arrhythmic mutation tim(01) is a 64-base pair deletion that truncates TIM to 749 amino acids. Absence of sequence similarity to the PER dimerization motif (PAS) indicates that direct interaction between PER and TIM would require a heterotypic protein association.	ROCKEFELLER UNIV,CTR BIOL TIMING,HOWARD HUGHES MED INST,NATL SCI FDN SCI & TECHNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; Rockefeller University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine			, 机智的马小跳和机智的羊不愁/ABC-5169-2020					BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.biochem.56.1.467; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COHEN SA, COMMUNICATION; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, EMBO J, V11, P1; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1992, J NEUROSCI, V12, P2735; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MYERS M, UNPUB; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROTHENFLUHHILFI.A, UNPUB; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHUBO Z, 1995, EMBO J, V14, P2884; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WESLEY CS, 1994, NUCLEIC ACIDS RES, V22, P538, DOI 10.1093/nar/22.3.538; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; YU Q, 1987, P NATL ACAD SCI USA, V84, P784, DOI 10.1073/pnas.84.3.784; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	40	211	220	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					805	808		10.1126/science.270.5237.805	http://dx.doi.org/10.1126/science.270.5237.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481771				2022-12-01	WOS:A1995TC71200043
J	NOGUCHI, S; MCNALLY, EM; BENOTHMANE, K; HAGIWARA, Y; MIZUNO, Y; YOSHIDA, M; YAMAMOTO, H; BONNEMANN, CG; GUSSONI, E; DENTON, PH; KYRIAKIDES, T; MIDDLETON, L; HENTATI, F; BENHAMIDA, M; NONAKA, I; VANCE, JM; KUNKEL, LM; OZAWA, E				NOGUCHI, S; MCNALLY, EM; BENOTHMANE, K; HAGIWARA, Y; MIZUNO, Y; YOSHIDA, M; YAMAMOTO, H; BONNEMANN, CG; GUSSONI, E; DENTON, PH; KYRIAKIDES, T; MIDDLETON, L; HENTATI, F; BENHAMIDA, M; NONAKA, I; VANCE, JM; KUNKEL, LM; OZAWA, E			MUTATIONS IN THE DYSTROPHIN-ASSOCIATED PROTEIN GAMMA-SARCOGLYCAN IN CHROMOSOME-13 MUSCULAR-DYSTROPHY	SCIENCE			English	Article							GLYCOPROTEIN COMPLEX; GENE; ORGANIZATION; DOMAIN; ACTIN; CDNA	Severe childhood autosomal recessive muscular dystrophy (SCARMD) is a progressive muscle-wasting disorder common in North Africa that segregates with microsatellite markers at chromosome 13q12. Here, it is shown that a mutation in the gene encoding the 35-kilodalton dystrophin-associated glycoprotein, gamma-sarcoglycan, is likely to be the primary genetic defect in this disorder. The human gamma-sarcoglycan gene was mapped to chromosome 13q12, and deletions that alter its reading frame were identified in three families and one of four sporadic cases of SCARMD. These mutations not only affect gamma-sarcoglycan but also disrupt the integrity of the entire sarcoglycan complex.	CHILDRENS HOSP, DIV GENET, BOSTON, MA 02155 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02155 USA; DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; CYPRUS INST NEUROL & GENET, NICOSIA, CYPRUS; INST NEUROL, TUNIS, TUNISIA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Duke University; Universite de Tunis-El-Manar; Institut National de Neurologie	NOGUCHI, S (corresponding author), NATL CTR NEUROL & PSYCHIAT, NATL INST NEUROSCI, 4-1-1 OGAWA HIGASHI CHO, KODAIRA, TOKYO 187, JAPAN.		Gussoni, Emanuela/AAL-6150-2021; McNally, Elizabeth/W-4909-2019	Gussoni, Emanuela/0000-0002-9915-3677; McNally, Elizabeth/0000-0002-1221-719X; Vance, Jeffery/0000-0003-3815-8199	NINDS NIH HHS [P01-NS26630, NS23740] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, R01NS023740] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZIBI K, 1993, HUM MOL GENET, V2, P1423; AZIBI K, 1991, CYTOGENET CELL GENET, V58, P1907; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BENOTHMANE K, 1995, AM J HUM GENET, V57, P732; BENOTHMANE K, UNPUB; BONNEMANN CG, IN PRESS NATURE GENE; BUENO MRP, 1994, AMJ HUM GENET, V55, pA199; BURGHES AHM, 1987, NATURE, V328, P434, DOI 10.1038/328434a0; BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P337, DOI 10.1016/0960-8966(95)00005-8; ELKERCH F, 1994, J MED GENET, V31, P342, DOI 10.1136/jmg.31.4.342; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FARAG TI, 1990, AM J MED GENET, V37, P290, DOI 10.1002/ajmg.1320370229; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LIM LE, IN PRESS NATURE GENE; LJUNGGREN A, 1995, ANN NEUROL, V38, P367, DOI 10.1002/ana.410380305; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; MCNALLY EM, UNPUB; MIZUNO Y, 1994, BIOCHEM BIOPH RES CO, V203, P979, DOI 10.1006/bbrc.1994.2278; MIZUNO Y, UNPUB; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NOGUCHI S, UNPUB; OZAWA E, IN PRESS HUM MOL GEN; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZATZ M, 1995, HUM MOL GENET, V4, P401, DOI 10.1093/hmg/4.3.401; ZATZ M, 1989, AM J MED GENET, V32, P407, DOI 10.1002/ajmg.1320320328	35	465	475	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					819	822		10.1126/science.270.5237.819	http://dx.doi.org/10.1126/science.270.5237.819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481775				2022-12-01	WOS:A1995TC71200047
J	NOSAKA, T; VANDEURSEN, JMA; TRIPP, RA; THIERFELDER, WE; WITTHUHN, BA; MCMICKLE, AP; DOHERTY, PC; GROSVELD, GC; IHLE, JN				NOSAKA, T; VANDEURSEN, JMA; TRIPP, RA; THIERFELDER, WE; WITTHUHN, BA; MCMICKLE, AP; DOHERTY, PC; GROSVELD, GC; IHLE, JN			DEFECTIVE LYMPHOID DEVELOPMENT IN MICE LACKING JAK3	SCIENCE			English	Article							RECEPTOR	The Janus tyrosine kinases (Jaks) play a central role in signaling through cytokine receptors. Although Jak1, Jak2, and Tyk2 are widely expressed, Jak3 is predominantly expressed in hematopoietic cells and is known to associate only with the common gamma (gamma(c)) chain of the interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 receptors. Homozygous mutant mice in which the Jak3 gene had been disrupted were generated by gene targeting. Jak3-deficient mice had profound reductions in thymocytes and severe B cell and T cell lymphopenia similar to severe combined immunodeficiency disease (SCID), and the residual T cells and B cells were functionally deficient. Thus, Jak3 plays a critical role in gamma(c) signaling and lymphoid development.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Tripp, Ralph A./F-5218-2011; witthuhn, bruce/GSE-3193-2022; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph A./0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK/HL42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, UNPUB; OUELLE FW, 1995, MOL CELL BIOL, V15, P3336; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SECKINGER P, 1994, J IMMUNOL, V153, P97; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	23	549	574	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					800	802		10.1126/science.270.5237.800	http://dx.doi.org/10.1126/science.270.5237.800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481769				2022-12-01	WOS:A1995TC71200041
J	REINSCHEID, RK; NOTHACKER, HP; BOURSON, A; ARDATI, A; HENNINGSEN, RA; BUNZOW, JR; GRANDY, DK; LANGEN, H; MONSMA, FJ; CIVELLI, O				REINSCHEID, RK; NOTHACKER, HP; BOURSON, A; ARDATI, A; HENNINGSEN, RA; BUNZOW, JR; GRANDY, DK; LANGEN, H; MONSMA, FJ; CIVELLI, O			ORPHANIN-FQ - A NEUROPEPTIDE THAT ACTIVATES AN OPIOID-LIKE G-PROTEIN-COUPLED RECEPTOR	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; CLONING; BRAIN; CDNA	A heptadecapeptide was identified and purified from porcine brain tissue as a ligand for an orphan heterotrimeric GTP- binding protein (G protein)- coupled receptor (LC132) that is similar in sequence to opioid receptors. This peptide, orphanin FQ, has a primary structure reminiscent of that of opioid peptides. Nanomolar concentrations of orphanin FQ inhibited forskolin-stimulated adenylyl cyclase activity in cells transfected with LC132. This inhibitory activity was not affected by the addition of opioid ligands, nor did the peptide activate opioid receptors. Orphanin FQ bound to its receptor in a saturable manner and with high affinity. When injected intracerebroventricularly into mice, orphanin FQ caused a decrease in locomotor activity but did not induce analgesia in the hot-plate test. However, the peptide produced hyperalgesia in the tail-flick assay. Thus, orphanin FQ may act as a transmitter in the brain by modulating nociceptive and locomotor behavior.	HOFFMANN LA ROCHE AG,CNS RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; HOFFMANN LA ROCHE AG,DIV PHARMA,GENE TECHNOL RES,CH-4002 BASEL,SWITZERLAND	Roche Holding; Oregon Health & Science University; Roche Holding			Civelli, Olivier/A-8392-2012		NIDA NIH HHS [DA 09620, DA 08562] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008562, R21DA009620] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; BOURSON A, UNPUB; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; CIVELLI O, 1987, MOL NEUROBIOL, V1, P373, DOI 10.1007/BF02935742; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; HALL ZW, 1987, TRENDS NEUROSCI, V10, P99, DOI 10.1016/0166-2236(87)90049-X; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LACHOWICZ JE, 1995, J NEUROCHEM, V64, P34; LI CH, 1983, BIOCH CLIN ASPECTS N, P17; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LYNCH DR, 1986, ANNU REV BIOCHEM, V55, P773, DOI 10.1146/annurev.bi.55.070186.004013; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSON N, 1987, ANAL BIOCHEM, V165, P287, DOI 10.1016/0003-2697(87)90271-5; REINSCHEID RK, UNPUB; STEVENS CF, 1987, NATURE, V328, P198, DOI 10.1038/328198b0; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; WOOD PL, 1984, ANALGESICS NEUROCHEM, P175; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	26	1690	1775	1	47	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					792	794		10.1126/science.270.5237.792	http://dx.doi.org/10.1126/science.270.5237.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481766				2022-12-01	WOS:A1995TC71200038
J	SEHGAL, A; ROTHENFLUHHILFIKER, A; HUNTERENSOR, M; CHEN, YF; MYERS, MP; YOUNG, MW				SEHGAL, A; ROTHENFLUHHILFIKER, A; HUNTERENSOR, M; CHEN, YF; MYERS, MP; YOUNG, MW			RHYTHMIC EXPRESSION OF TIMELESS - A BASIS FOR PROMOTING CIRCADIAN CYCLES IN PERIOD GENE AUTOREGULATION	SCIENCE			English	Article							MESSENGER-RNA LEVELS; DROSOPHILA-MELANOGASTER; MOSAIC ANALYSIS; MUTANTS	The clock gene timeless (tim) is required for circadian rhythmicity in Drosophila. The accumulation of tim RNA followed a circadian rhythm, and the phase and period of the tim RNA rhythm were indistinguishable from those that have been reported for per. The tim RNA oscillations were found to be dependent on the presence of PER and TIM proteins, which demonstrates feedback control of tim by a mechanism previously shown to regulate per expression. The cyclic expression of tim appears to dictate the timing of PER protein accumulation and nuclear localization, suggesting that tim promotes circadian rhythms of per and tim transcription by restricting per RNA and PER protein accumulation to separate times of day.	UNIV PENN,MED CTR,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104; ROCKEFELLER UNIV,CTR BIOL TIMING,HOWARD HUGHES MED INST,NATL SCI FDN SCI & TECHNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; Rockefeller University	SEHGAL, A (corresponding author), UNIV PENN,MED CTR,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Rothenfluh, Adrian/0000-0002-3813-5723				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BAYLIES MK, 1993, MOL GENETICS BIOL RH, P123; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, EMBO J, V11, P1; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; KONOPKA R, 1983, MOL GEN GENET, V190, P284, DOI 10.1007/BF00330652; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; ROTHENFLUHHILFI.A, UNPUB; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SEHGAL A, UNPUB; THERKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x	24	293	305	4	34	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 3	1995	270	5237					808	810		10.1126/science.270.5237.808	http://dx.doi.org/10.1126/science.270.5237.808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481772				2022-12-01	WOS:A1995TC71200044
J	THOMIS, DC; GURNIAK, CB; TIVOL, E; SHARPE, AH; BERG, LJ				THOMIS, DC; GURNIAK, CB; TIVOL, E; SHARPE, AH; BERG, LJ			DEFECTS IN B-LYMPHOCYTE MATURATION AND T-LYMPHOCYTE ACTIVATION IN MICE LACKING JAK3	SCIENCE			English	Article							RECEPTOR; IDENTIFICATION; MUTATION; MOUSE	Biochemical studies of signaling mediated by many cytokine and growth factor receptors have implicated members of the Jak family of tyrosine kinases in these pathways. Specifically, Jak3 has been shown to be associated with the interleukin-2 (IL-2) receptor gamma chain, a component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15. Mice lacking Jak3 showed a severe block in B cell development at the pre-B stage in the bone marrow. In contrast, although the thymuses of these mice were small, T cell maturation progressed relatively normally. In response to mitogenic signals, peripheral T cells in Jak3-deficient mice did not proliferate and secreted small amounts of IL-2. These data demonstrate that Jak3 is critical for the progression of B cell development in the bone marrow and for the functional competence of mature T cells.	HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042689] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HLO7627] Funding Source: Medline; NIAMS NIH HHS [1PO30AR42689] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIERER BE, 1994, CHEM IMMUNOL, V59, P128; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; GROSS JA, 1992, J IMMUNOL, V149, P380; GURNIAK CB, UNPUB; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RANE SG, 1994, ONCOGENE, V9, P2415; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCOLLAY R, 1995, IMMUNOL TODAY, V16, P268, DOI 10.1016/0167-5699(95)80179-0; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; THOMIS DC, UNPUB; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	25	450	469	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	1995	270	5237					794	797		10.1126/science.270.5237.794	http://dx.doi.org/10.1126/science.270.5237.794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC712	7481767				2022-12-01	WOS:A1995TC71200039
J	BENNETT, MB; TAYLOR, GC				BENNETT, MB; TAYLOR, GC			SCALING OF ELASTIC STRAIN-ENERGY IN KANGAROOS AND THE BENEFITS OF BEING BIG	NATURE			English	Article							TERRESTRIAL LOCOMOTION; COST; MECHANICS; WALLABY; TENDONS	LARGE kangaroos are unique among mammals in their ability to uncouple aerobic metabolic energy costs from the speed of locomotion(1,2), making hopping an economical gait. During the first half of the ground-contact phase, kinetic energy lost from the body is stored as elastic strain energy, predominantly in the hind limbs(3-5). The subsequent recoil returns kinetic and potential energy to the body. Here we show that the allometry of structures in the legs and feet of Macropodoidea is different from that of quadrupedal eutherian mammals. The potential for elastic energy storage in hoppers is shown to stale with strong positive allometry. This is a function of the structural properties of muscle-tendon units in the distal hind limbs and the postures adopted by hopping kangaroos. Our findings demonstrate how the use of tissue elasticity is strongly mass dependent and help explain the observed energetic phenomena.			BENNETT, MB (corresponding author), UNIV QUEENSLAND,DEPT ANAT SCI,ST LUCIA,QLD 4072,AUSTRALIA.		Bennett, Michael/A-7218-2012; Bennett, Michael/L-4483-2019	Bennett, Michael/0000-0001-8051-0040				ALEXANDER RM, 1979, J ZOOL, V187, P169; ALEXANDER RM, 1975, J ZOOL, V177, P265, DOI 10.1111/j.1469-7998.1975.tb05983.x; ALEXANDER RM, 1988, ELASTIC MECHANISMS A; BAUDINETTE RV, 1992, AM J PHYSIOL, V262, pR771, DOI 10.1152/ajpregu.1992.262.5.R771; BENNETT MB, 1987, J ZOOL, V212, P457, DOI 10.1111/j.1469-7998.1987.tb02916.x; BENNETT MB, 1986, J ZOOL, V209, P537, DOI 10.1111/j.1469-7998.1986.tb03609.x; BENNETT MB, 1995, J ZOOL, V235, P33, DOI 10.1111/j.1469-7998.1995.tb05125.x; BIEWENER AA, 1990, SCIENCE, V250, P1097, DOI 10.1126/science.2251499; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; DAWSON TJ, 1973, NATURE, V246, P313, DOI 10.1038/246313a0; FARLEY CT, 1993, J EXP BIOL, V185, P71; HERZOG W, 1993, J BIOMECH, V26, P945, DOI 10.1016/0021-9290(93)90056-K; KER RF, 1986, J ZOOL, V208, P417; Murray Peter, 1991, P1071; POLLOCK CM, 1994, AM J PHYSIOL, V266, pR1022, DOI 10.1152/ajpregu.1994.266.3.R1022; THOMPSON SD, 1980, NATURE, V287, P223, DOI 10.1038/287223a0; WINDSOR DE, 1971, J ZOOL LOND, V153, P165	17	76	77	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					56	59		10.1038/378056a0	http://dx.doi.org/10.1038/378056a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477284				2022-12-01	WOS:A1995TC46900047
J	BERN, C; PHILEN, RM; FREDMAN, D; BOWMAN, BA; NEWMAN, NJ; GERR, F; RIDEL, GM; PENA, EZ; MALILAY, J; MILLER, DT; SOWELL, AL; MILLER, MA; FLANDERS, WD; FALTER, KH; OLSON, DR; KILBOURNE, EM; SINKS, T; ING, R; STAEHLING, N; BOYD, M; GUNTER, EW; PASCHAL, DC; MUELLER, PW; SPIERTO, FW; NEEDHAM, LL; HILL, RH; ASHLEY, DL; HANNON, WH; MARQUEZ, AR; FERNANDEZ, JRD; HADAD, JH; MILORD, DR; CRISTIA, RP; PEREZ, MAH; VERDURA, CS; ALBA, MAM; HODELIN, MT; GORBEA, MB; DIAZ, ED; HIORTLORENZEN, CLC; CLUA, AM; GUTIERREZ, PM; ACOSTA, SJ; CABRERA, A; FERNANDEZ, MM; FREIXAS, RS; ESTRADA, R; ARIAS, L; MESTRE, PF; PLA, E; ROMERO, MC; FERRET, AC; LLANOS, G; JIMENEZ, JS; ROMAN, GC; OBERMEYER, W; CASTRO, MD; RUIZ, CAP; RICO, NS; BETANCOURT, IP; FUENTES, BEE; CABRERA, AP; CALDELLICEHIO, LET; MEDINA, AG; GOMEZ, N; MOJARRIETA, MS; VARA, JAC; PORTALES, JMR; HERNANDEZ, GR; GINALY, SM; GARCIA, PP; GARCIA, M; HERNANDEZ, CS; DIAZ, EI; RECIO, EM; GARCIA, SH; SANCHEZ, AL; VALDES, P; RODRIGUEZ, OM; OLIVA, NB; DIAZ, D; PEREZ, MC; HERNANDEZ, MCR; GONEZ, JMR; AMADO, SN; DELLLANO, AC; BREIJO, DH; ACOSTA, AC; GONZALEZ, MM; ROMERO, RM; CHAVEZ, OC; VALDES, MH; OTERO, GR; CABALLERO, MM; VALDES, AG; OLIVERA, BR; BENITEZ, EE; BEADE, C; LEON, LS; MARIMON, FD; ROMAN, AS; RODRIGUEZ, R; RODRIGUEZ, FD; ALVAREZ, MR; COLUMBE, MS; MARRERO, A; ZULUETA, D; GARCIA, CR; SANTOS, JPA; PEDROSO, F; RODRIGUEZ, HM; VALDES, NM; ACOSTA, MS; CHOBEL, ER; GODOY, MM; LUGO, MM; LOPEZ, LL; DIAZ, EM; MARTINEZ, JCB; DELGADO, NA; VALDES, MT; MORENO, ARD; SANCHEZ, SH; HERNANDEZ, LEP; VALDES, OM; MARTINEZ, AO; DOMINGUEZ, I; DEARMAS, MR; IGLESIAS, OR; CASTELL, OR; TRUJILLO, OG; BEUNE, MDM; RODRIGUEZ, FM; MEDINA, RM; RUIZCALDERON, JC; FERNANDEZ, B; BARROSO, EV; MACHIN, JL; ARMENTEROS, LR; MENDEZ, CV; PEREZ, JH; CAMPOS, AC; DIAZ, NA; PEREZ, AO; MILIAN, J; LEON, OH; CAPOTE, BR; LEZCANOS, MR; EZMORIZ, LP; MOYA, O; VITRIAGO, A; MURGUIA, AU				BERN, C; PHILEN, RM; FREDMAN, D; BOWMAN, BA; NEWMAN, NJ; GERR, F; RIDEL, GM; PENA, EZ; MALILAY, J; MILLER, DT; SOWELL, AL; MILLER, MA; FLANDERS, WD; FALTER, KH; OLSON, DR; KILBOURNE, EM; SINKS, T; ING, R; STAEHLING, N; BOYD, M; GUNTER, EW; PASCHAL, DC; MUELLER, PW; SPIERTO, FW; NEEDHAM, LL; HILL, RH; ASHLEY, DL; HANNON, WH; MARQUEZ, AR; FERNANDEZ, JRD; HADAD, JH; MILORD, DR; CRISTIA, RP; PEREZ, MAH; VERDURA, CS; ALBA, MAM; HODELIN, MT; GORBEA, MB; DIAZ, ED; HIORTLORENZEN, CLC; CLUA, AM; GUTIERREZ, PM; ACOSTA, SJ; CABRERA, A; FERNANDEZ, MM; FREIXAS, RS; ESTRADA, R; ARIAS, L; MESTRE, PF; PLA, E; ROMERO, MC; FERRET, AC; LLANOS, G; JIMENEZ, JS; ROMAN, GC; OBERMEYER, W; CASTRO, MD; RUIZ, CAP; RICO, NS; BETANCOURT, IP; FUENTES, BEE; CABRERA, AP; CALDELLICEHIO, LET; MEDINA, AG; GOMEZ, N; MOJARRIETA, MS; VARA, JAC; PORTALES, JMR; HERNANDEZ, GR; GINALY, SM; GARCIA, PP; GARCIA, M; HERNANDEZ, CS; DIAZ, EI; RECIO, EM; GARCIA, SH; SANCHEZ, AL; VALDES, P; RODRIGUEZ, OM; OLIVA, NB; DIAZ, D; PEREZ, MC; HERNANDEZ, MCR; GONEZ, JMR; AMADO, SN; DELLLANO, AC; BREIJO, DH; ACOSTA, AC; GONZALEZ, MM; ROMERO, RM; CHAVEZ, OC; VALDES, MH; OTERO, GR; CABALLERO, MM; VALDES, AG; OLIVERA, BR; BENITEZ, EE; BEADE, C; LEON, LS; MARIMON, FD; ROMAN, AS; RODRIGUEZ, R; RODRIGUEZ, FD; ALVAREZ, MR; COLUMBE, MS; MARRERO, A; ZULUETA, D; GARCIA, CR; SANTOS, JPA; PEDROSO, F; RODRIGUEZ, HM; VALDES, NM; ACOSTA, MS; CHOBEL, ER; GODOY, MM; LUGO, MM; LOPEZ, LL; DIAZ, EM; MARTINEZ, JCB; DELGADO, NA; VALDES, MT; MORENO, ARD; SANCHEZ, SH; HERNANDEZ, LEP; VALDES, OM; MARTINEZ, AO; DOMINGUEZ, I; DEARMAS, MR; IGLESIAS, OR; CASTELL, OR; TRUJILLO, OG; BEUNE, MDM; RODRIGUEZ, FM; MEDINA, RM; RUIZCALDERON, JC; FERNANDEZ, B; BARROSO, EV; MACHIN, JL; ARMENTEROS, LR; MENDEZ, CV; PEREZ, JH; CAMPOS, AC; DIAZ, NA; PEREZ, AO; MILIAN, J; LEON, OH; CAPOTE, BR; LEZCANOS, MR; EZMORIZ, LP; MOYA, O; VITRIAGO, A; MURGUIA, AU			EPIDEMIC OPTIC NEUROPATHY IN CUBA - CLINICAL CHARACTERIZATION AND RISK-FACTORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBLYOPIA	Background. From 1991 to 1993, epidemic optic and peripheral neuropathy affected more than 50,000 people in Cuba. The number of new cases decreased after the initiation of vitamin supplementation in the population. In September 1993, Cuban and U.S. investigators conducted a study to characterize and identify risk factors for the optic form of the syndrome. Methods. We conducted ophthalmologic and neurologic examinations, assessed exposure to potential toxins, administered a semiquantitative food-frequency questionnaire, and assessed serum measures of nutritional status in 123 patients with severe optic neuropathy, matched for sex and age to randomly chosen normal subjects. Results. In the case patients, prominent clinical features were subacute loss of visual acuity with field defects, diminished color vision, optic-nerve pallor, and decreased sensitivity to vibration and temperature in the legs. Tobacco use, particularly cigar smoking, was associated with an increased risk of optic neuropathy. The risk was reduced among subjects with higher dietary intakes of methionine, vitamin B-12, riboflavin, and niacin and higher serum concentrations of antioxidant carotenoids, The risk was also reduced among subjects who raised chickens at home or had relatives living overseas - factors that may be indirect measures of increased food availability. Conclusions. The epidemic of optic and peripheral neuropathy in Cuba between 1991 and 1993 appears to be linked to reduced nutrient intake caused by the country's deteriorating economic situation and the high prevalence of tobacco use.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; EMORY UNIV, ATLANTA, GA 30322 USA; MINIST PUBL HLTH CUBA, HAVANA, CUBA; PAN AMER HLTH ORG, WASHINGTON, DC USA; NIH, BETHESDA, MD 20892 USA; US FDA, ROCKVILLE, MD 20857 USA	Centers for Disease Control & Prevention - USA; Emory University; Pan American Health Organization; National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)			Hernandez-Triana, Manuel T/B-4513-2015; Needham, Larry/E-4930-2011; Newman, Nancy/AAB-2532-2021	Hernandez-Triana, Manuel T/0000-0002-2752-2592; Santos Hernandez, Carmen/0000-0002-8433-554X				BOVE FJ, 1989, J OCCUP ENVIRON MED, V31, P320; Breslow NE, 1980, IARC SCI PUBL, V32, P248; BROWN CC, 1994, AM J EPIDEMIOL, V139, P323, DOI 10.1093/oxfordjournals.aje.a117000; Costagliola C, 1990, Metab Pediatr Syst Ophthalmol (1985), V13, P96; DANG CV, 1981, MED HYPOTHESES, V7, P1317, DOI 10.1016/0306-9877(81)90122-5; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DIXON ZR, 1994, FREE RADICAL BIO MED, V17, P537, DOI 10.1016/0891-5849(94)90093-0; Gay John, 1994, Boletin de la Oficina Sanitaria Panamericana, V117, P389; GERR F, 1990, ARCH ENVIRON HEALTH, V45, P148, DOI 10.1080/00039896.1990.9936708; Hernandez Teresa, 1995, Natural Toxins, V3, P114, DOI 10.1002/nt.2620030210; Hosmer D, 2013, APPL LOGISTIC REGRES; KNOX DL, 1982, RETINA-J RET VIT DIS, V2, P288, DOI 10.1097/00006982-198202040-00014; LANNAN S, 1994, AM J PHYSIOL, V266, pL92, DOI 10.1152/ajplung.1994.266.1.L92; LESSELL S, 1971, ARCH OPHTHALMOL-CHIC, V86, P194; LETZ R, 1994, NEUROTOXICOLOGY, V15, P603; LINCOFF NS, 1994, JAMA-J AM MED ASSOC, V271, P664; LINCOFF NS, 1993, JAMA-J AM MED ASSOC, V270, P511, DOI 10.1001/jama.270.4.511; MADAN D, 1898, CRONICA MED QUIRURGI, V24, P81; MATHIOWETZ V, 1985, ARCH PHYS MED REHAB, V66, P69; MCCORMICK DB, 1994, MODERN NUTR HLTH DIS, P366; MILLER NR, 1982, WALSH HOYTS CLIN NEU, P289; NEWMAN NJ, 1993, ARCH NEUROL-CHICAGO, V50, P540, DOI 10.1001/archneur.1993.00540050082021; NEWMAN NJ, 1994, AM J OPHTHALMOL, V118, P158, DOI 10.1016/S0002-9394(14)72895-8; PASCHAL DC, 1986, ATOM SPECTROSC, V7, P75; Pennington JA, 1994, BOWES CHURCHS FOOD V; RIZZO JF, 1993, AM J OPHTHALMOL, V116, P84, DOI 10.1016/S0002-9394(14)71749-0; RODRIGUEZ A, 1992, NUTRISIS VERSIION 4; Schaumburg H. H., 1992, DISORDERS PERIPHERAL; SOWELL AL, 1994, CLIN CHEM, V40, P411; SPILLANE JD, 1947, NUTRITIONAL DISORDER; TOPPING MD, 1986, CLIN CHEM, V32, P1863; TORRONI A, 1995, HUM MUTAT, V5, P310, DOI 10.1002/humu.1380050407; WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL, V15, P245; 1984, B WORLD HEALTH ORGAN, V62, P477; 1993, EPIDEMIC NEUROPATHY; 1994, MMWR-MORBID MORTAL W, V43, P183; 1986, AGR HDB SERIES DEP A, V8	38	113	116	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1176	1182						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565972				2022-12-01	WOS:A1995TB56000003
J	BOSMA, PJ; CHOWDHURY, JR; BAKKER, C; GANTLA, S; DEBOER, A; OOSTRA, BA; LINDHOUT, D; TYTGAT, GNJ; JANSEN, PLM; ELFERINK, RPJO; CHOWDHURY, NR				BOSMA, PJ; CHOWDHURY, JR; BAKKER, C; GANTLA, S; DEBOER, A; OOSTRA, BA; LINDHOUT, D; TYTGAT, GNJ; JANSEN, PLM; ELFERINK, RPJO; CHOWDHURY, NR			THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRIGLER-NAJJAR SYNDROME; RNA POLYMERASE-II; BETA-GLOBIN GENE; COMPLEX LOCUS; MUTATION; IDENTIFICATION; TRANSCRIPTION; PATIENT; HYPERBILIRUBINEMIA; DISEASE	Background. People with Gilbert's syndrome have mild, chronic unconjugated hyperbilirubinemia in the absence of liver disease or overt hemolysis. Hepatic glucuronidating activity, essential for efficient biliary excretion of bilirubin, is reduced to about 30 percent of normal. Methods. We sequenced the coding and promoter regions of the gene for bilirubin UDP-glucuronosyltransferase 1 (bilirubin/uridine diphosphoglucuronate-glucuronosyltransferase 1) - the only enzyme that contributes substantially to bi[irubin glucuronidation - in 10 unrelated patients with Gilbert's syndrome, 16 members of a kindred with a history of Crigler-Najjar syndrome type II, and 55 normal subjects. Results. The coding region of the gene for the enzyme was normal in the 10 patients with Gilbert's syndrome. These patients were homozygous for two extra bases (TA) in the TATAA element of the 5' promoter region of the gene (A(TA)(7)TAA rather than the normal A(TA)(6)TAA). The presence of the. longer TATAA element resulted in the reduced expression of a reporter gene, encoding firefly luciferase, in a human hepatoma cell line. The frequency of the abnormal allele was 40 percent among the normal subjects. The 3 men in the control group who were homozygous for the longer TATAA element had significantly higher serum bilirubin levels than the other 52 normal subjects (P = 0.009). Among the kindred with a history of Crigler-Najjar syndrome type II, only the six heterozygous carriers who had a longer TATAA element on the structurally normal allele had mild hyperbilirubinemia, characteristic of Gilbert's syndrome. Conclusions. Reduced expression of bilirubin UDP-glucuronosyltransferase 1 due to an abnormality in the promoter region of the gene for this enzyme appears to be necessary for Gilbert's syndrome but not sufficient for the complete manifestation of the syndrome.	ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,DEPT MED,DIV GASTROENTEROL & LIVER DIS,BRONX,NY; ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP GRONINGEN,DEPT GASTROENTEROL & HEPATOL,GRONINGEN,NETHERLANDS	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Erasmus University Rotterdam; University of Groningen	BOSMA, PJ (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL & HEPATOL,FO-116,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Lindhout, Dick/AAH-5765-2019; Jansen, Peter LM/I-4509-2013	Lindhout, Dick/0000-0001-9580-624X	NIDDK NIH HHS [P30-DK41296, R01-DK39137, R01-DK46057] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK039137, R01DK046057] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altman DG, 1991, PRACTICAL STATISTICS; ARIAS IM, 1969, AM J MED, V47, P395, DOI 10.1016/0002-9343(69)90224-1; ARIAS IM, 1957, SCIENCE, V126, P563, DOI 10.1126/science.126.3273.563; BAILEY A, 1977, LANCET, V1, P931; BENSINGER TA, 1973, P SOC EXP BIOL MED, V144, P417, DOI 10.3181/00379727-144-37603; BERK PD, 1972, ANN INTERN MED, V77, P527, DOI 10.7326/0003-4819-77-4-527; BERK PD, 1972, GASTROENTEROLOGY, V63, P472; BILLING BH, 1964, CLIN SCI, V27, P245; BLACK M, 1969, NEW ENGL J MED, V280, P1266, DOI 10.1056/NEJM196906052802303; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BOSMA PJ, 1992, FASEB J, V6, P2859, DOI 10.1096/fasebj.6.10.1634050; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; BOSMA PJ, 1994, J BIOL CHEM, V269, P2542; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chowdhury Jayanta Roy, 1994, P471; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; ERPS LT, 1994, J CLIN INVEST, V93, P564, DOI 10.1172/JCI117008; FELSHER BF, 1979, J LAB CLIN MED, V93, P414; FEVERY J, 1977, J CLIN INVEST, V60, P970, DOI 10.1172/JCI108877; Gilbert A., 1901, SEMAINE MEDICALE, V21, P241; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GROSVELD GC, 1982, NATURE, V295, P120, DOI 10.1038/295120a0; HUNTER JO, 1973, GUT, V14, P46, DOI 10.1136/gut.14.1.46; Jendrassik L, 1938, BIOCHEM Z, V297, P81; LABRUNE P, 1993, HEPATOLOGY, V18, pA126, DOI 10.1016/0270-9139(93)92034-W; LUNDH B, 1972, SCAND J CLIN LAB INV, V30, P421, DOI 10.3109/00365517209080280; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARTIN JF, 1976, GASTROENTEROLOGY, V70, P385; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; MOGHRABI N, 1993, AM J HUM GENET, V53, P722; MURACA M, 1984, GASTROENTEROLOGY, V87, P308; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; OWENS IS, 1992, PHARMACOGENETICS, V2, P93, DOI 10.1097/00008571-199206000-00001; PLATT T, 1972, EXPT MOL GENETICS, P352; POWELL LW, 1967, NEW ENGL J MED, V277, P1108, DOI 10.1056/NEJM196711232772102; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1993, J BIOL CHEM, V268, P23573; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SEPPEN J, 1994, J CLIN INVEST, V94, P2385, DOI 10.1172/JCI117604; SIEG A, 1987, DEUT MED WOCHENSCHR, V112, P1206, DOI 10.1055/s-2008-1068222; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; Thompson R.P.H., 1981, FAMILIAL HYPERBILIRU, P91	45	1124	1172	1	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1171	1175		10.1056/NEJM199511023331802	http://dx.doi.org/10.1056/NEJM199511023331802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565971				2022-12-01	WOS:A1995TB56000002
J	COBB, SR; BUHL, EH; HALASY, K; PAULSEN, O; SOMOGYI, P				COBB, SR; BUHL, EH; HALASY, K; PAULSEN, O; SOMOGYI, P			SYNCHRONIZATION OF NEURONAL-ACTIVITY IN HIPPOCAMPUS BY INDIVIDUAL GABAERGIC INTERNEURONS	NATURE			English	Article							MEMBRANE-POTENTIAL OSCILLATIONS; INHIBITORY INTERNEURONS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; THETA-RHYTHM; CELLS; CA1	SYNCHRONIZATION Of neuronal activity is fundamental in the operation of cortical networks(1). With respect to an ongoing synchronized oscillation, the precise timing of action potentials is an attractive candidate mechanism for information coding(2-5) Networks of inhibitory interneurons have been proposed to have a role in entraining cortical, synchronized 40-Hz activity(6,7). Here we demonstrate that individual GABAergic interneurons(8) can effectively phase spontaneous firing and subthreshold oscillations in hippocampal pyramidal cells at theta frequencies (4-7 Hz). The efficiency of this entrainment is due to interaction of GABA(A)-receptor-mediated hyperpolarizing synaptic events with intrinsic oscillatory mechanisms tuned to this frequency range in pyramidal cells. Moreover, this GABAergic mechanism is sufficient to synchronize the firing of pyramidal cells. Thus, owing to the divergence of each GABAergic interneuron(9,10), more than a thousand pyramidal cells may share a common temporal reference established by an individual interneuron.	ATTILA JOZSEF UNIV, DEPT ZOOL & CELL BIOL, H-6722 SZEGED, HUNGARY	Szeged University	COBB, SR (corresponding author), UNIV OXFORD, DEPT PHARMACOL, MRC, ANAT NEUROPHARMACOL UNIT, MANSFIELD RD, OXFORD OX1 3TH, ENGLAND.		Paulsen, Ole/ABB-4843-2020	Paulsen, Ole/0000-0002-2258-5455	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; ANDERSEN P, 1962, NATURE, V196, P645, DOI 10.1038/196645a0; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; [Anonymous], 1982, ELECTROEN CLIN NEURO; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; FOX SE, 1989, EXP BRAIN RES, V77, P283, DOI 10.1007/BF00274985; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; GINSBORG BL, 1973, BIOCHIM BIOPHYS ACTA, V300, P289, DOI 10.1016/0304-4157(73)90007-5; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; LEUNG LWS, 1991, BRAIN RES, V553, P261, DOI 10.1016/0006-8993(91)90834-I; LI XG, 1992, EXP BRAIN RES, V90, P519; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; SIK A, IN PRESS J NEUROSCI; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; SOMOGYI P, 1989, P RET RES F, V2, P35; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; YLINEN A, 1995, J NEUROSCI, V15, P30; YLINEN A, 1995, HIPPOCAMPUS, V5, P79	28	1145	1158	3	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					75	78		10.1038/378075a0	http://dx.doi.org/10.1038/378075a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477292				2022-12-01	WOS:A1995TC46900053
J	DOLL, DC				DOLL, DC			SPUR CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DOLL, DC (corresponding author), HARRY S TRUMAN VET AFFAIRS MED CTR,COLUMBIA,MO 65201, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1183	1183		10.1056/NEJM199511023331804	http://dx.doi.org/10.1056/NEJM199511023331804			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB560	7565973				2022-12-01	WOS:A1995TB56000004
J	FLEGAL, KM; TROIANO, RP; PAMUK, ER; KUCZMARSKI, RJ; CAMPBELL, SM				FLEGAL, KM; TROIANO, RP; PAMUK, ER; KUCZMARSKI, RJ; CAMPBELL, SM			THE INFLUENCE OF SMOKING CESSATION ON THE PREVALENCE OF OVERWEIGHT IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUITTING CIGARETTE-SMOKING; BODY-WEIGHT; GENDER DIFFERENCES; HIGH-SCHOOL; GAIN; POPULATION; MORTALITY; CONSUMPTION; PREVENTION; FRAMINGHAM	Background. The proportion of U.S. adults, 35 to 74 years of age who were overweight increased by 9.6 percent for men and 8.0 percent for women between 1978 and 1990. Since the prevalence of smoking declined over the same period, smoking cessation has been suggested as a factor contributing to the increasing prevalence of overweight. Methods. To estimate the influence of smoking cessation on the increase in the prevalence of overweight, we analyzed data on current and past weight and smoking status for a national sample of 5247 adults 35 years of age or older who participated in the third National Health and Nutrition Examination Survey, conducted from 1988 through 1998. The results were adjusted for age, sociodemographic characteristics, level of physical activity, alcohol consumption, and (for women) parity. Results. The weight gain over a 10-year period that was associated with the cessation of smoking (i.e., the gain among smokers who quit that was in excess of the gain among continuing smokers) was 4.4 kg for men and 5.0 kg for women. Smokers who had quit within the past 10 years were significantly more likely than respondents who had never smoked to become overweight (odds ratios, 2.4 for men and 2.0 for women). For men, about a quarter (2.3 of 9.6 percentage points) and for women, about a sixth (1.3 of 8.0 percentage points) of the increase in the prevalence of overweight could be attributed to smoking cessation within the past 10 years. Conclusions. Although its health benefits are undeniable, smoking cessation may nevertheless be associated with a small increase in the prevalence of overweight.			FLEGAL, KM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, RM 900, HYATTSVILLE, MD 20782 USA.		Flegal, Katherine M/A-4608-2013; Troiano, Richard/AAK-3540-2021	Troiano, Richard/0000-0002-6807-989X; Flegal, Katherine/0000-0002-0838-469X				AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BIENER L, 1992, HEALTH PSYCHOL, V11, P52; BOYLE CA, 1994, INT J OBESITY, V18, P55; CAMP DE, 1993, HEALTH PSYCHOL, V12, P24, DOI 10.1037/0278-6133.12.1.24; CASEY VA, 1991, AM J CLIN NUTR, V53, P1493, DOI 10.1093/ajcn/53.6.1493; DYER AR, 1975, J CHRON DIS, V28, P109, DOI 10.1016/0021-9681(75)90067-3; FISHER M, 1991, J ADOLESCENT HEALTH, V12, P377, DOI 10.1016/0197-0070(91)90051-M; FRENCH SA, 1994, AM J PUBLIC HEALTH, V84, P1818, DOI 10.2105/AJPH.84.11.1818; FRIEDMAN GD, 1980, CIRCULATION, V61, P716, DOI 10.1161/01.CIR.61.4.716; GARRISON RJ, 1985, ANN INTERN MED, V103, P1006, DOI 10.7326/0003-4819-103-6-1006; GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8; GRITZ ER, 1992, HEALTH PSYCHOL, V11, P17, DOI 10.1037/h0090341; GRITZ ER, 1991, HEALTH PSYCHOL, V10, P330, DOI 10.1037/0278-6133.10.5.330; GROSS J, 1989, J CONSULT CLIN PSYCH, V57, P87, DOI 10.1037/0022-006X.57.1.87; HALL SM, 1989, J CONSULT CLIN PSYCH, V57, P81, DOI 10.1037/0022-006X.57.1.81; HALL SM, 1992, AM J PUBLIC HEALTH, V82, P799, DOI 10.2105/AJPH.82.6.799; Higgins M, 1988, ACTA MED SCAND, V723, P23; KLESGES RC, 1989, PSYCHOL BULL, V106, P204, DOI 10.1037/0033-2909.106.2.204; KLESGES RC, 1988, INT J EAT DISORDER, V7, P413, DOI 10.1002/1098-108X(198805)7:3<413::AID-EAT2260070314>3.0.CO;2-D; KLESGES RC, 1987, INT J EAT DISORDER, V6, P409, DOI 10.1002/1098-108X(198705)6:3<409::AID-EAT2260060311>3.0.CO;2-O; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MOFFATT RJ, 1991, METABOLISM, V40, P465, DOI 10.1016/0026-0495(91)90225-L; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; PERKINS KA, 1993, J CONSULT CLIN PSYCH, V61, P768, DOI 10.1037/0022-006X.61.5.768; PERKINS KA, 1992, J APPL PHYSIOL, V72, P401, DOI 10.1152/jappl.1992.72.2.401; PIRIE PL, 1991, AM J PUBLIC HEALTH, V81, P324, DOI 10.2105/AJPH.81.3.324; PIRIE PL, 1992, AM J PUBLIC HEALTH, V82, P1238, DOI 10.2105/AJPH.82.9.1238; PISUNYER FX, 1994, JAMA-J AM MED ASSOC, V272, P238; SHAH BV, 1991, SUDAAN USERS MANUAL; STAMFORD BA, 1986, AM J CLIN NUTR, V43, P486, DOI 10.1093/ajcn/43.4.486; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; WALDRON I, 1991, SOC SCI MED, V32, P989, DOI 10.1016/0277-9536(91)90157-8; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; 1990, DHHS CDC908416 DEP H; 1994, VITAL HLTH STATIST 1, V32; 1990, SAS PROCEDURES GUIDE; 1987, VITAL HLTH STATIS 11, V238; 1993, JAMA-J AM MED ASSOC, V269, P1931; 1993, JAMA-J AM MED ASSOC, V269, P2198	42	344	355	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1165	1170		10.1056/NEJM199511023331801	http://dx.doi.org/10.1056/NEJM199511023331801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565970				2022-12-01	WOS:A1995TB56000001
J	HART, AC; SIMS, S; KAPLAN, JM				HART, AC; SIMS, S; KAPLAN, JM			SYNAPTIC CODE FOR SENSORY MODALITIES REVEALED BY C-ELEGANS GLR-1 GLUTAMATE-RECEPTOR	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EXPRESSION	How does the nervous system encode environmental stimuli as sensory experiences? Both the type (visual, olfactory, gustatory, mechanical or auditory) and the quality of a stimulus (spatial position, intensity or frequency) are represented as a neural code. Here we undertake a genetic analysis of sensory modality coding in Caenorhabditis elegans. The ASH sensory neurons respond to two distinct sensory stimuli (nose touch and osmotic stimuli). A mutation in the glr-1 (glutamate receptor) gene eliminates the response to nose touch but not to osmotic repellents. The predicted GLR-1 protein is roughly 40% identical to mammalian AMPA-class glutamate receptor (GluR) subunits. Analysis of glr-1 expression and genetic mosaics indicates that GLR-1 receptors act in synaptic targets of the ASH neurons. We propose that discrimination between the ASH sensory modalities arises from differential release of ASH neurotransmitters in response to different stimuli.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BARGMANN CI, 1990, COLD SH Q B, V55, P529; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1983, GENETICS, V103, P43; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; PENG YY, 1993, NEURON, V10, P465, DOI 10.1016/0896-6273(93)90334-N; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WHIM MD, 1994, J NEUROSCI, V14, P4244; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	18	309	320	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					82	85		10.1038/378082a0	http://dx.doi.org/10.1038/378082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477294				2022-12-01	WOS:A1995TC46900055
J	HE, GP; MUISE, A; LI, AW; RO, HS				HE, GP; MUISE, A; LI, AW; RO, HS			A EUKARYOTIC TRANSCRIPTIONAL REPRESSOR WITH CARBOXYPEPTIDASE ACTIVITY	NATURE			English	Article							ENHANCER BINDING-PROTEIN; GENE-EXPRESSION; MOLECULAR-CLONING; FACTOR-VIII; ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; MESSENGER-RNA; CDNA CLONING; C-JUN; DNA	ADIPOCYTE differentiation involves the transcriptional activation of several genes in triglyceride metabolism, including the adipose P2 (aP2 or 422) gene that encodes the adipocyte lipid-binding protein ALBP(1-3). Within the mouse aP2 promoter region, the AE1 sequence functions as either a positive or a negative element in the regulation of aP2 gene expression(4-8). The AE-1 sequence is the binding site for the positive murine (3T3) adipocyte factor C/EBP-alpha(5,6), several human preadipocyte factors(7), and a 3T3 preadipocyte factor(s) that has been implicated as a repressor of aP2 gene expression(4,5,7,8). Here we report the cloning of new complementary DNAs that encode the 3T3 preadipocyte factor (termed AEBP1), and demonstrate that AEBP1 expression is abolished during adipocyte differentiation. Furthermore, we show that an activity of a carboxypeptidase associated with AEBP1 is important in the transcriptional repression function of AEBP1. Thus AEBP1 might represent a new type of transcription factor that regulates transcription by cleavage of factors involved in transcription.	DALHOUSIE UNIV,FAC MED,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA	Dalhousie University				Ro, Hyo-Sung/0000-0003-4411-0386				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOLK JE, 1960, J BIOL CHEM, V235, P2272; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RO HS, 1991, MOL CELL BIOL, V11, P2303, DOI 10.1128/MCB.11.4.2303; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAN FL, 1989, J BIOL CHEM, V264, P13165; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	29	130	141	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					92	96		10.1038/378092a0	http://dx.doi.org/10.1038/378092a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477299				2022-12-01	WOS:A1995TC46900058
J	KIM, E; NIETHAMMER, M; ROTHSCHILD, A; JAN, YN; SHENG, M				KIM, E; NIETHAMMER, M; ROTHSCHILD, A; JAN, YN; SHENG, M			CLUSTERING OF SHAKER-TYPE K+ CHANNELS BY INTERACTION WITH A FAMILY OF MEMBRANE-ASSOCIATED GUANYLATE KINASES	NATURE			English	Article							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; POTASSIUM CHANNEL; NMDA RECEPTOR; NEURONS; DIVERSITY; HOMOLOG; BRAIN; GENE	ANCHORING Of ion channels at specific subcellular sites is critical for neuronal signalling, but the mechanisms underlying channel localization and clustering are largely unknown (reviewed in ref. 1). Voltage-gated K+ channels are concentrated in various neuronal domains, including presynaptic terminals, nodes of Ranvier and dendrites, where they regulate local membrane excitability. Here we present functional and biochemical evidence that cell-surface clustering of Shaker-subfamily K+ channels is mediated by the PSD-95 family of membrane-associated putative guanylate kinases, as a result of direct binding of the carboxy-terminal cytoplasmic tails of the K+ channel subunits to two PDZ (also known as GLGF or DHR) domains in the PSD-95 protein(2). The ability of PDZ domains to function as independent modules for protein-protein interaction, and their presence in other junction-associated molecules (such as ZO-1 (ref. 3) and syntrophin(4)), suggest that PDZ-domain-containing polypeptides may be widely involved in the organization of proteins at sites of membrane specialization.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02114; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Kim, Eunjoon/C-1566-2011	Sheng, Morgan/0000-0002-8703-5366				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Bartel PL, 1993, USING 2 HYBRID SYSTE, P153; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII T, 1993, J BIOL CHEM, V268, P2836; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; SHENG M, 1994, J NEUROSCI, V14, P2408; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	29	880	911	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					85	88		10.1038/378085a0	http://dx.doi.org/10.1038/378085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477295				2022-12-01	WOS:A1995TC46900056
J	LOPEZ, MJ; WONG, SKF; KISHIMOTO, I; DUBOIS, S; MACH, V; FRIESEN, J; GARBERS, DL; BEUVE, A				LOPEZ, MJ; WONG, SKF; KISHIMOTO, I; DUBOIS, S; MACH, V; FRIESEN, J; GARBERS, DL; BEUVE, A			SALT-RESISTANT HYPERTENSION IN MICE LACKING THE GUANYLYL CYCLASE-A RECEPTOR FOR ATRIAL-NATRIURETIC-PEPTIDE	NATURE			English	Article							BLOOD-PRESSURE; SODIUM SENSITIVITY; CLEARANCE RECEPTOR; BRAIN; GENES	AROUND half of all humans with essential hypertension are resistant to salt (blood pressure does not change by more than 5 mm Hg when salt intake is high)(1-5), and although various inbred strains of rats display salt-insensitive elevated blood pressure(6), a gene defect to account for the phenotype has not been described. Atrial natriuretic peptide (ANP) is released from the heart in response to atrial stretch and is thought to mediate its natriuretic and vasorelaxant effects through the guanylyl cyclase-A receptor (GC-A)(7). Here we report that disruption of the GC-A gene results in chronic elevations of blood pressure in mice on a normal salt diet. Unexpectedly, the blood pressure remains elevated and unchanged in response to either minimal or high salt diets. Aldosterone and ANP concentrations are not affected by the genotype. Therefore, mutations in the GC-A gene could explain some salt-resistant forms of essential hypertension and, coupled with previous works further suggest that the GC-A signalling pathway dominates at the level of peripheral resistance, where it can operate independently of ANP.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LOPEZ, MJ (corresponding author), UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.							ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; ATLAS SA, 1990, HYPERTENSION PATHOPH, P861; BALLERMANN BJ, 1991, KIDNEY, P510; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DIETZ JR, 1994, CLIN EXP PHARMACOL P, V21, P599, DOI 10.1111/j.1440-1681.1994.tb02560.x; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FUJITA T, 1980, AM J MED, V69, P334, DOI 10.1016/0002-9343(80)90002-9; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FULLER F, 1988, J BIOL CHEM, V263, P9395; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KAWASAKI T, 1978, AM J MED, V64, P193, DOI 10.1016/0002-9343(78)90045-1; Kimura G, 1994, Curr Opin Nephrol Hypertens, V3, P1; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OGAWA Y, 1994, J CLIN INVEST, V93, P1911, DOI 10.1172/JCI117182; OPARIL S, 1988, J CARDIOVASC PHARM, V12, pS56; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SULLIVAN JM, 1988, HYPERTENSION, V11, P717, DOI 10.1161/01.HYP.11.6.717; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WEINBERGER MH, 1990, HYPERTENSION PATHOPH, P1999; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414	28	386	399	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 2	1995	378	6552					65	68		10.1038/378065a0	http://dx.doi.org/10.1038/378065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477288				2022-12-01	WOS:A1995TC46900050
J	MARICQ, AV; PECKOL, E; DRISCOLL, M; BARGMANN, CI				MARICQ, AV; PECKOL, E; DRISCOLL, M; BARGMANN, CI			MECHANOSENSORY SIGNALING IN C-ELEGANS MEDIATED BY THE GLR-1 GLUTAMATE-RECEPTOR	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; GENE; NEURODEGENERATION; ACETYLCHOLINE; EXPRESSION; SEQUENCE; CLONING; FAMILY; SET	NEURONAL signalling across synapses involves activation of many neurotransmitter receptors on postsynaptic cells. glr-1 encodes a potential glutamate receptor in the nematode Caenorhabditis elegans which is most similar to vertebrate AMPA-type ionotropic glutamate receptors(1). glr-1 is expressed in motor neurons and interneurons, including interneurons implicated in the control of locomotion(2). Here we investigate the contribution of glr-1 to the normal signalling of these neurons, by generating a deletion mutation in glr-1. We find that mutant worms are deficient in their ability to withdraw backwards when mechanically stimulated, but they withdraw normally in response to chemical repellents. The ASH sensory neurons mediate withdrawal responses both to mechanical stimuli and to chemical repellents(3,4), and ASH makes chemical synapses with glr-1-expressing interneurons. Our results suggest that postsynaptic interneurons use different neurotransmitter receptors to process two sensory stimuli detected by one sensory neuron.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, PROGRAM NEUROSCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, GENET PROGRAM, SAN FRANCISCO, CA 94143 USA; RUTGERS STATE UNIV, CTR ADV BIOTECHNOL & MED, DEPT MOLEC BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Rutgers State University New Brunswick				Bargmann, Cornelia/0000-0002-8484-0618				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARGMANN CI, 1990, COLD SH Q B, V55, P529; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOCHET P, 1994, NEURON, V12, P383, DOI 10.1016/0896-6273(94)90279-8; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHURCH PJ, 1993, J NEUROSCI, V13, P2790; CULOTTI JG, 1978, GENETICS, V90, P243; Darlison Mark G., 1993, V63, P48; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; SCHOTLAND J, 1995, NATURE, V374, P266, DOI 10.1038/374266a0; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; ULTSCH A, 1992, P NATL ACAD SCI USA, V89, P10484, DOI 10.1073/pnas.89.21.10484; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	31	274	282	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	1995	378	6552					78	81		10.1038/378078a0	http://dx.doi.org/10.1038/378078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477293				2022-12-01	WOS:A1995TC46900054
J	OKAMURA, H; TSUTSUI, H; KOMATSU, T; YUTSUDO, M; HAKURA, A; TANIMOTO, T; TORIGOE, K; OKURA, T; NUKADA, Y; HATTORI, K; AKITA, K; NAMBA, M; TANABE, F; KONISHI, K; FUKUDA, S; KURIMOTO, M				OKAMURA, H; TSUTSUI, H; KOMATSU, T; YUTSUDO, M; HAKURA, A; TANIMOTO, T; TORIGOE, K; OKURA, T; NUKADA, Y; HATTORI, K; AKITA, K; NAMBA, M; TANABE, F; KONISHI, K; FUKUDA, S; KURIMOTO, M			CLONING OF A NEW CYTOKINE THAT INDUCES IFN-GAMMA PRODUCTION BY T-CELLS	NATURE			English	Article								THE mechanism underlying the differentiation of CD4(+) T cells into functionally distinct subsets (Th1 and Th2) is incompletely understood(1-3), and hitherto unidentified cytokines may be required for the functional maturation of these cells(4). Here we report the cloning of a recently identified IFN-gamma-inducing factor (IGIF) that augments natural killer (NK) activity in spleen cells(5,6). The gene encodes a precursor protein of 192 amino acids and a mature protein of 157 amino acids, which have no obvious similarities to any peptide in the databases. Messenger RNAs for IGIF and interleukin-12 (IL-12) are readily detected in Kupffer cells and activated macrophages. Recombinant IGIF induces IFN-gamma more potently than does IL-12, apparently through a separate pathway. Administration of anti-IGIF antibodies prevents liver damage in mice inoculated with Propionibacterium acnes and challenged with lipopolysaccharide, which induces toxic shock. IGIF may he involved in the development of Th1 cells and also in mechanisms of tissue injury in inflammatory reactions.	HYOGO MED UNIV,DEPT IMMUNOL & MED ZOOL,NISHINOMIYA,HYOGO,JAPAN; OSAKA CITY UNIV,TONEYAMA INST TB,TOYONAKA,OSAKA,JAPAN; INST MICROBIAL DIS,SUITA,OSAKA,JAPAN; HAYASHIBARA CO INC,FUJISAKI INST,HAYASHIBARA BIOCHEM LABS,OKAYAMA,JAPAN	Hyogo College of Medicine; University of Hyogo; Osaka Metropolitan University; Hayashibara Biochemical Laboratories, Inc.	OKAMURA, H (corresponding author), HYOGO MED UNIV,DEPT BACTERIOL,1-1 MUKOGAWA CHO,NISHINOMIYA,HYOGO,JAPAN.			Tsutsui, Hiroko/0000-0001-7928-4875				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EYHORN S, 1988, J HEPATOL, V6, P23, DOI 10.1016/S0168-8278(88)80459-8; FERLUGA J, 1978, LANCET, P661; KARASUYAMA H, 1989, J EXP MED, V196, P13; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LOCKSLEY RM, 1993, P NATL ACAD SCI USA, V90, P5879, DOI 10.1073/pnas.90.13.5879; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; NAKAMURA K, 1993, INFECT IMMUN, V61, P64, DOI 10.1128/IAI.61.1.64-70.1993; OKAMURA H, IN PRESS INFECT IMMU; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; TSUTSUI H, 1992, HEPATO-GASTROENTEROL, V39, P553; WYNN TA, 1994, J EXP MED, V179, P1551, DOI 10.1084/jem.179.5.1551; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307	13	2249	2522	4	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					88	91		10.1038/378088a0	http://dx.doi.org/10.1038/378088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477296				2022-12-01	WOS:A1995TC46900057
J	PARGE, HE; FOREST, KT; HICKEY, MJ; CHRISTENSEN, DA; GETZOFF, ED; TAINER, JA				PARGE, HE; FOREST, KT; HICKEY, MJ; CHRISTENSEN, DA; GETZOFF, ED; TAINER, JA			STRUCTURE OF THE FIBER-FORMING PROTEIN PILIN AT 2.6-ANGSTROM RESOLUTION	NATURE			English	Article							PSEUDOMONAS-AERUGINOSA; NEISSERIA-GONORRHOEAE; POLAR PILI; DISSOCIATION; EXPRESSION; ANTIBODIES; FIMBRIAE; MUTANT; ACTIN; PAO	The crystallographic structure of Neisseria gonorrhoeae pilin, which assembles into the multifunctional pilus adhesion and virulence factor, reveals an alpha-beta roll fold with a striking 85 Angstrom alpha-helical spine and an O-linked disaccharide. Hey residues stabilize interactions that allow sequence hypervariability, responsible for pilin's celebrated antigenic variation, within disulphide region beta-strands and connections. Pilin surface shape, hydrophobicity and sequence variation constrain pilus assembly to the packing of flat subunit faces against alpha(1) helices. Helical fibre assembly is postulated to form a core of coiled alpha(1) helices banded by beta-sheet, leaving carbohydrate and hypervariable sequence regions exposed to solvent.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				BISWAS GD, 1977, J BACTERIOL, V129, P983, DOI 10.1128/JB.129.2.983-992.1977; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; BRADLEY DE, 1974, VIROLOGY, V58, P149, DOI 10.1016/0042-6822(74)90150-0; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BUCHANAN TM, 1976, INFECT IMMUN, V13, P1483, DOI 10.1128/IAI.13.5.1483-1489.1976; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DALRYMPLE B, 1987, J MOL EVOL, V25, P261, DOI 10.1007/BF02100020; DUPUY B, 1994, J BACTERIOL, V176, P1323, DOI 10.1128/jb.176.5.1323-1331.1994; ELLEMAN TC, 1987, MOL MICROBIOL, V1, P377, DOI 10.1111/j.1365-2958.1987.tb01945.x; FOLKHARD W, 1981, J MOL BIOL, V149, P79, DOI 10.1016/0022-2836(81)90261-8; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; HAMADEH RM, 1994, 9TH INT PATH NEISS C, P132; JONSSON AB, 1994, MOL MICROBIOL, V13, P403, DOI 10.1111/j.1365-2958.1994.tb00435.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTICK JS, 1987, J BACTERIOL, V169, P33, DOI 10.1128/jb.169.1.33-41.1987; Mattick JS, 1993, GENETICS MOL BIOL AN, P517; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MORGAN DG, 1995, J MOL BIOL, V249, P88, DOI 10.1006/jmbi.1995.0282; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; OTTOW JCG, 1975, ANNU REV MICROBIOL, V29, P79, DOI 10.1146/annurev.mi.29.100175.000455; PARGE HE, 1990, J BIOL CHEM, V265, P2278; PASLOSKE BL, 1989, J BACTERIOL, V171, P2142, DOI 10.1128/jb.171.4.2142-2147.1989; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTHBARD JB, 1985, P NATL ACAD SCI USA, V82, P915, DOI 10.1073/pnas.82.3.915; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; SCHOOLNIK GK, 1990, NEW GENERATION VACCI, P565; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SEGAL E, 1985, CELL, V40, P293, DOI 10.1016/0092-8674(85)90143-6; Seifert H, 1984, MICROBIOL REV, V52, P327; SEIFERT HS, 1994, J CLIN INVEST, V93, P2744, DOI 10.1172/JCI117290; STEWART DJ, 1982, RES VET SCI, V32, P140, DOI 10.1016/S0034-5288(18)32404-4; STROM MS, 1994, METHOD ENZYMOL, V235, P527; Swanson J., 1989, MOBILE DNA, P743; TANIGUCHI T, 1995, INFECT IMMUN, V63, P724, DOI 10.1128/IAI.63.2.724-728.1995; VIRJI M, 1989, J GEN MICROBIOL, V135, P3239; VIRJI M, 1993, MOL MICROBIOL, V10, P1013, DOI 10.1111/j.1365-2958.1993.tb00972.x; WATTS TH, 1983, BIOCHEMISTRY-US, V22, P3640, DOI 10.1021/bi00284a016; WATTS TH, 1982, CAN J BIOCHEM CELL B, V60, P867, DOI 10.1139/o82-110; WATTS TH, 1982, J BACTERIOL, V151, P1508, DOI 10.1128/JB.151.3.1508-1513.1982; WOODS DE, 1980, INFECT IMMUN, V29, P1146	50	391	404	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					32	38		10.1038/378032a0	http://dx.doi.org/10.1038/378032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477282				2022-12-01	WOS:A1995TC46900040
J	SCHEIFFELE, P; PERANEN, J; SIMONS, K				SCHEIFFELE, P; PERANEN, J; SIMONS, K			N-GLYCANS AS APICAL SORTING SIGNALS IN EPITHELIAL-CELLS	NATURE			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; PLASMA-MEMBRANE; PROTEINS; SECRETION; SURFACE; EXPRESSION; GLYCOSYLATION; TRANSPORT	IN epithelial Madin-Darby canine kidney (MDCK) cells newly synthesized molecules are sorted in the trans-Golgi network and directly delivered to their apical and basolateral surface destinations(1). Sorting is mediated by signals in the cytoplasmic domains of basolateral transmembrane proteins whereas glycosylphosphatidylinositol-linked proteins have apical sorting information in their glycolipid tails(5,6). Signals for apical transmembrane proteins are thought to reside in their ectodomains, because truncated forms lacking the cytoplasmic tail and the membrane anchor are secreted apically(7,8). Here we demonstrate that carbohydrates act as an apical targeting signal for secretory proteins. Growth hormone, which is non-glycosylated and secreted from both sides of MDCK cell lagers(9), is secreted from the apical side when glycosylated. Thus glycans not only play a general role in protein folding(10) but also appear to function in protein sorting in biosynthetic traffic.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,D-69112 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Simons, Kai/0000-0002-9231-9996				BALCAROVASTANDE.J, 1984, EMBO J, V3, P2687; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, CELL, V81, P1; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HUNZIKER W, 1991, CELL, V66, P1; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; MUSTO NA, 1993, EXP CELL RES, V209, P271, DOI 10.1006/excr.1993.1311; RAGNO P, 1992, EXP CELL RES, V203, P236, DOI 10.1016/0014-4827(92)90060-L; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cellbio.8.1.395; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1993, FEBS LETT, V330, P293, DOI 10.1016/0014-5793(93)80891-W; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	30	408	411	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					96	98		10.1038/378096a0	http://dx.doi.org/10.1038/378096a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477300				2022-12-01	WOS:A1995TC46900059
J	VANDENBERG, C; WILLEMSEN, V; HAGE, W; WEISBEEK, P; SCHERES, B				VANDENBERG, C; WILLEMSEN, V; HAGE, W; WEISBEEK, P; SCHERES, B			CELL FATE IN THE ARABIDOPSIS ROOT-MERISTEM DETERMINED BY DIRECTIONAL SIGNALING	NATURE			English	Article							LINEAGE PATTERNS; CAENORHABDITIS-ELEGANS; SHOOT MERISTEM; ZEA-MAYS; REGENERATION; EMBRYO; PLANTS	POSTEMBRYONIC development in plants is achieved by apical meristems. Surgical studies and clonal analysis have revealed indirectly that cells in shoot meristems have no predictable destiny(1-3) and that position is likely to play a role in the acquisition of cell identity(4-7). In contrast to animal systems(8-10) there has been no direct evidence for inductive signalling in plants until now. Here we present evidence for such signalling using laser ablation of cells in the root meristem of Arabidopsis thaliana. Although these cells show rigid clonal relationships, we now demonstrate that it is positional control that is most important in the determination of cell fate. Positional signals can be perpetuated from more mature to initial cells to guide the pattern of meristem cell differentiation. This offers an alternative to the general opinion that meristems are the source of patterning information(12).	NETHERLANDS INST DEV BIOL,3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	VANDENBERG, C (corresponding author), UNIV UTRECHT,DEPT MOLEC CELL BIOL,PADUALAAN 8,3584 CH UTRECHT,NETHERLANDS.			Scheres, Ben/0000-0001-5400-9578				ALBERTS B, 1994, MOL BIOL CELL, P1108; BARLOW P, 1974, NEW PHYTOL, V73, P937, DOI 10.1111/j.1469-8137.1974.tb01323.x; BENFEY PN, 1993, DEVELOPMENT, V119, P57; BENFEY PN, 1990, EMBO J, V9, P1685, DOI 10.1002/j.1460-2075.1990.tb08292.x; BERGER F, 1994, SCIENCE, V263, P1421, DOI 10.1126/science.263.5152.1421; DAWE RK, 1991, PLANT J, V1, P3, DOI 10.1111/j.1365-313X.1991.00003.x; DOLAN L, 1993, DEVELOPMENT, V119, P71; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; FELDMAN LJ, 1976, AM J BOT, V63, P345, DOI 10.2307/2441580; GODDIJN OJM, 1993, PLANT J, V4, P863, DOI 10.1046/j.1365-313X.1993.04050863.x; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAESMAN J, 1984, CELL, V37, P185; JEGLA DE, 1989, DEV BIOL, V131, P215, DOI 10.1016/S0012-1606(89)80053-3; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; Pilkington M, 1929, NEW PHYTOL, V28, P37; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SCHIAVONE FM, 1991, DEVELOPMENT, V113, P1305; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEEVES TA, 1989, PATTERNS PLANT DEV, P86; STEWART RN, 1975, AM J BOT, V57, P816; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; WARDLAW CW, 1950, PHILOS T ROY SOC B, V234, P583, DOI 10.1098/rstb.1950.0012	27	400	414	0	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					62	65		10.1038/378062a0	http://dx.doi.org/10.1038/378062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477287	Green Submitted			2022-12-01	WOS:A1995TC46900049
J	WANG, XQ; MERZENICH, MM; SAMESHIMA, K; JENKINS, WM				WANG, XQ; MERZENICH, MM; SAMESHIMA, K; JENKINS, WM			REMODELING OF HAND REPRESENTATION IN ADULT CORTEX DETERMINED BY TIMING OF TACTILE STIMULATION	NATURE			English	Article							SOMATOSENSORY CORTEX; OWL MONKEYS; TOPOGRAPHIC REORGANIZATION; FUNCTIONAL REORGANIZATION; SQUIRREL-MONKEYS; DIGIT AMPUTATION; AREA-3B; PLASTICITY; DEAFFERENTATION; DENERVATION	THE primate somatosensory cortex, which processes tactile stimuli, contains a topographic representation of the signals it receives, but the way in which such maps are maintained is poorly understood. Previous studies of cortical plasticity(1-20) indicated that changes in cortical representation during learning arise largely as a result of hebbian synaptic change mechanisms. Here we show, using adult owl monkeys trained to respond to specific stimulus sequence events, that serial application of stimuli to the fingers results in changes to the neuronal response specificity and maps of the hand surfaces in the true primary somatosensory cortical field (S1 area 3b). In this representational remodelling stimuli applied sychronously to the fingers resulted in these fingers being integrated in their representation, whereas fingers to which stimuli were applied asynchronously were segregated in their representation. Ventroposterior thalamus response maps derived in these monkeys were not equivalently reorganized. This representational plasticity appears to be cortical in origin.	UNIV CALIF SAN FRANCISCO,COLEMAN LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,KECK CTR INTEGRAT NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Sameshima, Koichi/AHA-5593-2022; Sameshima, Koichi/C-2857-2012	Sameshima, Koichi/0000-0002-0290-2927; Sameshima, Koichi/0000-0002-0290-2927				ARMSTRONGJAMES M, 1994, J NEUROSCI, V14, P6978; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; CODE RA, 1992, EXP BRAIN RES, V88, P341, DOI 10.1007/BF02259109; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; DIAMOND ME, 1993, P NATL ACAD SCI USA, V90, P2082, DOI 10.1073/pnas.90.5.2082; GARRAGHTY PE, 1991, P NATL ACAD SCI USA, V88, P6976, DOI 10.1073/pnas.88.16.6976; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KALASKA J, 1979, J NEUROPHYSIOL, V42, P618, DOI 10.1152/jn.1979.42.2.618; MERZENICH MM, 1987, J COMP NEUROL, V258, P281, DOI 10.1002/cne.902580208; MERZENICH MM, 1978, J COMP NEUROL, V181, P41, DOI 10.1002/cne.901810104; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MERZENICH MM, 1991, COLD SPRING HARB SYM, V55, P873; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; RECANZONE GH, 1991, BEHAV RES METH INS C, V23, P357, DOI 10.3758/BF03203397; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; STRYKER MP, 1987, J COMP NEUROL, V258, P297, DOI 10.1002/cne.902580209; SUR M, 1980, J NEUROPHYSIOL, V44, P295, DOI 10.1152/jn.1980.44.2.295; WALL JT, 1983, SCIENCE, V221, P771, DOI 10.1126/science.6879175; XERRI C, 1994, J NEUROSCI, V14, P1710, DOI 10.1523/JNEUROSCI.14-03-01710.1994; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	27	349	352	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					71	75		10.1038/378071a0	http://dx.doi.org/10.1038/378071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477291				2022-12-01	WOS:A1995TC46900052
J	ZHOU, JN; HOFMAN, MA; GOOREN, LJG; SWAAB, DF				ZHOU, JN; HOFMAN, MA; GOOREN, LJG; SWAAB, DF			A SEX DIFFERENCE IN THE HUMAN BRAIN AND ITS RELATION TO TRANSSEXUALITY	NATURE			English	Article							BED NUCLEUS; STRIA TERMINALIS; GONADAL-STEROIDS; RAT; ANDROGEN; IMMUNOREACTIVITY; FOREBRAIN; SEPTUM; AREA	TRANSSEXUALS have the strong feeling, often from childhood onwards, of having been born the wrong sex. The possible psychogenic or biological aetiology of transsexuality has been the subject of debate for many years(1,2). Here we show that the volume of the central subdivision of the bed nucleus of the stria terminalis (BSTc), a brain area that is essential for sexual behaviour(3,4), is larger in men than in women. A female-sized BSTc was found in male-to-female transsexuals. The size of the BSTc was not influenced by sex hormones in adulthood and was independent of sexual orientation. Our study is the first to show a female brain structure in genetically male transsexuals and supports the hypothesis that gender identity develops as a result of an interaction between the developing brain and sex hormones(5,6).	NETHERLANDS INST BRAIN RES,GRAD SCH NEUROSCI,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT ENDOCRINOL,1007 MB AMSTERDAM,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER			Oostenbruggen, Belle/D-7966-2012; Zhou, JiangNing/N-3374-2013; Hofman, Michel A./ABG-7621-2020	Swaab, Dick/0000-0002-9665-7845				ALLEN LS, 1990, J COMP NEUROL, V302, P697, DOI 10.1002/cne.903020402; ARLUISON M, 1994, BRAIN RES BULL, V34, P319, DOI 10.1016/0361-9230(94)90026-4; BLEIER R, 1982, J COMP NEUROL, V212, P118, DOI 10.1002/cne.902120203; CLARO F, 1995, BRAIN RES BULL, V36, P1, DOI 10.1016/0361-9230(94)00118-K; COMMINS D, 1985, J COMP NEUROL, V231, P473, DOI 10.1002/cne.902310406; DELABRIL A, 1987, DEV BRAIN RES, V32, P295, DOI 10.1016/0165-3806(87)90110-6; DEOLMOS JS, 1990, HUMAN NERVOUS SYSTEM, P597; DEVRIES GJN, 1990, NEUROENDOCRINOLOGY, V20, P1; EIDEN LE, 1985, NEUROSCIENCE, V15, P999, DOI 10.1016/0306-4522(85)90249-0; EMERY DE, 1976, PHYSIOL BEHAV, V17, P803, DOI 10.1016/0031-9384(76)90044-5; GOOREN L, 1990, PSYCHONEUROENDOCRINO, V15, P3, DOI 10.1016/0306-4530(90)90041-7; GUILLAMON A, 1988, DEV BRAIN RES, V44, P281, DOI 10.1016/0165-3806(88)90226-X; JAKAB RL, 1993, J STEROID BIOCHEM, V44, P481, DOI 10.1016/0960-0760(93)90253-S; KAWAKAMI M, 1974, ENDOCRINOL JAPON, V21, P125; MONEY J, 1984, PSYCHONEUROENDOCRINO, V9, P405, DOI 10.1016/0306-4530(84)90048-9; Money J, 1970, Int J Psychiatry, V9, P249; PILGRIM C, 1992, HORM METAB RES, V24, P353, DOI 10.1055/s-2007-1003334; SHERIDAN PJ, 1979, ENDOCRINOLOGY, V104, P130, DOI 10.1210/endo-104-1-130; SIMERLY RB, 1990, TRENDS NEUROSCI, V13, P104, DOI 10.1016/0166-2236(90)90186-E; SIMERLY RB, 1987, P NATL ACAD SCI USA, V84, P2087, DOI 10.1073/pnas.84.7.2087; SWAAB DF, 1995, TRENDS NEUROSCI, V18, P264, DOI 10.1016/0166-2236(95)93913-I; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; SWAAB DF, 1994, BRAIN RES, V7, P249; WALTER A, 1991, J CHEM NEUROANAT, V4, P281, DOI 10.1016/0891-0618(91)90019-9; WOODHAMS PL, 1983, NEUROSCIENCE, V8, P677, DOI 10.1016/0306-4522(83)90003-9; ZHOU JN, 1995, BRAIN RES, V672, P285, DOI 10.1016/0006-8993(94)01430-P; ZHOU JN, 1995, NEUROBIOL AGING, V16, P571, DOI 10.1016/0197-4580(95)00043-E; 1991, LANCET, V338, P603	28	451	458	2	130	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 2	1995	378	6552					68	70		10.1038/378068a0	http://dx.doi.org/10.1038/378068a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC469	7477289	Green Submitted			2022-12-01	WOS:A1995TC46900051
J	BROWN, SS; EISENBERG, L				BROWN, SS; EISENBERG, L			UNINTENDED PREGNANCY AND THE WELL-BEING OF CHILDREN AND FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	BROWN, SS (corresponding author), NATL ACAD SCI,INST MED,WASHINGTON,DC 20418, USA.								0	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1332	1332		10.1001/jama.274.17.1332	http://dx.doi.org/10.1001/jama.274.17.1332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563544				2022-12-01	WOS:A1995TB27800003
J	BUTLER, VP; ODEL, JG; RATH, E; WOLIN, MJ; BEHRENS, MM; MARTIN, TJ; KARDON, RH; GOURAS, P				BUTLER, VP; ODEL, JG; RATH, E; WOLIN, MJ; BEHRENS, MM; MARTIN, TJ; KARDON, RH; GOURAS, P			DIGITALIS-INDUCED VISUAL DISTURBANCES WITH THERAPEUTIC SERUM DIGITALIS CONCENTRATIONS	ANNALS OF INTERNAL MEDICINE			English	Note							RAT RETINA; DIGOXIN; INTOXICATION; LOCALIZATION; DEGENERATION; CELLS	Objective: To assess the role of digitalis in the development of visual symptoms severe enough to warrant ophthalmologic consultation in patients who received digitalis and who had no other clinical or laboratory evidence of digitalis toxicity. Design: Clinical case study. Setting: Neuro-ophthalmology referral practice. Patients: Six elderly patients (aged 66 to 85 years) who received digitalis were referred to ophthalmologists for evaluation of photopsia (five patients) or decreased visual acuity (one patient). No patient had chromatopsia or nonvisual clinical manifestations of digitalis intoxication at the time of examination. Measurements: All patients had serum digitalis concentrations within or below the therapeutic range. In most patients, the electroretinographic cone b-wave implicit time was longer than normal. Results: Discontinuation of digitalis therapy, which was possible in five patients, was followed by resolution of visual symptoms and by shortening of the b-wave implicit time. Characteristic features of digitalis-induced photopsia were its dependence on illumination and its tendency to be localized in peripheral visual fields. Conclusions: In an elderly patient receiving digitalis, the development of photopsia characterized by innumerable points of light in the peripheral visual fields or a decrease in visual acuity raises the possibility that the patient's visual disturbance may have been digitalis induced. Digitalis-induced visual disturbances other than chromatopsia or disturbances of color vision may occur in elderly patients who have no other clinical manifestations of digitalis intoxication and who have a serum digitalis concentration within or below the therapeutic range.	UNIV IOWA, DEPT OPHTHALMOL, IOWA CITY, IA 52242 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; VET AFFAIRS HOSP, IOWA CITY, IA USA	University of Iowa; Columbia University; NewYork-Presbyterian Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System				Kardon, Randy/0000-0002-3173-7123	NATIONAL EYE INSTITUTE [R01EY004138] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL010608] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 04138-10] Funding Source: Medline; NHLBI NIH HHS [R01 HL 10608-27] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURKE JM, 1993, EXP EYE RES, V57, P51, DOI 10.1006/exer.1993.1098; BUTLER V P JR, 1972, Progress in Cardiovascular Diseases, V14, P571, DOI 10.1016/0033-0620(72)90009-6; CARROLL FD, 1945, AM J OPHTHALMOL, V28, P373, DOI 10.1016/0002-9394(45)90940-8; DENDEN A, 1962, GRAEFE ARCH OPHTHAL, V165, P185; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; FISHER CM, 1981, NEUROLOGY, V31, P1569, DOI 10.1212/WNL.31.12.1569; GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23; GIBSON HC, 1965, ARCH OPHTHALMOL-CHIC, V74, P154, DOI 10.1001/archopht.1965.00970040156004; GILLETTE DF, 1946, T AM OPHTHAL SOC, V44, P156; GOURAS P, 1989, INVEST OPHTH VIS SCI, V30, P619; HOFFMAN B F, 1990, P814; LEAHEY EB, 1978, JAMA-J AM MED ASSOC, V240, P533, DOI 10.1001/jama.240.6.533; LELY AH, 1970, BRIT MED J, V3, P737, DOI 10.1136/bmj.3.5725.737; MADREPERLA SA, 1994, ARCH OPHTHALMOL-CHIC, V112, P807, DOI 10.1001/archopht.1994.01090180105044; MASSARO FJ, 1983, DRUG INTEL CLIN PHAR, V17, P368, DOI 10.1177/106002808301700509; MCGRAIL KM, 1986, J NEUROSCI, V6, P1272; MCGRAIL KM, 1990, EUR J NEUROSCI, V2, P170, DOI 10.1111/j.1460-9568.1990.tb00409.x; Moore C E, 1973, Aust J Ophthalmol, V1, P76, DOI 10.1111/j.1442-9071.1973.tb01413.x; OAKLEY B, 1992, EXP EYE RES, V55, P539, DOI 10.1016/S0014-4835(05)80166-6; REICHENBACH A, 1992, CAN J PHYSIOL PHARM, V70, pS239, DOI 10.1139/y92-267; ROBERTSON DM, 1966, ARCH OPHTHALMOL-CHIC, V76, P640, DOI 10.1001/archopht.1966.03850010642004; ROBERTSON DM, 1966, ARCH OPHTHALMOL-CHIC, V76, P852; SMITH TW, 1972, CIRCULATION, V46, P188; SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457; Sprague HB, 1925, J AMER MED ASSOC, V85, P716, DOI 10.1001/jama.1925.02670100004002; STAHL WL, 1984, J HISTOCHEM CYTOCHEM, V32, P248, DOI 10.1177/32.2.6319483; WAGENER HP, 1946, ARCH OPHTHALMOL-CHIC, V36, P478, DOI 10.1001/archopht.1946.00890210486003; WELEBER RG, 1981, ARCH OPHTHALMOL-CHIC, V99, P1568, DOI 10.1001/archopht.1981.03930020442007; WHITE PD, 1965, NEW ENGL J MED, V272, P904, DOI 10.1056/NEJM196504292721709; Withering W., 1785, ACCOUNT FOXGLOVE SOM	30	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					676	680		10.7326/0003-4819-123-9-199511010-00006	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574223				2022-12-01	WOS:A1995TA69600006
J	GIANAKOS, D				GIANAKOS, D			UMANA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											GIANAKOS, D (corresponding author), LYNCHBURG FAMILY PRACTICE RESIDENCY, 2097 LANGHORNE RD, LYNCHBURG, VA 24501 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					730	730		10.7326/0003-4819-123-9-199511010-00016	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574233				2022-12-01	WOS:A1995TA69600016
J	PAAUW, DS; WENRICH, MD; CURTIS, JR; CARLINE, JD; RAMSEY, PG				PAAUW, DS; WENRICH, MD; CURTIS, JR; CARLINE, JD; RAMSEY, PG			ABILITY OF PRIMARY-CARE PHYSICIANS TO RECOGNIZE PHYSICAL FINDINGS ASSOCIATED WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ORAL HAIRY LEUKOPLAKIA; KAPOSIS SARCOMA; AIDS; VIRUS	Objective.-To assess the ability of primary care physicians to identify physical findings associated with human immunodeficiency virus (HIV) infection. Design.-Standardized patient examination. Participants.-A total of 134 general internists and family practitioners were randomly selected after stratifying by year of medical school graduation, specialty, and experience caring for patients with HIV infection. Main Outcome Measures.-Recognition of physical findings of Kaposi's sarcoma, oral hairy leukoplakia, and diffuse lymphadenopathy. Results.-Despite being directed by presenting histories to sites of prominent physical abnormalities, only 23 (25.8%) of 89 physicians evaluating a patient with Kaposi's sarcoma and 22 (22.7%) of 97 physicians evaluating a patient with oral hairy leukoplakia detected and correctly diagnosed the abnormalities. Twenty-th ree (17%) of 133 physicians detected diffuse lymphadenopathy in a patient complaining of fatigue, fever, and arthralgias. Physicians with the most experience treating patients with HIV infection more frequently identified oral hairy leukoplakia, but HIV experience did not influence identification of Kaposi's sarcoma or detection of lymphadenopathy. There were no differences between general internists and family practitioners or among physicians by year of medical school graduation in identifying the three physical findings associated with HIV infection. Conclusions.-Primary care physicians may frequently miss important physical findings related to HIV infection during patient examinations,	UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED EDUCAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					AHRQ HHS [HS-06454-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMS JE, 1993, 1ST NAT C HUM RETR W; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CALABRESE LH, 1991, ARCH INTERN MED, V151, P1157, DOI 10.1001/archinte.151.6.1157; COONEY TG, 1991, J GEN INTERN MED, V6, pS12, DOI 10.1007/BF02599252; CURTIS JR, 1995, J GEN INTERN MED, V10, P395, DOI 10.1007/BF02599841; GALLANT JE, 1995, CHEST, V107, P1018, DOI 10.1378/chest.107.4.1018; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; GREENSPAN D, 1984, LANCET, V2, P831; GREENSPAN JS, 1989, ORAL SURG ORAL MED O, V67, P396, DOI 10.1016/0030-4220(89)90381-2; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; KROWN SE, 1987, B NEW YORK ACAD MED, V63, P679; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCANCE KL, 1991, AM J PREV MED, V7, P141, DOI 10.1016/S0749-3797(18)30929-2; RAMSEY PG, 1994, FINAL REPORT AGENCY; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; Van der Vleuten CPM, 1990, TEACH LEARN MED, V2, P58, DOI DOI 10.1080/10401339009539432; WENRICH MD, IN PRESS AM J PREV M	18	92	94	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1380	1382		10.1001/jama.274.17.1380	http://dx.doi.org/10.1001/jama.274.17.1380			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563564				2022-12-01	WOS:A1995TB27800030
J	RIUNITI, O; BARBUI, T; FINAZZI, G; NEGRI, M; SUD, CMN; DEGAETANO, G; MARCHIOLI, R; TOGNONI, G; PATRONO, C; LANDOLFI, R; DITORRETTE, ON; LEONI, P; RUPOLI, S; CORTELAZZO, S; VESTRI, O; TURA, S; FINELLI, C; NOCENTINI, F; ANGELI, G; DIPASQUALE, A; KRAMER, V; MARFISI, R; OLIVIERI, M; SCIULLI, L; SPOLTORE, R; CAREGGI, P; FERRINI, PR; GROSSI, A; LONGO, G; NIGUARDA, O; DECATALDO, F; GARGANTINI, L; BAUDO, F; GERARDO, S; POGLIANI, EM; MICCOLIS, IR; BIZZI, B; ROCCA, B; TARTAGLIONE, R; MANDELLI, F; MONTEFUSCO, E; SPADEA, A; GIOVANNI, S; CAROTENUTO, M; NOBILE, M; MORELLI, R; MOLINETTE, O; RESEGOTTI, L; VASINO, MAC; BARTOLO, OS; RODEGHIERO, F; RUGGERI, M; ROSSIFERRINI, P				RIUNITI, O; BARBUI, T; FINAZZI, G; NEGRI, M; SUD, CMN; DEGAETANO, G; MARCHIOLI, R; TOGNONI, G; PATRONO, C; LANDOLFI, R; DITORRETTE, ON; LEONI, P; RUPOLI, S; CORTELAZZO, S; VESTRI, O; TURA, S; FINELLI, C; NOCENTINI, F; ANGELI, G; DIPASQUALE, A; KRAMER, V; MARFISI, R; OLIVIERI, M; SCIULLI, L; SPOLTORE, R; CAREGGI, P; FERRINI, PR; GROSSI, A; LONGO, G; NIGUARDA, O; DECATALDO, F; GARGANTINI, L; BAUDO, F; GERARDO, S; POGLIANI, EM; MICCOLIS, IR; BIZZI, B; ROCCA, B; TARTAGLIONE, R; MANDELLI, F; MONTEFUSCO, E; SPADEA, A; GIOVANNI, S; CAROTENUTO, M; NOBILE, M; MORELLI, R; MOLINETTE, O; RESEGOTTI, L; VASINO, MAC; BARTOLO, OS; RODEGHIERO, F; RUGGERI, M; ROSSIFERRINI, P			POLYCYTHEMIA-VERA - THE NATURAL-HISTORY OF 1213 PATIENTS FOLLOWED FOR 20 YEARS	ANNALS OF INTERNAL MEDICINE			English	Article						POLYCYTHEMIA VERA; THROMBOSIS; MYOCARDIAL INFARCTION; CEREBROVASCULAR DISORDERS; ASPIRIN	PORTAL-VEIN THROMBOSIS; CEREBRAL BLOOD-FLOW; MYELOPROLIFERATIVE DISORDERS; PRIMARY THROMBOCYTHEMIA; VASCULAR COMPLICATIONS; VENOUS THROMBOSIS; YOUNG-PEOPLE; RISK-FACTORS; ERYTHROMELALGIA; INVITRO	Objective: To reassess the natural history of polycythemia vera and to obtain reliable estimates of both incidence of thrombosis and survival for use in defining the sample size for therapeutic clinical trials. Study Design: Retrospective cohort study of patients with polycythemia who had been followed for 20 years. Setting: 11 Italian hematology institutions. Patients: 1213 patients with polycythemia vera, which was diagnosed according to criteria established by the Polycythemia Vera Study Group and commonly used in clinical practice. Main Outcome Measures: All-cause mortality, venous and arterial thrombosis, and hematologic and nonhematologic neoplastic disease. Myocardial infarction and stroke were classified as major thrombotic events, and venous and peripheral arterial thrombosis were considered minor thrombotic events. The number of patients who died and the number of those who had major thrombotic events (combined end point) were used as a comprehensive measure of the benefit-risk ratio associated with the use of myelosuppressive agents. Results: 634 fatal and nonfatal arterial and venous thromboses were recorded in 485 patients (41%); 36% of these episodes occurred during follow-up in 230 patients (19%), and 64% occurred either at presentation or before diagnosis. Thrombotic events occurred more frequently in the 2 years preceding diagnosis, suggesting a causal relation between the latent myeloproliferative disorder and the vascular event. The incidence of thrombosis during follow-up was 3.4%/y; older patients or those with a history of thrombosis had a higher risk for thrombosis. Overall mortality was 2.9/100 patients per year; thrombotic events and hematologic or nonhematologic cancers had similar effects on mortality. Patients receiving chemotherapy died three to four times more frequently than those not receiving chemotherapy. The increased risk for cancer in patients receiving myelosuppressive agents was seen approximately 6 years after diagnosis. In addition, the combined end point, computed as the sum of the hardest available events (death, nonfatal myocardial infarction, or stroke), suggests that myelosuppressive agents have an overall unfavorable effect. Conclusions: Cytoreduction favorably affects the incidence of thrombotic events, but aggressive treatment seems to be associated with increased risk for neoplasm. These results provide a basis for reevaluating the therapeutic strategy in patients with polycythemia vera and for estimating the size of clinical trials aimed at testing new therapeutic approaches.	CONSORZIO MARIO NEGRI SUD, CLIN PHARMACOL & EPIDEMIOL LAB, I-66030 SANTA MARIA IMBARO, ITALY; OSPED RIUNITI BERGAMO, BERGAMO, ITALY; CONSORZIO MARIO NEGRI SUD, IST RIC FARMACOL MARIO NEGRI, I-66030 SANTA MARIA IMBARO, ITALY; UNIV GABRIELE DANNUNZIO, CHIETI, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; OSPED NUOVO TORRETTE, ANCONA, ITALY; UNIV BOLOGNA, BOLOGNA, ITALY; POLICLIN CAREGGI, FLORENCE, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED SAN GERARDO, MONZA, ITALY; UNIV ROMA LA SAPIENZA, ROME, ITALY; CASA SOLLIEVO SOFFERENZA, SAN GIOVANNI ROTONDO, ITALY; OSPED MOLINETTE, TURIN, ITALY; OSPED SAN BARTOLO, VICENZA, ITALY	Consorzio Mario Negri Sud; Ospedali Riuniti di Bergamo; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Bologna; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; San Gerardo Hospital; Sapienza University Rome; IRCCS Casa Sollievo Della Sofferenza; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; ULSS 8 Berica; Ospedale San Bortolo di Vicenza			Finelli, Carlo/AAB-9686-2019; Landolfi, Raffaele/AAL-4496-2020; rocca, bianca/K-3922-2018	Finelli, Carlo/0000-0001-9372-1197; Landolfi, Raffaele/0000-0002-7913-8576; Patrono, Carlo/0000-0002-6447-2424				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1991, Lancet, V338, P1345; BARBUI T, 1983, EUR J CANCER CLIN ON, V19, P1593, DOI 10.1016/0277-5379(83)90091-3; BAROSI G, 1991, CANCER, V68, P2310, DOI 10.1002/1097-0142(19911115)68:10<2310::AID-CNCR2820681034>3.0.CO;2-2; BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CARDIN F, 1992, DIGEST DIS SCI, V37, P335, DOI 10.1007/BF01307724; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; DRENOU B, 1992, NOUV REV FR HEMATOL, V34, P399; EGLI F, 1988, SCHWEIZ MED WSCHR, V118, P1969; FROHLI P, 1983, SCHWEIZ MED WSCHR, V113, P1622; HOFFMAN R, 1991, HEMATOLOGY BASIC PRI, P834; LANDOLFI R, 1992, BLOOD, V80, P1965; MCCARTHY DM, 1985, BRIT J HAEMATOL, V59, P1, DOI 10.1111/j.1365-2141.1985.tb02956.x; MICHIELS JJ, 1993, MEDIAT INFLAMM, V2, P385, DOI 10.1155/S0962935193000547; MICHIELS JJ, 1992, AM J HEMATOL, V39, P131, DOI 10.1002/ajh.2830390211; MICHIELS JJ, 1985, ANN INTERN MED, V102, P466, DOI 10.7326/0003-4819-102-4-466; MICHIELS JJ, 1993, NEUROLOGY, V43, P1107, DOI 10.1212/WNL.43.6.1107; NAJEAN Y, 1987, BRIT J HAEMATOL, V67, P285, DOI 10.1111/j.1365-2141.1987.tb02349.x; NAJEAN Y, 1994, BRIT J HAEMATOL, V86, P233, DOI 10.1111/j.1365-2141.1994.tb03289.x; NAJEAN Y, 1983, ANN MED INTERNE, V134, P390; PAGLIUCA A, 1990, Q J MED, V76, P981; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEARCE JMS, 1983, BRIT MED J, V287, P935, DOI 10.1136/bmj.287.6397.935; PEARSON TC, 1978, LANCET, V2, P1219; Pearson TC, 1981, CLIN ASPECTS BLOOD V; PEETERMANS N, 1981, BRIT J CANCER, V44, P75; RANDI ML, 1991, J MED, V22, P213; REID CD, 1982, LANCET, V1, P14; ROZMAN C, 1991, CANCER, V67, P2658, DOI 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C; TARTAGLIA AP, 1986, SEMIN HEMATOL, V23, P172; TEOFILI L, 1992, THROMB HAEMOSTASIS, V67, P297; THOMAS DJ, 1977, LANCET, V2, P161; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; TOSSOU H, 1991, J CLIN GASTROENTEROL, V13, P597; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329; VALLA D, 1988, GASTROENTEROLOGY, V94, P1063, DOI 10.1016/0016-5085(88)90567-7; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; WEHMEIER A, 1991, ANN HEMATOL, V63, P101, DOI 10.1007/BF01707281; WESTWOOD N, 1993, EUR J HAEMATOL, V51, P228; ZANKOVICH R, 1987, MED KLIN, V82, P889	42	378	390	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					656	+		10.7326/0003-4819-123-9-199511010-00003	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574220				2022-12-01	WOS:A1995TA69600003
J	SAKSELA, K; STEVENS, CE; RUBINSTEIN, P; TAYLOR, PE; BALTIMORE, D				SAKSELA, K; STEVENS, CE; RUBINSTEIN, P; TAYLOR, PE; BALTIMORE, D			HIV-1 MESSENGER-RNA IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS AN EARLY MARKER OF RISK FOR PROGRESSION TO AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; RNA, MESSENGER; LEUKOCYTES, MONONUCLEAR; BIOLOGICAL MARKER	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 LYMPHOCYTE COUNTS; ANTIGEN CAPTURE ASSAY; NEW-YORK-CITY; HOMOSEXUAL MEN; TYPE-1 INFECTION; VIRAL BURDEN; SERUM BETA-2-MICROGLOBULIN; DISEASE PROGRESSION; PROGNOSTIC VALUE	Objective: To establish human immunodeficiency virus type 1 (HIV-1) messenger RNA (mRNA) expression in peripheral blood mononuclear cells as a marker of risk for progression to the acquired immunodeficiency syndrome (AIDS) in a large cohort of HIV-infected persons followed for a prolonged period. Design: Retrospective testing of cryopreserved, coded specimens. Setting: Research laboratories at the New York Blood Center and the Rockefeller University. Patients: 150 homosexual men infected with HIV-I who did not have an AIDS diagnosis at the time of testing. Measurements: Multiply spliced and unspliced HIV-I mRNAs in total peripheral blood mononuclear cell RNA were quantitated using reverse transcriptase-initiated polymerase chain reaction (PCR) and compared with other laboratory data and clinical outcome during the subsequent 8 years. Results: Although HIV-1 mRNA expression generally correlated with immunologic status, it was associated with future disease progression independently of CD4(+) cell counts or their rate of decrease at the time of sampling. The association of HIV-1 mRNA with disease progression in persons with CD4(+) cell counts higher than the median (>624 cells/mm(3)) was particularly noteworthy; further variation in the CD4(+) cell counts within this group was not prognostically significant. Conclusions: The expression of HIV-1 mRNA in peripheral blood mononuclear cells is a strong independent marker for future HIV disease progression, even in persons with normal T-cell subsets.	NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA; MIT, CAMBRIDGE, MA 02139 USA	New York Blood Center; Massachusetts Institute of Technology (MIT)	SAKSELA, K (corresponding author), ROCKEFELLER UNIV, BOX 285, 1230 YORK AVE, NEW YORK, NY 10021 USA.				PHS HHS [A122346] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804; ASCHER DP, 1992, J ACQ IMMUN DEF SYND, V5, P1080; ASJO B, 1986, LANCET, V2, P660; BAGNARELLI P, 1994, J VIROL, V68, P2495, DOI 10.1128/JVI.68.4.2495-2502.1994; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BRIGGS NC, 1993, AIDS RES HUM RETROV, V9, P811, DOI 10.1089/aid.1993.9.811; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; Cox DR., 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438/ANALYSIS-SURVIVAL-DATA-COX-OAKES; DAILEY PJ, 1994, 34TH INT C ANT AG CH; DETELS R, 1988, J ACQ IMMUN DEF SYND, V1, P390; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FERRE F, 1992, AIDS RES HUM RETROV, V8, P269, DOI 10.1089/aid.1992.8.269; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GUPTA P, 1993, VIROLOGY, V196, P586, DOI 10.1006/viro.1993.1514; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOBLIN BA, 1992, AM J EPIDEMIOL, V136, P646, DOI 10.1093/oxfordjournals.aje.a116544; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KRAMER A, 1990, NEW ENGL J MED, V322, P1886; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J; LU W, 1993, J INFECT DIS, V168, P1165, DOI 10.1093/infdis/168.5.1165; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MATHEZ D, 1990, P NATL ACAD SCI USA, V87, P7438, DOI 10.1073/pnas.87.19.7438; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULDER JW, 1992, J INFECT DIS, V165, P413, DOI 10.1093/infdis/165.3.413; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, 1993, AIDS, V7, P975, DOI 10.1097/00002030-199307000-00011; PHILLIPS AN, 1991, AIDS, V5, P1217, DOI 10.1097/00002030-199110000-00010; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; SABIN CA, 1994, BRIT J HAEMATOL, V86, P366, DOI 10.1111/j.1365-2141.1994.tb04741.x; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SAKSELA K, 1993, J VIROL, V67, P7423, DOI 10.1128/JVI.67.12.7423-7427.1993; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SEMPLE M, 1991, J MED VIROL, V35, P38, DOI 10.1002/jmv.1890350109; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TERSMETTE M, 1989, LANCET, V1, P983; VASUDEVACHARI MB, 1993, J CLIN IMMUNOL, V13, P185, DOI 10.1007/BF00919971; VENET A, 1991, AIDS, V5, P283, DOI 10.1097/00002030-199103000-00006; WOOD R, 1993, J ACQ IMMUN DEF SYND, V6, P237; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 1989, MMWR MORB MORTAL S7, V38, P1; 1987, MMWR MORB MORTAL S1, V36, pS1	70	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1995	123	9					641	+		10.7326/0003-4819-123-9-199511010-00001	http://dx.doi.org/10.7326/0003-4819-123-9-199511010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA696	7574218				2022-12-01	WOS:A1995TA69600001
J	SANDLER, RS; NYREN, O; EKBOM, A; EISEN, GM; YUEN, J; JOSEFSSON, S				SANDLER, RS; NYREN, O; EKBOM, A; EISEN, GM; YUEN, J; JOSEFSSON, S			THE RISK OF ESOPHAGEAL CANCER IN PATIENTS WITH ACHALASIA - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARCINOMA	Objective.-To determine more precise and accurate cancer risk estimates for achalasia that could be used to plan surveillance. Design.-Cohort. Setting.-Swedish population. Participants.--All patients with achalasia listed in the population-based Swedish Inpatient Register from 1964 through 1989. Main Outcome Measures.-The observed number of cancers in the cohort was compared with expected numbers of cancers (standardized incidence ratio [SIR]) for each 5-year age group and calendar year of observation, calculated using data from the Swedish Cancer Registry. Results.-A total of 1062 patients with achalasia accumulated 9864 years of follow-up. The mean age at entry was 57.2 years, and the mean age at cancer diagnosis was 71.0 years. Esophageal cancer occurred in 24 patients, The risk of esophageal cancer in the first year after achalasia diagnosis was extremely high (SIR, 126.3; 95% confidence interval [CI], 63.0 to 226.1) as a consequence of prevalent cancers leading to distal esophageal obstruction simulating achalasia. During years 1 to 24, the risk was increased more than 16-fold (SIR, 16.6; 95% CI, 8.8 to 28.3). Annual surveillance after the first year would require 406 endoscopic examinations in men and 2220 in women to detect one cancer. Conclusions.-Patients with achalasia are at markedly increased risk of developing esophageal cancer. A substantial number of surveillance examinations might be required to screen for cancers, especially in women. It is not known whether surveillance will result in improved survival.	UNIV N CAROLINA,CTR GASTROINTESTINAL BIOL & DIS,CHAPEL HILL,NC 27599; UPPSALA UNIV,DEPT EPIDEMIOL,UPPSALA,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	University of North Carolina; University of North Carolina Chapel Hill; Uppsala University; Harvard University; Harvard T.H. Chan School of Public Health	SANDLER, RS (corresponding author), UNIV N CAROLINA,DEPT MED,DIV DIGEST DIS & NUTR,CB 7080,423A BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Yuen, Jonathan/AAI-2035-2021	Yuen, Jonathan/0000-0003-2944-9226	NCI NIH HHS [CP85636] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07634, P30 DK34987] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007634, P30DK034987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGESTRUP S, 1992, CHEST, V102, P1013, DOI 10.1378/chest.102.4.1013; Bolivar J C, 1970, Ann Thorac Surg, V10, P81; CAMARALOPES LH, 1981, AM J DIG DIS, V6, P742; CARTER R, 1975, AM J SURG, V130, P114, DOI 10.1016/0002-9610(75)90358-X; CHUONG JJH, 1984, DIGEST DIS SCI, V29, P1105, DOI 10.1007/BF01317084; CODINI RT, 1981, PRACTICAL GASTRO NOV, P6; DENT TL, 1989, SURG CLIN N AM, V69, P1205; FAGGE CH, 1872, GUYS HOSP REP, V17, P43; FRANK MS, 1979, AM J GASTROENTEROL, V71, P206; HANKINS JR, 1975, J THORAC CARDIOV SUR, V69, P355; HEISS FW, 1984, DIGEST DIS SCI, V29, P1066, DOI 10.1007/BF01311263; JUSTVIERA JO, 1976, SURG GYNECOL OBSTET, V128, P1081; LORTATJA.JL, 1969, SURGERY, V66, P969; LUNDE AS, 1985, DHHS PHS801358 PUBL; MEIJSSEN MAC, 1992, GUT, V33, P155, DOI 10.1136/gut.33.2.155; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; PERACCHIA A, 1991, HEPATO-GASTROENTEROL, V38, P514; PIERCE WS, 1970, J THORAC CARDIOV SUR, V59, P335, DOI 10.1016/S0022-5223(19)42467-7; SELIGER G, 1972, AM J GASTROENTEROL, V57, P20; SONNENBERG A, 1993, DIGEST DIS SCI, V38, P233, DOI 10.1007/BF01307540; TUCKER HJ, 1978, ANN INTERN MED, V89, P315, DOI 10.7326/0003-4819-89-3-315; WYCHULIS AR, 1971, J AMER MED ASSOC, V215, P1638, DOI 10.1001/jama.215.10.1638; 1965, CAUSES DEATH SWEDEN; 1988, GASTROINTEST ENDOS S, V34, pS18; 1960, 1960 1988 SWED BOARD; 1991, PATIENT REGISTER INP, P20	26	114	119	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1359	1362		10.1001/jama.274.17.1359	http://dx.doi.org/10.1001/jama.274.17.1359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563560				2022-12-01	WOS:A1995TB27800026
J	SISCOVICK, DS; RAGHUNATHAN, TE; KING, I; WEINMANN, S; WICKLUND, KG; ALBRIGHT, J; BOVBJERG, V; ARBOGAST, P; SMITH, H; KUSHI, LH; COBB, LA; COPASS, MK; PSATY, BM; LEMAITRE, R; RETZLAFF, B; CHILDS, M; KNOPP, RH				SISCOVICK, DS; RAGHUNATHAN, TE; KING, I; WEINMANN, S; WICKLUND, KG; ALBRIGHT, J; BOVBJERG, V; ARBOGAST, P; SMITH, H; KUSHI, LH; COBB, LA; COPASS, MK; PSATY, BM; LEMAITRE, R; RETZLAFF, B; CHILDS, M; KNOPP, RH			DIETARY-INTAKE AND CELL-MEMBRANE LEVELS OF LONG-CHAIN N-3 POLYUNSATURATED FATTY-ACIDS AND THE RISK OF PRIMARY CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR-FIBRILLATION THRESHOLD; CORONARY HEART-DISEASE; FISH CONSUMPTION; MARMOSET MONKEY; MODULATION; MORTALITY	Objective.-To assess whether the dietary intake of long-chain n-3 polyunsaturated fatty acids from seafood, assessed both directly and indirectly through a biomarker, is associated with a reduced risk of primary cardiac arrest. Design.-Population-based case-control study. Setting.-Seattle and suburban King County, Washington, Participants.-A total of 334 case patients with primary cardiac arrest, aged 25 to 74 years, attended by paramedics during 1988 to 1994 and 493 population-based control cases and controls, matched for age and sex, randomly identified from the community. All cases and controls were free of prior clinical heart disease, major comorbidity, and use of fish oil supplements. Measures of Exposure.-Spouses of case patients and control subjects were interviewed to quantify dietary n-3 polyunsaturated fatty acid intake from seafood during the prior month and other clinical characteristics. Blood specimens from 82 cases (collected in the field) and 108 controls were analyzed to determine red blood cell membrane fatty acid composition, a biomarker of dietary n-3 polyunsaturated fatty acid intake. Results.-Compared with no dietary intake of eicosapentaenoic acid (C-20:5n-3) and docosahexaenoic acid (C-22:6n-3), an intake of 5.5 g of n-3 fatty acids per month (the mean of the third quartile and the equivalent of one fatty fish meal per week) was associated with a 50% reduction in the risk of primary cardiac arrest (odds ratio [OR], 0.5; 95% confidence interval [CI], 0.4 to 0.8), after adjustment for potential confounding factors. Compared with a red blood cell membrane n-3 polyunsaturated fatty acid level of 3.3% of total fatty acids (the mean of the lowest quartile), a red blood cell n-3 polyunsaturated fatty acid level of 5.0% of total fatty acids (the mean of the third quartile) was associated with a 70% reduction in the risk of primary cardiac arrest (OR, 0.3; 95% CI, 0.2 to 0.6). Conclusion.-Dietary intake of n-3 polyunsaturated fatty acids from seafood is associated with a reduced risk of primary cardiac arrest.	WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA 98101; WASHINGTON UNIV,DEPT BIOSTAT,SEATTLE,WA 98101; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	Fred Hutchinson Cancer Center; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	SISCOVICK, DS (corresponding author), WASHINGTON UNIV,DEPT MED,CARDIOVASC HLTH RES UNIT,METROPOLITAN PK 2 BLDG,SUITE 1360,SEATTLE,WA 98101, USA.			Kushi, Lawrence/0000-0001-9136-1175	NHLBI NIH HHS [HL41993] Funding Source: Medline; NIDDK NIH HHS [DK-35816] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; BURR ML, 1989, LANCET, V9, P757; CHARNOCK JS, 1992, COMP BIOCHEM PHYS A, V101, P387, DOI 10.1016/0300-9629(92)90551-Z; CHARNOCK JS, 1994, NUTRITION, V10, P161; CUMMINGS KM, 1979, PUBLIC OPIN QUART, V43, P233, DOI 10.1086/268514; CURB JD, 1985, NEW ENGL J MED, V313, P821; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOWDY A, 1993, J AM DIET ASSOC, V93, pA65; FARQUHAR JW, 1963, J CLIN INVEST, V42, P675, DOI 10.1172/JCI104759; GLOMSET JA, 1985, NEW ENGL J MED, V312, P1253, DOI 10.1056/NEJM198505093121909; HALLAQ H, 1992, P NATL ACAD SCI USA, V89, P1760, DOI 10.1073/pnas.89.5.1760; KANG JX, 1994, P NATL ACAD SCI USA, V91, P9886, DOI 10.1073/pnas.91.21.9886; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LEPAGE G, 1986, J LIPID RES, V27, P114; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MCLENNAN PL, 1993, AM J CLIN NUTR, V58, P666, DOI 10.1093/ajcn/58.5.666; MCLENNAN PL, 1989, AUST NZ J MED, V19, P1, DOI 10.1111/j.1445-5994.1989.tb01662.x; Nomenclature and criteria for diagnosis of ischemic heart disease, 1979, CIRCULATION, V59, P607; NORDOY A, 1971, ACTA MED SCAND, V190, P27; NORDOY A, 1987, BIBL NUTR DIET, V40, P33; PEPE S, 1994, P NATL ACAD SCI USA, V91, P8832, DOI 10.1073/pnas.91.19.8832; ROSE HG, 1965, J LIPID RES, V6, P428; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; 1991, USDA NUTRITION MONIT, V815	30	728	777	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1363	1367		10.1001/jama.274.17.1363	http://dx.doi.org/10.1001/jama.274.17.1363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563561				2022-12-01	WOS:A1995TB27800027
J	SLOAND, EM; PITT, E; KLEIN, HG				SLOAND, EM; PITT, E; KLEIN, HG			SAFETY OF THE BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; T-CELL LEUKEMIA; HTLV-II INFECTION; NON-B HEPATITIS; TRANSFUSION-ASSOCIATED HEPATITIS; POLYMERASE CHAIN-REACTION; INTRAVENOUS-DRUG-USERS; LYMPHOTROPIC VIRUS; TRYPANOSOMA-CRUZI		NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	SLOAND, EM (corresponding author), NHLBI, 31 CTR DR, MSC 2490, BLDG 31, ROOM 4A11, BETHESDA, MD 20892 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ADLER SP, 1989, TRANSFUSION, V29, P667, DOI 10.1046/j.1537-2995.1989.29890020436.x; ALI AM, 1987, BLOOD S, V70, pA325; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1966, BLOOD-J HEMATOL, V27, P297, DOI 10.1182/blood.V27.3.297.297; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; Alter HJ, 1987, TRANSFUSION TRANSMIT, P53; [Anonymous], 1995, JAMA, V274, P1374; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; APPLEMAN MD, 1993, TRANSFUSION, V33, P61, DOI 10.1046/j.1537-2995.1993.33193142312.x; BACKER U, 1988, 4TH P INT C AIDS STO, V2, P364; BARRETT BB, 1993, TRANSFUSION, V33, P228, DOI 10.1046/j.1537-2995.1993.33393174449.x; BLOCH M, 1982, REV I INVEST MED, V11, P148; BOWDEN R, 1990, TRANSFUSION, V30, P762, DOI 10.1046/j.1537-2995.1990.30891020340.x; BOWDEN RA, 1992, BLOOD SAFETY CURRENT, P201; BRAINE HG, 1986, TRANSFUSION, V26, P391, DOI 10.1046/j.1537-2995.1986.26486262752.x; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUCHHOLZ DH, 1992, TRANSFUSION, V32, P667, DOI 10.1046/j.1537-2995.1992.32792391043.x; BUCHHOLZ DH, 1971, NEW ENGL J MED, V285, P429, DOI 10.1056/NEJM197108192850803; BUSCH M, 1994, SEP FOOD DRUG ADM C; BUSCH MP, 1990, NEW ENGL J MED, V323, P1308, DOI 10.1056/NEJM199011083231904; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CARVALHO MR, 1993, TRANSFUSION, V33, P830, DOI 10.1046/j.1537-2995.1993.331094054620.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DESCHRYVER A, 1990, TRANSFUSION, V30, P844; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1988, INFECT CONT HOSP EP, V9, P357; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1990, TRANSFUSION, V30, P851, DOI 10.1046/j.1537-2995.1990.30991048798.x; ESTEBAN JI, 1985, LANCET, V2, P1083; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FEIGAL E, 1991, J INFECT DIS, V164, P36, DOI 10.1093/infdis/164.1.36; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; GRANT IH, 1989, ANN INTERN MED, V111, P849, DOI 10.7326/0003-4819-111-10-849; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; HORSBURGH CR, 1989, LANCET, V2, P637; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KERNDT PR, 1991, TRANSFUSION, V31, P814, DOI 10.1046/j.1537-2995.1991.31992094668.x; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIM DM, 1992, TRANSFUSION, V32, P221, DOI 10.1046/j.1537-2995.1992.32392213804.x; KLEINMAN S, 1991, Transfusion (Bethesda), V31, p41S; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KRECH U, 1973, B WORLD HEALTH ORGAN, V49, P103; LANDER JJ, 1978, VOX SANG, V34, P77, DOI 10.1111/j.1423-0410.1978.tb03726.x; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEFRERE JJ, 1990, LANCET, V335, P1400, DOI 10.1016/0140-6736(90)91277-H; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; LOIACONO BR, 1989, TRANSFUSION, V29, P823, DOI 10.1046/j.1537-2995.1989.29990070189.x; MACKINNON S, 1988, J CLIN PATHOL, V41, P948, DOI 10.1136/jcp.41.9.948; MANEZ R, 1993, TRANSFUSION, V33, P594, DOI 10.1046/j.1537-2995.1993.33793325057.x; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MAURICE J, 1987, TROPICAL DISEASE RES, P89; MORDUCHOWICZ G, 1991, REV INFECT DIS, V13, P307; MORROW JF, 1991, JAMA-J AM MED ASSOC, V266, P555; MURPHY EL, 1993, LANCET, V341, P757, DOI 10.1016/0140-6736(93)90529-P; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NICKERSON P, 1989, ANN INTERN MED, V111, P851, DOI 10.7326/0003-4819-111-10-851; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PINDYCK J, 1985, TRANSFUSION, V25, P3, DOI 10.1046/j.1537-2995.1985.25185116497.x; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROY MJ, 1993, JAMA-J AM MED ASSOC, V269, P2876, DOI 10.1001/jama.269.22.2876; SARIN PS, 1989, P NATL ACAD SCI USA, V86, P2021, DOI 10.1073/pnas.86.6.2021; SAYERS MH, 1992, ANN INTERN MED, V116, P55, DOI 10.7326/0003-4819-116-1-55; SCHMIDT PJ, 1994, ARCH PATHOL LAB MED, V118, P454; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; SCHOECHETMAN G, 1994, SEP FOOD DRUG ADM C; Selbie FR, 1943, BRIT J EXP PATHOL, V24, P150; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SHIH LN, 1990, J MED VIROL, V32, P257, DOI 10.1002/jmv.1890320412; SILVER H, 1970, Transfusion (Bethesda), V10, P315; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; SULLIVAN MT, 1991, ARCH INTERN MED, V151, P2043, DOI 10.1001/archinte.151.10.2043; TAYLOR PE, 1990, TRANSFUSION, V30, P783, DOI 10.1046/j.1537-2995.1990.30991048782.x; THIERS V, 1988, LANCET, V2, P1273; THOMPSON KS, 1992, TRANSFUSION, V32, pS65; TIPPLE MA, 1990, TRANSFUSION, V30, P207, DOI 10.1046/j.1537-2995.1990.30390194338.x; VISCIDI RP, 1991, J ACQ IMMUN DEF SYND, V4, P1190; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WIKTOR SZ, 1991, LANCET, V338, P512, DOI 10.1016/0140-6736(91)90585-D; WRENN HE, 1974, TRANSFUSION, V14, P171, DOI 10.1111/j.1537-2995.1974.tb04512.x; ZIERDT CH, 1983, J CLIN MICROBIOL, V17, P628, DOI 10.1128/JCM.17.4.628-630.1983; 1993, ATTITUDES US ADULTS; 1991, MMWR-MORBID MORTAL W, V40, P176; 1991, TRANSFUSION S8S, V31, pS41	107	69	73	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1368	1373		10.1001/jama.274.17.1368	http://dx.doi.org/10.1001/jama.274.17.1368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563562				2022-12-01	WOS:A1995TB27800028
J	ANDERSON, HV				ANDERSON, HV			INTRAVENOUS THROMBOLYSIS IN REFRACTORY UNSTABLE ANGINA-PECTORIS	LANCET			English	Editorial Material							TRIAL; PLACEBO		HERMANN HOSP,HOUSTON,TX		ANDERSON, HV (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225, USA.							ANDERSON HV, IN PRESS J AM COLL C; BAR FW, 1992, CIRCULATION, V86, P131, DOI 10.1161/01.CIR.86.1.131; DUVVURI S, 1994, J MYOCARD ISCHEMIA, V6, P11; FREEMAN MR, 1992, CIRCULATION, V85, P150, DOI 10.1161/01.CIR.85.1.150; GRAVES EJ, 1993, NATIONAL CTR HLTH 13, V114; GURKFINKEL E, 1995, J AM COLL CARDIOL, pA420; ROMEO F, 1995, J AM COLL CARDIOL, V25, P1295, DOI 10.1016/0735-1097(95)00002-L; SCHREIBER TL, 1992, CIRCULATION, V86, P1407, DOI 10.1161/01.CIR.86.5.1407; Theroux P, 1993, Curr Probl Cardiol, V18, P157	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1113	1114						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475596				2022-12-01	WOS:A1995TB54900003
J	BLOCH, S; KISSANE, DW				BLOCH, S; KISSANE, DW			PSYCHOSOCIAL CARE AND BREAST-CANCER	LANCET			English	Editorial Material							TRIAL		MONASH UNIV,DEPT PSYCHOL MED,CLAYTON,VIC 3168,AUSTRALIA	Monash University	BLOCH, S (corresponding author), UNIV MELBOURNE,DEPT PSYCHIAT,MELBOURNE,VIC,AUSTRALIA.			Kissane, David/0000-0002-5930-4573				ANDERSEN BL, 1992, J CONSULT CLIN PSYCH, V60, P552, DOI 10.1037/0022-006X.60.4.552; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; GREER S, 1990, LANCET, V335, P49, DOI 10.1016/0140-6736(90)90173-3; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Moorey S., 1989, PSYCHOL THERAPY PATI; MULDER CL, 1992, PSYCHO-ONCOLOGY, V1, P155; PRESBERG BA, 1993, PSYCHO-ONCOLOGY, V2, P215; SPIEGEL D, 1989, LANCET, V1, P888; TRIJSBURG RW, 1992, PSYCHOSOM MED, V54, P489, DOI 10.1097/00006842-199207000-00011; 1995, CLIN PRACTICE GUIDEL; 1994, MED J AUST S, V161	12	17	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1114	1115		10.1016/S0140-6736(95)91794-2	http://dx.doi.org/10.1016/S0140-6736(95)91794-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475597				2022-12-01	WOS:A1995TB54900004
J	CANDINAS, D; GUNSON, BK; NIGHTINGALE, P; HUBSCHER, S; MCMASTER, P; NEUBERGER, JM				CANDINAS, D; GUNSON, BK; NIGHTINGALE, P; HUBSCHER, S; MCMASTER, P; NEUBERGER, JM			SEX MISMATCH AS A RISK FACTOR FOR CHRONIC REJECTION OF LIVER ALLOGRAFTS	LANCET			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; VANISHING-BILEDUCT SYNDROME; DUCT SYNDROME; TRANSPLANTATION; GRAFT; IMMUNOSUPPRESSION; INFECTION	Chronic irreversible rejection is a major cause of graft loss and retransplantation after orthotopic liver allotransplantation. To identify risk factors we retrospectively analysed 423 adult consecutive primary liver allograft recipients. The endpoint of the study was graft failure due to chronic rejection leading either to retransplantation or death. Chronic rejection developed in 22 (5.2%) patients. Pretransplant diagnosis of primary biliary cirrhosis or autoimmune hepatitis, recipient age less than 30 years, 1 or more episodes of acute cellular rejection, and transplantation of an organ from cytomegalovirus (CMV). IgG positive donor to an IgG negative recipient were identified as risk factors for chronic rejection. Transplantation of a liver from a male donor into a female recipient was also associated with an increased probability of chronic rejection. By logistic regression analysis, the probability of chronic rejection was predicted by: sex and cytomegalovirus match of donor and recipient, the presence of acute rejection, recipient age, transplantation for autoimmune hepatitis or primary biliary cirrhosis, and recipients receiving no azathioprine during the third month after transplantation. Sensitisation to antigens expressed by bile-duct epithelium as in primary biliary cirrhosis or exposure to donor bile-duct minor histocompatibility antigens, such as the male sex related H-Y antigen, may provide an explanation, More selective allocation of donor organs may allow a reduction in the incidence of ductopaenic rejection and graft loss.	QUEEN ELIZABETH HOSP,LIVER & HEPATOBILIARY UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,WOLFSON COMP LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PATHOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham			Neuberger, James/ABG-3010-2020	Gunson, Bridget/0000-0001-6149-9915				ADAMS DH, 1990, J HEPATOL, V10, P113, DOI 10.1016/0168-8278(90)90081-2; BACKMAN L, 1993, TRANSPLANTATION, V55, P1078; BASADONNA GP, 1995, TRANSPLANTATION, V55, P993; BISMUTH A, 1991, REV FR TRANSFUS HEM, V34, P449, DOI 10.1016/S1140-4639(05)80139-X; BLATTS KP, 1988, TRANSPLANTATION, V45, P376; DEMETRIS AJ, 1988, HEPATOLOGY, V8, P939, DOI 10.1002/hep.1840080439; DEVLIN JJ, 1993, TRANSPLANTATION, V56, P1381, DOI 10.1097/00007890-199312000-00020; DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1002/hep.1840170611; DONALDSON PT, 1987, LANCET, V1, P945; DOUSSET B, 1993, TRANSPLANTATION, V55, P529, DOI 10.1097/00007890-199303000-00014; GNANT MFX, 1991, TRANSPLANT P, V23, P1434; GOULMY E, 1991, BONE MARROW TRANSPL, V7, P49; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; GUBERNATIS G, 1988, TRANSPLANT INT, V1, P155, DOI 10.1007/BF00348839; HUBSCHER S, 1993, IMMUNOLOGY LIVER TRA, P216; LESOURD BM, 1994, IMMUNOL LETT, V40, P235, DOI 10.1016/0165-2478(94)00062-X; MANEZ R, 1993, TRANSPLANTATION, V55, P1067, DOI 10.1097/00007890-199305000-00024; MCMASTER P, 1994, TRANSPL INT S1, V7, P32; OGRADY JG, 1988, LANCET, V2, P302; PADBURY RTA, 1993, TRANSPLANTATION, V55, P789, DOI 10.1097/00007890-199304000-00020; PAYA CV, 1992, HEPATOLOGY, V16, P66, DOI 10.1002/hep.1840160113; SIMPSON E, 1991, IMMUNOL LETT, V29, P9, DOI 10.1016/0165-2478(91)90192-D; SOIN AS, 1995, TRANSPLANT P, V27, P1129; VANHOEK B, 1991, TRANSPLANT P, V23, P1403; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WIESNER RH, 1991, HEPATOLOGY, V14, P721, DOI 10.1016/0270-9139(91)90064-3	26	111	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1117	1121		10.1016/S0140-6736(95)91797-7	http://dx.doi.org/10.1016/S0140-6736(95)91797-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475600				2022-12-01	WOS:A1995TB54900007
J	EASTWOOD, M				EASTWOOD, M			THE DILEMMA OF LAXATIVE ABUSE	LANCET			English	Editorial Material											EASTWOOD, M (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							MORTON J, 1987, ANN CLIN BIOCHEM, V24, P107, DOI 10.1177/000456328702400116; NEIMS DM, 1995, INT J EAT DISORDER, V17, P211, DOI 10.1002/1098-108X(199504)17:3<211::AID-EAT2260170302>3.0.CO;2-I; PHILLIPS S, 1995, ANN INTERN MED, V123, P97, DOI 10.7326/0003-4819-123-2-199507150-00003; READ NW, 1980, GASTROENTEROLOGY, V78, P264; WELTZIN TE, 1995, INT J EAT DISORDER, V17, P141, DOI 10.1002/1098-108X(199503)17:2<141::AID-EAT2260170206>3.0.CO;2-5	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1115	1115		10.1016/S0140-6736(95)91795-0	http://dx.doi.org/10.1016/S0140-6736(95)91795-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475598				2022-12-01	WOS:A1995TB54900005
J	GORE, SM; BIRD, AG; ROSS, AJ				GORE, SM; BIRD, AG; ROSS, AJ			PRISON RITES - STARTING TO INJECT INSIDE	BRITISH MEDICAL JOURNAL			English	Article									CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND; BIAS,MRC,CTR HIV RES,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND	University of Oxford; University of Edinburgh	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1995, IN PRESS AIDS; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; STRANG J, 1989, BRIT MED J, V298, P1310, DOI 10.1136/bmj.298.6683.1310; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289	5	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 28	1995	311	7013					1135	1136		10.1136/bmj.311.7013.1135	http://dx.doi.org/10.1136/bmj.311.7013.1135			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580709	Green Published			2022-12-01	WOS:A1995TC46600018
J	HARDING, SP; BROADBENT, DM; NEOH, C; WHITE, MC; VORA, J				HARDING, SP; BROADBENT, DM; NEOH, C; WHITE, MC; VORA, J			SENSITIVITY AND SPECIFICITY OF PHOTOGRAPHY AND DIRECT OPHTHALMOSCOPY IN SCREENING FOR SIGHT THREATENING EYE DISEASE - THE LIVERPOOL DIABETIC EYE STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYDRIATIC RETINAL PHOTOGRAPHY; PRIMARY CARE PHYSICIANS; FUNDUS PHOTOGRAPHY; RETINOPATHY; PREVENTION; BLINDNESS; DIAGNOSIS; CAMERA	Objective-To evaluate different methods for community based screening for sight threatening diabetic eye disease. Design-Prospective study. Setting-Mobile screening unit visiting inner city community clinics; hospital assessment clinic (tertiary centre). Subjects Subjects-395 diabetic patients registered with four general practices in an inner city location. Interventions-Community based photography with mydriasis and direct ophthalmoscopy through dilated pupils by an experienced ophthalmologist, both compared with reference standard of slit lamp biomicroscopy by a consultant specialist in medical retinal disease. Main outcome measures-Sensitivity and specificity of screening method and prevalence of sight threatening diabetic eye disease (moderate preproliferative retinopathy, circinate maculopathy, exudate within 1 disc diameter of fixation, other diabetes related eye disease). Results-358 subjects underwent photography, 326 attended hospital clinic for ophthalmoscopy, and six were ungradable on photographs and biomicroscopy, leaving 320 for analysis. Of these 295 (91%) attended clinic within four months of photography. Sensitivity of detection of eye disease by photography was 89% (95% confidence interval 80% to 98%), significantly better than for direct ophthalmoscopy (65% (51% to 79%)). Analysis of patients with false negative results indicated possible improvement of photographic sensitivity to 93% by addition of stereoscopic macular pair photographs. Specificity of detection of sight threatening eye disease was 86% (82% to 90%) for photography and 97% (95% to 99%) for direct ophthalmoscopy. Conclusions-Since high sensitivity is essential for an effective screening programme, a photographic method should be considered as preferred option in national, community based screening programmes. Even in the hands of an experienced ophthalmologist, direct ophthalmoscopy is limited by weaknesses inherent to the instrument.	ROYAL LIVERPOOL UNIV HOSP, DEPT ENDOCRINOL & DIABET, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	HARDING, SP (corresponding author), ROYAL LIVERPOOL UNIV HOSP, ST PAULS EYE UNIT, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND.			Harding, Simon/0000-0003-4676-1158				ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; [Anonymous], 1987, Int Ophthalmol Clin, V27, P265; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; AWH CC, 1993, INVEST OPHTH VIS SCI, V34, P713; BURNSCOX CJ, 1985, BMJ-BRIT MED J, V290, P1052, DOI 10.1136/bmj.290.6474.1052; BUXTON MJ, 1991, DIABETIC MED, V8, P371, DOI 10.1111/j.1464-5491.1991.tb01612.x; DCCT Res Grp, 1987, ARCH OPHTHALMOL-CHIC, V105, P1344; ELLINGFORD A, 1992, Journal of Audiovisual Media in Medicine, V15, P104, DOI 10.3109/17453059209018361; FINLAY R, 1991, HLTH TRENDS, V23, P104; FORREST RD, 1987, DIABETES RES CLIN EX, V5, P39; Foulds W S, 1983, Health Bull (Edinb), V41, P318; GEHRS KM, 1993, INVEST OPHTH VIS SCI, V34, P1182; JACOB J, 1995, DIABETIC MED, V12, P419, DOI 10.1111/j.1464-5491.1995.tb00506.x; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; JONES D, 1988, BRIT MED J, V296, P1029, DOI 10.1136/bmj.296.6628.1029; KINYOUN JL, 1992, INVEST OPHTH VIS SCI, V33, P1888; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; Kleinstein R N, 1987, J Am Optom Assoc, V58, P879; KOHNER EM, 1984, DIABETOLOGIA, V26, P173; KOHNER EM, 1991, BRIT MED J, V302, P176, DOI 10.1136/bmj.302.6769.176; LEE CM, 1991, OPHTHALMOLOGY, V98, P1594; LEESE GP, 1993, BRIT MED J, V306, P187, DOI 10.1136/bmj.306.6871.187; MOHAN R, 1988, BRIT J OPHTHALMOL, V72, P841, DOI 10.1136/bjo.72.11.841; MOSS SE, 1985, OPHTHALMOLOGY, V92, P62; ROGERS D, 1990, DIABETIC MED, V7, P165, DOI 10.1111/j.1464-5491.1990.tb01353.x; ROHAN TE, 1989, BMJ-BRIT MED J, V299, P1198, DOI 10.1136/bmj.299.6709.1198; RYDER REJ, 1985, BRIT MED J, V291, P1256, DOI 10.1136/bmj.291.6504.1256; RYDER REJ, 1985, PRACTICAL DIABETES, V2, P34; RYDER REJ, 1995, BRIT MED J, V311, P207; SAVOLAINEN EA, 1982, DIABETOLOGIA, V23, P138, DOI 10.1007/BF01271176; SCHACHAT AP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1064, DOI 10.1001/archopht.1993.01090080060019; SPARROW JM, 1993, EYE, V7, P158, DOI 10.1038/eye.1993.34; SUSSMAN EJ, 1982, JAMA-J AM MED ASSOC, V247, P3231, DOI 10.1001/jama.247.23.3231; TAYLOR R, 1990, BRIT MED J, V301, P1243, DOI 10.1136/bmj.301.6763.1243; WAREHAM N, 1991, DIABETIC MED, V8, P607, DOI 10.1111/j.1464-5491.1991.tb01665.x; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; WILLIAMS R, 1986, BRIT MED J, V293, P1140, DOI 10.1136/bmj.293.6555.1140; 1991, BRIT MED J, V302, P174; 1991, DIABETIC MED, V8, P263; 1988, CAUSES BLINDNESS PAR	41	197	202	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	1995	311	7013					1131	1135		10.1136/bmj.311.7013.1131	http://dx.doi.org/10.1136/bmj.311.7013.1131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC466	7580708	Green Published			2022-12-01	WOS:A1995TC46600017
J	HIETALA, J; SYVALAHTI, E; VUORIO, K; RAKKOLAINEN, V; BERGMAN, J; HAAPARANTA, M; SOLIN, O; KUOPPAMAKI, M; KIRVELA, O; RUOTSALAINEN, U; SALOKANGAS, RKR				HIETALA, J; SYVALAHTI, E; VUORIO, K; RAKKOLAINEN, V; BERGMAN, J; HAAPARANTA, M; SOLIN, O; KUOPPAMAKI, M; KIRVELA, O; RUOTSALAINEN, U; SALOKANGAS, RKR			PRESYNAPTIC DOPAMINE FUNCTION IN STRIATUM OF NEUROLEPTIC-NAIVE SCHIZOPHRENIC-PATIENTS	LANCET			English	Note							POSITRON EMISSION TOMOGRAPHY; ABNORMALITIES; RECEPTORS	Presynaptic dopamine function (6-[F-18]-fluorodopa uptake) in the brains of seven neuroleptic-naive first-admission schizophrenic patients and eight healthy controls was studied with positron emission tomography. The fluorodopa influx constant (K-i) in putamen was higher in the patients than in controls (average mean: 0.0149 vs 0.0129, p=0.034). The changes in caudate were smaller but significantly lateralised to the left caudate. There was one catatonic schizophrenic patient in our sample. This patient had lower striatal K-i than any control. Alterations in striatal presynaptic dopamine function may constitute a part of disrupted neural circuits that predispose to schizophrenic psychosis.	TURKU MED CYCLOTRON PET PROJECT,TURKU,FINLAND; TURKU CITY PSYCHIAT HOSP,TURKU,FINLAND; ABO AKAD UNIV,ACCELERATOR LAB,TURKU,FINLAND; TURKU UNIV HOSP,DEPT ANAESTHESIOL,SF-20520 TURKU,FINLAND; TURKU UNIV HOSP,DEPT PSYCHIAT,SF-20520 TURKU,FINLAND	Abo Akademi University; University of Turku; University of Turku	HIETALA, J (corresponding author), UNIV TURKU,DEPT PHARMACOL,KIINAMYLLYNKATU 10,SF-20520 TURKU,FINLAND.		Ruotsalainen, Ulla/J-5678-2014	Ruotsalainen, Ulla/0000-0001-7775-3412				Bergman J., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P476; BILDER RM, 1994, AM J PSYCHIAT, V151, P1437; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; HIETALA J, 1994, ARCH GEN PSYCHIAT, V51, P116; PELLIZARI A, 1989, J COMPUT ASSIST TOMO, V13, P20; PILOWSKY LS, 1994, BRIT J PSYCHIAT, V164, P16, DOI 10.1192/bjp.164.1.16; REITH J, 1994, P NATL ACAD SCI USA, V91, P11651, DOI 10.1073/pnas.91.24.11651; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495	10	261	265	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1130	1131		10.1016/S0140-6736(95)91801-9	http://dx.doi.org/10.1016/S0140-6736(95)91801-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB549	7475604				2022-12-01	WOS:A1995TB54900011
J	JUNGERS, P; HOUILLIER, P; FORGET, D; LABRUNIE, M; SKHIRI, H; GIATRAS, I; DESCAMPSLATSCHA, B				JUNGERS, P; HOUILLIER, P; FORGET, D; LABRUNIE, M; SKHIRI, H; GIATRAS, I; DESCAMPSLATSCHA, B			INFLUENCE OF PREGNANCY ON THE COURSE OF PRIMARY CHRONIC GLOMERULONEPHRITIS	LANCET			English	Article							GLOMERULAR-DISEASE; RENAL-DISEASE; WOMEN	According to some nephrologists, pregnancy has damaging effects on renal function in primary glomerulonephritis, but the evidence is conflicting. We evaluated the effect of pregnancy on the occurrence of end-stage renal failure (ESRF) in 360 patients with various histological forms of primary glomerulonephritis but with normal renal function (serum creatinine less than or equal to 0.11 mmol/L) at presentation. In actuarial analyses, overall ESRF-free survival did not significantly differ between women who became pregnant after clinical onset of renal disease (n=171) and those who did not conceive (n=189). Furthermore, in a case-control study pregnancy did not emerge as a risk factor for progression to ESRF (odds ratio 1.15 [95% CI 0.61-2.18]), whereas the type of glomerulonephritis and hypertension were major determinants. We conclude that pregnancy does not affect the course of renal disease in patients who have normal renal function al conception.	HOP NECKER ENFANTS MALAD,INSERM,U25,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	JUNGERS, P (corresponding author), HOP NECKER ENFANTS MALAD,DEPT NEPHROL,149 RUE SEVRES,F-75015 PARIS,FRANCE.		Houillier, Pascal/AAD-4903-2019	Houillier, Pascal/0000-0003-4953-6917				ABE S, 1985, AM J OBSTET GYNECOL, V153, P508, DOI 10.1016/0002-9378(85)90463-6; ABE S, 1994, CLIN NEPHROL, V41, P61; BARCELO P, 1986, KIDNEY INT, V30, P914, DOI 10.1038/ki.1986.272; HOU SH, 1985, AM J MED, V78, P185, DOI 10.1016/0002-9343(85)90425-5; IMBASCIATI E, 1986, AM J NEPHROL, V6, P193, DOI 10.1159/000167114; Jungers P, 1986, Adv Nephrol Necker Hosp, V15, P103; KATZ AI, 1980, KIDNEY INT, V18, P192, DOI 10.1038/ki.1980.128; PACKHAM DK, 1989, Q J MED, V266, P537; SURIAN M, 1984, NEPHRON, V36, P101, DOI 10.1159/000183126; 1989, LANCET, V2, P253	10	64	69	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1122	1124		10.1016/S0140-6736(95)91798-5	http://dx.doi.org/10.1016/S0140-6736(95)91798-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475601				2022-12-01	WOS:A1995TB54900008
J	LEVY, D				LEVY, D			HAVE EXPERT PANEL GUIDELINES KEPT PACE WITH NEW CONCEPTS IN HYPERTENSION	LANCET			English	Editorial Material							RISK				LEVY, D (corresponding author), NHLBI, BLDG 10, BETHESDA, MD 20892 USA.							ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; BLACK HR, 1994, HYPERTENSION, V23, P275; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; JACKSON R, BRIT MED J, V307, P107; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; OPARIL S, 1993, NEW ENGL J MED, V328, P959, DOI 10.1056/NEJM199304013281311; SAGIE A, 1993, NEW ENGL J MED, V329, P1912, DOI 10.1056/NEJM199312233292602; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312; ZANCHETTI A, 1993, J HYPERTENS, V11, P905	16	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1112	1113		10.1016/S0140-6736(95)91792-6	http://dx.doi.org/10.1016/S0140-6736(95)91792-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475595				2022-12-01	WOS:A1995TB54900002
J	REES, DC; COX, M; CLEGG, JB				REES, DC; COX, M; CLEGG, JB			WORLD DISTRIBUTION OF FACTOR-V LEIDEN	LANCET			English	Note							POOR ANTICOAGULANT RESPONSE; ACTIVATED PROTEIN-C; THROMBOPHILIA; EPIDEMIOLOGY; THROMBOSIS	We have analysed 3380 chromosomes (1690 unrelated individuals) from twenty-four populations for the presence of factor V Leiden, an important risk factor in venous thromboembolism, The allele frequency in 618 Europeans was 4.4%, with the highest prevalence among Greeks (7%). It was 0.6% in Asia Minor. Factor V Leiden was not found in any of 1600 chromosomes from Africa, Southeast Asia, Australasia, and the Americas. This distribution may partly explain the rarity of thromboembolic disease in these populations, The high prevalence in Europeans suggests that screening for this mutation should be considered in some circumstances.			REES, DC (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Rees, David/B-6789-2011	Rees, David/0000-0003-3647-1050				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BURKITT DP, 1972, BMJ-BRIT MED J, V2, P556, DOI 10.1136/bmj.2.5813.556; COOPER DN, 1994, BAILLIERE CLIN HAEM, V7, P637, DOI 10.1016/S0950-3536(05)80102-7; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FLINT J, 1993, HUM GENET, V91, P91; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504	10	1065	1089	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1133	1134		10.1016/S0140-6736(95)91803-5	http://dx.doi.org/10.1016/S0140-6736(95)91803-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475606				2022-12-01	WOS:A1995TB54900013
J	VANITERSON, M; VANDERWAART, FJM; ERDMANN, W; TROUWBORST, A				VANITERSON, M; VANDERWAART, FJM; ERDMANN, W; TROUWBORST, A			SYSTEMIC HEMODYNAMICS AND OXYGENATION DURING HEMODILUTION IN CHILDREN	LANCET			English	Article							HEMODILUTION ANESTHESIA; BLOOD-TRANSFUSION; JEHOVAH WITNESSES; SURGERY; RESECTION	Transfusion of homologous blood should be avoided when possible, and one technique that diminishes perioperative requirement for donor blood is haemodilution. In children its effects on systemic haemodynamics and systemic oxygenation have not been reported. Six children aged 4-12 yr were anaesthetised for major surgery and blood was withdrawn to reduce packed cell volume to 25%. Cardiac index increased from 3.1 (SD 0.5) L min(-1) m(-2) at baseline to 4.4 (0.5) L min(-1) m(-2) at the end of surgery, when packed cell volume was 16 (1)%; this change, compensating for the decline in oxygen carrying capacity, was associated with a fall in systemic vascular resistance and a rise in stroke volume. Oxygen extraction from haemoglobin rose from 0.22 (0.05) to 0.33 (0.06). Perioperative blood loss was 40% of circulating blood volume; however, owing to reinfusion of autologous blood (and use of a cell saver in three patients), the haemoglobin one day after operation was only 19% lower than preoperatively (9.9 [1.5] vs 12.5 [2.5] g/dL). In this study, children seemed at least as able as adults to compensate for the effects of haemodilution, which allowed major surgery without transfusion of homologous blood.	UNIV AMSTERDAM, ACAD MED CTR, DEPT ANAESTHESIOL, 1105 AZ AMSTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT ANAESTHESIOL, ROTTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam								ADZICK NS, 1985, J PEDIATR SURG, V20, P372, DOI 10.1016/S0022-3468(85)80222-0; BERKMAN SA, 1988, BLOOD REV, V2, P206, DOI 10.1016/0268-960X(88)90026-4; BLUMBERG N, 1989, TRANSFUSION, V29, P236, DOI 10.1046/j.1537-2995.1989.29389162731.x; CUTLER BS, 1984, SURGERY, V95, P717; DESA VP, 1991, ANESTH ANALG, V72, P645; HENDERSON AM, 1986, ANAESTHESIA, V41, P748, DOI 10.1111/j.1365-2044.1986.tb12846.x; HENLING CE, 1985, J THORAC CARDIOV SUR, V89, P914; KRAFT M, 1981, ANAESTHESIA, V36, P402, DOI 10.1111/j.1365-2044.1981.tb10247.x; LICHTIGER B, 1982, ANESTH ANALG, V61, P618; MESSMER K, 1986, EUR SURG RES, V18, P254, DOI 10.1159/000128533; NADLER SB, 1962, SURGERY, V51, P224; SCHALLER RT, 1983, AM J SURG, V146, P79, DOI 10.1016/0002-9610(83)90263-5; SCHALLER RT, 1984, J PEDIATR SURG, V19, P705, DOI 10.1016/S0022-3468(84)80356-5; SPAHN DR, 1994, ANESTH ANALG, V78, P1000; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TROUWBORST A, 1990, LANCET, V336, P1295, DOI 10.1016/0140-6736(90)92973-L; TROUWBORST A, 1990, ANESTH ANALG, V70, P523; ZETTERSTROM H, 1986, ACTA ANAESTH SCAND, V30, P300, DOI 10.1111/j.1399-6576.1986.tb02418.x	18	23	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1127	1129		10.1016/S0140-6736(95)91800-0	http://dx.doi.org/10.1016/S0140-6736(95)91800-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475603				2022-12-01	WOS:A1995TB54900010
J	YOSHIBA, M; OKAMOTO, H; MISHIRO, S				YOSHIBA, M; OKAMOTO, H; MISHIRO, S			DETECTION OF THE GBV-C HEPATITIS-VIRUS GENOME IN SERUM FROM PATIENTS WITH FULMINANT-HEPATITIS OF UNKNOWN ETIOLOGY	LANCET			English	Note								Hepatitis viruses A, B, C, D, and E have not accounted for all cases of hepatitis, hence ''non A-E'' agent(s) might be implicated. A set of new viruses (GBV-A, -B, and -C) whose genomes have been sequenced, are being investigated as possible causes of non A-E hepatitis. We investigated six cases of fulminant hepatitis of unknown aetiology for the presence of GBV-C genome in their serum, and three showed positive signals by semi-nested PCR using primers derived from the NS3/helicase region. Nucleotide sequence analyses confirmed these signals to be derived from a GBV-C sequence. The results suggest the importance of GBV-C in the aetiology of fulminant hepatitis.	TOSHIBA GEN HOSP, DEPT MED SCI, SHINAGAWA KU, TOKYO 140, JAPAN; SHOWA UNIV, FUJIGAOKA HOSP, SCH MED, DEPT GASTROENTEROL, YOKOHAMA, KANAGAWA 227, JAPAN; JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	Toshiba Corporation; Showa University; Jichi Medical University			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; FAGAN EA, 1992, J MED VIROL, V38, P71, DOI 10.1002/jmv.1890380115; OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1002/hep.1840200505; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SUZUKI H, 1994, VIRAL HEPATITIS LIVE, P426; YOSHIBA M, 1994, HEPATOLOGY, V19, P829	7	474	484	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1131	1132		10.1016/S0140-6736(95)91802-7	http://dx.doi.org/10.1016/S0140-6736(95)91802-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475605				2022-12-01	WOS:A1995TB54900012
J	ARIGONI, F; POGLIANO, K; WEBB, CD; STRAGIER, P; LOSICK, R				ARIGONI, F; POGLIANO, K; WEBB, CD; STRAGIER, P; LOSICK, R			LOCALIZATION OF PROTEIN IMPLICATED IN ESTABLISHMENT OF CELL-TYPE TO SITES OF ASYMMETRIC DIVISION	SCIENCE			English	Article							ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SPORULATION; MORPHOGENESIS	Asymmetric division in Bacillus subtilis generates progeny cells with dissimilar fates. SpoIIE, a membrane protein required for the establishment of cell type, was shown to localize near sites of potential polar division. SpoIIE initially localizes in a bipolar pattern, coalescing at marks in the cell envelope at which asymmetric division can take place. Then, during division, SpoIIE becomes restricted to the polar septum and is lost from the distal pole. Thus, when division is complete, SpoIIE sits at the boundary between the progeny from which it dictates cell fate by the activation of a cell-specific transcription factor.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138; INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE	Harvard University				Pogliano, Kit/0000-0002-7868-3345; STRAGIER, Patrick/0000-0003-0849-3025	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, UNPUB; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DNCAN L, 1995, SCIENCE, V270, P641; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; GUZMAN P, 1988, J BACTERIOL, V170, P1598, DOI 10.1128/jb.170.4.1598-1609.1988; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; ILLING N, 1991, J BACTERIOL, V173, P3159, DOI 10.1128/JB.173.10.3159-3169.1991; LEWIS PJ, 1994, P NATL ACAD SCI USA, V91, P3849, DOI 10.1073/pnas.91.9.3849; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; POGLIANO K, IN PRESS MOL MICROBI; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SALAMITOU S, 1994, J BACTERIOL, V176, P2828, DOI 10.1128/JB.176.10.2828-2834.1994; SETLOW B, 1991, J BACTERIOL, V173, P6270, DOI 10.1128/jb.173.19.6270-6278.1991; SPRINGER M, 1986, P NATL ACAD SCI USA, V83, P4384, DOI 10.1073/pnas.83.12.4384; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P116; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; WEBB CD, IN PRESS J BACTERIOL; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	29	153	153	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					637	640		10.1126/science.270.5236.637	http://dx.doi.org/10.1126/science.270.5236.637			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570022				2022-12-01	WOS:A1995TB55700041
J	DUNCAN, L; ALPER, S; ARIGONI, F; LOSICK, R; STRAGIER, P				DUNCAN, L; ALPER, S; ARIGONI, F; LOSICK, R; STRAGIER, P			ACTIVATION OF CELL-SPECIFIC TRANSCRIPTION BY A SERINE PHOSPHATASE AT THE SITE OF ASYMMETRIC DIVISION	SCIENCE			English	Article							ANTI-SIGMA FACTOR; BACILLUS-SUBTILIS; EXPRESSION; SPOIIAB	Cell fate is determined by cell-specific activation of transcription factor sigma(F) after asym metric division during sporulation by Bacillus subtilis. The activity of sigma(F) is governed by SpoIIAA, SpoIIAB, and SpoIIE, a membrane protein localized at the polar septum. SpoIIAB binds to and inhibits of, and SpoIIAA inhibits SpoIIAB, which prevents SpoIIAB from binding to sigma(F). SpoIIAB is also a serine kinase that inactivates SpoIIAA. Here, it is demonstrated that SpoIIE dephosphorylates SpoIIAA-P and overcomes SpoIIAB-mediated inhibition of sigma(F). The finding that SpoIIE is a serine phosphatase links asymmetric division to the pathway governing cell-specific gene transcription.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138; INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE	Harvard University				STRAGIER, Patrick/0000-0003-0849-3025	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; ARIGONI F, UNPUB; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; DUNCAN LL, UNPUB; ERINGTON J, 1993, MICROBIOL REV, V57, P1; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KAIMAN S, 1990, J BACTERIOL, V172, P5575; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; NAJAFI SMA, 1995, J BACTERIOL, V177, P2912, DOI 10.1128/jb.177.10.2912-2913.1995; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SUN DX, 1991, J BACTERIOL, V173, P7867, DOI 10.1128/jb.173.24.7867-7874.1991; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; WISE AA, 1995, J BACTERIOL, V177, P123, DOI 10.1128/jb.177.1.123-133.1995	24	204	209	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					641	644		10.1126/science.270.5236.641	http://dx.doi.org/10.1126/science.270.5236.641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570023				2022-12-01	WOS:A1995TB55700042
J	HWANG, J; TAMM, LK; BOHM, C; RAMALINGAM, TS; BETZIG, E; EDIDIN, M				HWANG, J; TAMM, LK; BOHM, C; RAMALINGAM, TS; BETZIG, E; EDIDIN, M			NANOSCALE COMPLEXITY OF PHOSPHOLIPID MONOLAYERS INVESTIGATED BY NEAR-FIELD SCANNING OPTICAL MICROSCOPY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; ATOMIC-FORCE MICROSCOPY; DIMYRISTOYLPHOSPHATIDIC ACID; LIPID MONOLAYERS; INTERFACE; TRANSITIONS; RESOLUTION; DIFFUSION; BILAYERS; SYSTEM	Near-field scanning optical microscopy of phospholipid monolayers doped with fluorescent lipid analogs reveals previously undescribed features in various phases, including a concentration gradient at the liquid-expanded/liquid-condensed domain boundary and weblike structures in the solid-condensed phase. Presumably, the web structures are grain boundaries between crystalline solid lipid. These structures are strongly modulated by the addition of low concentrations of cholesterol and ganglioside G(M1) in the monolayer.	UNIV VIRGINIA,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; AT&T BELL LABS,MURRAY HILL,NJ 07974	University of Virginia; AT&T; Nokia Corporation; Nokia Bell Labs	HWANG, J (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NIAID NIH HHS [AI14584, R37 AI030557, AI30557] Funding Source: Medline; NIDDK NIH HHS [DK44375] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014584, R01AI014584, R01AI030557, R37AI030557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044375] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETZIG E, 1992, SCIENCE, V257, P189, DOI 10.1126/science.257.5067.189; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; BOHM C, 1993, BIOPHYS J, V64, P553; CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213; Fischer A., 1984, Journal de Physique Lettres, V45, P785, DOI 10.1051/jphyslet:019840045016078500; FISHER A, 1984, J PHYSIQUE, V45, P517; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; HECKL WM, 1988, LANGMUIR, V4, P1352, DOI 10.1021/la00084a026; HICKEL W, 1990, J APPL PHYS, V67, P3572, DOI 10.1063/1.345307; HINTERDORFER P, 1994, J BIOL CHEM, V269, P20360; HWANG JS, 1994, BIOPHYS J, V66, pA277; LEE KYC, 1994, SCIENCE, V263, P655, DOI 10.1126/science.8303272; LOSCHE M, 1983, BER BUNSEN PHYS CHEM, V87, P848; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.pc.42.100191.001131; MCCONNELL HM, 1984, P NATL ACAD SCI USA, V81, P3249, DOI 10.1073/pnas.81.10.3249; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MIKRUT JM, 1993, PHYS REV B, V48, P14479, DOI 10.1103/PhysRevB.48.14479; MOERS MHP, 1994, LANGMUIR, V10, P2774, DOI 10.1021/la00020a044; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PETERS R, 1983, P NATL ACAD SCI-BIOL, V80, P7183, DOI 10.1073/pnas.80.23.7183; SEUL M, 1985, J PHYS CHEM-US, V89, P3592, DOI 10.1021/j100263a003; TAMM LK, 1988, BIOCHEMISTRY-US, V27, P1450, DOI 10.1021/bi00405a009; WEIS RM, 1984, NATURE, V310, P47, DOI 10.1038/310047a0; WEIS RM, 1985, J PHYS CHEM-US, V89, P4453, DOI 10.1021/j100267a011; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; YANG J, 1993, J MICROSC-OXFORD, V171, P183, DOI 10.1111/j.1365-2818.1993.tb03375.x	27	135	135	0	27	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					610	614		10.1126/science.270.5236.610	http://dx.doi.org/10.1126/science.270.5236.610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570018				2022-12-01	WOS:A1995TB55700032
J	JANSEN, ASP; NGUYEN, XV; KARPITSKIY, V; METTENLEITER, TC; LOEWY, AD				JANSEN, ASP; NGUYEN, XV; KARPITSKIY, V; METTENLEITER, TC; LOEWY, AD			CENTRAL COMMAND NEURONS OF THE SYMPATHETIC NERVOUS-SYSTEM - BASIS OF THE FIGHT-OR-FLIGHT RESPONSE	SCIENCE			English	Article							PSEUDORABIES VIRUS; PREGANGLIONIC NEURONS; CHEMICAL-STIMULATION; RAT; MARKER; CATECHOLAMINES; INNERVATION; HEART	During stress, the activity of the sympathetic nervous system is changed in a global fashion, leading to an increase in cardiovascular function and a release of adrenal catecholamines. This response is thought to be regulated by a common set of brain neurons that provide a dual input to the sympathetic preganglionic neurons regulating cardiac and adrenal medullary functions. By using a double-virus transneuronal labeling technique, the existence of such a set of central autonomic neurons in the hypothalamus and brainstem was demonstrated. These neurons innervate both of the sympathetic outflow systems and likely function in circumstances where parallel sympathetic processing occurs, such as in the fight-or-flight response.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; FED RES CTR VIRUS DIS ANIM,FRIEDRICH LOEFFLER INST,INST MOLEC & CELLULAR VIROL,D-17498 INSEL RIEMS,GERMANY	Washington University (WUSTL); Friedrich Loeffler Institute			Mettenleiter, h. c. Thomas C./U-1016-2019		NHLBI NIH HHS [HL-25449] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025449, R37HL025449] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEREITER DA, 1990, PAIN, V42, P81, DOI 10.1016/0304-3959(90)91094-Y; Cannon WB, 1930, LANCET, V1, P1109; Cannon WB., 1915, BODILY CHANGES PAIN; CARD JP, 1993, J NEUROSCI, V13, P2515, DOI 10.1523/JNEUROSCI.13-06-02515.1993; DIAMANT M, 1992, NEUROENDOCRINOLOGY, V56, P750, DOI 10.1159/000126303; JANSEN ASP, 1995, BRAIN RES, V683, P1, DOI 10.1016/0006-8993(95)00276-V; JANSEN ASP, 1993, BRAIN RES, V617, P103, DOI 10.1016/0006-8993(93)90619-X; KATAFUCHI T, 1988, NEUROSCI LETT, V86, P195, DOI 10.1016/0304-3940(88)90570-8; METTENLEITER TC, 1990, J VIROL METHODS, V30, P55, DOI 10.1016/0166-0934(90)90043-F; METTENLEITER TC, 1988, J VIROL, V62, P2712, DOI 10.1128/JVI.62.8.2712-2717.1988; MINSON JB, 1987, J AUTONOM NERV SYST, V13, P39; PARDINI BJ, 1989, J AUTONOM NERV SYST, V28, P193, DOI 10.1016/0165-1838(89)90146-X; PARDINI BJ, 1990, NEUROSCI LETT, V117, P300, DOI 10.1016/0304-3940(90)90681-X; RINAMAN L, 1993, J NEUROSCI, V13, P684; ROSS CA, 1984, J NEUROSCI, V4, P474; SAMS JM, 1995, BRAIN RES, V687, P182, DOI 10.1016/0006-8993(95)00484-8; STANEK KA, 1984, AM J PHYSIOL, V246, pH44, DOI 10.1152/ajpheart.1984.246.1.H44; STRACK AM, 1990, J NEUROSCI, V10, P2139; STRACK AM, 1989, BRAIN RES, V491, P274, DOI 10.1016/0006-8993(89)90063-2; STRACK AM, 1988, BRAIN RES, V455, P187, DOI 10.1016/0006-8993(88)90132-1; SWANSON LW, 1992, BRAINMAPS	21	493	503	2	111	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					644	646		10.1126/science.270.5236.644	http://dx.doi.org/10.1126/science.270.5236.644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570024				2022-12-01	WOS:A1995TB55700043
J	NELSON, MT; CHENG, H; RUBART, M; SANTANA, LF; BONEV, AD; KNOT, HJ; LEDERER, WJ				NELSON, MT; CHENG, H; RUBART, M; SANTANA, LF; BONEV, AD; KNOT, HJ; LEDERER, WJ			RELAXATION OF ARTERIAL SMOOTH-MUSCLE BY CALCIUM SPARKS	SCIENCE			English	Article							TRANSIENT OUTWARD CURRENTS; SIZED CEREBRAL-ARTERIES; RABBIT PORTAL-VEIN; SARCOPLASMIC-RETICULUM; POTASSIUM CHANNELS; K+ CURRENTS; CELLS; RELEASE; THAPSIGARGIN; CONTRACTION	Local increases in intracellular calcium ion concentration ([Ca2+](i)) resulting from activation of the ryanodine-sensitive calcium-release channel in the sarcoplasmic reticulum (SR) of smooth muscle cause arterial dilation. Ryanodine-sensitive, spontaneous local increases in [Ca2+](i) (Ca2+ sparks) from the SR were observed just under the surface membrane of single smooth muscle cells from myogenic cerebral arteries. Ryanodine and thapsigargin inhibited Ca2+ sparks and Ca2+-dependent potassium (K-Ca), currents, suggesting that Ca2+ sparks activate K-Ca channels. Furthermore, K-Ca channels activated by Ca2+ sparks appeared to hyperpolarize and dilate pressurized myogenic arteries because ryanodine and thapsigargin depolarized and constricted these arteries to an extent similar to that produced by blockers of K-Ca channels. Ca2+ sparks indirectly cause vasodilation through activation of K-Ca channels, but have little direct effect on spatially averaged [Ca2+](i), which regulates contraction.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; UNIV VERMONT,DEPT PHARMACOL,COLCHESTER,VT 05446; INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Vermont; Indiana University System; Indiana University-Purdue University Indianapolis			Heping, Cheng/AAE-2680-2019; Lederer, William/B-1285-2010; Santana, Luis/AAF-9298-2019	Heping, Cheng/0000-0002-9604-6702; Santana, Luis/0000-0002-4297-8029; Nelson, Mark/0000-0002-6608-8784	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044455, R01HL025675, R01HL051728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51728, HL44455, HL25675] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BOLTON TB, 1989, J PHYSIOL-LONDON, V409, P385, DOI 10.1113/jphysiol.1989.sp017504; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; BRAYDEN JE, 1989, J CEREBR BLOOD F MET, V9, P256, DOI 10.1038/jcbfm.1989.42; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; DEVINE CE, 1972, J CELL BIOL, V52, P690, DOI 10.1083/jcb.52.3.690; FFLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914; FLEISCHMANN BK, P NATL ACAD SCI USA, V91, P11914; GANITKEVICH V, 1990, CIRC RES, V67, P525, DOI 10.1161/01.RES.67.2.525; GANITKEVICH VY, 1995, J PHYSIOL-LONDON, V484, P287, DOI 10.1113/jphysiol.1995.sp020665; GELBAND CH, 1993, CIRC RES, V73, P24, DOI 10.1161/01.RES.73.1.24; GLANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDER DR, 1984, CIRC RES, V55, P197, DOI 10.1161/01.RES.55.2.197; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HOGG RC, 1993, PFLUG ARCH EUR J PHY, V425, P233, DOI 10.1007/BF00374172; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUME JR, 1989, J PHYSIOL-LONDON, V413, P49, DOI 10.1113/jphysiol.1989.sp017641; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; KAPICKA CL, 1994, AM J PHYSIOL, V266, pC601, DOI 10.1152/ajpcell.1994.266.3.C601; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348, DOI 10.1152/ajpheart.1995.269.1.H348; LANGTONPD, 1991, AM J PHYSIOL, V260, pH927; LU X, 1994, P NATL ACAD SCI USA, V91, P3294; MATSUYAMA S, 1993, LIFE SCI, V53, P681, DOI 10.1016/0024-3205(93)90244-W; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; MEININGERGA, 1991, AM J PHYSL, V261, pH950; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; MORITOKI H, 1994, BRIT J PHARMACOL, V111, P655, DOI 10.1111/j.1476-5381.1994.tb14788.x; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NILSSON H, 1994, J VASC RES, V31, P314, DOI 10.1159/000159059; QUAYLE JM, 1993, AM J PHYSIOL, V264, pH470, DOI 10.1152/ajpheart.1993.264.2.H470; QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363, DOI 10.1152/ajpcell.1993.265.5.C1363; QUAYLE JM, 1994, J PHYSIOL-LONDON, V475, P9, DOI 10.1113/jphysiol.1994.sp020045; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEHNOBITTEL L, 1992, J PHYSIOL-LONDON, V451, P49, DOI 10.1113/jphysiol.1992.sp019153; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIPATHY A, 1994, BIOPHYS J, V66, pA416; TTHEDFORD SE, 1994, BIOPHYS J, V66, pA20; WATANABE J, 1993, CIRC RES, V73, P465, DOI 10.1161/01.RES.73.3.465; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	48	1141	1172	1	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					633	637		10.1126/science.270.5236.633	http://dx.doi.org/10.1126/science.270.5236.633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570021				2022-12-01	WOS:A1995TB55700040
J	TAFURI, A; ALFERINK, J; MOLLER, P; HAMMERLING, GJ; ARNOLD, B				TAFURI, A; ALFERINK, J; MOLLER, P; HAMMERLING, GJ; ARNOLD, B			T-CELL AWARENESS OF PATERNAL ALLOANTIGENS DURING PREGNANCY	SCIENCE			English	Article							DIFFERENTIAL EXPRESSION; ALPHA-CHAINS; MICE; TOLERANCE; RECEPTOR; PLACENTA; ANTIGEN; IMMUNE; GRAFT	During pregnancy a semiallogeneic fetus survives despite the presence of maternal T cells specific for paternally inherited histocompatibility antigens. A mouse transgenic for a T cell receptor recognizing the major histocompatibility (MHC) antigen H-2K(b) was used to follow the fate of T cells reactive to paternal alloantigens. In contrast to syngeneic and third-party allogeneic pregnancies, mice bearing a Kb-positive conceptus had reduced numbers of Kb-reactive T cells and accepted K-b-positive tumor grafts. T cell phenotype and responsiveness were restored after delivery. Thus, during pregnancy maternal T cells acquire a transient state of tolerance specific for paternal alloantigens.	DEUTSCH KREBSFORSCHUNGSZENTRUM,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST PATHOL,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263; alferink, judith/0000-0002-3251-6584				ABRAMSKY O, 1984, PROG CLIN BIOL RES, V12, P695; ALFERIINK B, 1995, INT IMMUNOL, V7, P331; CHAOUAT G, 1993, IMMUNOLOGY PREGNANCY, P1; CLARK DA, 1991, CRIT REV IMMUNOL, V11, P215; CLARK DA, 1990, J IMMUNOL, V144, P3008; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DELASSUS S, 1994, J IMMUNOL, V152, P2411; FABRIS N, 1977, CLIN EXP IMMUNOL, V28, P306; GILL TJI, 1984, CRIT REV IMMUNOL, V5, P201; GUIMEZANES A, COMMUNICATION; HEATH WR, 1993, J EXP MED, V178, P1807, DOI 10.1084/jem.178.5.1807; HEDLEY ML, 1989, J IMMUNOL, V142, P4046; HERRERAGONZALEZ NE, 1993, DEV COMP IMMUNOL, V17, P1, DOI 10.1016/0145-305X(93)90011-E; HETHERINGTON CM, 1990, IMMUNOLOGY, V71, P449; LIMMER A, UNPUB; NICKLIN S, 1982, CLIN EXP IMMUNOL, V49, P135; OHEARN M, 1981, TRANSPLANTATION, V32, P389, DOI 10.1097/00007890-198111000-00009; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PARVIN M, 1992, MICROBIOL IMMUNOL, V36, P77; PAVIA CS, 1979, J IMMUNOL, V123, P2194; PHILIP PJM, 1982, IMMUNOL LETT, V4, P175, DOI 10.1016/0165-2478(82)90032-3; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; RAGHUPATHY R, 1981, J IMMUNOL, V127, P2074; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SIMMONS RL, 1962, ANN NY ACAD SCI, V99, P717, DOI 10.1111/j.1749-6632.1962.tb45356.x; VARNER MW, 1991, SEMIN PERINATOL, V15, P238; VOISIN GA, 1994, FOLIA BIOL-PRAGUE, V40, P505; WAITES GT, 1987, CLIN EXP IMMUNOL, V67, P467; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	33	442	472	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 27	1995	270	5236					630	633		10.1126/science.270.5236.630	http://dx.doi.org/10.1126/science.270.5236.630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB557	7570020				2022-12-01	WOS:A1995TB55700039
J	AGASHE, VR; SHASTRY, MCR; UDGAONKAR, JB				AGASHE, VR; SHASTRY, MCR; UDGAONKAR, JB			INITIAL HYDROPHOBIC COLLAPSE IN THE FOLDING OF BARSTAR	NATURE			English	Article							FLOW CIRCULAR-DICHROISM; GLOBULAR-PROTEINS; SECONDARY STRUCTURE; INTERMEDIATE; MECHANISM; STABILITY; FRAMEWORK; PATHWAYS; STATE	Two models are commonly used to describe the poorly understood earliest steps of protein folding. The framework model(1-3) stresses very early formation of nascent secondary structures, which coalesce into a compact, molten, globule-like form(4,5) from which structure slowly develops(6,7). The hydrophobic collapse model(8-10) gives overriding precedence to a nonspecific collapse of the polypeptide chain which facilitates subsequent formation of specific secondary and tertiary structure(11,12). Here we report our analysis of the earliest observable events of the major folding pathway of barstar, a small protein. We compare the kinetics of folding using circular dichroism at 222 nm and 270 nm, intrinsic tryptophan fluorescence, fluorescence of the hydrophobic dye 8-anilino-1-naphthalene-sulphonic acid on binding, and restoration of tryptophan-dansyl fluorescence energy transfer as structure-monitoring probes. We show that the polypeptide chain rapidly collapses (within 4 ms) to a compact globule with a solvent-accessible hydrophobic core(6), but with no optically active secondary or tertiary structure. Thus the earliest event of the major folding pathway of barstar is a nonspecific hydrophobic collapse that does not involve concomitant secondary structure formation.	NATL CTR BIOL SCI,CTR TIFR,BANGALORE 560012,KARNATAKA,INDIA	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)								CHAN HS, 1989, J CHEM PHYS, V90, P492, DOI 10.1063/1.456500; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; FENG HP, 1994, BIOCHEMISTRY-US, V33, P13382, DOI 10.1021/bi00249a026; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; GUIJARRO JI, 1995, BIOCHEMISTRY-US, V34, P2998, DOI 10.1021/bi00009a031; GUTIN AM, 1995, BIOCHEMISTRY-US, V34, P3066, DOI 10.1021/bi00009a038; ITZHAKI LS, 1994, BIOCHEMISTRY-US, V33, P5212, DOI 10.1021/bi00183a026; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KHORASANIZADEH S, 1993, BIOCHEMISTRY-US, V32, P7054, DOI 10.1021/bi00078a034; KHURANA R, 1994, BIOCHEMISTRY-US, V33, P106, DOI 10.1021/bi00167a014; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1993, FEBS LETT, V334, P265, DOI 10.1016/0014-5793(93)80691-M; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; MANN CJ, 1993, BIOCHEMISTRY-US, V32, P5282, DOI 10.1021/bi00071a002; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; PTITSYN OB, 1973, DOKL AKAD NAUK SSSR+, V210, P1213; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Ptitsyn Oleg B., 1992, P243; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; ROBSON B, 1971, J MOL BIOL, V58, P237, DOI 10.1016/0022-2836(71)90243-9; RODER H, 1994, MECHANISMS PROTEIN F, P26; SCHREIBER G, 1993, BIOCHEMISTRY-US, V32, P11195, DOI 10.1021/bi00092a032; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; SHASTRY MCR, 1994, PROTEIN SCI, V3, P1409, DOI 10.1002/pro.5560030907; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553	31	192	195	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					754	757		10.1038/377754a0	http://dx.doi.org/10.1038/377754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477269				2022-12-01	WOS:A1995TB46900063
J	DEWEERD, P; GATTASS, R; DESIMONE, R; UNGERLEIDER, LG				DEWEERD, P; GATTASS, R; DESIMONE, R; UNGERLEIDER, LG			RESPONSES OF CELLS IN MONKEY VISUAL-CORTEX DURING PERCEPTUAL FILLING-IN OF AN ARTIFICIAL SCOTOMA	NATURE			English	Article							RECEPTIVE-FIELDS; MACAQUE MONKEY; STRIATE CORTEX; CONNECTIONS	WHEN we view a scene through one eye, we typically do not see the scotomas created by the optic disc and the blood vessels overlying the retinal surface. Similarly, when a texture field containing a hole is steadily viewed in peripheral vision (artificial scotoma), the hole appears to fill in with the surrounding texture in a matter of seconds, demonstrating that the visual system fills in information across regions where no information is available(1-5). Here we show that, in monkeys viewing a similar texture field with a hole, the responses of extrastriate visual neurons with receptive fields covering the hole increase gradually to a level comparable to that elicited by the same texture without a hole. The time course of these dynamic changes in activity parallels the time course of perceived filling-in of the hole by human observers, suggesting that this process mediates perceptual filling-in.	NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892; NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892; UNIV FED RIO DE JANEIRO,BIOPHYS INST CARLOS CHAGAS,DEPT NEUROBIOL,BR-21941 RIO JANEIRO,BRAZIL	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Universidade Federal do Rio de Janeiro			Desimone, Robert/G-1121-2018	Desimone, Robert/0000-0002-5938-4227				BENDER MB, 1946, ARCH NEURO PSYCHIATR, V55, P627, DOI 10.1001/archneurpsyc.1946.02300170075008; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; DISTLER C, 1993, J COMP NEUROL, V334, P125, DOI 10.1002/cne.903340111; FIORANI M, 1992, P NATL ACAD SCI USA, V89, P8547, DOI 10.1073/pnas.89.18.8547; GATTASS R, 1988, J NEUROSCI, V8, P1831; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; GROSSBERG S, 1994, PERCEPT PSYCHOPHYS, V55, P48, DOI 10.3758/BF03206880; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; KOMATSU H, 1994, VISUAL NEUROSCI, V11, P1103, DOI 10.1017/S0952523800006921; LEVITT JB, 1994, J COMP NEUROL, V342, P551, DOI 10.1002/cne.903420405; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MILLER EK, 1993, J NEUROSCI, V13, P1460; NELSON JI, 1985, EXP BRAIN RES, V61, P54; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; OHZAWA I, 1985, J NEUROPHYSIOL, V42, P833; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; RAMACHANDRAN VS, 1993, VISION RES, V33, P717, DOI 10.1016/0042-6989(93)90191-X; SPILLMANN L, 1992, VISION RES, V32, P1941, DOI 10.1016/0042-6989(92)90053-L; YOSHIOKA T, 1992, J NEUROSCI, V12, P2785; Zipser K., 1994, Society for Neuroscience Abstracts, V20, P1477	22	176	176	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					731	734						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477262				2022-12-01	WOS:A1995TB46900056
J	GODDARD, AD; COVELLO, R; LUOH, SM; CLACKSON, T; ATTIE, KM; GESUNDHEIT, N; RUNDLE, AC; WELLS, JA; CARLSSON, LMS				GODDARD, AD; COVELLO, R; LUOH, SM; CLACKSON, T; ATTIE, KM; GESUNDHEIT, N; RUNDLE, AC; WELLS, JA; CARLSSON, LMS			MUTATIONS OF THE GROWTH-HORMONE RECEPTOR IN CHILDREN WITH IDIOPATHIC SHORT STATURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARON-TYPE DWARFISM; SERUM BINDING-PROTEIN; EXTRACELLULAR DOMAIN; PURIFICATION; ASSAY	Background. Short stature in children who are not deficient in growth hormone (GH) is probably caused by a variety of defects. Some children with idiopathic short stature have low serum concentrations of GH-binding protein, which is derived from the GH receptor. The possibility that low serum concentrations of GH-binding protein might indicate partial insensitivity to GH led us to investigate possible defects in the gene for the GH receptor in children with idiopathic short stature and low serum concentrations of GH-binding protein. Methods. We studied 14 children with idiopathic short stature who were selected on the basis of normal GH secretion and low serum concentrations of GH-binding protein. Analysis of single-strand conformation polymorphisms and DNA sequencing were both used to identify mutations in the GH-receptor gene. Results. Mutations in the region of the GH-receptor gene that codes for the extracellular domain of the receptor were found in 4 of the 14 children, but in none of 24 normal subjects. One of the four children with mutations was a compound heterozygote, with one mutation that reduced the affinity of the receptor for GH and a second mutation that may affect a function other than ligand binding. The remaining three children had single mutations in one allele of the gene. One mutation introduced a premature termination codon, and two caused substitutions of single amino acids in a structurally conserved domain of the receptor. Conclusions. Some children with idiopathic short stature may have partial insensitivity to GH due to mutations in the GH-receptor gene.	GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MED AFFAIRS,S SAN FRANCISCO,CA 94080; GOTHENBURG UNIV,DEPT INTERNAL MED,ENDOCRINOL & METAB RES CTR,GOTHENBURG,SWEDEN; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of Gothenburg; Roche Holding; Genentech			Carlsson, Lena/F-7570-2018; Wells, Jim A/O-9854-2016	Carlsson, Lena/0000-0003-4145-6242; 				AGUIRRE A, 1990, HORM RES, V34, P4, DOI 10.1159/000181786; AMIT T, 1990, J CLIN ENDOCR METAB, V71, P474, DOI 10.1210/jcem-71-2-474; AMSELEM S, 1993, HUM MOL GENET, V2, P355, DOI 10.1093/hmg/2.4.355; ATTIE KM, 1995, J PEDIATR-US, V127, P244, DOI 10.1016/S0022-3476(95)70302-0; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; CARLSSON LMS, 1994, J CLIN ENDOCR METAB, V78, P1325, DOI 10.1210/jc.78.6.1325; CARLSSON LMS, 1991, J CLIN ENDOCR METAB, V73, P1216, DOI 10.1210/jcem-73-6-1216; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1990, J BIOL CHEM, V265, P3111; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; LARON Z, 1989, ACTA ENDOCRINOL-COP, V121, P603, DOI 10.1530/acta.0.1210603; LARON Z, 1993, ENDOCRINOLOGIST, V3, P21; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MAURAS N, 1994, METABOLISM, V43, P357, DOI 10.1016/0026-0495(94)90104-X; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; ROSENBLOOM AL, 1994, ACTA PAEDIATR S, V399, P125; ROSENFELD RG, 1994, ENDOCR REV, V15, P369, DOI 10.1210/er.15.3.369; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490	27	227	238	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1093	1098		10.1056/NEJM199510263331701	http://dx.doi.org/10.1056/NEJM199510263331701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565946				2022-12-01	WOS:A1995TA37200001
J	HEATH, SL; TEW, JG; TEW, JG; SZAKAL, AK; BURTON, GF				HEATH, SL; TEW, JG; TEW, JG; SZAKAL, AK; BURTON, GF			FOLLICULAR DENDRITIC CELLS AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIVITY	NATURE			English	Article							MONOCLONAL-ANTIBODY; HIV-INFECTION; EXPRESSION; RETENTION; TISSUE; CLONE; AIDS	LARGE amounts of human immunodeficiency virus (HIV) localize on follicular dendritic cells (FDC) in the follicles of secondary lymploid tissues following viral infection(1,2). During clinical latency, active viral infection occurs primarily at these sites(3,4). As HIV on FDC is in the form of immune complexes(5), some of which may be formed with neutralizing antibody, we investigated whether HIV on FDC is infectious. We report here that HIV on FDC is highly infectious. Furthermore, FDC can convert neutralized HIV into an infectious form even in the presence of a vast excess of neutralizing antibody. Thus FDC may provide a mechanism whereby HIV infection can continue in the presence of neutralizing antibody.	VIRGINIA COMMONWEALTH UNIV, DEPT MICROBIOL & IMMUNOL, DIV IMMUNOBIOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, DEPT ANAT, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BIBERFELD P, 1988, CANCER DETECT PREV, V12, P217; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON GF, 1993, J IMMUNOL, V150, P31; BUTCH AW, 1994, CELL IMMUNOL, V155, P27, DOI 10.1006/cimm.1994.1099; BUTCH AW, 1993, J IMMUNOL, V150, P39; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CLOUSE KA, 1989, J IMMUNOL, V142, P431; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FOX CH, 1992, IMMUNOL TODAY, V13, P353, DOI 10.1016/0167-5699(92)90171-3; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; KOSCO MH, 1992, J IMMUNOL, V148, P2331; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PINCUS SH, 1989, J IMMUNOL, V142, P3070; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POSNER MR, 1991, J IMMUNOL, V146, P4325; POSNER MR, 1995, J ACQU IMMUN DEFIC S, V6, P7; Racz P, 1989, APMIS Suppl, V8, P16; SZAKAL AK, 1983, J IMMUNOL, V131, P1714; TENNERRACZ K, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P83; TEW JG, 1976, CELL IMMUNOL, V26, P141, DOI 10.1016/0008-8749(76)90358-0; TEW JG, 1979, AUST J EXP BIOL MED, V57, P401, DOI 10.1038/icb.1979.40; TEW JG, IN PRESS HDB EXPT IM	29	251	258	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					740	744		10.1038/377740a0	http://dx.doi.org/10.1038/377740a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477265				2022-12-01	WOS:A1995TB46900059
J	HEIN, L; BARSH, GS; PRATT, RE; DZAU, VJ; KOBILKA, BK				HEIN, L; BARSH, GS; PRATT, RE; DZAU, VJ; KOBILKA, BK			BEHAVIORAL AND CARDIOVASCULAR EFFECTS OF DISRUPTING THE ANGIOTENSIN-II TYPE-2 RECEPTOR GENE IN MICE	NATURE			English	Article							RAT-BRAIN; WATER-INTAKE; EXPRESSION; INJECTION; MECHANISMS; SUBTYPES; APPETITE; DRINKING; CLONING; FETUS	ANGIOTENSIN II, a potent regulator of blood pressure and of water and electrolyte balance, binds to two different G-protein-coupled receptors. The type-1 receptor (AT(1)) mediates the vasopressive and aldosterone-secreting effects of angiotensin II, but the function of the type-2 receptor (AT(2); refs 1, 2) is unknown, although it is expressed in both adult(3) and embryonic(4) life. To address this question, we have generated mice lacking the gene encoding the AT(2) receptor. Mutant mice develop normally, but have an impaired drinking response to water deprivatian as well as a reduction in spontaneous movements. Their baseline blood pressure is normal, but they show an increased vasopressor response to injection of angiotensin II. Thus, although the AT(2) receptor is not required for embryonic development, it plays a role in the central nervous system and cardiovascular functions that are mediated by the renin-angiotensin system.	STANFORD UNIV, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MED, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990				CHAASSAGNE C, 1995, GENOMICS, V25, P601, DOI 10.1016/0888-7543(95)80072-T; COONEY AS, 1993, EXP PHYSIOL, V78, P767, DOI 10.1113/expphysiol.1993.sp003724; DOURISH CT, 1992, EUR J PHARMACOL, V211, P113, DOI 10.1016/0014-2999(92)90271-5; FEUILLAN PP, 1993, REGUL PEPTIDES, V44, P159, DOI 10.1016/0167-0115(93)90239-5; GEORGIEV V, 1991, METHOD FIND EXP CLIN, V13, P5; GEORGIEV V, 1990, POL J PHARMACOL PHAR, V42, P553; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; GRADY EF, 1993, REGUL PEPTIDES, V44, P171, DOI 10.1016/0167-0115(93)90240-9; HOGARTY DC, 1992, BRAIN RES, V586, P289, DOI 10.1016/0006-8993(92)91638-U; HUANG Y, 1987, J NEUROCHEM, V49, P1541, DOI 10.1111/j.1471-4159.1987.tb01025.x; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; PETKOVA B, 1991, Acta Physiologica et Pharmacologica Bulgarica, V17, P84; ROWE BP, 1992, NEUROENDOCRINOLOGY, V55, P563, DOI 10.1159/000126177; ROWLAND NE, 1992, BRAIN RES BULL, V29, P389, DOI 10.1016/0361-9230(92)90073-7; ROWLAND NE, 1993, BRAIN RES BULL, V32, P391, DOI 10.1016/0361-9230(93)90205-P; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUMNERS C, 1983, AM J PHYSIOL, V244, pR257, DOI 10.1152/ajpregu.1983.244.2.R257; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; VISWANATHAN M, 1992, J CLIN INVEST, V90, P1707, DOI 10.1172/JCI116043; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0; WRIGHT JW, 1994, NEUROSCI BIOBEHAV R, V18, P21, DOI 10.1016/0149-7634(94)90034-5; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; ZHUO, 1995, HYPERTENSION PATHOPH, P1739	30	646	657	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					744	747		10.1038/377744a0	http://dx.doi.org/10.1038/377744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477266				2022-12-01	WOS:A1995TB46900060
J	HENKEMEYER, M; ROSSI, DJ; HOLMYARD, DP; PURI, MC; MBAMALU, G; HARPAL, K; SHIH, TS; JACKS, T; PAWSON, T				HENKEMEYER, M; ROSSI, DJ; HOLMYARD, DP; PURI, MC; MBAMALU, G; HARPAL, K; SHIH, TS; JACKS, T; PAWSON, T			VASCULAR SYSTEM DEFECTS AND NEURONAL APOPTOSIS IN MICE LACKING RAS GTPASE-ACTIVATING PROTEIN	NATURE			English	Article							TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; GAP; BINDING; RECEPTORS; KINASES; DOMAIN; CELLS; P21	The gene encoding p120-rasGAP, a negative regulator of pas, has been disrupted in mice. This Gap mutation affects the ability of endothelial cells to organize into a highly vascularized network and results in extensive neuronal cell death. Mutations in the Gap and Nf1 genes have a synergistic effect, such that embryos homozygous for mutations in both genes show an exacerbated Gap phenotype. Thus rasGAP and neurofibromin act together to regulate pas activity during embryonic development.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Toronto; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	HENKEMEYER, M (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOLEC BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Pawson, Tony J/E-4578-2013; Puri, Mira/C-4412-2014	Henkemeyer, Mark/0000-0002-7525-1061				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CONLON RA, 1995, DEVELOPMENT, V121, P1533; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FOX PL, 1994, ONCOGENE, V9, P3519; GASCA S, 1995, DEV GENET, V17, P141, DOI 10.1002/dvg.1020170206; GOU D, 1995, J BIOL CHEM, V270, P6729; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIMENEZ B, 1995, ONCOGENE, V10, P811; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM HA, 1995, ONCOGENE, V11, P325; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARSHALL CJ, 1991, TRENDS GENET, V7; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Risau W., 1991, DEV VASCULAR SYSTEM, P58; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAITENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WURST W, 1993, GENE TARGETING PRACT, P31; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	50	286	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					695	701		10.1038/377695a0	http://dx.doi.org/10.1038/377695a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477259				2022-12-01	WOS:A1995TB46900045
J	ICHIKI, T; LABOSKY, PA; SHIOTA, C; OKUYAMA, S; IMAGAWA, Y; FOGO, A; NIIMURA, F; ICHIKAWA, I; HOGAN, BLM; INAGAMI, T				ICHIKI, T; LABOSKY, PA; SHIOTA, C; OKUYAMA, S; IMAGAWA, Y; FOGO, A; NIIMURA, F; ICHIKAWA, I; HOGAN, BLM; INAGAMI, T			EFFECTS ON BLOOD-PRESSURE AND EXPLORATORY-BEHAVIOR OF MICE LACKING ANGIOTENSIN-II TYPE-2 RECEPTOR	NATURE			English	Article							RAT-BRAIN; EXPRESSION; SUBTYPES; CLONING; ANTAGONISTS; MECHANISMS; AT1	THERE are two major angiotensin II receptor isoforms, AT(1) and AT(2). AT(1) mediates the well-known presser and mitogenic effects of angiotensin II (refs 1-5), but the signalling mechanism and physiological role of AT(2) (refs 6-11) has not been established. Its abundant expression in fetal tissues(12) and certain brain nuclei(13) suggest possible roles in growth, development and neuronal functions. Here we report the unexpected finding that the targeted disruption of the mouse AT(2) gene resulted in a significant increase in blood pressure and increased sensitivity to the presser action of angiotensin II. Thus AT(2) mediates a depressor effect and antagonizes the AT(1)-mediated presser action of angiotensin II. In addition, disruption of the AT(2) gene attenuated exploratory behaviour and lowered body temperature. Our results show that angiotensin II activates AT(1) and AT(2), which have mutually counteracting haemodynamic effects, and that AT(2) regulates central nervous system functions, including behaviour.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PEDIAT,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; TAISHO PHARMACEUT CO LTD,MED RES LABS,LAB 1,OMIYA,SAITAMA 330,JAPAN	Vanderbilt University; Vanderbilt University; Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University; Taisho Pharmaceutical Holdings Co Ltd				Labosky, Patricia/0000-0001-5880-2194				ASHTON H, 1987, BRAIN SYSTEMS DISORD, P1; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; ICHIHARA K, 1993, J PHARMACOL EXP THER, V264, P122; ICHIKI T, 1995, CIRC RES, V76, P693, DOI 10.1161/01.RES.76.5.693; Irwin S., 1964, DRUG EVALUATION, P36; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KEISER JA, 1992, J PHARMACOL EXP THER, V262, P1154; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LO M, 1995, J CLIN INVEST, V95, P1394, DOI 10.1172/JCI117792; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAVERI L, 1994, REGUL PEPTIDES, V52, P21, DOI 10.1016/0167-0115(94)90017-5; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHEUER DA, 1993, AM J PHYSIOL, V264, pR917, DOI 10.1152/ajpregu.1993.264.5.R917; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; SOLISRAMIRES R, 1993, GUIDE TECHNIQUES MOU, P855; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOFOVIC SP, 1991, HYPERTENSION, V18, P774, DOI 10.1161/01.HYP.18.6.774; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; YOSHIDA M, 1994, AM J PHYSIOL, V266, pR802, DOI 10.1152/ajpregu.1994.266.3.R802	29	765	776	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					748	750		10.1038/377748a0	http://dx.doi.org/10.1038/377748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477267				2022-12-01	WOS:A1995TB46900061
J	LABARRERE, CA; PITTS, D; NELSON, DR; FAULK, WP				LABARRERE, CA; PITTS, D; NELSON, DR; FAULK, WP			VASCULAR TISSUE-PLASMINOGEN ACTIVATOR AND THE DEVELOPMENT OF CORONARY-ARTERY DISEASE IN HEART-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CARDIAC ALLOGRAFTS; ENDOTHELIAL-CELLS; PROCOAGULANT ACTIVITY; MESSENGER-RNA; VESSEL WALL; ATHEROSCLEROSIS; IMMUNOPATHOLOGY; INTERLEUKIN-1; LOCALIZATION; EXPRESSION	Background. An aggressive and potentially fatal form of coronary artery disease may develop after cardiac transplantation. We studied the role of vascular tissue plasminogen activator (t-PA), the primary mediator of fibrinolysis, in the development of this problem. Methods. We studied 78 consecutive recipients of cardiac allografts over a five-year period, and we collected follow-up data over a mean (+/-SE) of 32.5+/-2.0 months. The patients were studied with ventricular function tests, serial endomyocardial biopsies (16.6+/-0.5 per patient), and annual coronary angiography. Measurements of t-PA and its inhibitor were performed immunocytochemically on unfixed cryostat sections of endomyocardial-biopsy specimens with the use of monoclonal antibodies to t-PA and its inhibitor. Results. In biopsy specimens obtained during the first three months of follow-up, 38 allografts had a normal distribution of t-PA in arteriolar smooth-muscle cells, whereas in 40 allografts there was depletion of t-PA that persisted in subsequent follow-up. Coronary artery disease developed during follow-up in 31 of 40 allografts (78 percent) with depletion of t-PA, but the disease developed in only 9 of the 38 allografts (24 percent) with normal t-PA levels (P<0.001). Allografts with depletion of tPA also had the t-PA inhibitor and were at greater risk for earlier and more severe disease than were allografts with normal arteriolar t-PA levels. Twelve patients whose allografts were depleted of t-PA either received a second transplant or died, whereas only one of the patients whose allografts had persistently normal t-PA levels died (P<0.001). Conclusions. These findings reveal an association between the depletion of t-PA from arteriolar smooth-muscle cells and the subsequent development of coronary artery disease and decreased graft survival. Although we cannot be certain about a cause-and-effect relation, our data suggest a possible role for deficient fibrinolysis in the development of coronary artery disease in transplanted human hearts.	METHODIST HOSP INDIANA,CTR REPROD & TRANSPLANTAT IMMUNOL,INDIANAPOLIS,IN 46202; METHODIST HOSP INDIANA,DEPT TRANSPLANTAT,INDIANAPOLIS,IN 46202; METHODIST HOSP INDIANA,CTR HLTH SERV RES,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University System; Indiana University System				Nelson, David/0000-0002-3240-0725				BAJAJ S, 1993, CIRCULATION, V88, P263; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Billingham M E, 1990, J Heart Transplant, V9, P587; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1; DICHEK D, 1989, BLOOD, V74, P222; FAULK WP, 1993, HAEMOSTASIS, V23, P194; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; FAULK WP, 1995, TRANSPLANT P, V27, P1944; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, pS125; FAULK WP, 1994, SEMIN HEMATOL, V31, P26; FAULK WP, 1992, ARCH PATHOL LAB MED, V116, P1337; FAULK WP, 1994, MAJOR PROBL PATHOL, V30, P49; GAO SZ, 1988, J AM COLL CARDIOL, V12, P334, DOI 10.1016/0735-1097(88)90402-0; HAMSTEN A, 1994, FIBRINOLYSIS, V8, P253, DOI 10.1016/0268-9499(94)90723-4; HASUI Y, 1988, THROMB RES, V51, P453, DOI 10.1016/0049-3848(88)90381-7; HUNT BJ, 1993, TRANSPLANTATION, V55, P309, DOI 10.1097/00007890-199302000-00016; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; JAMIESON SW, 1992, CIRCULATION, V85, P1211, DOI 10.1161/01.CIR.85.3.1211; JANSSON JH, 1993, CIRCULATION, V88, P2030, DOI 10.1161/01.CIR.88.5.2030; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KERMAN RH, 1994, TRANSPLANTATION, V57, P884, DOI 10.1097/00007890-199403270-00020; KOOISTRA T, 1991, THROMB HAEMOSTASIS, V65, P565; LABARRERE CA, 1993, TRANSPLANTATION, V55, P1056, DOI 10.1097/00007890-199305000-00021; LABARRERE CA, 1994, CIRCULATION, V89, P1599, DOI 10.1161/01.CIR.89.4.1599; LABARRERE CA, 1995, TRANSPLANT P, V27, P1941; LABARRERE CA, 1995, TRANSPLANT P, V27, P1939; LARSSON A, 1985, J CLIN PATHOL, V38, P140, DOI 10.1136/jcp.38.2.140; Meade TW, 1992, THROMBOSIS CARDIOVAS, P79; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALOMON RN, 1991, AM J PATHOL, V138, P791; SCHROEDER JS, 1991, NEW ENGL J MED, V324, P1805, DOI 10.1056/NEJM199106203242509; SMITH EB, 1994, THROMB RES, V73, P1, DOI 10.1016/0049-3848(94)90049-3; STOVIN PGI, 1993, J HEART LUNG TRANSPL, V12, P110; TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013; VANZONNEVELD AJ, 1986, BIOCHEM J, V235, P385, DOI 10.1042/bj2350385; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469	41	87	87	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1111	1116		10.1056/NEJM199510263331704	http://dx.doi.org/10.1056/NEJM199510263331704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565949				2022-12-01	WOS:A1995TA37200004
J	MILLS, SL; MASSEY, SC				MILLS, SL; MASSEY, SC			DIFFERENTIAL PROPERTIES OF 2 GAP JUNCTIONAL PATHWAYS MADE BY AII AMACRINE CELLS	NATURE			English	Article							ROD BIPOLAR CELLS; RABBIT RETINA; NITRIC-OXIDE; 2-AMINO-4-PHOSPHONOBUTYRIC ACID; MAMMALIAN RETINA; TARGET-CELLS; CAT RETINA; GLUTAMATE; PERMEABILITY; CHANNELS	THE retina is sensitive to light stimuli varying over more than 12 log units in intensity. It accomplishes this, in part, by switching between rod-dominated circuits designed for maximum utilization of scarce photons and cone circuits designed for greater acuity. Rod signals are integrated into the cone pathways through AII amacrine cells, which are connected by gap junctions both to other AII amacrine cells and to cone bipolar cells. To determine the relative permeabilities of the two junctional pathways, we have measured the distribution of biotinylated tracers across this heterologous cell assembly after injecting a single An amacrine cell. We found that neurobiotin (relative molecular mass, 286) passed easily through both types of gap junctions, but that biotin-X cadaverine (relative molecular mass, 442) passed through AII/bipolar cell gap junctions poorly compared to AII/AII gap junctions. Thus, the AII/bipolar cell channel has a lower permeability to large molecules than does the AII/AII amacrine cell channel. The two pathways are also regulated differently. Dopamine and cyclic AMP agonists, known to diminish AII-AII coupling(1), did not change the relative labelling intensity of AII to bipolar cells. However, nitric oxide and cGMP agonists selectively reduced labelling in bipolar cells relative to AII amacrine cells, perhaps by acting at the bipolar side of this gap junction. This suggests that increased cGMP controls the network switching between rod and cone pathways associated with light adaptation.			MILLS, SL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT OPHTHALMOL & VISUAL SCI,HOUSTON,TX 77030, USA.		Massey, Stephen/A-7217-2009					BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BRINK PR, 1980, NATURE, V285, P101, DOI 10.1038/285101a0; BRUZZONE R, 1994, J CELL SCI, V107, P955; FLAGGNEWTON J, 1979, SCIENCE, V205, P406; HAMPSON ECGM, 1992, J NEUROSCI, V12, P4911; KOISTINAHO J, 1993, NEUROSCIENCE, V57, P587, DOI 10.1016/0306-4522(93)90008-4; KOLB H, 1974, SCIENCE, V186, P47, DOI 10.1126/science.186.4158.47; MASSEY SC, 1993, INVEST OPHTH VIS SCI, V34, P1382; MILLS SL, 1991, J COMP NEUROL, V304, P491, DOI 10.1002/cne.903040312; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Rae J L, 1979, Curr Top Eye Res, V1, P37; SHIELLS R, 1992, NEUROREPORT, V3, P845, DOI 10.1097/00001756-199210000-00006; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; STERLING P, 1983, ANNU REV NEUROSCI, V6, P149, DOI 10.1146/annurev.ne.06.030183.001053; STRETTOI E, 1992, J COMP NEUROL, V325, P152, DOI 10.1002/cne.903250203; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TIAN N, 1994, J NEUROPHYSIOL, V71, P2258, DOI 10.1152/jn.1994.71.6.2258; TORK I, 1979, BRAIN RES, V169, P261, DOI 10.1016/0006-8993(79)91029-1; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; VOIGT T, 1987, J NEUROSCI, V7, P4115; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WITKOVSKY P, 1991, PROG RETIN RES, V11, P247, DOI 10.1016/0278-4327(91)90031-V; YAMAMOTO R, 1993, NEUROSCIENCE, V54, P189, DOI 10.1016/0306-4522(93)90393-T; YAMASHITA M, 1991, J NEUROSCI, V11, P2372; ZIMMERMAN AL, 1985, J MEMBRANE BIOL, V84, P269, DOI 10.1007/BF01871390	29	299	305	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					734	737		10.1038/377734a0	http://dx.doi.org/10.1038/377734a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477263				2022-12-01	WOS:A1995TB46900057
J	MONTAGUE, PR; DAYAN, P; PERSON, C; SEJNOWSKI, TJ				MONTAGUE, PR; DAYAN, P; PERSON, C; SEJNOWSKI, TJ			BEE FORAGING IN UNCERTAIN ENVIRONMENTS USING PREDICTIVE HEBBIAN LEARNING	NATURE			English	Article							BUMBLE BEES; HONEYBEES; CHOICE; BEHAVIOR; DOPAMINE; REWARD	RECENT work has identified a neuron with widespread projections to odour processing regions of the honeybee brain whose activity represents the reward value of gustatory stimuli(1,2). We have constructed a model of bee foraging in uncertain environments based on this type of neuron and a predictive form of hebbian synaptic plasticity. The model uses visual input from a simulated three-dimensional world and accounts for a wide range of experiments on bee learning during foraging, including risk aversion. The predictive model shows how neuromodulatory influences can be used to bias actions and control synaptic plasticity in a way that goes beyond standard correlational mechanisms. Although several behavioural models of conditioning in bees have been proposed(3-7), this model is based on the neural substrate and was tested in a simulation of bee flight.	MIT,DEPT BRAIN & COGNIT SCI,CBCL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	MONTAGUE, PR (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030, USA.		Sejnowski, Terrence/AAV-5558-2021	Dayan, Peter/0000-0003-3476-1839				BARTO AG, 1989, 8995 U MASS COMP INF; Berry DA., 1985, BANDIT PROBLEMS SEQU; COUVILLON PA, 1991, ANIM LEARN BEHAV, V19, P381, DOI 10.3758/BF03197899; COUVILLON PA, 1986, ANIM LEARN BEHAV, V14, P225, DOI 10.3758/BF03200062; COUVILLON PA, 1985, ANIM LEARN BEHAV, V13, P246, DOI 10.3758/BF03200017; GOLDSTEIN RS, 1991, J COMP PHYSIOL A, V168, P103, DOI 10.1007/BF00217108; GREGGERS U, 1993, BEHAV ECOL SOCIOBIOL, V32, P17, DOI 10.1007/BF00172219; Hammer M., 1994, Society for Neuroscience Abstracts, V20, P582; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HAMMER M, 1995, NEUROSCIENCE, V15, P1617; HARDER LD, 1987, ECOLOGY, V68, P1104, DOI 10.2307/1938384; HARRISWARRICK RM, 1995, J NEUROSCI, V15, P342; HEBB DO, 1949, ORG BEHAVIOR; Konorski J., 1948, CONDITIONED REFLEXES; KREBS JR, 1978, NATURE, V275, P27, DOI 10.1038/275027a0; LOCKERY SR, 1991, J COMP PHYSIOL A, V168, P165, DOI 10.1007/BF00218409; Menzel Randolf, 1993, P79; Montague P. R., 1993, ADV NEURAL INFORMATI, V5, P969; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; REAL L, 1990, ECOLOGY, V71, P1625, DOI 10.2307/1938299; REAL LA, 1991, SCIENCE, V253, P980, DOI 10.1126/science.1887231; REAL LA, 1981, ECOLOGY, V62, P20, DOI 10.2307/1936663; Rescorla R., 1972, CLASSICAL CONDITION, P64; SAMUEL AL, 1956, IBM J RES DEV, V3, P211; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SPUDICH JL, 1975, P NATL ACAD SCI USA, V72, P710, DOI 10.1073/pnas.72.2.710; Sutton R. S., 1988, Machine Learning, V3, P9, DOI 10.1007/BF00115009; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; SUTTON RS, 1987, LEARNING COMPUTATION, P497; Widrow B., 1985, ADAPTIVE SIGNAL PROC	30	199	204	4	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 26	1995	377	6551					725	728		10.1038/377725a0	http://dx.doi.org/10.1038/377725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TB469	7477260				2022-12-01	WOS:A1995TB46900054
J	MOORMAN, JR; ACKERMAN, SJ; KOWDLEY, GC; GRIFFIN, MP; MOUNSEY, JP; CHEN, ZH; CALA, SE; OBRIAN, JJ; SZABO, G; JONES, LR				MOORMAN, JR; ACKERMAN, SJ; KOWDLEY, GC; GRIFFIN, MP; MOUNSEY, JP; CHEN, ZH; CALA, SE; OBRIAN, JJ; SZABO, G; JONES, LR			UNITARY ANION CURRENTS THROUGH PHOSPHOLEMMAN CHANNEL MOLECULES	NATURE			English	Article							PROTEIN; TAURINE; MYOCARDIUM; EXPRESSION; TRANSPORT; CLONING; HEART; ISK; K+	PHOSPHOLEMMAN (PLM) is a 72-amino-acid peptide with a single transmembrane domain(1-3), the expression of which induces chloride currents in Xenopus oocytes(4-6). It has remained unknown whether PLM is an ion channel or acts as a channel regulator. Here we show, by measuring unitary anion currents across planar phospholipid bilayers to which immunoaffinity-purified recombinant PLM was added, that it does indeed form ion channels. Excised patches of oocytes expressing PLM had similar currents. Of the ions tested, the sulphonic amino acid taurine was the most permeant, and expression of PLM increased fluxes of radiolabelled taurine in oocytes. Phospholemman is the smallest protein in cell membranes known to form an ion channel and the taurine selectivity suggests that it is involved in cell volume regulation.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MOLEC PHYSIOL & BIOL PHYS, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PEDIAT, DIV NEONATOL, CHARLOTTESVILLE, VA 22908 USA; INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, DEPT INTERNAL MED, INDIANAPOLIS, IN 46202 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19898 USA	University of Virginia; University of Virginia; Indiana University System; Indiana University-Purdue University Indianapolis; DuPont	MOORMAN, JR (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, DIV CARDIOVASC, CHARLOTTESVILLE, VA 22908 USA.		Moorman, J Randall/ABG-9946-2020					ATLAS M, 1984, J MOL CELL CARDIOL, V16, P311, DOI 10.1016/S0022-2828(84)80602-1; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; CALA SE, 1994, BIOPHYS J, V66, pA226; DIAMOND JM, 1969, PHYSIOL REV, V49, P581; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN L, 1994, AM J PHYSIOL, V267, pR426, DOI 10.1152/ajpregu.1994.267.2.R426; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF SF, 1991, BIOCHEMISTRY-US, V30, P3341, DOI 10.1021/bi00227a025; Hille B., 1992, IONIC CHANNELS EXCIT; HUXTABLE R, 1977, SCIENCE, V198, P409, DOI 10.1126/science.198879; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; KIRK K, 1992, J BIOL CHEM, V267, P23475; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; LINDEMANN JP, 1986, J BIOL CHEM, V261, P4860; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1994, ONCOGENE, V9, P3417; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754	25	128	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					737	740		10.1038/377737a0	http://dx.doi.org/10.1038/377737a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477264				2022-12-01	WOS:A1995TB46900058
J	POMBO, CM; KEHRL, JH; SANCHEZ, I; KATZ, P; AVRUCH, J; ZON, LI; WOODGETT, JR; FORCE, T; KYRIAKIS, JM				POMBO, CM; KEHRL, JH; SANCHEZ, I; KATZ, P; AVRUCH, J; ZON, LI; WOODGETT, JR; FORCE, T; KYRIAKIS, JM			ACTIVATION OF THE SAPK PATHWAY BY THE HUMAN STE20 HOMOLOG GERMINAL CENTER KINASE	NATURE			English	Article								EUKARYOTIC cells respond to different extracellular stimuli by recruiting homologous signalling pathways that use members of the MEKK, MEK and ERK families of protein kinases. The MEKK-->MEK-->ERK core pathways of Saccharomyces cerevisiae may themselves be regulated by members of the STE20 family of protein kinases(1,2). Here we report specific activation of the mammalian stress-activated protein kinase (SAPK) pathway by germinal centre kinase (GCK; ref. 3), a human STE20 homologue(3,4). SAPKs, members of the ERK family, are activated in situ by inflammatory stimuli, including tumour-necrosis factor (TNF) and interleukin-1, and phosphorylate and probably stimulate the transactivation function of c-Jun(5-7). Although GCK is found in many tissues, its expression in lymphoid follicles is restricted to the cells of the germinal centre, where it may participate in B-cell differentiation(3). Activation of the SAPK pathway by GCK illustrates further the striking, conservation of eukaryotic signalling mechanisms and defines the first physiological function of a mammalian Ste20.	MASSACHUSETTS GEN HOSP E, DIABET RES LAB, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP E, CARDIOL UNIT, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20007 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; PRINCESS MARGARET HOSP, ONTARIO CANC INST, TORONTO, ON M4X 1K9, CANADA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Woodgett, Jim/F-1087-2010; Pombo, Celia M/L-4479-2014; Kehrl, John/AAE-6292-2019	Woodgett, Jim/0000-0003-3731-5797; Pombo, Celia M/0000-0003-2541-9468; Kehrl, John/0000-0002-6526-159X; Force, Thomas/0000-0002-0450-8659				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; YAN MH, 1994, NATURE, V372, P798	23	207	215	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	1995	377	6551					750	754		10.1038/377750a0	http://dx.doi.org/10.1038/377750a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TB469	7477268				2022-12-01	WOS:A1995TB46900062
J	BUNDENS, WP; BERGAN, JJ; HALASZ, NA; MURRAY, J; DREHOBL, M				BUNDENS, WP; BERGAN, JJ; HALASZ, NA; MURRAY, J; DREHOBL, M			THE SUPERFICIAL FEMORAL VEIN - A POTENTIALLY LETHAL MISNOMER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THROMBOSIS; ULTRASOUND; DIAGNOSIS	Objective.-To assess the potential for error in interpretation of venous duplex reports that use the term ''superficial femoral vein.'' Design.-Three surveys conducted by mail. Setting-Three multispecialty medical groups, anatomy departments of all US medical schools, and vascular laboratories. Participants.-A total of 46 family practitioners and general internists, 95 chairpersons of departments of anatomy, and 85 laboratory directors. Main Outcome Measures.-Proposed treatment of a patient with leg pain and an acute thrombosis of the superficial femoral vein; what nomenclature(s) for the deep thigh veins is (are) felt to be correct, what are acceptable alternatives, what is taught to students and which is preferred; and what terminology is being used in lower limb venous duplex reports. Results.-Only 24% (11/46) of the respondents would have administered anticoagulants to the patient as described. Only 3% (3/95) of anatomists felt the term ''superficial femoral vein'' was correct, 22% (21/95) felt it was an acceptable alternative (though only 9% [9/95] taught it to medical students), and only 7% (7/95) of anatomists felt the term was preferred for everyday use, The term ''superficial femoral vein'' is used by 93% (79/85) of vascular laboratories in lower limb venous duplex reports. Conclusion.-Although the overwhelming majority of vascular laboratories use the term ''superficial femoral vein'' in venous duplex reports, the use of this term is potentially hazardous to patients. Most primary care physicians have not been taught and are not aware that the superficial femoral vein is a deep vein and that acute thrombosis of this vessel is potentially life threatening.	USN,MED CTR,SAN DIEGO,CA 92152; USN,CTR HLTH CARE,SAN DIEGO,CA 92152	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	BUNDENS, WP (corresponding author), UNIV CALIF SAN DIEGO,DEPT SURG,9500 GILMAN DR,0643,ROOM 147,LA JOLLA,CA 92093, USA.							BILLINGS JS, 1890, NATIONAL MED DICT, V1, P507; DOUGHERTY J, 1940, SURG GYNECOL OBSTET, V71, P697; ELIAS A, 1987, INT ANGIOL, V6, P175; Homans J, 1941, NEW ENGL J MED, V224, P179, DOI 10.1056/NEJM194101302240501; Homans J, 1934, N ENGL J MED, V211, P993; HOMANS J, 1937, AM J SURG, V38, P316; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MARKEL A, 1992, ARCH SURG-CHICAGO, V127, P305; Markel A, 1991, J VASC MED BIOL, V3, P432; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P133; RUBIN BG, 1994, J VASC SURG, V20, P698, DOI 10.1016/S0741-5214(94)70156-3; STRANDNESS DE, 1993, VASCULAR DIAGNOSIS, P772; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; 1989, NOMINA ANATOMICA, pA65	14	37	38	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1296	1298						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563535				2022-12-01	WOS:A1995TA10400025
J	DOLE, VP				DOLE, VP			ON FEDERAL-REGULATION OF METHADONE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAINTENANCE				DOLE, VP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							[Anonymous], 1995, FEDERAL REGULATION M; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; DOLE VP, 1982, NEW ENGL J MED, V306, P169, DOI 10.1056/NEJM198201213060310; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234	4	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1307	1307						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563538				2022-12-01	WOS:A1995TA10400028
J	HAIRE, WD; RUBY, EI; GORDON, BG; PATIL, KD; STEPHENS, LC; KOTULAK, GD; REED, EC; VOSE, JM; BIERMAN, PJ; KESSINGER, A; ARMITAGE, JO				HAIRE, WD; RUBY, EI; GORDON, BG; PATIL, KD; STEPHENS, LC; KOTULAK, GD; REED, EC; VOSE, JM; BIERMAN, PJ; KESSINGER, A; ARMITAGE, JO			MULTIPLE ORGAN DYSFUNCTION SYNDROME IN BONE-MARROW TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISSEMINATED INTRAVASCULAR COAGULATION; RESPIRATORY-DISTRESS SYNDROME; TUMOR-NECROSIS-FACTOR; HEPATIC VENOOCCLUSIVE DISEASE; ESCHERICHIA-COLI INFUSION; VENO-OCCLUSIVE DISEASE; PROTEIN-C DEFICIENCY; ANTITHROMBIN-III; SEPTIC SHOCK; MULTIORGAN FAILURE	Objective.-To define the frequency and outcome of organ dysfunction in bone marrow transplantation (BMT) and to determine if patients with organ dysfunction have lower levels of protein C (PC) and/or antithrombin III (ATIII) than those without organ dysfunction. Design.-Inception cohort of patients undergoing BMT, followed for 28 days, until hospital dismissal, or until death. Setting.-Bone marrow transplant department of a university hospital. Patients.-A total of 199 consecutive patients admitted for BMT. Interventions.-Standard supportive care was given to all patients. Main Outcome Measures.-Definitions of organ dysfunction were arrived at prior to beginning the study. They include pulmonary, central nervous system (CNS), hepatic, and renal dysfunction. Protein C and ATIII levels were measured prior to beginning the preparative regimen and weekly thereafter. Results.-Single organ dysfunction, manifesting as pulmonary, CNS, or hepatic dysfunction, occurred in 33 (48.5%) of the 199 patients and was a strong predictor of multiple organ dysfunction syndrome (MODS) and death, Death occurred in 14 (7.0%) of the patients. Cause of death was precisely identified in only four patients. Low levels of either PC or ATIII were associated with death and pulmonary, CNS, and hepatic dysfunction, Multivariate analysis showed ATIII and PC levels were associated with single organ dysfunction independent of the type of transplant, the type of preparative regimen, and the presence of bacteremia. Conclusions.-Single organ dysfunction during BRAT is a marker for a systemic abnormality that has a high likelihood of progressing to MODS, similar to that seen in other critically ill patient populations. MODS is the leading cause of death in series of BMT patients. Low levels of ATIII and PC are markers of and may be involved in the pathogenesis of MODS in BMT.	UNIV NEBRASKA,MED CTR,DEPT PEDIAT,OMAHA,NE 68182; UNIV NEBRASKA,MED CTR,DEPT PREVENT & SOCIAL MED,OMAHA,NE 68182	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	HAIRE, WD (corresponding author), UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198, USA.							AMBRUS JL, 1990, J MED, V21, P67; ARMITAGE JO, 1991, AM J MED, V91, P605, DOI 10.1016/0002-9343(91)90213-H; AYASH LJ, 1990, J CLIN ONCOL, V8, P1699, DOI 10.1200/JCO.1990.8.10.1699; BAGGE L, 1989, SCAND J CLIN LAB INV, V49, P63, DOI 10.3109/00365518909089079; BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BERNAUER W, 1991, ANN INTERN MED, V115, P925, DOI 10.7326/0003-4819-115-12-925; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BONE RC, 1992, ARCH INTERN MED, V152, P1381, DOI 10.1001/archinte.152.7.1381; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1992, CHEST, V101, P594, DOI 10.1378/chest.101.3.594; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; CARRERAS E, 1993, ANN HEMATOL, V66, P77, DOI 10.1007/BF01695888; CARVALHO AC, 1988, J LAB CLIN MED, V112, P270; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CLARK JG, 1993, AM REV RESPIR DIS, V147, P1601, DOI 10.1164/ajrccm/147.6_Pt_1.1601; DICKNEITE G, 1993, THROMB HAEMOSTASIS, V69, P98; EMERSON TE, 1987, CIRC SHOCK, V21, P1; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; FAIONI EM, 1993, BLOOD, V81, P3458; FAIST FN, 1983, J TRAUMA, V9, P775; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; FOURRIER F, 1990, INTENS CARE MED, V16, P121, DOI 10.1007/BF01699858; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; FUGGER R, 1993, EUR J SURG, V159, P525; GORDON B, 1991, BONE MARROW TRANSPL, V8, P497; GORDON BG, 1993, BONE MARROW TRANSPL, V11, P61; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; HARPER PL, 1990, BONE MARROW TRANSPL, V5, P39; HENAO FJ, 1991, J TRAUMA, V31, P74, DOI 10.1097/00005373-199101000-00014; HESSELVIK JF, 1991, THROMB HAEMOSTASIS, V65, P126; HESSELVIK JF, 1989, CRIT CARE MED, V17, P724, DOI 10.1097/00003246-198908000-00002; HOLLER E, 1990, BLOOD, V75, P1011; KAUFMAN PA, 1990, CANCER, V66, P515, DOI 10.1002/1097-0142(19900801)66:3<515::AID-CNCR2820660319>3.0.CO;2-7; KESSINGER A, 1989, BLOOD, V74, P1260; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LAMMLE B, 1984, AM J CLIN PATHOL, V823, P396; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LORENTE JA, 1993, CHEST, V103, P1536, DOI 10.1378/chest.103.5.1536; MARSHALL WG, 1983, J TRAUMA, V23, P102, DOI 10.1097/00005373-198302000-00005; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MILLER RS, 1994, J TRAUMA, V37, P442, DOI 10.1097/00005373-199409000-00019; MODIG J, 1983, ACTA ANAESTH SCAND, V27, P369, DOI 10.1111/j.1399-6576.1983.tb01970.x; NEDORN E, 1991, KLIN WOCHENSCHR, V69, P817, DOI 10.1007/BF01744277; PRELLWITZ W, 1982, CLIN CHEM, V28, P2249; REDENS TB, 1988, CIRC SHOCK, V26, P15; SCHIPPER HG, 1981, THROMB RES, V21, P73, DOI 10.1016/0049-3848(84)90034-3; SHETH SB, 1991, AM J HEMATOL, V36, P14, DOI 10.1002/ajh.2830360104; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TAYLOR FB, 1991, BLOOD, V78, P364; TAYLOR FB, 1988, CIRC SHOCK, V26, P227; TRACEY KJ, 1993, CRIT CARE MED, V21, pS415; WINGARD JR, 1989, BONE MARROW TRANSPL, V4, P685	57	58	62	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1289	1295		10.1001/jama.274.16.1289	http://dx.doi.org/10.1001/jama.274.16.1289			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563534				2022-12-01	WOS:A1995TA10400024
J	BERRY, GT; NISSIM, I; LIN, ZP; MAZUR, AT; GIBSON, JB; SEGAL, S				BERRY, GT; NISSIM, I; LIN, ZP; MAZUR, AT; GIBSON, JB; SEGAL, S			ENDOGENOUS SYNTHESIS OF GALACTOSE IN NORMAL MEN AND PATIENTS WITH HEREDITARY GALACTOSEMIA	LANCET			English	Note							VEGETABLES; FRUITS	Despite restricted ingestion of lactose, patients with galactose-1-phosphate uridyltransferase deficiency have raised concentrations of galactose metabolites in blood and urine. Endogenous production of galactose may underlie this phenomenon. Using isotopically labelled galactose in a continuous intravenous infusion, we employed the steady-state flux method to calculate endogenous galactose production rate in three normal men and three patients with classic galactosaemia. We found that galactosaemic patients and normal subjects synthesise gram quantities of galactose per day. The rate of synthesis ranged from 0.53-1.05 mg/kg per h. Endogenous production of galactose may be an important factor in the pathogenesis of the complications of the brain and ovary, and could explain the persistent elevation of galactose metabolites in patients despite dietary restriction of galactose.			BERRY, GT (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV BIOCHEM DEV & MOLEC DIS,PHILADELPHIA,PA 19104, USA.			Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [MO1-RR-00240] Funding Source: Medline; NICHD NIH HHS [P01-HD-29847] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD029847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERRY GT, 1993, J INHERIT METAB DIS, V16, P91, DOI 10.1007/BF00711320; Elsas LJ, 1993, INT PEDIATR, V8, P101; Gitzelmann R, 1975, NORMAL PATHOLOGICAL, P25; GROSS KC, 1991, J INHERIT METAB DIS, V14, P253, DOI 10.1007/BF01800599; HOLTON JB, 1994, LANCET, V344, P1242, DOI 10.1016/S0140-6736(94)90745-5; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; Segal S, 1995, METABOLIC MOL BASES, P967; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; WIECKO J, 1976, J AM CHEM SOC, V98, P7631, DOI 10.1021/ja00440a030; YUDKOFF M, 1995, CLIN PERINATOL, V22, P97	10	112	115	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1073	1074		10.1016/S0140-6736(95)91745-4	http://dx.doi.org/10.1016/S0140-6736(95)91745-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564790	hybrid			2022-12-01	WOS:A1995TA69700014
J	CARNEY, AS; WEIR, J; BALDWIN, DL				CARNEY, AS; WEIR, J; BALDWIN, DL			CONTAMINATION WITH BLOOD DURING MANAGEMENT OF EPISTAXIS	BRITISH MEDICAL JOURNAL			English	Article									SOUTHMEAD GEN HOSP,DEPT OTOLARYNGOL,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital			Carney, A/W-8202-2019	Carney, A/0000-0001-7507-7983				BOON D, 1994, J ACCID EMERG MED, V11, P175; BREARLY S, 1989, BRIT MED J, V299, P131; LITTLECHILD P, 1992, BRIT MED J, V305, P156, DOI 10.1136/bmj.305.6846.156; STEEDMAN DJ, 1994, J ACCID EMERG MED, V11, P17; 1990, GUIDANCE CLIN HLTH W	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1064	1064		10.1136/bmj.311.7012.1064	http://dx.doi.org/10.1136/bmj.311.7012.1064			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580665	Green Published			2022-12-01	WOS:A1995TB35400024
J	CROSS, SS; HARRISON, RF; KENNEDY, RL				CROSS, SS; HARRISON, RF; KENNEDY, RL			INTRODUCTION TO NEURAL NETWORKS	LANCET			English	Note									UNIV SHEFFIELD,DEPT AUTOMAT CONTROL & SYST ENGN,SHEFFIELD,S YORKSHIRE,ENGLAND; UNIV EDINBURGH,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Sheffield; University of Edinburgh	CROSS, SS (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PATHOL,BEECH HILL RD,SHEFFIELD S10 2UL,S YORKSHIRE,ENGLAND.		Harrison, Robert/B-9034-2008					Ash T., 1989, Connection Science, V1, P365, DOI 10.1080/09540098908915647; BRAHAMS D, 1989, LANCET, V1, P632; CARPENTER GA, 1991, NEURAL NETWORKS, V4, P565, DOI 10.1016/0893-6080(91)90012-T; CARPENTER GA, 1987, COMPUT VISION GRAPH, V37, P54, DOI 10.1016/S0734-189X(87)80014-2; CARPENTER GA, 1993, P WORLD C NEURAL NET, V1, P501; Cybenko G., 1989, Mathematics of Control, Signals, and Systems, V2, P303, DOI 10.1007/BF02551274; Fausett L.V., 1994, FUNDAMENTALS NEURAL, V1st ed.).; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrison R. F., 1994, Journal of Artificial Neural Networks, V1, P183; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kohonen T, 1984, SELF ORG ASS MEMORY; McCulloch Warren S., 1943, BULL MATH BIOPHYS, V5, P115, DOI 10.1007/BF02459570; Moody J, 1989, NEURAL COMPUT, V1, P281, DOI 10.1162/neco.1989.1.2.281; Mozer M. C., 1989, Connection Science, V1, P3, DOI 10.1080/09540098908915626; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; STEEN PM, 1994, ANN THORAC SURG, V58, P1836, DOI 10.1016/0003-4975(94)91723-X; WYATT J, 1991, 15TH P ANN S COMP AP, P3	19	378	383	1	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1075	1079		10.1016/S0140-6736(95)91746-2	http://dx.doi.org/10.1016/S0140-6736(95)91746-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564791				2022-12-01	WOS:A1995TA69700015
J	HERNANDEZRODRIGUEZ, NA; CAMBREY, AD; HARRISON, NK; CHAMBERS, RC; GRAY, AJ; SOUTHCOTT, AM; DUBOIS, RM; BLACK, CM; SCULLY, MF; MCANULTY, RJ; LAURENT, GJ				HERNANDEZRODRIGUEZ, NA; CAMBREY, AD; HARRISON, NK; CHAMBERS, RC; GRAY, AJ; SOUTHCOTT, AM; DUBOIS, RM; BLACK, CM; SCULLY, MF; MCANULTY, RJ; LAURENT, GJ			ROLE OF THROMBIN IN PULMONARY FIBROSIS	LANCET			English	Note							GROWTH-FACTORS	Pulmonary fibrosis commonly develops in systemic sclerosis. We assessed the role of thrombin in promoting fibroblast proliferation in the lungs in this disorder. Bronchoalveolar lavage fluid (BALF) thrombin concentrations were higher in ten patients with systemic sclerosis than in 12 healthy controls (14.6 vs 3.6 nmol/L, p<0.02), but values in patients with cryptogenic fibrosing alveolitis (n=10) or sarcoidosis (n=10) were not increased. BALF from all patients induced fibroblast proliferation. This proliferation was attenuated by thrombin inhibitors for BALF from systemic sclerosis patients only. We suggest thrombin contributes to lung fibroblast proliferation in this disorder.	UNIV LONDON UNIV COLL,SCH MED,CTR CARDIOPULM BIOCHEM & RESP MED,LONDON WC1E 6JJ,ENGLAND; MORRISTON HOSP,RESP UNIT,SWANSEA,W GLAM,WALES; NATL HEART & LUNG INST,INTERSTITIAL LUNG DIS UNIT,LONDON,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND; THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND	University of London; University College London; UCL Medical School; Morriston Hospital; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Thrombosis Research Institute			McAnulty, Robin J/C-2502-2008	McAnulty, Robin J/0000-0003-1936-4245; Chambers, Rachel/0000-0003-1370-9417				ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; CAMBREY AD, 1994, AM J RESP CELL MOL, V11, P439, DOI 10.1165/ajrcmb.11.4.7917311; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; GRAY AJ, 1990, J CELL SCI, V96, P271; HARRISON NK, 1991, AM REV RESPIR DIS, V144, P706, DOI 10.1164/ajrccm/144.3_Pt_1.706; HARRISON NK, 1994, CLIN SCI, V86, P141, DOI 10.1042/cs0860141; HARRISON NK, 1993, RESP MED, P190; IDELL S, 1987, AM REV RESPIR DIS, V136, P1466, DOI 10.1164/ajrccm/136.6.1466; LEROY EC, 1988, TXB MED, P1211; OLIVER MH, 1989, J CELL SCI, V92, P513	10	117	118	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1071	1073		10.1016/S0140-6736(95)91744-6	http://dx.doi.org/10.1016/S0140-6736(95)91744-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564789				2022-12-01	WOS:A1995TA69700013
J	HUGHES, CH; BAUMER, JH				HUGHES, CH; BAUMER, JH			MOVING HOUSE - A RISK FACTOR FOR THE DEVELOPMENT OF CHILDHOOD ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							SMOKING; ILLNESS		DERRIFORD HOSP,DEPT CHILD HLTH,PLYMOUTH PL6 8DH,DEVON,ENGLAND	Derriford Hospital	HUGHES, CH (corresponding author), CTR HLTH,ESTOVER,PLYMOUTH PL6 8UE,DEVON,ENGLAND.							ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1069	1070		10.1136/bmj.311.7012.1069	http://dx.doi.org/10.1136/bmj.311.7012.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580667	Green Published			2022-12-01	WOS:A1995TB35400026
J	PEET, SM; CASTLEDEN, CM; MCGROTHER, CW				PEET, SM; CASTLEDEN, CM; MCGROTHER, CW			PREVALENCE OF URINARY AND FECAL INCONTINENCE IN HOSPITALS AND RESIDENTIAL AND NURSING-HOMES FOR OLDER-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,LEICESTER LE2 7LX,LEICS,ENGLAND	University of Leicester	PEET, SM (corresponding author), UNIV LEICESTER,LEICESTER GEN HOSP,DIV MED ELEDRLY,LEICESTER LE5 4PW,LEICS,ENGLAND.							Clarke M, 1979, HLTH TRENDS, V11, P17; Donaldson L J, 1983, Health Trends, V15, P58; MCGROTHER CW, 1987, AGE AGEING, V16, P105, DOI 10.1093/ageing/16.2.105; STERN MC, 1993, BRIT MED J, V306, P827, DOI 10.1136/bmj.306.6881.827; TOBIN GW, 1986, AGE AGEING, V15, P292, DOI 10.1093/ageing/15.5.292	5	75	75	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1063	1064		10.1136/bmj.311.7012.1063	http://dx.doi.org/10.1136/bmj.311.7012.1063			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580664	Green Published			2022-12-01	WOS:A1995TB35400023
J	SAARINEN, UM; KAJOSAARI, M				SAARINEN, UM; KAJOSAARI, M			BREAST-FEEDING AS PROPHYLAXIS AGAINST ATOPIC DISEASE - PROSPECTIVE FOLLOW-UP-STUDY UNTIL 17 YEARS OLD	LANCET			English	Article							ALLERGIC DISEASES; NATURAL-HISTORY; CHILDHOOD; CHILDREN; ASTHMA; BREAST; MILK; INFANTS; ECZEMA; DIET	Atopic diseases constitute a common health problem. For infants at hereditary risk, prophylaxis of atopy has been sought in elimination diets and other preventive measures. We followed up healthy infants during their first year, and then at ages 1, 3, 5, 10, and 17 years to determine the effect on atopic disease of breastfeeding. Of the initial 236 infants, 150 completed the follow-up, which included history taking, physical examination, and laboratory tests for allergy. The subjects were divided into three groups: prolonged (>6 months), intermediate (1-6 months), and short or no (<1 month) breastfeeding. The prevalence of manifest atopy throughout follow-up was highest in the group who had little or no breastfeeding (p<0.05, analysis of variance and covariance with repeated measures [ANOVA]), Prevalence of eczema at ages 1 and 3 years was lowest (p=0.03, ANOVA) in the prolonged breastfeeding group, prevalence of food allery was highest in the little or no groups (p=0.02, ANOVA) at 1-3 years, and respiratory allergy was also most prevalent in the latter group (p=0.01, ANOVA) having risen to 65% at 17 years of age, Prevalences in the prolonged, intermediate, and little or no groups at age 17 were 42 (95% CI 31-52)%, 36 (28-44)%, and 65 (56-74)% (p=0.02, trend test) for atopy, respectively, and 8 (6-10)%, 23 (21-25)%, and 54 (52-56)% (p=0.0001, trend test) for substantial atopy. We conclude that breastfeeding is prophylactic against atopic disease-including atopic eczema, food allergy, and respiratory allergy-throughout childhood and adolescence.	UNIV HELSINKI,HOSP ALLERG DIS,HELSINKI,FINLAND	University of Helsinki	SAARINEN, UM (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,STENBACKINKATU 11,SF-00290 HELSINKI,FINLAND.							AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BUSINCO L, 1987, ANN ALLERGY, V59, P183; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COHEN GA, 1985, ANN ALLERGY, V4, P112; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GORDON RR, 1982, LANCET, V1, P910; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [DOI 10.2340/00015555924447, 10.2340/00015555924447]; HIDE DW, 1981, ARCH DIS CHILD, V56, P172, DOI 10.1136/adc.56.3.172; JACKSON PG, 1981, LANCET, V1, P1285; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; SAARINEN UM, 1979, LANCET, V2, P163; SAARINEN UM, 1979, CLIN ALLERGY, V9, P339, DOI 10.1111/j.1365-2222.1979.tb02492.x; SAARINEN UM, 1980, LANCET, V1, P166; SAARINEN UM, 1982, ALLERGY, V37, P345, DOI 10.1111/j.1398-9995.1982.tb01920.x; SARFATI M, 1986, EUR J IMMUNOL, V16, P1005, DOI 10.1002/eji.1830160822; SAVILAHTI E, 1981, ALLERGY, V36, P73, DOI 10.1111/j.1398-9995.1981.tb04101.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRANGERT K, 1976, PEDIATRICS, V57, P191; VANASPEREN PP, 1984, CLIN ALLERGY, V14, P525; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WALKER WA, 1977, M JOHNSON S PERINAT, V2, P111; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [10.1111/j.1399-3038.1992.tb00035.x, DOI 10.1111/J.1399-3038.1992.TB00035.X]	33	489	514	1	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1065	1069		10.1016/S0140-6736(95)91742-X	http://dx.doi.org/10.1016/S0140-6736(95)91742-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564787				2022-12-01	WOS:A1995TA69700011
J	STRACHAN, DP; CAREY, IM				STRACHAN, DP; CAREY, IM			HOME-ENVIRONMENT AND SEVERE ASTHMA IN ADOLESCENCE - A POPULATION-BASED CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; RISK-FACTORS; CHILDREN; PETS; SENSITIZATION; ALLERGY	Objective-To investigate the effects of the home environment on the risk of severe asthma during adolescence. Design-A questionnaire based case-control study drawn from a cross sectional survey of allergic diseases among secondary school pupils in Sheffield in 1991. Subjects-763 children whose parents had reported that over the previous 12 months they had suffered either 12 or more wheezing attacks or a speech limiting attack of wheeze. A further 763 children were frequency matched for age and school class to act as controls. Analysis was restricted to 486 affected children and 475 others born between 1975 and 1980 who had lived at their present address for more than three years. Results-Independent associations with severe wheeze were seen for non-feather bedding, especially foam pillows (odds ratio 2.78; 95% confidence interval 1.89 to 4.17), and the ownership of furry pets now (1.51; 1.04 to 2.20) and at birth (1.70; 1.20 to 2.40). These estimates were derived from subjects whose parents denied making changes in the bedroom or avoiding having a pet because of allergy. Parental smoking, use of gas for cooking, age of mattress, and mould growth in the child's bedroom were not significantly associated with wheezing. Conclusions-Either our study questionnaire failed to detect the avoidance or removal of feather bedding by allergic families or there is some undetermined hazard related to foam pillows. Synthetic bedding and furry pets were both widespread in this population and may represent remediable causes of childhood asthma.			STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Carey, Iain/O-6973-2014	Carey, Iain/0000-0003-1099-8460				ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Francis B., 1993, GLIM SYSTEM RELEASE; HONG CY, 1994, Q J MED, V87, P639; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; PEARCE N, 1993, EUR RESPIR J, V6, P1455; POPP W, 1990, ALLERGY, V45, P75, DOI 10.1111/j.1398-9995.1990.tb01087.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHATZ G, 1982, ANN ALLERGY, V48, P59; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; WARDLAW AJ, 1992, J ALLERGY CLIN IMMUN, V90, P358	17	137	142	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 21	1995	311	7012					1053	1056		10.1136/bmj.311.7012.1053	http://dx.doi.org/10.1136/bmj.311.7012.1053			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB354	7580660	Green Published			2022-12-01	WOS:A1995TB35400018
J	VANDERPUT, NMJ; STEEGERSTHEUNISSEN, RPM; FROSST, P; TRIJBELS, FJM; ESKES, TKAB; VANDENHEUVEL, LP; MARIMAN, ECM; DENHEYER, M; ROZEN, R; BLOM, HJ				VANDERPUT, NMJ; STEEGERSTHEUNISSEN, RPM; FROSST, P; TRIJBELS, FJM; ESKES, TKAB; VANDENHEUVEL, LP; MARIMAN, ECM; DENHEYER, M; ROZEN, R; BLOM, HJ			MUTATED METHYLENETETRAHYDROFOLATE REDUCTASE AS A RISK FACTOR FOR SPINA-BIFIDA	LANCET			English	Note								Periconceptional folate supplementation reduces the risk of neural-tube defects. We studied the frequency of the 677C-->T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in 55 patients with spina bifida and parents of such patients (70 mothers, 60 fathers). 5% of 207 controls were homozygous for the 677C-->T mutation compared with 16% of mothers, 10% of fathers, and 13% of patients. The mutation was associated with decreased MTHFR activity, low plasma folate, and high plasma homocysteine and red-cell folate concentrations. The 677C-->7 mutation should be regarded as a genetic risk factor for spina bifida.	UNIV NIJMEGEN HOSP,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT OBSTET & GYNECOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT EPIDEMIOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,THE HAGUE,NETHERLANDS; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ,CANADA	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; McGill University; McGill University; McGill University			van den Heuvel, L.P.W.J./H-8044-2014; Rozen, Rima/AAE-9294-2020; van den Heuvel, Lambertus/AAM-1772-2021	van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel, Lambertus/0000-0003-3917-6727; Blom, Henk/0000-0001-5202-9241				CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; KANG SS, 1991, AM J HUM GENET, V48, P536; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; STEEGERSTHEUNIS.RP, 1994, METABOLISM, V43, P1475; Te Poele-Pothoff M. T. W. B., 1995, Annals of Clinical Biochemistry, V32, P218; 1991, LANCET, V338, P131	10	738	756	0	37	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 21	1995	346	8982					1070	1071		10.1016/S0140-6736(95)91743-8	http://dx.doi.org/10.1016/S0140-6736(95)91743-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA697	7564788	Green Submitted, Bronze			2022-12-01	WOS:A1995TA69700012
J	ADAMES, N; BLUNDELL, K; ASHBY, MN; BOONE, C				ADAMES, N; BLUNDELL, K; ASHBY, MN; BOONE, C			ROLE OF YEAST INSULIN-DEGRADING ENZYME HOMOLOGS IN PROPHEROMONE PROCESSING AND BUD SITE SELECTION	SCIENCE			English	Article							FACTOR MATING PHEROMONE; STE6 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; A-FACTOR; FARNESYL CYSTEINE; RAS PROTEINS; TERMINAL METHYLATION; SHUTTLE VECTORS; ACTIVE-SITE; METHYLTRANSFERASE	The Saccharomyces cerevisiae AXL1 gene product Axl1p shares homology with the insulin-degrading enzyme family of endoproteases. Yeast axl1 mutants showed a defect in a-factor pheromone secretion, and a probable site of processing by Axl1p was identified within the a-factor precursor. In addition, Axl1p appears to function as a morphogenetic determinant for axial bud site selection. Amino acid substitutions within the presumptive active site of Axl1p caused defects in propheromone processing but failed to perturb bud site selection. Thus, Axl1p has been shown to participate in the dual regulation of distinct signaling pathways, and a member of the insulinase family has been implicated in propeptide processing.	SIMON FRASER UNIV, INST BIOCHEM & MOLEC BIOL, BURNABY, BC V5A 1S6, CANADA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Simon Fraser University; University of California System; University of California Berkeley			Adames, Neil/C-8863-2012; Adames, Neil/S-1460-2017; Adames, Neil/AAO-7913-2020	Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348; Adames, Neil/0000-0003-4331-9348				AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ANASTASI A, 1993, BIOCHEM J, V290, P601, DOI 10.1042/bj2900601; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; ASHBY MN, 1995, METHOD ENZYMOL, V250, P235; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BOONE C, 1992, NUCLEIC ACIDS RES, V20, P4661, DOI 10.1093/nar/20.17.4661; CALDWELL GA, 1994, J BIOL CHEM, V269, P19817; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHEN P, 1993, THESIS J HOPKINS U S; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LI D, 1992, J BIOL CHEM, V267, P2414; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MARR RS, 1990, J BIOL CHEM, V265, P20057; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; PIEROTTI AR, 1994, P NATL ACAD SCI USA, V91, P6078, DOI 10.1073/pnas.91.13.6078; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEINER DF, 1992, J BIOL CHEM, V267, P23435	50	113	114	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					464	467		10.1126/science.270.5235.464	http://dx.doi.org/10.1126/science.270.5235.464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569998				2022-12-01	WOS:A1995TA37400040
J	AIGNER, L; ARBER, S; KAPFHAMMER, JP; LAUX, T; SCHNEIDER, C; BOTTERI, F; BRENNER, HR; CARONI, P				AIGNER, L; ARBER, S; KAPFHAMMER, JP; LAUX, T; SCHNEIDER, C; BOTTERI, F; BRENNER, HR; CARONI, P			OVEREXPRESSION OF THE NEURAL GROWTH-ASSOCIATED PROTEIN GAP-43 INDUCES NERVE SPROUTING IN THE ADULT NERVOUS-SYSTEM OF TRANSGENIC MICE	CELL			English	Article							RETINAL GANGLION-CELLS; NEUROMUSCULAR-JUNCTIONS; TRANSPORTED PROTEINS; NEURITE OUTGROWTH; AXON REGENERATION; PC12 CELLS; EXPRESSION; INJURY; NEURONS; MUSCLE	Regulation of neurite outgrowth and structural plasticity may involve the expression of intrinsic determinants controlling growth competence. We have tested this concept by targeting constitutive expression of the growth-associated protein GAP-43 to the neurons of adult transgenic mice. Such mice showed striking spontaneous nerve sprouting at the neuromuscular junction and in the terminal field of hippocampal messy fibers. In control mice, these nerve fibers did not express GAP-43, and did not sprout spontaneously. Lesion-induced nerve sprouting and terminal arborization during reinnervation were greatly potentiated in GAP-43-overexpressing mice. A mutant GAP-43 that cannot be phosphorylated by PKC had reduced sprout-promoting activity. The results establish GAP-43 as an intrinsic presynaptic determinant for neurite outgrowth and plasticity.	UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND; UNIV BASEL,DEPT PHYSIOL,CH-4000 BASEL,SWITZERLAND	University of Zurich; University of Basel	AIGNER, L (corresponding author), FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND.			Aigner, Ludwig/0000-0002-1653-8046; Arber, Silvia/0000-0002-6261-250X				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; BISBY MA, 1993, SOC NEUROSCI, V23; BROWN MC, 1984, TRENDS NEUROSCI, V7, P10, DOI 10.1016/S0166-2236(84)80180-0; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CARONI P, 1992, J NEUROSCI, V12, P3849; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHONG MS, 1994, J NEUROSCI, V14, P4375; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MCKERRACHER L, 1993, J NEUROSCI, V13, P5294, DOI 10.1523/JNEUROSCI.13-12-05294.1993; MEIRI KF, 1990, J NEUROSCI, V10, P256; MOYA KL, 1988, J NEUROSCI, V8, P4445; PESTRONK A, 1978, MUSCLE NERVE, V1, P70, DOI 10.1002/mus.880010110; REYNOLDS ML, 1991, NEUROSCIENCE, V41, P201, DOI 10.1016/0306-4522(91)90210-F; REYNOLDS ML, 1992, J NEUROCYTOL, V21, P50, DOI 10.1007/BF01206897; ROBBINS N, 1988, J NEUROCYTOL, V17, P545, DOI 10.1007/BF01189809; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.neuro.12.1.491; SCHREYER DJ, 1991, J NEUROSCI, V11, P3738; SHEA TB, 1991, J NEUROSCI, V11, P1685; SHWEGLER G, 1995, J NEUROSCI, V15, P2756; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.neuro.12.1.127; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; SON YJ, 1995, NEURON, V114, P133; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; THESLEFF S, 1989, Q J EXP PHYSIOL CMS, V74, P1003, DOI 10.1113/expphysiol.1989.sp003329; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K	41	527	550	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					269	278		10.1016/0092-8674(95)90168-X	http://dx.doi.org/10.1016/0092-8674(95)90168-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585944	Bronze			2022-12-01	WOS:A1995TA96500013
J	COUCOUVANIS, E; MARTIN, GR				COUCOUVANIS, E; MARTIN, GR			SIGNALS FOR DEATH AND SURVIVAL - A 2-STEP MECHANISM FOR CAVITATION IN THE VERTEBRATE EMBRYO	CELL			English	Article							PROGRAMMED CELL-DEATH; MOUSE EMBRYOS; NERVOUS-SYSTEM; CARCINOMA-CELLS; APOPTOSIS; DIFFERENTIATION; TERATOCARCINOMA; FIBROBLASTS; BLASTOCYST; INDUCTION	Conversion of a solid primordium to a hollow tube of cells is a morphogenetic process used frequently during vertebrate embryogenesis. In the early mouse embryo, this process of cavitation transforms the solid embryonic ectoderm into a columnar epithelium surrounding a cavity. Using both established cell lines and normal embryos, we provide evidence that cavitation in the early mouse embryo is the result of the interplay of two signals, one from an outer layer of endoderm cells that acts over short distances to create a cavity by inducing apoptosis of the inner ectodermal cells, and the other a rescue signal mediated by contact with the basement membrane that is required for the survival of the columnar cells that line the cavity. This simple model provides a paradigm for investigating tube morphogenesis in diverse developmental settings.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	COUCOUVANIS, E (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022731] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD22731] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BORGHESE E, 1955, J ANAT, V84, P287; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROKS PC, 1994, CELL, V79, P1157; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CROSBY WM, 1962, OBSTET GYNECOL, V20, P507; ELLIOTT B, 1992, J CELL PHYSIOL, V152, P292, DOI 10.1002/jcp.1041520210; ELSHERSH.AM, 1974, J EMBRYOL EXP MORPH, V31, P643; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HAMBURGER V, 1949, J EXP ZOOL, V111, P451; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HINCHLIFFE JR, 1981, CELL DEATH BIOL PATH, P35; Hogan B., 1986, MANIPULATING MOUSE E, P17; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOFF ARTHUR K., 1933, CARNEGIE INST WASHINGTON [PUBL 443] CONTR TO EMBR, V24, P61; LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I; LEHMAN JM, 1974, J CELL PHYSIOL, V84, P13, DOI 10.1002/jcp.1040840103; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MUMMERY CL, 1991, DIFFERENTIATION, V46, P51, DOI 10.1111/j.1432-0436.1991.tb00865.x; MUMMERY CL, 1985, DEV BIOL, V108, P402; Nagy A., 1993, Gene targeting: a practical approach., P147; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Snow M.H.L., 1987, P202; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1975, P NATL ACAD SCI USA, V72, P5099, DOI 10.1073/pnas.72.12.5099; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251	48	484	498	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					279	287		10.1016/0092-8674(95)90169-8	http://dx.doi.org/10.1016/0092-8674(95)90169-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585945	Bronze			2022-12-01	WOS:A1995TA96500014
J	ELIEZER, D; JENNINGS, PA; WRIGHT, PE; DONIACH, S; HODGSON, KO; TSURUTA, H				ELIEZER, D; JENNINGS, PA; WRIGHT, PE; DONIACH, S; HODGSON, KO; TSURUTA, H			THE RADIUS OF GYRATION OF AN APOMYOGLOBIN FOLDING INTERMEDIATE	SCIENCE			English	Article							PATHWAY		STANFORD UNIV, DEPT APPL PHYS, STANFORD, CA 94305 USA; STANFORD UNIV, STANFORD SYNCHROTRON RADIAT LAB, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University	ELIEZER, D (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Eliezer, David/GRS-5702-2022	Wright, Peter/0000-0002-1368-0223	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034909, R01DK034909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014541] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01209] Funding Source: Medline; NIDDK NIH HHS [DK34909] Funding Source: Medline; NIGMS NIH HHS [GM14541] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ELIEZER D, 1993, BIOPHYS J, V65, P912, DOI 10.1016/S0006-3495(93)81124-X; ELIEZER D, 1994, EUR BIOPHYS J, V23, P297; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JENNINGS PA, 1994, STATISTICAL MECHANIC; NISHII I, 1994, BIOCHEMISTRY-US, V33, P4903, DOI 10.1021/bi00182a019	7	132	131	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					487	488		10.1126/science.270.5235.487	http://dx.doi.org/10.1126/science.270.5235.487			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570004				2022-12-01	WOS:A1995TA37400046
J	FRASER, CM; GOCAYNE, JD; WHITE, O; ADAMS, MD; CLAYTON, RA; FLEISCHMANN, RD; BULT, CJ; KERLAVAGE, AR; SUTTON, G; KELLEY, JM; FRITCHMAN, JL; WEIDMAN, JF; SMALL, KV; SANDUSKY, M; FUHRMANN, J; NGUYEN, D; UTTERBACK, TR; SAUDEK, DM; PHILLIPS, CA; MERRICK, JM; TOMB, JF; DOUGHERTY, BA; BOTT, KF; HU, PC; LUCIER, TS; PETERSON, SN; SMITH, HO; HUTCHISON, CA; VENTER, JC				FRASER, CM; GOCAYNE, JD; WHITE, O; ADAMS, MD; CLAYTON, RA; FLEISCHMANN, RD; BULT, CJ; KERLAVAGE, AR; SUTTON, G; KELLEY, JM; FRITCHMAN, JL; WEIDMAN, JF; SMALL, KV; SANDUSKY, M; FUHRMANN, J; NGUYEN, D; UTTERBACK, TR; SAUDEK, DM; PHILLIPS, CA; MERRICK, JM; TOMB, JF; DOUGHERTY, BA; BOTT, KF; HU, PC; LUCIER, TS; PETERSON, SN; SMITH, HO; HUTCHISON, CA; VENTER, JC			THE MINIMAL GENE COMPLEMENT OF MYCOPLASMA-GENITALIUM	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; DNA POLYMERASE-III; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; AMINO-ACIDS; PROTEIN; GENOME; PNEUMONIAE; CAPRICOLUM; SEQUENCE	The complete nucleotide sequence (580,070 base pairs) of the Mycoplasma genitalium genome, the smallest known genome of any free-living organism, has been determined by whole-genome random sequencing and assembly. A total of only 470 predicted coding regions were identified that include genes required for DNA replication, transcription and translation, DNA repair, cellular transport, and energy metabolism. Comparison of this genome to that of Haemophilus influenzae suggests that differences in genome content are reflected as profound differences in physiology and metabolic capacity between these two organisms.	SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	FRASER, CM (corresponding author), INST GENOM RES, 9712 MED CTR DR, ROCKVILLE, MD 20850 USA.			Fraser, Claire/0000-0003-1462-2428; Kerlavage, Anthony/0000-0002-3954-9653	NHLBI NIH HHS [HL19171] Funding Source: Medline; NIAID NIH HHS [AI33161, AIO8998] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008998, R21AI008998, R01AI033161, R01AI008998] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY CC, 1994, J BACTERIOL, V176, P5814, DOI 10.1128/JB.176.18.5814-5819.1994; BASEMAN JB, 1988, J CLIN MICROBIOL, V26, P2266, DOI 10.1128/JCM.26.11.2266-2269.1988; BORK P, 1995, MOL MICROBIOL, V16, P955, DOI 10.1111/j.1365-2958.1995.tb02321.x; BORODOVSKY M, 1988, METHOD ENZYMOL, V164, P123; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; COLLIER AM, 1992, ZENTRALBL BAKTERIO S, V20, P73; COLLIER DN, 1994, J BACTERIOL, V176, P4937, DOI 10.1128/jb.176.16.4937-4940.1994; COLMAN SD, 1990, MOL MICROBIOL, V4, P683, DOI 10.1111/j.1365-2958.1990.tb00638.x; DALLO SF, 1990, MICROB PATHOGENESIS, V8, P371, DOI 10.1016/0882-4010(90)90096-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; HAYFLICK L, 1965, TEX REP BIOL MED, VS 23, P285; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HU PC, 1987, INFECT IMMUN, V55, P1126, DOI 10.1128/IAI.55.5.1126-1131.1987; INAMINE JM, 1989, GENE, V82, P259, DOI 10.1016/0378-1119(89)90051-6; JENSEN JS, 1993, GENITOURIN MED, V69, P265; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOMBERG A, 1992, DNA REPLICATION; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LUCIER TS, 1994, GENE, V150, P27, DOI 10.1016/0378-1119(94)90853-2; LUCIER TS, UNPUB; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; Maniloff Jack, 1992, P549; MARTIN N, 1976, J MOL BIOL, V101, P285, DOI 10.1016/0022-2836(76)90148-0; MARTIN NC, 1977, BIOCHEMISTRY-US, V16, P4672, DOI 10.1021/bi00640a022; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; MIYATA M, 1993, NUCLEIC ACIDS RES, V21, P4816, DOI 10.1093/nar/21.20.4816; OGASAWARA N, 1990, BACTERIAL CHROMOSOME, P287; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; PATERSON SN, 1995, IN PRESS P NATL ACAD; PETERSON SN, 1995, J BACTERIOL, V177, P3199, DOI 10.1128/jb.177.11.3199-3204.1995; PETERSON SN, 1993, J BACTERIOL, V175, P7918, DOI 10.1128/JB.175.24.7918-7930.1993; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PROULX M, 1983, J BIOL CHEM, V258, P753; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAZIN S, 1985, MICROBIOL REV, V49, P419, DOI 10.1128/MMBR.49.4.419-455.1985; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROGERS MJ, 1985, P NATL ACAD SCI USA, V82, P1160, DOI 10.1073/pnas.82.4.1160; ROGERS MJ, 1984, ISRAEL J MED SCI, V20, P768; SANJANWALA B, 1989, P NATL ACAD SCI USA, V86, P4421, DOI 10.1073/pnas.86.12.4421; SANJANWALA B, 1991, MOL GEN GENET, V226, P467, DOI 10.1007/BF00260660; SAWADA M, 1981, MOL GEN GENET, V182, P502, DOI 10.1007/BF00293942; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; SIMONEAU P, 1993, NUCLEIC ACIDS RES, V21, P4967, DOI 10.1093/nar/21.21.4967; STRAUCH MA, 1988, J BACTERIOL, V170, P916, DOI 10.1128/jb.170.2.916-920.1988; SU CJ, 1990, J BACTERIOL, V172, P4705, DOI 10.1128/jb.172.8.4705-4707.1990; Sutton G.G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; TAYLORROBINSON D, 1994, LANCET, V13, P1066; TULLY JG, 1983, INT J SYST BACTERIOL, V33, P387, DOI 10.1099/00207713-33-2-387; UTTERBACK TR, 1995, GENOME SCI TECHNOL, V1, P1; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; WEISBURG WG, 1989, J BACTERIOL, V171, P6455, DOI 10.1128/jb.171.12.6455-6467.1989; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; ZHU PP, 1994, PROTEIN SCI, V3, P2115, DOI 10.1002/pro.5560031125; ZHU PP, 1993, J BIOL CHEM, V268, P26531	59	1999	2613	3	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					397	403		10.1126/science.270.5235.397	http://dx.doi.org/10.1126/science.270.5235.397			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569993				2022-12-01	WOS:A1995TA37400030
J	HIBBS, ML; TARLINTON, DM; ARMES, J; GRAIL, D; HODGSON, G; MAGLITTO, R; STACKER, SA; DUNN, ARR				HIBBS, ML; TARLINTON, DM; ARMES, J; GRAIL, D; HODGSON, G; MAGLITTO, R; STACKER, SA; DUNN, ARR			MULTIPLE DEFECTS IN THE IMMUNE-SYSTEM OF LYN-DEFICIENT MICE, CULMINATING IN AUTOIMMUNE-DISEASE	CELL			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; AFFINITY IGE RECEPTOR; CELL ANTIGEN RECEPTOR; LYMPHOCYTES-B; SRC FAMILY; KINASES; IMMUNOGLOBULIN; STIMULATION; ASSOCIATION; ALPHA	Mice homozygous for a disruption at the Lyn locus display abnormalities associated with the B lymphocyte lineage and in mast cell function, Despite reduced numbers of recirculating B lymphocytes, Lyn(-/-) mice are immunoglobulin M (IgM) hyperglobulinemic. Immune responses to T-independent and T-dependent antigens are affected. Lyn(-/-) mice fail to mediate an allergic response to IgE cross-linking, indicating that activation of LYN plays an indispensable role in Fc epsilon RI signaling. Lyn(-/-) mice have circulating autoreactive antibodies, and many show severe glomerulonephritis caused by the deposition of IgG immune complexes in the kidney, a pathology reminiscent of systemic lupus erythematosus. Collectively, these results implicate LYN as having an indispensable role in immunoglobulin-mediated signaling, particularly in establishing B cell tolerance.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; AUSTIN HOSP,DEPT ANAT PATHOL,HEIDELBERG,VIC 3084,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	HIBBS, ML (corresponding author), ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Hibbs, Margaret L/D-7013-2011; Armes, Jane/D-6396-2012	Hibbs, Margaret L/0000-0002-3751-6751; Armes, Jane/0000-0002-2215-0347; Tarlinton, David/0000-0001-9928-686X; Stacker, Steven/0000-0003-4096-9273	PHS HHS [A1-03958] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.immunol.12.1.881; BELMONT JW, 1995, TRENDS GENET, V11, P112, DOI 10.1016/S0168-9525(00)89012-5; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DRAKE CG, 1992, CURR OPIN IMMUNOL, V4, P733, DOI 10.1016/0952-7915(92)90054-I; EISEMAN E, 1992, NATURE, V355, P78; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P8; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; HIBBS ML, 1995, GENE, V156, P175, DOI 10.1016/0378-1119(95)00022-X; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MOUNTZ J D, 1991, Current Opinion in Rheumatology, V3, P738, DOI 10.1097/00002281-199110000-00004; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARMUS HE, 1994, BLOOD, V83, P5; WECHSLER RJ, 1995, J IMMUNOL, V154, P3234; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	47	596	614	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					301	311		10.1016/0092-8674(95)90171-X	http://dx.doi.org/10.1016/0092-8674(95)90171-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585947	Bronze			2022-12-01	WOS:A1995TA96500016
J	HOFMEISTER, AEM; LONDONOVALLEJO, A; HARRY, E; STRAGIER, P; LOSICK, R				HOFMEISTER, AEM; LONDONOVALLEJO, A; HARRY, E; STRAGIER, P; LOSICK, R			EXTRACELLULAR SIGNAL PROTEIN TRIGGERING THE PROTEOLYTIC ACTIVATION OF A DEVELOPMENTAL TRANSCRIPTION FACTOR IN BACILLUS-SUBTILIS	CELL			English	Article							CONTROL GENE-EXPRESSION; ENCODING SIGMA-FACTORS; BACILLUS-SUBTILIS; RNA-POLYMERASE; ESCHERICHIA-COLI; ENDOSPORE FORMATION; CELL-TYPE; SPORULATION; DNA; FORESPORE	We present biochemical evidence for an intercellular signal transduction pathway in B. subtilis. This pathway governs the conversion of the proprotein pro-sigma(E) to the mature transcription factor rho(E). Proteolytic processing is mediated by the membrane protein SpoIIGA and is triggered by the inferred extracellular signal protein SpoIIR. A factor in conditioned medium from B. subtilis cells engineered to produce SpoIIR during growth triggered processing in protoplasts of B. subtilis cells that had been engineered to produce SpoIIGA and pro-sigma(E). The factor was also detected in, and partially purified from, extracts of SpoIIR-producing cells of E. coli. We speculate that SpoIIGA is both a receptor and a protease and that SpoIIR interacts with SpoIIGA on the outside of the cytoplasmic membrane, activating the intracellular protease domain of SpoIIGA.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE		HOFMEISTER, AEM (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.		Harry, Elizabeth/G-8123-2017; Londono-Vallejo, Arturo/ABH-5555-2020; Harry, Liz/AAT-9396-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563; Harry, Elizabeth/0000-0003-0858-9473; STRAGIER, Patrick/0000-0003-0849-3025	NIGMS NIH HHS [GM18568] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018568, R01GM018568] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS LF, 1991, J BACTERIOL, V173, P3846, DOI 10.1128/JB.173.12.3846-3854.1991; BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CUTTING S, 1991, GENE DEV, V5, P456, DOI 10.1101/gad.5.3.456; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; Cutting SM, 1990, MOL BIOL METHODS BAC, P65; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DUBNAU D, 1971, J MOL BIOL, V56, P209, DOI 10.1016/0022-2836(71)90460-8; ERRLNGTON J, 1993, MICROBIOL REV, V57, P1; HARRY EJ, 1995, J BACTERIOL, V177, P3386, DOI 10.1128/jb.177.12.3386-3393.1995; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; KARMAZYNCAMPELL.C, 1989, GENES DEV, V3, P150, DOI 10.1101/gad.3.2.150; KAROW LM, 1995, P NATL ACAD SCI USA, V92, P2012; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LONDONOVALLEJO JA, 1995, GENE DEV, V9, P503, DOI 10.1101/gad.9.4.503; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MASUDA ES, 1988, P NATL ACAD SCI USA, V85, P7637, DOI 10.1073/pnas.85.20.7637; MIYAO A, 1993, J BACTERIOL, V175, P4081, DOI 10.1128/JB.175.13.4081-4086.1993; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS HK, 1991, J BACTERIOL, V173, P7821, DOI 10.1128/jb.173.24.7821-7827.1991; PETERS HK, 1994, J BACTERIOL, V176, P7763, DOI 10.1128/JB.176.24.7763-7766.1994; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; SHAZAND K, 1995, EMBO J, V14, P1439, DOI 10.1002/j.1460-2075.1995.tb07130.x; STRAGIER P, 1984, NATURE, V312, P376, DOI 10.1038/312376a0; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TREMPY JE, 1985, P NATL ACAD SCI USA, V82, P4189, DOI 10.1073/pnas.82.12.4189; TREMPY JE, 1985, J BACTERIOL, V161, P340, DOI 10.1128/JB.161.1.340-346.1985; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439; YOUNGMAN P, 1984, MOL GEN GENET, V195, P424, DOI 10.1007/BF00341443	39	93	94	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					219	226		10.1016/0092-8674(95)90163-9	http://dx.doi.org/10.1016/0092-8674(95)90163-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585939	Bronze			2022-12-01	WOS:A1995TA96500008
J	HUPP, TR; SPARKS, A; LANE, DP				HUPP, TR; SPARKS, A; LANE, DP			SMALL PEPTIDES ACTIVATE THE LATENT SEQUENCE-SPECIFIC DNA-BINDING FUNCTION OF P53	CELL			English	Article							WILD-TYPE P53; MONOCLONAL-ANTIBODIES; GROWTH ARREST; MOUSE CELLS; PROTEIN; FORMS; UV; IRRADIATION; APOPTOSIS; RADIATION	Normal cells contain p53 protein in a latent state that can be activated for sequence-specific transcription by low levels of UV radiation without an increase in protein levels. Microinjection of cells with an antibody specific to the C-terminal negative regulatory domain can activate the function of p53 as a specific transcription factor in the absence of irradiation damage, suggesting that posttranslational modification of a negative regulatory domain in vivo is a rate-limiting step for p53 activation. Small peptides derived from the negative regulatory domain of p53 have been used as biochemical tools to distinguish between allosteric and steric mechanisms of negative regulation of p53 tetramer activity. Presented is the development of a highly specific peptide activation system that is consistent with an allosteric mechanism of negative regulation and that forms a precedent for the synthesis of novel low molecular mass modifiers of the p53 response.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHLOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUPP TR, 1994, COLD SPRING HARB SYM, V59, P195; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MERRITT AJ, 1994, CANCER RES, V54, P614; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; YONISH RE, 1991, NATURE, V353, P345; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	38	439	471	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					237	245		10.1016/0092-8674(95)90165-5	http://dx.doi.org/10.1016/0092-8674(95)90165-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585941	Green Submitted, Bronze			2022-12-01	WOS:A1995TA96500010
J	KERREBROCK, AW; MOORE, DP; WU, JS; ORRWEAVER, TL				KERREBROCK, AW; MOORE, DP; WU, JS; ORRWEAVER, TL			MEI-S332, A DROSOPHILA PROTEIN REQUIRED FOR SISTER-CHROMATID COHESION, CAN LOCALIZE TO MEIOTIC CENTROMERE REGIONS	CELL			English	Article							DNA TOPOISOMERASE-II; GCN4 LEUCINE-ZIPPER; CHROMOSOME ORIENTATION; INNER CENTROMERE; CELL-DIVISION; COILED COILS; MELANOGASTER; SEPARATION; ANAPHASE; MITOSIS	Mutations in the Drosophila mei-S332 gene cause premature separation of the sister chromatids in late anaphase of meiosis I. Therefore, the mei-S332 protein was postulated to hold the centromere regions of sister chromatids together until anaphase II. The mei-3332 gene encodes a novel 44 kDa protein. Mutations in mei-S332 that differentially affect function in males or females map to distinct domains of the protein. a fusion of mei-S332 to the green fluorescent protein (GFP) is fully functional and localizes specifically to the centromere region of meiotic chromosomes. When sister chromatids separate at anaphase II, mei-S332-GFP disappears from the chromosomes, suggesting that the destruction or release of this protein is required for sister-chromatid separation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	KERREBROCK, AW (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Wu, JIm S/AAQ-3416-2021					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER BS, 1978, GENETICS, V90, P531; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLAYBERG CD, 1959, GENETICS, V44, P1335; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DAVIS BK, 1971, MOL GEN GENET, V113, P251, DOI 10.1007/BF00339546; DAVIS BK, 1977, DROS INFO SERV, V52, P100; DOBSON MJ, 1994, J CELL SCI, V107, P2749; DOMBRADI V, 1989, EUR J BIOCHEM, V183, P603, DOI 10.1111/j.1432-1033.1989.tb21089.x; EARNSHAW WC, 1991, J CELL SCI, V98, P443; GATTI M, 1991, METHOD CELL BIOL, V35, P543; GERMAN J, 1979, CLIN GENET, V16, P441; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KERREBROCK AW, 1992, GENETICS, V130, P827; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACKAY AM, 1993, J CELL BIOL, V123, P373, DOI 10.1083/jcb.123.2.373; MASON JM, 1976, GENETICS, V84, P545; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORRWEAVER TL, 1995, IN PRESS P NATL ACAD; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SANDLER L, 1968, GENETICS, V60, P525; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEPANOVA NG, 1985, HISTOCHEM J, V17, P131, DOI 10.1007/BF01003213; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0	57	215	220	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					247	256		10.1016/0092-8674(95)90166-3	http://dx.doi.org/10.1016/0092-8674(95)90166-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585942	Bronze			2022-12-01	WOS:A1995TA96500011
J	LIU, SH; WONG, ML; CRAIK, CS; BRODSKY, FM				LIU, SH; WONG, ML; CRAIK, CS; BRODSKY, FM			REGULATION OF CLATHRIN ASSEMBLY AND TRIMERIZATION DEFINED USING RECOMBINANT TRISKELION HUBS	CELL			English	Article							HEAVY-CHAIN; LIGHT-CHAINS; MOLECULAR-CLONING; SECONDARY-STRUCTURE; COATED VESICLES; PROTEINS; SEQUENCE; GENE; BINDING; TRIMERS	Clathrin polymerization into a polyhedral vesicle coat drives receptor sorting at cellular membranes during endocytosis and organelle biogenesis. To study clathrin self-assembly, we expressed the C-terminal third of the clathrin heavy chain in bacteria. The recombinant fragment trimerized, bound clathrin light chains, and morphologically resembled the hub domain of the triskelion-shaped clathrin molecule. Self-assembly of recombinant hubs demonstrated a regulatory role for clathrin light chains and for the distal portions of triskelion legs in clathrin coat formation. Deletion mutagenesis of the hub localized a domain mediating light chain binding and clathrin self-assembly and mapped a transferable trimerization domain. These studies define molecular interactions controlling clathrin self-assembly and establish a recombinant system for future analysis.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,GW HOOPER FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Brodsky, Frances/0000-0002-1334-9258	NIGMS NIH HHS [GM38093, GM26691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM026691, R01GM038093] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BAZINET C, 1993, GENETICS, V134, P1119; BLANK GS, 1986, EMBO J, V5, P2087, DOI 10.1002/j.1460-2075.1986.tb04470.x; BLANK GS, 1987, J CELL BIOL, V105, P2011, DOI 10.1083/jcb.105.5.2011; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DODGE GR, 1991, GENOMICS, V11, P174, DOI 10.1016/0888-7543(91)90115-U; ENNIS PD, 1988, J IMMUNOL, V141, P642; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.bi.59.070190.002215; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1993, J BIOL CHEM, V268, P10268; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LISANTI MP, 1982, EUR J BIOCHEM, V125, P463, DOI 10.1111/j.1432-1033.1982.tb06706.x; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MOOLBROEK MJ, 1987, J BIOL CHEM, V262, P25; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; OHALLORAN TJ, 1992, DNA CELL BIOL, V11, P321, DOI 10.1089/dna.1992.11.321; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PONNAMBALAM S, 1994, GENOMICS, V24, P440, DOI 10.1006/geno.1994.1650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; WONG DH, 1990, J NEUROSCI, V10, P3025	45	130	134	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					257	267		10.1016/0092-8674(95)90167-1	http://dx.doi.org/10.1016/0092-8674(95)90167-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585943	Bronze			2022-12-01	WOS:A1995TA96500012
J	RETALLACK, DM; FRIEDMAN, DI				RETALLACK, DM; FRIEDMAN, DI			A ROLE FOR A SMALL STABLE RNA IN MODULATING THE ACTIVITY OF DNA-BINDING PROTEINS	CELL			English	Article							ESCHERICHIA-COLI; 10SA RNA; PHAGE-LAMBDA; RIBONUCLEASE-P; GENE; TRANSCRIPTION; MECHANISM; ANTITERMINATION; IDENTIFICATION; EXPRESSION	The 10Sa RNA, encoded by the E. coli ssrA gene, appears to modulate action of some DNA-binding proteins. When ssrA is inactivated, lacZ expression from the lac operon, as well as galK from a gal operon fused to a phage lambda promoter, is reduced from that observed in bacteria wild-type for ssrA. These differences are not observed if the relevant repressor is inactive, suggesting that in the absence of 10Sa RNA binding of Lad and lambda cl repressors is enhanced. Gel mobility shifts show that 10Sa RNA binds these repressors and that an excess of 10Sa RNA competes for binding of lambda cl with a DNA fragment containing the O(R)2 repressor-binding sequence. Similar observations were made in studies of the E. coli LexA repressor and phage P22 C1 transcription activator proteins. These results suggest that direct interaction with 10Sa RNA may explain this modulation of protein-DNA interactions.			RETALLACK, DM (corresponding author), UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA.		Friedman, David/G-3198-2015	Friedman, David/0000-0002-2741-4671	NCRR NIH HHS [MO1-RR00042] Funding Source: Medline; NIGMS NIH HHS [5T32GM07544-14] Funding Source: Medline; PHS HHS [AL1459-10] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; ADHYA S, 1990, J BIOL CHEM, V265, P10797; ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Beckwith J.R., 1987, ESCHERICHIA COLI SAL, V2, P1444; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN JW, 1990, NUCLEIC ACIDS RES, V18, P2820, DOI 10.1093/nar/18.9.2820; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHAUHAN AK, 1989, MOL MICROBIOL, V3, P1481, DOI 10.1111/j.1365-2958.1989.tb00133.x; COURT D, 1993, CONTROL MRNA STABILI, V3, P71; DAMBLY-CHAUDIERE C, 1983, Journal of Molecular and Applied Genetics, V2, P45; DARR SC, 1992, BIOCHEMISTRY-US, V31, P328, DOI 10.1021/bi00117a003; DECROMBR.B, 1973, NATURE-NEW BIOL, V241, P260, DOI 10.1038/newbio241260a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1973, VIROLOGY, V51, P216, DOI 10.1016/0042-6822(73)90381-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HARRISON SC, 1992, TRANSCRIPTIONAL REGU, P449; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; INOUYE M, 1988, CELL, V53, P5, DOI 10.1016/0092-8674(88)90480-1; JENSEN CG, 1994, J BACTERIOL, V176, P2502, DOI 10.1128/JB.176.9.2502-2506.1994; KAMBEROV ES, 1994, PHOSPHATE IN MICROORGANISMS, P302; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1993, P NATL ACAD SCI USA, V90, P9562, DOI 10.1073/pnas.90.20.9562; REYES O, 1979, VIROLOGY, V94, P400, DOI 10.1016/0042-6822(79)90470-7; Sambrook J., 1989, MOL CLONING LAB MANU; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; STRAUCH MA, 1986, J BACTERIOL, V167, P191, DOI 10.1128/jb.167.1.191-200.1986; SUBBARAO MN, 1989, MOL GEN GENET, V217, P499, DOI 10.1007/BF02464923; SUSSKIND MM, 1975, J MOL BIOL, V98, P413, DOI 10.1016/S0022-2836(75)80127-6; SUSSMAN R, 1962, CR HEBD ACAD SCI, V254, P1517; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TYAGI JS, 1992, NUCLEIC ACIDS RES, V20, P138, DOI 10.1093/nar/20.1.138; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	51	46	48	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 20	1995	83	2					227	235		10.1016/0092-8674(95)90164-7	http://dx.doi.org/10.1016/0092-8674(95)90164-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585940	Bronze			2022-12-01	WOS:A1995TA96500009
J	SCHENA, M; SHALON, D; DAVIS, RW; BROWN, PO				SCHENA, M; SHALON, D; DAVIS, RW; BROWN, PO			QUANTITATIVE MONITORING OF GENE-EXPRESSION PATTERNS WITH A COMPLEMENTARY-DNA MICROARRAY	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; HUMAN GENOME	A high-capacity system was developed to monitor the expression of many genes in parallel. Microarrays prepared by high-speed robotic printing of complementary DNAs on glass were used for quantitative expression measurements of the corresponding genes. Because of the small format and high density of the arrays, hybridization volumes of 2 microliters could be used that enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA. Differential expression measurements of 45 Arabidopsis genes were made by means of simultaneous, two-color fluorescence hybridization.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University			Rosa, Bruce/F-6393-2010	Shalon, Tidhar Dari/0000-0003-2646-6215	NHGRI NIH HHS [R21HG00450] Funding Source: Medline; NIA NIH HHS [R37AG00198] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ausubel F.M., 2002, SHORT PROTOCOLS MOL, V5th; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; COX DR, 1994, SCIENCE, V265, P2031, DOI 10.1126/science.8091223; GREEN ED, 1991, JAMA-J AM MED ASSOC, V266, P1966, DOI 10.1001/jama.266.14.1966; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HWANG I, 1991, PLANT J, V1, P367, DOI 10.1046/j.1365-313X.1991.t01-5-00999.x; JARVIS P, 1994, PLANT MOL BIOL, V24, P685, DOI 10.1007/BF00023565; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; MEYEROWITZ EM, 1985, SCIENCE, V229, P1214, DOI 10.1126/science.229.4719.1214; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; SCHENA M, 1994, P NATL ACAD SCI USA, V91, P8393, DOI 10.1073/pnas.91.18.8393; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SCHENA M, 1993, GENE DEV, V7, P367, DOI 10.1101/gad.7.3.367; SHALON D, 1995, THESIS STANFORD U; SHALON D, UNPUB	18	6688	7873	25	945	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					467	470		10.1126/science.270.5235.467	http://dx.doi.org/10.1126/science.270.5235.467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7569999				2022-12-01	WOS:A1995TA37400041
J	SCHMIDT, R; WEST, J; LOVE, K; LENEHAN, Z; LISTER, C; THOMPSON, H; BOUCHEZ, D; DEAN, C				SCHMIDT, R; WEST, J; LOVE, K; LENEHAN, Z; LISTER, C; THOMPSON, H; BOUCHEZ, D; DEAN, C			PHYSICAL MAP AND ORGANIZATION OF ARABIDOPSIS-THALIANA CHROMOSOME-4	SCIENCE			English	Article							POLYMORPHISM LINKAGE MAP; REPEATED DNA-SEQUENCES; DISEASE RESISTANCE; YEAST; GENOME; GENES; LIBRARY; PROTEIN; CONSTRUCTION; CHROMATIN	A physical map of Arabidopsis thaliana chromosome 4 was constructed in yeast artificial chromosome clones and used to analyze the organization of the chromosome. Mapping of the nucleolar organizing region and the centromere integrated the physical and cytogenetic maps. Detailed comparison of physical with genetic distances showed that the frequency of recombination varied substantially, with relative hot and cold spots occurring along the whole chromosome. Eight repeated DNA sequence families were found in a complex arrangement across the centromeric region and nowhere else on the chromosome.	JOHN INNES CTR PLANT SCI RES, BIOTECHNOL & BIOL SCI RES COUNCIL, DEPT MOLEC GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND; INRA, BIOL CELLULAIRE LAB, F-78026 VERSAILLES, FRANCE	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Thompson, Henry J/K-7242-2012; Thompson, Helen L/E-7726-2017; Bouchez, David/B-7463-2019	Thompson, Henry J/0000-0002-3730-9322; Thompson, Helen L/0000-0003-4414-8018; Bouchez, David/0000-0003-3545-4339; Schmidt, Renate/0000-0002-8037-3581				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALBINI SM, 1994, PLANT J, V5, P665, DOI 10.1111/j.1365-313X.1994.00665.x; BAUWENS S, 1991, CHROMOSOMA, V101, P41, DOI 10.1007/BF00360685; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COPENHAVER G, COMMUNICATION; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COUPLAND G, 1994, PLANT CELL, V6, P75; CREUSOT F, IN PRESS PLANT J; DEAN C, 1995, ANNU REV PLANT PHYS, V46, P395, DOI 10.1146/annurev.pp.46.060195.002143; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; GANAL MW, 1988, MOL GEN GENET, V213, P262, DOI 10.1007/BF00339590; GOODMAN H, GT148 DEP MOL BIOL; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; HESLOPHARRISON JS, 1991, J CELL SCI, V100, P15; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; HUBEL A, 1994, PLANT MOL BIOL, V26, P353, DOI 10.1007/BF00039545; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KEITH B, 1991, P NATL ACAD SCI USA, V88, P8821, DOI 10.1073/pnas.88.19.8821; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KORFHAGE U, 1994, PLANT CELL, V6, P695, DOI 10.1105/tpc.6.5.695; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LAST RL, 1991, PLANT CELL, V3, P345, DOI 10.1105/tpc.3.4.345; LEPINIEC L, 1995, FEBS LETT, V364, P103, DOI 10.1016/0014-5793(95)00335-7; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LISTER C, UNPUB; Lui Y., UNPUB; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MCGRATH JM, 1993, THEOR APPL GENET, V86, P880, DOI 10.1007/BF00212616; Meyerowitz E. M., 1992, Methods in Arabidopsis research., P100; MEYEROWITZ EM, 1994, ARABIDOPSIS; MOORE G, 1991, GENOMICS, V10, P461, DOI 10.1016/0888-7543(91)90333-A; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PALME K, 1992, PLANT CELL, V4, P193, DOI 10.1105/tpc.4.2.193; PARKER JE, 1993, PLANT J, V4, P821, DOI 10.1046/j.1365-313X.1993.04050821.x; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; SCHMIDT R, 1994, PLANT J, V5, P735, DOI 10.1111/j.1365-313X.1994.00735.x; SCHMIDT R, UNPUB; Schweizer D, 1987, ARABID INF SERV, V25, P27; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; TANKSLEY SD, 1992, GENETICS, V132, P1141; THOMPSON H, UNPUB; TOURMENTE S, 1994, NUCLEIC ACIDS RES, V22, P3317, DOI 10.1093/nar/22.16.3317; VANLIJSEBETTENS M, 1994, EMBO J, V13, P3378, DOI 10.1002/j.1460-2075.1994.tb06640.x; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; WALKER M, PLM117 U CAMBR DEP P; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9	60	175	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 20	1995	270	5235					480	483		10.1126/science.270.5235.480	http://dx.doi.org/10.1126/science.270.5235.480			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570002				2022-12-01	WOS:A1995TA37400044
J	VELCULESCU, VE; ZHANG, L; VOGELSTEIN, B; KINZLER, KW				VELCULESCU, VE; ZHANG, L; VOGELSTEIN, B; KINZLER, KW			SERIAL ANALYSIS OF GENE-EXPRESSION	SCIENCE			English	Article							CDNA CLONES; SEQUENCE; DNA; IDENTIFICATION	The characteristics of an organism are determined by the genes expressed within it. A method was developed, called serial analysis of gene expression (SAGE), that allows the quantitative and simultaneous analysis of a large number of transcripts. To demonstrate this strategy, short diagnostic sequence tags were isolated from pancreas, concatenated, and cloned. Manual sequencing of 1000 tags revealed a gene expression pattern characteristic of pancreatic function. New pancreatic transcripts corresponding to novel tags were identified. SAGE should provide a broadly applicable means for the quantitative cataloging and comparison of expressed genes in a variety of normal, developmental, and disease states.	JOHNS HOPKINS UNIV,CTR ONCOL,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21231	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University			Zhang, Lin/A-7389-2009; Velculescu, Victor/ABF-4846-2020	Zhang, Lin/0000-0003-0018-3903; Velculescu, Victor/0000-0003-1195-438X	NATIONAL CANCER INSTITUTE [R01CA035494, R37CA057345, R37CA035494, R01CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345, CA35494] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SZYBALSKI W, 1985, GENE, V40, P169, DOI 10.1016/0378-1119(85)90039-3; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	16	3211	3837	5	186	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 20	1995	270	5235					484	487		10.1126/science.270.5235.484	http://dx.doi.org/10.1126/science.270.5235.484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA374	7570003				2022-12-01	WOS:A1995TA37400045
J	WINANDY, S; WU, P; GEORGOPOULOS, K				WINANDY, S; WU, P; GEORGOPOULOS, K			A DOMINANT MUTATION IN THE IKAROS GENE LEADS TO RAPID DEVELOPMENT OF LEUKEMIA AND LYMPHOMA	CELL			English	Article							MATURE T-CELLS; RETINOBLASTOMA; MICE; LYMPHOCYTES; SELECTION; GLD; REARRANGEMENT; AUTOIMMUNITY; COMMITMENT; SUICIDE	The Ikaros gene is essential for lymphoid lineage specification. As previously reported, mice homozygous fora mutation in the Ikaros DNA-binding domain fail to generate mature lymphocytes as well as their earliest described progenitors. In addition, our studies with mice heterozygous for this mutation establish the Ikaros gene as an essential regulator of T cell proliferation. Thymocytes display augmented TCR-mediated proliferative responses, and peripheral T cells are autoproliferative. A general lymphoproliferation precedes the T cell leukemia and lymphoma that rapidly develop in all heterozygotes. The first step toward leukemic transformation occurs within the maturing thymocyte population and is demarcated by clonal expansions and loss of the single Ikaros wild-type allele. From these studies, we propose that within developing and mature T lymphocytes, distinct thresholds of Ikaros activity are required to regulate proliferation. A decrease in Ikaros activity below the first threshold causes the rapid accumulation of T lymphoblasts, whereas a further decrease leads to neoplastic transformation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital					NIAID NIH HHS [R01-AI33062-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1995, IMMUNOL TODAY, V16, P99, DOI 10.1016/0167-5699(95)80096-4; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GEORGOPOULOS K, 1994, CELL, V78, P143; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JANEWAY CA, 1994, IMMUNITY, V1, P3, DOI 10.1016/1074-7613(94)90003-5; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOLNAR A, 1995, IN PRESS J IMMUNOL; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RODEWALD HR, 1994, EMBO J, V13, P7229; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; VASQUEZ NJ, 1994, IMMUNITY, V1, P45, DOI 10.1016/1074-7613(94)90008-6; VONBOEHMER H, 1993, CELL, V73, P207, DOI 10.1016/0092-8674(93)90220-K; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1	35	349	364	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 20	1995	83	2					289	299		10.1016/0092-8674(95)90170-1	http://dx.doi.org/10.1016/0092-8674(95)90170-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TA965	7585946	Bronze			2022-12-01	WOS:A1995TA96500015
J	BARNARD, MR; MICHELSON, AD				BARNARD, MR; MICHELSON, AD			A MORPHOLOGIC QUESTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BARNARD, MR (corresponding author), UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01655, USA.		Michelson, Alan/ABE-8487-2021	Michelson, Alan/0000-0002-1746-4819					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	1995	333	16					1051	1051		10.1056/NEJM199510193331605	http://dx.doi.org/10.1056/NEJM199510193331605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ340	7675048				2022-12-01	WOS:A1995RZ34000005
J	BARRY, MA; LAI, WC; JOHNSTON, SA				BARRY, MA; LAI, WC; JOHNSTON, SA			PROTECTION AGAINST MYCOPLASMA-INFECTION USING EXPRESSION-LIBRARY IMMUNIZATION	NATURE			English	Article							IMMUNE-RESPONSES; GENETIC IMMUNIZATION; DNA; TRYPTOPHAN; UBIQUITIN; PULMONIS; ANTIGEN; CELLS; READ; UGA	As is evident from the human immunodeficiency virus epidemic, there is no systematic method for producing a vaccine, Genetic immunization(1) is a new approach to vaccine production that has many of the advantages of live/attenuated pathogens but no risk of infection. It involves introducing DNA encoding a pathogen protein into host cells and has shown promise in several disease models(2-13) Here we describe a new method for vaccine development, expression-library immunization, which makes use of the technique of genetic immunization and the fact that all the antigens of a pathogen are encoded in its DNA. An expression library of pathogen DNA is used to immunize a host thereby producing the effects of antigen presentation of a live vaccine without the risk. We show that even partial expression libraries made from the DNA of Mycoplasma pulmonis, a natural pathogen in rodents, provide protection against challenge from the pathogen. Expression library immunization may prove to be a general method for vaccination against any pathogen.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DIV COMPARAT MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARRY MA, 1994, BIOTECHNIQUES, V16, P616; CASSELL GH, 1982, REV INFECT DIS, V4, P518; CONEY L, 1994, VACCINE, V12, P1545, DOI 10.1016/0264-410X(94)90082-5; CONRY RM, 1994, CANCER RES, V54, P1164; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; DAVIDSON MK, 1982, REV INFECT DIS, V4, pS243; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; INAMINE JM, 1990, J BACTERIOL, V172, P504, DOI 10.1128/JB.172.1.504-506.1990; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KATSUMI A, 1994, HUM GENE THER, V5, P1335, DOI 10.1089/hum.1994.5.11-1335; Lai Wayne C., 1995, P469, DOI 10.1016/B978-012583805-4/50050-9; LAI WC, 1991, INFECT IMMUN, V59, P346, DOI 10.1128/IAI.59.1.346-350.1991; LAI WC, 1990, J INFECT DIS, V161, P1269, DOI 10.1093/infdis/161.6.1269; LINDSEY JR, 1978, PATHOLOGY LABORATORY, P1482; NEIMARK HC, 1990, NUCLEIC ACIDS RES, V18, P5443, DOI 10.1093/nar/18.18.5443; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TAYLOR G, 1976, IMMUNOLOGY, V30, P611; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; XU D, 1994, VACCINE, V12, P1534, DOI 10.1016/0264-410X(94)90079-5; YAMAO F, 1985, P NATL ACAD SCI USA, V82, P2306, DOI 10.1073/pnas.82.8.2306	29	255	297	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					632	635		10.1038/377632a0	http://dx.doi.org/10.1038/377632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566175				2022-12-01	WOS:A1995TA27500053
J	BELLGRAU, D; GOLD, D; SELAWRY, H; MOORE, J; FRANZUSOFF, A; DUKE, RC				BELLGRAU, D; GOLD, D; SELAWRY, H; MOORE, J; FRANZUSOFF, A; DUKE, RC			A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION	NATURE			English	Article							FAS ANTIGEN; TRANSPLANTATION; SURVIVAL; AUTOIMMUNITY; EXPRESSION; APOPTOSIS; TESTIS; DEATH; CELLS; MICE	TESTIS is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants(1-4). Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Ape-1) ligand(5-8) survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligands(8,9), were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.	UNIV COLORADO,SCH MED,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT CELLULAR & STRUCT BIOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DIV MED ONCOL,DENVER,CO 80262; SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121; VET ADM MED CTR,MEMPHIS,TN 38104	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center								BARKER CF, 1977, ADV IMMUNOL, V25, P1; BOBZIEN B, 1983, DIABETES, V32, P213, DOI 10.2337/diabetes.32.3.213; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CAMERON DF, 1990, TRANSPLANTATION, V50, P649, DOI 10.1097/00007890-199010000-00024; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; HAO LM, 1990, TRANSPLANTATION, V49, P609, DOI 10.1097/00007890-199003000-00025; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; LUCIANI MF, 1994, PHILOS T R SOC B, V345, P303, DOI 10.1098/rstb.1994.0110; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SELAWRY HP, 1991, TRANSPLANTATION, V52, P846, DOI 10.1097/00007890-199111000-00018; SELAWRY HP, 1993, CELL TRANSPLANT, V2, P123, DOI 10.1177/096368979300200206; SELAWRY HP, 1989, DIABETES, V38, P220, DOI 10.2337/diab.38.1.S220; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOBEL ES, 1993, INT IMMUNOL, V5, P1275, DOI 10.1093/intimm/5.10.1275; STALDER T, 1994, J IMMUNOL, V152, P1127; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHITMORE WF, 1985, J UROLOGY, V134, P782, DOI 10.1016/S0022-5347(17)47438-6	30	1055	1110	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					630	632		10.1038/377630a0	http://dx.doi.org/10.1038/377630a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566174				2022-12-01	WOS:A1995TA27500052
J	BORIES, JC; WILLERFORD, DM; GREVIN, D; DAVIDSON, L; CAMUS, A; MARTIN, P; STEHELIN, D; ALT, FW				BORIES, JC; WILLERFORD, DM; GREVIN, D; DAVIDSON, L; CAMUS, A; MARTIN, P; STEHELIN, D; ALT, FW			INCREASED T-CELL APOPTOSIS AND TERMINAL B-CELL DIFFERENTIATION-INDUCED BY INACTIVATION OF THE ETS-1 PROTOONCOGENE	NATURE			English	Article							DNA-BINDING; TRANSCRIPTION FACTORS; GENE ENHANCER; MICE; ACTIVATION; THYMOCYTES; SEQUENCE	THE Ets-1 proto-oncogene is a member of a transcription factor family characterized by homology to the v-ets oncogene(1-4). In adult mice, Ets-1 is expressed predominantly in lymphoid cells where it has been implicated in regulating transcription of lymphocyte-specific genes(5-7). Following T-cell activation, the specific DNA binding activity of Ets-1 is inactivated by transient phosphorylation, suggesting a function in the transition from the resting to activated state(8,9). Ets-1 has also been suggested to cooperate with the AP-1 transcription factor complex to mediate cellular growth factor responses(4). Here we show, by using RAG-2-deficient blastocyst complementation(10), that Ets-1 deficiency has dramatic, but different, effects on development and function of T- and B-lineage cells, Ets-1-deficient T cells were present in reduced numbers and were highly susceptible to cell death in vitro. In contrast, Ets-1-deficient B cells were present in normal numbers but a large proportion were IgM plasma cells, Our data demonstrate that Ets-1 is essential for maintenance of the normal pool of resting T- and B-lineage cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115; HOP ST LOUIS,INSERM,U93,F-75475 PARIS,FRANCE; INST PASTEUR,MOLEC ONCOL LAB,CNRS,URA 1160,F-59019 LILLE,FRANCE; INST PASTEUR,UNITE BIOL DEV,CNRS,URA 1960,F-75724 PARIS,FRANCE	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BORIES, JC (corresponding author), CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Camus, Anne/P-1515-2014; Bories, Jean-Christophe/L-6952-2017	Camus, Anne/0000-0002-8820-0407				BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CHEN J, 1992, P NATL ACAD SCI USA, V90, P4528; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; JORCYK CL, 1991, ONCOGENE, V6, P523; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIDMAN CL, 1986, SCIENCE, V232, P1423, DOI 10.1126/science.3487115; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	24	269	276	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					635	638		10.1038/377635a0	http://dx.doi.org/10.1038/377635a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566176				2022-12-01	WOS:A1995TA27500054
J	BUCKBINDER, L; TALBOTT, R; VELASCOMIGUEL, S; TAKENAKA, I; FAHA, B; SEIZINGER, BR; KLEY, N				BUCKBINDER, L; TALBOTT, R; VELASCOMIGUEL, S; TAKENAKA, I; FAHA, B; SEIZINGER, BR; KLEY, N			INDUCTION OF THE GROWTH INHIBITOR IGF-BINDING PROTEIN-3 BY P53	NATURE			English	Article							KINASES; P21	TRANSCRIPTIONAL activation of target genes represents an important component of the tumour-suppressor function of p53 and provides a functional link between p53 and various growth-regulatory processes, including cell cycle progression (p21/WAF1)(1-3), DNA repair (GADD45)(4) and apoptosis (bax)(5). Here we use a differential cloning approach to identify the gene encoding insulin-like growth factor binding protein 3 (IGF-BP3) as a novel p53-regulated target gene. Induction of IGF-BP3 gene expression by wild-type but not mutant p53 is associated with enhanced secretion of an active form of IGF-BP3 capable of inhibiting mitogenic signalling by the insulin-like growth factor IGF-1, Our results indicate that ICF-BP3 may link p53 to potential novel autocrine/paracrine signalling pathways and to processes regulated by or dependent on IGF(s), such as cellular growth, transformation and survival.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC GENET,PRINCETON,NJ 08543	Bristol-Myers Squibb								BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRIGORIEV VG, 1994, J CELL PHYSIOL, V160, P203, DOI 10.1002/jcp.1041600123; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; MIYASHITA T, 1994, ONCOGENE, V9, P1799; RESNICOFF M, 1995, CANCER RES, V55, P2463; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIMASAKI S, 1992, PROG GROWTH FACTOR R, V3, P243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YU H, 1995, CANCER RES, V55, P1603; YU H, 1995, CANCER RES, V55, P2104	21	735	758	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					646	649		10.1038/377646a0	http://dx.doi.org/10.1038/377646a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566179				2022-12-01	WOS:A1995TA27500057
J	HIRATA, J; NAKAGOSHI, H; NABESHIMA, Y; MATSUZAKI, F				HIRATA, J; NAKAGOSHI, H; NABESHIMA, Y; MATSUZAKI, F			ASYMMETRIC SEGREGATION OF THE HOMEODOMAIN PROTEIN PROSPERO DURING DROSOPHILA DEVELOPMENT	NATURE			English	Article							GENE; TRANSFORMATION; EMBRYOS; CELLS	ASYMMETRIC divisions that produce two distinct cells play fundamental roles in generating different cell types during development(1,2). In the Drosophila central nervous system, neural stem cells called neuroblasts divide unequally into another neuroblast and a ganglion mother cell which is Subsequently cleaved into neurons. Correct gene expression of ganglion mother tells requires the transcription factor Prospero(3-5). Here we demonstrate the asymmetric segregation of Prospero on neuroblast division, Prospero synthesized in neuroblasts is retained in the cytoplasm and at mitosis is exclusively partitioned to ganglion mother cells, in which it is translocated to the nucleus, Differential segregation of Prospero was also found in the endoderm. We have identified a region in Prospero that is responsible for this event, The region shares a common motif with Numb(6), which also shows unequal segregation(7). We propose that asymmetric segregation of transcription factors is an intrinsic mechanism for establishing asymmetry in gene expression between sibling cells.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	HIRATA, J (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOLEC GENET,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN.		NAKAGOSHI, Hideki/B-2145-2011	NAKAGOSHI, Hideki/0000-0003-0850-1814				BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Campos-Ortega JAVH, 1985, EMBRYONIC DEV DROSOP; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; PRATT WB, 1989, CANCER RES, V49, pS2222; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Skaer Helen, 1993, P941; SPANA EP, IN PRESS DEVELOPMENT; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TEPASS U, 1995, DEVELOPMENT, V121, P393; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WARTON RP, 1991, CELL, V67, P955; ZINMAN M, 1993, MOL BIOL CELL, V4, P1307	27	300	300	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					627	630		10.1038/377627a0	http://dx.doi.org/10.1038/377627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566173				2022-12-01	WOS:A1995TA27500051
J	KNOBLICH, JA; JAN, LY; JAN, YN				KNOBLICH, JA; JAN, LY; JAN, YN			ASYMMETRIC SEGREGATION OF NUMB AND PROSPERO DURING CELL-DIVISION	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYOS; GENE; EMBRYOGENESIS; VISUALIZATION; CYTOKINESIS; PATTERNS; GRANULES	A CELL can divide asymmetrically by specifically segregating a determinant into one of its daughter cells(1). The Numb protein is a candidate for such a determinant in the asymmetric cell divisions of the developing Drosophila nervous system(2,3). Numb is a membrane-associated protein that localizes asymmetrically during cell division and segregates into one daughter cell, where it is required for the specification of the correct cell fate(3-5). Here we show that a nuclear protein, Prospero(6,7), translocates to the membrane at the beginning of cell division and colocalizes with Numb throughout mitosis, suggesting a common mechanism for asymmetric segregation. Numb and Prospero localization is coupled to mitosis and tightly correlated with the position of one of the two centrosomes. In contrast to centrosome positioning, however, Numb and Prospero localization is independent of microtubules. Cytochalasin D treatment suggests that the process is also independent of actin, We propose that there is an organizer of asymmetric cell division which provides positional information for both the orientation of the mitotic spindle and asymmetric localization of Numb and Prospero.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KNOBLICH, JA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1992, DEVELOPMENT, V116, P855; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HIME G, 1992, DEVELOPMENT, V114, P165; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; LEHNER CF, 1992, J CELL SCI, V103, P1021; ORSULIC S, 1994, BIOTECHNIQUES, V16, P441; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, IN PRESS DEVELOPMENT; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; TEPASS U, 1995, DEVELOPMENT, V121, P393; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	26	409	417	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					624	627		10.1038/377624a0	http://dx.doi.org/10.1038/377624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566172				2022-12-01	WOS:A1995TA27500050
J	MUTHUSAMY, N; BARTON, K; LEIDEN, JM				MUTHUSAMY, N; BARTON, K; LEIDEN, JM			DEFECTIVE ACTIVATION AND SURVIVAL OF T-CELLS LACKING THE ETS-1 TRANSCRIPTION FACTOR	NATURE			English	Article							GENE PROMOTER; EXPRESSION; BINDING; PROTOONCOGENE; PROTEINS; ONCOGENE; FAMILY; DOMAIN; MICE	THE Ets-1 proto-oncogene(1) is a member of the Ets family of eukaryotic transcription factors(2-7). Members of this family play important roles in regulating gene expression in response to multiple developmental and mitogenic signals(4,5,8,9) Ets-1 is preferentially expressed at high levels in B and T cells of adult mice(10,11) and is regulated during both thymocyte development(11) and T-cell activation(12,13), To study the role of Ets-1 in T-cell development and function we have used the RAG-2(-/-) complementation system(14) and murine embryonic stem (ES) cells containing homozygous deletions in the Ets-1 gene (Ets-1(-/-)). Ets-1(-/-)-RAG-2(-/-) chimaeric mice displayed markedly decreased numbers of mature thymocytes and peripheral T cells. Ets-1(-/-) T cells expressed normal levels of CD3 and T-cell antigen receptor (TCR)-alpha/beta. However, they displayed a severe proliferative defect in response to multiple activational signals and demonstrated increased rates of spontaneous apoptosis in vitro. These findings demonstrate that Ets-1 is required for the normal survival and activation of murine T cells.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago			Muthusamy, Natarajan/A-6915-2009					BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUNG S, 1993, ONCOGENE, V8, P989; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOTTON D, 1993, LEUKEMIA, V7, pS55	25	282	286	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					639	642		10.1038/377639a0	http://dx.doi.org/10.1038/377639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566177				2022-12-01	WOS:A1995TA27500055
J	PARADISO, AM; MASON, SJ; LAZAROWSKI, ER; BOUCHER, RC				PARADISO, AM; MASON, SJ; LAZAROWSKI, ER; BOUCHER, RC			MEMBRANE-RESTRICTED REGULATION OF CA2+ RELEASE AND INFLUX IN POLARIZED EPITHELIA	NATURE			English	Article							PAROTID ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CALCIUM; EXTRACELLULAR ATP; AIRWAY EPITHELIUM; OSCILLATIONS; METABOLISM; TRANSPORT; MESSENGER; CULTURE	EPITHELIAL cells exist in a complex setting in which responses to mucosal or serosal environments are mediated by receptors expressed on specialized cellular domains, such as apical versus basolateral cell membranes, We investigated whether airway epithelia can react selectively through G-protein-coupled receptors to stimuli in the mucosal or serosal environments by measuring inositol phosphate and intracellular Ca2+ responses in polarized human nasal epithelial monolayers, We report here that unilateral ATP (10(-4) M) administration stimulated P-2 purinoceptors and tapped pools of intracellular Ca2+ associated with the plasma membrane ipsilateral but not contralateral to stimulated receptors. Similarly, activation of plasma membrane Ca2+ influx by ATP was confined to the membrane ipsilateral to receptor stimulation. These findings demonstrate that polarized epithelia restrict P-2 receptor-mediated responses to a single domain of the cell, reflecting membrane-specific generation and catabolism of inositol phosphates and confinement of calcium influx regulation to the membrane ipsilateral to the stimulated receptors.	UNIV N CAROLINA,CTR CYST FIBROSIS PULM RES & TREATMENT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	PARADISO, AM (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CHAPEL HILL,NC 27599, USA.							ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BROWN HA, 1991, MOL PHARMACOL, V40, P648; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HANSEN M, 1993, J CELL SCI, V106, P995; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LARSEN EH, 1990, J PHYSIOL-LONDON, V424, P109, DOI 10.1113/jphysiol.1990.sp018058; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; WU R, 1985, AM REV RESPIR DIS, V132, P311	16	102	103	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					643	646		10.1038/377643a0	http://dx.doi.org/10.1038/377643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566178				2022-12-01	WOS:A1995TA27500056
J	TAKAHARA, PM; ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ				TAKAHARA, PM; ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ			CRYSTAL-STRUCTURE OF DOUBLE-STRANDED DNA CONTAINING THE MAJOR ADDUCT OF THE ANTICANCER DRUG CISPLATIN	NATURE			English	Article							MOLECULAR-STRUCTURE; A-DNA; CIS-DIAMMINEDICHLOROPLATINUM(II); PLATINUM; CIS-<PT(NH3)2(D(PGPG))>; PROTEIN; SINGLE; DUPLEX; GROOVE	THE success of cisplatin in cancer chemotherapy derives from its ability to crosslink DNA and alter the structure, Most cisplatin-DNA adducts are intrastrand d(GpG) and d(ApG) crosslinks(1), which unwind and bend the duplex to facilitate the binding of proteins that contain one or more high-mobility-group (HMG) domains(2). When HMG-domain proteins such as HMG1, IXR (intrastrand-crosslink recognition) protein from yeast, or human upstream-binding factor (hUBF) bind cisplatin intrastrand crosslinks, they can be diverted from their natural binding sites on the genome and shield the adducts from excision repair(3-5). These activities sensitize cells to cisplatin and contribute to its cytotoxic properties, Crystallographic information about the structure of cisplatin-DNA adducts has been limited to short single-stranded deoxyoligonucleotides such as Cis-[Pt(NH3)(2){d(pGpG)}](6-8). Here we describe the X-ray structure at 2.6 Angstrom resolution of a double-stranded DNA dodecamer containing this adduct. Our information provides, to our knowledge, the first crystallographic look at a platinated DNA duplex and should help the design of new platinum and other metal crosslinking antitumour drug candidates. Moreover, the structure reveals a unique fusion of A- and B-type DNA segments that could be of more general importance.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	TAKAHARA, PM (corresponding author), MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA.							ADMIRAAL G, 1987, J AM CHEM SOC, V109, P592, DOI 10.1021/ja00236a053; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DENHARTOG JHJ, 1985, J BIOMOL STRUCT DYN, V2, P1137, DOI 10.1080/07391102.1985.10507629; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FREDERICK CA, 1989, EUR J BIOCHEM, V181, P295, DOI 10.1111/j.1432-1033.1989.tb14724.x; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SHERMAN SE, 1988, J AM CHEM SOC, V110, P7368, DOI 10.1021/ja00230a017; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; WANG AHJ, 1982, P NATL ACAD SCI-BIOL, V79, P3968, DOI 10.1073/pnas.79.13.3968; WANG AHJ, 1988, J CRYST GROWTH, V90, P295; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITEHEAD JP, METAL IONS BIOL SYST	27	698	716	1	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 19	1995	377	6550					649	652		10.1038/377649a0	http://dx.doi.org/10.1038/377649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566180				2022-12-01	WOS:A1995TA27500058
J	YAGAMIHIROMASA, T; SATO, T; KURISAKI, T; KAMIJO, K; NABESHIMA, Y; FUJISAWASEHARA, A				YAGAMIHIROMASA, T; SATO, T; KURISAKI, T; KAMIJO, K; NABESHIMA, Y; FUJISAWASEHARA, A			A METALLOPROTEASE-DISINTEGRIN PARTICIPATING IN MYOBLAST FUSION	NATURE			English	Article							PLATELET-AGGREGATION INHIBITOR; CELL-ADHESION MOLECULE; SPERM-EGG FUSION; HEMORRHAGIC PROTEIN; N-CADHERIN; MYOGENESIS; INTEGRIN; SEQUENCE; VENOM; PURIFICATION	SKELETAL muscle development involves the formation of multinucleated myotubes. This is thought to proceed by the induction of differentiation (acquisition of fusion competence) of myoblast cells, their aggregation, and union of their plasma membranes(1-3) Various membrane proteins including N-(4,5) and M-cadherins(6), N-(5,7-9) and V-CAMs(10) and integrins(10,11) participate in myotube formation, but the molecular mechanisms of muscle cell fusion are poorly understood. Here we report the identification of three new, myoblast-expressed gene products, mcltrin-alpha, beta and gamma, with homology to both viper haemorrhagic factors(12,13) and fertilin (PH-30)(14,15), a membrane protein involved in egg-sperm fusion. Meltrin-alpha, a member of the metalloproteinase/disintegrin protein family, appears to be required for myotube formation. Involvement of a fertilin-related protein in myogenesis suggests that there are common mechanisms in gamete and myoblast fusion.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV MOLEC GENET,KODAIRA,TOKYO 187,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 260,JAPAN	National Center for Neurology & Psychiatry - Japan; Chiba University								AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KNUDSEN KA, 1992, MEMBRANE FUSION, P601; LAMB RA, 1993, VIROLOGY, V197, P1, DOI 10.1006/viro.1993.1561; MEGE RM, 1992, J CELL SCI, V103, P897; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINTZ B, 1967, P NATL ACAD SCI USA, V58, P592, DOI 10.1073/pnas.58.2.592; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORRISON TG, 1988, VIRUS RES, V10, P113, DOI 10.1016/0168-1702(88)90010-X; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PECK D, 1993, J CELL BIOL, V123, P1587, DOI 10.1083/jcb.123.6.1587; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1965, DEV BIOL, V11, P300, DOI 10.1016/0012-1606(65)90062-X; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	30	418	439	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 19	1995	377	6550					652	656		10.1038/377652a0	http://dx.doi.org/10.1038/377652a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA275	7566181				2022-12-01	WOS:A1995TA27500059
J	DESJARLAIS, DC; HAGAN, H; FRIEDMAN, SR; FRIEDMANN, P; GOLDBERG, D; FRISCHER, M; GREEN, S; TUNVING, K; LJUNGBERG, B; WODAK, A; ROSS, M; PURCHASE, D; MILLSON, ME; MYERS, T				DESJARLAIS, DC; HAGAN, H; FRIEDMAN, SR; FRIEDMANN, P; GOLDBERG, D; FRISCHER, M; GREEN, S; TUNVING, K; LJUNGBERG, B; WODAK, A; ROSS, M; PURCHASE, D; MILLSON, ME; MYERS, T			MAINTAINING LOW HIV SEROPREVALENCE IN POPULATIONS OF INJECTING DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYRINGE EXCHANGE; INFECTION; AIDS; PREVENTION; BEHAVIORS; SAMPLES; GLASGOW; SWEDEN; HEALTH	Objectives.-To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5%) during at least 5 years. Design and Setting.-A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario, Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants.-Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions.-A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results.-There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs, Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions.-In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.	NATL DEV & RES INST INC,NEW YORK,NY; TACOMA PIERCE CTY HLTH DEPT,TACOMA,WA; POINT DEFIANCE AIDS PREVENT PROJECT,TACOMA,WA; RUCHILL HOSP,COMMUNICABLE DIS SCOTLAND UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; LUND UNIV,DEPT PSYCHIAT & NEUROCHEM,S-22101 LUND,SWEDEN; LUND UNIV,DEPT INFECT DIS,S-22101 LUND,SWEDEN; ST VINCENTS HOSP,ALCOHOL & DRUG SERV,SYDNEY,NSW 2010,AUSTRALIA; NATL CTR HIV SOCIAL RES,SYDNEY,NSW,AUSTRALIA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT HLTH ADM,TORONTO,ON,CANADA	National Development & Research Institutes, Inc; Lund University; Lund University; St Vincents Hospital Sydney; University of Toronto; University of Toronto	DESJARLAIS, DC (corresponding author), BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,11 BEACH ST,NEW YORK,NY 10013, USA.			Ross, Michael/0000-0002-5718-9989	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003574] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03574] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BAKER M, 1991, 7TH INT C AIDS FLOR; BROWN BS, 1993, HDB RISK AIDS; CARR SV, 1992, AIDS, V6, P1553, DOI 10.1097/00002030-199212000-00028; CHITWOOD DD, 1994, AM J PUBLIC HEALTH, V84, P350, DOI 10.2105/AJPH.84.3.350; CHRISTENSSON B, 1991, INT J ADDICT, V26, P1293, DOI 10.3109/10826089109062161; CORDERO LA, 1986, REV ROUM MATH PURE A, V31, P9; DESJARLAIS DC, 1994, AM J PUBLIC HEALTH, V84, P452, DOI 10.2105/AJPH.84.3.452; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1994, FINAL REPORT WHO PRO; DESJARLAIS DC, 1992, AIDS OTHER MANIFESTA, P645; DESJARLAIS DC, 1994, 10TH INT C AIDS YOK; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; Dolan K A, 1993, Drug Alcohol Rev, V12, P133, DOI 10.1080/09595239300185561; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FRIEDMAN S R, 1991, AIDS Care, V3, P239, DOI 10.1080/09540129108253069; FRIEDMAN SR, 1993, AIDS, V7, pS263, DOI 10.1097/00002030-199301001-00037; FRISCHER M, 1992, AIDS, V6, P1371, DOI 10.1097/00002030-199211000-00022; FRISCHER M, 1992, INT J STD AIDS, V3, P288, DOI 10.1177/095646249200300412; FRISCHER M, 1993, INT J ADDICT, V28, P129, DOI 10.3109/10826089309039619; FRISCHER M, 1993, ADDICTION, V88, P681, DOI 10.1111/j.1360-0443.1993.tb02081.x; HAGAN H, 1993, ADDICTION, V88, P1691, DOI 10.1111/j.1360-0443.1993.tb02044.x; HAGAN H, 1991, Journal of Addictive Diseases, V10, P81, DOI 10.1300/J069v10n04_06; HAGAN H, 1993, HIV 1 SEROPREVALENCE; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; Lamothe F, 1992, Can Commun Dis Rep, V18, P98; LAMPINEN TM, 1992, AIDS, V6, P123, DOI 10.1097/00002030-199201000-00017; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MILLSON P, 1991, NHRDP66064333AIDS NA; MILLSON P, 1993, 9 INT C AIDS BERL; MILLSON P, 1992, 2ND ANN CAN NAT C HI; NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026; NEAIGUS A, 1994, SOC SCI MED, V38, P67, DOI 10.1016/0277-9536(94)90301-8; OSMOND DH, 1992, ONDCP B, V7; PAPAEVANGELOU G, 1991, 7 INT C AIDS FLOR; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROSS MW, 1992, AIDS CARE, V4, P139, DOI 10.1080/09540129208253085; ROSS MW, IN PRESS J R SOC HLT; ROSS MW, IN PRESS AIDS CARE; STALL R, 1993, J ACQ IMMUN DEF SYND, V3, P1181; STIMSON GV, 1995, 6TH INT C RED DRUG R; STIMSON GV, IN PRESS SOC SCI MED; STIMSON GV, 1990, 6TH INT C AIDS SAN F; TAYLOR A, IN PRESS ADDICTION; TUNVING K, 1992, 8TH INT C AIDS AMST; VANICHSENI S, 1990, 6TH INT C AIDS SAN F	48	189	193	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1226	1231		10.1001/jama.274.15.1226	http://dx.doi.org/10.1001/jama.274.15.1226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RZ120	7563513				2022-12-01	WOS:A1995RZ12000032
J	DOBSON, S; SCHEIFELE, D; BELL, A				DOBSON, S; SCHEIFELE, D; BELL, A			ASSESSMENT OF A UNIVERSAL, SCHOOL-BASED HEPATITIS-B VACCINATION PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess a hepatitis B vaccination program offered to all grade 6 students in British Columbia in 1992. Design.-Cohort study. Setting.-British Columbia, Canada. Participants.-All grade 6 students were offered vaccine. Subsets of 454 and 259 students participated in studies of minor adverse events and seroresponse, respectively. Intervention.-The vaccine used was Engerix-B, 20 mu g, given at intervals of 0, 1, and 6 months. Main Outcome Measures.-Province-wide acceptance and series completion rates and reports of severe adverse events. Minor adverse events and immunogenicity in subsamples. Results.-A total of 127 922 vaccine doses were administered. initial enrollment totaled 43 358 students or 95.4% of those eligible. The series was completed by 41 594 students (95.6%). Minor adverse events were infrequent in the cohort assessed: no absenteeism or physician visits resulted from vaccination. Sixty-nine reported severe adverse events met surveillance definitions, the major categories being injection site reactions (23% of reports), fainting (20%), and rashes (17%). There was one instance of anaphylaxis. Only 13 of these events resulted in recommendations to discontinue the series. Of students tested following the series, 98% had levels of antibody to hepatitis B surface antigen considered to be protective (greater than or equal to 10 IU/L), the geometric mean titer being 690 IU/L (95% confidence interval, 498 to 957 IU/J). Conclusion.-Our experience indicates that school-based programs for universal vaccination of preadolescents can be highly acceptable and efficient.	BRITISH COLUMBIA CTR DIS CONTROL, DIV EPIDEMIOL, VANCOUVER, BC, CANADA		DOBSON, S (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP, CTR VACCINE EVALUAT, 4500 OAK ST, ROOM L427, VANCOUVER, BC V5Z 4H4, CANADA.			Scheifele, David/0000-0001-6078-7843				ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; DELAGE G, 1992, CAN FAM PHYSICIAN, V38, P2656; HALL CB, 1992, PEDIATRICS, V89, P795; HUTTON F, 1993, BC HLTH DIS SURVEILL, V2, P2; SCHIFF GM, 1995, J ADOLESCENT HEALTH, V16, P12, DOI 10.1016/1054-139X(94)00105-N; WEST DJ, 1989, AM J INFECT CONTROL, V17, P172, DOI 10.1016/0196-6553(89)90213-7; WONG VK, 1994, PEDIATR INFECT DIS J, V13, P936, DOI 10.1097/00006454-199410000-00019; 1995, INFECT DIS CHILD, V8, P14; 1994, MMWR-MORBID MORTAL W, V43, P605; 1991, CAN DIS WKLY REP, V17, P165; 1992, CAN MED ASSOC J, V146, P25; 1994, CAN COMMUN DIS REP, V20, P105	14	69	69	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1209	1213		10.1001/jama.274.15.1209	http://dx.doi.org/10.1001/jama.274.15.1209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563510				2022-12-01	WOS:A1995RZ12000029
J	FRANCIS, GS				FRANCIS, GS			ROTATING TOURNIQUETS FOR ACUTE CARDIOGENIC PULMONARY-EDEMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FRANCIS, GS (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.							INGRAM RH, 1992, HEART DIS TXB CARDIO, P563	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1192	1192		10.1001/jama.274.15.1192	http://dx.doi.org/10.1001/jama.274.15.1192			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563500				2022-12-01	WOS:A1995RZ12000011
J	LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW				LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW			THE ROLE OF POLYNEUROPATHY IN MOTOR CONVALESCENCE AFTER PROLONGED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICAL ILLNESS POLYNEUROPATHY; MULTIPLE-ORGAN FAILURE; ILL PATIENTS; SEPSIS; DEFINITIONS; NEUROPATHY; SEVERITY	Objective.-To test the hypothesis that prolonged motor recovery after longterm ventilation may be due to polyneuropathy and can be foreseen at an early stage by electromyography (EMG). Design.-Cohort study with an entry period of 18 months. Polyneuropathy was identified by EMG studies in the intensive care unit (ICU). During a 1-year followup, amount of time was recorded to reach a rehabilitation end point. Setting.-The general ICU of a community hospital. Patients.-Fifty patients younger than 75 years who were receiving mechanical ventilation for more than 7 days. Main Outcome Measures.-A rehabilitation end point was defined as return of normal muscle strength and ability to walk 50 m independently. Results.-In 29 of 50 patients, an EMG diagnosis of polyneuropathy was made in the ICU. Patients with polyneuropathy had a higher mortality in the ICU (14 vs 4; P=.03), probably related to multiple organ failure (22 vs 11; P=.08) oraminoglycoside treatment of suspected gram-negative sepsis (17 vs 4; P=.05). Rehabilitation was more prolonged in 12 patients with polyneuropathy than in 12 without polyneuropathy (P=.001). Of nine patients with delays beyond 4 weeks, eight had polyneuropathy, five of whom had persistent motor handicap after 1 year. In particular, axonal polyneuropathy with conduction slowing on EMG indicated a poor prognosis. Conclusions.-Polyneuropathy in the critically ill is related to multiple organ failure and gram-negative sepsis, is associated with higher mortality, and causes important rehabilitation problems. EMG recordings in the ICU can identify patients at risk.	WESTEINDE ZIEKENHUIS,DEPT NEUROL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT CLIN NEUROPHYSIOL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT ANESTHESIOL & INTENS CARE,THE HAGUE,NETHERLANDS									[Anonymous], 1976, AIDS INVESTIGATION P; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BARAT M, 1987, REV NEUROL, V143, P823; BOLTON CF, 1986, J NEUROL NEUROSUR PS, V49, P563, DOI 10.1136/jnnp.49.5.563; BOLTON CF, 1984, J NEUROL NEUROSUR PS, V47, P1223, DOI 10.1136/jnnp.47.11.1223; Bolton CF, 1983, NEUROLOGY CLEVELA S2, V33, P186; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; CORONEL B, 1990, CRIT CARE MED, V18, P486, DOI 10.1097/00003246-199005000-00004; DECOUL AAW, 1983, CLIN NEUROL NEUROSUR, V85, P197; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; DECOUL AAWO, 1991, CLIN NEUROL NEUROSUR, V93, P27, DOI 10.1016/0303-8467(91)90005-A; DODSON BA, 1995, CRIT CARE MED, V23, P815, DOI 10.1097/00003246-199505000-00007; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GORSON KC, 1993, CRIT CARE MED, V21, P267, DOI 10.1097/00003246-199302000-00020; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEIJTEN FSS, 1994, CLIN NEUROL NEUROSUR, V96, P10, DOI 10.1016/0303-8467(94)90023-X; LEMAIRE F, 1993, INTENS CARE MED, V19, pS69, DOI 10.1007/BF01708804; MESSA JBL, 1990, INTENS CARE MED, V16, P159, DOI 10.1007/BF01724794; NIJHOLT JLA, 1987, HDB CLIN NEUROLOGY, V7, P575; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RIVNER MH, 1983, NEUROLOGY S2, V33, P164; Roelofs RI, 1983, NEUROLOGY S, V33, P240; SEISER A, 1992, WIEN KLIN WOCHENSCHR, V104, P294; SPITZER AR, 1992, MUSCLE NERVE, V15, P682, DOI 10.1002/mus.880150609; SPRUNG CL, 1991, CRIT CARE MED, V19, P849; WILLIAMS AC, 1986, BRIT MED J, V293, P790, DOI 10.1136/bmj.293.6550.790-a; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	30	201	204	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1221	1225		10.1001/jama.274.15.1221	http://dx.doi.org/10.1001/jama.274.15.1221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563512				2022-12-01	WOS:A1995RZ12000031
J	MARGOLIS, HS; COLEMAN, PJ; BROWN, RE; MAST, EE; SHEINGOLD, SH; AREVALO, JA				MARGOLIS, HS; COLEMAN, PJ; BROWN, RE; MAST, EE; SHEINGOLD, SH; AREVALO, JA			PREVENTION OF HEPATITIS-B VIRUS TRANSMISSION BY IMMUNIZATION - AN ECONOMIC-ANALYSIS OF CURRENT RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS ANALYSIS; UNITED-STATES; CARRIER STATE; FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; VACCINATION STRATEGIES; IMMUNE GLOBULIN; NATURAL-HISTORY; LIVER-DISEASE; DOUBLE-BLIND	Objective.-To evaluate the outcome of immunization strategies to prevent hepatitis B virus (HBV) transmission. Design and Setting.-A decision model was used to determine the incremental effects of the following hepatitis B immunization strategies in a birth cohort receiving immunization services in the public sector: (1) prevention of perinatal HBV infection, (2) routine infant vaccination, or (3) routine adolescent vaccination. Main Outcome Measures.-Over the lifetime of the cohort, the reduction in infections and medical and work-loss costs of HBV-related liver disease were determined for each strategy and compared with the outcome without immunization. Results.-Prevention of perinatal infection and routine infant vaccination would lower the 4.8% lifetime risk of HBV infection by at least 68%, compared with a 45% reduction for adolescent vaccination. From a societal perspective, each strategy was found to be cost saving, but was not cost saving with respect to direct medical costs. The estimated cost per year of life saved was $164 to prevent perinatal HBV infection, $1522 for infant vaccination, and $3730 for adolescent vaccination. Conclusions.-Routine vaccination of infants in successive birth cohorts to prevent HBV transmission is cost-effective over a wide range of assumptions. While economically less attractive than infant vaccination, adolescent vaccination could serve to protect those children who were not vaccinated as infants.	BATTELLE HUMAN AFFAIRS RES CTR,WASHINGTON,DC; US HLTH CARE FINANCING ADM,BUR POLICY DEV,OFF TECHNOL & SPECIAL ANAL,WASHINGTON,DC; PLANNED PARENTHOOD SACRAMENTO VALLEY,SACRAMENTO,CA		MARGOLIS, HS (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH A-33,ATLANTA,GA 30333, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1994, J MED VIROL, V44, P144, DOI 10.1002/jmv.1890440206; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BRUCE BR, 1990, STANDARDS SOCIOECONO; BUYLE MH, 1983, NEW ENGL J MED, V308, P1330; CHEN DS, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P716; CHOTARD J, 1992, J INFECT DIS, V166, P764, DOI 10.1093/infdis/166.4.764; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; FATTOVICH G, 1991, GUT, V32, P294, DOI 10.1136/gut.32.3.294; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; GANIATS TG, 1993, J FAM PRACTICE, V36, P147; GOH KT, 1992, B WORLD HEALTH ORGAN, V70, P233; GREENBERG DP, 1992, 32ND INT C ANT AG CH; HADLER SC, 1986, NEW ENGL J MED, V215, P209; HADLER SC, 1992, CURRENT CLIN TOPICS, P282; HEYWARD WL, 1985, AM J EPIDEMIOL, V121, P914, DOI 10.1093/oxfordjournals.aje.a114061; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HORNEY JT, 1977, GASTROENTEROLOGY, V73, P639; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; HURIE MB, 1992, PEDIATRICS, V89, P269; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; KARVOUNTZIS GG, 1974, GASTROENTEROLOGY, V67, P870; KRAHN M, 1993, MED DECIS MAKING, V13, P4, DOI 10.1177/0272989X9301300103; LASHNER BA, 1988, AM J MED, V85, P609; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LO KJ, 1982, J INFECT DIS, V146, P205, DOI 10.1093/infdis/146.2.205; MAHONEY FJ, 1993, J INFECT DIS, V167, P203, DOI 10.1093/infdis/167.1.203; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; MARGOLIS HS, 1990, VACCINE, V8, pS81, DOI 10.1016/0264-410X(90)90224-A; MARGOLIS HS, 1993, PEDIATR INFECT DIS J, V12, P542; MARION SA, 1994, AM J EPIDEMIOL, V140, P734, DOI 10.1093/oxfordjournals.aje.a117321; MAST EE, 1990, JAMA-J AM MED ASSOC, V264, P2529, DOI 10.1001/jama.264.19.2529; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCMAHON BJ, 1987, LANCET, V2, P1134; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MCQUILLAN GM, 1989, AM J MED S3A, V87, P5; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; SCHARTZ G, 1990, PROGR HEPATITIS B IM, P533; SINGH S, 1989, PRENATAL CARE US STA; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVENS CE, 1992, PEDIATRICS, V90, P170; STEVENS CE, 1995, UNPUB INFANTS HIGH R; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P211; TONG MJ, 1984, J PEDIATR-US, V105, P945, DOI 10.1016/S0022-3476(84)80084-0; TORRANCE GW, 1984, CLIN PERINATOL, V11, P267, DOI 10.1016/S0095-5108(18)30920-5; VIOLA LA, 1981, LANCET, V2, P1156; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; Weinstein MC, 1980, CLIN DECISION ANAL; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WEST DJ, 1992, PEDIATR INFECT DIS J, V11, P866, DOI 10.1097/00006454-199210000-00012; XU ZY, 1985, PEDIATRICS, V76, P713; 1992, PEDIATRICS, V89, P795; 1994, MMWR-MORBID MORTAL W, V43, P605; 1991, FED REGISTER, V56, P64004; 1991, EMPLOY EARN, P37; [No title captured]; 1990, 52 CTR DIS CONTR HEP; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1994, MMWR-MORBID MORTAL W, V43, P317; 1988, MMWR-MORBID MORTAL W, V37, P341; 1994, MMWR-MORBID MORTAL W, V43, P311; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, MMWR-MORBID MORTAL W, V40, P700	72	232	239	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1201	1208		10.1001/jama.274.15.1201	http://dx.doi.org/10.1001/jama.274.15.1201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563509				2022-12-01	WOS:A1995RZ12000028
J	PIERCE, MA; JOHNSON, MD; MACIUNAS, RJ; MURRAY, MJ; ALLEN, GS; HARBISON, MA; CREASY, JL; KESSLER, RM				PIERCE, MA; JOHNSON, MD; MACIUNAS, RJ; MURRAY, MJ; ALLEN, GS; HARBISON, MA; CREASY, JL; KESSLER, RM			EVALUATING CONTRAST-ENHANCING BRAIN-LESIONS IN PATIENTS WITH AIDS BY USING POSITRON EMISSION TOMOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; NERVOUS-SYSTEM LYMPHOMA; BIOPSY; NEUROPATHOLOGY; ENCEPHALITIS	Objective: To determine whether a noninvasive method for evaluating contrast-enhancing brain lesions in patients with the acquired immunodeficiency syndrome (AIDS) can accurately differentiate between lymphoma and nonlymphoma diagnoses. This method is based on Toxoplasma serologic testing and positron emission tomography. Design: Prospective, nonrandomized, criterion-standard clinical study. Setting: An academic center in the mid-southeastern United States. Patients: 20 patients with AIDS and contrast-enhancing brain lesions. Interventions: Positron emission tomographic scanning and Toxoplasma serologic testing. Main Outcome Measure: Diagnoses were confirmed by clinical response, autopsy, or brain biopsy. Results: Eight patients had a confirmed diagnosis of toxoplasmosis, six had lymphoma, four had other diagnoses, and two were not evaluable. Seven of eight patients with toxoplasmosis had positron emission tomographic scans; all of these scans showed hypometabolic lesions consistent with a nonlymphoma diagnosis. The six patients with lymphoma all had hypermetabolic lesions on positron emission tomographic scans. The difference between these two sets of results was statistically significant (P < 0.001, Fisher exact test, two-tailed). The anti-Toxoplasma titer was greater than or equal to 1:4 in all patients with confirmed toxoplasmosis who had serologic testing and in three of six patients with lymphoma. Conclusions: Evaluating contrast-enhancing brain lesions in patients with AIDS by using Toxoplasma serologic testing and positron emission tomography can accurately guide therapy and obviate the need for most brain biopsies in these patients. A larger, national, multicenter study is needed to confirm our findings and to determine the effect of earlier diagnosis and treatment on morbidity and mortality in patients with AIDS and primary central nervous system lymphoma.			PIERCE, MA (corresponding author), VANDERBILT UNIV, MED CTR,SCH MED,DIV INFECT DIS,1211 21ST AVE S, MED ARTS BLDG, SUITE 539, NASHVILLE, TN 37232 USA.				NCRR NIH HHS [5M01RR00095] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERS KH, 1986, AM J PATHOL, V124, P537; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CIMINO C, 1991, ARCH INTERN MED, V151, P1381, DOI 10.1001/archinte.151.7.1381; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DEGIROLAMI U, 1990, ARCH PATHOL LAB MED, V114, P643; GALETTO G, 1993, JAMA-J AM MED ASSOC, V269, P92, DOI 10.1001/jama.269.1.92; HOFFMAN JM, 1993, J NUCL MED, V34, P567; LEVY RM, 1992, NEUROSURGERY, V30, P186, DOI 10.1227/00006123-199202000-00006; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MOSKOWITZ LB, 1984, ARCH PATHOL LAB MED, V108, P368; ROSENBLUM ML, 1988, AIDS NERVOUS SYSTEM, P1; ROSENFELD SS, 1992, J NUCL MED, V33, P532; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; 1990, ARCH INTERN MED, V150, P735	16	71	73	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					594	598		10.7326/0003-4819-123-8-199510150-00005	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677300				2022-12-01	WOS:A1995RY82800005
J	WALD, TG; SHULT, P; KRAUSE, P; MILLER, BA; DRINKA, P; GRAVENSTEIN, S				WALD, TG; SHULT, P; KRAUSE, P; MILLER, BA; DRINKA, P; GRAVENSTEIN, S			A RHINOVIRUS OUTBREAK AMONG RESIDENTS OF A LONG-TERM-CARE FACILITY	ANNALS OF INTERNAL MEDICINE			English	Article						RHINOVIRUS; NURSING HOMES; RESPIRATORY TRACT INFECTIONS; DISEASE OUTBREAKS; LUNG DISEASES, OBSTRUCTIVE	ILLNESS; INFECTIONS; PRECIPITANTS; VIRUSES; ASTHMA	Objective: To describe the epidemiology of and clinical findings associated with a rhinovirus outbreak that occurred among institutionalized elderly persons. Design: Retrospective review of medical records and nursing surveillance reports. Setting: A 685-bed, long-term care facility for veterans and their spouses. Patients: 33 persons from whom rhinovirus was cultured. Measurements: Throat and nasopharyngeal virus culture; review of medical records to determine under-lying diseases, signs and symptoms of respiratory illness, illness duration, and interventions during illness; and review of nursing surveillance reports to determine room locations of ill persons. Results: Between 14 August and 2 September 1993, the number of respiratory illnesses increased. Throat and nasopharyngeal virus cultures were taken from 67 ill residents; 33 cultures yielded rhinovirus, and no other respiratory virus was isolated. Geographic clustering of persons infected with rhinovirus was observed. Of those persons with rhinovirus infections, 100% had upper respiratory symptoms, 34% had gastrointestinal symptoms, 71% had systemic symptoms, 66% had lower respiratory symptoms (including productive cough), and 52% had new abnormalities on lung auscultation. The 17 persons with rhinovirus infection who had chronic obstructive pulmonary disease had more severe illnesses: Five (29%) required glucocorticoid or bronchodilator therapy for illness-associated bronchospasm; 2 required transfer out of the facility; 1 developed a radiographically documented infiltrate; and 1 died of respiratory failure. Conclusions: Rhinovirus may cause epidemic, clinically important respiratory illness in nursing home residents. A large proportion of residents may become ill, and infection may be severe in persons with underlying lung disease.	UNIV WISCONSIN, SCH MED, INST AGING, MADISON, WI 53706 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, MADISON, WI USA; UNIV WISCONSIN, WISCONSIN STATE LAB HYG, MADISON, WI 53706 USA; WISCONSIN VET HOME, KING, WI 54946 USA	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison			Gravenstein, Stefan/O-1809-2019; Gravenstein, Stefan/G-1681-2011	Gravenstein, Stefan/0000-0001-6000-6859; 	NIA NIH HHS [AG09632, AG00213, AG00548] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009632, K08AG000548] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DICK EC, 1967, AM J EPIDEMIOL, V86, P386, DOI 10.1093/oxfordjournals.aje.a120749; DICK EC, 1992, TXB PEDIATRIC INFECT, P1507; DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159; EADIE MB, 1966, BMJ-BRIT MED J, V2, P671, DOI 10.1136/bmj.2.5515.671; FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x; FOX JP, 1985, AM J EPIDEMIOL, V122, P830, DOI 10.1093/oxfordjournals.aje.a114166; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184, DOI 10.1093/oxfordjournals.aje.a120928; MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P321, DOI 10.1097/00006454-199304000-00011; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; STENHOUSE AC, 1967, BMJ-BRIT MED J, V3, P461, DOI 10.1136/bmj.3.5563.461; VALENTI WM, 1982, J PEDIATR-US, V100, P722, DOI 10.1016/S0022-3476(82)80571-4; 1993, MMWR-MORBID MORTAL W, V42, P689	18	75	76	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1995	123	8					588	593		10.7326/0003-4819-123-8-199510150-00004	http://dx.doi.org/10.7326/0003-4819-123-8-199510150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY828	7677299				2022-12-01	WOS:A1995RY82800004
J	ABRAHAMOV, A; ELSTEIN, D; GROSSTSUR, V; FARBER, B; GLASER, Y; HADASHALPERN, I; RONEN, S; TAFAKJDI, M; HOROWITZ, M; ZIMRAN, A				ABRAHAMOV, A; ELSTEIN, D; GROSSTSUR, V; FARBER, B; GLASER, Y; HADASHALPERN, I; RONEN, S; TAFAKJDI, M; HOROWITZ, M; ZIMRAN, A			GAUCHERS-DISEASE VARIANT CHARACTERIZED BY PROGRESSIVE CALCIFICATION OF HEART-VALVES AND UNIQUE GENOTYPE	LANCET			English	Article							INVOLVEMENT; GLUCOCEREBROSIDASE; DEFICIENCY; MUTATIONS	Gaucher's disease is the most prevalent sphingolipid storage disease, characterised by substantial genetic and phenotypic variability. Cardiac manifestations are rare. We report 12 Arab Gaucher's disease patients, 2-20 years of age, who presented with oculomotor apraxia but only slight classic signs of the disease. All but the youngest had calcifications of the aortic or mitral valves or both. All these patients were homozygous for the rare point mutation D409H (1342C). Valvular calcifications increased with age and showed progression during 2 years of follow-up. Two of the oldest patients underwent aortic valve replacement, and one sibling had died suddenly at age 16, before this study. Corneal opacities were another common feature. The potentially fatal course of this Gaucher's disease variant, and the availability of a reliable PCR-based method for heterozygote detection, mean that population screening and genetic counselling in the geographic area at risk are important. Affected individuals should be closely monitored by echocardiography to gauge the need for valve replacement. The potential of enzyme replacement to prevent these cardiac complications cannot be ascertained at present, because of the high cost of therapy.	SHAARE ZEDEK MED CTR,GAUCHER CLIN,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PEDIAT,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PEDIAT CARDIOL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PEDIAT NEUROL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT OPHTHALMOL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT MED,IL-91031 JERUSALEM,ISRAEL; TEL AVIV UNIV,FAC LIFE SCI,DEPT CELLULAR BIOL & IMMUNOL,RAMAT AVIV,ISRAEL; JENIN HLTH DIST OFF,JENIN,JORDAN	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Tel Aviv University								BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BENBASSA.J, 1968, AM J MED, V44, P647, DOI 10.1016/0002-9343(68)90067-3; Beutler E., 1995, METABOLIC MOL BASES, P2641; BRADY RO, 1994, 4TH INT GAUCH DIS C; CASTA A, 1984, AM J CARDIOL, V54, P1390, DOI 10.1016/S0002-9149(84)80115-0; CHABAS A, 1995, J MED GENET, V32, P740, DOI 10.1136/jmg.32.9.740; EDWARDS WD, 1983, AM J CARDIOL, V52, P654, DOI 10.1016/0002-9149(83)90052-8; GROSSTSUR V, 1989, PEDIATR NEUROL, V5, P128, DOI 10.1016/0887-8994(89)90042-8; HOROWITZ M, 1993, AM J HUM GENET, V53, P921; Lee R. E., 1982, GaAs IC Symposium. IEEE Gallium Arsenide Integrated Circuit Symposium. Technical Digest 1982, P177; PATTERSON MC, 1993, NEUROLOGY, V43, P1993, DOI 10.1212/WNL.43.10.1993; ROBERTS WC, 1967, CIRCULATION, V35, P783, DOI 10.1161/01.CIR.35.4.783; SARACLAR M, 1991, PEDITA CARDIOLOGY, V13, P56; SMITH RRL, 1978, AM J MED, V65, P352, DOI 10.1016/0002-9343(78)90832-X; TAMARI I, 1983, ARCH INTERN MED, V143, P2010, DOI 10.1001/archinte.143.10.2010; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TSUTSUMI A, 1982, GANKA RHINSHOIHO, V76, P1730; UYAMA E, 1992, ACTA NEUROL SCAND, V86, P407, DOI 10.1111/j.1600-0404.1992.tb05109.x; WILSON ER, 1985, ARCH PATHOL LAB MED, V109, P82	19	154	160	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1000	1003		10.1016/S0140-6736(95)91688-1	http://dx.doi.org/10.1016/S0140-6736(95)91688-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475546				2022-12-01	WOS:A1995RZ59900010
J	ASSCHER, AW; PARR, GD; WHITMARSH, VB				ASSCHER, AW; PARR, GD; WHITMARSH, VB			TOWARDS THE SAFER USE OF MEDICINES	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG-REACTIONS; GENERAL-PRACTICE; DISEASE; RISKS	In Britain the tools are now available to provide better information on safety of medicines in both hospital and community settings, and this could be done at relatively modest cost. The needs of patients, doctors, and pharmacists are changing; although more research is needed, such information as is presently available must be both better and more widely publicised and understood. Universities, government, the pharmaceutical industry, and educated journalism all have an important part to play in this process.	MED BENEFIT RISK FDN,PHARMACOEPIDEMIOL GRP,LONDON W1M 8AE,ENGLAND									ABRAMSON NS, 1980, JAMA-J AM MED ASSOC, V244, P1582, DOI 10.1001/jama.244.14.1582; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BROWN PJ, PERCEPTION MANAGEMEN, P149; BURKHOLDER DF, 1979, DRUG INTEL CLIN PHAR, V13, P421, DOI 10.1177/106002807901300708; CARTWRIGHT A, 1988, OLDER PEOPLE THEIR M; CONI N, 1988, LECTURE NOTES GERIAT; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P591; DODDSSMITH I, 1995, 2ND P S, P1; DRURY VVM, 1986, DOCTOR MONITORING DR, P651; EVANS JG, 1993, HLTH FUNCTION 3RD AG; FERNER RE, 1992, BRIT J CLIN PHARMACO, V33, P125, DOI 10.1111/j.1365-2125.1992.tb04013.x; FERNER RE, 1994, J ROY SOC MED, V87, P145; GEORGE CF, 1983, BRIT MED J, V287, P1193, DOI 10.1136/bmj.287.6400.1193; GIBBS S, 1987, Pharmaceutical Medicine (London), V2, P23; HAYES A, 1990, PHARM J, V245, pR36; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Keeney R. L., 1976, DECISIONS MULTIPLE O; KNIGHT R, 1987, J ROY COLL GEN PRACT, V37, P19; LAWSON DH, 1978, SCOTTISH MED J, V24, P127; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LIVINGSTONE C, 1993, PHARM J S, V251, pR6; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MARTYS CR, 1979, BMJ-BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6199.1194; MILLER RR, 1974, ARCH INTERN MED, V43, P219; MULROY R, 1973, BRIT MED J, V2, P407, DOI 10.1136/bmj.2.5863.407; OBRIEN BJ, 1990, J EPIDEMIOL COMMUN H, V44, P249, DOI 10.1136/jech.44.3.249; OBRIEN BJ, 1990, J RHEUMATOL, V17, P503; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; RAWLINS MD, 1988, BRIT J CLIN PHARMACO, V26, P1; RAWLINS MD, 1988, BRIT J CLIN PHARMACO, V26, P7, DOI 10.1111/j.1365-2125.1988.tb03357.x; RAWLINS MD, 1989, RISK AND CONSENT TO RISK IN MEDICINE, P193; RAWLINS MD, 1991, BRIT MED J, V302, P322; RIDOUT S, 1986, BRIT J CLIN PHARMACO, V21, P701, DOI 10.1111/j.1365-2125.1986.tb05236.x; ROBERTS K, 1986, BR J PHARM PRACT, V8, P387; SLOVIC P, 1981, P ROY SOC LOND A MAT, V376, P17, DOI 10.1098/rspa.1981.0073; Slovic P, 1989, PERCEPTION MANAGEMEN; VINCENT C, 1993, MED ACCIDENTS; WILKIE A, 1994, J ROY SOC MED, V87, P594; 1995, WAY HLTH         JUN, P80; 1982, RISK ANAL PERCEPTION; 1994, OBSERVER        0529, P26; 1991, CONSUMER EXPECTATION; 1992, PHARM CARE FUTURE CO; 1993, CHEAPER THAN PRESCRI	49	24	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					1003	1006						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580589				2022-12-01	WOS:A1995TA07900031
J	AUSTIN, D; SLEIGH, J				AUSTIN, D; SLEIGH, J			PREDICTION OF ACUTE MOUNTAIN-SICKNESS	BRITISH MEDICAL JOURNAL			English	Article											AUSTIN, D (corresponding author), WAIKATO HOSP,DEPT ANAESTHESIA,HAMILTON,NEW ZEALAND.		Austin, David/A-5703-2012	Austin, David/0000-0001-6829-7937				GUZ A, 1957, CLIN SCI, V30, P161; Houston C. S., 1985, AM ALPINE J, V27, P162; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063; WRIGHT AD, 1985, AVIAT SPACE ENVIR MD, V56, P572; 1981, LANCET, V1, P180	5	14	16	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					989	990						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580641				2022-12-01	WOS:A1995TA07900024
J	DIEPOLDER, HM; ZACHOVAL, R; HOFFMANN, RM; WIERENGA, EA; SANTANTONIO, T; JUNG, MC; EICHENLAUB, D; PAPE, GR				DIEPOLDER, HM; ZACHOVAL, R; HOFFMANN, RM; WIERENGA, EA; SANTANTONIO, T; JUNG, MC; EICHENLAUB, D; PAPE, GR			POSSIBLE MECHANISM INVOLVING T-LYMPHOCYTE RESPONSE TO NONSTRUCTURAL PROTEIN-3 IN VIRAL CLEARANCE IN ACUTE HEPATITIS-C VIRUS-INFECTION	LANCET			English	Note								In acute hepatitis C virus (HCV) infection only 20-50% of patients spontaneously clear the virus. To characterise the immune reaction during that phase we studied the response of peripheral blood mononuclear cells (PBMC) to the recombinant HCV proteins core, non-structural protein 3 (NS3), NS4, and NS5 in 14 patients with acute hepatitis C. All eight patients with self-limited disease compared with two of six with evolving chronic infection showed an NS3- specific PBMC response (p=0.015). Of 65 patients with established chronic hepatitis C, five showed a PBMC response to NS3. NS3-specific CD4 T-cell clones from patients with self-limited infection predominantly produced interferon-gamma and may thus support cytotoxic effector mechanisms important for viral clearance.	UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81377 MUNICH,GERMANY; UNIV AMSTERDAM,CELL BIOL & HISTOL LAB,1105 AZ AMSTERDAM,NETHERLANDS; UNIV BARI,MALATTIE INFETT CLIN,BARI,ITALY; HOSP SCHWABING,DEPT INTERNAL MED 4,MUNICH,GERMANY	University of Munich; University of Amsterdam; Universita degli Studi di Bari Aldo Moro	DIEPOLDER, HM (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,INST IMMUNOL,D-81377 MUNICH,GERMANY.		Yang, Chen/G-1379-2010					ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BOTARELLI P, 1993, GASTROENTEROLOGY, V104, P580, DOI 10.1016/0016-5085(93)90430-K; CERNY A, 1995, J CLIN INVEST, V95, P521, DOI 10.1172/JCI117694; FARCI P, 1991, SCIENCE, V258, P135; FERRARI C, 1994, HEPATOLOGY, V19, P286; HOFFMANN RM, 1995, HEPATOLOGY, V21, P632, DOI 10.1016/0270-9139(95)90510-3; JUNG MC, 1995, J VIROL, V69, P3358, DOI 10.1128/JVI.69.6.3358-3368.1995; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; MINUTELLO MA, 1993, J EXP MED, V178, P17, DOI 10.1084/jem.178.1.17	10	624	654	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1006	1007		10.1016/S0140-6736(95)91691-1	http://dx.doi.org/10.1016/S0140-6736(95)91691-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475549				2022-12-01	WOS:A1995RZ59900013
J	ERNEST, JT				ERNEST, JT			INTRAOCULAR DEVICE FOR CYTOMEGALOVIRUS-INFECTION	LANCET			English	Editorial Material							SUSTAINED-RELEASE GANCICLOVIR; VIRUS RETINITIS				ERNEST, JT (corresponding author), UNIV CHICAGO,DEPT OPHTHALMOL & VISUAL SCI,CHICAGO,IL 60637, USA.							ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; JABS DA, 1987, OPHTHALMOLOGY, V94, P824; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; ROWE WP, 1956, P SOC EXP BIOL MED, V92, P418, DOI 10.3181/00379727-92-22497; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; SMITH TJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P255, DOI 10.1001/archopht.1992.01080140111037; 1994, ARCH OPHTHALMOL-CHIC, V112, P19; 1995, INVEST OPHTH VIS SCI, V36, pS180	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					983	984		10.1016/S0140-6736(95)91681-4	http://dx.doi.org/10.1016/S0140-6736(95)91681-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475587				2022-12-01	WOS:A1995RZ59900003
J	HEITMANN, BL; LISSNER, L				HEITMANN, BL; LISSNER, L			DIETARY UNDERREPORTING BY OBESE INDIVIDUALS - IS IT SPECIFIC OR NONSPECIFIC	BRITISH MEDICAL JOURNAL			English	Article							AGED 35-65 YEARS; ENERGY-EXPENDITURE; BODY-COMPOSITION; DANISH POPULATION; URINE NITROGEN; WOMEN; PREDICTION; FAT; MEN	Objective-To examine the distribution of patterns of macronutrient density in relation to obesity. Design-Cross sectional. Setting-Denmark. Subjects-323 men and women aged 35-65 years, selected randomly from a larger population sample of Danish adults. Main outcome measure-Bias in dietary reporting of energy and protein intake in relation to percentage body fat, assessed by comparison of data from an interview on dietary intake with data estimated from 24 hour nitrogen output, validated by administering p-aminobenzoic acid, and estimated 24 hour energy expenditure. Results-Degree of obesity was positively associated with underreporting of total energy and protein, whereas compared with total energy reported, protein was overreported by the obese subjects. Conclusion-Errors in dietary reporting of protein seem to occur disproportionately with respect to total energy, suggesting a differential reporting pattern of different foods. Although, on average, all subjects showed a greater underreporting of energy than of protein, this was most common in the obese subjects. Snack-type foods may be preferentially forgotten when obese people omit food items in dietary reporting. These results seem to agree with the general assumption that obese people tend to underreport fatty foods and foods rich in carbohydrates rather than underreport their total dietary intake. These results may have implications for the interpretation of studies of diet and comorbidities related to obesity.	DANISH EPIDEMIOL SCI CTR,INST PREVENT MED,COPENHAGEN,DENMARK; GLOSTRUP CTY HOSP,DEPT MED C,GLOSTRUP,DENMARK; GOTHENBURG UNIV,DEPT INTERNAL MED & PRIMARY HLTH CARE,GOTHENBURG,SWEDEN	Aarhus University; University of Copenhagen; University of Gothenburg				Heitmann, Berit Lilienthal/0000-0002-6809-4504				ASTRUP A, 1990, AM J CLIN NUTR, V52, P777, DOI 10.1093/ajcn/52.5.777; BINGHAM S, 1983, CLIN SCI, V64, P629, DOI 10.1042/cs0640629; BINGHAM SA, 1985, AM J CLIN NUTR, V42, P1276, DOI 10.1093/ajcn/42.6.1276; BINGHAM SA, 1991, BIOMARKERS DIETARY E, P41; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; BLACK AE, 1991, P NUTR SOC, V50, pA108; CUNNINGHAM JJ, 1991, AM J CLIN NUTR, V54, P963, DOI 10.1093/ajcn/54.6.963; DREWNOWSKI A, 1992, APPETITE, V18, P207, DOI 10.1016/0195-6663(92)90198-F; GARBY L, 1988, EUR J CLIN NUTR, V42, P301; HEITMANN BL, 1992, J CLIN EPIDEMIOL, V45, P693, DOI 10.1016/0895-4356(92)90046-P; HEITMANN BL, 1993, INT J OBESITY, V17, P329; HEITMANN BL, 1991, INT J OBESITY, V15, P535; HEITMANN BL, 1990, INT J OBESITY, V14, P789; HULTEN B, 1990, EUR J CLIN NUTR, V44, P169; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; JENSEN KH, 1991, GASTROENTEROLOGY, V100, P790, DOI 10.1016/0016-5085(91)80027-7; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; LISSNER L, 1994, EUR J CLIN NUTR, V48, P453; LISSNER L, 1989, AM J CLIN NUTR, V49, P320, DOI 10.1093/ajcn/49.2.320; LIVINGSTONE MBE, 1990, BRIT MED J, V300, P708, DOI 10.1136/bmj.300.6726.708; MOLLER A, 1986, PUBLICATION MINISTRY, V75; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; RUTISHAUSER IHE, 1995, EUR J CLIN NUTR, V49, P219; SCHOELLER DA, 1990, NUTR REV, V48, P373, DOI 10.1111/j.1753-4887.1990.tb02882.x; SUMMERBELL CD, 1995, EUR J CLIN NUTR, V49, P33; 1989, WHO EUR ICP NUT125 N	26	510	512	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					986	989						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580640				2022-12-01	WOS:A1995TA07900023
J	KINGHAM, JGC				KINGHAM, JGC			PEPPERMINT OIL AND COLON SPASM	LANCET			English	Editorial Material							IRRITABLE BOWEL SYNDROME				KINGHAM, JGC (corresponding author), SINGLETON HOSP,SWANSEA SA2 8QA,W GLAM,WALES.							DEW MJ, 1984, BRIT J CLIN PRACT, V38, P394; DUTHIE HL, 1981, BRIT J SURG, V68, P820; FINK AM, 1995, CLIN RADIOL, V50, P160, DOI 10.1016/S0009-9260(05)83047-8; GOEI R, 1995, CLIN RADIOL, V50, P553, DOI 10.1016/S0009-9260(05)83191-5; HAWTHORN M, 1988, Alimentary Pharmacology and Therapeutics, V2, P101; HILLS JM, 1991, GASTROENTEROLOGY, V101, P55, DOI 10.1016/0016-5085(91)90459-X; JARVIS LJ, 1992, CLIN RADIOL, V46, pA435; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; LEICESTER RJ, 1982, LANCET, V2, P989; NASH P, 1986, BRIT J CLIN PRACT, V40, P292; REES WDW, 1979, BMJ-BRIT MED J, V2, P835, DOI 10.1136/bmj.2.6194.835; ROGERS J, 1988, LANCET, V2, P98; SKUCAS J, 1994, AM J ROENTGENOL, V162, P1323, DOI 10.2214/ajr.162.6.8191992; SPARKS MJW, 1995, BRIT J RADIOL, V68, P841, DOI 10.1259/0007-1285-68-812-841; THOENI RF, 1988, RADIOLOGY, V167, P7, DOI 10.1148/radiology.167.1.3347749; 1988, LANCET, V1, P1144	16	14	15	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					986	986		10.1016/S0140-6736(95)91684-9	http://dx.doi.org/10.1016/S0140-6736(95)91684-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475590				2022-12-01	WOS:A1995RZ59900006
J	LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ				LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ			SPECIFIC THERAPEUTIC GROUP AGE-SEX RELATED PRESCRIBING UNITS (STAR-PUS) - WEIGHTINGS FOR ANALYZING GENERAL PRACTICES PRESCRIBING IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To derive cost comparators for prescribing by English general practitioners in eight specific therapeutic groups, based on age-sex related weightings, and to confirm, from a new dataset, earlier age-sex weightings for overall prescribing (ASTRO-PUs). Design-Calculations based on one year's prescribing data from selected practices using AAH Meditel software, held on MediPlus by Intercontinental Medical Statistics (IMS, UK and Ireland), and research practices using VAMP software, held on the General Practice Research Database. Setting-112 English practices with 739 672 patients and 510 British practices with 3 126 570 patients. Main outcome measures-Cost based weightings for 18 age-sex groups and for temporary residents for eight leading specific therapeutic groups and for prescribing overall. Results-The two datasets were similar in age distribution and in the way that prescription numbers were distributed by age-sex band in each therapeutic group. The cost based weightings for specific therapeutic groups showed great variation in the use of these groups for patients in different age-sex groups. When these weightings were applied to the prescribing of practices in two family health services authorities they differed in their power to predict prescribing costs: for cardiovascular and gastrointestinal drugs predictive power was particularly high; for drugs for infections it was particularly low, since these are widely used at all ages and for both sexes. Cost based weightings for overall prescribing derived from the IMS data were similar to those of the ASTRO-PU system even though they were derived by different methods from different datasets. Conclusions-The weightings (STAR-PUs) offer a sound basis for cost comparisons at the therapeutic group level. Cost-based weightings for overall prescribing derived from the UMS data were reassuringly similar to those of the existing ASTRO-PU system.	UNIV LEEDS,RES SCH MED,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND	University of Leeds								BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102	5	53	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580642				2022-12-01	WOS:A1995TA07900027
J	SHARP, NC; CRONIN, N; FELDBERG, I; EVANS, M; HODGSON, D; ELLIS, S				SHARP, NC; CRONIN, N; FELDBERG, I; EVANS, M; HODGSON, D; ELLIS, S			MICROWAVES FOR MENORRHAGIA - A NEW FAST TECHNIQUE FOR ENDOMETRIAL ABLATION	LANCET			English	Note								Current ablative techniques for treating menorrhagia are unsatisfactory. We tried microwave energy, delivered by an 8 mm diameter probe in the uterine cavity, to treat 23 patients with functional menorrhagia. The mean treatment time was 2 min 12 s (range 50-310 s). 6 months after treatment the success rate is 83%, 13 patients (57%) are amenorrhoeic, and six (26%) are experiencing light menstruation. Three initial failures have been successfully retreated. The technique is safe, and is easier and quicker to perform than current alternatives.	UNIV BATH,SCH PHYS,BATH BA2 7AY,AVON,ENGLAND; ROYAL UNITED HOSP,DEPT MED PHYS,BATH,AVON,ENGLAND	University of Bath	SHARP, NC (corresponding author), ROYAL UNITED HOSP,DEPT OBSTET & GYNAECOL,PRINCESS ANNE WING,BATH BA1 3NG,AVON,ENGLAND.							ARIEFF AI, 1993, JAMA-J AM MED ASSOC, V270, P1230, DOI 10.1001/jama.270.10.1230; BAUMANN R, 1990, BRIT MED J, V300, P304, DOI 10.1136/bmj.300.6720.304; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; 1994, MISTLETOE SURGERY UP	4	85	94	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1003	1004		10.1016/S0140-6736(95)91689-X	http://dx.doi.org/10.1016/S0140-6736(95)91689-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475547				2022-12-01	WOS:A1995RZ59900011
J	TELI, MR; DAY, CP; BURT, AD; BENNETT, MK; JAMES, OFW				TELI, MR; DAY, CP; BURT, AD; BENNETT, MK; JAMES, OFW			DETERMINANTS OF PROGRESSION TO CIRRHOSIS OR FIBROSIS IN PURE ALCOHOLIC FATTY LIVER	LANCET			English	Article							LIPID-PEROXIDATION; DISEASE; INJURY	''Pure'' alcoholic fatty liver has been widely assumed to be ''benign'' with very low risk of progression to cirrhosis. Studies thus far have included either patients with coexisting recognised precursor lesions of cirrhosis or have been restricted to short-term histological follow-up. We have followed 88 patients, first seen between 1978 and 1985, with a histological diagnosis of pure alcoholic fatty liver and no evidence of fibrosis or alcoholic hepatitis, for a median of 10.5 years, to determine any factors predictive of disease progression. Of the 88, at follow-up nine had developed cirrhosis and a further seven fibrosis. Eight of nine patients with cirrhosis had continuing alcohol consumption of more than 40 units per week at follow-up; in the other patients, consumption was unknown. Independent histological predictors of progression on index biopsy were: presence of mixed macro/microvesicular fat, and presence of giant mitochondria. We can no longer regard alcoholic fatty liver as benign. in the presence of continuing high alcohol consumption the above histological features identified those at high risk (47-61%) of disease progression. Therefore, patients with these features should be counselled intensively regarding their alcohol consumption.	MED SCH NEWCASTLE UPON TYNE, DEPT MED, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; MED SCH NEWCASTLE UPON TYNE, DEPT PATHOL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK; Newcastle University - UK			Burt, Alastair D/D-3634-2013; Day, Christopher/Z-3305-2019	Burt, Alastair D/0000-0002-3011-7774; 				CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4; CHEDID A, 1986, GASTROENTEROLOGY, V90, P1858, DOI 10.1016/0016-5085(86)90253-2; CHRISTOFFERSEN P, 1972, ACTA PATH MICRO IM A, VA 80, P557; EDMONDSON HA, 1967, MEDICINE, V46, P119, DOI 10.1097/00005792-196703000-00006; FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1; ITOH S, 1987, AM J GASTROENTEROL, V82, P650; LEEVY CM, 1962, MEDICINE, V41, P249, DOI 10.1097/00005792-196209000-00003; LEEVY CM, 1968, MED CLIN N AM, V52, P1445, DOI 10.1016/S0025-7125(16)32838-3; LETTERON P, 1993, GUT, V34, P409, DOI 10.1136/gut.34.3.409; LIEBER CS, 1976, FED PROC, V35, P1232; LIEBER CS, 1965, J CLIN INVEST, V44, P1009, DOI 10.1172/JCI105200; MORGAN MY, 1977, BRIT MED J, V1, P939, DOI 10.1136/bmj.1.6066.939; MORGAN MY, 1991, OXFORD TXB CLIN HEPA, P816; PAROLA M, 1993, BIOCHEM BIOPH RES CO, V194, P1044, DOI 10.1006/bbrc.1993.1927; PORTA EA, 1965, AM J PATHOL, V46, P657; SHERLOCK S, 1995, LANCET, V345, P227; SORENSEN TIA, 1984, LANCET, V2, P241, DOI 10.1016/S0140-6736(84)90295-2; TELI MR, IN PRESS HEPATOLOGY; WORNER TM, 1985, JAMA-J AM MED ASSOC, V254, P627, DOI 10.1001/jama.254.5.627; ZAKIM D, 1990, HEPATOLOGY TXB LIVER, P848	20	344	351	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	1995	346	8981					987	990		10.1016/S0140-6736(95)91685-7	http://dx.doi.org/10.1016/S0140-6736(95)91685-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475591				2022-12-01	WOS:A1995RZ59900007
J	VENN, A; WATSON, L; LUMLEY, J; GILES, G; KING, C; HEALY, D				VENN, A; WATSON, L; LUMLEY, J; GILES, G; KING, C; HEALY, D			BREAST AND OVARIAN-CANCER INCIDENCE AFTER INFERTILITY AND IN-VITRO FERTILIZATION	LANCET			English	Article							WOMEN; RISK	Concern has been expressed that exposure to fertility drugs might be associated with a risk of ovarian cancer. We have examined the incidence of breast and ovarian cancer in a cohort of 10 358 women referred for in-vitro fertilisation (IVF) treatment in Victoria, Australia, between 1978 and 1992. The ''exposed'' group (n=5564) had had ovarian stimulation to induce multiple folliculogenesis and the ''unexposed'' group (n=4794) had been referred for IVF but were untreated or had had ''natural cycle'' treatment without ovarian stimulation. Duration of follow-up ranged from 1 to 15 years. Cases of cancer were determined by record linkage with data from population-based cancer registries. 34 cases of invasive breast cancer and 6 of invasive ovarian cancer were observed. A comparison with the expected numbers, derived by applying age-standardised general population rates to the cohort gave standardised incidence ratios (SIR) for breast cancer of 0.89 (95% CI 0.55-1.46) in the exposed group and 0.98 (0.62-1.56) in the unexposed group, and for ovarian cancer SIRs were 1.70 (0.55-5.27) and 1.62 (0.52-5.02), respectively. Rates of all cancers were not significantly different from general population rates. The relative risk (RR) of cancer, adjusted for age and infertility type, was, in the treated group compared with the untreated group, 1.11 (95% CI 0.56-2.20) for breast cancer and 1.45 (0.28-7.55) for ovarian cancer. The risk of body of uterus cancer was increased in the exposed and unexposed groups combined (SIR 2.84 [1.18-6.81]). Women with unexplained infertility, independent of IVF exposure, had significantly increased risks of ovarian cancer (RR=19.19 [2.23-165.0]) and body of uterus cancer (RR=6.34 [1.06-38.0]) compared with women with known causes of infertility. This relatively short-term follow-up suggests that ovarian stimulation with IVF is not associated with an increased risk of breast cancer. Although there was no significantly increased risk of ovarian cancer after ovarian stimulation with IVF the small number of cases limits the conclusions that can be drawn. Longer-term follow-up of large cohorts of women who have been in IVF programmes will be necessary.	NATL PERINATAL EPIDEMIOL UNIT,OXFORD,ENGLAND; ANTICANC COUNCIL VICTORIA,CTR EPIDEMIOL,CARLTON,VIC,AUSTRALIA; MAROONDAH BREASTSCREEN,E RINGWOOD,VIC,AUSTRALIA; MONASH UNIV,MONASH MED CTR,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA	University of Oxford; Monash University	VENN, A (corresponding author), LA TROBE UNIV,CTR STUDY MOTHERS & CHILDRENS HLTH,463 CARDIGAN ST,CARLTON,VIC 3053,AUSTRALIA.		Venn, Alison J/J-2803-2013					BRINTON LA, 1989, AM J EPIDEMIOL, V129, P712, DOI 10.1093/oxfordjournals.aje.a115186; COWAN LD, 1981, AM J EPIDEMIOL, V114, P209, DOI 10.1093/oxfordjournals.aje.a113184; Creasy G W, 1992, Obstet Gynecol Surv, V47, P654, DOI 10.1097/00006254-199209000-00026; DEWAARD F, 1982, CANCER EPIDEMIOL, P901; Fischel S., 1989, BRIT MED J, V299, P309; GAMMON MD, 1990, AM J EPIDEMIOL, V132, P708, DOI 10.1093/oxfordjournals.aje.a115712; GILES GG, 1992, CANCER VICTORIA 1982; HEALY DL, 1994, LANCET, V343, P1539, DOI 10.1016/S0140-6736(94)92941-6; MACLACHLAN V, 1989, NEW ENGL J MED, V320, P1233, DOI 10.1056/NEJM198905113201902; Preston DL, 1993, EPICURE USERS GUIDE; RON E, 1987, AM J EPIDEMIOL, V125, P780, DOI 10.1093/oxfordjournals.aje.a114595; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; TROUNSON AO, 1981, SCIENCE, V212, P616; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; 1995, LONG TERM EFFECTS WO	15	255	261	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					995	1000		10.1016/S0140-6736(95)91687-3	http://dx.doi.org/10.1016/S0140-6736(95)91687-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475593				2022-12-01	WOS:A1995RZ59900009
J	WHATLEY, SD; ROBERTS, AG; ELDER, GH				WHATLEY, SD; ROBERTS, AG; ELDER, GH			DE-NOVO MUTATION AND SPORADIC PRESENTATION OF ACUTE INTERMITTENT PORPHYRIA	LANCET			English	Note							PORPHOBILINOGEN DEAMINASE GENE	Acute intermittent porphyria (AIP) is a low-penetrant autosomal dominant disorder characterised by life-threatening neurovisceral attacks, often precipitated by drugs. Prognosis is improved by presymptomatic diagnosis and counselling. We found that 29 of 103 (28%) unrelated patients presented as sporadic cases. One patient had a de-novo mutation. The same mutation has arisen de novo at least three times in 12% of British AIP families. About 3% (95% CI 1-8%) of all AIP index cases may have de-novo mutations. These findings emphasise the high frequency of sporadic presentation of AIP and indicate the limitations of presymptomatic diagnosis as an aid to management.	UNIV WALES HOSP,COLL MED,DEPT BIOCHEM MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University				Anderson, Karl/0000-0002-6499-8573	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONKOVSKY HL, 1993, GASTROENTEROLOGY, V105, P590, DOI 10.1016/0016-5085(93)90739-Y; BROWNLIE PD, 1994, PROTEIN SCI, V3, P1644, DOI 10.1002/pro.5560031004; CHEN CH, 1994, J CLIN INVEST, V94, P1927, DOI 10.1172/JCI117543; Cooper D. N., 1993, HUMAN GENE MUTATION; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KAUPPINEN R, 1995, HUM MOL GENET, V4, P215, DOI 10.1093/hmg/4.2.215; LLEWELLYN DH, 1987, LANCET, V2, P706; ONG PML, 1995, J MED GENET, V32, pA141; SCOBIE GA, 1990, HUM GENET, V85, P157	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 14	1995	346	8981					1007	1008		10.1016/S0140-6736(95)91692-X	http://dx.doi.org/10.1016/S0140-6736(95)91692-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ599	7475550				2022-12-01	WOS:A1995RZ59900014
J	AUPHAN, N; DIDONATO, JA; ROSETTE, C; HELMBERG, A; KARIN, M				AUPHAN, N; DIDONATO, JA; ROSETTE, C; HELMBERG, A; KARIN, M			IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS	SCIENCE			English	Article							TRANSCRIPTION FACTOR; NEGATIVE REGULATION; GENE-EXPRESSION; LYMPHOCYTES-T; DNA-BINDING; ACTIVATION; CELLS; ALPHA; PROTEINS; HORMONES	Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive agents. They inhibit synthesis of almost all known cytokines and of several cell surface molecules required for immune function, but the mechanism underlying this activity has been unclear. Here it is shown that glucocorticoids are potent inhibitors of nuclear factor kappa B (NF-kappa B) activation in mice and cultured cells, This inhibition is mediated by induction of the I kappa B alpha inhibitory protein, which traps activated NF-kappa B in inactive cytoplasmic complexes. Because NF-kappa B activates many immunoregulatory genes in response to pro-inflammatory stimuli, the inhibition of its activity can be a major component of the anti-inflammatory activity of glucocorticoids.	UNIV CALIF SAN DIEGO,SCH MED,CTR GENET MOLEC,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego			AUPHAN-ANEZIN, Nathalie/E-7790-2018; Hazen, Stanley L/ABD-5845-2021	AUPHAN-ANEZIN, Nathalie/0000-0002-1967-5206; 				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ALLERGE ML, 1991, J IMMUNOL, V146, P1184; ARYA SK, 1984, J IMMUNOL, V133, P273; AUPHAN N, UNPUB; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COHEN JJ, 1989, ANTIINFLAMMATORY STE, P111; COLLART MA, 1987, J IMMUNOL, V139, P949; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; CULPEPPER JA, 1985, J IMMUNOL, V135, P3191; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIDONATO JA, UNPUB; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1990, EUR J IMMUNOL, V20, P35, DOI 10.1002/eji.1830200106; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAUGLER B, 1991, EUR J IMMUNOL, V21, P2581, DOI 10.1002/eji.1830211040; GODOWSKI PJ, 1989, UCLA S MOL CELLULAR, V95; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; Parillo J E, 1979, ANN REV PHARMACOL TO, V19, P179; PARK JH, 1993, J BIOL CHEM, V268, P6299; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROSETTE C, UNPUB; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.iy.08.040190.002225; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; WANG Y, 1993, J STEROID BIOCHEM, V44, P203, DOI 10.1016/0960-0760(93)90080-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040	57	2008	2091	1	75	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					286	290		10.1126/science.270.5234.286	http://dx.doi.org/10.1126/science.270.5234.286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569976				2022-12-01	WOS:A1995RZ34200035
J	JIN, YS; MEAD, J; LI, T; WOLBERGER, C; VERSHON, AK				JIN, YS; MEAD, J; LI, T; WOLBERGER, C; VERSHON, AK			ALTERED DNA RECOGNITION AND BENDING BY INSERTIONS IN THE ALPHA-2 TAIL OF THE YEAST A1/ALPHA-2 HOMEODOMAIN HETERODIMER	SCIENCE			English	Article							PROTEIN; BINDING; SPECIFICITY; DROSOPHILA; REPRESSOR; ORIENTATION; RECEPTORS; GENE; MCM1; A1	The yeast MAT alpha 2 and MATa1 homeodomain proteins bind cooperatively as a heterodimer to sites upstream of haploid-specific genes, repressing their transcription. In the crystal structure of alpha 2 and a1 bound to DNA, each homeodomain makes independent base-specific contacts with the DNA and the two proteins contact each other through an extended tail region of alpha 2 that tethers the two homeodomains to one another. Because this extended region may be flexible, the ability of the heterodimer to discriminate among DNA sites with altered spacing between alpha 2 and a1 binding sites was examined. Spacing between the half sites was critical for specific DNA binding and transcriptional repression by the complex. However, amino acid insertions in the tail region of alpha 2 suppressed the effect of altering an a1/alpha 2 site by increasing the spacing between the half sites. Insertions in the tail also decreased DNA bending by a1/alpha 2. Thus tethering the two homeodomains contributes to DNA bending by a1/alpha 2, but the precise nature of the resulting bend is not essential for repression.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University				Wolberger, Cynthia/0000-0001-8578-2969	NIGMS NIH HHS [GM49265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JIN Y, UNPUB; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MEAD J, UNPUB; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1992, MOL CELL BIOL, V12, P3706, DOI 10.1128/MCB.12.9.3706; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	31	20	21	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					290	293		10.1126/science.270.5234.290	http://dx.doi.org/10.1126/science.270.5234.290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569977				2022-12-01	WOS:A1995RZ34200036
J	LI, T; STARK, MR; JOHNSON, AD; WOLBERGER, C				LI, T; STARK, MR; JOHNSON, AD; WOLBERGER, C			CRYSTAL-STRUCTURE OF THE MATA1/MAT-ALPHA-2 HOMEODOMAIN HETERODIMER BOUND TO DNA	SCIENCE			English	Article							HUMAN PROTOONCOGENE PBX1; HOMEO DOMAIN PROTEIN; SINGLE AMINO-ACID; ANTENNAPEDIA HOMEODOMAIN; BINDING SPECIFICITY; TRANSCRIPTION FACTOR; TRANSACTIVATOR VP16; ALPHA-2 REPRESSOR; NMR-SPECTROSCOPY; OPERATOR COMPLEX	The Saccharomyces cerevisiae MATa1 and MAT alpha 2 homeodomain proteins, which play a role in determining yeast cell type, form a heterodimer that binds DNA and represses transcription in a cell type-specific manner. Whereas the alpha 2 and a1 proteins on their own have only modest affinity for DNA, the a1/alpha 2 heterodimer binds DNA with high specificity and affinity. The three-dimensional crystal structure of the a1/alpha 2 homeodomain heterodimer bound to DNA was determined at a resolution of 2.5 Angstrom. The a1 and alpha 2 homeodomains bind in a head-to-tail orientation, with heterodimer contacts mediated by a 16-residue tail located carboxyl-terminal to the alpha 2 homeodomain. This tail becomes ordered in the presence of a1, part of it forming a short amphipathic helix that packs against the a1 homeodomain between helices 1 and 2. A pronounced 60 degrees bend is induced in the DNA, which makes possible protein-protein and protein-DNA contacts that could not take place in a straight DNA fragment. Complex formation mediated by flexible protein-recognition peptides attached to stably folded DNA binding domains may prove to be a general feature of the architecture of other classes of eukaryotic transcriptional regulators.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of California System; University of California San Francisco				Wolberger, Cynthia/0000-0001-8578-2969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BAXTER SM, 1994, BIOCHEMISTRY-US, V33, P15309, DOI 10.1021/bi00255a012; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; FUREY W, 1990, AM CRYSTALLOGRAPHIC; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GLOVER M, UNPUB; GOUTTE C, 1994, EMBO J, V13, P1434, DOI 10.1002/j.1460-2075.1994.tb06397.x; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JIN YS, 1995, SCIENCE, V270, P290, DOI 10.1126/science.270.5234.290; JOHNSON A, 1992, TRANSCRIPTIONAL REGU, V2, P975; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, PROTEINS, V21, P161, DOI 10.1002/prot.340210210; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PHILLIPS CL, 1994, BIOCHEMISTRY-US, V33, P9294, DOI 10.1021/bi00197a033; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHEPHERD JCW, 1984, NATURE, V310, P70, DOI 10.1038/310070a0; SMITH DL, 1995, NUCLEIC ACIDS RES, V23, P1239, DOI 10.1093/nar/23.7.1239; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRATHERN J, 1988, GENETICS, V120, P75; TREISMAN J, 1989, CELL, V59, P553; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	64	234	239	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					262	269		10.1126/science.270.5234.262	http://dx.doi.org/10.1126/science.270.5234.262			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569974				2022-12-01	WOS:A1995RZ34200028
J	SHANNON, RV; ZENG, FG; KAMATH, V; WYGONSKI, J; EKELID, M				SHANNON, RV; ZENG, FG; KAMATH, V; WYGONSKI, J; EKELID, M			SPEECH RECOGNITION WITH PRIMARILY TEMPORAL CUES	SCIENCE			English	Article							INERAID COCHLEAR IMPLANT; CONSONANT RECOGNITION; ENVELOPE CUES; STIMULATION; PERCEPTION	Nearly perfect speech recognition was observed under conditions of greatly reduced spectral information. Temporal envelopes of speech were extracted from broad frequency bands and were used to modulate noises of the same bandwidths. This manipulation preserved temporal envelope cues in each band but restricted the listener to severely degraded information on the distribution of spectral energy. The identification of consonants, vowels, and words in simple sentences improved markedly as the number of bands increased; high speech recognition performance was obtained with only three bands of modulated noise. Thus, the presentation of a dynamic temporal pattern in only a few broad spectral regions is sufficient for the recognition of speech.			SHANNON, RV (corresponding author), HOUSE EAR RES INST,2100 W 3RD ST,LOS ANGELES,CA 90057, USA.		Zeng, Fan-Gang/G-4875-2012		NIDCD NIH HHS [R01 DCO1526] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001526] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Allen JB, 1994, IEEE T SPEECH AUDI P, V2, P567, DOI 10.1109/89.326615; DORMAN M, 1989, EAR HEARING, V10, P288, DOI 10.1097/00003446-198910000-00003; DORMAN M, 1988, J ACOUST SOC AM, V84, P5011; DORMAN MF, 1990, J ACOUST SOC AM, V88, P2074, DOI 10.1121/1.400104; DORMAN MF, 1992, J ACOUST SOC AM, V92, P3428, DOI 10.1121/1.404193; EDDINGTON DK, 1980, J ACOUST SOC AM, V68, P885, DOI 10.1121/1.384827; FREYMAN RL, 1991, J SPEECH HEAR RES, V34, P415, DOI 10.1044/jshr.3402.415; HILL FJ, 1968, J ACOUST SOC AM, V44, P13, DOI 10.1121/1.1911047; Licklider J.C.R., 1951, HDB EXPT PSYCHOL EDI, P1040; LICKLIDER JCR, 1948, J ACOUST SOC AM, V20, P42, DOI 10.1121/1.1906346; MILLER GA, 1955, J ACOUST SOC AM, V27, P338, DOI 10.1121/1.1907526; REMEZ RE, 1981, SCIENCE, V212, P947, DOI 10.1126/science.7233191; ROSEN S, 1989, J SPEECH HEAR RES, V32, P93, DOI 10.1044/jshr.3201.93; ROSEN S, 1992, PHILOS T ROY SOC B, V336, P367, DOI 10.1098/rstb.1992.0070; ROSEN SM, 1981, NATURE, V291, P150, DOI 10.1038/291150a0; SCHROEDE.MR, 1966, PR INST ELECTR ELECT, V54, P720, DOI 10.1109/PROC.1966.4841; SHANNON RV, 1989, J ACOUST SOC AM, V85, P2587, DOI 10.1121/1.397753; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SHANNON RV, 1992, J ACOUST SOC AM, V91, P1974; SHANNON RV, 1992, AUDITORY PROCESSING, P263; Stevens KN., 1981, PERSPECTIVES STUDY S, P1; TALLAL P, 1993, ANN NY ACAD SCI, V682; VANTASELL DJ, 1987, J ACOUST SOC AM, V82, P1152, DOI 10.1121/1.395251; VANTASSELL DJ, 1992, J ACOUST SOC AM, V92, P1247, DOI 10.1121/1.403920; WILSON B S, 1990, P339; WILSON BS, 1991, NATURE, V352, P236, DOI 10.1038/352236a0	26	2036	2083	9	177	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					303	304		10.1126/science.270.5234.303	http://dx.doi.org/10.1126/science.270.5234.303			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569981				2022-12-01	WOS:A1995RZ34200040
J	SIZEMORE, DR; BRANSTROM, AA; SADOFF, JC				SIZEMORE, DR; BRANSTROM, AA; SADOFF, JC			ATTENUATED SHIGELLA AS A DNA DELIVERY VEHICLE FOR DNA-MEDIATED IMMUNIZATION	SCIENCE			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; FLEXNERI; CONSTRUCTION; SELECTION; PLASMID; VECTOR; CELLS; GENES	Direct inoculation of DNA, in the form of purified bacterial plasmids that are unable to replicate in mammalian cells but are able to direct cell synthesis of foreign proteins, is being explored as an approach to vaccine development. Here, a highly attenuated Shigella vector invaded mammalian cells and delivered such plasmids into the cytoplasm of cells, and subsequent production of functional foreign protein was measured. Because this Shigella vector was designed to deliver DNA to colonic mucosa, the method is a potential basis for oral and other mucosal DNA immunization and gene therapy strategies.			SIZEMORE, DR (corresponding author), WALTER REED ARMY INST RES,DEPT BACTERIAL DIS,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307, USA.							Bethesda MD, 1985, NIH PUBLICATION, V86-23; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; HARTMAN AB, 1991, INFECT IMMUN, V59, P4075, DOI 10.1128/IAI.59.11.4075-4083.1991; HAZIZA C, 1982, EMBO J, V1, P379, DOI 10.1002/j.1460-2075.1982.tb01178.x; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; MILLS JA, 1988, INFECT IMMUN, V56, P2933, DOI 10.1128/IAI.56.11.2933-2941.1988; NAKAYAMA K, 1988, BIO-TECHNOL, V6, P693, DOI 10.1038/nbt0688-693; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SANDER B, 1993, J IMMUNOL METHODS, V166, P201, DOI 10.1016/0022-1759(93)90361-A; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SANSONETTI PJ, 1983, INFECT IMMUN, V39, P1392, DOI 10.1128/IAI.39.3.1392-1402.1983; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIZEMORE DR, UNPUB; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; VANDEVERG LL, 1995, INFECT IMMUN, V63, P1947, DOI 10.1128/IAI.63.5.1947-1954.1995; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	22	237	308	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 13	1995	270	5234					299	302		10.1126/science.270.5234.299	http://dx.doi.org/10.1126/science.270.5234.299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569980	Green Submitted			2022-12-01	WOS:A1995RZ34200039
J	SUNDARESAN, M; YU, ZX; FERRANS, VJ; IRANI, K; FINKEL, T				SUNDARESAN, M; YU, ZX; FERRANS, VJ; IRANI, K; FINKEL, T			REQUIREMENT FOR GENERATION OF H2O2 FOR PLATELET-DERIVED GROWTH-FACTOR SIGNAL-TRANSDUCTION	SCIENCE			English	Article							VITAMIN-E CONSUMPTION; CELLS; PROTEIN; DISEASE; PHOSPHORYLATION; INHIBITION; EXPRESSION; APOPTOSIS; RECEPTOR; RISK	Stimulation of rat vascular smooth muscle cells (VSMCs) by platelet-derived growth factor (PDGF) transiently increased the intracellular concentration of hydrogen peroxide (H2O2). This increase could be blunted by increasing the intracellular concentration of the scavenging enzyme catalase or by the chemical antioxidant N-acetylcysteine. The response of VSMCs to PDGF, which includes tyrosine phosphorylation, mitogen-activated protein kinase stimulation, DNA synthesis, and chemotaxis, was inhibited when the growth factor-stimulated rise in H2O2 concentration was blocked. These results suggest that H2O2 may act as a signal-transducing molecule, and they suggest a potential mechanism for the cardioprotective effects of antioxidants.	NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, PATHOL SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Irani, Kaikobad/0000-0001-9194-7387				ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Aebi H, 1994, METHOD ENZYMOL, V105, P121; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; CAMPBELL JH, 1987, VASCULAR SMOOTH MUSC, P15; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LEFF JA, 1992, FREE RADICAL BIO MED, V13, P143, DOI 10.1016/0891-5849(92)90076-S; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; SUNDARESAN M, UNPUB; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	31	2223	2297	2	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 13	1995	270	5234					296	299		10.1126/science.270.5234.296	http://dx.doi.org/10.1126/science.270.5234.296			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ342	7569979	Green Submitted			2022-12-01	WOS:A1995RZ34200038
J	AKOULITCHEV, S; MAKELA, TP; WEINBERG, RA; REINBERG, D				AKOULITCHEV, S; MAKELA, TP; WEINBERG, RA; REINBERG, D			REQUIREMENT FOR TFIIH KINASE-ACTIVITY IN TRANSCRIPTION BY RNA-POLYMERASE-II	NATURE			English	Article							C-TERMINAL DOMAIN; LARGEST SUBUNIT; PROMOTER; REPEAT	AN array of tandem heptapeptide repeats at the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II constitute a highly conserved structure essential for viability(1-3). Studies have established that the CTD is phosphorylated at different stages of the transcription cycle(4-7), and that it may be involved in transcriptional regulation(8-12). The exact role of the CTD remains elusive, as in vitro reconstituted transcription using the adenovirus major late promoter does not require the CTD13,14. Previous studies(7,15,16) showed that transcription from the murine dihydrofolate reductase (DHFR) promoter can be only accomplished by the form of RNA polymerase II that contains the hypophosphorylated CTD (RNAPIIA), but not by the form that lacks it (RNAPIIB)(7). Here we show that the CTD, but not its phosphorylation, is required for initiation of transcription. We also show that transcription requires CTD kinase activity provided by the CDK7 subunit of TFIIH17-19.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Reinberg, Danny/0000-0003-4288-2016				ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, V1, P109; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	27	161	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					557	560		10.1038/377557a0	http://dx.doi.org/10.1038/377557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566158				2022-12-01	WOS:A1995RZ33600070
J	BRUGAROLAS, J; CHANDRASEKARAN, C; GORDON, JI; BEACH, D; JACKS, T; HANNON, GJ				BRUGAROLAS, J; CHANDRASEKARAN, C; GORDON, JI; BEACH, D; JACKS, T; HANNON, GJ			RADIATION-INDUCED CELL-CYCLE ARREST COMPROMISED BY P21 DEFICIENCY	NATURE			English	Article							DEPENDENT KINASES; SUBUNIT; MOUSE; P53	THE protein p21 is a dual inhibitor of cyclin-dependent kinases(1-3) and proliferating-cell nuclear antigen (PCNA)(4), both of which are required for passage through the cell cycle. The p21 gene is under the transcriptional control of p53 (ref. 5), suggesting that p21 might promote p53-dependent cell cycle arrest or apoptosis. p21 has also been implicated in cell senescence(6) and in cell-cycle withdrawal upon termination differentiation(7-9). Here we investigate the role of p21 in these processes using chimaeric mice composed partly of p21(-/-) and partly of p21(+/+) cells. Immunohistochemical studies of the p21(+/+) and p21(-/-) components of adult small intestine indicated that deletion of p21 had no detectable effect on the migration-associated differentiation of the four principal intestinal epithelial cell lineages or on p53-dependent apoptosis following irradiation. However, p21(-/-) mouse embryo fibroblasts are impaired in their ability to undergo G1 arrest following DNA damage.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Washington University (WUSTL); Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	BRUGAROLAS, J (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Hannon, Gregory/AAB-3568-2019					BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CLARKE AR, 1994, ONCOGENE, V9, P1767; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LI YJ, 1994, ONCOGENE, V10, P599; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MERRITT AJ, 1994, CANCER RES, V54, P614; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P710	23	1153	1172	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					552	557		10.1038/377552a0	http://dx.doi.org/10.1038/377552a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566157				2022-12-01	WOS:A1995RZ33600069
J	CHEN, RH; MIETTINEN, PJ; MARUOKA, EM; CHOY, L; DERYNCK, R				CHEN, RH; MIETTINEN, PJ; MARUOKA, EM; CHOY, L; DERYNCK, R			A WD-DOMAIN PROTEIN THAT IS ASSOCIATED WITH AND PHOSPHORYLATED BY THE TYPE-II TGF-BETA RECEPTOR	NATURE			English	Article							CLONING; EXPRESSION; BINDING; COMPLEX; KINASES; ACTIVIN; CELLS; ACID	TRANSFORMING growth factor-beta (TGF-beta) is tbe prototype for a family of extracellular polypeptides that affect cell proliferation and differentiation, and tissue morphogenesis(1). TGF-beta signalling is mediated by two types of serine/threonine kinase receptors, the type I and II receptors, which are able to form a heteromeric complex(2). No cytoplasmic proteins that associate with these receptors in vivo, or are their kinase targets, have yet been described. We have now identified a WD-domain-containiag protein, TRIP-1, which specifically associates with the type II TGF-beta receptor in a kinase-dependent way. TRIP-1 does not interact with the type II activin or type I receptors, but associates with the heteromeric TGF-beta receptor complex, TRIP-1 is phosphorylated on serine and threonine by the receptor kinase, strongly suggesting that it has a role in TGF-beta signalling. This is supported by coexpression of TRIP-1 and type II receptor during development. The existence of TRIP-1 homologues in plant and yeast suggests a conserved function in all eukaryotes.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	CHEN, RH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143, USA.		Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HARPER JW, 1993, CELL, V75, P805; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MIETTINEN PJ, 1989, PEDIATR RES, V26, P25, DOI 10.1203/00006450-198907000-00009; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	29	174	196	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					548	552		10.1038/377548a0	http://dx.doi.org/10.1038/377548a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566156				2022-12-01	WOS:A1995RZ33600068
J	ERDELYI, M; MICHON, AM; GUICHET, A; GLOTZER, JB; EPHRUSSI, A				ERDELYI, M; MICHON, AM; GUICHET, A; GLOTZER, JB; EPHRUSSI, A			REQUIREMENT FOR DROSOPHILA CYTOPLASMIC TROPOMYOSIN IN OSKAR MESSENGER-RNA LOCALIZATION	NATURE			English	Article							MATERNAL MESSENGER-RNA; XENOPUS OOCYTES; CELL-FORMATION; GENE; MELANOGASTER; MICROTUBULES; ENCODES; DIFFERENTIATION; MICROFILAMENTS; PATTERN	THE localization of oskar (osk) RNA to the posterior pole of the developing fruit fly (Drosophila) oocyte induces the assembly of pole plasm, causing development of tbe abdomen and germ line(1,2). Failure to localize oskar RNA results in embryos that lack abdomen and germ cells. Conversely, mis-targeting of oskar RNA to the anterior of the oocyte causes formation of ectopic abdomen and germ cells at the anterior pole(3). Maternal mutants that have reduced pole plasm activity produce sterile adults with normal abdominal development, suggesting that germ cells are more sensitive than abdomen to defects in pole plasm assembly(4). Thus mutations in genes that reduce oskar RNA localization or activity can be recovered as viable sterile adults. In a screen for mutants defective in germ cell formation, we isolated nine alleles of the tropomyosin II gene(5). Here we show that mutations in tropomyosin II (TmII) virtually abolish oskar RNA localization to the posterior pole, suggesting an involvement of the actin network in oskar RNA localization.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020	Ephrussi, Anne/0000-0002-5061-4620; 				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HALES KH, 1994, DEV BIOL, V165, P639, DOI 10.1006/dbio.1994.1282; HANKE PD, 1987, J BIOL CHEM, V262, P17370; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; KARLIK CC, 1986, MOL CELL BIOL, V6, P1965, DOI 10.1128/MCB.6.6.1965; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; POKRYWKA NJ, 1994, DEV BIOL, V166, P210, DOI 10.1006/dbio.1994.1308; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; SQUIRE JM, 1983, TRENDS NEUROL SCI, V66, P409; STELZER EHK, 1989, SCANNING IMAGINGS, V1028, P146; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; WIESCHAUS E, 1979, DEV BIOL, V68, P29, DOI 10.1016/0012-1606(79)90241-0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	31	183	184	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					524	527		10.1038/377524a0	http://dx.doi.org/10.1038/377524a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566149				2022-12-01	WOS:A1995RZ33600061
J	FRANK, SA				FRANK, SA			MUTUAL POLICING AND REPRESSION OF COMPETITION IN THE EVOLUTION OF COOPERATIVE GROUPS	NATURE			English	Article							DICTYOSTELIUM	EVOLUTIONARY theory has not explained how competition among lower level units is suppressed in the formation of higher-level evolutionary units(1,2). For example, the key problem of early evolution is how small, individual replicators formed cooperative groups of sufficient complexity to allow accurate copying of the genetic material(3). The puzzle is why parasites did not subvert the formation of cells by obtaining benefits from the group without contributing to shared traits that enhance reproduction(4). These parasites would outcompete other replicators within the cell, disrupting reproductive fairness among subunits and destroying the functional coherence of the group. A similar problem arose at a later evolutionary stage with the orderly mendelian segregation of subunits (chromosomes) within cells, and reproductive fairness continued to be a problem in the evolution of insect(5) and human societies(6). Here I present a simple model to show how reproductive fairness evolves among subunits to create functional coherence and higher-level units. Self-restraint, which evolves according to the kin-selection coefficient of relatedness, is not sufficient: mutual policing and enforcement of reproductive fairness are also required for the evolution of increasing social complexity.			FRANK, SA (corresponding author), UNIV CALIF IRVINE, DEPT ECOL & EVOLUTIONARY BIOL, IRVINE, CA 92717 USA.			Frank, Steven/0000-0001-7348-7794				Alexander R., 2008, BIOL MORAL SYSTEMS; BONNER JT, 1967, CELLULAR SLIME MOLDS; BREMERMANN HJ, 1983, J THEOR BIOL, V100, P411, DOI 10.1016/0022-5193(83)90438-1; Eigen M., 1979, HYPERCYCLE PRINCIPLE; FRANK SA, 1994, P ROY SOC B-BIOL SCI, V258, P153, DOI 10.1098/rspb.1994.0156; HAMILTON WD, 1970, NATURE, V228, P1218, DOI 10.1038/2281218a0; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hardin G., 1993, LIVING LIMITS ECOLOG; HURST LD, 1994, P ROY SOC B-BIOL SCI, V258, P287, DOI 10.1098/rspb.1994.0175; LLOYD WF, 1833, 2 LECTURES CHECKS PO; Maynard Smith J., 1982, pi; Maynard Smith J., 1995, MAJOR TRANSITIONS EV; Morrissey J, 1982, DEV DICTYOSTELIUM DI, P411; OZAKI T, 1993, DEVELOPMENT, V117, P1299; PRICE GR, 1970, NATURE, V227, P520, DOI 10.1038/227520a0; RATNIEKS FLW, 1992, J THEOR BIOL, V158, P33, DOI 10.1016/S0022-5193(05)80647-2; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0; SMITH JM, 1979, NATURE, V280, P445, DOI 10.1038/280445a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILSON DS, 1994, BEHAV BRAIN SCI, V17, P585, DOI 10.1017/S0140525X00036104; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9	21	276	283	3	48	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 12	1995	377	6549					520	522		10.1038/377520a0	http://dx.doi.org/10.1038/377520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566147	Green Submitted			2022-12-01	WOS:A1995RZ33600059
J	FRETTS, RC; SCHMITTDIEL, J; MCLEAN, FH; USHER, RH; GOLDMAN, MB				FRETTS, RC; SCHMITTDIEL, J; MCLEAN, FH; USHER, RH; GOLDMAN, MB			INCREASED MATERNAL AGE AND THE RISK OF FETAL DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DELAYED CHILDBEARING; PREGNANCY; BIRTH	Background. Although the fetal death rate has declined over the past 30 years among women of all ages, ii is unknown whether particular characteristics of the mother, such as age, still affect the risk of fetal death. We undertook a study to determine whether older age, having a first child (nulliparity), or other characteristics of the mother are risk factors for fetal death. Methods. We used data from the McGill Obstetrical Neonatal Database to evaluate risk factors for fetal death among all deliveries at the Royal Victoria Hospital in Montreal (n=94,346) from 1961 through 1993, Data were available for two time periods (1961 through 1974 and 1978 through 1993); data for 1975 through 1977 have not been entered into the data base and were therefore not included. Using logistic regression, we estimated the effect of specific maternal characteristics and complications of pregnancy on the risk of fetal death. Results. The fetal death rate decreased significantly from 11.5 per 1000 total births (including live births and stillbirths) in the 1960s to 3.2 per 1000 in 1990 through 1993 (P<0,001), Between these periods, the average maternal age at delivery increased from 27 to 30 years (P<0.001), and the frequency of the diagnosis of diabetes and hypertension during pregnancy increased fivefold (P<0.001), Nevertheless, after we controlled for these and other maternal characteristics, women 35 years of age or older continued to have a significantly higher rate of fetal death than their younger counterparts (odds ratio for women 35 to 39 years of age as compared with women <30 years of age, 1.9; 95 percent confidence interval, 1.3 to 2.7; for those 40 or older, 2.4; 95 percent confidence interval, 1.3 to 4.5). Conclusions. Changes in maternal health and obstetrical practice have resulted in a 70 percent decline in the rate of fetal death among pregnant women of all ages since the 1960s. Advancing maternal age, however, continues to be a risk factor for fetal death.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; ROYAL VICTORIA HOSP, DEPT OBSTET & GYNECOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, MONTREAL, PQ, CANADA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; McGill University; Royal Victoria Hospital; McGill University	FRETTS, RC (corresponding author), BETH ISRAEL HOSP, DEPT OBSTET & GYNECOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ALES KL, 1990, SURG GYNECOL OBSTET, V171, P209; BARKAN SE, 1987, AM J EPIDEMIOL, V125, P101, DOI 10.1093/oxfordjournals.aje.a114491; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CNATTINGIUS S, 1992, Journal of the American Medical Association, V268, P886, DOI 10.1001/jama.268.7.886; CNATTINGIUS S, 1993, OBSTET GYNECOL, V81, P512; CUNNINGHAM FG, 1990, NEW ENGL J MED, V323, P414; EDGE V, 1993, AM J OBSTET GYNECOL, V168, P1881, DOI 10.1016/0002-9378(93)90706-O; FORMAN MR, 1984, JAMA-J AM MED ASSOC, V252, P3135, DOI 10.1001/jama.252.22.3135; FRETTS RC, 1992, OBSTET GYNECOL, V79, P35; KIELY JL, 1986, AM J EPIDEMIOL, V123, P444, DOI 10.1093/oxfordjournals.aje.a114259; KIRZ DS, 1985, AM J OBSTET GYNECOL, V152, P7, DOI 10.1016/S0002-9378(85)80166-6; LEYLAND AH, 1990, NEW ENGL J MED, V323, P413; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; PITKIN RM, 1991, AM J OBSTET GYNECOL, V164, P1045, DOI 10.1016/0002-9378(91)90584-E; PRYSAK M, 1995, OBSTET GYNECOL, V85, P65, DOI 10.1016/0029-7844(94)00330-G; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P285; SLUTSKER L, 1992, OBSTET GYNECOL, V79, P778; 1990, SAS USERS GUIDE STAT; 1989, VITAL HLTH STATIS 21, V47; 1979, LANCET, V1, P142	21	293	306	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					953	957		10.1056/NEJM199510123331501	http://dx.doi.org/10.1056/NEJM199510123331501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666913				2022-12-01	WOS:A1995RY58600001
J	GOLDSTEIN, AM; FRASER, MC; STRUEWING, JP; HUSSUSSIAN, CJ; RANADE, K; ZAMETKIN, DP; FONTAINE, LS; ORGANIC, SM; DRACOPOLI, NC; CLARK, WH; TUCKER, MA				GOLDSTEIN, AM; FRASER, MC; STRUEWING, JP; HUSSUSSIAN, CJ; RANADE, K; ZAMETKIN, DP; FONTAINE, LS; ORGANIC, SM; DRACOPOLI, NC; CLARK, WH; TUCKER, MA			INCREASED RISK OF PANCREATIC-CANCER IN MELANOMA-PRONE KINDREDS WITH P16(INK4) MUTATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANT-MELANOMA; FAMMM SYNDROME; FAMILIAL MELANOMA; DYSPLASTIC NEVUS; PROGRESSION; LINKAGE; LOCUS	Background. A gene on chromosome 9p, p16(INK4), has been implicated in the pathogenesis of cutaneous malignant melanoma in 19 melanoma-prone families. In 10 of these kindreds mutations that impaired the function of the p16(INK4) protein (p16M alleles) cosegregated with the disease. By contrast, in the other nine kindreds the mutation did not alter the function of p16(INK4) (p16W alleles). We looked for differences in clinical and genetic epidemiologic features in these two groups of families. Methods. We compared the median ages at diagnosis of melanoma, number of melanomas, thickness of the tumors, and number of nevi in the kindreds. We estimated prospectively the risks of melanoma or other cancers in families followed for 6 to 18 years and the risks of other cancers since 1925 (the entire period) by comparing the number of cancer cases observed with the number expected. Results. The risk of invasive melanoma was increased by a factor of 75 in kindreds with p16W alleles and a factor of 38 in kindreds with p16W alleles. Although this difference was not significant (P=0.14), there was a striking difference in the risk of other tumors. In kindreds with p16M alleles, the risk of pancreatic cancer was increased by a factor of 13 in the prospective period (2 cases observed, 0.15 expected; standardized incidence ratio, 13.1; 95 percent confidence interval, 1.5 to 47.4) and by a factor of 22 in the entire period (7 cases observed, 0.32 expected; standardized incidence ratio, 21.8; 95 percent confidence interval, 8.7 to 44.8). In contrast, we found no cases of pancreatic cancer in kindreds with p16W alleles. Conclusions. The development of pancreatic cancer in kindreds prone to melanoma may require a p16M mutation. Genetic factors, such as the kind of mutation found in p16(INK4), may explain the inconsistent occurrence of other cancers in these kindreds.	NIH, WARREN G MAGNUSON CLIN CTR, DEPT NURSING, BETHESDA, MD 20892 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; WESTAT CORP, ROCKVILLE, MD USA; WASHINGTON UNIV, SCH MED, DEPT SURG, ST LOUIS, MO 63110 USA; BATTELLE SRA, ROCKVILLE, MD USA; SEQUANA THERAPEUT INC, LA JOLLA, CA USA; UNIV PENN, SCH MED, PIGMENTED LES STUDY GRP, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Westat; Washington University (WUSTL); University of Pennsylvania; University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	GOLDSTEIN, AM (corresponding author), NCI, GENET EPIDEMIL BRANCH,EXECUT PLAZA N,RM 439, 6130 EXECUT BLVD, MSC 7372, BETHESDA, MD 20892 USA.		Struewing, Jeffery P/C-3221-2008; Struewing, Jeffery P/I-7502-2013; Tucker, Margaret A/B-4297-2015	Struewing, Jeffery P/0000-0002-4848-3334; Dracopoli, Nicholas/0000-0003-3962-4059				BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BERGMAN W, 1990, BRIT J CANCER, V61, P932, DOI 10.1038/bjc.1990.209; BOICE JD, 1991, NIH913180 PUBL; CALDAS C, 1994, NAT GENET, V8, P410, DOI 10.1038/ng1294-410c; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIXON WJ, 1992, BMDP STATISTICAL SOF; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1993, MELANOMA RES, V3, P271; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; KAMB A, 1994, SCIENCE, V264, P40; KOPF A W, 1986, Journal of the American Medical Association, V256, P1915, DOI 10.1001/jama.256.14.1915; LI FP, 1988, CANCER RES, V48, P5358; LYNCH HT, 1981, BRIT J CANCER, V44, P553, DOI 10.1038/bjc.1981.225; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MILLER BA, 1993, NIH932789 PUBL; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PETTY EM, 1993, AM J HUM GENET, V53, P96; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SWERDLOW AJ, 1995, INT J CANCER, V61, P773, DOI 10.1002/ijc.2910610606; TUCKER MA, 1993, J INVEST DERMATOL, V100, pS350, DOI 10.1111/1523-1747.ep12470264; Walker G. J., 1994, American Journal of Human Genetics, V55, pA73; YOUNG JL, 1981, NCI MONOGRAPH, V57	32	476	485	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					970	974		10.1056/NEJM199510123331504	http://dx.doi.org/10.1056/NEJM199510123331504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666916	Bronze			2022-12-01	WOS:A1995RY58600004
J	MANDEL, MA; YANOFSKY, MF				MANDEL, MA; YANOFSKY, MF			A GENE TRIGGERING FLOWER FORMATION IN ARABIDOPSIS	NATURE			English	Article							INFLORESCENCE DEVELOPMENT; FLORAL DEVELOPMENT; THALIANA; LEAFY	IN Arabidopsis, the apical shoot meristem produces lateral meristems that develop into either shoots or flowers. The decision to form flowers instead of shoots is mediated by the action of floral-meristem-identity genes, such as APETALA1 (API) and LEAFY (LFY), which specify meristem fate(1-7). Here we show that transgenic plants which constitutively express the AP1 gene show transformations of apical and lateral shoots into flowers, and that these plants flower much earlier than wild-type plants. These results indicate that AP1 alone can convert infloresence shoot meristems into floral meristems, and that ectopic AP1 expression can dramatically reduce the time to flowering.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; CHUNG YY, PL MOL BIOL, V26, P657; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KEMPIN SA, 1995, SCIENCE, V267, P522, DOI 10.1126/science.7824951; LEVIN J, 1995, CELL, V7, P529; MANDEL MA, 1992, NATURE, V380, P273; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; Weigel D, 1995, ANNU REV GENET, V29, P19, DOI 10.1146/annurev.ge.29.120195.000315; WEIGEL D, 1992, CELL, V89, P843; WEIGEL D, IN PRESS NATURE; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	20	408	474	4	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					522	524		10.1038/377522a0	http://dx.doi.org/10.1038/377522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566148				2022-12-01	WOS:A1995RZ33600060
J	MANJUNATH, N; CORREA, M; ARDMAN, M; ARDMAN, B				MANJUNATH, N; CORREA, M; ARDMAN, M; ARDMAN, B			NEGATIVE REGULATION OF T-CELL ADHESION AND ACTIVATION BY CD43	NATURE			English	Article							WISKOTT-ALDRICH SYNDROME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; EXPRESSION; DIFFERENTIATION; MOLECULE; IDENTIFICATION; LEUKOSIALIN; SIALOPHORIN; ENHANCEMENT	CD43 is a cell-surface sialoglycoprotein expressed by a variety of haematopoietically derived cells, including T lymphocytes(1-9). Earlier observations of defective CD43 expression by T lymphocytes from boys with the X-chromosome-linked Wiskott-Aldrich syndrome suggested the importance of CD43 in lymphocyte function(10,11). Subsequent studies have suggested that CD43 facilitates leukocyte adhesion(12-14) and has a co-stimulatory role during T-cell activation(15). To define the physiologically relevant functions(s) of CD43, we have generated CD43-knockout mice. We report here that CD43-deficient T cells from such mice show a marked increase in their in vitro proliferative response to concanavalin A, anti-CD3, the superantigen SEB and allostimulation. Additionally, CD43-deficient T cells show a substantial enhancement in homotypic adhesion and in their ability to bind different ligands, including fibronectin and the intercellular adhesion molecule ICAM-1. Vaccinia-virus-infected CD43-knockout mice mounted an augmented anti-vaccinia, cytotoxic T-cell response compared with their wild-type littermates, yet developed an increased virus load. We conclude that CD43 negatively regulates T-cell activation and adhesion and is important for viral clearance.			MANJUNATH, N (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV HAEMATOL ONCOL,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Correa, Mariangela/K-8700-2019; Correa, Mariangela/A-6666-2010; Correa, Mariangela/B-3426-2019	Correa, Mariangela/0000-0003-4856-7578				ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BETTAIEB A, 1988, BLOOD, V71, P1226; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.iy.07.040189.003051; BORCHE L, 1987, EUR J IMMUNOL, V17, P1623; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CYSTER JG, 1991, EMBO J, V4, P893; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; GULLEY ML, 1988, J IMMUNOL, V140, P3751; GUNJI Y, 1992, BLOOD, V80, P429; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; MANJUNATH N, 1994, J IMMUNOL, V151, P1528; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MENTZER SJ, 1987, J EXP MED, V165, P1382; MOORE T, 1994, J IMMUNOL, V153, P4978; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PARKMAN R, 1981, LANCET, V2, P1387; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1987, BLOOD, V70, P104; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; WIKEN M, 1988, SCAND J IMMUNOL, V28, P457, DOI 10.1111/j.1365-3083.1988.tb01476.x	30	187	190	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					535	538		10.1038/377535a0	http://dx.doi.org/10.1038/377535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566153				2022-12-01	WOS:A1995RZ33600065
J	MEUNIER, JC; MOLLEREAU, C; TOLL, L; SUAUDEAU, C; MOISAND, C; ALVINERIE, P; BUTOUR, JL; GUILLEMOT, JC; FERRARA, P; MONSARRAT, B; MAZARGUIL, H; VASSART, G; PARMENTIER, M; COSTENTIN, J				MEUNIER, JC; MOLLEREAU, C; TOLL, L; SUAUDEAU, C; MOISAND, C; ALVINERIE, P; BUTOUR, JL; GUILLEMOT, JC; FERRARA, P; MONSARRAT, B; MAZARGUIL, H; VASSART, G; PARMENTIER, M; COSTENTIN, J			ISOLATION AND STRUCTURE OF THE ENDOGENOUS AGONIST OF OPIOID RECEPTOR-LIKE ORL(1) RECEPTOR	NATURE			English	Article							PITUITARY; DYNORPHIN	THE ORL(1) receptor, an orphan receptor whose human(1) and murine(2-8) complementary DNAs have recently been characterized, structurally resembles opioid receptors and is negatively coupled with adenylate cyclase(1). ORL(1) transcripts are particularly abundant in the central nervous system. Here we report the isolation, on the basis of its ability to inhibit the cyclase in a stable recombinant CHO(ORL(1)(+)) cell line, of a neuropeptide that resembles dynorphin A(9) and whose amino acid sequence is Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn- Gln. A rat-brain cDNA encodes the peptide flanked by Lys-Arg proteolytic cleavage motifs. The synthetic heptadecapeptide potently inhibits adenylate cyclase in CHO(ORL(1)(+)) cells in culture and induces hyperalgesia when administered intracerebroventricularly to mice. Taken together, these data indicate that the newly discovered heptadecapeptide is an endogenous agonist of the ORL(1) receptor and that it may be endowed with pro-nociceptive properties.	FAC MED & PHARM ST ETIENNE ROUVRAY, IFRMP,CNRS,UNITE NEUROPSYCHOPHARMACOL EXPTL, URA 1969, F-76803 ST ETIENNE DU ROUVRAY, FRANCE; SANOFI RECH, UNITE BIOCHIM PROT, F-31676 LABEGE, FRANCE; FREE UNIV BRUSSELS, CAMPUS HOSP ERASME, IRIBHN, B-1070 BRUSSELS, BELGIUM; SRI INT, MENLO PK, CA 94025 USA	Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France; Universite Libre de Bruxelles; Vrije Universiteit Brussel; SRI International	MEUNIER, JC (corresponding author), CNRS, UPR 8221, PHARMACOL & TOXICOL FONDAMENTALES LAB, 205 ROUTE NARBONNE, F-31077 TOULOUSE, FRANCE.		hu, jenny/AAK-8712-2020	Mollereau, Catherine/0000-0003-1543-5624				ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; EDDY NB, 1953, J PHARMACOL EXP THER, V107, P385; EVANS CJ, 1988, OPIATE RECEPTORS, P23; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GOLDSTEIN A, 1981, P NATL ACAD SCI-BIOL, V78, P7219, DOI 10.1073/pnas.78.11.7219; LACHOWICZ JE, 1995, J NEUROCHEM, V64, P34; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; NISHI M, 1994, BIOCHEM BIOPH RES CO, V205, P1353, DOI 10.1006/bbrc.1994.2814; TESCHEMACHER H, 1975, LIFE SCI, V16, P1771, DOI 10.1016/0024-3205(75)90271-4; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; WANG JB, 1994, J BIOL CHEM, V269, P25966; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; XUE JC, 1994, J BIOL CHEM, V269, P30195	17	1733	1829	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 12	1995	377	6549					532	535		10.1038/377532a0	http://dx.doi.org/10.1038/377532a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566152				2022-12-01	WOS:A1995RZ33600064
J	MULLER, B; ZULEWSKI, H; HUBER, P; RATCLIFFE, JG; STAUB, JJ				MULLER, B; ZULEWSKI, H; HUBER, P; RATCLIFFE, JG; STAUB, JJ			IMPAIRED ACTION OF THYROID-HORMONE ASSOCIATED WITH SMOKING IN WOMEN WITH HYPOTHYROIDISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; GOITER; THYROTROPIN; SMOKERS; DISEASE; TISSUES; CANCER; TSH	Background. The effect of smoking on thyroid function is controversial, and its effect on thyroid hormone action is unknown. We investigated the effects of cigarette smoking in women with various grades of hypothyroidism and in normal women. Methods. We studied 138 normal women and 135 women with primary hypothyroidism, of whom 84 had subclinical hypothyroidism and 51 overt hypothyroidism. Sixty of the women with hypothyroidism were reevaluated during thyroxine therapy. The women were categorized as smokers or nonsmokers according to their responses to a questionnaire. Thyroid function was evaluated by measurements of serum thyrotropin, free thyroxine, and triiodothyronine. Peripheral thyroid hormone action was assessed by a clinical score and measurements of ankle-reflex time and serum lipids and creatine kinase. Results. Among the women with subclinical hypothyroidism, the smokers had a higher mean (+/-SD) serum thyrotropin concentration (21.3+/-16.6 vs. 12.7+/-7.2 mU per liter, P=0.004) and a higher ratio of serum triiodothyronine to serum free thyroxine (by 30 percent, P=0.003) than the nonsmokers. Their serum concentrations of total cholesterol and low-density lipoprotein (LDL) cholesterol were higher (by 16 percent, P=0.013; and 28 percent, P=0.003, respectively). Among the women with overt hypothyroidism, the serum concentrations of thyrotropin, free thyroxine, and triiodothyronine were similar in the smokers and nonsmokers. As compared with the nonsmokers, the smokers had a clinical score indicating a greater degree of hypothyroidism (P<0.001), higher serum concentrations of total and LDL cholesterol (by 25 percent, P<0.001; and 24 percent, P=0.002, respectively), longer ankle-reflex time (by 25 percent, P<0.001), and higher serum concentrations of creatine kinase (by 236 percent, P<0.001). There were dose-response relations between smoking and serum concentrations of total and LDL cholesterol, serum creatine kinase concentrations, and ankle-reflex time in the women with overt hypothyroidism, and between smoking and serum concentrations of total and LDL cholesterol in the women with subclinical hypothyroidism. Conclusions. Smoking increases the metabolic effects of hypothyroidism in a dose-dependent way. This may be explained by alteration of both thyroid function and hormone action.	UNIV BASEL HOSP, DEPT CHEM PATHOL, HORMONE LAB, CH-4031 BASEL, SWITZERLAND; QUEEN ELIZABETH MED CTR, DEPT CLIN CHEM, WOLFSON RES LABS, BIRMINGHAM, W MIDLANDS, ENGLAND	University of Basel; Birmingham City University; University of Birmingham	MULLER, B (corresponding author), UNIV BASEL HOSP, DEPT MED, DIV ENDOCRINOL DIABET & METAB, PETERSGRABEN 4, CH-4031 BASEL, SWITZERLAND.		Mueller, Beat/G-2662-2012					ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; BERGHOUT A, 1987, CLIN ENDOCRINOL, V26, P273, DOI 10.1111/j.1365-2265.1987.tb00784.x; BILLEWICZ WZ, 1969, Q J MED, V38, P255; BRENT GA, 1994, NEW ENGL J MED, V331, P847; BROWMAN GP, 1993, NEW ENGL J MED, V328, P159, DOI 10.1056/NEJM199301213280302; CHRISTENSEN SB, 1984, J CLIN ENDOCR METAB, V58, P615, DOI 10.1210/jcem-58-4-615; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; EDELMAN IS, 1974, NEW ENGL J MED, V290, P1303, DOI 10.1056/NEJM197406062902308; ERICSSON UB, 1991, J INTERN MED, V229, P67, DOI 10.1111/j.1365-2796.1991.tb00308.x; ERMANS AM, 1980, ROLE CASSAVA ETIOLOG, P93; HANDA K, 1990, ATHEROSCLEROSIS, V84, P189, DOI 10.1016/0021-9150(90)90090-6; HEGEDUS L, 1985, CLIN ENDOCRINOL, V22, P287, DOI 10.1111/j.1365-2265.1985.tb03242.x; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; LAVECCHIA C, 1988, PREV MED, V17, P712, DOI 10.1016/0091-7435(88)90090-4; LOEB JN, 1991, WERNER INGBARS THYRO, P1064; MELANDER A, 1981, ACTA MED SCAND, V209, P41; MUSCAT JE, 1991, AM HEART J, V121, P141, DOI 10.1016/0002-8703(91)90967-M; PETERSEN K, 1991, J INTERN MED, V229, P407, DOI 10.1111/j.1365-2796.1991.tb00367.x; ROSS DS, 1991, WERNER INGBARS THYRO, P1256; SACHS L, 1984, APPLIED STATISTICS H; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; Searle S.R., 1971, LINEAR MODELS; SEPKOVIC DW, 1984, ARCH INTERN MED, V144, P501, DOI 10.1001/archinte.144.3.501; STAUB JJ, 1985, CLIN ENDOCRINOL, V22, P567, DOI 10.1111/j.1365-2265.1985.tb00158.x; STAUB JJ, 1983, J CLIN ENDOCR METAB, V56, P449, DOI 10.1210/jcem-56-3-449; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; SUGAWARA M, 1982, P SOC EXP BIOL MED, V170, P431	27	115	119	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 12	1995	333	15					964	969		10.1056/NEJM199510123331503	http://dx.doi.org/10.1056/NEJM199510123331503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY586	7666915	Bronze			2022-12-01	WOS:A1995RY58600003
J	OHASHI, M; DEVRIES, KJ; FRANK, R; SNOEK, G; BANKAITIS, V; WIRTZ, K; HUTTNER, WB				OHASHI, M; DEVRIES, KJ; FRANK, R; SNOEK, G; BANKAITIS, V; WIRTZ, K; HUTTNER, WB			A ROLE FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN SECRETORY VESICLE FORMATION	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; SACCHAROMYCES-CEREVISIAE; REQUIREMENT	VESICULAR traffic in eukaryotic cells is characterized by two steps of membrane rearrangement: the formation of vesicles from donor membranes and their fusion with acceptor membranes. With respect to vesicle formation, several of the cytosolic proteins implicated in budding and fission have been identified. A feature common to all these proteins is that their targets, when known, are other proteins rather than lipids. Here we report, using a previously established cell-free system(1,2) derived from a neuroendocrine cell line, the purification of cytosolic factors that stimulate the formation of constitutive secretory vesicles and immature secretory granules from the trans-Golgi network. One such factor, referred to as CAST1, was identified as the alpha and beta isoforms of the mammalian phosphatidylinositol transfer protein (PtdIns-TP) (refs 3-5). The yeast PtdIns-TP, SEC14p (ref. 6), which has no sequence homology to mammalian PtdIns-TP (refs 7,8), was able to substitute for the mammalian PtdIns-TP in secretory vesicle formation. Our results suggest a highly conserved role for phosphoinositides in vesicle formation.	UNIV HEIDELBERG,DEPT NEUROBIOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CTR BIOL MOLEC,D-69120 HEIDELBERG,GERMANY; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Utrecht University; University of Alabama System; University of Alabama Birmingham			Huttner, Wieland B./P-4080-2018					BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECK KA, 1991, J BIOL CHEM, V266, P4442; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; DICKESON SK, 1989, J BIOL CHEM, V294, P16557; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GEITENBEEK TB, 1994, BIOCHIM BIOPHYS ACTA, V1213, P309; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; OHASHI M, 1994, J BIOL CHEM, V269, P24897; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VANDENAKKER WMR, 1990, FEBS LETT, V276, P123, DOI 10.1016/0014-5793(90)80523-L; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.bi.60.070191.000445; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	30	166	173	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					544	547		10.1038/377544a0	http://dx.doi.org/10.1038/377544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566155				2022-12-01	WOS:A1995RZ33600067
J	SALADIN, R; DEVOS, P; GUERREMILLO, M; LETURQUE, A; GIRARD, J; STAELS, B; AUWERX, J				SALADIN, R; DEVOS, P; GUERREMILLO, M; LETURQUE, A; GIRARD, J; STAELS, B; AUWERX, J			TRANSIENT INCREASE IN OBESE GENE-EXPRESSION AFTER FOOD-INTAKE OR INSULIN ADMINISTRATION	NATURE			English	Article							PROTEIN	OBESITY is a disorder of energy balance, indicating a chronic disequilibrium between energy intake and expenditure(1). Recently, the mouse ob gene(2), and subsequently its human and rat homologues(2-6), have been cloned. The ob gene product, leptin(7), is expressed exclusively in adipose tissue, and appears to be a signalling factor regulating body-weight homeostasis and energy balance(2,7-9). Because the level of ob gene expression might indicate the size of the adipose depot, we suggest that it is regulated by factors modulating adipose tissue size. Here we show that ob gene exhibits diurnal variation, increasing during the night, after rats start eating. This variation was linked to changes in food intake, as fasting prevented the cyclic variation and decreased ob messenger RNA. Furthermore, refeeding fasted rats restored ob mRNA within 4 hours to levels of fed animals. A single insulin injection in fasted animals increased ob mRNA to levels of fed controls. Experiments to control glucose and insulin independently in animals, and studies in primary adipocytes, showed that insulin regulates ob gene expression directly in rats, regardless of its glucose-lowering effects. Whereas the ob gene product, leptin, has been shown to reduce food intake and increase energy expenditure(7-9) our data demonstrate that ob gene expression is increased after food ingestion in rats, perhaps through a direct action of insulin on the adipocyte.	INST BIOMED CORDELIERS,INSERM,U177,F-75006 PARIS,FRANCE; CNRS,UPR 1511,CEREMOD,F-92190 MEUDON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	SALADIN, R (corresponding author), INST PASTEUR,BIOL REGULAT CHEZ EUCARYOTES LAB,INSERM,U325,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Staels, Bart/N-9497-2016; Leturque, Armelle/Q-9437-2017; Auwerx, Johan/ABE-9307-2021	Staels, Bart/0000-0002-3784-1503; Leturque, Armelle/0000-0001-6570-6387; Auwerx, Johan/0000-0002-5065-5393				CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; GAZDAR AF, 1990, CANCER RES, V50, P5488; GEFFROY S, 1995, GENOMICS, V28, P603, DOI 10.1006/geno.1995.1201; GRUNDY SM, 1990, DM-DIS MON, V36, P641; HAJDUCH EJ, 1992, J CELL BIOCHEM, V49, P251, DOI 10.1002/jcb.240490307; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERET J, 1973, J NUTR, V103, P866, DOI 10.1093/jn/103.6.866; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	17	1037	1064	0	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					527	529		10.1038/377527a0	http://dx.doi.org/10.1038/377527a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566150				2022-12-01	WOS:A1995RZ33600062
J	STEPHENS, TW; BASINSKI, M; BRISTOW, PK; BUEVALLESKEY, JM; BURGETT, SG; CRAFT, L; HALE, J; HOFFMANN, J; HSIUNG, HM; KRIAUCIUNAS, A; MACKELLAR, W; ROSTECK, PR; SCHONER, B; SMITH, D; TINSLEY, FC; ZHANG, XY; HEIMAN, M				STEPHENS, TW; BASINSKI, M; BRISTOW, PK; BUEVALLESKEY, JM; BURGETT, SG; CRAFT, L; HALE, J; HOFFMANN, J; HSIUNG, HM; KRIAUCIUNAS, A; MACKELLAR, W; ROSTECK, PR; SCHONER, B; SMITH, D; TINSLEY, FC; ZHANG, XY; HEIMAN, M			THE ROLE OF NEUROPEPTIDE-Y IN THE ANTIOBESITY ACTION OF THE OBESE GENE-PRODUCT	NATURE			English	Article							AGENT; RATS	RECENTLY Zhang et al.(1) cloned a gene that is expressed only in adipose tissue of tbe mouse. The obese phenotype of the ob/ob mouse is linked to a mutation in the obese gene that results in expression of a truncated inactive protein. Human and rat homologues for this gene are known(1,2). Previous experiments(3,4) predict such a hormone to have a hypothalamic target. Hypothalamic neuropeptide Y stimulates food intake, decreases thermogenesis, and increases plasma insulin and corticosterone levels making it a potential target(5). Here we express the obese protein in Escherichia coli and find that it suppresses food intake and decreases body weight dramatically when administered to normal and ob/ob mice but not db/db (diabetic) mice, which are thought to lack the appropriate receptor. High-affinity binding was detected in the rat hypothalamus. One mechanism by which this protein regulated food intake and metabolism was inhibition of neuropeptide-Y synthesis and release.	ELI LILLY & CO,LILLY RES LABS,DIV TECHNOL CORE,INDIANAPOLIS,IN 46285	Eli Lilly	STEPHENS, TW (corresponding author), ELI LILLY & CO,LILLY RES LABS,DIV ENDOCRINE RES,INDIANAPOLIS,IN 46285, USA.							BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; CORDER R, 1988, LIFE SCI, V43, P1879, DOI 10.1016/S0024-3205(88)80005-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HULSEY MG, 1992, PHYSIOL BEHAV, V52, P1141, DOI 10.1016/0031-9384(92)90473-F; KARAKASH C, 1977, AM J PHYSIOL, V232, pE286, DOI 10.1152/ajpendo.1977.232.3.E286; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; [No title captured]	12	1418	1467	1	57	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					530	532		10.1038/377530a0	http://dx.doi.org/10.1038/377530a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566151				2022-12-01	WOS:A1995RZ33600063
J	WEIGEL, D; NILSSON, O				WEIGEL, D; NILSSON, O			A DEVELOPMENTAL SWITCH SUFFICIENT FOR FLOWER INITIATION IN DIVERSE PLANTS	NATURE			English	Article							ARABIDOPSIS FLORAL DEVELOPMENT; INFLORESCENCE DEVELOPMENT; HOMEOTIC GENES; THALIANA; LEAFY; APETALA1; PROMOTER	We have generated transgenic plants in which the flower-meristem-identity gene LEAFY of Arabidopsis is constitutively expressed. LEAFY is sufficient to determine floral fate in lateral shoot meristems of both Arabidopsis and the heterologous species aspen, with the consequence that flower development is induced precociously. Our results also suggest a new level of regulation during flower development, as indicated by the competence of the main shoot to respond to LEAFY activity.	SWEDISH UNIV AGR SCI,S-90183 UMEA,SWEDEN	Swedish University of Agricultural Sciences	WEIGEL, D (corresponding author), SALK INST BIOL STUDIES,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Nilsson, Ove/0000-0002-1033-1909				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; KEMPIN SA, 1994, SCIENCE, V267, P522; LAMB CJ, 1992, BIO-TECHNOL, V10, P1436, DOI 10.1038/nbt1192-1436; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MCDANIEL CN, 1992, DEV BIOL, V153, P59, DOI 10.1016/0012-1606(92)90091-T; NILSSON O, 1995, THESIS SWEDISH U AGR; Nilsson Ove, 1992, Transgenic Research, V1, P209, DOI 10.1007/BF02524751; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Schreiner E. J., 1974, USDA AGR HDB, P645; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SINGER SR, 1992, PLANTA, V188, P546, DOI 10.1007/BF00197047; STRAUSS SH, 1995, MOL BREEDING, V1, P5, DOI 10.1007/BF01682086; TANKSLEY SD, 1989, BIO-TECHNOL, V7, P257, DOI 10.1038/nbt0389-257; Telfer A., 1994, ARABIDOPSIS, P379, DOI DOI 10.1083/JCB.201205114; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL DA, 1995, REV GENET, V29, P19	31	609	757	5	63	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 12	1995	377	6549					495	500		10.1038/377495a0	http://dx.doi.org/10.1038/377495a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RZ336	7566146				2022-12-01	WOS:A1995RZ33600051
J	KILGORE, PE; HOLMAN, RC; CLARKE, MJ; GLASS, RI				KILGORE, PE; HOLMAN, RC; CLARKE, MJ; GLASS, RI			TRENDS OF DIARRHEAL DISEASE - ASSOCIATED MORTALITY IN US CHILDREN, 1968 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; DEATHS; CARE; INTERVENTIONS; ROTAVIRUS; THERAPY; MEASLES; MEXICO	Objectives.-To describe temporal patterns in mortality related to diarrheal disease in US children and to assess progress toward its prevention and control. Design.-Retrospective analyses of death certificate data on diarrhea of all causes compiled by the National Center for Health Statistics, Centers for Disease Control and Prevention, Atlanta, Ga. Patients.-Children aged 1 month through 4 years who died with diarrhea. Setting.-United States, 1968 through 1991. Results.-A total of 14 137 deaths associated with diarrhea among children were reported in the United States between 1968 and 1991. Of these, 78% occurred in infants (ie, aged 1 to 11 months); the median age at the time of death has declined from 5 to 1.5 months. Diarrheal disease mortality dropped by approximately 75% during the first 18 years of the study, but no decline has occurred since 1985. Infant mortality due to diarrhea (per 100 000 live births) averaged 12.8 and was found to be high for blacks (33.1) and for residents of the southern United States (18.5). The infant mortality due to diarrhea from 1986 through 1991 is 5.9. Peaks in winter deaths previously associated with rotavirus were prominent in the early years among infants aged 4 through 11 months. Such peaks have virtually disappeared since 1985. Diarrhea was the principal cause of death, as the leading associated diagnoses (electrolyte disorders [30%], cardiac arrest [16%], shock [8%], and nausea/vomiting [4%]) were commonly recognized complications of diarrhea. Since 1979, prematurity has emerged as a common associated diagnosis. Conclusions.-Diarrheal deaths nationwide have declined 75% from 1968 to 1985 but stabilized since then at about 300 deaths per year. Because many of these deaths may still be preventable by early rehydration, future prevention efforts should be directed at educating health care providers about the continuing problem and recognition of the high-risk infant and at teaching mothers of such infants to begin rehydration early and to seek medical attention when their infant develops diarrhea.	CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	KILGORE, PE (corresponding author), CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,VIRAL GASTROENTERITIS SECT,MAILSTOP G-04,ATLANTA,GA 30333, USA.		Kilgore, Paul E/L-1462-2013; Kilgore, Paul/AAD-2869-2019	Kilgore, Paul E/0000-0003-3214-4482; Kilgore, Paul/0000-0003-3214-4482				AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BERN C, 1993, J PEDIATR-US, V122, P920, DOI 10.1016/S0022-3476(09)90020-8; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; CHAMBLEE RF, 1986, VITAL HLTH STAT 1, V20; CHURCH DL, 1995, 95TH GEN M AM SOC MI; Duggan C, 1992, MMWR Recomm Rep, V41, P1; FEACHEM RG, 1983, B WORLD HEALTH ORGAN, V61, P641; GANGAROSA RE, 1992, AM J EPIDEMIOL, V135, P281, DOI 10.1093/oxfordjournals.aje.a116282; GARTHRIGHT WE, 1988, PUBLIC HEALTH REP, V103, P107; GLASS RI, 1991, J PEDIATR, V118, P527; HEMMING VG, 1976, NEW ENGL J MED, V294, P1310, DOI 10.1056/NEJM197606102942403; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; HOLMAN RC, 1989, AM J PUBLIC HEALTH, V79, P987, DOI 10.2105/AJPH.79.8.987; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KLEIN JD, 1982, REPORT COMMITTEE INF; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOSTER FT, 1981, B WORLD HEALTH ORGAN, V59, P901; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; LEW JF, 1991, JAMA-J AM MED ASSOC, V265, P3280, DOI 10.1001/jama.265.24.3280; MEYERS A, 1991, JAMA-J AM MED ASSOC, V265, P1724, DOI 10.1001/jama.265.13.1724; Millman M, 1993, ACCESS HLTH CARE AM; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; SNYDER J, 1988, JAMA-J AM MED ASSOC, V260, P3329; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; WOODS PA, 1992, J CLIN MICROBIOL, V30, P781, DOI 10.1128/JCM.30.4.781-785.1992; 1977, MANUAL INT STATISTIC, P1; 1981, PHS911101 US DEP HLT, P91; 1993, 1991 US DEP HLTH HUM; 1975, INT CLASSIFICATION D, P1; 1993, MULTIPLE CAUSE DEATH; 1985, PEDIATRICS, V75, P358	32	108	116	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1143	1148		10.1001/jama.274.14.1143	http://dx.doi.org/10.1001/jama.274.14.1143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563485				2022-12-01	WOS:A1995RY05600029
J	MINKOFF, H; WILLOUGHBY, A				MINKOFF, H; WILLOUGHBY, A			PEDIATRIC HIV DISEASE, ZIDOVUDINE IN PREGNANCY, AND UNBLINDING HEELSTICK SURVEYS - REFRAMING THE DEBATE ON PRENATAL HIV TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; WOMEN; POPULATION		NICHHD,CTR RES MOTHERS & CHILDREN,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MINKOFF, H (corresponding author), SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,450 CLARKSON AVE,BOX 24,BROOKLYN,NY 11203, USA.							BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BAYER R, 1995, WASHINGTON POST 0526, pA27; BAYER R, 1994, NEW ENGL J MED, V318, P1223; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; MINKOFF HL, 1988, NEW ENGL J MED, V319, P1018; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; WHEAT ME, 1993, AM J PREV MED, V9, P307, DOI 10.1016/S0749-3797(18)30707-4; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, NATIONAL HIV SEROSUR, P3; 1992, HUMAN IMMUNODEFICIEN, V162, P1	14	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1165	1168		10.1001/jama.274.14.1165	http://dx.doi.org/10.1001/jama.274.14.1165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563489				2022-12-01	WOS:A1995RY05600033
J	NEUMANN, HPH; ENG, C; MULLIGAN, LM; GLAVAC, D; ZAUNER, I; PONDER, BAJ; CROSSEY, PA; MAHER, ER; BRAUCH, H				NEUMANN, HPH; ENG, C; MULLIGAN, LM; GLAVAC, D; ZAUNER, I; PONDER, BAJ; CROSSEY, PA; MAHER, ER; BRAUCH, H			CONSEQUENCES OF DIRECT GENETIC TESTING FOR GERMLINE MUTATIONS IN THE CLINICAL MANAGEMENT OF FAMILIES WITH MULTIPLE ENDOCRINE NEOPLASIA, TYPE-II	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VONHIPPEL-LINDAU DISEASE; RET PROTOONCOGENE; PHEOCHROMOCYTOMAS; FEATURES	Objective.-Multiple endocrine neoplasia, type II (MEN-II) is an autosomal dominant disorder characterized by tumors of thyroid C cells and pheochromocytoma. Recently, germline mutations in the RET proto-oncogene have been identified in patients with MEN-II. The aims of this study were (1) to define the mutations in clinically diagnosed MEN-II families, (2) to compare the results of genetic and biochemical testing, and (3) to evaluate the impact of mutation analyses for the members of these families. Design.-Register-based survey study of clinically affected and unaffected members of MEN-II families. Setting.-Register of families from Germany and Spain with pheochromocytomas. Two research laboratories at Cambridge University in the United Kingdom. Patients.-We investigated consenting affected and unaffected members belonging to a series of 10 families who met the clinical criteria for MEN-II. Main Outcome Measures.-(1) Presence or absence of germline mutation in the RET proto-oncogene in affected and unaffected members of the 10 families, and (2) in the absence of RET mutation in a given family, presence or absence of germline mutation in the von Hippel-Lindau (VHL) gene, which is the susceptibility gene involved in a closely related syndrome, von Hippel-Lindau disease. Results.-In eight of these families, RET mutations were identified. The specific mutations were detected in all affected members. The remaining two families without RET mutations were subsequently shown to have a mutation within the VHL gene. The VHL mutations were identified in both families and represent a previously undescribed base change, After identification of the mutation, premorbid genetic testing was performed in all MEN-II and VHL families, resulting in detection of asymptomatic carriers in the MEN-II families. Clinically, the two VHL families differed from the eight MEN-II families by the presence of a C-cell tumor in only one individual from each family and extra-adrenal pheochromocytoma in three of nine affected individuals in the two families combined. Conclusions.-The diagnosis of MEN-II should be confirmed by molecular genetic analysis and the diagnosis of VHL syndrome should be considered for families with an absence of RET mutations and a preponderance of pheochromocytomas.	UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; TECH UNIV MUNICH,DEPT PATHOL,W-8000 MUNICH,GERMANY; NATL INST CHEM,LJUBLJANA,SLOVENIA; UNIV CAMBRIDGE,DEPT PATHOL,MOLEC GENET GRP,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN GENET,CAMBRIDGE,ENGLAND	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada; Technical University of Munich; National Institute of Chemistry - Slovenia; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT HYPERTENS & NEPHROL,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.		MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918; Brauch, Hiltrud/0000-0001-7531-2736; Eng, Charis/0000-0002-3693-5145				BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V8, P1303; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; HOFFMAN RW, 1982, ARCH INTERN MED, V142, P1962, DOI 10.1001/archinte.142.10.1962; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, IN PRESS J INTERN ME; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; SCHIMKE RN, 1990, AM J MED GENET, V37, P375, DOI 10.1002/ajmg.1320370317; WHALEY JM, 1994, AM J HUM GENET, V55, P1092	21	78	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1149	1151						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563486				2022-12-01	WOS:A1995RY05600030
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CIDOFOVIR AVAILABLE UNDER TREATMENT IND FOR CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-01	WOS:A1995RY05600008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACEUTICAL PROMOTION HEARINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0814, V60, P41891; 1995, FED REG         0816, V60, P42581	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-01	WOS:A1995RY05600006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PATIENT EDUCATION-PROGRAM PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0823, V60, P44182	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-01	WOS:A1995RY05600009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSED RULE RESTRICTING SALE OF TOBACCO PRODUCTS TO CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0811, V60, P41313	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-01	WOS:A1995RY05600007
J	ALLAART, CF; ROSENDAAL, FR; NOTEBOOM, WMP; VANDENBROUCKE, JP; BRIET, E				ALLAART, CF; ROSENDAAL, FR; NOTEBOOM, WMP; VANDENBROUCKE, JP; BRIET, E			SURVIVAL IN FAMILIES WITH HEREDITARY PROTEIN-C DEFICIENCY, 1820 TO 1993	BRITISH MEDICAL JOURNAL			English	Article							THROMBOTIC DISEASE; VENOUS THROMBOSIS; FACTOR-V; INACTIVATION; MORTALITY; NEWBORN	Objectives-To establish the survival of individuals heterozygous for hereditary protein C deficiency, who have an increased risk of venous thrombotic events, and to compare it with the survival of the general population. Design-Retrospective study in pedigrees of 23 families with hereditary protein C deficiency for period 1820 and 1993. Setting-23 completed family trees of 24 probands from various parts of the Netherlands with symptoms of protein C deficiency. Subjects-All 736 members of the 23 families with a 50% or 100%, probability of being (or having been) heterozygous for the genetic defect on the basis of DNA analysis or their place in the pedigrees, following mendelian rules. Main outcome measures-Observed mortality compared with the mortality of the general Dutch population; the standardised mortality ratio was calculated by dividing the observed mortality by the expected mortality. Results-No excess mortality was found in the 206 proved heterozygous individuals and ''obligatory transmitters'' (those who have definitely passed on the deficiency) (standardised mortality ratio 0.95 (95% confidence interval 0.5 to 1.2)) or in the 530 family members with a 50%, genetic probability of heterozygosity (1.10 (0.9 to 1.3)). Conclusion-Heterozygous individuals with hereditary protein C deficiency type I have normal survival compared with the general population. Prophylactic anticoagulant treatment may prevent thrombotic events in heterozygous individuals but may not be expected to improve their survival.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ALLAART, CF (corresponding author), UNIV LEIDEN HOSP,HAEMOSTASIS & THROMBOSIS RES CTR,DEPT HAEMATOL,BLDG 1,C2-R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BERTINA RM, 1982, THROMB HAEMOSTASIS, V48, P1; BRANSON HE, 1983, LANCET, V2, P1165; BROEKMANS AW, 1983, NEW ENGL J MED, V309, P340, DOI 10.1056/NEJM198308113090604; FULCHER CA, 1984, BLOOD, V63, P486; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; MARLAR RA, 1989, J PEDIATR-US, V114, P528, DOI 10.1016/S0022-3476(89)80688-2; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SELIGSOHN U, 1984, NEW ENGL J MED, V310, P559, DOI 10.1056/NEJM198403013100904; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1157	12	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					910	913						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580547				2022-12-01	WOS:A1995RZ23700018
J	BRODIE, MJ; PELLOCK, JM				BRODIE, MJ; PELLOCK, JM			TAMING THE BRAIN STORMS - FELBAMATE UPDATED	LANCET			English	Editorial Material									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	Virginia Commonwealth University	BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,EPILEPSY RES UNIT,GLASGOW,LANARK,SCOTLAND.							BRODIE MJ, 1993, LANCET, V341, P1445, DOI 10.1016/0140-6736(93)90888-N; LEPPIK IE, 1995, EPILEPSIA, V36, pS66, DOI 10.1111/j.1528-1157.1995.tb06000.x; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248	3	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					918	919		10.1016/S0140-6736(95)91550-8	http://dx.doi.org/10.1016/S0140-6736(95)91550-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564721				2022-12-01	WOS:A1995RY80800002
J	CHABRIAT, H; VAHEDI, K; IBAZIZEN, MT; JOUTEL, A; NIBBIO, A; NAGY, TG; KREBS, MO; JULIEN, J; DUBOIS, B; DUCROCQ, X; LEVASSEUR, M; HOMEYER, P; MAS, JL; LYONCAEN, O; LASSERVE, ET; BOUSSER, MG				CHABRIAT, H; VAHEDI, K; IBAZIZEN, MT; JOUTEL, A; NIBBIO, A; NAGY, TG; KREBS, MO; JULIEN, J; DUBOIS, B; DUCROCQ, X; LEVASSEUR, M; HOMEYER, P; MAS, JL; LYONCAEN, O; LASSERVE, ET; BOUSSER, MG			CLINICAL SPECTRUM OF CADASIL - A STUDY OF 7 FAMILIES	LANCET			English	Article							MULTI-INFARCT DEMENTIA; MIGRAINE; LEUKOENCEPHALOPATHY; DISEASE; HEADACHES; STROKES; BRAIN	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited arterial disease of the brain recently mapped to chromosome 19. We studied 148 subjects belonging to seven families by magnetic resonance imaging and genetic linkage analysis. 45 family members (23 males and 22 females) were clinically affected. Frequent signs were recurrent subcortical ischaemic events (84%), progressive or stepwise subcortical dementia with pseudobulbar palsy (31%), migraine with aura (22%), and mood disorders with severe depressive episodes (20%). All symptomatic subjects had prominent signal abnormalities on MRI with hyperintense lesions on T2-weighted images in the subcortical white-matter and basal ganglia which were also present in 19 asymptomatic subjects. The age at onset of symptoms was mean 45 (SD [10.6]) years, with attacks of migraine with aura occurring earlier in life (38.1[8.03] years) than ischaemic events (49.3 [10.7] years). The mean age at death was 64.5 (10.6) years. On the basis of MRI data, the penetrance of the disease appears complete between 30 and 40 years of age. Genetic analysis showed strong linkage to the CADASIL locus for all seven families, suggesting genetic homogeneity. CADASIL is a hereditary cause of stroke, migraine with aura, mood disorders and dementia. The diagnosis should be considered not only in patients with recurrent small subcortical infarcts leading to dementia, but also in patients with transient ischaemic attacks, migraine with aura or severe mood disturbances, whenever MRI reveals prominent signal abnormalities in the subcortical white-matter and basal ganglia. Clinical and MRI investigations of family members are then crucial for the diagnosis which can be confirmed by genetic linkage analysis. The disease is probably largely undiagnosed.	HOP ST ANTOINE,SERV NEUROL,PARIS 12,FRANCE; HOP QUINZE VINGTS,SERV NEURORADIOL,PARIS,FRANCE; FAC MED NECKER ENFANTS MALAD,INSERM,U25,PARIS,FRANCE; HOP ST ANNE,SERV PSYCHIAT PR LOO,F-75674 PARIS,FRANCE; CHU BORDEAUX,SERV NEUROL,BORDEAUX,FRANCE; CHU NANCY,SERV NEUROL,NANCY,FRANCE; CHG ORSAY,SERV MED INTERNE,ORSAY,FRANCE; HOP ST ANNE,SERV NEUROL,F-75674 PARIS,FRANCE; HOP LA PITIE SALPETRIERE,FEDERAT NEUROL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU de Nancy; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Joutel, Anne/K-5601-2017; Krebs, Marie-Odile/O-2104-2017; Chabriat, Hugues/G-5699-2010	Joutel, Anne/0000-0003-3963-3860; Krebs, Marie-Odile/0000-0002-4715-9890; Chabriat, Hugues/0000-0001-8436-6074				AYLWARD ED, 1994, AM J PSYCHIAT, V5, P687; BABIKIAN V, 1987, STROKE, V18, P2, DOI 10.1161/01.STR.18.1.2; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; COLMANT HJ, 1980, PATHOLOGIE, V124, P163; Davous P, 1991, REV NEUROL-FRANCE, V5, P376; De Reuck J, 1972, Acta Neurol Belg, V72, P323; FERBERT A, 1991, STROKE, V22, P1010, DOI 10.1161/01.STR.22.8.1010; GRENBERG SM, 1993, NEUROLOGY, V43, P2073; GUTIERREZMOLINA M, 1994, ACTA NEUROPATHOL, V87, P98; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; IGARASHI H, 1991, CEPHALALGIA, V11, P69, DOI 10.1046/j.1468-2982.1991.1102069.x; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; LOPEZ OL, 1994, NEUROLOGY, V44, P1240, DOI 10.1212/WNL.44.7.1240; MAS JL, 1992, NEUROLOGY, V42, P1015, DOI 10.1212/WNL.42.5.1015; MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751; OSBORN RE, 1991, AM J NEURORADIOL, V12, P521; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; SALVI F, 1992, ITAL J NEUROL SCI, V13, P135, DOI 10.1007/BF02226962; SCHELTENS P, 1992, BRAIN, V115, P735, DOI 10.1093/brain/115.3.735; SCHYER B, 1990, SCHEDULE AFFECTIVE D; SONNINEN V, 1987, EUR NEUROL, V27, P209, DOI 10.1159/000116158; SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704; STCLAIR D, 1995, J MED GENET, V32, P57, DOI 10.1136/jmg.32.1.57; STEVENS DL, 1977, LANCET, V2, P1364; TOKUNAGA M, 1994, ANN NEUROL, V35, P413, DOI 10.1002/ana.410350407; TOURNIERLASSERV.E, 1994, AM J HUM GENET, V55, pA205; TOURNIERLASSERV.E, 1993, NAT GENET, V3, P356; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; VAHEDI K, 1995, ANN NEUROL, V37, P289, DOI 10.1002/ana.410370304; VANBOGAERT L, 1955, MED HELLEN, V24, P961; VERIN M, 1994, NEUROLOGY, V44, P288; WEISSENBACH J, 1992, NATURE, V359, P494; 1987, DIAGNOSTIC STATISTIC; 1988, CEPHALALGIA S, V7, P8	35	523	541	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					934	939		10.1016/S0140-6736(95)91557-5	http://dx.doi.org/10.1016/S0140-6736(95)91557-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564728				2022-12-01	WOS:A1995RY80800009
J	CHIN, DP; HOPEWELL, PC				CHIN, DP; HOPEWELL, PC			HOW TO TREAT BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE	LANCET			English	Editorial Material							INFECTION; AIDS; CIPROFLOXACIN; ETHAMBUTOL; RIFAMPIN		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CHIN, DP (corresponding author), SAN FRANCISCO GEN HOSP,DIV PULM & CRIT CARE MED,SAN FRANCISCO,CA 94110, USA.							CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; DAUTZENBERG B, 1991, AM REV RESPIR DIS, V144, P564, DOI 10.1164/ajrccm/144.3_Pt_1.564; GORDON SM, 1993, J INFECT DIS, V168, P1559, DOI 10.1093/infdis/168.6.1559; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; ISEMAN MD, 1991, AM REV RESPIR DIS, V143, P697, DOI 10.1164/ajrccm/143.4_Pt_1.697; KEMPER CA, 1994, J INFECT DIS, V170, P157, DOI 10.1093/infdis/170.1.157; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; WALLACE RJ, 1995, J INFECT DIS, V171, P747, DOI 10.1093/infdis/171.3.747; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					920	921		10.1016/S0140-6736(95)91552-4	http://dx.doi.org/10.1016/S0140-6736(95)91552-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564723				2022-12-01	WOS:A1995RY80800004
J	CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE				CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE			VOLUNTARY, NAMED TESTING FOR HIV IN A COMMUNITY-BASED ANTENATAL CLINIC - A PILOT-STUDY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; WOMEN; RISK	Despite the increasing advantages of identifying HIV infection in pregnant women, only some 12% of HIV positive women attending antenatal clinics in London have been identified by named testing. As virtually all antenatal care will be community based within the next two to three years, we assessed the problems of introducing named HIV testing during pregnancy into the primary care setting. Planning the service took a considerable time and required the production of educational material for both staff and pregnant women and some reorganisation of procedures. Over a one year period an uptake of 44% was noted. Several problems were encountered including an average of 21 minutes needed to give information on AIDS and HIV, an adverse effect on the midwife-mother relationship, and anxiety (affecting both women and midwives). Possible solutions to this difficult problem are discussed.	UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT VIROL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DIRECTORATE OBSTET & GYNAECOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; King's College London				Wolfe, Charles/0000-0001-8264-0981				ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; BANATVALA JE, 1994, LANCET, V343, P1113, DOI 10.1016/S0140-6736(94)90230-5; BANATVALA JE, 1991, LANCET, V337, P1218, DOI 10.1016/0140-6736(91)92885-6; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; Chrystie I, 1992, Health Trends, V24, P13; CHRYSTIE IL, 1995, AIDS CARE, V7, P135, DOI 10.1080/09540129550126650; CHRYSTIE IL, 1992, LANCET, V339, P364, DOI 10.1016/0140-6736(92)91682-X; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; DELAMOTHE T, 1995, BRIT MED J, V310, P213, DOI 10.1136/bmj.310.6974.213; DESMOND N, 1994, BRIT MED J, V309, P877, DOI 10.1136/bmj.309.6958.877a; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Holland F J, 1994, J Med Screen, V1, P176; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; MEADOWS J, 1994, INT J STD AIDS, V5, P400, DOI 10.1177/095646249400500604; MEADOWS J, 1992, LANCET, V339, P622; NICOLL A, 1994, BRIT MED J, V309, P376, DOI 10.1136/bmj.309.6951.376a; 1993, CHANGING CHILDBIRTH; 1994, GUIDELINES OFFERING; 1995, UNLINKED ANONYMOUS H; 1994, LANCET, V343, P1464; 1992, GUIDELINES OFFERING	24	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					928	931						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580555	Green Published			2022-12-01	WOS:A1995RZ23700026
J	DROBNIEWSKI, F				DROBNIEWSKI, F			TUBERCULOSIS IN PRISONS - FORGOTTEN PLAGUE	LANCET			English	Editorial Material											DROBNIEWSKI, F (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461, USA.							BELLIN E, 1993, JAMA-J AM MED ASSOC, V270, P940, DOI 10.1001/jama.1993.03510080044026; CHAVES F, 1993, MED CLIN-BARCELONA, V101, P525; DROBNIEWSKI F, IN PRESS TUBERCLE; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; DROBNIEWSKI FA, 1994, J HOSP INFECT, V28, P249, DOI 10.1016/0195-6701(94)90089-2; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; MARTIN V, 1994, TUBERCLE LUNG DIS, V75, P49, DOI 10.1016/0962-8479(94)90102-3; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; 1995, BRIDGING GAP; 1994, TUBERCULOSIS RUSSIA	12	54	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					948	949		10.1016/S0140-6736(95)91562-1	http://dx.doi.org/10.1016/S0140-6736(95)91562-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564733				2022-12-01	WOS:A1995RY80800014
J	GARRED, P; MADSEN, HO; HOFMANN, B; SVEJGAARD, A				GARRED, P; MADSEN, HO; HOFMANN, B; SVEJGAARD, A			INCREASED FREQUENCY OF HOMOZYGOSITY OF ABNORMAL MANNAN-BINDING-PROTEIN ALLELES IN PATIENTS WITH SUSPECTED IMMUNODEFICIENCY	LANCET			English	Note							CHILDREN; GENE	A low plasma concentration of mannan-binding protein (MBP) impairs opsonisation and phagocytosis. Three different mutations in the MBP gene have a dominant effect on MBP concentration. We investigated the frequency of the abnormal MBP alleles in 228 unrelated patients suspected of various non-HIV-related immunodeficiencies. The frequency of heterozygotes for the abnormal alleles was not different from that in the background population (36.0% and 37.4%, respectively). By contrast, the frequency of homozygotes for the abnormal alleles was significantly increased (8.3% and 0.8%, respectively; p=0.0017). This finding implies that homozygotes for abnormal MBP alleles are predisposed to recurrent infections.			GARRED, P (corresponding author), RIGSHOSP,DEPT CLIN IMMUNOL,TISSUE TYPING LAB,DK-2200 COPENHAGEN,DENMARK.		Madsen, Hans O/Q-2035-2015	Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; GARRED P, 1993, CLIN EXP IMMUNOL, V94, P99; GARRED P, 1994, EUR J IMMUNOGENET, V21, P125, DOI 10.1111/j.1744-313X.1994.tb00183.x; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8	10	223	243	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					941	943		10.1016/S0140-6736(95)91559-1	http://dx.doi.org/10.1016/S0140-6736(95)91559-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564730				2022-12-01	WOS:A1995RY80800011
J	OMAHONY, D				OMAHONY, D			PATHOPHYSIOLOGY OF CAROTID-SINUS HYPERSENSITIVITY IN ELDERLY PATIENTS	LANCET			English	Note							BLOOD-PRESSURE; CLINICAL CHARACTERISTICS; BAROREFLEX SENSITIVITY; AGE; SYNCOPE	Carotid sinus hypersensitivity (CSH) is recognised in up to 45% of elderly patients with syncope, falls, and dizziness that may not be attributed to specific myocardial sinus node dysfunction, various diseases that affect pacemaker activity, cardiac output and blood supply to the brain. The pathophysiology of CSH is unclear but it is associated with ageing, hypertension, and ischaemic heart disease. CSH is potentially treatable with dual chamber pacing for prolonged sinus arrest (cardio-inhibitory CSH) but therapy for the more prevalent hypotension (vasodepressor CSH) is unsatisfactory. However, hypersensitivity of the carotid sinus is not consistent with the known blunting effects of senescence and hypertension on baroreflex sensitivity. The present hypothesis proposes that CSH patients results from up-regulation of postsynaptic alpha-2 adrenoceptors. Reduced carotid sinus compliance in elderly arteriosclerotic hypertensive patients will reduce afferent impulse traffic in the baroreflex pathway. Such relative deafferentation may be expected to cause baroreflex postsynaptic hypersensitivity, mediated by up-regulation of the dominant postsynaptic receptor population in the baroreflex pathway, ie, alpha-2 adrenoceptors. Vigorous carotid sinus stimulation, eg, massage, could thus cause an overshoot baroreflex efferent response, resulting in profound hypotension and bradycardia. Hypotension and bradycardia are compounded by the effects of age, hypertension, ischaemic heart disease and arteriosclerosis on rapid cardiovascular compensation, resulting in cerebral hypoperfusion and syncope. Thus, CSH in elderly patients should be considered as a clinical marker of widespread arteriosclerotic disease, rather than as a distinct disease entity. If correct, this hypothesis has potentially important implications for the pharmacotherapy of hypotension-related symptoms in elderly arteriosclerotic patients.			OMAHONY, D (corresponding author), UNIV BIRMINGHAM,DEPT GERIATR MED,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND.							BRIGNOLE M, 1992, AM J CARDIOL, V69, P1039, DOI 10.1016/0002-9149(92)90860-2; CLIFFORD JM, 1989, BRIT J CLIN PHARMACO, V28, pP224; DEHN TCB, 1984, J PHYSL, V49, P37; GILLIS RA, 1985, J CARDIOVASC PHARM, V7, pS38; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; HAEUSLER G, 1974, N-S ARCH PHARMACOL, V286, P97, DOI 10.1007/BF00499107; HALLIDAY CA, 1991, BRIT J PHARMACOL, V102, P887, DOI 10.1111/j.1476-5381.1991.tb12272.x; HYLAND L, 1985, EUR J PHARMACOL, V114, P361, DOI 10.1016/0014-2999(85)90381-4; KANNEL WB, 1985, HDB BIOL AGING, P859; KAPOOR WN, 1994, J AM GERIATR SOC, V42, P426, DOI 10.1111/j.1532-5415.1994.tb07493.x; KENNY RA, 1991, AGE AGEING, V20, P449, DOI 10.1093/ageing/20.6.449; KOBINGER W, 1976, EUR J PHARMACOL, V40, P311, DOI 10.1016/0014-2999(76)90068-6; LIPSITZ LA, 1985, CLIN SCI, V69, P337, DOI 10.1042/cs0690337; MCGARRY K, 1983, HYPERTENSION, V5, P8763; MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53; MCINTOSH SJ, 1993, AM J MED, V95, P203, DOI 10.1016/0002-9343(93)90261-M; MINAKER KL, 1980, GERONTOLOGIST, V20, P163; MORLEY CA, 1984, INT J CARDIOL, V6, P287, DOI 10.1016/0167-5273(84)90188-8; REIFFEL JA, 1983, PACE, V6, P1143, DOI 10.1111/j.1540-8159.1983.tb04451.x; ROBERTSON HA, 1985, CAN J PHYSIOL PHARM, V63, P1190, DOI 10.1139/y85-195; ROSS RT, 1988, MAJOR PROBLEMS NEURO, V18, P107; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Schmitt H, 1971, Actual Pharmacol (Paris), V24, P93; SHIMADA K, 1986, CLIN SCI, V70, P489, DOI 10.1042/cs0700489; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; STRASBERG B, 1989, PROG CARDIOVASC DIS, V31, P379, DOI 10.1016/0033-0620(89)90032-7; Wallin B.G., 1992, AUTONOMIC FAILURE TX, P359; WIEDEMANN G, 1985, J NEUROL, V232, P318, DOI 10.1007/BF00313874	29	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					950	952		10.1016/S0140-6736(95)91563-X	http://dx.doi.org/10.1016/S0140-6736(95)91563-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564734				2022-12-01	WOS:A1995RY80800015
J	RAO, JK; ALLEN, NB; FEUSSNER, JR; WEINBERGER, M				RAO, JK; ALLEN, NB; FEUSSNER, JR; WEINBERGER, M			A PROSPECTIVE-STUDY OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (C-ANCA) AND CLINICAL-CRITERIA IN DIAGNOSING WEGENERS GRANULOMATOSIS	LANCET			English	Article							ANTICYTOPLASMIC AUTOANTIBODIES; TEMPORAL ARTERITIS; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; TESTS; BIAS	Antineutrophil cytoplasmic antibody (c-ANCA) has a reported sensitivity and specificity greater than 90% for active Wegener's granulomatosis in selected patients with previously-defined disease. Because of these reports, some clinicians believe that a positive c-ANCA result provides strong circumstantial evidence for the diagnosis of Wegener's granulomatosis in patients with compatible clinical symptoms. However, this approach has not been examined prospectively. We prospectively studied 346 consecutive patients suspected of having vasculitis; those with previously established Wegener's granulomatosis (n=29) or receiving immunosuppressives other than corticosteroids (n=65) at baseline were excluded. Measures included a baseline cANCA, blinded chart reviews to record symptoms, physical findings, and corticosteroid use at baseline, and 2 to 8 months later to record final diagnoses and biopsy results. Wegener's granulomatosis was defined using the 1990 American College of Rheumatology (ACR) criteria, which does not require a biopsy. Follow-up information was available for 212 (84%) of the 252 patients eligible for this study (no corticosteroids: n=174; corticosteroids: n=78). 25 patients with compatible symptoms were classified with Wegener's granulomatosis by ACR criteria; only 6 of the 25 had biopsy-proven disease. 14 of these 212 patients had positive c-ANCA results. The overall sensitivity of c-ANCA for ACR-defined Wegener's granulomatosis were 28% (95% CI, 10%-46%) and 96% respectively. The positive and negative and 0.91. The specificity regardless of baseline corticosteroid use or disease activity; however, the sensitivity and positive predictive value remained poor. For Wegener's granulomatosis defined by biopsy criteria and compatible clinical symptoms, the sensitivity was 83% (53%-100%); however, the positive predictive value was 36%. These results raise serious questions about the use of positive c-ANCA tests in diagnosing Wegener's granulomatosis in patients with clinical symptoms alone.	VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705; DUKE UNIV,MED CTR,DIV RHEUMATOL & IMMUNOL,DURHAM,NC; DUKE UNIV,MED CTR,DIV GEN INTERNAL MED,DURHAM,NC 27710	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	RAO, JK (corresponding author), RICHARD L ROUDEBUSH VET AFFAIRS MED CTR,1481 W 10TH ST,INDIANAPOLIS,IN 46208, USA.							ANDRASSY K, 1989, CLIN NEPHROL, V32, P159; AYMARD B, 1990, DIS COLON RECTUM, V33, P427, DOI 10.1007/BF02156272; BEGG CB, 1988, RADIOLOGY, V167, P565, DOI 10.1148/radiology.167.2.3357976; BRAY VJ, 1991, AM J KIDNEY DIS, V17, P578, DOI 10.1016/S0272-6386(12)80500-2; COHENTERVAERT JW, 1991, AM J MED, V91, P59; DAVENPORT A, 1992, CLIN NEPHROL, V37, P124; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DEREMEE RA, 1976, MAYO CLIN PROC, V51, P777; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GROSS WL, 1986, LANCET, V1, P806; HAYNES BF, 1986, MED CLIN N AM, V70, P355, DOI 10.1016/S0025-7125(16)30958-0; HERREROBEAUMONT G, 1991, BRIT J RHEUMATOL, V30, P382; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JENNETTE J C, 1992, Current Opinion in Rheumatology, V4, P9; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LICHTENSTEIN MJ, 1988, J GEN INTERN MED, V3, P435, DOI 10.1007/BF02595919; MAINS B, 1989, J LARYNGOL OTOL, V103, P524, DOI 10.1017/S0022215100156774; MANDELL BF, 1994, RHEUM DIS CLIN N AM, V20, P409; MUSTONEN J, 1990, AM J NEPHROL, V10, P482, DOI 10.1159/000168173; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; ONEIL KM, 1992, DIGEST DIS SCI, V37, P702, DOI 10.1007/BF01296425; PALAIC M, 1991, NEUROLOGY, V41, P1694, DOI 10.1212/WNL.41.10.1694-a; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SHMERLING RH, 1992, ARCH INTERN MED, V152, P2417, DOI 10.1001/archinte.152.12.2417; SMALL P, 1991, ARTHRITIS RHEUM, V34, P220, DOI 10.1002/art.1780340215; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; VANDERWOUDE FJ, 1985, LANCET, V1, P425; VANDERWOUDE FJ, 1985, LANCET, V2, P48; 1989, APMIS S, V97, P5	29	94	98	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					926	931		10.1016/S0140-6736(95)91555-9	http://dx.doi.org/10.1016/S0140-6736(95)91555-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564726				2022-12-01	WOS:A1995RY80800007
J	REES, MR; MICHALIS, LK				REES, MR; MICHALIS, LK			ACTIVATED-GUIDEWIRE TECHNIQUE FOR TREATING CHRONIC CORONARY-ARTERY OCCLUSION	LANCET			English	Note							ANGIOPLASTY; RECANALIZATION; SYSTEMS	Coronary angioplasty was successfully carried out with an activated guidewire technique in 33 of 47 patients who had undergone a failed attempt at conventional angioplasty for the treatment of chronic coronary artery occlusion. 80% of these occlusions were stump-like occlusions. This technique involves the attachment of a hand-held battery-driven motorised device to standard angioplasty equipment and can be used at any time during the procedure. The device generates complex vibratory movement in the guidewire to facilitate crossing of occluded vessels.	KEELE UNIV,POSTGRAD MED SCH,STOKE ON TRENT,STAFFS,ENGLAND	Keele University			Rees, Michael/Y-4640-2019	Mihalis, Lampros/0000-0001-8834-4462				ABELA GS, 1986, J AM COLL CARDIOL, P184; DANCHIN N, 1995, AM J CARDIOL, V75, P330, DOI 10.1016/S0002-9149(99)80548-7; GRAY DF, 1993, CATHETER CARDIO DIAG, V30, P293, DOI 10.1002/ccd.1810300406; HAMM CW, 1990, AM J CARDIOL, V66, P1459, DOI 10.1016/0002-9149(90)90534-8; MEIER B, 1990, TXB INTERVENTIONAL C, P300; MILKER JP, 1987, AM J CARDIOL, V59, P535; PANDE AK, 1992, AM HEART J, V123, P1182, DOI 10.1016/0002-8703(92)91020-2; SANBORN TA, 1993, CIRCULATION, V88, P504; TIWARI P, 1995, P ROENTGEN CENTURARY, V1, P365	9	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					943	944		10.1016/S0140-6736(95)91560-5	http://dx.doi.org/10.1016/S0140-6736(95)91560-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564731				2022-12-01	WOS:A1995RY80800012
J	RYLANCE, G; BOWEN, C; RYLANCE, J				RYLANCE, G; BOWEN, C; RYLANCE, J			MEASLES AND RUBELLA IMMUNIZATION - INFORMATION AND CONSENT IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									KING EDWARD VI CAMP HILL SCH GIRLS,BIRMINGHAM B14 7QJ,W MIDLANDS,ENGLAND; KING EDWARD VI CAMP HILL SCH BOYS,BIRMINGHAM B14 7QJ,W MIDLANDS,ENGLAND		RYLANCE, G (corresponding author), CHILDRENS HOSP,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.		Rylance, Jamie/ABD-9314-2021	Rylance, Jamie/0000-0002-2323-3611				Alderson P., 1993, CHILDRENS CONSENT SU; 1994, DOH PL CNO9412 DEP H; 1994, DOH1525 95M994 DEP H; 1994, 9000M894 DEP HLTH HL	4	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					923	924						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580552	Green Published			2022-12-01	WOS:A1995RZ23700023
J	SMITH, J; CHANNER, KS				SMITH, J; CHANNER, KS			INCREASING PRESCRIPTION OF DRUGS FOR SECONDARY PREVENTION AFTER MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							TRIALS		ROYAL HALLAMSHIRE HOSP,DEPT CARDIOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAWSONMATTHEW PJ, 1994, J ROY COLL PHYS LOND, V28, P49; 1990, DRUG THER B, V28, P47	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					917	918						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580549				2022-12-01	WOS:A1995RZ23700020
J	TURNER, GM; COULTHARD, MG				TURNER, GM; COULTHARD, MG			FEVER CAN CAUSE PYURIA IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION		ROYAL VICTORIA INFIRM,PAEDIAT NEPHROL UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK								BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; DOGUNRO AS, 1991, TROP DOCT, V21, P26, DOI 10.1177/004947559102100111; HOGG RJ, 1987, PEDIATR INFECT DIS J, V6, P233, DOI 10.1097/00006454-198703000-00002; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					924	924						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580553				2022-12-01	WOS:A1995RZ23700024
J	WU, JC; CHOO, KB; CHEN, CM; CHEN, TZ; HUE, TL; LEE, SD				WU, JC; CHOO, KB; CHEN, CM; CHEN, TZ; HUE, TL; LEE, SD			GENOTYPING OF HEPATITIS-D VIRUS BY RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM AND RELATION TO OUTCOME OF HEPATITIS-D	LANCET			English	Article							DELTA-VIRUS; MOLECULAR-CLONING; RNA; SEQUENCE; EXPRESSION; LIVER	The outcome of hepatitis D virus (HDV) superinfection varies among patients and in different geographical areas. To find out whether HDV genotype affects outcome, we used a simple genotyping method based on restriction-fragment length polymorphism with enzymes Xhol and SacII for cleavage of PCR products of the HDV genome. Of samples from 88 patients studied, the genotypes of 61 were confirmed by two methods-analysis with both enzymes or by combined restriction-enzyme and direct sequencing analyses-with consistent results. No genotype III HDV was detected among these patients. The majority of patients with acute HDV infection (35/41 [85%]) had genotype II HDV. Among the 41 patients with acute infection, four of six with genotype I had fulminant disease compared with two of 35 with genotype II. Among patients in chronic stage, cirrhosis or hepatocellular carcinoma were found in 12 of 18 with genotype I HDV and eight of 29 with genotype II. Thus genotype II was the predominant HDV genotype in this study in Taiwan. Genotype II HDV was less frequently associated with fulminant hepatitis at the acute stage or with an unfavourable long-term clinical outcome at the chronic stage than was genotype I.	NATL YANG MING UNIV,SCH MED,DEPT MED,TAIPEI,TAIWAN; NATL YANG MING UNIV,SCH MED,GRAD INST CLIN MED,TAIPEI,TAIWAN; VET GEN HOSP,DEPT MED RES,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	WU, JC (corresponding author), VET GEN HOSP,DEPT MED,DIV GASTROENTEROL,TAIPEI 112,TAIWAN.		Chen, Chuan-Mu/K-7049-2013	Chen, Chuan-Mu/0000-0003-2461-9150				CASEY JL, 1993, P NATL ACAD SCI USA, V90, P9016, DOI 10.1073/pnas.90.19.9016; CHAO YC, 1991, HEPATOLOGY, V13, P345, DOI 10.1002/hep.1840130223; CHAO YC, 1990, VIROLOGY, V178, P384; GOVINDARAJAN S, 1986, HEPATOLOGY, V6, P640, DOI 10.1002/hep.1840060415; GOVINDARAJAN S, 1984, GASTROENTEROLOGY, V86, P1417; HADLER SC, 1984, ANN INTERN MED, V100, P339, DOI 10.7326/0003-4819-100-3-339; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEE CM, 1992, VIROLOGY, V188, P266; LEE HH, 1992, ANAL BIOCHEM, V205, P289, DOI 10.1016/0003-2697(92)90437-C; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; RIZZETTO M, 1983, ANN INTERN MED, V98, P437, DOI 10.7326/0003-4819-98-4-437; SALDANHA JA, 1990, J GEN VIROL, V71, P1603, DOI 10.1099/0022-1317-71-7-1603; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU JC, 1995, GASTROENTEROLOGY, V108, P796, DOI 10.1016/0016-5085(95)90453-0; WU JC, 1994, HEPATOLOGY, V19, P836, DOI 10.1002/hep.1840190406	17	119	123	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 7	1995	346	8980					939	941		10.1016/S0140-6736(95)91558-3	http://dx.doi.org/10.1016/S0140-6736(95)91558-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY808	7564729				2022-12-01	WOS:A1995RY80800010
J	BOCHKAREV, A; BARWELL, JA; PFUETZNER, RA; FUREY, W; EDWARDS, AM; FRAPPIER, L				BOCHKAREV, A; BARWELL, JA; PFUETZNER, RA; FUREY, W; EDWARDS, AM; FRAPPIER, L			CRYSTAL-STRUCTURE OF THE DNA-BINDING DOMAIN OF THE EPSTEIN-BARR-VIRUS ORIGIN-BINDING PROTEIN EBNA1	CELL			English	Article							LATENT REPLICATION ORIGIN; NUCLEAR ANTIGEN EBNA-1; FUNCTIONAL DOMAINS; HUMAN-CELLS; E1 PROTEIN; E2; ACTIVATION; PLASMIDS; COMPLEX; IDENTIFICATION	The crystal structure of the DNA-binding and dimerization domains of the Epstein-Barr virus nuclear antigen 1 (EBNA1), which binds to and activates DNA replication from the latent origin of replication in Epstein-Barr virus, was solved at 2.5 Angstrom resolution. EBNA1 appears to bind DNA via two independent regions termed the core and the flanking DNA-binding domains. The core DNA-binding domain, which comprises both the dimerization domain and a helix predicted to bind the inner portion of the EBNA1 DNA recognition element, was remarkably similar to the structure of the papillomavirus E2 protein, despite a complete lack of sequence conservation. The flanking DNA-binding domain, only a portion of which is contained in the current structure, consists in part of an a helix whose N-terminus contacts the outer regions of the EBNA1 DNA recognition element.	UNIV PITTSBURGH,VET ADM MED CTR,BIOCRYSTALLOG LAB,PITTSBURGH,PA 15240; UNIV PITTSBURGH,DEPT CRYSTALLOG,PITTSBURGH,PA 15240	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BOCHKAREV, A (corresponding author), MCMASTER UNIV,DEPT PATHOL,INST MOLEC BIOL & BIOTECHNOL,CANC RES GRP,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.			Edwards, Aled/0000-0002-4782-6016				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FUREY W, 1982, J APPL CRYSTALLOGR, V15, P160, DOI 10.1107/S0021889882011716; FUREY W, 1995, IN PRESS METH ENZYMO; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MILLER G, 1990, VIROLOGY, P1921; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; ROIZMANN B, 1990, VIROLOGY; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	46	127	132	1	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					39	46		10.1016/0092-8674(95)90232-5	http://dx.doi.org/10.1016/0092-8674(95)90232-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553871	Bronze			2022-12-01	WOS:A1995RY58300008
J	COLETURNER, R				COLETURNER, R			RELIGION AND GENE PATENTING	SCIENCE			English	Editorial Material											COLETURNER, R (corresponding author), MEMPHIS THEOL SEMINARY,168 E PKWY S,MEMPHIS,TN 38104, USA.							Cole-Turner Ronald, 1993, NEW GENESIS THEOLOGY; Holifield EB, 1986, HLTH MED METHODIST T; STONE R, 1995, SCIENCE, V268, P1126, DOI 10.1126/science.7761825; 1995, MAY F EC TRENDS GEN; 1995, US TODAY        0519, pA12	5	12	12	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					52	52		10.1126/science.270.5233.52	http://dx.doi.org/10.1126/science.270.5233.52			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	RY302	7569950				2022-12-01	WOS:A1995RY30200029
J	CRANE, BR; SIEGEL, LM; GETZOFF, ED				CRANE, BR; SIEGEL, LM; GETZOFF, ED			SULFITE REDUCTASE STRUCTURE AT 1.6 ANGSTROM - EVOLUTION AND CATALYSIS FOR REDUCTION OF INORGANIC ANIONS	SCIENCE			English	Article							ESCHERICHIA-COLI HEMOFLAVOPROTEIN; ELECTRON-PARAMAGNETIC-RES; SPINACH NITRITE REDUCTASE; PROSTHETIC GROUPS; HEMOPROTEIN SUBUNIT; MACROMOLECULAR CRYSTALLOGRAPHY; DESULFOVIBRIO-VULGARIS; SALMONELLA-TYPHIMURIUM; ANOMALOUS DIFFRACTION; SYNCHROTRON RADIATION	Fundamental chemical transformations for biogeochemical cycling of sulfur and nitrogen are catalyzed by sulfite and nitrite reductases. The crystallographic structure of Escherichia coli sulfite reductase hemoprotein (SiRHP), which catalyzes the concerted six-electron reductions of sulfite to sulfide and nitrite to ammonia, was solved with multiwavelength anomalous diffraction (MAD) of the native siroheme and Fe4S4 cluster cofactors, multiple isomorphous replacement, and selenomethionine sequence markers. Twofold symmetry within the 84-kilodalton polypeptide generates a distinctive three-domain alpha/beta fold that controls cofactor assembly and reactivity. Homology regions conserved between the symmetry-related halves of SiRHP and among other sulfite and nitrite reductases revealed key residues for stability and function, and identified a sulfite or nitrite reductase repeat (SNiRR) common to a redox-enzyme superfamily. The saddle-shaped siroheme shares a cysteine thiolate ligand with the Fe4S4 cluster and ligates an unexpected phosphate anion. In the substrate complex, sulfite displaces phosphate and binds to siroheme iron through sulfur. An extensive hydrogen-bonding network of positive side chains, water molecules, and siroheme carboxylates activates S-O bonds for reductive cleavage.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Scripps Research Institute; Duke University					NIGMS NIH HHS [GM37684, GM212226] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; BACK E, 1988, MOL GEN GENET, V212, P20, DOI 10.1007/BF00322440; BOMINAAR EL, 1995, J AM CHEM SOC, V117, P6976, DOI 10.1021/ja00131a021; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CAMERON EM, 1982, NATURE, V296, P145, DOI 10.1038/296145a0; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CCP4 C, 1994, ACTA CRYSTALLOGR D, V50, P760; CHANG CK, 1981, P NATL ACAD SCI USA, V78, P2652, DOI 10.1073/pnas.78.5.2652; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1147; CLINE JF, 1985, BIOCHEMISTRY-US, V25, P7942; COLE JA, 1988, 42ND S SOC GEN MICR; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CRANE BR, UNPUB; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DAHL C, 1993, J GEN MICROBIOL, V139, P1817, DOI 10.1099/00221287-139-8-1817; DAY EP, 1988, BIOCHEMISTRY-US, V27, P2126, DOI 10.1021/bi00406a046; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GILSON MK, 1985, J MOL BIOL, V183, P503; GISSELMANN G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P102, DOI 10.1016/0005-2728(93)90037-G; HAN SW, 1989, BIOCHEMISTRY-US, V28, P5461, DOI 10.1021/bi00439a022; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUYNH BH, 1984, J BIOL CHEM, V259, P5373; JANICK PA, 1982, BIOCHEMISTRY-US, V21, P3538, DOI 10.1021/bi00258a003; JANICK PA, 1983, BIOCHEMISTRY-US, V22, P396, DOI 10.1021/bi00271a025; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAUFMAN J, 1993, BIOCHEMISTRY-US, V32, P2853, DOI 10.1021/bi00062a017; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; KRUEGER RJ, 1982, BIOCHEMISTRY-US, V21, P2892, DOI 10.1021/bi00541a014; LEE J, 1973, J BACTERIOL, V259, P15373; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; LIDE DR, 1990, HDB CHEM PHYSICS; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; MADDEN JF, 1989, BIOCHEMISTRY-US, V28, P5471, DOI 10.1021/bi00439a023; MCREE DE, 1986, J BIOL CHEM, V261, P277; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MOURA I, 1988, J AM CHEM SOC, V110, P1075, DOI 10.1021/ja00212a013; MOURA I, 1986, BIOCHEM BIOPH RES CO, V141, P1032, DOI 10.1016/S0006-291X(86)80148-6; MURPHY MJ, 1973, J BIOL CHEM, V248, P6911; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PECK HD, 1988, S SOC GEN MICROBIOL, V42, P99; Postgate J.R, 1979, SULPHATE REDUCING BA; Price C. C., 1962, SULFUR BONDING; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTTEN M, 1972, ORIGIN LIFE NATURAL; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; Schidlowski M., 1983, P149; SEKI Y, 1979, J BIOCHEM-TOKYO, V86, P273; SEKI Y, 1981, J BIOCHEM-TOKYO, V90, P1487, DOI 10.1093/oxfordjournals.jbchem.a133615; SIEGEL LM, 1982, J BIOL CHEM, V257, P6343; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SIEGEL LM, 1975, METABOLIC PATHWAYS, V7, P217; Singleton Jr R., 1993, SULFATE REDUCING BAC; SORIANO A, 1995, J AM CHEM SOC, V117, P4724, DOI 10.1021/ja00121a038; TAN J, 1991, BIOCHEMISTRY-US, V30, P9900, DOI 10.1021/bi00105a013; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Wray J.L., 1989, MOL GENETIC ASPECTS; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YOUNG LJ, 1988, BIOCHEMISTRY-US, V27, P2790, DOI 10.1021/bi00408a020	74	281	287	3	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					59	67		10.1126/science.270.5233.59	http://dx.doi.org/10.1126/science.270.5233.59			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569952				2022-12-01	WOS:A1995RY30200031
J	DEMENOCAL, PB				DEMENOCAL, PB			PLIOPLEISTOCENE AFRICAN CLIMATE	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; EQUATORIAL ATLANTIC; TROPICAL ATLANTIC; LAST GLACIATION; NORTH-ATLANTIC; 2.4 MYR; DROUGHT; CIRCULATION; ETHIOPIA; SAHEL	Marine records of African climate variability document a shift toward more arid conditions after 2.8 million years ago (Ma), evidently resulting from remote forcing by cold North Atlantic sea-surface temperatures associated with the onset of Northern Hemisphere glacial cycles. African climate before 2.8 Ma was regulated by low-latitude insolation forcing of monsoonal climate due to Earth orbital precession. Major steps in the evolution of African hominids and other vertebrates are coincident with shifts to more arid, open conditions near 2.8 Ma, 1.7 Ma, and 1.0 Ma, suggesting that some Pliocene (Plio)-Pleistocene speciation events may have been climatically mediated.			DEMENOCAL, PB (corresponding author), LAMONT DOHERTY EARTH OBSERV,PALISADES,NY 10964, USA.		demenocal, peter/B-1386-2013	demenocal, peter/0000-0002-7191-717X				ASFAW B, 1992, NATURE, V362, P732; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Blackman R.B., 1958, MEASUREMENT POWER SP, P1; BLOEMENDAL J, 1989, NATURE, V342, P897, DOI 10.1038/342897a0; BONNEFILLE R, 1983, NATURE, V303, P487, DOI 10.1038/303487a0; BONNEFILLE R, 1987, PALAEOGEOGR PALAEOCL, V60, P249, DOI 10.1016/0031-0182(87)90035-6; BONNEFILLE R, 1990, NATURE, V345, P347; BRAIN CK, 1981, ANN GEOL SOC S AFR, V84, P1; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Brown F.H., 1992, QUATERN INT, V13-14, P55, DOI DOI 10.1016/1040-6182(92)90010-Y; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CERLING TE, 1992, NATURE, V97, P241; Clark J.D., 1980, HUMAN ECOLOGY SAVANN, P41; CLEMENS SC, 1991, P OCEAN DRILLING PRO, V0117; DAVIES TD, 1985, J CLIMATOL, V5, P17, DOI 10.1002/joc.3370050103; DEMENOCAL PB, 1993, J GEOPHYS RES-ATMOS, V98, P7265, DOI 10.1029/92JD02924; DEMENOCAL PB, 1993, PALEOCEANOGRAPHY, V8, P209, DOI 10.1029/93PA02688; DEMENOCAL PB, IN PRESS PALEOCLIMAT; DRUYAN LM, 1989, INT J CLIMATOL, V9, P77, DOI 10.1002/joc.3370090107; DUPONT LM, 1989, ACTA BOT NEERL, V38, P405, DOI 10.1111/j.1438-8677.1989.tb01372.x; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; GASSE F, 1990, NATURE, V346, P141, DOI 10.1038/346141a0; GASSE F, 1989, NATURE, V342, P57, DOI 10.1038/342057a0; GRINE FE, 1986, S AFR J SCI, V82, P87; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hamilton A. C., 1982, ENV HIST E AFRICA; HARRIS JWK, 1983, AFRICAN ACHAEOLOGICA, P3; HASTENRATH S, 1985, CLIMATE CIRCULATION; Hilgen FJ, 1989, TERRA NOVA, V1, P409, DOI 10.1111/j.1365-3121.1989.tb00401.x; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; JANSEN E, 1991, NATURE, V349, P600, DOI 10.1038/349600a0; KIMBEL W, IN PRESS PALEOCLIMAT; KLEIN RG, 1988, EVOLUTION HIST ROBUS; LAMB PJ, 1978, MON WEATHER REV, V106, P482, DOI 10.1175/1520-0493(1978)106<0482:CSOTAS>2.0.CO;2; LEROY S, 1994, NATURE, V109, P295; McIntyre A, 1989, PALEOCEANOGRAPHY, V4, P19, DOI 10.1029/PA004i001p00019; MIDDLETON NJ, 1985, NATURE, V316, P431, DOI 10.1038/316431a0; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; NAIR RR, 1989, NATURE, V338, P749, DOI 10.1038/338749a0; NEWELL RE, 1984, J CLIMATOL, V4, P27, DOI 10.1002/joc.3370040103; NICHOLSON SE, LIMNOLOGY CLIMATOLOG; POKRAS EM, 1985, QUATERNARY RES, V24, P137, DOI 10.1016/0033-5894(85)90001-8; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; PROSPERO JM, 1977, SCIENCE, V196, P1196, DOI 10.1126/science.196.4295.1196; Pye K., 1987, AEOLIAN DUST DUST DE; RAYMO ME, 1990, EARTH PLANET SC LETT, V97, P353, DOI 10.1016/0012-821X(90)90051-X; REA DK, 1994, REV GEOPHYS, V32, P159, DOI 10.1029/93RG03257; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; Rossignol-Strick M., 1983, NATURE, V303, P46; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1989, P OCEAN DRILLING PRO, V0108; Sama-Wojcicki A. M., 1985, NATURE, V313, P306; SARNTHEIN M, 1981, NATURE, V293, P193, DOI 10.1038/293193a0; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; SHACKLETON NJ, IN PRESS P OCEAN DRI; SIROCKO F, 1991, QUATERNARY RES, V36, P72, DOI 10.1016/0033-5894(91)90018-Z; SIROCKO F, 1989, NATO ASI SER C-MATH, P401; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; VRBA ES, 1989, OSSA, V14, P127; VRBA ES, IN PRESS PALEOCLIMAT; WEBB R, 1994, EOS, V75, P381; WEBSTER PJ, 1978, QUATERNARY RES, V10, P279, DOI 10.1016/0033-5894(78)90024-8; WESSELMAN HB, 1985, S AFR J SCI, V81, P260; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; YEMANE K, 1985, NATURE, V318, P653, DOI 10.1038/318653a0; 1981, GEOL SOC AM MAP CHAR, V36; [No title captured]	76	839	875	7	142	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					53	59		10.1126/science.270.5233.53	http://dx.doi.org/10.1126/science.270.5233.53			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569951				2022-12-01	WOS:A1995RY30200030
J	EARLY, A; ABE, T; WILLIAMS, J				EARLY, A; ABE, T; WILLIAMS, J			EVIDENCE FOR POSITIONAL DIFFERENTIATION OF PRESTALK CELLS AND FOR A MORPHOGENETIC GRADIENT IN DICTYOSTELIUM	CELL			English	Article							ANTERIOR-LIKE CELLS; GENE-EXPRESSION; CYCLE PHASE; STALK-CELL; PATTERN-FORMATION; PRESPORE PATTERN; DISCOIDEUM; SLUG; CAMP; DIF	We present evidence that Dictyostelium slug tip cells, the pstA cells, may arise by positional differentiation, but at a site remote from that which they will eventually occupy. When first detectable, the pstA cells form a peripheral ring surrounding the other prestalk cell subtype, the pstO cells, but subsequently move above the pstO cells to form the tip. Because pstA cell differentiation requires a 10-fold higher concentration of differention-inducing factor, the stalk cell inducer, the initial patterning seems likely to reflect the existence of a morphogenetic gradient. The subsequent redistribution of the two cell types is explicable by their different rates of chemotaxis to cyclic AMP, These results help reconcile the two apparently opposing views of pattern formation in Dictyostelium, that there is positional differentiation and that pattern formation occurs by cell sorting.	UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	EARLY, A (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE T, 1994, CELL, V77, P687, DOI 10.1016/0092-8674(94)90053-1; ARAKI T, 1994, DEV BIOL, V162, P221, DOI 10.1006/dbio.1994.1080; BROOKMAN JJ, 1982, DEV BIOL, V91, P191, DOI 10.1016/0012-1606(82)90022-7; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; BUHL B, 1993, DEV BIOL, V156, P481, DOI 10.1006/dbio.1993.1094; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; DATTA S, 1986, MOL CELL BIOL, V6, P811, DOI 10.1128/MCB.6.3.811; DETTERBECK S, 1994, DEVELOPMENT, V120, P2847; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DURSTON AJ, 1976, NATURE, V263, P126, DOI 10.1038/263126a0; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1993, DEVELOPMENT, V118, P353; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; ESCH RK, 1991, GENE DEV, V5, P9, DOI 10.1101/gad.5.1.9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; INSALL R, 1992, EMBO J, V11, P2849, DOI 10.1002/j.1460-2075.1992.tb05352.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1993, P NATL ACAD SCI USA, V90, P487, DOI 10.1073/pnas.90.2.487; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KOPACHIK WJ, 1985, DIFFERENTIATION, V28, P209, DOI 10.1111/j.1432-0436.1985.tb00827.x; MAEDA Y, 1989, DIFFERENTIATION, V41, P169, DOI 10.1111/j.1432-0436.1989.tb00744.x; MAEDA Y, 1993, DEV GROWTH DIFFER, V35, P609; MATSUKUMA S, 1979, J EMBRYOL EXP MORPH, V50, P243; MCDONALD SA, 1986, DEV BIOL, V117, P546, DOI 10.1016/0012-1606(86)90322-2; MCDONALD SA, 1984, J CELL SCI, V66, P195; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MEE JD, 1986, BIOCHEM CELL BIOL, V64, P722, DOI 10.1139/o86-099; MEINHARDT H, 1983, DIFFERENTIATION, V24, P191, DOI 10.1111/j.1432-0436.1983.tb01319.x; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRISON A, 1992, EXP CELL RES, V199, P383, DOI 10.1016/0014-4827(92)90449-I; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; OHMORI T, 1987, CELL DIFFER DEV, V22, P11, DOI 10.1016/0045-6039(87)90409-X; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; RUBIN J, 1975, J EMBRYOL EXP MORPH, V33, P227; SCHAAP P, 1986, DIFFERENTIATION, V33, P1, DOI 10.1111/j.1432-0436.1986.tb00404.x; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; TAKEUCHI I, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P249; TAKEUCHI I, 1978, BOT MAG TOKYO, V1, P47; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRAYNOR D, 1992, P NATL ACAD SCI USA, V89, P8303, DOI 10.1073/pnas.89.17.8303; WANG M, 1985, DIFFERENTIATION, V30, P7, DOI 10.1111/j.1432-0436.1985.tb00506.x; WANG M, 1988, DEV BIOL, V125, P410, DOI 10.1016/0012-1606(88)90221-7; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEEKS G, 1991, BIOCHEM CELL BIOL, V69, P608, DOI 10.1139/o91-090; WEIJER CJ, 1984, J CELL SCI, V70, P133; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WOLPERT L, 1971, CURR TOP DEV BIOL, V6, P183; ZIMMERMAN W, 1993, DEV BIOL, V160, P178, DOI 10.1006/dbio.1993.1296	59	123	124	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					91	99		10.1016/0092-8674(95)90237-6	http://dx.doi.org/10.1016/0092-8674(95)90237-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553878	Bronze			2022-12-01	WOS:A1995RY58300013
J	FISHER, RP; JIN, P; CHAMBERLIN, HM; MORGAN, DO				FISHER, RP; JIN, P; CHAMBERLIN, HM; MORGAN, DO			ALTERNATIVE MECHANISMS OF CAK ASSEMBLY REQUIRE AN ASSEMBLY FACTOR OR AN ACTIVATING KINASE	CELL			English	Article							MYC TRANSGENIC MICE; ZINC-FINGER; VIRUS TYPE-1; CATALYTIC SUBUNIT; PROTEIN-KINASE; COILED COILS; RING FINGER; IDENTIFICATION; MOTIF; PURIFICATION	We have cloned a mouse cDNA that encodes p36, a novel subunit of the CDK-activating kinase (CAK). p36 contains a C3HC4 zinc-binding domain or RING finger and is associated both with a TFIIH-bound form of CAK and with a free trimeric form. p36 promotes the assembly of CDK7 and cyclin H in vitro, stabilizing the transient CDK7-cyclin H complex. Stabilization and activation of CAK by p36 is independent of the phosphorylation state of T170, the conserved activating residue of CDK7. Assembly of active CDK7-cyclin H dimers can also occur through an alternative p36-independent pathway that requires phosphorylation of T170 by a CAK-activating kinase, or CAKAK. Thus, CDK7-cyclin H complex formation can be achieved by multiple mechanisms.			FISHER, RP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.			Morgan, David/0000-0001-8753-4416				BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CHAN WK, 1991, CHEM ENG PROG, V87, P63; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; O'Reilly DR, 1993, BACULOVIRUS EXPRESSI; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHLEKHATTAR R, 1995, NATURE, V374, P283; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, IN PRESS EMBO J; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626	47	212	215	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					47	57		10.1016/0092-8674(95)90233-3	http://dx.doi.org/10.1016/0092-8674(95)90233-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553872	Bronze			2022-12-01	WOS:A1995RY58300009
J	GRANDEA, AG; ANDROLEWICZ, MJ; ATHWAL, RS; GERAGHTY, DE; SPIES, T				GRANDEA, AG; ANDROLEWICZ, MJ; ATHWAL, RS; GERAGHTY, DE; SPIES, T			DEPENDENCE OF PEPTIDE BINDING BY MHC CLASS-I MOLECULES ON THEIR INTERACTION WITH TAP	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ENDOPLASMIC-RETICULUM; CELL BIOLOGY; HLA-A; ANTIGEN; TRANSPORTER; TRANSLOCATION; PROTEIN; GENE; EXPRESSION	Major histocompatibility complex (MHC) class I molecules bind peptides that are delivered from the cytosol into the endoplasmic reticulum by the MHC-encoded transporter associated with antigen processing (TAP). Peptide capture by immature heterodimers of class I heavy chains and beta(2)-microglobulin may be facilitated by their physical association with TAP. A genetic defect in a human mutant cell line causes the complete failure of diverse class I heterodimers to associate with TAP. This deficiency impairs the ability of the class I heterodimers to efficiently capture peptides and results from loss of function of an unidentified gene or genes linked to the MHC.	FRED HUTCHINSON CANC RES CTR,DIV CLIN RES,SEATTLE,WA 98104; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR,PROGRAM IMMUNOL,TAMPA,FL 33612; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19104	Fred Hutchinson Cancer Center; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038508, R37AI030581, R01AI030581] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30581, AI38508] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BARBER LD, 1993, ANNU REV CELL BIOL, V9, P163; BURROWS SR, 1992, EUR J IMMUNOL, V22, P191, DOI 10.1002/eji.1830220128; CEMAN S, 1994, J IMMUNOL, V152, P2865; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nelson K, 1989, IMMUNOBIOLOGY HLA, P292; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; STUBBLEFIELD E, 1992, SOMAT CELL MOLEC GEN, V18, P485, DOI 10.1007/BF01232645; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	38	177	177	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					105	108		10.1126/science.270.5233.105	http://dx.doi.org/10.1126/science.270.5233.105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569935				2022-12-01	WOS:A1995RY30200044
J	HERMAN, MA; VASSILIEVA, LL; HORVITZ, HR; SHAW, JE; HERMAN, RK				HERMAN, MA; VASSILIEVA, LL; HORVITZ, HR; SHAW, JE; HERMAN, RK			THE C-ELEGANS GENE LIN-44, WHICH CONTROLS THE POLARITY OF CERTAIN ASYMMETRIC CELL DIVISIONS, ENCODES A WNT PROTEIN AND ACTS CELL NONAUTONOMOUSLY	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA HOMOLOG; EXPRESSION; WINGLESS; YEAST; REGION; PLAKOGLOBIN; SEQUENCES; VECTORS; LINEAGE	Mutations in the C. elegans gene lin-44 lead to reversals in the polarity of certain asymmetric cell divisions. We have discovered that lin-44 is a member of the Wnt family of genes, which encode secretory glycoproteins implicated in intercellular signaling. Both in situ hybridization experiments using lin-44 transcripts and experiments using reporter constructs designed to mimic patterns of lin-44 expression indicate that lin-44 is expressed in hypodermal cells at the tip of the tail and posterior to the cells with polarities affected by lin-44 mutations. Our mosaic analysis indicates that lin-44 acts cell nonautonomously. We propose that LIN-44 protein is secreted by tail hypodermal cells and affects the polarity of asymmetric cell divisions that occur more anteriorly in the tail.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	HERMAN, MA (corresponding author), UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108, USA.			Herman, Michael/0000-0001-6796-1568	NICHD NIH HHS [HD22163] Funding Source: Medline; NIGMS NIH HHS [GM24943, GM22387] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024943, R01GM022387] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHISHOLM AD, 1989, GENE DEV, V3, P1413, DOI 10.1101/gad.3.9.1413; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DEVENISH RJ, 1982, GENE, V18, P277, DOI 10.1016/0378-1119(82)90166-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HOWELL AM, 1990, GENETICS, V126, P583; Kaiser K, 1985, DNA CLONING PRACTICA, P1; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, IN PRESS METH CELL B; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUSSELL J, 1992, DEVELOPMENT, V115, P475; SAMBROOK J, 1989, MO LCLONING LABORATO; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEYDOUX G, 1995, IN PRES METH CELL BI; SHACKLEFORD GM, 1993, ONCOGENE, V8, P1857; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P9909; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERSTON RH, 1981, GENETICS, V97, P307; WYMAN AR, 1987, METHOD ENZYMOL, V152, P173	48	166	173	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					101	110		10.1016/0092-8674(95)90238-4	http://dx.doi.org/10.1016/0092-8674(95)90238-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553861	Bronze			2022-12-01	WOS:A1995RY58300014
J	HOCHMAN, DW; BARABAN, SC; OWENS, JWM; SCHWARTZKROIN, PA				HOCHMAN, DW; BARABAN, SC; OWENS, JWM; SCHWARTZKROIN, PA			DISSOCIATION OF SYNCHRONIZATION AND EXCITABILITY IN FUROSEMIDE BLOCKADE OF EPILEPTIFORM ACTIVITY	SCIENCE			English	Article							RAT HIPPOCAMPAL SLICE; EXTRACELLULAR POTASSIUM; WATER-INTOXICATION; CHEMICAL SYNAPSES; TRANSPORT; SEIZURES; NEURONS; CELLS; BRAIN; POTENTIALS	Furosemide, a chloride cotransport inhibitor, reversibly blocked synchronized burst discharges in hippocampal slices without reducing the pyramidal cell response to single electrical stimuli. Images of the intrinsic optical signal acquired during these slice experiments indicated that furosemide coincidentally blocked changes in extracellular space. In urethane-anesthetized rats, systemically injected furosemide blocked kainic acid-induced electrical discharges recorded from cortex. These results suggest that (i) neuronal synchronization involved in epileptiform activity can be dissociated from synaptic excitability; (ii) nonsynaptic mechanisms, possibly associated with furosemide-sensitive cell volume regulation, may be critical for synchronization of neuronal activity; and (iii) agents that affect extracellular volume may have clinical utility as antiepileptic drugs.	UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Baraban, Scott/0000-0003-1975-9781	NINDS NIH HHS [NS07144, NS15317] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015317] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGHAJANIAN AK, 1989, SYNAPSE, V31, P331; ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6; BARAN H, 1987, NEUROSCIENCE, V21, P679, DOI 10.1016/0306-4522(87)90029-7; BUCKMASTER PS, 1993, J NEUROPHYSIOL, V70, P1281, DOI 10.1152/jn.1993.70.4.1281; CARTER CH, 1962, EPILEPSIA, V3, P198; DELVA NJ, 1988, BRIT J PSYCHIAT, V152, P242, DOI 10.1192/bjp.152.2.242; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; Dudek F E, 1986, Adv Neurol, V44, P593; DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F; FERRIER IN, 1985, BRIT MED J, V291, P1594, DOI 10.1136/bmj.291.6509.1594; FORSYTHE WI, 1981, DEV MED CHILD NEUROL, V23, P761; GALVAN M, 1982, BRAIN RES, V241, P75, DOI 10.1016/0006-8993(82)91230-6; Garland HG, 1943, LANCET, V2, P566; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; GUILLAUME D, 1991, EPILEPSIA, V32, P10, DOI 10.1111/j.1528-1157.1991.tb05603.x; HAMMARLUND MM, 1982, BIOPHARM DRUG DISPOS, V3, P345, DOI 10.1002/bdd.2510030408; JEFFERYS JGR, 1982, NATURE, V200, P448; KIMELBERG HK, 1985, BRAIN RES, V361, P125, DOI 10.1016/0006-8993(85)91282-X; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KONNERTH A, 1984, EXP BRAIN RES, V51, P153; LANGTON PD, 1993, J PHYSIOL-LONDON, V471, P1; LIPTON P, 1973, J PHYSIOL-LONDON, V231, P365, DOI 10.1113/jphysiol.1973.sp010238; LOTHMAN EW, 1981, NEUROLOGY, V31, P806, DOI 10.1212/WNL.31.7.806; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MEDANI CR, 1987, SOUTHERN MED J, V80, P421, DOI 10.1097/00007611-198704000-00003; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; READ DJ, 1964, J PHARM, V146, P154; RICHARDSON TL, 1984, BRAIN RES, V294, P255, DOI 10.1016/0006-8993(84)91037-0; ROPER SN, 1992, ANN NEUROL, V31, P81, DOI 10.1002/ana.410310115; ROSEN AS, 1990, NEUROSCIENCE, V38, P579, DOI 10.1016/0306-4522(90)90052-6; SCHWARTZKROIN PA, 1980, BRAIN RES, V183, P61, DOI 10.1016/0006-8993(80)90119-5; Schwartzkroin Philip A., 1993, P83; STASHEFF SF, 1985, BRAIN RES, V344, P296, DOI 10.1016/0006-8993(85)90807-8; TANIMUKAI H, 1965, BIOCHEM PHARMACOL, V14, P961; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; THOMPSON SM, 1988, J NEUROPHYSIOL, V60, P105, DOI 10.1152/jn.1988.60.1.105; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; Van Harreveld A., 1967, Journal of Neurophysiology, V30, P911; VANHARREVELD A, 1971, EXP MOL PATHOL, V15, P61, DOI 10.1016/0014-4800(71)90019-0; WALZ W, 1984, J CEREBR BLOOD F MET, V4, P301, DOI 10.1038/jcbfm.1984.42; White H S, 1986, Adv Neurol, V44, P695; ZHANG CL, 1995, EPILEPSY RES, V20, P105	49	161	173	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					99	102		10.1126/science.270.5233.99	http://dx.doi.org/10.1126/science.270.5233.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569957				2022-12-01	WOS:A1995RY30200042
J	KNUDSON, CM; TUNG, KSK; TOURTELLOTTE, WG; BROWN, GAJ; KORSMEYER, SJ				KNUDSON, CM; TUNG, KSK; TOURTELLOTTE, WG; BROWN, GAJ; KORSMEYER, SJ			BAX-DEFICIENT MICE WITH LYMPHOID HYPERPLASIA AND MALE GERM-CELL DEATH	SCIENCE			English	Article							APOPTOSIS; BCL-2; PROTEIN; SURVIVAL; GENE; P53	BAX, a heterodimeric partner of BCL2, counters BCL2 and promotes apoptosis in gain-of-function experiments, A Bax knockout mouse was generated that proved viable but displayed lineage-specific aberrations in cell death, Thymocytes and B cells in this mouse displayed hyperplasia, and Bax-deficient ovaries contained unusual atretic follicles with excess granulosa cells. In contrast, Bax-deficient males were infertile as a result of disordered seminiferous tubules with an accumulation of atypical premeiotic germ cells, but no mature haploid sperm, Multinucleated giant cells and dysplastic cells accompanied massive cell death. Thus, the loss of Bax results in hyperplasia or hypoplasia, depending on the cellular context.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV MOLEC ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Virginia				Knudson, Charles Michael/0000-0003-3964-5466	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028934, R01HD027500] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NICHD NIH HHS [P30-HD28934, HD27500] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARINAGA M, 1994, SCIENCE, V263, P754, DOI 10.1126/science.8303290; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLSE LS, 1995, IMMUNITY, V3, P87; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GAURIELI Y, 1992, J CELL BIOL, V119, P493; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; KAMADA S, 1995, CANCER RES, V55, P354; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MERRY DE, 1994, DEVELOPMENT, V120, P301; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; RUSSELL L, 1977, AM J ANAT, V148, P313, DOI 10.1002/aja.1001480303; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	40	1276	1305	0	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					96	99		10.1126/science.270.5233.96	http://dx.doi.org/10.1126/science.270.5233.96			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569956				2022-12-01	WOS:A1995RY30200041
J	MARTIN, A; HAXBY, JV; LALONDE, FM; WIGGS, CL; UNGERLEIDER, LG				MARTIN, A; HAXBY, JV; LALONDE, FM; WIGGS, CL; UNGERLEIDER, LG			DISCRETE CORTICAL REGIONS ASSOCIATED WITH KNOWLEDGE OF COLOR AND KNOWLEDGE OF ACTION	SCIENCE			English	Article							VISUAL-CORTEX; PET IMAGES; VERBS; RETRIEVAL; SYSTEMS; NOUNS; BRAIN; COMPREHENSION; ACHROMATOPSIA; ORGANIZATION	The areas of the brain that mediate knowledge about objects were investigated by measuring changes in regional cerebral blood flow (rCBF) using positron emission tomography (PET). Subjects generated words denoting colors and actions associated with static, achromatic line drawings of objects in one experiment, and with the written names of objects in a second experiment. In both studies, generation of color words selectively activated a region in the ventral temporal lobe just anterior to the area involved in the perception of color, whereas generation of action words activated a region in the middle temporal gyrus just anterior to the area involved in the perception of motion. These data suggest that object knowledge is organized as a distributed system in which the attributes of an object are stored close to the regions of the cortex that mediate perception of those attributes.			MARTIN, A (corresponding author), NIMH,PSYCHOL & PSYCHOPATHOL LAB,BLDG 10,ROOM 4C110,10 CTR DR,MSC 1366,BETHESDA,MD 20892, USA.		martin, alex/B-6176-2009					ALBERT ML, 1981, CLIN ASPECTS DYSPHAG, P69; Allport D.A., 1985, CURRENT PERSPECTIVES, P32; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO A, 1980, NEUROLOGY, V30, P1064, DOI 10.1212/WNL.30.10.1064; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DAMASIO AR, 1983, NEUROLOGY, V33, P1573, DOI 10.1212/WNL.33.12.1573; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; FARAH MJ, 1992, J EXP PSYCHOL HUMAN, V18, P241, DOI 10.1037/0096-1523.18.1.241; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; FRISTON KJ, 1990, BLOOD FLOW METAB, V10, P458; GESCHWIND N, 1966, ARCH NEUROL-CHICAGO, V15, P137, DOI 10.1001/archneur.1966.00470140027004; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; GOLDBERG E, 1989, J CLIN EXP NEUROPSYC, V11, P489, DOI 10.1080/01688638908400909; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HURTIG RR, 1994, J CEREBR BLOOD F MET, V14, P423, DOI 10.1038/jcbfm.1994.53; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KOSSLYN SM, 1994, BRAIN, V117, P15; Kuera H., 1967, COMPUTATIONAL ANAL P; LEE KS, 1991, J CEREB BLOOD FLO S2, V11, pS557; LUZZATTI C, 1994, NEUROPSYCHOLOGIA, V32, P933, DOI 10.1016/0028-3932(94)90044-2; MCCARTHY R, 1985, NEUROPSYCHOLOGIA, V23, P709, DOI 10.1016/0028-3932(85)90079-X; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MICELI G, 1984, CORTEX, V20, P207, DOI 10.1016/S0010-9452(84)80038-6; Milner B., 1964, FRONTAL GRANULAR COR, P313; Neely J., 1991, BASIC PROCESSES READ, P264; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; Vaina L., 1994, CEREB CORTEX, V5, P555; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI S, 1990, BRAIN, V113, P1721, DOI 10.1093/brain/113.6.1721; ZEKI S, 1991, BRAIN, V114, P1721; ZIHL J, 1991, BRAIN, V114, P2235, DOI 10.1093/brain/114.5.2235; ZINGESER LB, 1990, BRAIN LANG, V39, P14, DOI 10.1016/0093-934X(90)90002-X	45	811	828	2	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					102	105		10.1126/science.270.5233.102	http://dx.doi.org/10.1126/science.270.5233.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RY302	7569934				2022-12-01	WOS:A1995RY30200043
J	MASISON, DC; WICKNER, RB				MASISON, DC; WICKNER, RB			PRION-INDUCING DOMAIN OF YEAST URE2P AND PROTEASE RESISTANCE OF URE2P PRION-CONTAINING CELLS	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PSI	The genetic properties of the [URE3] non-Mendelian element of Saccharomyces cerevisiae suggest that it is a prion (infectious protein) form of Ure2p, a regulator of nitrogen catabolism. In extracts from [URE3] strains, Ure2p was partially resistant to proteinase K compared with Ure2p from wild-type extracts. Overexpression of Ure2p in wild-type strains induced a 20- to 200-fold increase in the frequency with which [URE3] arose, Overexpression of just the amino-terminal 65 residues of Ure2p increased the frequency of [URE3] induction 6000-fold. Without this ''prion-inducing domain'' the carboxyl-terminal domain performed the nitrogen regulation function of Ure2p, but could not be changed to the [URE3] prion state. Thus, this domain induced the prion state in trans, whereas in cis it conferred susceptibility of the adjoining nitrogen regulatory domain to prion infections.	NIDDKD, BIOCHEM PHARMACOL LAB, GENET SIMPLE EUKARYOTES SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COX B, 1994, CURR BIOL, V4, P744, DOI 10.1016/S0960-9822(00)00167-6; Cox Brian, 1993, P219; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOEL SM, 1994, GENETICS, V137, P659; GAJDUSEK DC, 1991, EUR J EPIDEMIOL, V7, P567, DOI 10.1007/BF00143141; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH A, 1979, P NATL ACAD SCI USA, V76, P1952, DOI 10.1073/pnas.76.4.1952; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TUITE MF, 1994, NATURE, V370, P327, DOI 10.1038/370327a0; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	26	319	324	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					93	95		10.1126/science.270.5233.93	http://dx.doi.org/10.1126/science.270.5233.93			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569955	Green Submitted			2022-12-01	WOS:A1995RY30200040
J	MUELLER, PR; COLEMAN, TR; KUMAGAI, A; DUNPHY, WG				MUELLER, PR; COLEMAN, TR; KUMAGAI, A; DUNPHY, WG			MYT1 - A MEMBRANE-ASSOCIATED INHIBITORY KINASE THAT PHOSPHORYLATES CDC2 ON BOTH THREONINE-14 AND TYROSINE-15	SCIENCE			English	Article							PROTEIN-KINASE; NEGATIVE REGULATION; WEE1; ACTIVATION; MITOSIS; XENOPUS; GENE	Cdc2 is the cyclin-depefident kinase that controls entry of cells into mitosis. Phosphorylation of Cdc2 on threonine-14 and tyrosine-15 inhibits the activity of the enzyme and prevents premature initiation of mitosis. Although Wee1 has been identified as the kinase that phosphorylates tyrosine-15 in various organisms, the threonine-14-specific kinase has not been isolated. A complementary DNA was cloned from Xenopus that encodes Myt1, a member of the Wee1 family that was discovered io phosphorylate Cdc2 efficiently on both threonine-14 and tyrosine-15. Myt1 is a membrane-associated protein that contains a putative transmembrane segment. Immunodepletion studies suggested that Myt1 is the predominant threonine-14-specific kinase in Xenopus egg extracts, Myt1 activity is highly regulated during the cell cycle, suggesting that this relative of Wee1 plays a role in mitotic control.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL 21676, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute			Mueller, Paul/B-6699-2012	Coleman, Thomas/0000-0002-1665-4768				ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LEE MS, 1994, J BIOL CHEM, V269, P30530; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, UNPUB; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	26	533	546	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 6	1995	270	5233					86	90		10.1126/science.270.5233.86	http://dx.doi.org/10.1126/science.270.5233.86			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569953				2022-12-01	WOS:A1995RY30200038
J	OSSIPOW, V; TASSAN, JP; NIGG, EA; SCHIBLER, U				OSSIPOW, V; TASSAN, JP; NIGG, EA; SCHIBLER, U			A MAMMALIAN RNA-POLYMERASE-II HOLOENZYME CONTAINING ALL COMPONENTS REQUIRED FOR PROMOTER-SPECIFIC TRANSCRIPTION INITIATION	CELL			English	Article							TATA-BINDING PROTEIN; ALBUMIN GENE; BASAL TRANSCRIPTION; CATALYTIC SUBUNIT; ACTIVATION DOMAIN; PHOSPHORYLATION; EXPRESSION; KINASE; P40(MO15); P34(CDC2)	The protein kinase MO15/CDK7 has recently been shown to be associated with the general transcription factor TFIIH and to be capable of phosphorylating the RNA polymerase II carboxy-terminal domain. Here, we show that a monoclonal MO15/CDK7 antibody coimmunoprecipitates, from a rat liver nuclear extract, all components of the RNA polymerase II transcription apparatus required for initiation at the albumin and adenovirus major late promoters. The immunoprecipitate includes RNA polymerase II, TFIID, TFIIB, TFIIH, TFIIF, and TFIIE, but is devoid of transcriptional activator proteins, such as HNF1, HNF4, and C/EBP alpha. The finding of an autonomously initiating RNA polymerase II holoenzyme in mammalian cells suggests conceptual similarities between transcription initiation in prokaryotes and eukaryotes.	INST SUISSE RECH EXPTL CANC,CH-1066 EPALINGES,SWITZERLAND		OSSIPOW, V (corresponding author), UNIV GENEVA,DEPT BIOL MOLEC SCI 2,CH-1211 GENEVA 4,SWITZERLAND.			nigg, erich/0000-0003-4835-5719				BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KNAUS R, 1990, NUCLEIC ACIDS MOL BI, V4, P110; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, GENE DEV, V2, P786; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRUANT R, 1993, J BIOL CHEM, V268, P2284; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZHU KY, 1994, BIOTECHNIQUES, V18, P222	61	181	182	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					137	146		10.1016/0092-8674(95)90242-2	http://dx.doi.org/10.1016/0092-8674(95)90242-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553866	Bronze			2022-12-01	WOS:A1995RY58300018
J	POON, RYC; HUNTER, T				POON, RYC; HUNTER, T			DEPHOSPHORYLATION OF CDK2 THR(160) BY THE CYCLIN-DEPENDENT KINASE-INTERACTING PHOSPHATASE KAP IN THE ABSENCE OF CYCLIN	SCIENCE			English	Article							GENE	The activation of cyclin-dependent kinases (CDKs) requires the phosphorylation of a conserved threonine (Thr(160) in Cdk2) by CDK-activating kinase (CAK). Human KAP (also called Cdl1), a CDK-associated phosphatase, was shown to dephosphorylate Thr(160) in human Cdk2. KAP was unable to dephosphorylate Tyr(15) and only dephosphorylated Thr(160) in native monomeric Cdk2. The binding of cyclin A to Cdk2 inhibited the dephosphorylation of Thr(160) by KAP but did not preclude the binding of KAP to the cyclin A-Cdk2 complex. Moreover, the dephosphorylation of Thr(160) bit KAP prevented Cdk2 kinase activity upon subsequent association with cyclin A. These results suggest that KAP binds to Cdk2 and dephosphorylates Thr(160) when the associated cyclin subunit is degraded or dissociates.			POON, RYC (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10100 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Poon, Randy/0000-0001-5571-6231	NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA14195, CA39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; POON RYC, 1994, ANAL BIOCHEM, V218, P26, DOI 10.1006/abio.1994.1137; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, UNPUB; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	24	149	154	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 6	1995	270	5233					90	93		10.1126/science.270.5233.90	http://dx.doi.org/10.1126/science.270.5233.90			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY302	7569954				2022-12-01	WOS:A1995RY30200039
J	SCHUMACHER, MA; CHOI, KY; LU, F; ZALKIN, H; BRENNAN, RG				SCHUMACHER, MA; CHOI, KY; LU, F; ZALKIN, H; BRENNAN, RG			MECHANISM OF COREPRESSOR-MEDIATED SPECIFIC DNA-BINDING BY THE PURINE REPRESSOR	CELL			English	Article							ESCHERICHIA-COLI; CYTR REPRESSOR; MET REPRESSOR; X-RAY; PROTEIN; LIGAND; COMPLEX; CAMP; CRP; CRYSTALLIZATION	The modulation of the affinity of DNA-binding proteins by small molecule effecters for cognate DNA sites is common to both prokaryotes and eukaryotes. However, the mechanisms by which effector binding to one domain affects DNA binding by a distal domain are poorly understood structurally. In initial studies to provide insight into the mechanism of effector-modulated DNA binding of the lactose repressor family, we determined the crystal structure of the purine repressor bound to a corepressor and purF operator. To extend our understanding, we have determined the structure of the corepressor-free corepressor-binding domain of the purine repressor at 2.2 Angstrom resolution. In the unliganded state, structural changes in the corepressor-binding pocket cause each subunit to rotate open by as much as 23 degrees, the consequences of which are the disengagement of the minor groove-binding hinge helices and repressor-DNA dissociation.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	SCHUMACHER, MA (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244, R01GM024658, R37GM024658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-24658, GM-49244] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BIOL CHEM, V269, P24066; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GRALLA JD, 1992, TRANSCRIPTIONAL REGU, V2, P629; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; NAGADOI A, 1995, IN PRESS STRUCTURE; OH BH, 1993, J BIOL CHEM, V268, P11348; OLAH GA, 1993, J BIOL CHEM, V268, P16241; OTWINOWSKI Z, 1988, NATURE, V334, P321; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SAIER MH, 1995, TRENDS BIOCHEM SCI, V20, P267, DOI 10.1016/S0968-0004(00)89041-6; SCHUMACHER MA, 1992, J MOL BIOL, V225, P1131, DOI 10.1016/0022-2836(92)90111-V; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SOMERVILLE R, 1992, PROG NUCLEIC ACID RE, V42, P1, DOI 10.1016/S0079-6603(08)60572-3; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	42	92	94	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					147	155		10.1016/0092-8674(95)90243-0	http://dx.doi.org/10.1016/0092-8674(95)90243-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553867	Bronze			2022-12-01	WOS:A1995RY58300019
J	STUDITSKY, VM; CLARK, DJ; FELSENFELD, G				STUDITSKY, VM; CLARK, DJ; FELSENFELD, G			OVERCOMING A NUCLEOSOMAL BARRIER TO TRANSCRIPTION	CELL			English	Article							RNA-POLYMERASE-II; ELONGATION COMPLEXES; HISTONE ACETYLATION; CHROMATIN STRUCTURE; BACTERIOPHAGE-T7; INITIATION; INVITRO; DNA; INHIBIT; GENES	We have studied the kinetics of transcription through a nucleosome core. RNA polymerase transcribes the first similar to 25 bp of nucleosomal DNA rapidly, but then hits a barrier and continues slowly to the nucleosomal dyad region. Here, the barrier disappears and the transcript is completed at a rapid rate, as if on free DNA, indicating that histone octamer transfer is completed as polymerase reaches the dyad, If DNA behind the polymerase is removed during transcription, the barrier does not appear until the polymerase has penetrated up to 15 bp farther into the nucleosome. On a longer template, the barrier is almost eliminated. We have shown previously that the octamer is transferred around the transcribing polymerase via an intermediate containing an intranucleosomal DNA loop, Our results exclude the possibility that polymerase has difficulty breaking histone-DNA contacts and suggest instead that polymerase pauses because it has difficulty transcribing DNA in the loop.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Studitsky, Vasily/A-9382-2014					ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cb.08.110192.003023; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P203; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCKNIGHT SL, 1979, CELL, V7, P551; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)80114-A; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TRAVERS AA, 1994, BIOESSAYS, V16, P657, DOI 10.1002/bies.950160911; TURNER BM, 1991, J CELL SCI, V99, P13; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V26, P5695; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	43	128	133	1	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					19	27		10.1016/0092-8674(95)90230-9	http://dx.doi.org/10.1016/0092-8674(95)90230-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553869	Bronze			2022-12-01	WOS:A1995RY58300006
J	TELLING, GC; SCOTT, M; MASTRIANNI, J; GABIZON, R; TORCHIA, M; COHEN, FE; DEARMOND, SJ; PRUSINER, SB				TELLING, GC; SCOTT, M; MASTRIANNI, J; GABIZON, R; TORCHIA, M; COHEN, FE; DEARMOND, SJ; PRUSINER, SB			PRION PROPAGATION IN MICE EXPRESSING HUMAN AND CHIMERIC PRP TRANSGENES IMPLICATES THE INTERACTION OF CELLULAR PRP WITH ANOTHER PROTEIN	CELL			English	Article							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; CULTURED-CELLS; MISSENSE VARIANT; SCRAPIE ISOFORM; REPLICATION; CONVERSION; FORM	Transgenic (Tg) mice expressing human (Hu) and chimeric prion protein (PrP) genes were inoculated with brain extracts from humans with inherited or sporadic prion disease to investigate the mechanism by which PrPC is transformed into PrPSc. Although Tg(HuPrP) mice expressed high levels of HUPrPC, they were resistant to human prions, They became susceptible to human prions upon ablation of the mouse (Mo) PrP gene. In contrast, mice expressing low levels of the chimeric transgene were susceptible to human prions and registered only a modest decrease in incubation times upon MoPrP gene disruption. These and other findings argue that a species-specific macromolecule, provisionally designated protein X, participates in prion formation. While the results demonstrate that PrPSc binds to PrPC in a region delimited by codons 96 to 167, they also suggest that PrPC binds protein X through residues near the C-terminus. Protein X might function as a molecular chaperone in the formation of PrPSc.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MOLEC & CELLULAR PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; HADASSAH UNIV HOSP, DEPT NEUROL, IL-91120 JERUSALEM, ISRAEL	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hebrew University of Jerusalem	TELLING, GC (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805				BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CARLSON GA, 1986, CLIN RES, V34, pA675; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHANDLER RL, 1961, LANCET, V1, P1378; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; GABIZON R, 1993, AM J HUM GENET, V53, P828; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1993, BRIT MED BULL, V49, P913, DOI 10.1093/oxfordjournals.bmb.a072653; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Liautard J P, 1993, Arch Virol Suppl, V7, P227; MANUELIDIS EE, 1978, P NATL ACAD SCI USA, V75, P3432, DOI 10.1073/pnas.75.7.3432; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PETERSEN RB, 1995, NEUROLOGY, V45, P1062, DOI 10.1212/WNL.45.6.1062; PRUSINER S B, 1987, P83; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1983, PROG NEUROPATH, V5, P195; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	56	727	763	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					79	90		10.1016/0092-8674(95)90236-8	http://dx.doi.org/10.1016/0092-8674(95)90236-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553876	Bronze			2022-12-01	WOS:A1995RY58300012
J	WARD, CL; OMURA, S; KOPITO, RR				WARD, CL; OMURA, S; KOPITO, RR			DEGRADATION OF CFTR BY THE UBIQUITIN-PROTEASOME PATHWAY	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; SITE-DIRECTED MUTAGENESIS; CYSTIC-FIBROSIS GENE; ENDOPLASMIC-RETICULUM; DELTA-F508; PROTEIN; IDENTIFICATION; TRANSLOCATION; MUTATIONS; CHAIN	Most cases of cystic fibrosis are caused by mutations that interfere with the biosynthetic folding of the cystic fibrosis transmembrane conductance regulator (CFTR), leading to the rapid degradation of CFTR molecules that have not matured beyond the endoplasmic reticulum (ER). The mechanism by which integral membrane proteins including CFTR are recognized and targeted for ER degradation and the proteolytic machinery involved in this process are not well understood. We show here that the degradation of both wild-type and mutant CFTR is inhibited by two potent proteasome inhibitors that induce the accumulation of polyubiquitinated forms of immature CFTR. CFTR degradation was also inhibited by coexpression of a dominant negative ubiquitin mutant and in cells bearing a temperature-sensitive mutation in the ubiquitin-activating enzyme, confirming that ubiquitination is required for rapid CFTR degradation.	KITASATO INST,MINATO KU,TOKYO 108,JAPAN		WARD, CL (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fra A, 1993, Subcell Biochem, V21, P143; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KULKA RG, 1988, J BIOL CHEM, V162, P15726; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARSHALL J, 1994, J BIOL CHEM, V269, P2978; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1994, J BIOL CHEM, V269, P25710; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	31	1101	1130	1	90	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					121	127		10.1016/0092-8674(95)90240-6	http://dx.doi.org/10.1016/0092-8674(95)90240-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553863	Bronze			2022-12-01	WOS:A1995RY58300016
J	WU, H; LIU, X; JAENISCH, R; LODISH, HF				WU, H; LIU, X; JAENISCH, R; LODISH, HF			GENERATION OF COMMITTED ERYTHROID BFU-E AND CFU-E PROGENITORS DOES NOT REQUIRE ERYTHROPOIETIN OR THE ERYTHROPOIETIN RECEPTOR	CELL			English	Article							COLONY-FORMING CELLS; HEMATOPOIETIC PROGENITORS; INSITU HYBRIDIZATION; GENE; EXPRESSION; MICE; CLONING; PURIFICATION; LOCALIZATION; MATURATION	Erythropoietin (EPO) is the principal growth factor regulating the production of circulating erythrocytes. We introduced null mutations into both Epo and the EPO receptor (EpoR) gene. Both heterozygotes appeared normal. Homozygous animals exhibited reduced primitive erythropoiesis and died around embryonic day 13, owing to failure of definitive fetal liver erythropoiesis. Both types of mutations exhibited identical phenotypes, indicating that EPO and the EPOR are crucial for definitive erythropoiesis in vivo and that no other ligands or receptors can replace them. Committed erythroid BFU-E and CFU-E progenitors were present in both homozygous fetal livers. Thus, neither EPO nor the EPOR is required for erythroid lineage commitment or for the proliferation and differentiation of BFU-E to CFU-E progenitors. EPO and the EPOR are crucial in vivo for the proliferation and survival of CFU-E progenitors and their irreversible terminal differentiation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WU, H (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NCI NIH HHS [R35-CA44339] Funding Source: Medline; NHLBI NIH HHS [HL32262, P01-HL-41484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, P01HL041484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; COLE RJ, 1966, J EMBRYOL EXP MORPH, V15, P245; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DESSYPRIS EN, 1988, BLOOD, V72, P2060; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1985, J CLIN INVEST, V76, P1286, DOI 10.1172/JCI112087; GREGORY CJ, 1978, BLOOD, V51, P527; GREGORY CJ, 1977, BLOOD, V49, P855; HARA H, 1977, EXP HEMATOL, V5, P141; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1988, J CLIN INVEST, V82, P154, DOI 10.1172/JCI113564; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; KRANTZ SB, 1991, BLOOD, V77, P419; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PESCHLE C, 1979, EXP HEMATOL, V7, P87; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; Tavassoli M, 1983, BONE MARROW STRUCTUR; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZANJANI ED, 1993, PATHOBIOLOGY, V61, P211, DOI 10.1159/000163796	31	807	843	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					59	67		10.1016/0092-8674(95)90234-1	http://dx.doi.org/10.1016/0092-8674(95)90234-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553874	Bronze			2022-12-01	WOS:A1995RY58300010
J	BAIK, JH; PICETTI, R; SAIARDI, A; THIRIET, G; DIERICH, A; DEPAULIS, A; LEMEUR, M; BORRELLI, E				BAIK, JH; PICETTI, R; SAIARDI, A; THIRIET, G; DIERICH, A; DEPAULIS, A; LEMEUR, M; BORRELLI, E			PARKINSONIAN-LIKE LOCOMOTOR IMPAIRMENT IN MICE LACKING DOPAMINE D2 RECEPTORS	NATURE			English	Article							BASAL GANGLIA; MESSENGER-RNA; EXPRESSION; NEURONS; GENE; SEQUENCE; ANTAGONISTS; CATALEPSY; SCH-23390; PROTEINS	DOPAMINERGIC neuronal pathways arise from mesencephalic nuclei and project axons to the striatum, cortex, limbic system and hypothalamus(1,2). Through these pathways dopamine affects many physiological functions, such as the control of coordinated movement and hormone secretion(3). Here we have studied the physiological involvement of the dopamine D2 receptors in dopaminergic transmission, using homologous recombination to generate D2-receptor-deficient mice. Absence of D2 receptors leads to animals that are akinetic and bradykinetic in behavioural tests, and which show significantly reduced spontaneous movements. This phenotype presents analogies with symptoms characteristic of Parkinson's disease(4,5). Our study shows that D2 receptors have a key role in the dopaminergic control of nervous function. These mice have therapeutic potential as a model for investigating and correcting dysfunctions of the dopaminergic system.	INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED STRASBOURG,INSERM,U398,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Depaulis, Antoine/B-6098-2012; Picetti, Roberto/B-9944-2011; Borrelli, Emiliana/M-8994-2018	Depaulis, Antoine/0000-0001-6543-6700; Picetti, Roberto/0000-0003-4756-5271; 				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BANNON MJ, 1986, J BIOL CHEM, V261, P6640; CASEY DE, 1992, PSYCHOPHARMACOLOGY, V107, P18, DOI 10.1007/BF02244960; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FUXE K, 1987, NEUROENDOCRINOLOGY, V5, P5; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JANSSEN PAJ, 1960, PSYCHOPHARMACOLOGIA, V1, P389, DOI 10.1007/BF00441186; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KITA H, 1988, BRAIN RES, V447, P346, DOI 10.1016/0006-8993(88)91138-9; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MEYER ME, 1992, PHARMACOL BIOCHEM BE, V41, P507, DOI 10.1016/0091-3057(92)90365-M; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORELLI M, 1985, EUR J PHARMACOL, V117, P179, DOI 10.1016/0014-2999(85)90602-8; OGREN SO, 1988, NEUROSCI LETT, V85, P333, DOI 10.1016/0304-3940(88)90588-5; PERTWEE RG, 1972, BRIT J PHARMACOL, V46, P753, DOI 10.1111/j.1476-5381.1972.tb06900.x; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; WOLFFGRAMM J, 1990, PHARM BIOCH BEHAV, V36, P9007; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	30	455	466	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					424	428		10.1038/377424a0	http://dx.doi.org/10.1038/377424a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566118				2022-12-01	WOS:A1995RY19000048
J	BROWN, EJ; BEAL, PA; KEITH, CT; CHEN, J; SHIN, TB; SCHREIBER, SL				BROWN, EJ; BEAL, PA; KEITH, CT; CHEN, J; SHIN, TB; SCHREIBER, SL			CONTROL OF P70 S6 KINASE BY KINASE-ACTIVITY OF FRAP IN-VIVO	NATURE			English	Article							RAPAMYCIN-INDUCED INHIBITION; PROTEIN-KINASE; LYMPHOCYTES-T; RAT-LIVER; ACTIVATION; IDENTIFICATION; ENZYME; VPS34	WHEN complexed with the inh acellular protein FKBP12, rapamycin is a potent immunosuppressant(1,2) and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase(3-6) (p70(S6k)) and cyclin-dependent kinases(7-10) (CDKs). A recently cloned FKBP12-rapamycin-associated protein (FRAP/RAFT) is the likely mediator of these effects(11,12). Using FRAP variants that do not bind FKBP12-rapamycin, we demonstrate here that FRAP is a rapamycin-sensitive regulator of p70(S6k) in vivo and that the kinase activity of FRAP is required for this regulation. In addition, we show that FRAP autophosphorylates in vitro. Consistent with an essential role for FRAP kinase activity in vivo, autophosphorylation of FRAP is inhibited by FKBP12-rapamycin. Deletion studies indicate that the kinase activity of FRAP alone is not sufficient for control of p70(S6k) and that an amino-terminal domain in FRAP is also required.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, PROGRAM IMMUNOL, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute; Harvard University				Chen, Jie/0000-0002-7887-3747				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	26	602	612	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					441	446		10.1038/377441a0	http://dx.doi.org/10.1038/377441a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566123				2022-12-01	WOS:A1995RY19000053
J	CHEN, CC; AKOPIAN, AN; SIVILOTTI, L; COLQUHOUN, D; BURNSTOCK, G; WOOD, JN				CHEN, CC; AKOPIAN, AN; SIVILOTTI, L; COLQUHOUN, D; BURNSTOCK, G; WOOD, JN			A P2X PURINOCEPTOR EXPRESSED BY A SUBSET OF SENSORY NEURONS	NATURE			English	Article							ATP-ACTIVATED CHANNELS; RAT; TRANSCRIPTION; RECEPTORS; INVITRO	ATP is known to depolarize sensory neurons, and may play a role in nociceptor activation when released from damaged tissue(1-10). Here we report the molecular cloning and characterization of a new member of the P2X receptor family(3,11,12), P2X(3), expressed by these cells, The channel transcript was present in a subset of rat dorsal-root-ganglion sensory neurons, some of which express nociceptor-associated markers; it was absent in other tissues that were tested, including sympathetic, enteric and central nervous system neurons. Moreover, when expressed in Xenopus oocytes, the channel showed an ATP-dependent cation flux, P2X(3) is the only ligand-gated channel known to be expressed exclusively by a subset of sensory neurons. The remarkable selectivity of expression of the channel coupled with its sensory neuron-like pharmacology suggests that this channel may transduce ATP-evoked nociceptor activation.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	CHEN, CC (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Colquhoun, David/C-1664-2008; Chen, Chih-Cheng/S-7015-2018; Chen, Chih-Cheng/AAT-1062-2021; Sivilotti, Lucia/D-8919-2011	Colquhoun, David/0000-0002-4263-017X; Chen, Chih-Cheng/0000-0003-4768-5660; Chen, Chih-Cheng/0000-0003-4768-5660; Sivilotti, Lucia/0000-0003-2510-8424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AKOPIAN A, IN PRESS J BIOL CHEM; ANDREWS PW, 1984, LAB INVEST, V50, P147; BEAN BP, 1990, J NEUROSCI, V10, P11; BEAN BP, 1990, J NEUROSCI, V10, P1; BEAN BP, 1990, ION CHANNELS, V2, P163; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BOUVIER MM, 1991, EUR J NEUROSCI, V3, P285, DOI 10.1111/j.1460-9568.1991.tb00090.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1993, DRUG DEVELOP RES, V28, P195, DOI 10.1002/ddr.430280303; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; COLQUHOUN D, 1971, LECTURES BIOSTATISTI; ESCURAT M, 1990, J NEUROSCI, V10, P764; HO BT, 1992, ANTI-CANCER DRUG, V2, P91; HOONG K, 1994, NATURE, V367, P470; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISHTAL OA, 1986, BIOMED RES-TOKYO, V7, P79; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; ROBERTSON SJ, IN PRESS BR J PHARM; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084	29	881	945	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					428	431		10.1038/377428a0	http://dx.doi.org/10.1038/377428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566119				2022-12-01	WOS:A1995RY19000049
J	CHEN, JD; EVANS, RM				CHEN, JD; EVANS, RM			A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS	NATURE			English	Article							RETINOIC ACID RECEPTOR; A ONCOGENE PRODUCT; THYROID-HORMONE; V-ERBA; PROTEIN; BINDING; SILENCER; ALPHA; BETA	TRANSCRIPTIONAL silencing mediated by nuclear receptors is important in development, differentiation and oncogenesis(1-3). The mechanism underlying this effect is unknown but is one key to understanding the molecular basis of hormone action. Here we identify a receptor-interacting factor, SMRT, as a silencing mediator (co-repressor) for retinoid and thyroid-hormone receptors. SMRT is a previously undiscovered protein whose association with receptors both in solution and bound to DNA-response elements is destabilized by ligand. The interaction with mutant receptors correlates with their transcriptional silencing activities. In vivo, SMRT functions as a potent co-repressor, and a GAL4 DNA-binding domain fusion of SMRT behaves as a frank repressor of a GALA-dependent reporter. Together, our results identify a new class of cofactors which may be important mediators of hormone action.			CHEN, JD (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	31	1637	1675	0	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					454	457		10.1038/377454a0	http://dx.doi.org/10.1038/377454a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566127				2022-12-01	WOS:A1995RY19000057
J	CUNDELL, DR; GERARD, NP; GERARD, C; IDANPAANHEIKKILA, I; TUOMANEN, EI				CUNDELL, DR; GERARD, NP; GERARD, C; IDANPAANHEIKKILA, I; TUOMANEN, EI			STREPTOCOCCUS-PNEUMONIAE ANCHOR TO ACTIVATED HUMAN-CELLS BY THE RECEPTOR FOR PLATELET-ACTIVATING-FACTOR	NATURE			English	Article							HUMAN ENDOTHELIAL-CELLS; INFLAMMATION; LUNG; EXPRESSION; INDUCTION; CLONING; WALL	THE Gram-positive bacterium Streptococcus pneumoniae is a major cause of pneumonia, sepsis and meningitis(1). Although the invasive disease is severe, some 40% of individuals harbour the pneumococcus in the nasopharynx asymptomatically(2). Here we investigate the molecular elements of the encounter between host and pathogen that distinguish these different outcomes. We show that inflammatory activation of human cells shifts the targeting of the pneumococcos to a new receptor, that for the G-protein-coupled platelet-activating factor (PAF). Only virulent pneumococci engage the PAF receptor. Attachment of the bacterial phosphorylcholine to the PAF receptor enhanced adherence, which was coupled to invasion of endothelial, epithelial and PAF-receptor-transfected cells. This progression could be arrested in vitro and in vivo by PAF-receptor-specific antagonists, suggesting a possible approach to therapy.	ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,INA SUE PERLMUTTER CYST FIBROSIS LAB,BOSTON,MA 02115	Rockefeller University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Cundell, Diana/0000-0003-3119-180X				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; BKAILY G, 1993, BRIT J PHARMACOL, V110, P519, DOI 10.1111/j.1476-5381.1993.tb13841.x; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CUNDELL D, 1934, MICROB PATHOG, V17, P361; ELIAS JA, 1990, AM J RESP CELL MOL, V3, P13, DOI 10.1165/ajrcmb/3.1.13; GARDNER CR, 1993, J LEUKOCYTE BIOL, V53, P190, DOI 10.1002/jlb.53.2.190; GEELEN S, 1993, INFECT IMMUN, V61, P1538, DOI 10.1128/IAI.61.4.1538-1543.1993; GEELEN S, 1992, INFECT IMMUN, V60, P4179, DOI 10.1128/IAI.60.10.4179-4183.1992; GERARD NP, 1994, J IMMUNOL, V152, P793; HELLER R, 1992, J IMMUNOL, V149, P3682; HENSON PM, 1992, AM REV RESPIR DIS, V145, P726, DOI 10.1164/ajrccm/145.3.726; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LINDER TE, 1994, MICROB PATHOGENESIS, V16, P435, DOI 10.1006/mpat.1994.1043; SHIRASAKI H, 1994, AM J RESP CELL MOL, V10, P533, DOI 10.1165/ajrcmb.10.5.8179916; STOLL LL, 1994, J BIOL CHEM, V269, P4254; SUN DX, 1992, ACTA PHARMACOL SIN, V13, P326; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WINDKELSTEIN J, 1978, J IMMUNOL, V120, P174; WISSNER A, 1986, J MED CHEM, V29, P328, DOI 10.1021/jm00153a005; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	30	556	582	10	54	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					435	438		10.1038/377435a0	http://dx.doi.org/10.1038/377435a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566121				2022-12-01	WOS:A1995RY19000051
J	DARMON, AJ; NICHOLSON, DW; BLEACKLEY, RC				DARMON, AJ; NICHOLSON, DW; BLEACKLEY, RC			ACTIVATION OF THE APOPTOTIC PROTEASE CPP32 BY CYTOTOXIC T-CELL-DERIVED GRANZYME-B	NATURE			English	Article							SERINE PROTEASES; LYMPHOCYTES-T; PURIFICATION; INHIBITION; POLYMERASE	CYTOTOXIC T lymphocyte (CTL)-mediated cytotoxicity represents the body's major defence against virus-infected and tumorigenic cells, and contributes to transplant rejection and autoimmune disease. During killing, CTL granules are exocytosed, releasing their contents into the intercellular space between the target cell and the effector. Perforin facilitates the entry of cytotoxic cell serine proteases, the granzymes, into the target cell, where they induce apoptotic death by an unknown pathway(1). Granzyme B is essential for the induction of DNA fragmentation and apoptosis in target cells(2-5), yet its substrate is unknown. Identification of the intracellular substrate far granzyme B is therefore the key to understanding the mechanism of CTL-mediated killing. Here we show that granzyme B cleaves and activates CPP32, the precursor of the protease responsible for cleavage of poly(ADP-ribose) polymerase.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA	University of Alberta; Merck & Company								BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DING RC, 1994, CANCER RES, V54, P4627; GARNER R, 1994, J IMMUNOL, V153, P5413; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NICHOLSON DW, 1994, NATURE, V376, P37; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; REDEGELD FA, 1992, J IMMUNOL, V149, P3509; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; SU B, 1994, EUR J IMMUNOL, V24, P2073, DOI 10.1002/eji.1830240921; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	23	616	633	1	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					446	448		10.1038/377446a0	http://dx.doi.org/10.1038/377446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566124				2022-12-01	WOS:A1995RY19000054
J	GRIFFITH, LL; SHOCK, EL				GRIFFITH, LL; SHOCK, EL			A GEOCHEMICAL MODEL FOR THE FORMATION OF HYDROTHERMAL CARBONATES ON MARS	NATURE			English	Article							ICELAND; ORIGIN; REYKJANES; DEPOSITS; SYSTEMS	IT IS often argued(1-3) that substantially more carbon dioxide and water were degassed from the martian interior that can be found at present in the atmosphere, polar caps and regolith. Calculations have shown that atmospheric escape cannot account for all of the missing volatiles(4). Suggestions that carbon dioxide is stored as marine or lacustrine deposits(5), are challenged by Earth-based and spacecraft remote-sensing data(6,7). Moreover, recent modelling of the martian atmosphere suggests that rainfall or open bodies of water are in any case unlikely to have persisted for extended periods of time(8,9). Hydrothermal carbonates therefore provide a possible solution to this dilemma. Using an accessible terrestrial system (Iceland) as a guide to the underlying processes, and a host rock composition inferred from the least-altered martian meteorite(10), we present a geochemical model for the formation of carbonates in possible martian hydrothermal systems. Our results suggest that an extensive reservoir of carbonate minerals--equivalent to an atmospheric pressure of carbon dioxide of at least one bar--could have been sequestered beneath the surface by widespread hydrothermal activity in the martian past.			GRIFFITH, LL (corresponding author), WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,DEPT EARTH & PLANETARY SCI,CAMPUS BOX 1169,ST LOUIS,MO 63130, USA.			Shock, Everett/0000-0002-4283-0163				ARNORSSON S, 1983, GEOCHIM COSMOCHIM AC, V47, P547, DOI 10.1016/0016-7037(83)90277-6; BLANEY DL, 1990, J GEOPHYS RES, V94, P10159; CARMICHAEL ISE, 1964, J PETROL, V5, P435, DOI 10.1093/petrology/5.3.435; CARR MH, 1986, ICARUS, V68, P187, DOI 10.1016/0019-1035(86)90019-9; EXLEY RA, 1982, J GEOPHYS RES, V87, P6547, DOI 10.1029/JB087iB08p06547; Fanale F.P., 1992, MARS, P1135; HABERLE RM, 1994, ICARUS, V109, P102, DOI 10.1006/icar.1994.1079; Helgeson HC, 1979, GEOCHEMISTRY HYDROTH, P568; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; LONKER SW, 1993, AM J SCI, V293, P605, DOI 10.2475/ajs.293.7.605; MEHEGAN JM, 1982, J GEOPHYS RES, V87, P6511, DOI 10.1029/JB087iB08p06511; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; NEWSOM HE, 1980, ICARUS, V44, P207, DOI 10.1016/0019-1035(80)90066-4; PALMASON G, 1974, ANNU REV EARTH PL SC, V2, P25, DOI 10.1146/annurev.ea.02.050174.000325; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SHOCK EL, 1992, ORIGINS LIFE EVOL B, V22, P67, DOI 10.1007/BF01808019; Squyres S. W., 1992, MARS, P523; STOLPER E, 1979, GEOCHIM COSMOCHIM AC, V43, P1475, DOI 10.1016/0016-7037(79)90142-X; SVEINBJORNSDOTT.AE, 1986, CONTRIB MINERAL PET, V94, P99; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VIERECK LG, 1982, J GEOPHYS RES, V87, P6459, DOI 10.1029/JB087iB08p06459; WALTER MR, 1993, ICARUS, V101, P129, DOI 10.1006/icar.1993.1011; WOLERY TJ, 1986, UCRLMA110662 LAWR LI	27	58	59	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					406	408		10.1038/377406a0	http://dx.doi.org/10.1038/377406a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566116				2022-12-01	WOS:A1995RY19000041
J	HACKNEY, DD				HACKNEY, DD			HIGHLY PROCESSIVE MICROTUBULE-STIMULATED ATP HYDROLYSIS BY DIMERIC KINESIN HEAD DOMAINS	NATURE			English	Article							MOLECULES; MOVEMENT	STUDIES of immobilized kinesin have shown that a single dimeric molecule can maintain contact with and drive sliding of a microtubule(1,2). In solution, however, native kinesin binds microtubules too weakly(3) and hydrolyses ATP too slowly to produce the high sliding velocities seen in motility assays(4). This apparent inhibition in solution appears to be caused by the binding of kinesin's tail domains to its motor (head) domains in a folded conformation(5). DKH392, a construct containing two heads but no tails, has been shown to display both tight binding to microtubules and high ATPase rates(6). Furthermore, it retains one molecule of ADP per dimer when bound to microtubules(7), which could facilitate a 'hand-over-hand' mechanism for processive motion. Here we show that DKH392 hydrolyses more than 100 ATP molecules per diffusional encounter with a microtubule, even in the high-salt conditions encountered physiologically. This provides direct evidence that kinesin's activity is highly processive, with the motor remaining attached to a microtubule through many cycles of ATP hydrolysis.			HACKNEY, DD (corresponding author), CARNEGIE MELLON UNIV,DEPT BIOL SCI,4400 5TH AVE,PITTSBURGH,PA 15213, USA.							BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Hackney D. D., 1995, Biophysical Journal, V68, pA286; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1995, BIOPHYS J, V68, pS267; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; SADHU A, 1992, J BIOL CHEM, V267, P11352; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	15	159	159	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					448	450		10.1038/377448a0	http://dx.doi.org/10.1038/377448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566125				2022-12-01	WOS:A1995RY19000055
J	HORLEIN, AJ; NAAR, AM; HEINZEL, T; TORCHIA, J; GLOSS, B; KUROKAWA, R; RYAN, A; KAMEL, Y; SODERSTROM, M; GLASS, CK; ROSENFELD, MG				HORLEIN, AJ; NAAR, AM; HEINZEL, T; TORCHIA, J; GLOSS, B; KUROKAWA, R; RYAN, A; KAMEL, Y; SODERSTROM, M; GLASS, CK; ROSENFELD, MG			LIGAND-INDEPENDENT REPRESSION BY THE THYROID-HORMONE RECEPTOR-MEDIATED BY A NUCLEAR RECEPTOR CO-REPRESSOR	NATURE			English	Article							RETINOID X-RECEPTOR; V-ERBA; TRANSCRIPTION FACTOR; RXR-BETA; PROTEIN; ACID; BINDING; ACTIVATION; INHIBITION; SILENCER	Thyroid-hormone and retinoic-acid receptors exert their regulatory functions by acting as both activators and repressors of gene expression. A nuclear receptor co-repressor (N-CoR) of relative molecular mass 270K has been identified which mediates ligand-independent inhibition of gene transcription by these receptors, suggesting that the molecular mechanisms of repression by thyroid-hormone and retinoic-acid receptors are analogous to the co-repressor-dependent transcriptional inhibitory mechanisms of yeast and Drosophila.	UNIV CALIF SAN DIEGO, DEPT MED, GRAD PROGRAM MOLEC PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	HORLEIN, AJ (corresponding author), UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA.		Heinzel, Thorsten/B-1013-2015; Söderström, Mats/C-4005-2009; Glass, Christopher/AAI-3933-2021	Söderström, Mats/0000-0003-3927-4394; Glass, Christopher/0000-0003-4344-3592				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANLAHMAD A, 1992, EMBO J, V11, P1015; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BRENT G A, 1989, New Biologist, V1, P329; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; ING NH, 1992, J BIOL CHEM, V267, P17617; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; MADDEN SL, 1993, ONCOGENE, V8, P1713; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARTIN B, 1994, NUCLEIC ACIDS RES, V22, P4898, DOI 10.1093/nar/22.23.4898; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; QI JS, 1995, MOL CELL BIOL, V15, P1817; RENKAWITZ R, 1993, ANN NY ACAD SCI, V684, P1, DOI 10.1111/j.1749-6632.1993.tb32266.x; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	1668	1688	2	49	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					397	404		10.1038/377397a0	http://dx.doi.org/10.1038/377397a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566114				2022-12-01	WOS:A1995RY19000039
J	HUMMEL, M; ZIEMANN, K; LAMMERT, H; PILERI, S; SABATTINI, E; STEIN, H				HUMMEL, M; ZIEMANN, K; LAMMERT, H; PILERI, S; SABATTINI, E; STEIN, H			HODGKINS-DISEASE WITH MONOCLONAL AND POLYCLONAL POPULATIONS OF REED-STERNBERG CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECEPTOR BETA-CHAIN; GENE REARRANGEMENTS; LYMPHOID-TISSUE; BIOPSY MATERIAL; IMMUNOGLOBULIN; EXPRESSION; PHENOTYPE; INFECTION; ANTIGENS; GENOTYPE	Background. There is strong evidence that Reed-Sternberg cells have a lymphoid phenotype, but clonally rearranged genes for B-cell and T-cell antigen receptors have not been demonstrable in tumor tissue from most patients with Hodgkin's disease. To elucidate this issue, we assayed single Reed-Sternberg cells from 12 patients with classic Hodgkin's disease of a B-cell immunophenotype to detect rearranged immunoglobulin variable-region heavy-chain (V-H) genes. Methods. We isolated single Reed-Sternberg cells from frozen sections that had been immunostained for CD30. The rearranged V-H genes of these cells were amplified by the polymerase chain reaction and analyzed by gel electrophoresis and nucleotide sequencing. Results. In all 12 patients, the Reed-Sternberg cells studied contained rearranged V-H genes. Three patterns were observed: in three patients the rearrangements in each patient were identical, in six patients all the rearrangements were unrelated and unique, and in three patients both identical and unrelated rearrangements were detected. Apparently somatic mutations of V-H genes were present in some Reed-Sternberg cells but absent in others. Conclusions. Reed-Sternberg cells with B-cell phenotypes have rearranged V-H genes; therefore, these cells arise from B cells. The pattern of V-H gene mutations suggests that Reed-Sternberg cells can correspond to either immunologically naive or memory B cells. In half our patients the population of Reed-Sternberg cells was polyclonal; in the other half, monoclonal or mixed cell populations were found. Correlation with the clinical stage suggests that polyclonal Hodgkin's disease can present as a widespread lymphoma.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, INST PATHOL, D-12200 BERLIN, GERMANY; UNIV BOLOGNA, SERV PATHOL ANAT 2, HEMATOPATHOL UNIT, BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bologna			Pileri, Stefano/AAP-6337-2020					ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BARRIOS L, 1988, HUM GENET, V78, P320, DOI 10.1007/BF00291727; BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; BEREK C, 1993, IMMUNOL TODAY, V14, P479; CIBULL ML, 1989, HISTOPATHOLOGY, V15, P597, DOI 10.1111/j.1365-2559.1989.tb01625.x; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DALLENBACH FE, 1989, LANCET, V2, P828; DELABIE J, 1994, BLOOD, V84, P3291; DIEHL V, 1989, MED ONCOL TUMOR PHAR, V6, P155; DREXLER HG, 1992, LEUKEMIA LYMPHOMA, V8, P283, DOI 10.3109/10428199209051008; FALINI B, 1987, HISTOPATHOLOGY, V11, P1229, DOI 10.1111/j.1365-2559.1987.tb01869.x; FALK MH, 1987, INT J CANCER, V40, P262, DOI 10.1002/ijc.2910400223; GUPTA RK, 1993, P NATL ACAD SCI USA, V90, P2817, DOI 10.1073/pnas.90.7.2817; HABER MM, 1992, BLOOD, V80, P2851; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HERBST H, 1989, LEUKEMIA RES, V13, P103, DOI 10.1016/0145-2126(89)90134-3; HESSOL NA, 1992, ANN INTERN MED, V117, P309, DOI 10.7326/0003-4819-117-4-309; HUMMEL M, 1994, BLOOD, V84, P403; HUMMEL M, 1992, BRIT J HAEMATOL, V82, P689, DOI 10.1111/j.1365-2141.1992.tb06945.x; INGHIRAMI G, 1994, P NATL ACAD SCI USA, V91, P9842, DOI 10.1073/pnas.91.21.9842; KADIN ME, 1988, AM J PATHOL, V130, P345; KAPP U, 1993, BLOOD, V82, P1247; KLITZ W, 1994, AM J HUM GENET, V54, P497; KNOWLES DM, 1986, P NATL ACAD SCI USA, V83, P7942, DOI 10.1073/pnas.83.20.7942; KODURU PRK, 1989, CANCER GENET CYTOGEN, V43, P109, DOI 10.1016/0165-4608(89)90134-9; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MASIH A, 1991, AM J PATHOL, V139, P37; PASMAN PC, 1994, ANN ONCOL, V5, pS89, DOI 10.1093/annonc/5.suppl_1.S89; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; RAPHAEL MM, 1994, AM J CLIN PATHOL, V101, P773, DOI 10.1093/ajcp/101.6.773; ROTH J, 1994, INT J CANCER, V57, P799, DOI 10.1002/ijc.2910570607; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; Stein H, 1983, Hematol Oncol, V1, P21; TAMARU J, 1994, BLOOD, V84, P708; Teale J M, 1992, Int Rev Immunol, V8, P95, DOI 10.3109/08830189209055566; TEERENHOVI L, 1988, CANCER GENET CYTOGEN, V34, P305, DOI 10.1016/0165-4608(88)90277-4; WEISS LM, 1986, HUM PATHOL, V17, P1009, DOI 10.1016/S0046-8177(86)80084-3; WEISS LM, 1987, AM J PATHOL, V129, P86; WOLF J, 1994, ANN ONCOL, V5, pS105, DOI 10.1093/annonc/5.suppl_1.S105	44	179	180	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					901	906		10.1056/NEJM199510053331403	http://dx.doi.org/10.1056/NEJM199510053331403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7545266				2022-12-01	WOS:A1995RX19900003
J	IWASA, Y; POMIANKOWSKI, A				IWASA, Y; POMIANKOWSKI, A			CONTINUAL CHANGE IN MATE PREFERENCES	NATURE			English	Article							SEXUAL SELECTION; EVOLUTION; FISHER; SPECIATION; PRINCIPLE; MUTATION	SECONDARY sexual characters are highly variable both within(1) and between species(2-6). Closely related species often differ markedly in sexual morphology but hardly at all In non-sexual traits(2-5). Here we show that Fisher's runaway process of sexual selection is intrinsically unstable and naturally leads to continual change in sexual traits. Runaway leads to semi-stable exaggeration of female preference for a malt sexual character, followed by a slow decay of both traits until runaway is triggered again In a different direction. The process then repeats itself resulting in continual change in male sexual traits through time. Allopatric populations are thus expected to diverge without drift or substantial changes in selective pressures. If there is significant mutation bias acting on the male trait, continual change stops and a stable equilibrium appears. Such an outcome is more likely when exaggeration of the male sexual trait signals good genes.	UNIV LONDON UNIV COLL, DEPT GENET & BIOMETRY, LONDON NW1 2HE, ENGLAND; KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 81281, JAPAN	University of London; University College London; Kyushu University			Pomiankowski, Andrew/X-3888-2019; Iwasa, Yoh/G-5368-2010	Pomiankowski, Andrew/0000-0002-5171-8755; Iwasa, Yoh/0000-0003-0691-1852				Andersson Malte, 1994; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; Darwin C., 1871, P475; Eberhard W.G., 1985, SEXUAL SELECTION ANI; Fisher R.A., 1930, GENETICAL THEORY NAT; FRYER G, 1980, CICHLID FISHES GREAT; Hirsch M. W., 1974, DIFF EQUAT+; IWASA Y, 1994, EVOLUTION, V48, P853, DOI [10.2307/2410492, 10.1111/j.1558-5646.1994.tb01367.x]; IWASA Y, 1991, EVOLUTION, V45, P1431, DOI [10.2307/2409890, 10.1111/j.1558-5646.1991.tb02646.x]; KARLIN S, 1990, THEOR POPUL BIOL, V38, P306, DOI 10.1016/0040-5809(90)90017-P; KIRKPATRICK M, 1990, EVOLUTION, V44, P180, DOI 10.1111/j.1558-5646.1990.tb04288.x; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LANDE R, 1982, EVOLUTION, V36, P213, DOI 10.1111/j.1558-5646.1982.tb05034.x; MUKAI T, 1977, P NATL ACAD SCI USA, V74, P2514, DOI 10.1073/pnas.74.6.2514; POMIANKOWSKI A, 1995, P ROY SOC B-BIOL SCI, V260, P21, DOI 10.1098/rspb.1995.0054; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI [10.1111/j.1558-5646.1991.tb02645.x, 10.2307/2409889]; POMIANKOWSKI A, 1993, P ROY SOC B-BIOL SCI, V253, P173, DOI 10.1098/rspb.1993.0099; TEMPLETON AR, 1980, GENETICS, V94, P1011; YOUNG JR, 1994, ANIM BEHAV, V47, P1353, DOI 10.1006/anbe.1994.1183	19	167	169	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 5	1995	377	6548					420	422		10.1038/377420a0	http://dx.doi.org/10.1038/377420a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566117				2022-12-01	WOS:A1995RY19000046
J	JOUAVILLE, LS; ICHAS, F; HOLMUHAMEDOV, EL; CAMACHO, P; LECHLEITER, JD				JOUAVILLE, LS; ICHAS, F; HOLMUHAMEDOV, EL; CAMACHO, P; LECHLEITER, JD			SYNCHRONIZATION OF CALCIUM WAVES BY MITOCHONDRIAL SUBSTRATES IN XENOPUS-LAEVIS OOCYTES	NATURE			English	Article							INOSITOL TRISPHOSPHATE; ACINAR-CELLS; PROPAGATION; MECHANISMS; CHANNELS; RECEPTOR; PROTEIN	IN Xenopus oocytes, as well as other cells, inositol-1,4,5-trisphosphate (Ins(1,4,5)P-3)-induced Ca2+ release(1-4) is an excitable process that generates propagating Ca2+ waves(5-7) that annihilate upon collision(8-12). The fundamental property responsible for excitability appears to be the Ca2+ dependency of the Ins(1,4,5)P-3 receptor(9). Here we report that Ins(1,4,5)P-3-induced Ca2+ were activity is strengthened by oxidizable substrates that energize mitochrondria, increasing Ca2+ wave amplitude, velocity and interwave period. The effects of pyruvate/malate are blocked by ruthenium red at the Ca2+ uniporter, by rotenone at complex I, and by antimycin A at complex III, and are subsequently rescued at complex IV by ascorbate tetramethylphenylenediamine (TMPD)(14). Our data reveal that potential-driven mitochondrial Ca2+ uptake is a major factor in the regulation of Ins(1,4,5)P-3-induced Ca2+ release and clearly demonstrate a physiological role of mitrochondria in intracellular Ca2+ signalling.			JOUAVILLE, LS (corresponding author), UNIV VIRGINIA,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908, USA.		Holmuhamedov, Ekhson L/P-5228-2016; Ichas, François/ABD-8277-2020	Holmuhamedov, Ekhson L/0000-0002-0809-350X; Ichas, François/0000-0001-8184-5248				BEMENT WM, 1989, CELL TISSUE RES, V255, P183; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CAHCON E, 1994, BIOPHYS J, V66, P942; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DELISLE S, 1992, J BIOL CHEM, V267, P7963; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GOLDSTONE TP, 1987, BIOCHEMISTRY-US, V26, P246, DOI 10.1021/bi00375a034; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN OH, 1994, REV PHYSL, V56, P297; POZAN T, 1994, PHYSIOL REV, V74, P595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/edrv-14-5-610; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SPEKSNIJDER JE, 1993, J CELL BIOL, V120, P1337, DOI 10.1083/jcb.120.6.1337; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; WERTH JL, 1994, J NEUROSCI, V14, P348; WINFREE AT, 1980, GEOMETRY BIOL TIME, P246	30	356	362	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					438	441		10.1038/377438a0	http://dx.doi.org/10.1038/377438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566122				2022-12-01	WOS:A1995RY19000052
J	KUROKAWA, R; SODERSTROM, M; HORLEIN, A; HALACHMI, S; BROWN, M; ROSENFELD, MG; GLASS, CK				KUROKAWA, R; SODERSTROM, M; HORLEIN, A; HALACHMI, S; BROWN, M; ROSENFELD, MG; GLASS, CK			POLARITY-SPECIFIC ACTIVITIES OF RETINOIC ACID RECEPTORS DETERMINED BY A CO-REPRESSOR	NATURE			English	Article							BINDING PROTEIN; DIRECT REPEAT; HORMONE; RAR	RETINOIC acid receptors (RARs) and retinoid-X receptors (RXRs) activate or repress transcription by binding as heterodimers to DNA-response elements that generally consist of two direct repeat half-sites of consensus sequence AGGTCA (reviewed in ref. 1). On response elements consisting of direct repeats spaced by five base pairs (DR + 5 elements), RAR/RXR heterodimers activate transcription in response to RAR-specific ligands, such as all-trans-retinoic acid (RA)(2). In contrast, on elements consisting of direct repeats spaced by one base pair (DR + 1 elements), RAR/RXR heterodimers exhibit little or no response to activating ligands and repress RXR-dependent transcription(3). Here we show that ligand-dependent transactivation by RAR on DR + 5 elements requires the dissociation of a new nuclear receptor co-repressor, N-CoR, and recruitment of the putative co-activators p140 and p160 (refs 4, 5). Surprisingly, on DR + 1 elements, N-CoR remains associated with RAR/RXR heterodimers even in the presence of RAR ligands, resulting in constitutive repression. These observations indicate that DNA-response elements can allosterically regulate RAR-co-repressor interactions to determine positive or negative regulation of gene expression.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute			Söderström, Mats/C-4005-2009; Glass, Christopher/AAI-3933-2021; Brown, Myles/B-6906-2008; Brown, Myles/AAX-5332-2021	Söderström, Mats/0000-0003-3927-4394; Glass, Christopher/0000-0003-4344-3592; Brown, Myles/0000-0002-8213-1658; Halachmi, Shlomit/0000-0001-5921-9515				BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CASANOVA J, 1995, MOL CELL BIOL, V14, P5756; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FOREMAN BM, 1995, CELL, V81, P541; GLASS C. K., 1994, ENDOCR REV, V15, P1503; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; TONE Y, 1994, J BIOL CHEM, V269, P31157; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	21	475	481	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					451	454		10.1038/377451a0	http://dx.doi.org/10.1038/377451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566126				2022-12-01	WOS:A1995RY19000056
J	LEWIS, C; NEIDHART, S; HOLY, C; NORTH, RA; BUELL, G; SURPRENANT, A				LEWIS, C; NEIDHART, S; HOLY, C; NORTH, RA; BUELL, G; SURPRENANT, A			COEXPRESSION OF P2X(2) AND P2X(3) RECEPTOR SUBUNITS CAN ACCOUNT FOR ATP-GATED CURRENTS IN SENSORY NEURONS	NATURE			English	Article							RAT	Cation-selective P2X receptor channels were first described in sensory neurons(1-4) where they are important for primary afferent neurotransmission and nociception(5,6). Here we report the cloning of a complementary DNA (P2X(3)) from rat dorsal root ganglia that had properties dissimilar to those of sensory neurons. We also found RNA for (P2X(1)) (ref. 7), (P2X(2)) (ref. 8) and P2X(4) (ref. 9) in sensory neurons; channels expressed from individual cDNAs did not reproduce those of sensory ganglia. Coexpression of P2X(3) with P2X(2), but not other combinations, yielded ATP-activated currents that closely resembled those in sensory neurons. These properties could not be accounted for by addition of the two sets of channels, indicating that a new channel had formed by subunit heteropolymerization. Although in some tissues responses to ATP can be accounted for by homomeric channels(1,7-10), our results indicate that ATP-gated channels of sensory neurons may form by a specific heteropolymerization of P2X receptor subunits.			LEWIS, C (corresponding author), GLAXO INST MOLEC BIOL SA,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022					ABBRACCHIO MP, 1995, PHARMACOL THERAPEUT, V64, P445; BEAN BP, 1990, J NEUROSCI, V10, P1; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BUELL G, IN PRESS SOC NEUR AB; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; FYFFE REW, 1984, P NATL ACAD SCI-BIOL, V81, P6890, DOI 10.1073/pnas.81.21.6890; HOLTON FA, 1954, J PHYSIOL-LONDON, V126, P124, DOI 10.1113/jphysiol.1954.sp005198; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; KHAKH BS, 1995, J PHYSIOL-LONDON, V484, P385, DOI 10.1113/jphysiol.1995.sp020672; KHAKH BS, 1995, J PHARM, V115, P117; KRISHTAL OA, 1988, BRIT J PHARMACOL, V95, P1057, DOI 10.1111/j.1476-5381.1988.tb11739.x; KRISHTAL OA, NEUROSCI LETT, V35, P41; LEWIS C, IN PRESS SOC NEUR AB; LINDSTROM JM, 1995, LIGAND VOLTAGE GATED, P153; SPRENGEL R, 1995, LIGAND VOLTAGE GATED, P213; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VULCANOVA L, IN PRESS SOC NEUR AB	20	880	905	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					432	435		10.1038/377432a0	http://dx.doi.org/10.1038/377432a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566120				2022-12-01	WOS:A1995RY19000050
J	MENDILLO, M; BAUMGARDNER, J				MENDILLO, M; BAUMGARDNER, J			CONSTRAINTS ON THE ORIGIN OF THE MOONS ATMOSPHERE FROM OBSERVATION DURING A LUNAR ECLIPSE	NATURE			English	Article							EXTENDED SODIUM ATMOSPHERE; POTASSIUM	THE properties of the Moon's rarefied atmosphere, which can be traced through observations of sodium and potassium(1-4), provide important insights into the formation and maintenance of atmospheres on other primitive Solar System bodies(5-7). The lunar atmosphere is believed to be composed of atoms from the surface rocks and soil, which might have been sputtered by micrometeorites(8), by ions in the solar wind(9), or by photons(10,11). It might also form by the evaporation of atoms from the hot, illuminated surface(10,11) Here we report the detection of sodium emission from the Moon's atmosphere during a total lunar eclipse (which occurs when the Moon is full). The sodium atmosphere is considerably more extended at full Moon than expected--it extends to at least nine lunar radii--and its brightness distribution is incompatible with sources involving either solar-wind or micrometeorite sputtering. This leaves photon sputtering or thermal desorption as the preferred explanations for the lunar atmosphere, and suggests that sunlight might also be responsible for the transient atmospheres of other primitive bodies (such as Mercury).	BOSTON UNIV,DEPT ASTRON,BOSTON,MA 02215	Boston University	MENDILLO, M (corresponding author), BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215, USA.		Mendillo, Michael/H-4397-2014					AHEARN MF, 1992, ICARUS, V98, P54, DOI 10.1016/0019-1035(92)90206-M; ELFORD WG, 1964, 9 HARV U RES REP; FLYNN B, 1993, SCIENCE, V261, P184, DOI 10.1126/science.261.5118.184; FLYNN B, IN PRESS J GEOPHYS R; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; IP WH, 1991, GEOPHYS RES LETT, V18, P2093, DOI 10.1029/91GL02549; KOZLOWSKI RWH, 1990, GEOPHYS RES LETT, V17, P2253, DOI 10.1029/GL017i012p02253; MENDILLO M, 1991, GEOPHYS RES LETT, V18, P2097, DOI 10.1029/91GL02622; MENDILLO M, 1993, ADV SPACE RES, V13, P313; MORGAN T, 1991, EOS, V72, P225; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; PAPAGLANNIS MD, 1972, SPACE PHYSICS ASTROP, P94; POTTER AE, 1988, SCIENCE, V241, P675, DOI 10.1126/science.241.4866.675; POTTER AE, 1988, GEOPHYS RES LETT, V15, P1515, DOI 10.1029/GL015i013p01515; POTTER AE, 1994, GEOPHYS RES LETT, V21, P2263, DOI 10.1029/94GL01702; SMYTH WH, 1995, ASTROPHYS J, V441, P839, DOI 10.1086/175407; SMYTH WH, 1995, ASTROPHYS J, V443, P371, DOI 10.1086/175532; SPRAGUE AL, 1990, ICARUS, V84, P93, DOI 10.1016/0019-1035(90)90160-B; SPRAGUE AL, 1992, ICARUS, V96, P27, DOI 10.1016/0019-1035(92)90004-Q; SPRAGUE AL, 1990, THESIS U ARIZONA; STERN SA, 1995, ASTRON J, V109, P835, DOI 10.1086/117327; TYLER AL, 1988, GEOPHYS RES LETT, V15, P1141, DOI 10.1029/GL015i010p01141	22	42	42	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 5	1995	377	6548					404	406		10.1038/377404a0	http://dx.doi.org/10.1038/377404a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RY190	7566115				2022-12-01	WOS:A1995RY19000040
J	POSTMA, DS; BLEECKER, ER; AMELUNG, PJ; HOLROYD, KJ; XU, JF; PANHUYSEN, CIM; MEYERS, DA; LEVITT, RC				POSTMA, DS; BLEECKER, ER; AMELUNG, PJ; HOLROYD, KJ; XU, JF; PANHUYSEN, CIM; MEYERS, DA; LEVITT, RC			GENETIC SUSCEPTIBILITY TO ASTHMA - BRONCHIAL, HYPERRESPONSIVENESS COINHERITED WITH A MAJOR GENE FOR ATOPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIRWAY RESPONSIVENESS; PULMONARY-FUNCTION; POPULATION-SAMPLE; SERUM IGE; METHACHOLINE; EXPRESSION; LINKAGE; HYPERREACTIVITY; CHROMOSOME-11Q; INTERLEUKIN-5	Background. Bronchial hyperresponsiveness, a risk factor for asthma, consists of a heightened bronchoconstrictor response to a variety of stimuli. The condition has a heritable component and is closely related to serum IgE levels and airway inflammation. The basis for these relations is unknown, as is the mechanism of genetic susceptibility to bronchial hyperresponsiveness. We attempted to define the interrelation between atopy and bronchial hyperresponsiveness and to investigate the chromosomal location of this component of asthma. Methods. We studied 303 children and grandchildren of 84 probands with asthma selected from a homogeneous population in the Netherlands. Ventilatory function, bronchial responsiveness to histamine, and serum total IgE were measured. The association between the last two variables was evaluated. Using analyses involving pairs of siblings, we tested for linkage between bronchial hyperresponsiveness and genetic markers on chromosome 5q31-q33, previously shown to be linked to a genetic locus regulating serum total IgE levels. Results. Serum total IgE levels were strongly correlated (r=0.65, P<0.01) in pairs of siblings concordant for bronchial hyperresponsiveness (defined as a greater than or equal to 20 percent decrease in the forced expiratory volume in one second produced by histamine [threshold dose, less than or equal to 16 mg per milliliter]), suggesting that these traits are coinherited. However, bronchial hyperresponsiveness was not correlated with serum IgE levels (r=0.04, P>0.10). Analyses of pairs of siblings showed linkage of bronchial hyperresponsiveness with several genetic markers on chromosome 5q, including D5S436 (P<0.001 for a histamine threshold value of less than or equal to 16 mg per milliliter). Conclusions. This study demonstrates that a trait for an elevated level of serum total IgE is coinherited with a trait for bronchial hyperresponsiveness and that a gene governing bronchial hyperresponsiveness is located near a major locus that regulates serum IgE levels on chromosome 5q. These findings are consistent with the existence of one or more genes on chromosome 5q31-q33 causing susceptibility to asthma.	UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; UNIV MARYLAND,SCH MED,BALTIMORE,MD; ASTHMA CTR,HAREN,NETHERLANDS; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Groningen; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University				Holroyd, Kenneth/0000-0001-6050-3935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; CAULFIELD M, 1994, NEW ENGL J MED, V300, P1629; CHANDRASEKHARAP.SC, 1990, GENOMICS, V6, P94; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COOKSON WOCM, 1989, LANCET, V1, P1292; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; KATZ MF, 1993, ADV INTERNAL MED, V38, P189; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KELLEHER K, 1991, BLOOD, V77, P1436; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P280, DOI 10.1016/0091-6749(74)90014-1; LANDER ES, 1994, SCIENCE, V266, P1584; LEVITT RC, 1989, J APPL PHYSIOL, V67, P1125, DOI 10.1152/jappl.1989.67.3.1125; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157, DOI 10.1152/ajplung.1990.258.4.L157; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LNADER ES, 1994, SCIENCE, V265, P2037; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; Orie NGM, 1961, BRONCHITIS INT S; Ott J., 1991, ANAL HUMAN GENETIC L; PAUWELS R, 1985, EUR J RESPIR DIS, V66, P98; POSTMA DS, 1989, AM REV RESPIR DIS, V140, pS100, DOI 10.1164/ajrccm/140.3_Pt_2.S100; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P277; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1992, SAGE STATISTICAL ANA	53	635	662	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					894	900		10.1056/NEJM199510053331402	http://dx.doi.org/10.1056/NEJM199510053331402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666875	Bronze			2022-12-01	WOS:A1995RX19900002
J	TELZAK, EE; SEPKOWITZ, K; ALPERT, P; MANNHEIMER, S; MEDARD, F; ELSADR, W; BLUM, S; GAGLIARDI, A; SALOMON, N; TURETT, G				TELZAK, EE; SEPKOWITZ, K; ALPERT, P; MANNHEIMER, S; MEDARD, F; ELSADR, W; BLUM, S; GAGLIARDI, A; SALOMON, N; TURETT, G			MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITHOUT HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEW-YORK-CITY; PULMONARY TUBERCULOSIS; DRUG	Background. Investigations of outbreaks of multidrug-resistant tuberculosis have found low rates of treatment response and very high mortality, and they have mainly involved patients with advanced human immunodeficiency virus (HIV) infection. For patients without HIV infection, one study reported an overall rate of response to treatment of 56 percent, and the mortality from tuberculosis was 22 percent. We investigated treatment response and mortality rates in 26 HIV-negative patients in New York with multidrug-resistant tuberculosis. Methods. We obtained detailed data from seven teaching hospitals in New York City on patients with multidrug-resistant tuberculosis - defined as tuberculosis resistant at least to isoniazid and rifampin - who were HIV-negative on serologic testing. Lengths of times from diagnosis to the initiation of appropriate therapy and from the initiation of appropriate therapy to conversion to negative cultures were assessed. Therapeutic responses were evaluated by both microbiologic and clinical criteria. Results. Between March 1991 and September 1994, 26 HIV-negative patients were identified and treated. Of the 25 patients for whom adequate data were available for analysis, 24 (96 percent) had clinical responses; all 17 patients for whom data on microbiologic response were available had such a response. The median times from diagnosis to the initiation of appropriate therapy and from the initiation of therapy to culture conversion were 44 days (range, 0 to 181) and 69 days (range, 2 to 705), respectively. Side effects requiring the discontinuation of medication occurred in 4 of 23 patients (17 percent) who were treated with second-line antituberculosis medications. The median follow-up for the 23 patients who responded and who received appropriate therapy was 91 weeks (range, 41 to 225). Conclusions. In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically.	ST CLARES HOSP & HLTH CTR,NEW YORK,NY 10019; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY; HARLEM HOSP MED CTR,NEW YORK,NY; MONTEFIORE MED CTR,BRONX,NY; N CENT BRONX HOSP,BRONX,NY 10467; ST VINCENTS MED CTR,NEW YORK,NY 10011; BETH ISRAEL MED CTR,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Saint Vincents Hospital Manhattan; Harvard University; Beth Israel Deaconess Medical Center	TELZAK, EE (corresponding author), ALBERT EINSTEIN COLL MED,BRONX LEBANON HOSP CTR,DIV INFECT DIS,1650 GRAND CONCOURSE,BRONX,NY 10457, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EDLIN BR, 1993, 9TH INT C AIDS 4TH S; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Heifets Leonid B., 1994, P85; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755; SHAFER RW, 1995, J INFECT DIS, V171, P170, DOI 10.1093/infdis/171.1.170; SHARP V, 1994, 8TH INT S INF IMM HO; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; TELZAK EE, 1994, 8TH INT S INF IMM HO; VALLSPINOSA A, 1970, NEW ENGL J MED, V283, P616, DOI 10.1056/NEJM197009172831202; 1993, MMWR-MORBID MORTAL W, V42, P427; 1991, MMWR-MORBID MORTAL W, V40, P585	18	199	205	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					907	911		10.1056/NEJM199510053331404	http://dx.doi.org/10.1056/NEJM199510053331404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666876	Green Published			2022-12-01	WOS:A1995RX19900004
J	WINN, WC; WESTENFELD, FW				WINN, WC; WESTENFELD, FW			INFLUENZA-A VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WINN, WC (corresponding author), UNIV VERMONT,COLL MED,BURLINGTON,VT 05405, USA.								0	5	5	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					912	912		10.1056/NEJM199510053331405	http://dx.doi.org/10.1056/NEJM199510053331405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7666877				2022-12-01	WOS:A1995RX19900005
J	ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E				ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E			HOSPITALIZATION FOR CONGESTIVE-HEART-FAILURE - EXPLAINING RACIAL-DIFFERENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MORTALITY CROSSOVER; PREVALENCE; POPULATION; SYSTEM; RATES; CARE	Objective.-To determine whether the higher rate of hospitalization among African Americans for congestive heart failure (CHF) could be explained by racial differences in the prevalence of clinical risk factors for CHF. Design.-Retrospective cohort study. Setting.-A large health maintenance organization (HMO). Patients.-A sample of 64 877 enrollees (27% African American and 73% white) of the Northern California Kaiser Permanente Medical Care Program who took at least one multiphasic health checkup (MHC) at or after the age of 40 years and were free of CHF at that time. Main Outcome Measures.-First hospitalization with a principal diagnosis of CHF. Results.-Among cohort members younger than 60 years at baseline MHC, the age-adjusted risk ratio (RR) (African American/white) for CHF hospitalization was 2.14 for men and 2.73 for women, while for persons 60 years of age and older at MHC, the age-adjusted RR was 1.48 for both sexes. Cox proportional hazards models were used to adjust for risk factors and length of follow-up. In persons aged 60 years and older, the race difference was explained by greater prevalence of hypertension and diabetes in African Americans (RR=1.12; 95% confidence interval [CI], 0.94 to 1.34 after adjustment for hypertension and diabetes). In those younger than 60 years, findings differed by sex. For men, African-American race was no longer a significant predictor of CHF after adjusting for hypertension, diabetes, left ventricular hypertrophy on electrocardiogram, and body mass index (adjusted RR=1.16; 95% CI, 0.86 to 1.56). However, among younger women, African Americans continued at increased risk despite adjustment for these variables as well as smoking, plasma cholesterol, renal function, alcohol use, and myocardial infarction (adjusted RR=1.49; 95% CI, 1.00 to 2.21). Conclusions.-In this HMO population, the race differences in first hospitalization for CHF are largely explained by known clinical and behavioral risk factors, although in younger women these risk factors do not completely explain the excess risk among African Americans. These findings highlight the role of hypertension and diabetes in the development of CHF, particularly among African Americans.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; KAISER PERMANENTE MED CARE PROGRAM NO CALIF REG,DIV RES,OAKLAND,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	ALEXANDER, M (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,MED EFFECTIVENESS RES CTR DIVERSE POPULAT,BOX 0856,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016	Brown, Arleen/0000-0001-9948-8955	AHRQ HHS [HS07373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BINDMAN AB, 1992, JAMA-J AM MED ASSOC, V268, P2426, DOI 10.1001/jama.268.17.2426; COLLEN MF, 1973, INT C SERIES, P332; GARFIELD SR, 1970, NEW ENGL J MED, V283, P1087, DOI 10.1056/NEJM197011122832006; GARFIELD SR, 1970, SCI AM, V222, P15, DOI 10.1038/scientificamerican0470-15; GARRISON GE, 1966, AM J EPIDEMIOL, V83, P338, DOI 10.1093/oxfordjournals.aje.a120589; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; GRAVES EJ, 1994, ADV DATA VITAL HLTH, V249; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; NAM CB, 1978, SOC BIOL, V25, P306, DOI 10.1080/19485565.1978.9988352; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; YUSEF S, 1989, HYPERTENSION S1, V13, P74; 1994, MMWR-MORBID MORTAL W, V43, P77	27	98	98	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1037	1042		10.1001/jama.274.13.1037	http://dx.doi.org/10.1001/jama.274.13.1037			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563454				2022-12-01	WOS:A1995RX10800026
J	DOHERTY, PC				DOHERTY, PC			THE KEYS TO CELL-MEDIATED-IMMUNITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOXIC LYMPHOCYTES-T; BIOLOGICAL ROLE; NUCLEOPROTEIN; ANTIGENS				DOHERTY, PC (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				AMOS DB, 1972, FED PROC, V31, P1087; Benacerraf B, 1975, Adv Cancer Res, V21, P121, DOI 10.1016/S0065-230X(08)60972-0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1977, P NATL ACAD SCI USA, V74, P1209, DOI 10.1073/pnas.74.3.1209; McDevitt H O, 1969, Adv Immunol, V11, P31, DOI 10.1016/S0065-2776(08)60477-0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZINKERNAGEL RM, 1995, JAMA-J AM MED ASSOC, V274, P1069, DOI 10.1001/jama.274.13.1069	12	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1067	1068		10.1001/jama.274.13.1067	http://dx.doi.org/10.1001/jama.274.13.1067			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563461				2022-12-01	WOS:A1995RX10800033
J	GENTILELLO, LM; DONOVAN, DM; DUNN, CW; RIVARA, FP				GENTILELLO, LM; DONOVAN, DM; DUNN, CW; RIVARA, FP			ALCOHOL INTERVENTIONS IN TRAUMA CENTERS - CURRENT PRACTICE AND FUTURE-DIRECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCREENING-TEST; PROBLEM DRINKING; BLOOD-ALCOHOL; INTOXICATION; QUESTIONNAIRE; ABUSE; CARE; DEPENDENCE; EMERGENCY; MORTALITY	Nearly half of all trauma beds are occupied by patients who were injured while under the influence of alcohol. Alcoholism plays such a significant role in trauma that efforts to reduce injury recurrence are unlikely to be successful if it remains untreated. An injury requiring hospitalization creates a unique opportunity to intervene and to motivate patients to alter their drinking behavior, thereby making trauma centers ideal sites to implement an alcohol screening, intervention, and referral program. However, despite emphasis on injury control and prevention, little has been done to incorporate alcohol intervention programs into care of the injured patient. Effective means of intervention exist that are consistent with the time, financial, and staffing constraints of trauma centers, and they should be implemented.	UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT PSYCHIAT & BEHAV SCI, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT PEDIAT, SEATTLE, WA 98104 USA; UNIV WASHINGTON, INST ALCOHOL & DRUG ABUSE, SEATTLE, WA 98195 USA; HARBORVIEW INJURY PREVENT & RES CTR, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	GENTILELLO, LM (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR,SCH MED,DEPT SURG,325 9TH AVE, MAILSTOP ZA-16, SEATTLE, WA 98104 USA.			Donovan, Dennis/0000-0003-2237-4292	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009045] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AAO9045] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Babor T.F., 1989, ALCOHOL USE DISORDER; BABOR TF, 1986, BRIT J ADDICT, V81, P23; Babor TF., 1989, ALCOHOL HEALTH RES W, V13, P71; BABOR TF, 1992, REPORT PHASE 2 RANDO; BERNADT MW, 1982, LANCET, V1, P325; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BLOSE JO, 1991, AM J PUBLIC HEALTH, V81, P1571, DOI 10.2105/AJPH.81.12.1571; Braiker H.B., 1980, COURSE ALCOHOLISM 4; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; CHERPITEL CJ, 1993, ALCOHOL CLIN EXP RES, V17, P762, DOI 10.1111/j.1530-0277.1993.tb00837.x; CHERPITEL CJS, 1989, DRUG ALCOHOL DEPEN, V24, P195; COLQUITT M, 1987, NEW ENGL J MED, V317, P1262, DOI 10.1056/NEJM198711123172005; DAVIDSON R, 1987, BRIT J CLIN PSYCHOL, V26, P243, DOI 10.1111/j.2044-8260.1987.tb01358.x; DAVIDSON R, 1986, BRIT J ADDICT, V81, P217; DiClemente C C, 1990, J Subst Abuse, V2, P217, DOI 10.1016/S0899-3289(05)80057-4; ELVY GA, 1988, BRIT J ADDICT, V83, P83; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P587, DOI 10.1016/0001-4575(90)90030-O; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GENTILELLO LM, 1993, J TRAUMA, V34, P669, DOI 10.1097/00005373-199305000-00009; GERBERICH SG, 1989, J TRAUMA, V29, P338, DOI 10.1097/00005373-198903000-00010; GOLDBERG HI, 1991, MED CARE, V29, pJS49; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; HABERMAN PW, 1986, J STUD ALCOHOL, V47, P316, DOI 10.15288/jsa.1986.47.316; HEATHER N, 1989, HDB ALCOHOLISM TREAT, P93; HOLDER H, 1991, J STUD ALCOHOL, V52, P517, DOI 10.15288/jsa.1991.52.517; HOLDER HD, 1992, J STUD ALCOHOL, V53, P293, DOI 10.15288/jsa.1992.53.293; JACOBS LM, 1988, TRAUMA, P15; Jacobson GR, 1989, HDB ALCOHOLISM TREAT, P17; Jones K R, 1979, Med Care, V17, P1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; LOWENSTEIN SR, 1990, J TRAUMA, V30, P1252, DOI 10.1097/00005373-199010000-00010; Marlatt G. A., 1988, ASSESSMENT ADDICTIVE; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MAYNARD A, 1994, BRIT MED BULL, V50, P221, DOI 10.1093/oxfordjournals.bmb.a072880; MCLELLAN BA, 1990, J TRAUMA, V30, P418, DOI 10.1097/00005373-199030040-00008; Miller W. R., 1986, TREATING ADDICTIVE B, P121; Miller WR, 1989, HDB ALCOHOLISM TREAT, P3; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P67; Miller WR., 2012, MOTIVATIONAL INTERVI; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P261; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; NILSSEN O, 1991, PREV MED, V20, P518, DOI 10.1016/0091-7435(91)90049-A; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; REYNA TM, 1985, ANN SURG, V201, P194; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1992, J ADOLESCENT HEALTH, V13, P663, DOI 10.1016/1054-139X(92)90060-O; RIVARA FP, 1981, B AM COLL SURG, V66, P5; Robins L. N., 1989, NIMH DIAGNOSTIC INTE; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; RUSSELL M, 1994, ALCOHOL CLIN EXP RES, V18, P1156, DOI 10.1111/j.1530-0277.1994.tb00097.x; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAXE L, 1983, OTAHCS22 OFF TECHN A; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SILVER BA, 1990, PSYCHOSOMATICS, V31, P420, DOI 10.1016/S0033-3182(90)72138-X; SODERSTROM CA, 1994, J TRAUMA, V36, P68, DOI 10.1097/00005373-199401000-00010; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; WALLER JA, 1990, J TRAUMA, V30, P1298; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; WELTE JW, 1987, DRUG ALCOHOL DEPEN, V19, P313, DOI 10.1016/0376-8716(87)90018-4; WHITFIELD RA, 1985, ACCIDENT ANAL PREV, V17, P367, DOI 10.1016/0001-4575(85)90090-9; WIECZOREK WF, 1990, J CRIM JUST, V18, P217, DOI 10.1016/0047-2352(90)90002-S; WIECZOREK WF, 1990, PROBLEM DRINKER DRIV, P90; Zuska J J, 1983, Bull Am Coll Surg, V68, P22; Zuska J J, 1981, Bull Am Coll Surg, V66, P5; 1986, MMWR-MORBID MORTAL W, V35, P703; 1985, MMWR-MORBID MORTAL W, V34, P161; 1991, SCREENING ALCOHOL OT; 1987, DIAGNOSTIC STATISTIC; 1966, PHS1071A13 PUBL; 1989, GUIDE CLIN PREVENTIV, P277; 1990, BROADENING BASE TREA; 1993, 3RD NEW YORK STAT OF; 1987, SCREENING ALCOHOLISM; 1993, RESOURCES OPTIMAL CA; 1993, 8TH NAT I ALC AB ALC; 1985, MMWR-MORBID MORTAL W, V34, P493; 1991, PUBLIC POLICY STATEM	86	134	136	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1043	1048		10.1001/jama.274.13.1043	http://dx.doi.org/10.1001/jama.274.13.1043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563455				2022-12-01	WOS:A1995RX10800027
J	MARSHALL, BJ				MARSHALL, BJ			HELICOBACTER-PYLORI - THE ETIOLOGIC AGENT FOR PEPTIC-ULCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAMPYLOBACTER-PYLORI; GASTRITIS; ERADICATION; BISMUTH; TRIAL		UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA	University of Virginia				Marshall, Barry/0000-0003-4853-5015				CULLEN DJE, 1993, GUT, V34, P1681, DOI 10.1136/gut.34.12.1681; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; MARSHALL BJ, 1987, AM J GASTROENTEROL, V82, P200; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; MARSHALL BJ, 1987, DIGESTION, V37, P16, DOI 10.1159/000199555; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MARSHALL BJ, 1986, J INFECT DIS, V52, P650; MARSHALL BJ, 1985, CAMPYLOBACTER, V3, P188; MARSHALL BJ, 1985, MED J AUSTRALIA, V149, P439; The EUROGAST Study Group, 1993, GUT, V34, P1672; WARREN JR, 1983, LANCET, V1, P273; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; 1994, JAMA-J AM MED ASSOC, V272, P65	16	136	139	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1064	1066		10.1001/jama.274.13.1064	http://dx.doi.org/10.1001/jama.274.13.1064			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563460				2022-12-01	WOS:A1995RX10800032
J	STROMINGER, JL; WILEY, DC				STROMINGER, JL; WILEY, DC			THE CLASS-I AND CLASS-II PROTEINS OF THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOLECULES; ANTIGEN; PEPTIDE; HLA-A2		DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,DEPT MED,MOLEC MED LAB,BOSTON,MA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	STROMINGER, JL (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P513; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Urban R G, 1993, Chem Immunol, V57, P197; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; WUCHERPFENNIG KW, IN PRESS P NATL ACAD	16	9	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1074	1076		10.1001/jama.274.13.1074	http://dx.doi.org/10.1001/jama.274.13.1074			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563464				2022-12-01	WOS:A1995RX10800036
J	UNANUE, ER				UNANUE, ER			THE CONCEPT OF ANTIGEN-PROCESSING AND PRESENTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL; LYMPHOCYTES-T; IDENTIFICATION; MACROPHAGES; LYSOZYME; PEPTIDES; BINDING		WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110	Washington University (WUSTL)	UNANUE, ER (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID ST,CAMPUS BOX 8118,ST LOUIS,MO 63110, USA.							ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BABBITT BP, 1986, P NATL ACAD SCI USA, V83, P4509, DOI 10.1073/pnas.83.12.4509; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENACERRAF B, 1967, COLD SPRING HARB SYM, V32, P569, DOI 10.1101/SQB.1967.032.01.069; BUUS S, 1991, SCIENCE, V235, P1353; CALDERON J, 1975, NATURE, V253, P359, DOI 10.1038/253359a0; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MCDEVITT HO, 1969, SCIENCE, V163, P1207, DOI 10.1126/science.163.3872.1207; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; Schwartz R., 1984, FUNDAMENTAL IMMUNOLO, P379; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UNANUE ER, 1968, IMMUNOLOGY, V15, P287; UNANUE ER, 1981, ADV IMMUNOL, V31, P1, DOI 10.1016/S0065-2776(08)60919-0; ZIEGLER K, 1981, J IMMUNOL, V127, P1869; ZIEGLER K, 1982, P NATL ACAD SCI USA, V78, P175; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	19	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1071	1073		10.1001/jama.274.13.1071	http://dx.doi.org/10.1001/jama.274.13.1071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563463				2022-12-01	WOS:A1995RX10800035
J	ZINKERNAGEL, RM				ZINKERNAGEL, RM			MHC-RESTRICTED T-CELL RECOGNITION - THE BASIS OF IMMUNE SURVEILLANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYMPHOCYTIC CHORIOMENINGITIS; MEDIATED CYTOTOXICITY; ANTIGENS; DISEASE; THYMUS; HLA				ZINKERNAGEL, RM (corresponding author), UNIV ZURICH HOSP,INST EXPTL IMMUNOL,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND.							DAUSSET J, 1977, HLA DISEASE, V9; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1995, JAMA-J AM MED ASSOC, V274, P1067, DOI 10.1001/jama.274.13.1067; DOHERTY PC, 1975, LANCET, V2, P1406; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; KLEIN J, 1979, SCIENCE, V203, P516, DOI 10.1126/science.104386; MCMICHAEL AJ, 1977, NATURE, V270, P524, DOI 10.1038/270524a0; MILLER JF, 1961, LANCET, V2, P748; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; SHEARER GM, 1974, EUR J IMMUNOL, V4, P527, DOI 10.1002/eji.1830040802; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1979, ANNU REV MICROBIOL, V33, P201, DOI 10.1146/annurev.mi.33.100179.001221; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	19	3	3	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1069	1071		10.1001/jama.274.13.1069	http://dx.doi.org/10.1001/jama.274.13.1069			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563462				2022-12-01	WOS:A1995RX10800034
J	BERTOLET, BD; MCMURTRIE, EB; HILL, JA; BELARDINELLI, L				BERTOLET, BD; MCMURTRIE, EB; HILL, JA; BELARDINELLI, L			THEOPHYLLINE FOR THE TREATMENT OF ATRIOVENTRICULAR-BLOCK AFTER MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Note							SICK SINUS SYNDROME; ENDOGENOUS ADENOSINE; ORAL THEOPHYLLINE; AMINOPHYLLINE; ANTAGONISM; ATROPINE	Objective: To show that second- or third-degree atrioventricular block occurring as an early complication of acute inferior myocardial infarction is mediated by adenosine. Setting: Cardiac care unit. Design: Uncontrolled, observational, hypothesis-driven study. Patients: Patients who developed clinically significant atrioventricular nodal blockade within 4 hours of admission for acute inferior myocardial infarction. Intervention: Theophylline, 100 mg/min intravenously to a maximum of 250 mg. Measurements: Continuous multilead electrocardiographic monitoring before and after administration of theophylline. Results: During a 6-month period, eight men who had had acute inferior myocardial infarction developed clinically significant atrioventricular block. Three had third-degree block, and five had high-grade second-degree block. In all patients, 1:1 atrioventricular nodal conduction was restored and normal sinus rhythm reappeared within 3 minutes of the administration of theophylline. All patients remained free of arrhythmia for at least 24 hours. Conclusions: Adenosine produced by the ischemic myocardium may induce atrioventricular nodal block. In our patients, atrioventricular nodal block was resistant to conventional therapy such as atropine, but it responded to the adenosine antagonist theophylline.	VET AFFAIRS MED CTR, GAINESVILLE, FL USA; UNIV FLORIDA, HLTH SCI CTR, GAINESVILLE, FL 32610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; University of Florida	BERTOLET, BD (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, BOX 100-277, GAINESVILLE, FL 32610 USA.							ALBONI P, 1991, AM HEART J, V122, P1361, DOI 10.1016/0002-8703(91)90578-6; [Anonymous], 1992, JAMA, V268, P2171; BELARDINELLI L, 1982, CIRC RES, V51, P569, DOI 10.1161/01.RES.51.5.569; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELARDINELLI L, 1987, TOPICS PERSPECTIVES, P346; BERTOLET BD, 1994, J AM COLL CARDIOL, pA329; DIMARCO JP, 1985, J AM COLL CARDIOL, V6, P417, DOI 10.1016/S0735-1097(85)80181-9; ELLENHOGEN KA, 1988, AM HEART J 1, V16, P202; FREDHOLM BB, 1980, TRENDS PHARMACOL SCI, V1, P129; HAUGHT WH, 1994, AM HEART J, V128, P1255; ROFMAN M, 1972, CIRCULATION, V45, P703; SAITO D, 1993, J AM COLL CARDIOL, V21, P1199, DOI 10.1016/0735-1097(93)90246-W; SCLAROVSKY S, 1984, AM HEART J, V108, P19, DOI 10.1016/0002-8703(84)90539-8; SHAH PK, 1987, AM HEART J, V113, P194, DOI 10.1016/0002-8703(87)90029-9; VISKIN S, 1993, ANN INTERN MED, V118, P279, DOI 10.7326/0003-4819-118-4-199302150-00006; WESLEY RC, 1989, CIRCULATION, V80, P128, DOI 10.1161/01.CIR.80.1.128; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5	17	43	43	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					509	511		10.7326/0003-4819-123-7-199510010-00006	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661495				2022-12-01	WOS:A1995RW49500006
J	HOES, AW; GROBBEE, DE; LUBSEN, J; TVELD, AJMI; VANDERDOES, E; HOFMAN, A				HOES, AW; GROBBEE, DE; LUBSEN, J; TVELD, AJMI; VANDERDOES, E; HOFMAN, A			DIURETICS, BETA-BLOCKERS, AND THE RISK FOR SUDDEN CARDIAC DEATH IN HYPERTENSIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						DEATH, SUDDEN, CARDIAC; HYPERTENSION; ADRENERGIC BETA-ANTAGONISTS; DIURETICS; POTASSIUM	CORONARY HEART-DISEASE; BLOOD-PRESSURE; ABNORMALITIES; ARRHYTHMIAS; MANAGEMENT; STROKE; MEN	Objective: To determine whether the use of non-potassium-sparing diuretics and beta-blockers is associated with an excess risk for sudden cardiac death in hypertensive patients. Design: Case-control study. Setting: Rotterdam, the Netherlands. Patients: 257 case-patients who had died suddenly while receiving drug therapy for hypertension and 257 living controls also receiving drug therapy for hypertension. Measurements: Detailed information on medication use and clinical characteristics of all case-patients and controls was collected from the files of general practitioners. Additional information on medication use was obtained from computerized pharmacy records. Results: Patients receiving non-potassium-sparing diuretics had an increased risk for sudden cardiac death (relative risk, 1.8 [95% CI, 1.0 to 3.1]) compared with a reference group treated primarily with potassium-sparing diuretics. The corresponding relative risk for beta-blocker use was 1.7 (CI, 1.1 to 2.6). The use of non-potassium-sparing diuretics without beta-blockers was associated with a higher risk for sudden death (relative risk, 2.2 [CI, 1.1 to 4.6]) than was concomitant use of non-potassium-sparing diuretics and beta-blockers (relative risk, 1.4 [CI, 0.6 to 3.0]). The risk for sudden cardiac death among recipients of non-potassium-sparing diuretics was more pronounced in those who had been receiving the diuretic for less than 1 year and in those aged 75 years or younger. Conclusions: The use of non-potassium-sparing diuretics and beta-blockers is associated with an increased risk for sudden cardiac death. This association may offset part of the mortality benefit of these drugs in the treatment of hypertension.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT GEN PRACTICE, 3000 DR ROTTERDAM, NETHERLANDS; SOC RECH CARDIOL SA, CH-1261 GIVRINS, SWITZERLAND; ERASMUS UNIV ROTTERDAM, SCH MED, ACAD HOSP DIJKZIGT, DEPT INTERNAL MED 1, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	HOES, AW (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1970, JAMA, V213, P1143; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BRESLOW N. E., 1980, STATISTICAL METHODS; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUPPLES LA, 1992, CIRCULATION S1, V85; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HOES AW, 1994, DRUGS, V47, P711, DOI 10.2165/00003495-199447050-00002; HOLME I, 1984, JAMA-J AM MED ASSOC, V251, P1298, DOI 10.1001/jama.251.10.1298; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; LOWN B, 1986, HEART DISEASE TXB CA; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MIALL WE, 1987, NEPHRON S1, V47; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; MYERBURG RJ, 1992, CIRCULATION, V85, P2; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; PAPADEMETRIOU V, 1986, AM HEART J, V111, P1217, DOI 10.1016/0002-8703(86)90041-4; PITT B, 1992, CIRCULATION, V85, P107; POOLEWILSON PA, 1987, J HYPERTENS, V5, pS51; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SINGH S, 1984, CIRCULATION, V70, P996; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603	27	124	125	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1995	123	7					481	+		10.7326/0003-4819-123-7-199510010-00001	http://dx.doi.org/10.7326/0003-4819-123-7-199510010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW495	7661490				2022-12-01	WOS:A1995RW49500001
J	ASPINALL, RL; GOODMAN, NW				ASPINALL, RL; GOODMAN, NW			DENIAL OF EFFECTIVE TREATMENT AND POOR QUALITY OF CLINICAL INFORMATION IN PLACEBO-CONTROLLED TRIALS OF ONDANSETRON FOR POSTOPERATIVE NAUSEA AND VOMITING - A REVIEW OF PUBLISHED TRIALS	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; INTRAVENOUS ONDANSETRON; PREVENTION; SURGERY; METOCLOPRAMIDE; ANESTHESIA; EFFICACY	Objective-To determine how many patients were deprived of treatment by being given placebo as comparator in trials of ondansetron for postoperative nausea and vomiting. Design-Review of published trials of ondansetron during 1991 to July 1994. Setting-Medline search in a university department of anaesthesia. Subjects-8806 patients who had been included in 18 indexed placebo controlled trials of ondansetron as prophylaxis against or treatment of postoperative nausea and vomiting. Results-Five studies (1236 patients) had been published by July 1992. All were placebo controlled trials. By July 1994, 8806 patients had been included in 18 indexed placebo controlled studies of prophylaxis or treatment. Only 462 patients had been in studies that compared ondansetron with other drugs, and there were no indexed comparative trials of treatment of nausea and vomiting. Roughly 2180 patients had been given placebo as prophylaxis and 440 had been given placebo when already experiencing postoperative nausea or vomiting. Conclusions-Around 2620 patients in the reviewed studies were denied existing drugs, which, though not completely effective or without side effects, do bring some relief from postoperative nausea and vomiting. Drug regulatory bodies should collaborate with drug companies to ensure better comparison of new with established drugs. This would avoid placebos being given to more than the fewest patients necessary to confirm effect and would allow doctors to be informed more quickly about relative efficacies.	SOUTHMEAD GEN HOSP,MED SCH UNIT,UNIV DEPT ANAESTHESIA,BRISTOL BS10 5NB,AVON,ENGLAND	Southmead Hospital								ALON E, 1992, ANESTH ANALG, V75, P561; ALTMAN DG, 1991, PRACTICAL STAT MED R, P450; [Anonymous], 1993, LANCET, V341, P1507; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; BODNER M, 1991, ANESTH ANALG, V73, P250; Bohrer H, 1994, Anaesthesiol Reanim, V19, P11; BOULY A, 1992, ANN FR ANESTH, V11, P496, DOI 10.1016/S0750-7658(05)80754-3; CHALMERS J, 1993, DRUG COSTS TREATMENT, P14; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; DERSHWITZ M, 1992, CLIN PHARMACOL THER, V52, P96, DOI 10.1038/clpt.1992.107; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x; GAN TJ, 1994, BRIT J ANAESTH, V72, P544, DOI 10.1093/bja/72.5.544; HELMERS JH, 1992, EUROPEAN J ANAEST S6, V9, P49; HELMERS JHJH, 1993, CAN J ANAESTH, V40, P1155; HERXHEIMER A, 1990, BRIT MED J, V300, P307, DOI 10.1136/bmj.300.6720.307; HERXHEIMER A, 1993, J MED ETHICS, V19, P211, DOI 10.1136/jme.19.4.211; HERXHEIMER A, 1993, J MED ETHICS, V19, P218; ISAL JP, 1992, EUR J ANAESTH     S6, V9, P33; JOSLYN AF, 1994, ANAESTHESIA, V49, P34, DOI 10.1111/j.1365-2044.1994.tb03581.x; KAUFMANN MA, 1994, ANESTH ANALG, V78, P988; KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466; Kovac A, 1992, Eur J Anaesthesiol Suppl, V6, P37; LARIJANI GE, 1991, ANESTH ANALG, V73, P246; LEESER J, 1991, ANESTH ANALG, V72, P751; LITMAN RS, 1994, ANESTH ANALG, V78, P478; MALINS AF, 1994, BRIT J ANAESTH, V72, P231, DOI 10.1093/bja/72.2.231; MCKENZIE R, 1993, J CLIN ANESTH, V5, P30, DOI 10.1016/0952-8180(93)90084-R; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; PEARMAN MH, 1994, ANAESTHESIA, V49, P11, DOI 10.1111/j.1365-2044.1994.tb03577.x; RAPHAEL JH, 1993, BRIT J ANAESTH, V71, P845, DOI 10.1093/bja/71.6.845; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROSEN M, 1994, ANAESTHESIA, V49, P1, DOI 10.1111/j.1365-2044.1994.tb03574.x; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; RUSSELL D, 1992, BRIT J ANAESTH, V69, pS63, DOI 10.1093/bja/69.supplement_1.63S; RUST M, 1994, ANAESTHESIA, V49, P16, DOI 10.1111/j.1365-2044.1994.tb03578.x; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; SUNG YF, 1993, J CLIN ANESTH, V5, P22, DOI 10.1016/0952-8180(93)90083-Q; 1994, 2ND DEP HLTH REP	40	66	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					844	846		10.1136/bmj.311.7009.844	http://dx.doi.org/10.1136/bmj.311.7009.844			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580491	Green Published			2022-12-01	WOS:A1995RY19100022
J	BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P				BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P			MORBIDITY AND SEVERITY OF ILLNESS DURING INTERHOSPITAL TRANSFER - IMPACT OF A SPECIALIZED PEDIATRIC RETRIEVAL TEAM	BRITISH MEDICAL JOURNAL			English	Article							AIRWAY MANAGEMENT; TRANSPORT; STABILIZATION	Objective-To evaluate the morbidity and severity of illness during interhospital transfer of critically ill children by a specialised paediatric retrieval team. Design-Prospective, descriptive study. Setting-Hospitals without paediatric intensive care facilities in and around the London area, and a paediatric intensive care unit at a tertiary centre. Subjects-51 critically ill children transferred to the paediatric intensive care unit. Main outcome measures-Adverse events related to equipment and physiological deterioration during transfer. Paediatric risk of mortality score before and after retrieval. Therapeutic intervention score before and after arrival of retrieval team. Results-Two (4%) patients had preventable physiological deterioration during transport. There were no adverse events related to equipment. Severity of illness decreased during stabilisation and transport by the retrieval team, suggested by the difference between risk of mortality scores before and after retrieval (P < 0.001). The median (range) difference between the two scores was 3.0 (-6 to 17). Interventions during stabilisation by the retrieval team increased, demonstrated by the difference between intervention scores before and after retrieval, median (range) difference between the two scores being 6 (-8 to 38) (P < 0.001). Conclusions-Our study indicates that a specialised paediatric retrieval team can rapidly deliver intensive care to critically iu children awaiting transfer. Such children can be transferred to a paediatric intensive care unit with minimal morbidity and mortality related to transport. There was no deterioration in the clinical condition of most patients during transfer.			BRITTO, J (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,PRAED ST,LONDON W2 1NY,ENGLAND.			Maconochie, Ian/0000-0001-6319-8550; Levin, Michael/0000-0003-2767-6919				BARRY PW, 1994, ARCH DIS CHILD, V71, P8, DOI 10.1136/adc.71.1.8; BLACK RE, 1982, NEW ENGL J MED, V307, P1465, DOI 10.1056/NEJM198212023072342; EDGE WE, 1994, CRIT CARE MED, V22, P1186, DOI 10.1097/00003246-199407000-00023; FULLER J, 1991, CAN J ANAESTH, V38, P252, DOI 10.1007/BF03008156; HENNING R, 1992, MED J AUSTRALIA, V156, P117; KANTER RK, 1989, PEDIATRICS, V84, P43; KANTER RK, 1993, CRIT CARE MED, V21, pS265; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; MACNAB AJ, 1991, J TRAUMA, V31, P205, DOI 10.1097/00005373-199131020-00009; MCCLOSKEY K A, 1991, Emergency Medicine Clinics of North America, V9, P475; MCDONALD TB, 1993, PEDIATR CLIN N AM, V40, P381; ORR RA, 1994, CRIT CARE MED, V22, P101, DOI 10.1097/00003246-199401000-00020; ORR RA, 1992, TXB PEDIATRIC INTENS, P1571; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; ROBB HM, 1992, BRIT J INTENSIVE CAR, V2, P371; WETZEL RC, 1992, TXB PEDIATRIC INTENS, P563; WHITFIELD JM, 1993, PEDIATR EMERG CARE, V9, P69, DOI 10.1097/00006565-199304000-00002; 1995, CRD1 NHS CTR REV DIS; 1993, CARE CRITICALLY ILL	20	96	98	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					836	839		10.1136/bmj.311.7009.836	http://dx.doi.org/10.1136/bmj.311.7009.836			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580489	Green Published			2022-12-01	WOS:A1995RY19100019
J	CLEMESSY, JL; FAVIER, C; BORRON, SW; HANTSON, PE; VICAUT, E; BAUD, FJ				CLEMESSY, JL; FAVIER, C; BORRON, SW; HANTSON, PE; VICAUT, E; BAUD, FJ			HYPOKALEMIA RELATED TO ACUTE CHLOROQUINE INGESTION	LANCET			English	Article							HEART	Large doses of chloroquine can cause poisoning. Our aim was to determine the possible relation between the plasma potassium concentration on admission with the severity of acute chloroquine poisoning and to assess the mechanism of chloroquine-induced hypokalaemia. We conducted a retrospective study of 191 consecutive cases. The main data included the occurrence of vomiting before admission, plasma, and urinary potassium concentration at admission, whole blood chloroquine concentration on admission, haemodynamic parameters and EGG, administration of catecholamines and outcome. Mean blood chloroquine level was 20.1 mu mol/L (SD 14.3) (therapeutic level less than or equal to 6 mu mol/L). Mean plasma potassium concentration was 3.0 mmol/L (0.8) and was lower in the subjects who died than in those who survived (p=0.0003). Plasma potassium varied directly with the systolic blood pressure and inversely with the QRS and QT. Plasma potassium varied inversely with the blood chloroquine (p=0.0001; tau=-0.42). Acute chloroquine intoxication is responsible for a hypokalaemia which correlates with the gravity of the intoxication and may be due to a transport-dependent mechanism. Plasma potassium concentrations should be carefully observed, particularly among patients who also receive catecholamine infusions. We should keep in mind, however, that overzealous repletion invokes the risk of subsequent hyperkalaemia and thus should be avoided.	HOP ST ROCHE,DEPT ANESTHESE REANIMAT,F-06000 NICE,FRANCE; UNIV NICE,HOP ST ROCH,F-06000 NICE,FRANCE; CLIN UNIV ST LUC,B-1200 BRUSSELS,BELGIUM; HOP FERNAND WIDAL,DEPT BIOPHYS,F-75010 PARIS,FRANCE	CHU Nice; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	CLEMESSY, JL (corresponding author), UNIV PARIS 07,HOP FERNAND WIDAL,200 RUE FAUBOURG ST DENIS,F-75010 PARIS,FRANCE.							AGARWAL SL, 1960, ARCH INT PHARMACOD T, V123, P305; ARMITAGE AK, 1957, BRIT J PHARM CHEMOTH, V12, P74, DOI 10.1111/j.1476-5381.1957.tb01365.x; BAUER P, 1991, J TOXICOL-CLIN TOXIC, V29, P23, DOI 10.3109/15563659109038594; BONDURAND A, 1980, AF MED, V179, P239; BRANDFONBRENER M, 1966, J PHARMACOL EXP THER, V154, P250; BRIVET F, 1987, PRESSE MED, V16, P1433; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ENSINGER H, 1992, EUR J ANAESTH, V9, P435; HOLLAND WC, 1957, AM J PHYSIOL, V190, P492, DOI 10.1152/ajplegacy.1957.190.3.492; JAEGER A, 1987, MED TOXICOL ADV DRUG, V2, P242, DOI 10.1007/BF03259868; LECHAT P, 1988, REAN SOINS INTENS ME, V4, P51; LOFASO F, 1987, PRESSE MED, V16, P22; MICHAEL TAD, 1970, AM HEART J, V79, P831, DOI 10.1016/0002-8703(70)90371-6; MONNET R, 1964, Ann Biol Clin (Paris), V22, P429; RAKOTOSON L, 1973, J EUR TOXICOL, V2, P85; RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101; SOFOLA OA, 1983, CLIN PHYSIOL, V3, P75, DOI 10.1111/j.1475-097X.1983.tb00701.x; SOFOLA OA, 1979, CAN J PHARM, V58, P836; Vitris M, 1983, Dakar Med, V28, P593; 1988, REAN SOINS INTENS ME, V4, P43	20	54	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					877	880		10.1016/S0140-6736(95)92711-5	http://dx.doi.org/10.1016/S0140-6736(95)92711-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564673				2022-12-01	WOS:A1995RX19600011
J	FISHERHOCH, SP; TOMORI, O; NASIDI, A; PEREZORONOZ, GI; FAKILE, Y; HUTWAGNER, L; MCCORMICK, JB				FISHERHOCH, SP; TOMORI, O; NASIDI, A; PEREZORONOZ, GI; FAKILE, Y; HUTWAGNER, L; MCCORMICK, JB			REVIEW OF CASES OF NOSOCOMIAL LASSA FEVER IN NIGERIA - THE HIGH PRICE OF POOR MEDICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate two hospital outbreaks of Lassa fever in southern central Nigeria. Setting-Hospitals and clinics in urban and rural areas of Imo State, Nigeria. Design-Medical records were reviewed in hospitals and clinics in both areas. Patients with presumed and laboratory confirmed Lassa fever were identified and contracts traced. Hospital staff, patients, and local residents were questioned, records were carefully reviewed, and serum samples were taken. Serum samples were assayed for antibody specific to Lassa virus, and isolates of Lassa virus were obtained. Results-Among 34 patients with Lassa fever, including 20 patients, six nurses, two surgeons, one physician, and the son of a patient, there were 22 deaths (65% fatality rate). Eleven cases were laboratory confirmed, five by isolation of virus. Most patients had been exposed in hospitals (attack rate in patients in one hospital 55%). Both outbreak hospitals were inadequately equipped and staffed, with poor medical practice. Compelling, indirect evidence revealed that parenteral drug rounds with sharing of syringes, conducted by minimally educated and supervised staff, fuelled the epidemic among patients. Staff were subsequently infected during emergency surgery and while caring for nosocomially infected patients. Conclusion-This outbreak illustrates the high price exacted by the practice of modern medicine, particularly use of parenteral injections and surgery, without due attention to good medical practice. High priority must be given to education of medical staff in developing countries and to guidelines for safe operation of clinics and hospitals. Failure to do so will have far reaching, costly, and ultimately devastating consequences.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,BIOSTAT BRANCH,ATLANTA,GA 30333; UNIV IBADAN,COLL MED,DEPT VIROL,IBADAN,NIGERIA; FED MINIST HLTH,FED EPIDEMIOL DIV,LAGOS,NIGERIA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Ibadan			TOMORI, OYEWALE/GWQ-4419-2022; Fakile, Yetunde F/AAL-7938-2020; TOMORI, OYEWALE/X-3021-2019	TOMORI, OYEWALE/0000-0002-6959-5749; Fakile, Yetunde F/0000-0002-6439-8981; McCormick, Joseph/0000-0002-5844-8102				ALTER MJ, 1991, HEPATOLOGY, V14, P389, DOI 10.1002/hep.1840140228; [Anonymous], 1978, Bull World Health Organ, V56, P271; BOWEN GS, 1975, B WORLD HEALTH ORGAN, V52, P599; CAREY DE, 1972, T ROY SOC TROP MED H, V66, P402, DOI 10.1016/0035-9203(72)90271-4; FABIYI A, 1979, NIGERIAN MED J, V9, P23; FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; JOHNSON KM, 1987, J INFECT DIS, V155, P456, DOI 10.1093/infdis/155.3.456; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; TOMORI O, 1988, AM J TROP MED HYG, V38, P407, DOI 10.4269/ajtmh.1988.38.407	11	225	235	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					857	859		10.1136/bmj.311.7009.857	http://dx.doi.org/10.1136/bmj.311.7009.857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580496	Green Published			2022-12-01	WOS:A1995RY19100029
J	KALKSTEIN, LS				KALKSTEIN, LS			LESSONS FROM A VERY HOT SUMMER	LANCET			English	Editorial Material							IMPACTS				KALKSTEIN, LS (corresponding author), UNIV DELAWARE,CTR CLIMAT RES,DEPT GEOG,NEWARK,DE 19711, USA.							HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Kalkstein L.S., 1993, EXPERIENTIA, V49, P469; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; MCKENZIE D, 1995, NEW SCI, P4; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; IN PRESS ASSESSING I; 1994, NATIONAL CLIMATE SUR; IN PRESS HUMAN HLTH; 1995, MMWR-MORBID MORTAL W, V44, P577	9	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					857	859						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564666				2022-12-01	WOS:A1995RX19600004
J	KAUPPILA, LI				KAUPPILA, LI			CAN LOW-BACK-PAIN BE DUE TO LUMBAR-ARTERY DISEASE	LANCET			English	Note									HELSINKI UNIV,DEPT FORENS MED,SF-00014 HELSINKI,FINLAND	University of Helsinki								CHIRAS J, 1979, J NEURORADIOLOGY, V6, P169; CLUROE AD, 1992, PATHOLOGY, V24, P140, DOI 10.3109/00313029209063161; Crock H.V., 1977, BLOOD SUPPLY VERTEBR; EDWARDS EA, 1955, SURGERY, V38, P950; Kauppila L I, 1993, Duodecim, V109, P1929; KAUPPILA LI, 1995, J BONE JOINT SURG AM, V77A, P26, DOI 10.2106/00004623-199501000-00004; KAUPPILA LI, 1994, ACTA RADIOL, V35, P541; KAUPPILA LI, 1993, J SPINAL DISORD, V6, P124; KAUPPILA LI, 1994, SPINE, V19, P923, DOI 10.1097/00007632-199404150-00010; VIHERT AM, 1976, B WORLD HEALTH ORGAN, V53, P501; WALTER BJ, 1979, GEN PATHOLOGY, P509	11	45	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 30	1995	346	8979					888	889		10.1016/S0140-6736(95)92714-X	http://dx.doi.org/10.1016/S0140-6736(95)92714-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564676				2022-12-01	WOS:A1995RX19600014
J	KUH, D; STIRLING, S				KUH, D; STIRLING, S			SOCIOECONOMIC VARIATION IN ADMISSION FOR DISEASES OF FEMALE GENITAL SYSTEM AND BREAST IN A NATIONAL COHORT AGED 15-43	BRITISH MEDICAL JOURNAL			English	Article							HYSTERECTOMY; WOMEN; EPIDEMIOLOGY; MENORRHAGIA	Objective-To investigate socioeconomic variation among young women in the risk of hospital admission for diseases (including neoplasms) of the female genital system and breast and for the common surgical procedures of dilatation and curettage and hysterectomy. Design-Large nationally representative cohort study with individual records of confirmed admissions to NHS and private hospitals since birth and data on occupational and educational experience. Setting-England, Scotland, and Wales. Patients-General population sample of 1628 women, 1549 of whom had a complete admissions record for the ages of 15-43 years. Main outcome measures-The percentage of women admitted for neoplasms or other diseases of the female genital system and breast or who had dilatation and curettage or hysterectomy between the ages of 15 and 43 years. Results-By the age of 43, 35% of women had been admitted, 17% had undergone dilatation and curettage at least once, and 10% had had a hysterectomy. There were significant inverse educational gradients, the risk of admission increasing more than twofold between the most and least educated women. The differential risk was most striking for disorders of menstruation, in which only 1% of those with the highest educational qualifications and 19% of those with minimal qualifications had been admitted to hospital. There was a significant educational gradient in the hysterectomy rate (from 1% to 15%) and a twofold difference in the risk of dilatation and curettage. There were also significant gradients in risk of admission and of hysterectomy according to partner's social class. Conclusions-Socioeconomic variations in the risk of dilatation and curettage and of hysterectomy were large. Lessening the socioeconomic gradient in risks of admissions and surgery for diseases of the female genital system. and breast, particularly for menstrual disorders, could have important resource implications.			KUH, D (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MED RES COUNCIL NATL SURVEY HLTH DEV,LONDON WC1E 6BT,ENGLAND.		Kuh, Diana/L-6019-2014	Kuh, Diana/0000-0001-7386-2857				BAYER LM, 1981, PRESENT PAST MIDDLE, P55, DOI DOI 10.1016/B978-0-12-233680-5.50009-5; BLAXTER M, 1987, LANCET, V2, P30; BLAXTER N, 1987, HLTH LIFESTYLE SURVE, P5; BOTO TCA, 1990, BRIT J HOSP MED, V44, P93; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Buchan IC, 1973, TIME STUDY CONSULTAT; CARTWRIGHT A, 1976, SOCIOL REV MONOGR, V22, P77; CENTERWALL BS, 1981, AM J OBSTET GYNECOL, V139, P58, DOI 10.1016/0002-9378(81)90412-9; COLE SK, 1971, J OBSTET GYN BR COMM, V78, P933; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; COULTER A, 1986, Q J SOC AFF, V2, P379; COULTER A, 1985, BRIT MED J, V291, P183, DOI 10.1136/bmj.291.6489.183; COULTER A, 1995, EUROPEAN J PUBLIC HL, V5, P123; GATH D, 1987, BMJ-BRIT MED J, V294, P213, DOI 10.1136/bmj.294.6566.213; GOLDBLATT P, 1990, 1971 1981 LONGITUDIN, P163; KJERULFF K, 1993, AM J PUBLIC HEALTH, V83, P106, DOI 10.2105/AJPH.83.1.106; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; Moser K., 1990, LONGITUDINAL STUDY M, P145; PENDLETON DA, 1980, SOC SCI MED, V36, P669; SIDDLE N, 1987, FERTIL STERIL, V47, P94; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; Wadsworth M E, 1987, Paediatr Perinat Epidemiol, V1, P95, DOI 10.1111/j.1365-3016.1987.tb00093.x; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; 1977, MB4 DEP HLTH SOC SEC; 1972, 1968 1972 DEP HLTH S; 1986, MB5 OFF POP CENS SUR; 1994, INPATIENT TREATMENT; 1982, MB1 OFF POP CENS SUR; 1964, 1961 1966 MIN HLTH G; 1972, BURNHAM FURTHER ED C; 1977, 1973 DEP HLTH SOC SE; 1983, MB4 OFF POP CENS SUR	35	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					840	843		10.1136/bmj.311.7009.840	http://dx.doi.org/10.1136/bmj.311.7009.840			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580490	Green Published			2022-12-01	WOS:A1995RY19100021
J	LOCKWOOD, DNJ; SAUNDERSON, PR				LOCKWOOD, DNJ; SAUNDERSON, PR			HARNESSING THE STRENGTHS OF THE LEPROSY PROGRAM TO CONTROL TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article								Tuberculosis remains a leading cause of death in Ethiopia but there is no effective national tuberculosis control programme, By contrast, the leprosy control programme has been very successful, with a 10-fold reduction in the number of leprosy cases requiring antibacterial treatment, though patients with nerve damage require continuing care. The paradox of rising numbers of tuberculosis cases and declining numbers of leprosy cases may be solved by joint leprosy-tuberculosis clinics. The strengths of leprosy fieldworkers in control management, case holding, and compliance can be harnessed in developing an effective tuberculosis control programme. Implementing a joint programme in Ethiopia may be beneficial not only for tuberculosis patients but also for leprosy patients, who are thus brought closer to general medical services.	ALERT,LEPROSY & TB CONTROL PROGRAMME,ADDIS ABABA,ETHIOPIA				Saunderson, Paul/AAH-8770-2021					1994, HLTH INDICATORS 1994	1	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					862	863		10.1136/bmj.311.7009.862	http://dx.doi.org/10.1136/bmj.311.7009.862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580498	Green Published			2022-12-01	WOS:A1995RY19100031
J	MELE, A; STROFFOLINI, T; CATAPANO, R; PALUMBO, F; MOIRAGHI, A; NOVACO, F				MELE, A; STROFFOLINI, T; CATAPANO, R; PALUMBO, F; MOIRAGHI, A; NOVACO, F			INCIDENCE OF TRANSFUSION-ASSOCIATED BHEPATITIS AND NON-AHEPATITIS, NON-B-HEPATITIS IN ITALY	BRITISH MEDICAL JOURNAL			English	Article									IST SUPER SANITA,EPIDEMIOL & BIOSTAT LAB,I-00161 ROME,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO SANITA PUBBL,ROME,ITALY; ASSESSORATO SANITA REG CAMPANIA,NAPLES,ITALY; UNIV TURIN,DIPARTIMENTO SANITA PUBBL,TURIN,ITALY; REG EMILIA ROMAGNA,ASSESSORATO SANITA,BOLOGNA,ITALY	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Turin								CAMPS J, 1994, HEPATOLOGY, V20, pA200; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; MELE A, 1986, European Journal of Epidemiology, V2, P300, DOI 10.1007/BF00419494; THIERS V, 1988, LANCET, V2, P1273; 1991, LANCET, V338, P1040	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					846	847		10.1136/bmj.311.7009.846	http://dx.doi.org/10.1136/bmj.311.7009.846			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580492	Green Published			2022-12-01	WOS:A1995RY19100023
J	MULDER, D; NUNN, A; KAMALI, A; KENGEYAKAYONDO, J				MULDER, D; NUNN, A; KAMALI, A; KENGEYAKAYONDO, J			DECREASING HIV-1 SEROPREVALENCE IN YOUNG-ADULTS IN A RURAL UGANDAN COHORT	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; INFECTION; ZAIRE	Objective-To assess the trend in HIV-1 seroprevalence in an adult population in Uganda. Design-An observational cohort study with four year follow up. Setting-A cluster of 15 villages in rural Uganda. Subjects-All residents of the 15 villages-about 10 000 people. Main outcome measure-Prevalence of HIV-1 infection as assessed by enzyme immunoassay. Results-During the five year period the overall standardised seroprevalence of HIV-1 showed little change; 8.2% in 1990, 7.6% in 1994. Among males aged 13-24 years the prevalence decreased from 3.4% to 1.0% (P for trend < 0.001); among females of the same age the corresponding values were 9.9% and 7.3%. The decrease was greatest in males aged 20-24 years and females aged 13-19 years. Conclusion-This is the first report of a decline in HIV-1 prevalence among young adults in a general population in sub-Saharan Africa with high overall HIV-1 prevalence. It is too early to conclude that the epidemic in this population is in decline, but the results of this study should be reason for some cautious optimism and encourage the vigorous pursuit of AIDS control measures.	MRC PROGRAMME AIDS UGANDA,ENTEBBE,UGANDA; UGANDA VIRUS RES INST,ENTEBBE,UGANDA	Uganda Virus Research Institute				Nunn, Andrew/0000-0002-9158-4595				ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BATTER V, 1994, AIDS, V8, P811, DOI 10.1097/00002030-199406000-00014; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HEYWARD WL, 1994, AIDS, V8, P1285, DOI 10.1097/00002030-199409000-00011; KARITA E, 1993, INT J STD AIDS, V4, P211, DOI 10.1177/095646249300400406; KENGEYAKAYONDO JF, 1995, ANN TROP PAEDIATR, V15, P115, DOI 10.1080/02724936.1995.11747758; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MAGAZANI K, 1993, J ACQ IMMUN DEF SYND, V6, P419; MALAMBA SS, 1994, AIDS, V8, P253, DOI 10.1097/00002030-199402000-00014; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NUNN AJ, 1994, AIDS, V8, P81, DOI 10.1097/00002030-199401000-00012; NUNN AJ, 1994, METHOD INFORM MED, V33, P170; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; NUNN AJ, 1995, AIDS, V9, P503, DOI 10.1097/00002030-199509050-00013; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SOKAL DC, 1993, AIDS, V7, P1481, DOI 10.1097/00002030-199311000-00012; WAGNER HU, 1994, INT J STD AIDS, V5, P332, DOI 10.1177/095646249400500509; WAGNER HU, 1993, AIDS, V7, P1461, DOI 10.1097/00002030-199311000-00009; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; 1994, WHOGPATCOSEF944; 1995, 1995 MIN HLTH SURV R	23	93	93	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					833	836		10.1136/bmj.311.7009.833	http://dx.doi.org/10.1136/bmj.311.7009.833			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580488	Green Published			2022-12-01	WOS:A1995RY19100018
J	RUIZ, J; BLANCHE, H; JAMES, RW; GARIN, MCB; VAISSE, C; CHARPENTIER, G; COHEN, N; MORABIA, A; PASSA, P; FROGUEL, P				RUIZ, J; BLANCHE, H; JAMES, RW; GARIN, MCB; VAISSE, C; CHARPENTIER, G; COHEN, N; MORABIA, A; PASSA, P; FROGUEL, P			GLN-ARG192 POLYMORPHISM OF PARAOXONASE AND CORONARY HEART-DISEASE IN TYPE-2 DIABETES	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; SERUM; MELLITUS	Paraoxonase is a high-density-lipoprotein-associated enzyme capable of hydrolysing lipid peroxides. Thus it might protect lipoproteins from oxidation. It has two isoforms, which arise from a glutamine (A isoform) to arginine (B isoform) interchange at position 199. The relevance of this polymorphism to coronary heart disease (CHD) in non-insulin-dependent diabetic patients was investigated in case-control study. Of the 434 patients, 171 had confirmed coronary artery disease; the other 263 had no history of such disease. The B allele and AB+BB genotypes were associated with an increased risk of coronary heart disease. Compared with subjects homozygous for the A allele (AA genotype), the odds ratio of CHD for subjects homozygous for the B allele was 2.5 (95% CI 1.2-5.3) and that for those heterozygous for the B allele was 1.6 (95% CI 1.1-2.4), suggesting a codominant effect on cardiovascular risk. When subjected to multivariate analysis, the B allele remained significantly associated with CHD (odds ratio 1.94, p=0.03). The paraoxonase gene polymorphism is thus an independent cardiovascular risk factor in non-insulin-dependent diabetic patients. A possible explanation for this finding is that activity of the paraoxonase B isotype does not protect well against lipid oxidation, a major atherogenic pathway.	UNIV HOSP GENEVA, DIV CLIN EPIDEMIOL, GENEVA, SWITZERLAND; FDN JEAN DAUSSET, CEPH, PARIS, FRANCE; UNIV HOSP GENEVA, DIV ENDOCRINOL & DIABETOL, GENEVA, SWITZERLAND; HOP CORBEIL, CORBEIL ESSONNES, FRANCE; ST LOUIS HOSP, SERV DIABETOL, PARIS, FRANCE; INST PASTEUR, CNRS, EP 10, LILLE, FRANCE	University of Geneva; Foundation Jean Dausset-CEPH; University of Geneva; Centre Hospitalier Sud Francilien; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			FROGUEL, Philippe/O-6799-2017; Vaisse, Christian/F-1067-2011	FROGUEL, Philippe/0000-0003-2972-0784; 				ASSMANN G, 1988, AM HEART J, V116, P1713, DOI 10.1016/0002-8703(88)90220-7; BELLOMO G, 1995, DIABETES, V44, P60, DOI 10.2337/diabetes.44.1.60; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; CHISOLM GM, 1992, DIABETES, V41, P61, DOI 10.2337/diab.41.2.S61; GARIN MCB, 1994, BIOCHEM J, V304, P549, DOI 10.1042/bj3040549; HAFFNER SM, 1995, DIABETES CARE, V18, P646, DOI 10.2337/diacare.18.5.646; HEGELE RA, 1995, ARTERIOSCL THROM VAS, V15, P89, DOI 10.1161/01.ATV.15.1.89; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; LORENTZ K, 1979, CLIN CHEM, V25, P1714; LYONS TJ, 1991, DIABETIC MED, V8, P411, DOI 10.1111/j.1464-5491.1991.tb01624.x; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; MACKNESS MI, 1991, ATHEROSCLEROSIS, V86, P193, DOI 10.1016/0021-9150(91)90215-O; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; NISHIGAKI I, 1981, BIOCHEM MED METAB B, V25, P373, DOI 10.1016/0006-2944(81)90096-X; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; RUIZ J, 1994, P NATL ACAD SCI USA, V91, P3662, DOI 10.1073/pnas.91.9.3662; Sambrook J., 1989, MOL CLONING LAB MANU; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; TAS S, 1994, LANCET, V343, P1194, DOI 10.1016/S0140-6736(94)92402-3; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; WATSON AD, 1994, CIRCULATION, V90, P353; 1985, WHO TECH REP SER, V727	26	326	344	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 30	1995	346	8979					869	872		10.1016/S0140-6736(95)92709-3	http://dx.doi.org/10.1016/S0140-6736(95)92709-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX196	7564671				2022-12-01	WOS:A1995RX19600009
J	SHEPHERD, RM; DENT, THS; ALEXANDER, GJM; LONDON, M				SHEPHERD, RM; DENT, THS; ALEXANDER, GJM; LONDON, M			PREVALENCE OF ALCOHOL HISTORIES IN MEDICAL AND NURSING NOTES OF PATIENTS ADMITTED WITH SELF-POISONING	BRITISH MEDICAL JOURNAL			English	Article									FULBOURNE HOSP,CAMBRIDGE & HUNTINGDON HLTH COMMISS,DEPT HLTH POLICY & PUBL HLTH,CAMBRIDGE CB1 5EF,ENGLAND; DRINKING PROBLEMS SERV,CAMBRIDGE CB1 3DF,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								DALY M, 1988, CURRENT RES SUICIDE; FREEMANTLE N, 1993, BRIEF INTERVENTIONS; GROOTENHUIS M, 1994, BRIT J PSYCHIAT, V165, P73, DOI 10.1192/bjp.165.1.73; PATEL AR, 1975, BRIT MED J, V2, P426, DOI 10.1136/bmj.2.5968.426; 1992, HLTH NATION STRATEGY	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					847	847		10.1136/bmj.311.7009.847	http://dx.doi.org/10.1136/bmj.311.7009.847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580493	Green Published			2022-12-01	WOS:A1995RY19100024
J	BUMP, NJ; HACKETT, M; HUGUNIN, M; SESHAGIRI, S; BRADY, K; CHEN, P; FERENZ, C; FRANKLIN, S; GHAYUR, T; LI, P; LICARI, P; MANKOVICH, J; SHI, LF; GREENBERG, AH; MILLER, LK; WONG, WW				BUMP, NJ; HACKETT, M; HUGUNIN, M; SESHAGIRI, S; BRADY, K; CHEN, P; FERENZ, C; FRANKLIN, S; GHAYUR, T; LI, P; LICARI, P; MANKOVICH, J; SHI, LF; GREENBERG, AH; MILLER, LK; WONG, WW			INHIBITION OF ICE FAMILY PROTEASES BY BACULOVIRUS ANTIAPOPTOTIC PROTEIN P35	SCIENCE			English	Article							CELL-DEATH; APOPTOSIS; GENE; EXPRESSION; ENZYME	The baculovirus antiapoptotic protein p35 inhibited the proteolytic activity of human interleukin-1 beta converting enzyme (ICD) and three of its homologs in enzymatic assays. Coexpression of p35 prevented the autoproteolytic activation on ICE from its precursor form and blocked ICE-induced apoptosis, Inhibition of enzymatic activity correlated with the cleavage of p35 and the formation of a stable ICE-p35 complex. The ability of p35 to block apoptosis in different pathways and in distantly related organisms suggests a central and conserved role for ICE-like proteases in the induction of apoptosis.	BASF BIORES CORP,WORCESTER,MA 01605; UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA	BASF; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Manitoba				Seshagiri, Somasekar/0000-0003-4272-6443	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038262] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38262] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUMP N, UNPUB; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; HAY BA, 1994, DEVELOPMENT, V120, P2121; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORRIS TD, 1992, J VIROL, V66, P7397, DOI 10.1128/JVI.66.12.7397-7405.1992; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SESHAGIRI S, UNPUB; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	27	584	606	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1885	1888		10.1126/science.7569933	http://dx.doi.org/10.1126/science.7569933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569933				2022-12-01	WOS:A1995RX19400043
J	DANIAL, NN; PERNIS, A; ROTHMAN, PB				DANIAL, NN; PERNIS, A; ROTHMAN, PB			JAK-STAT SIGNALING INDUCED BY THE V-ABL ONCOGENE	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; MURINE LEUKEMIA-VIRUS; ABELSON VIRUS; BONE-MARROW; CELL-LINE; MYELOID CELLS; TRANSFORMATION; GROWTH; DEPENDENCE; MECHANISM	The effect of the v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) on the Jak-STAT pathway of cytokine signal transduction was investigated. In murine pre-B lymphocytes transformed with A-MuLV, the Janus kinases (Jaks) Jak1 and Jak3 exhibited constitutive tyrosine kinase activity, acid the STAT proteins (signal transducers and activators of transcription) normally activated by interleukin-4, and interleukin-7 were tyrosine-phosphorylated in the absence of these cytokines. Coimmunoprecipitation experiments revealed that in these cells v-Abl was physically associated with Jak1 and Jak3. Inactivation of v-Abl tyrosine kinase in a pre-B cell line transformed with a temperature-sensitive mutant of v-abl resulted in abrogation of constitutive Jak-STAT signaling. A direct link may exist between transformation by v-abl and cytokine signal transduction.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,INTEGRATED PROGRAM MOLEC CELLULAR & BIOPHYS STUD,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NIAID NIH HHS [AI 33540-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033540] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DANIAL NN, UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; Hariharan I K, 1988, Oncogene Res, V3, P387; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; QUELLE FW, 1995, MOL CELL BIOL, V15, P336; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; WHITLOCK CA, 1983, CELL, V32, P903, DOI 10.1016/0092-8674(83)90075-2; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	36	314	319	1	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1875	1877		10.1126/science.7569929	http://dx.doi.org/10.1126/science.7569929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569929				2022-12-01	WOS:A1995RX19400039
J	DESCOTEAUX, A; LUO, Y; TURCO, SJ; BEVERLEY, SM				DESCOTEAUX, A; LUO, Y; TURCO, SJ; BEVERLEY, SM			A SPECIALIZED PATHWAY AFFECTING VIRULENCE GLYCOCONJUGATES OF LEISHMANIA	SCIENCE			English	Article							SECRETED ACID-PHOSPHATASE; MONOCLONAL-ANTIBODIES; DONOVANI PROMASTIGOTES; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; PROTEINS; EXPRESSION; EPITOPES; MUTANT	For virulence and transmission, the protozoan Leishmania must assemble a complex glycolipid on the cell surface, the lipophosphoglycan (LPG). Functional complementation identified the gene LPG2, which encodes an integral Golgi membrane protein implicated in intracellular compartmentalization of LPG biosynthesis. Ipg2(-) mutants lack only characteristic disaccharide-phosphate repeats, normally present on both LPG and other surface or secreted molecules considered critical for infectivity. In contrast, a related yeast gene, VAN2/VRG4, is essential and required for general Golgi function. These results suggest that LPG2 participates in a specialized virulence pathway, which may offer an attractive target for chemotherapy.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40546	Harvard University; Harvard Medical School; University of Kentucky				Beverley, Stephen/0000-0001-5319-0811	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BATES PA, 1989, EXP PARASITOL, V68, P335, DOI 10.1016/0014-4894(89)90115-X; BATES PA, 1990, MOL BIOCHEM PARASIT, V39, P247, DOI 10.1016/0166-6851(90)90063-R; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CAPPAI R, 1994, PARASITOLOGY, V108, P397, DOI 10.1017/S0031182000075946; CARVER MA, 1992, ARCH BIOCHEM BIOPHYS, V295, P309, DOI 10.1016/0003-9861(92)90523-Y; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DESCOTEAUX A, 1993, METHODS MOL GENETICS, V1, P22; DESCOTEAUX A, UNPUB; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; FLINN HM, 1994, MOL BIOCHEM PARASIT, V65, P259, DOI 10.1016/0166-6851(94)90077-9; GUEIROSFILHO FJ, UNPUB; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HUANG CC, 1993, J BIOL CHEM, V268, P24060; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1994, PARASITOLOGY, V108, pS63, DOI 10.1017/S0031182000075739; JAFFE CL, 1990, J IMMUNOL, V144, P699; JARDIM A, 1991, J IMMUNOL, V147, P3538; JARDIM A, 1995, BIOCHEM J, V305, P305; KANIKENNULAT C, 1995, GENETICS, V140, P933; KATAKURA K, 1988, INFECT IMMUN, V56, P2856, DOI 10.1128/IAI.56.11.2856-2860.1988; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVELACE JK, 1987, MOL BIOCHEM PARASIT, V22, P19, DOI 10.1016/0166-6851(87)90065-X; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCNEELY T B, 1990, Glycobiology, V1, P63, DOI 10.1093/glycob/1.1.63; MCNEELY TB, 1990, J IMMUNOL, V144, P2475; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; POSTER JB, UNPUB; REEVES P, 1994, BACTERIAL CELL WALL, P281; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SACKS DL, 1994, PARASITOLOGY, V108, pS55, DOI 10.1017/S0031182000075727; SMITH DF, 1995, GLYCOBIOLOGY, V5, P161, DOI 10.1093/glycob/5.2.161; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.micro.46.1.65; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5	43	138	143	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1869	1872		10.1126/science.7569927	http://dx.doi.org/10.1126/science.7569927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569927				2022-12-01	WOS:A1995RX19400037
J	GARDNER, KA; MAYER, JM				GARDNER, KA; MAYER, JM			UNDERSTANDING C-H BOND OXIDATIONS - H-CENTER-DOT AND H- TRANSFER IN THE OXIDATION OF TOLUENE BY PERMANGANATE	SCIENCE			English	Article							AQUEOUS-SOLUTION; RATE CONSTANTS; METAL-OXIDES; RADICALS; HYDROXYLASE; MECHANISM; REDUCTION; ACID	The oxidation of toluene by permanganate has been studied as a model for the oxidation of C-H bonds by metal reagents, metalloenzymes, and metal oxide surfaces. In water, the reaction proceeds by hydride (H-) transfer from toluene to a permanganate oxygen, whereas in toluene solution, permanganate abstracts a hydrogen atom (H-.). The ability of permanganate to abstract a hydrogen atom is rationalized on the basis of the strong O-H bond formed on H addition to permanganate. This approach allows understanding and prediction of the rates of hydrogen atom transfer from substrates to metal active sites.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								AVILA DV, 1993, J AM CHEM SOC, V115, P466, DOI 10.1021/ja00055a015; BERKOWITZ J, 1994, J PHYS CHEM-US, V98, P2744, DOI 10.1021/j100062a009; BORDWELL FG, 1994, J AM CHEM SOC, V116, P6605, DOI 10.1021/ja00094a015; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRAUMAN JI, 1970, J AM CHEM SOC, V92, P329, DOI 10.1021/ja00705a642; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CENTI G, 1988, CHEM REV, V88, P55, DOI 10.1021/cr00083a003; COLUSSI AJ, 1988, CHEM KINETICS SMALL, P33; COOK GK, 1994, J AM CHEM SOC, V116, P8859, DOI 10.1021/ja00098a077; COOK GK, 1994, J AM CHEM SOC, V116, P1855, DOI 10.1021/ja00084a029; CULLIS CF, 1955, J CHEM SOC, P555, DOI 10.1039/jr9550000555; DEMONTELLANO PRO, 1985, CYTOCHROME P450 STRU; Exner O., 1978, CORRELATION ANAL CHE, P439; GARDNER KA, UNPUB; HOWARD JA, 1984, LANDOLTBORNSTEIN D, V13; INGOLD KU, 1973, FREE RADICALS, V1, P67; JONSSON M, 1994, J AM CHEM SOC, V116, P1423, DOI 10.1021/ja00083a030; KARAMAN H, 1984, J ORG CHEM, V49, P4509, DOI 10.1021/jo00197a037; Knox J. H., 1968, OXIDATION ORGANIC CO, P1; Kochi J.K., 1973, FREE RADICALS; Latimer W. M., 1952, OXIDATION STATES ELE; LEE DG, 1993, J AM CHEM SOC, V115, P11231, DOI 10.1021/ja00077a023; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; MAILLARD B, 1983, J AM CHEM SOC, V105, P5095, DOI 10.1021/ja00353a039; PEREZBENITO JF, 1992, J COLLOID INTERF SCI, V152, P70, DOI 10.1016/0021-9797(92)90009-B; PEREZBENITO JF, 1985, CAN J CHEM, V63, P1275; PEREZBENITO JF, 1979, J CHEM SOC CHEM COMM, V18, P69; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSS SD, 1975, ANODIC OXYDATION, P83; RUCHARDT C, 1992, ANGEW CHEM INT EDIT, V31, P1523, DOI 10.1002/anie.199215231; RUSSELL GA, 1973, FREE RADICALS, V1, P275; SCHMIDT HJ, 1979, ANGEW CHEM INT EDIT, V18, P68, DOI 10.1002/anie.197900681; STEENKEN S, 1982, J AM CHEM SOC, V104, P1244, DOI 10.1021/ja00369a017; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART R, 1964, OXIDATION MECHANISMS; THOMPSON MS, 1982, J AM CHEM SOC, V104, P5070, DOI 10.1021/ja00383a013; TONG YD, 1991, J AM CHEM SOC, V113, P4741, DOI 10.1021/ja00013a005; WATANABE Y, 1992, ENZYMES, V20, P405; WIBERG KB, 1963, J AM CHEM SOC, V85, P3487, DOI 10.1021/ja00904a040	39	218	221	2	104	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1849	1851		10.1126/science.7569922	http://dx.doi.org/10.1126/science.7569922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569922				2022-12-01	WOS:A1995RX19400030
J	JAYARAMAN, V; RODGERS, KR; MUKERJI, I; SPIRO, TG				JAYARAMAN, V; RODGERS, KR; MUKERJI, I; SPIRO, TG			HEMOGLOBIN ALLOSTERY - RESONANCE RAMAN-SPECTROSCOPY OF KINETIC INTERMEDIATES	SCIENCE			English	Article							HISTIDINE LINKAGE; PHOTOLYSIS; DYNAMICS; COOPERATIVITY; RELAXATION; BINDING	The end states, R and T, of the allosteric transition in hemoglobin (Hb) are structurally well characterized, but there is little information on intermediate structures along the allosteric pathway. These intermediates were examined by means of time-resolved resonance Raman spectroscopy in the nanosecond-to-microsecond interval after HbCO photolysis. Complementary spectra of the heme group and of the tyrosine and tryptophan residues were recorded during laser excitation at 436 and 230 nanometers. These spectra reveal a sequence of interleaved tertiary and quaternary motions during the photocycle, motions involving the proximal and distal helices, and the alpha(1) beta(2) subunit interface. This sequence leads to a modified form of the T state, in which the alpha(1) beta(2) interface is deformed as a result of two carbon monoxide molecules binding to the same dimer within the tetramer.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; N DAKOTA STATE UNIV,DEPT CHEM,FARGO,ND 58105; WESLEYAN UNIV,DEPT BIOCHEM & MOLEC BIOL,MIDDLETOWN,CT 06457	Princeton University; North Dakota State University Fargo; Wesleyan University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BANGCHAROENPAUR.O, 1984, J AM CHEM SOC, V106, P5688; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; GELLIN BR, 1983, J MOL BIOL, V171, P489; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; JAYARAMAN V, 1995, BIOCHEMISTRY-US, V34, P4511, DOI 10.1021/bi00014a002; JAYARAMAN V, 1993, BIOCHEMISTRY-US, V32, P4547, DOI 10.1021/bi00068a009; KAMINAKA S, 1990, J AM CHEM SOC, V112, P23, DOI 10.1021/ja00157a006; KAMINAKA S, 1992, J AM CHEM SOC, V114, P3256, DOI 10.1021/ja00035a015; KERR EA, 1987, BIOL APPLICATIONS RA, V3, P39; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LOCKE B, 1991, CHEM PHYS, V158, P409, DOI 10.1016/0301-0104(91)87080-F; MIURA S, 1982, BIOCHEMISTRY-US, V21, P6280, DOI 10.1021/bi00267a037; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PERUTZ MF, 1990, MECHANISMS COOPERATI; PIN S, 1986, CHEM PHYS LETT, V128, P79, DOI 10.1016/0009-2614(86)80149-X; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEAU DL, 1987, BIOL APPLICATIONS RA, V3, P133; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SCHUMACHER MA, 1995, NATURE, V375, P84, DOI 10.1038/375084a0; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701	33	171	172	2	37	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1843	1848		10.1126/science.7569921	http://dx.doi.org/10.1126/science.7569921			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569921				2022-12-01	WOS:A1995RX19400029
J	JOHNSON, CH; KNIGHT, MR; KONDO, T; MASSON, P; SEDBROOK, J; HALEY, A; TREWAVAS, A				JOHNSON, CH; KNIGHT, MR; KONDO, T; MASSON, P; SEDBROOK, J; HALEY, A; TREWAVAS, A			CIRCADIAN OSCILLATIONS OF CYTOSOLIC AND CHLOROPLASTIC FREE CALCIUM IN PLANTS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; CYTOPLASMIC CALCIUM; GENE-EXPRESSION; PROTEIN-KINASE; TRANSFORMATION; PHYTOCHROME; ARABIDOPSIS; CHANNELS; CELLS; PROTOPLASTS	Tobacco and Arabidopsis plants, expressing a transgene for the calcium-sensitive luminescent protein apoaequorin, revealed circadian oscillations in free cytosolic calcium that can be phase-shifted by light-dark signals. When apoaequorin was targeted to the chloroplast, circadian chloroplast calcium rhythms were likewise observed after transfer of the seedlings to constant darkness. Circadian oscillations in free calcium concentrations can be expected to control many calcium-dependent enzymes and processes accounting for circadian outputs. Regulation of calcium flux is therefore fundamental to the organization of circadian systems.	UNIV OXFORD,DEPT PLANT SCI,OXFORD OX1 3RB,ENGLAND; NAGOYA UNIV,FAC SCI,DEPT BIOL,NAGOYA,AICHI 46401,JAPAN; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV EDINBURGH,INST CELL & MOLEC BIOL,EDINBURGH EH9 3JH,MIDLOTHIAN,SCOTLAND	University of Oxford; Nagoya University; University of Wisconsin System; University of Wisconsin Madison; University of Edinburgh	JOHNSON, CH (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.		Johnson, Carl H/I-4655-2014	Knight, Marc/0000-0002-4830-8608	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH043836, K02MH001179, R01MH043836] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48053] Funding Source: Medline; NIMH NIH HHS [MH43836, MH01179] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMON DI, 1949, PLANT PHYSIOL, V24, P1; ANDERSON S, 1986, BIOCHEM J, V240, P709, DOI 10.1042/bj2400709; BRUSSLAN JA, 1992, P NATL ACAD SCI USA, V89, P7791, DOI 10.1073/pnas.89.16.7791; Campbell A.K, 1983, INTRACELLULAR CALCIU; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Edmunds LN, 1988, CELLULAR MOL BASES B; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GOMEZ LA, 1995, PHOTOCHEM PHOTOBIOL, V61, P210, DOI 10.1111/j.1751-1097.1995.tb03963.x; GOTO K, 1985, SCIENCE, V228, P1284, DOI 10.1126/science.2988128; GUESZ ME, 1994, NEUROSCI BIOBEHAV RE, V18, P555; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HETHERINGTON A, 1982, FEBS LETT, V145, P67, DOI 10.1016/0014-5793(82)81208-8; HORWITZ BA, 1978, PLANT SCI LETT, V13, P9, DOI 10.1016/0304-4211(78)90058-5; JOHANNES E, 1991, BIOESSAYS, V13, P331, DOI 10.1002/bies.950130704; Johnson Carl Hirschie, 1994, Seminars in Cell Biology, V5, P355, DOI 10.1006/scel.1994.1042; KIM HY, 1993, SCIENCE, V260, P960, DOI 10.1126/science.260.5110.960; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KNIGHT MR, 1993, J CELL BIOL, V121, P83, DOI 10.1083/jcb.121.1.83; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; LI HM, 1991, PLANT PHYSIOL, V96, P720, DOI 10.1104/pp.96.3.720; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MALHO R, 1993, PLANT J, V5, P331; MELKONIAN B, 1990, CURR T PL B, V9, P38; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MILLER AJ, 1987, NATURE, V326, P397, DOI 10.1038/326397a0; MOURIOUX G, 1981, PLANT PHYSIOL, V67, P470, DOI 10.1104/pp.67.3.470; NAKASHIMA H, 1984, PLANT PHYSIOL, V74, P268, DOI 10.1104/pp.74.2.268; NEGRUTIU I, 1987, PLANT MOL BIOL, V8, P363, DOI 10.1007/BF00015814; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OKAZAKI Y, 1990, J MEMBRANE BIOL, V114, P189, DOI 10.1007/BF01869213; PIERSON ES, 1994, PLANT CELL, V6, P1815, DOI 10.1105/tpc.6.12.1815; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; ROENNEBERG T, 1993, NATURE, V362, P362, DOI 10.1038/362362a0; Roux Stanley J., 1994, P187; SATTER RL, 1981, ANNU REV PLANT PHYS, V32, P83, DOI 10.1146/annurev.pp.32.060181.000503; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHIMOMURA O, 1993, BIOCHEM J, V296, P549, DOI 10.1042/bj2960549; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; TSUKAYA H, 1991, PLANT PHYSIOL, V97, P1414, DOI 10.1104/pp.97.4.1414; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	46	271	289	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1863	1865		10.1126/science.7569925	http://dx.doi.org/10.1126/science.7569925			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569925				2022-12-01	WOS:A1995RX19400035
J	MUTHUPILLAI, R; LOMAS, DJ; ROSSMAN, PJ; GREENLEAF, JF; MANDUCA, A; EHMAN, RL				MUTHUPILLAI, R; LOMAS, DJ; ROSSMAN, PJ; GREENLEAF, JF; MANDUCA, A; EHMAN, RL			MAGNETIC-RESONANCE ELASTOGRAPHY BY DIRECT VISUALIZATION OF PROPAGATING ACOUSTIC STRAIN WAVES	SCIENCE			English	Article							BLOOD-FLOW; TISSUES	A nuclear magnetic resonance imaging (MRI) method is presented for quantitatively mapping the physical response of a material to harmonic mechanical excitation. The resulting images allow calculation of regional mechanical properties. Measurements of shear modulus obtained with the MRI technique in gel materials correlate with independent measurements of static shear modulus. The results indicate that displacement patterns corresponding to cyclic displacements smaller than 200 nanometers can be measured. The findings suggest the feasibility of a medical imaging technique for delineating elasticity and other mechanical properties of tissue.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; ADDENBROOKES HOSP, DEPT RADIOL, CAMBRIDGE, ENGLAND	Mayo Clinic; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Muthupillai, Raja/D-6544-2017	Muthupillai, Raja/0000-0001-5041-2562; LOMAS, David/0000-0003-2904-8617	NCI NIH HHS [CA51124] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRYANT DJ, 1984, J COMPUT ASSIST TOMO, V8, P588, DOI 10.1097/00004728-198408000-00002; BURLEW MM, 1980, RADIOLOGY, V134, P517, DOI 10.1148/radiology.134.2.7352242; DUMOULIN CL, 1986, RADIOLOGY, V161, P717, DOI 10.1148/radiology.161.3.3786721; FUNG YC, 1981, BIOMECHANICS MECHANI, P35; HAHN EL, 1960, J GEOPHYS RES, V65, P776, DOI 10.1029/JZ065i002p00776; HUANG SR, 1990, THESIS U ROCHESTER R; KNUTSSON H, 1994, IEEE IMAGE PROC, P36, DOI 10.1109/ICIP.1994.413270; KOLSKY H, 1963, STRESS WAVES SOLIDS, P131; KUMAR A, 1975, J MAGN RESON, V18, P69, DOI 10.1016/0022-2364(75)90224-3; LEWA CJ, 1995, JMRI-J MAGN RESON IM, V5, P242, DOI 10.1002/jmri.1880050221; MADSEN EL, 1983, J ACOUST SOC AM, V74, P1346, DOI 10.1121/1.390158; MORAN P R, 1982, Magnetic Resonance Imaging, V1, P197; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; PARKER KJ, 1990, ULTRASOUND MED BIOL, V16, P241, DOI 10.1016/0301-5629(90)90003-U; PELC LR, 1992, RADIOLOGY, V185, P809, DOI 10.1148/radiology.185.3.1438767; PELC NJ, 1991, JMRI-J MAGN RESON IM, V1, P405, DOI 10.1002/jmri.1880010404; PLEWES DB, 1994, P SOC MAGN RESON, V1, P410; VANDIJK P, 1984, J COMPUT ASSIST TOMO, V8, P429, DOI 10.1097/00004728-198406000-00012	18	1498	1552	3	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 29	1995	269	5232					1854	1857		10.1126/science.7569924	http://dx.doi.org/10.1126/science.7569924			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569924				2022-12-01	WOS:A1995RX19400032
J	OHNO, H; STEWART, J; FOURNIER, MC; BOSSHART, H; RHEE, I; MIYATAKE, S; SAITO, T; GALLUSSER, A; KIRCHHAUSEN, T; BONIFACINO, JS				OHNO, H; STEWART, J; FOURNIER, MC; BOSSHART, H; RHEE, I; MIYATAKE, S; SAITO, T; GALLUSSER, A; KIRCHHAUSEN, T; BONIFACINO, JS			INTERACTION OF TYROSINE-BASED SORTING SIGNALS WITH CLATHRIN-ASSOCIATED PROTEINS	SCIENCE			English	Article							TRANS-GOLGI NETWORK; PLASMA-MEMBRANE; COATED VESICLES; CYTOPLASMIC DOMAIN; INVITRO BINDING; RECEPTOR; SEQUENCE; CLONING; TGN38; MOTIF	Tyrosine-based signals within the cytoplasmic domain of integral membrane proteins mediate clathrin-dependent protein sorting in the endocytic and secretory pathways. A yeast two-hybrid system was used to identify proteins that bind to tyrosine-based signals. The medium chains (mu(1) and mu(2)) of two clathrin-associated protein complexes (AP-1 and AP-2, respectively) specifically interacted with tyrosine-based signals of several integral membrane proteins. The interaction was confirmed by in vitro binding assays. Thus, it is likely that the medium chains serve as signal-binding components of the clathrin-dependent sorting machinery.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC GENET,CHIBA 260,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Chiba University			Yang, Chen/G-1379-2010; Ohno, Hiroshi/L-7899-2014; Saito, Takashi/C-9684-2009; Bosshart, Herbert/N-1367-2016	Ohno, Hiroshi/0000-0001-8776-9661; Saito, Takashi/0000-0001-9495-3547; Bosshart, Herbert/0000-0002-9315-9592; Bonifacino, Juan S./0000-0002-5673-6370				BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHO SG, 1991, NATURE, V353, P573, DOI 10.1038/353573a0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.bi.59.070190.002215; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MARKS MS, IN PRESS J CELL BIOL; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; NAKAYAMA Y, 1991, EUR J BIOCHEM, V202, P569, DOI 10.1111/j.1432-1033.1991.tb16409.x; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, UNPUB; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cellbio.9.1.129; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1993, J BIOL CHEM, V2368, P22853	35	811	821	2	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1872	1875		10.1126/science.7569928	http://dx.doi.org/10.1126/science.7569928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569928				2022-12-01	WOS:A1995RX19400038
J	PETERSEN, JM; SKALICKY, JJ; DONALDSON, LW; MCINTOSH, LP; ALBER, T; GRAVES, BJ				PETERSEN, JM; SKALICKY, JJ; DONALDSON, LW; MCINTOSH, LP; ALBER, T; GRAVES, BJ			MODULATION OF TRANSCRIPTION FACTOR ETS-1 DNA-BINDING - DNA-INDUCED UNFOLDING OF AN ALPHA-HELIX	SCIENCE			English	Article							INDUCED CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; PROTEIN-KINASES; BASIC REGION; DOMAIN; SEQUENCE; FAMILY; GCN4; REPRESSOR; SUBUNITS	Conformational changes, including local protein folding, play important roles in protein-DNA interactions. Here, studies of the transcription factor Ets-1 provided evidence that local protein unfolding also can accompany DNA binding. Circular dichroism and partial proteolysis showed that the secondary structure of the Ets-1 DNA-binding domain is unchanged in the presence of DNA. In contrast, DNA allosterically induced the unfolding of an cr helix that lies within a flanking region involved in the negative regulation of DNA binding. These findings suggest a structural basis for the intramolecular inhibition of DNA binding and a mechanism for the cooperative partnerships that are common features of many eukaryotic transcription factors.	UNIV UTAH,SCH MED,DEPT ONCOL SCI,DIV MOLEC BIOL & GENET,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,HUNTSMAN CANC INST,SALT LAKE CITY,UT 84132; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038663, R01GM048958, R01GM038663] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42014] Funding Source: Medline; NIGMS NIH HHS [GM38663, R01 GM038663, GM 48958] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DONALDSON LW, UNPUB; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JONSEN MD, UNPUB; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KUDDUS R, 1993, NUCLEIC ACIDS RES, V21, P1789, DOI 10.1093/nar/21.8.1789; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PETERSEN JH, UNPUB; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SKALICKY JJ, UNPUB; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Xu Q., UNPUB; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076	47	175	175	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1866	1869		10.1126/science.7569926	http://dx.doi.org/10.1126/science.7569926			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569926				2022-12-01	WOS:A1995RX19400036
J	SIMONICH, SL; HITES, RA				SIMONICH, SL; HITES, RA			GLOBAL DISTRIBUTION OF PERSISTENT ORGANOCHLORINE COMPOUNDS	SCIENCE			English	Article							AIR	The global distribution of 22 potentially harmful organochlorine compounds was investigated in more than 200 tree bark samples from 90 sites worldwide. High concentrations of organochlorines were found not only in some developing countries but also in industrialized countries, which continue to be highly contaminated even though the use of many of these compounds is restricted. The distribution of relatively volatile organochlorine compounds (such as hexachlorobenzene) is dependent on latitude and demonstrates the global distillation effect, whereas less volatile organochlorine compounds (such as endosulfan) are not as effectively distilled and tend to remain in the region of use.	INDIANA UNIV,SCH PUBL & ENVIRONM AFFAIRS,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington								ANDERSON DJ, 1989, ATMOS ENVIRON, V23, P2063, DOI 10.1016/0004-6981(89)90532-5; BUSER HR, 1993, ENVIRON SCI TECHNOL, V27, P1211, DOI 10.1021/es00043a023; CALAMARI D, 1991, ENVIRON SCI TECHNOL, V25, P1489, DOI 10.1021/es00020a020; CALAMARI D, 1994, ENVIRON SCI TECHNOL, V28, P429, DOI 10.1021/es00052a014; CHERNYAK SM, 1995, SCI TOTAL ENVIRON, V160-61, P75, DOI 10.1016/0048-9697(95)04346-3; HERMANSON MH, 1990, ENVIRON SCI TECHNOL, V24, P666, DOI 10.1021/es00075a008; HILEMAN B, 1994, CHEM ENG NEWS, V72, P19, DOI 10.1021/cen-v072n005.p019; HINCKLEY DA, 1990, J CHEM ENG DATA, V35, P232, DOI 10.1021/je00061a003; IWATA H, 1993, ENVIRON SCI TECHNOL, V27, P1080, DOI 10.1021/es00043a007; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; MACKAY D, 1995, SCI TOTAL ENVIRON, V160-61, P25, DOI 10.1016/0048-9697(95)04342-X; MACKAY D, 1995, SCI TOTAL ENVIRON, V160, P211; MUIR DCG, 1995, SCI TOTAL ENVIRON, V160-61, P447, DOI 10.1016/0048-9697(95)04378-E; SIMONICH SL, 1994, NATURE, V370, P49, DOI 10.1038/370049a0; SIMONICH SL, 1994, ENVIRON SCI TECHNOL, V28, P939, DOI 10.1021/es00054a028; SIMONICH SL, 1995, THESIS INDIANA U; TREMOLADA P, 1993, CHEMOSPHERE, V27, P2235, DOI 10.1016/0045-6535(93)90135-R; VOLDNER EC, 1995, SCI TOTAL ENVIRON, V160-61, P201, DOI 10.1016/0048-9697(95)04357-7; WANIA F, 1993, AMBIO, V22, P10; 1990, PUBLIC HLTH IMPACT P, P24; 1995, INSECT CONTROL GUIDE	21	526	550	8	188	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1851	1854		10.1126/science.7569923	http://dx.doi.org/10.1126/science.7569923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569923				2022-12-01	WOS:A1995RX19400031
J	STEMMLER, M; USHER, M; NIEBUR, E				STEMMLER, M; USHER, M; NIEBUR, E			LATERAL INTERACTIONS IN PRIMARY VISUAL-CORTEX - A MODEL BRIDGING PHYSIOLOGY AND PSYCHOPHYSICS	SCIENCE			English	Article							EXCITATORY POSTSYNAPTIC POTENTIALS; INTRINSIC CONNECTIONS; MACAQUE MONKEY; STRIATE CORTEX; FACILITATION; SUPPRESSION; NEOCORTEX; PATTERNS	Recent physiological studies show that the spatial context of visual stimuli enhances the response of cells in primary visual cortex to weak stimuli and suppresses the response to strong stimuli. A model of orientation-tuned neurons was constructed to explore the role of lateral cortical connections in this dual effect. The differential effect of excitatory and inhibitory current and noise conveyed by the lateral connections explains the physiological results as well as the psychophysics of pop-out and contour completion. Exploiting the model's property of stochastic resonance, the visual context changes the model's intrinsic input variability to enhance the detection of weak signals.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	STEMMLER, M (corresponding author), CALTECH,COMPUTAT & NEURAL SYST PROGRAM,139-74,PASADENA,CA 91125, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH047566, P50MH045156] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45156, MH47566] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGEN JR, 1983, IEEE T SYST MAN CYB, V13, P857, DOI 10.1109/TSMC.1983.6313080; BERNANDER O, 1994, J NEUROPHYSIOL, V72, P2743, DOI 10.1152/jn.1994.72.6.2743; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; CANNON MW, 1993, VISION RES, V33, P1685, DOI 10.1016/0042-6989(93)90034-T; CAULLER LJ, 1992, SINGLE NEURON COMPUT, P19; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1994, J NEUROSCI, V14, P2545; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, UNPUB VISION RES; Somers D., 1994, Society for Neuroscience Abstracts, V20, P1577; SOMERS DC, 1995, J NEUROSCI, V15, P5448; SOMERS DC, IN PRESS LATERAL INT; THOMSON AM, 1993, NEUROSCIENCE, V54, P347, DOI 10.1016/0306-4522(93)90257-G; THOMSON AM, 1993, NEUROSCIENCE, V54, P329, DOI 10.1016/0306-4522(93)90256-F; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; WORGOTTER F, 1991, J NEUROPHYSIOL, V66, P444, DOI 10.1152/jn.1991.66.2.444	27	174	175	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1877	1880		10.1126/science.7569930	http://dx.doi.org/10.1126/science.7569930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569930				2022-12-01	WOS:A1995RX19400040
J	TAUBES, G				TAUBES, G			CANCER BIOLOGY - ANOTHER BLOW WEAKENS EMF-CANCER LINK	SCIENCE			English	Editorial Material																			0	9	9	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1816	1817		10.1126/science.269.5232.1816-a	http://dx.doi.org/10.1126/science.269.5232.1816-a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569913				2022-12-01	WOS:A1995RX19400020
J	WOLPERT, DM; GHAHRAMANI, Z; JORDAN, MI				WOLPERT, DM; GHAHRAMANI, Z; JORDAN, MI			AN INTERNAL MODEL FOR SENSORIMOTOR INTEGRATION	SCIENCE			English	Article								On the basis of computational studies it has been proposed that the central nervous system internally simulates the dynamic behavior of the motor system in planning, control, acid learning; the existence and use of such an internal model is still under debate. A sensorimotor integration task was investigated in which participants estimated the location of one of their hands at the end of movements made in the dark and under externally imposed forces. The temporal propagation of errors in this task was analyzed within the theoretical framework of optimal state estimation. These results provide direct support for the existence of an internal model.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Jordan, Michael I/C-5253-2013	Wolpert, Daniel/0000-0003-2011-2790				CRAIG JJ, 1986, INTRO ROBOTICS; GALLISTEL C, 1990, ORG LEARNING, pCH4; Gallistel C.R., 1980, ORG ACTION; Goodwin G. C., 1984, ADAPTIVE FILTERING P; Hastie T.J., 2017, GEN ADDITIVE MODELS; Ito M., 1984, CEREBELLUM NEURAL CO; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; JORDAN MI, 1995, HDB PERCEPTION ACTIO; Kalman R.E., 1961, J BASIC ENG-T ASME, V83, P95, DOI [10.1115/1.3658902, DOI 10.1115/1.3658902]; Kawato M., 1987, BIOL CYBERN, V56, P1; MIALL RC, 1993, J MOTOR BEHAV, V25, P203, DOI 10.1080/00222895.1993.9942050; ROBINSON DA, 1986, BIOL CYBERN, V55, P43, DOI 10.1007/BF00363977; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; SUTTON RS, 1981, PSYCHOL REV, V88, P135, DOI 10.1037/0033-295X.88.2.135; WOLPERT DM, 1995, EXP BRAIN RES, V103, P460	15	2150	2160	6	154	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1880	1882		10.1126/science.7569931	http://dx.doi.org/10.1126/science.7569931			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX194	7569931				2022-12-01	WOS:A1995RX19400041
J	YAN, H; NEWPORT, J				YAN, H; NEWPORT, J			FFA-1, A PROTEIN THAT PROMOTES THE FORMATION OF REPLICATION CENTERS WITHIN NUCLEI	SCIENCE			English	Article							DNA-REPLICATION; EGG EXTRACTS; INVITRO; OCCURS; SITES	In the nuclei of eukaryotic cells, initiation of DNA replication occurs at a discrete number of foci. One component of these foci is the DNA replication factor RP-A. Here, the process leading to the association of RP-A with foci was reconstituted with cytosolic fractions derived from Xenopus eggs. With the use of this fractionated system, a 170-kilodalton protein required for the assembly of RP-A into foci was identified and purified. The protein appears to be an integral component of the foci at which replication of DNA is initiated in eukaryotic nuclei.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033523, R01GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENEDETTI P, 1983, EMBO J, V2, P1303, DOI 10.1002/j.1460-2075.1983.tb01585.x; COX LS, 1991, CELL, V66, P271, DOI 10.1016/0092-8674(91)90617-8; FANG F, 1993, J CELL SCI, V106, P983; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YAN H, UNPUB	18	36	37	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 29	1995	269	5232					1883	1885		10.1126/science.7569932	http://dx.doi.org/10.1126/science.7569932			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX194	7569932				2022-12-01	WOS:A1995RX19400042
J	ADAMS, MD; KERLAVAGE, AR; FLEISCHMANN, RD; FULDNER, RA; BULT, CJ; LEE, NH; KIRKNESS, EF; WEINSTOCK, KG; GOCAYNE, JD; WHITE, O; SUTTON, G; BLAKE, JA; BRANDON, RG; CHIU, MW; CLAYTON, RA; CLINE, RT; COTTON, MD; EARLEHUGHES, J; FINE, LD; FITZGERALD, LM; FITZHUGH, WM; FRITCHMAN, JL; GEOGHAGEN, NSM; GLODEK, A; GNEHM, CL; HANNA, MC; HEDBLOM, E; HINKLE, PS; KELLEY, JM; KLIMEK, KM; KELLEY, JC; LIU, LI; MARMAROS, SM; MERRICK, JM; MORENOPALANQUES, RF; MCDONALD, LA; NGUYEN, DT; PELLEGRINO, SM; PHILLIPS, CA; RYDER, SE; SCOTT, JL; SAUDEK, DM; SHIRLEY, R; SMALL, KV; SPRIGGS, TA; UTTERBACK, TR; WELDMAN, JF; LI, Y; BARTHLOW, R; BEDNARIK, DP; CAO, LA; CEPEDA, MA; COLEMAN, TA; COLLINS, EJ; DIMKE, D; FENG, P; FERRIE, A; FISCHER, C; HASTINGS, GA; HE, WW; HU, JS; HUDDLESTON, KA; GREENE, JM; GRUBER, J; HUDSON, P; KIM, A; KOZAK, DL; KUNSCH, C; JI, HJ; LI, HD; MEISSNER, PS; OLSEN, H; RAYMOND, L; WEI, YF; WING, J; XU, C; YU, GL; RUBEN, SM; DILLON, PJ; FANNON, MR; ROSEN, CA; HASELTINE, WA; FIELDS, C; FRASER, CM; VENTER, JC				ADAMS, MD; KERLAVAGE, AR; FLEISCHMANN, RD; FULDNER, RA; BULT, CJ; LEE, NH; KIRKNESS, EF; WEINSTOCK, KG; GOCAYNE, JD; WHITE, O; SUTTON, G; BLAKE, JA; BRANDON, RG; CHIU, MW; CLAYTON, RA; CLINE, RT; COTTON, MD; EARLEHUGHES, J; FINE, LD; FITZGERALD, LM; FITZHUGH, WM; FRITCHMAN, JL; GEOGHAGEN, NSM; GLODEK, A; GNEHM, CL; HANNA, MC; HEDBLOM, E; HINKLE, PS; KELLEY, JM; KLIMEK, KM; KELLEY, JC; LIU, LI; MARMAROS, SM; MERRICK, JM; MORENOPALANQUES, RF; MCDONALD, LA; NGUYEN, DT; PELLEGRINO, SM; PHILLIPS, CA; RYDER, SE; SCOTT, JL; SAUDEK, DM; SHIRLEY, R; SMALL, KV; SPRIGGS, TA; UTTERBACK, TR; WELDMAN, JF; LI, Y; BARTHLOW, R; BEDNARIK, DP; CAO, LA; CEPEDA, MA; COLEMAN, TA; COLLINS, EJ; DIMKE, D; FENG, P; FERRIE, A; FISCHER, C; HASTINGS, GA; HE, WW; HU, JS; HUDDLESTON, KA; GREENE, JM; GRUBER, J; HUDSON, P; KIM, A; KOZAK, DL; KUNSCH, C; JI, HJ; LI, HD; MEISSNER, PS; OLSEN, H; RAYMOND, L; WEI, YF; WING, J; XU, C; YU, GL; RUBEN, SM; DILLON, PJ; FANNON, MR; ROSEN, CA; HASELTINE, WA; FIELDS, C; FRASER, CM; VENTER, JC			INITIAL ASSESSMENT OF HUMAN GENE DIVERSITY AND EXPRESSION PATTERNS BASED UPON 83-MILLION NUCLEOTIDES OF CDNA SEQUENCE	NATURE			English	Article							CAENORHABDITIS-ELEGANS; HUMAN BRAIN; TAGS; DNA; LIBRARY; IDENTIFICATION; CLONES; EFFICIENT; INVENTORY; ALGORITHM	In an effort to identify new genes and analyse their expression patterns, 174,472 partial complementary DNA sequences (expressed sequence tags (ESTs)), totalling more than 52 million nucleotides of human DNA sequence, have been generated from 300 cDNA libraries constructed from 37 distinct organs and tissues. These ESTs have been combined with an additional 118,406 ESTs from the database dbEST, for a total of 83 million nucleotides, and treated as a shotgun sequence assembly project. The assembly process yielded 29,599 distinct tentative human consensus (THC) sequences and 58,384 non-overlapping ESTs. Of these 87,983 distinct sequences, 10,214 further characterize previously known genes based on statistically significant similarity to sequences in the available databases; the remainder identify previously unknown genes. Thirty tissues were sampled by over 1,000 ESTs each; only eight genes were matched by ESTs from all 30 tissues, and 227 genes were represented in 20 or more of the tissues sampled with more than 1,000 ESTs. Approximately 40% of identified human genes appear to be associated with basic energy metabolism, cell structure, homeostasis and cell division, 22% with RNA and protein synthesis and processing, and 12% with cell signalling and communication.	INST GENOM RES, ROCKVILLE, MD 20850 USA; HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	J. Craig Venter Institute; GlaxoSmithKline; Human Genome Sciences Inc			Bednarik, Daniel/GRN-7985-2022	Fraser, Claire/0000-0003-1462-2428; Blake, Judith/0000-0001-8522-334X; Kerlavage, Anthony/0000-0002-3954-9653; Fields, Chris/0000-0002-4812-0744; Fredrikson, Karin/0000-0001-7360-4276				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AFFARA NA, 1994, GENOMICS, V22, P205, DOI 10.1006/geno.1994.1363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; BENSON D, 1993, NUCLEIC ACIDS RES, V21, P2963, DOI 10.1093/nar/21.13.2963; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIE JM, 1992, GENOMICS, V12, P838, DOI 10.1016/0888-7543(92)90321-I; CLAVERIE JM, 1994, AUTOMATED DNA SEQUEN; COHEN D, 1995, NATURE, V377, P321; COLLET C, 1994, BIOCHEM GENET, V32, P181, DOI 10.1007/BF00554621; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; DUBNICK M, 1992, COMPUT APPL BIOSCI, V8, P601; DURKIN AS, 1994, CYTOGENET CELL GENET, V65, P86, DOI 10.1159/000133606; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAY B, 1992, STRATEGIES, V5, P16; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HORNES E, 1990, GENET ANAL-BIOMOL E, V7, P145, DOI 10.1016/0735-0651(90)90028-E; KEITH CS, 1993, PLANT PHYSIOL, V101, P329, DOI 10.1104/pp.101.1.329; KERLAVAGE AR, IN PRESS ENG MED BIO, V14; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; KHAN WN, 1992, GENOMICS, V12, P780, DOI 10.1016/0888-7543(92)90309-G; KIM CW, 1993, J MOL BIOL, V231, P960, DOI 10.1006/jmbi.1993.1345; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; LEE NH, INPRESS P NATN ACAD; LIEW CC, 1993, J MOL CELL CARDIOL, V25, P891, DOI 10.1006/jmcc.1993.1101; LIEW CC, 1994, P NATL ACAD SCI USA, V91, P10645, DOI 10.1073/pnas.91.22.10645; MATSUBARA K, 1993, GENE, V135, P265, DOI 10.1016/0378-1119(93)90076-F; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MCCOMBIE WR, 1993, DNA SEQ DNA SEQ MAP, V2, P289; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okubo K, 1994, DNA Res, V1, P37, DOI 10.1093/dnares/1.1.37; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK YS, 1993, PLANT PHYSIOL, V103, P359, DOI 10.1104/pp.103.2.359; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLYMEROPOULOS MH, 1993, NAT GENET, V4, P381, DOI 10.1038/ng0893-381; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; SUTTON GG, IN PRESS GENOME SCI; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TSAI JY, 1994, NAT GENET, V8, P321, DOI 10.1038/ng1294-321; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UCHIMIYA H, 1992, PLANT J, V2, P1005, DOI 10.1111/j.1365-313X.1992.01005.x; UTTERBACK T, IN PRESS GENOME SCI; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WARD CJ, 1994, CELL, V77, P881; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Watson J. D., 1987, MOL BIOL GENE; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85	68	727	868	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377			S			3	+						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566098				2022-12-01	WOS:A1995TA34300002
J	CHUMAKOV, IM; RIGAULT, P; LEGALL, I; BELLANNECHANTELOT, C; BILLAULT, A; GUILLOU, S; SOULARUE, P; GUASCONI, G; POULLIER, E; GROS, I; BELOVA, M; SAMBUCY, JL; SUSINI, L; GERVY, P; GLIBERT, F; BEAUFILS, S; BUI, H; MASSART, C; DETAND, MF; DUKASZ, F; LECOULANT, S; OUGEN, P; PERROT, V; SAUMLER, M; SORAVITO, C; BAHOUAYILA, R; COHENAKENINE, A; BARILLOT, E; BERTRAND, S; CODANI, JJ; CATERINA, D; GEORGES, I; LACROIX, B; LUCOTTE, G; SAHBATOU, M; SCHMIT, C; SANGOUARD, M; TUBACHER, E; DIB, C; FAURE, S; FIZAMES, C; GYAPAY, G; MILLASSEAU, P; NGUYEN, S; MUSELET, D; VIGNAL, A; MORISSETTE, J; MENNINGER, J; LIEMAN, J; DESAI, T; BANKS, A; BRAYWARD, P; WARD, D; HUDSON, T; GERETY, S; FOOTE, S; STEIN, L; PAGE, DC; LANDER, ES; WEISSENBACH, J; LEPASLIER, D; COHEN, D				CHUMAKOV, IM; RIGAULT, P; LEGALL, I; BELLANNECHANTELOT, C; BILLAULT, A; GUILLOU, S; SOULARUE, P; GUASCONI, G; POULLIER, E; GROS, I; BELOVA, M; SAMBUCY, JL; SUSINI, L; GERVY, P; GLIBERT, F; BEAUFILS, S; BUI, H; MASSART, C; DETAND, MF; DUKASZ, F; LECOULANT, S; OUGEN, P; PERROT, V; SAUMLER, M; SORAVITO, C; BAHOUAYILA, R; COHENAKENINE, A; BARILLOT, E; BERTRAND, S; CODANI, JJ; CATERINA, D; GEORGES, I; LACROIX, B; LUCOTTE, G; SAHBATOU, M; SCHMIT, C; SANGOUARD, M; TUBACHER, E; DIB, C; FAURE, S; FIZAMES, C; GYAPAY, G; MILLASSEAU, P; NGUYEN, S; MUSELET, D; VIGNAL, A; MORISSETTE, J; MENNINGER, J; LIEMAN, J; DESAI, T; BANKS, A; BRAYWARD, P; WARD, D; HUDSON, T; GERETY, S; FOOTE, S; STEIN, L; PAGE, DC; LANDER, ES; WEISSENBACH, J; LEPASLIER, D; COHEN, D			A YAC CONTIG MAP OF THE HUMAN GENOME	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; POLYMERASE CHAIN-REACTION; DNA; CLONES; SEQUENCES; CLONING; VECTORS; LIBRARY; REPEATS; GENES	A yeast artificial chromosome library containing 33,000 clones with an average insert size of one megabase of human genomic DNA was extensively analysed by several different procedures for detecting overlaps and positional information. We developed an analysis strategy that resulted, after confirmatory tests, in a YAC contig map reliably covering about 75% of the human genome in 225 contigs having an average size of about ten megabases.	GENETHON SA,F-91000 EVRY,FRANCE; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; MIT,WHITEHEAD INST BIOMED RES,CTR GENOME RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV LAVAL,CTR HOSP,CTR RECH,QUEBEC CITY,PQ G1V 4G2,CANADA	Yale University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Laval University	CHUMAKOV, IM (corresponding author), FDN JEAN DAUSSET,CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		susini, laurent/N-7913-2019; Foote, Simon J/F-2802-2013; Vignal, Alain/I-6253-2017; Susini, Laurent/O-4227-2016	Vignal, Alain/0000-0002-6797-2125; Susini, Laurent/0000-0002-5164-2770; Hudson, Thomas/0000-0002-1376-4849; BARILLOT, Emmanuel/0000-0003-2724-2002; Foote, Simon/0000-0002-9142-2107; Le Paslier, Denis/0000-0003-4335-9956; Fizames, Cecile/0000-0002-0551-8250				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ARATIA R, 1991, GENOMICS, V11, P806; BELL CJ, 1995, HUM MOL GENET, V4, P59; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; FIELDS CA, 1992, GENOMICS, V13, P431, DOI 10.1016/0888-7543(92)90264-S; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAIDI M, 1994, GENOMICS, V24, P478; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KAPLAN DJ, 1991, NUCLEIC ACIDS RES, V19, P4731, DOI 10.1093/nar/19.17.4731; LITT M, 1989, AM J HUM GENET, V44, P397; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; McKusick V.A., 1978, MENDELIAN INHERITANC; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MULLIVOR RA, 1991, AM J HUM GENET S, V49, P370; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; SHAFITZAGARDO B, 1982, NUCLEIC ACIDS RES, V10, P3175, DOI 10.1093/nar/10.10.3175; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANG SY, 1989, IMMUNOBIOLOGY HLA, V1; 1993, HUNTINGTON DISEASE C, V72, P971	31	320	325	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			175	&						0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566096				2022-12-01	WOS:A1995TA34300003
J	COLLINS, JE; COLE, CG; SMINK, LJ; GARRETT, CL; LEVERSHA, MA; SODERLUND, CA; MASLEN, GL; EVERETT, LA; RICE, KM; COFFEY, AJ; GREGORY, SG; GWILLIAM, R; DUNHAM, A; DAVIES, AF; HASSOCK, S; TODD, CM; LEHRACH, H; HULSEBOS, JM; WEISSENBACH, J; MORROW, B; KUCHERLAPATI, RS; WADEY, R; SCAMBLER, PJ; KIM, UJ; SIMON, MI; PEYRARD, M; XIE, YG; CARTER, NP; DURBIN, R; DUMANSKI, JP; BENTLEY, DR; DUNHAM, I				COLLINS, JE; COLE, CG; SMINK, LJ; GARRETT, CL; LEVERSHA, MA; SODERLUND, CA; MASLEN, GL; EVERETT, LA; RICE, KM; COFFEY, AJ; GREGORY, SG; GWILLIAM, R; DUNHAM, A; DAVIES, AF; HASSOCK, S; TODD, CM; LEHRACH, H; HULSEBOS, JM; WEISSENBACH, J; MORROW, B; KUCHERLAPATI, RS; WADEY, R; SCAMBLER, PJ; KIM, UJ; SIMON, MI; PEYRARD, M; XIE, YG; CARTER, NP; DURBIN, R; DUMANSKI, JP; BENTLEY, DR; DUNHAM, I			A HIGH-DENSITY YAC CONTIG MAP OF HUMAN-CHROMOSOME-22	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; SEQUENCE TAGGED SITES; HUMAN GENOME; HUMAN DNA; CLONES; LIBRARY; REGION; CLONING; GENES; TRANSPEPTIDASE	We have constructed a high-resolution clone map of human chromosome 22 which integrates the available physical and genetic information, establishing a single consensus. The map consists of all classes of DNA landmarks ordered on 705 yeast artificial chromosomes (YACs) at an average landmark density of more than one per 70 kilobases. This map represents the practical limits of currently available YAC resources and provides the basis for determination of the entire gene content and genomic DNA sequence of human chromosome 22.	SANGER CTR,CAMBRIDGE,ENGLAND; UNITED MED & DENT SCH,GUYS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY; UNIV AMSTERDAM,ACAD MED CTR,INST HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; GENETHON SA,CNRS,URA 1922,F-91002 EVRY,FRANCE; YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461; INST CHILD HLTH,DIV BIOCHEM & GENET,MOLEC MED UNIT,LONDON WC1N 1EH,ENGLAND; CALTECH,DIV BIOL,PASADENA,CA 91125; KAROLINSKA HOSP,DEPT MOLEC GENET,CLIN GENET UNIT,S-17176 STOCKHOLM,SWEDEN	Wellcome Trust Sanger Institute; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society; University of Amsterdam; Academic Medical Center Amsterdam; Centre National de la Recherche Scientifique (CNRS); Yeshiva University; Albert Einstein College of Medicine; University of London; University College London; California Institute of Technology; Karolinska Institutet; Karolinska University Hospital			Scambler, Peter/AAZ-6026-2020; Kucherlapati, Raju/ABC-8807-2021; Durbin, Richard/AAE-7178-2019; Scambler, Peter J/C-4998-2008	Scambler, Peter/0000-0002-1487-4628; Durbin, Richard/0000-0002-9130-1006; Scambler, Peter J/0000-0002-1487-4628; Maslen, Gareth/0000-0001-7318-3678; Dunham, Ian/0000-0003-2525-5598	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BAUER TR, 1993, IMMUNOGENETICS, V38, P387, DOI 10.1007/BF00184519; BELL CJ, 1995, HUM MOL GENET, V4, P59; BENTLEY DR, 1995, CURR OPIN GENET DEV, V5, P328, DOI 10.1016/0959-437X(95)80047-6; BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUETOW KH, 1993, GENOMICS, V18, P329, DOI 10.1006/geno.1993.1473; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COLE CG, 1992, GENOMICS, V14, P931, DOI 10.1016/S0888-7543(05)80114-4; COLLINS JE, 1992, GENOMICS, V14, P1098, DOI 10.1016/S0888-7543(05)80137-5; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DELATTRE O, 1991, GENOMICS, V9, P721, DOI 10.1016/0888-7543(91)90366-M; DUMANSKI JP, 1990, HUM GENET, V84, P219, DOI 10.1007/BF00200562; DUMANSKI JP, 1991, GENOMICS, V11, P709, DOI 10.1016/0888-7543(91)90079-T; DUNHAM I, 1994, GUIDE HUMAN GENOME C, P111; FIGLEWICZ DA, 1993, GENOMICS, V17, P299, DOI 10.1006/geno.1993.1325; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FRAZER KA, 1992, GENOMICS, V14, P574, DOI 10.1016/S0888-7543(05)80154-5; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALFORD S, 1993, HUM MOL GENET, V2, P191, DOI 10.1093/hmg/2.2.191; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HUDSON TJ, 1994, GENOMICS, V24, P588, DOI 10.1006/geno.1994.1671; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KOUPRINA N, 1994, GENOMICS, V21, P7, DOI 10.1006/geno.1994.1218; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LORONOV V, 1994, NUCLEIC ACIDS RES, V22, P4154; MACCOLLIN M, 1993, GENOMICS, V15, P680, DOI 10.1006/geno.1993.1125; MCDERMID HE, 1993, GENOMICS, V18, P308, DOI 10.1006/geno.1993.1470; MORROW B, 1995, AM J HUM GENET, V56, P1391; MURAKAWA K, 1994, GENOMICS, V23, P379, DOI 10.1006/geno.1994.1514; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NEIL DL, 1990, NUCLEIC ACIDS RES, V18, P1421, DOI 10.1093/nar/18.6.1421; PAWLAK A, 1988, J BIOL CHEM, V263, P9913; PORTER JC, 1993, GENOMICS, V156, P57; Riley B P, 1994, Eur J Hum Genet, V2, P246; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUTTLEDGE MH, 1994, GENOMICS, V19, P52, DOI 10.1006/geno.1994.1012; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; Sambrook J., 1989, MOL CLONING LAB MANU; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; VALLADA HP, 1994, HUM GENET, V93, P688; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; XIE YG, 1994, HUM GENET, V94, P339; XIE YG, 1993, HUM MOL GENET, V2, P1361; 1992, NIH CEPH COLLABORATI, V258, P67	53	95	96	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			367	379						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566101				2022-12-01	WOS:A1995TA34300007
J	DOGGETT, NA; GOODWIN, LA; TESMER, JG; MEINCKE, LJ; BRUCE, DC; CLARK, LM; ALTHERR, MR; FORD, AA; CHI, HC; MARRONE, BL; LONGMIRE, JL; LANE, SA; WHITMORE, SA; LOWENSTEIN, MG; SUTHERLAND, RD; MUNDT, MO; KNILL, EH; BRUNO, WJ; MACKEN, CA; TORNEY, DC; WU, JR; GRIFFITH, J; SUTHERLAND, GR; DEAVEN, LL; CALLEN, DF; MOYZIS, RK				DOGGETT, NA; GOODWIN, LA; TESMER, JG; MEINCKE, LJ; BRUCE, DC; CLARK, LM; ALTHERR, MR; FORD, AA; CHI, HC; MARRONE, BL; LONGMIRE, JL; LANE, SA; WHITMORE, SA; LOWENSTEIN, MG; SUTHERLAND, RD; MUNDT, MO; KNILL, EH; BRUNO, WJ; MACKEN, CA; TORNEY, DC; WU, JR; GRIFFITH, J; SUTHERLAND, GR; DEAVEN, LL; CALLEN, DF; MOYZIS, RK			AN INTEGRATED PHYSICAL MAP OF HUMAN-CHROMOSOME-16	NATURE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISMS; REPETITIVE DNA-SEQUENCES; HUMAN GENOME; CLONES; CLONING; FRAGMENTS; REGIONS; VECTOR	We describe an integrated physical, genetic and cytogenetic map of human chromosome 16 comprising both a low-resolution megaYAC map and a high-resolution cosmid contig/miniYAC map, which provides nearly complete coverage of the euchromatic arms of the chromosome. The physical map is anchored to a high-resolution cytogenetic breakpoint map and is integrated with genetic and gene transcript maps of the chromosome by sequence-tagged sites and clone hybridizations.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,APPLICAT PROGRAMMING GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,COMP RES & APPLICAT GRP,LOS ALAMOS,NM 87545; ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; UNIV NEW MEXICO,DEPT CELL BIOL,ALBUQUERQUE,NM 87131	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico	DOGGETT, NA (corresponding author), LOS ALAMOS NATL LAB,CTR HUMAN GENOME STUDIES,LOS ALAMOS,NM 87545, USA.		Callen, David F/G-1975-2012; Sutherland, Grant Robert/D-2606-2012					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ASLANIDIS C, 1991, P NATL ACAD SCI USA, V88, P6765, DOI 10.1073/pnas.88.15.6765; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BOTSTEIN D, 1990, DOEER0452P; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P190; CALLEN DF, IN PRESS GENOMICS, V29; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CINKOSKY MJ, 1992, LOS ALAMOS SCI, V20, P267; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DOGGETT NA, 1995, CYTOGENET CELL GENET, V68, P165; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; Green E D, 1991, PCR Methods Appl, V1, P77; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; HARRIS PC, 1994, GENOMICS, V23, P321, DOI 10.1006/geno.1994.1507; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KAHN AS, 1992, NAT GENET, V2, P180; KOZMAN HM, 1995, GENOMICS, V25, P44, DOI 10.1016/0888-7543(95)80108-X; LIU P, 1993, CANCER GENET CYTOGEN, V65, P92; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MARRONE BL, 1994, GENOMICS, V21, P202, DOI 10.1006/geno.1994.1243; MCCORMICK MK, 1993, P NATL ACAD SCI USA, V90, P1063, DOI 10.1073/pnas.90.3.1063; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; OKUMURA K, 1994, CYTOGENET CELL GENET, V67, P61, DOI 10.1159/000133799; OLSON MV, 1993, COLD SPRING HARB SYM, V57, P349; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAPPAPORT B, 1994, AUTOMATED DNA SEQUEN, P289; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; SELLERI L, 1992, GENOMICS, V14, P536, DOI 10.1016/S0888-7543(05)80263-0; SHEN Y, 1993, HUM MOL GENET, V2, P1745, DOI 10.1093/hmg/2.10.1745; SHEN Y, 1994, GENOMICS, V22, P68, DOI 10.1006/geno.1994.1346; SHEN Y, 1994, HUM MOL GENET, V3, P210, DOI 10.1093/hmg/3.1.210; SHEN Y, 1993, HUM MOL GENET, V2, P1505, DOI 10.1093/hmg/2.9.1505; SHEN Y, 1993, HUM MOL GENET, V2, P1504, DOI 10.1093/hmg/2.9.1504; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; STALLINGS RL, 1993, CYTOGENET CELL GENET, V63, P97, DOI 10.1159/000133509; STALLINGS RL, 1992, GENOMICS, V13, P332, DOI 10.1016/0888-7543(92)90249-R; STALLINGS RL, 1992, GENOMICS, V13, P1031, DOI 10.1016/0888-7543(92)90016-L; WHITMORE SA, 1994, GENOMICS, V20, P169, DOI 10.1006/geno.1994.1150; 1995, HUM MOL GENET, V4, P575	46	99	100	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			335	365						31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566100				2022-12-01	WOS:A1995TA34300006
J	GEMMILL, RM; CHUMAKOV, I; SCOTT, P; WAGGONER, B; RIGAULT, P; CYPSER, J; CHEN, Q; WEISSENBACH, J; GARDINER, K; WANG, H; PEKARSKY, Y; LEGALL, I; LEPASLIER, D; GUILLOU, S; LI, E; ROBINSON, L; HAHNER, L; TODD, S; COHEN, D; DRABKIN, HA				GEMMILL, RM; CHUMAKOV, I; SCOTT, P; WAGGONER, B; RIGAULT, P; CYPSER, J; CHEN, Q; WEISSENBACH, J; GARDINER, K; WANG, H; PEKARSKY, Y; LEGALL, I; LEPASLIER, D; GUILLOU, S; LI, E; ROBINSON, L; HAHNER, L; TODD, S; COHEN, D; DRABKIN, HA			A 2ND-GENERATION YAC CONTIG MAP OF HUMAN-CHROMOSOME-3	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; CYSTIC-FIBROSIS GENE; HUMAN GENOME PROJECT; HUMAN DNA; CLONING; LIBRARY; CLONES; IDENTIFICATION; FRAGMENTS	A map of human chromosome 3 which integrates both physical and genetic data has been developed from the fusion of two large collections of markers and corresponding yeast artificial chromosome (YAC) clones. The map contains 972 megabase-sized YACs identified with 593 primary markers, of which 162 are highly polymorphic sequence-tagged sites (STSs) and form a closely spaced genetic linkage map; the remaining markers are hybridization-based. Chromosome 3 is now represented by 24 large YAC contigs whose order and orientation is largely known. The map generated by fusion of these hybridization- and STS-based datasets covers about 80% (over 160 megabases) of the chromosome and will provide the foundation necessary for vapid development of a detailed genetic understanding for this large autosome.	FDN JEAN DAUSSET,CEPH,F-75010 PARIS,FRANCE; GENETHON SA,F-91002 EVRY,FRANCE; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	Foundation Jean Dausset-CEPH; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GEMMILL, RM (corresponding author), ELEANOR ROOSEVELT INST CANC RES,1899 GAYLORD ST,DENVER,CO 80206, USA.			Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; DAUSSET J, 1992, Behring Institute Mitteilungen, P13; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GORDEN J, 1991, CELL, V66, P589; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; ICANNOU PA, 1994, NAT GENET, V6, P84; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAYLOR SL, 1992, SCIENCE, V258, P67; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	22	71	73	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			299	319						21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566097				2022-12-01	WOS:A1995TA34300004
J	JARRIAULT, S; BROU, C; LOGEAT, F; SCHROETER, EH; KOPAN, R; ISRAEL, A				JARRIAULT, S; BROU, C; LOGEAT, F; SCHROETER, EH; KOPAN, R; ISRAEL, A			SIGNALING DOWNSTREAM OF ACTIVATED MAMMALIAN NOTCH	NATURE			English	Article							BINDING-PROTEIN; CELL-FATE; DROSOPHILA; EXPRESSION; GENE; DIFFERENTIATION; ENHANCER; SEQUENCE; RECEPTOR; HOMOLOG	NOTCH belongs to a family of transmembrane proteins that are widely conserved from flies to vertebrates and are thought to be involved in cell-fate decisions. In Drosophila, the Suppressor of hairless (Su(H)) gene(1,2) and genes of the Enhancer of split (E(Spl)) complex, which encode proteins of the basic helix-loop-helix type(3,4) have been implicated in the Notch signalling pathway. Mammalian homologues of E(Spl), such as the mouse Hairy enhancer of split (HES-1)(5), have been isolated. Both HES-1 and the intracellular domain of murine Notch (mNotch) are able to block MyoD-induced myogenesis(5-7). Here we show that activated forms of mNotch associate with the human analogue of Su(H), KBF2/RBP-J kappa (refs 8,9) and act as transcriptional activators through the KBF2-binding sites of the HES-1 promoter.	WASHINGTON UNIV, DIV DERMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	JARRIAULT, S (corresponding author), INST PASTEUR, CNRS, URA 1149, UNITE BIOL MOLEC EXPRESS GENET, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Kopan, Raphael/AAF-1357-2022; Kopan, Raphael/AFG-3275-2022	Kopan, Raphael/0000-0002-0350-2730				BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1994, DEVELOPMENT, V120, P2385; NYE JS, 1994, DEVELOPMENT, V120, P2421; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHWEISGUTH F, 1995, DEVELOPMENT, V121, P1875; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; TATA F, 1993, DEVELOPMENT, P139; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	24	1196	1246	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					355	358		10.1038/377355a0	http://dx.doi.org/10.1038/377355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566092				2022-12-01	WOS:A1995RX11100061
J	KOLB, FC; BRAUN, J				KOLB, FC; BRAUN, J			BLINDSIGHT IN NORMAL OBSERVERS	NATURE			English	Article							UNCONSCIOUS PERCEPTION; TEXTURE-DISCRIMINATION; VISUAL-STIMULI; LOCALIZATION; AWARENESS; VISION	SOME patients with lesions in visual cortex lack conscious visual experience but, when tested, exhibit a significant ability, termed 'blindsight', to discriminate visual stimuli(1-3,27). Here we report two different visual displays that induce blindsight in normal observers. Using an objective measure, we show that conscious experience remains defective at presentation times much longer (1 s) than the onset of visual sensitivity (similar to 60 ms). To obtain this effect, we generate a contrast between visual textures and then conceal the contrast by superimposing 'complementary' textures. Complementarity can involve either opposite motion or binocular rivalry and orthogonal orientation. In both cases, observers locate the texture contrast reliably but do not, by either subjective or objective measures, consciously experience it. Taken together with present knowledge of the visual cortical site(s) at which opposite motion and rivalrous orientation interact(4-7), this observation bears upon the functional anatomy of conscious visual experience.	CALTECH, PASADENA, CA 91125 USA	California Institute of Technology			Braun, Jochen/F-1370-2013	Braun, Jochen/0000-0002-8886-078X				ADAMS JK, 1957, PSYCHOL BULL, V54, P383, DOI 10.1037/h0043350; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DOBBINS A, 1994, J SOC NEUR ABSTR, V20, P624; FARAH MJ, 1991, NEUROPSYCHOLOGIA, V29, P949, DOI 10.1016/0028-3932(91)90059-H; Fox R, 1991, BINOCULAR VISION, V9, P93; GRAVES RE, 1992, COGN NEUROPSYCHOL, V9, P487, DOI 10.1080/02643299208252069; GREEN DM, 1967, SIGNAL DETECTION THE; GREENWALD AG, 1992, AM PSYCHOL, V47, P766, DOI 10.1037/0003-066X.47.6.766; KARNI A, 1993, SOC NEUR ABSTR, V19, P1503; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LEOPOLD DA, 1995, INVEST OPHTH VIS SCI, V36, pS813; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALIK J, 1990, J OPT SOC AM A, V7, P923, DOI 10.1364/JOSAA.7.000923; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P197, DOI 10.1016/0010-0285(83)90009-9; MEERES SL, 1990, NEUROPSYCHOLOGIA, V28, P1231, DOI 10.1016/0028-3932(90)90039-Q; MERIKLE PM, 1992, AM PSYCHOL, V47, P792, DOI 10.1037/0003-066X.47.6.792; POPPEL E, 1973, NATURE, V243, P295, DOI 10.1038/243295a0; Press W. A., 1994, Society for Neuroscience Abstracts, V20, P838; QIAN N, 1994, J NEUROSCI, V14, P7367; QIAN N, 1994, J NEUROSCI, V14, P7357; RUBENSTEIN BS, 1990, J OPT SOC AM A, V7, P1632, DOI 10.1364/JOSAA.7.001632; SCHACTER DL, 1992, P NATL ACAD SCI USA, V89, P11113, DOI 10.1073/pnas.89.23.11113; Sidis B., 1898, PSYCHOL SUGGESTION; STOREIG P, 1993, PROGR BRAIN RES, V95, P445; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; WEISKRANTZ L, 1995, P NATL ACAD SCI USA, V92, P6122, DOI 10.1073/pnas.92.13.6122	27	150	151	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					336	338		10.1038/377336a0	http://dx.doi.org/10.1038/377336a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RX111	7566086				2022-12-01	WOS:A1995RX11100055
J	KRAUTER, K; MONTGOMERY, K; YOON, SJ; LEBLANCSTRACESKI, J; RENAULT, B; MARONDEL, I; HERDMAN, V; CUPELLI, L; BANKS, A; LIEMAN, J; MENNINGER, J; BRAYWARD, P; NADKARNI, P; WEISSENBACH, J; LEPASLIER, D; RIGAULT, P; CHUMAKOV, I; COHEN, D; MILLER, P; WARD, D; KUCHERLAPATI, R				KRAUTER, K; MONTGOMERY, K; YOON, SJ; LEBLANCSTRACESKI, J; RENAULT, B; MARONDEL, I; HERDMAN, V; CUPELLI, L; BANKS, A; LIEMAN, J; MENNINGER, J; BRAYWARD, P; NADKARNI, P; WEISSENBACH, J; LEPASLIER, D; RIGAULT, P; CHUMAKOV, I; COHEN, D; MILLER, P; WARD, D; KUCHERLAPATI, R			A 2ND-GENERATION YAC CONTIG MAP OF HUMAN-CHROMOSOME-12	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN GENOME; LINKAGE MAP; CLONES; SEQUENCES	Human chromosome 12 constitutes approximately 4.5% of the human genome and has an estimated size of 135 million base pairs (Mb). We have started to construct a high-resolution physical map of chromosome 12 as overlapping yeast artificial chromosomes (YACs), using as a foundation the first-generation physical map which contained overlapping clones corresponding to 56 markers. Our second-generation map of this chromosome covers nearly 102 Mb of DNA and includes 426 highly polymorphic, monomorphic and gene-based markers. We also mapped 119 of the YACs, most of which are part of the physical map, by cytogenetic methods. Thus the map integrates genetic, physical and cytogenetic data and provides information about the organization of this chromosome and will help in the localization and cloning of disease-related genes. The strategy used here to generate the chromosome-12 map could be applied for the vapid construction of physical and expression maps for other human chromosomes.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR MED INFORMAT,NEW HAVEN,CT 06510; GENETHON SA,F-91002 EVRY,FRANCE; JEAN DAUSSET FDN,F-75010 PARIS,FRANCE	Yale University; Yale University	KRAUTER, K (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Kucherlapati, Raju/ABC-8807-2021	Le Paslier, Denis/0000-0003-4335-9956				BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BONNET D, 1994, NAT GENET, V6, P405, DOI 10.1038/ng0494-405; CARTER SA, 1994, GENOMICS, V24, P378, DOI 10.1006/geno.1994.1632; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DAWSON E, 1993, GENOMICS, V17, P245, DOI 10.1006/geno.1993.1314; ENGLE EC, 1994, NAT GENET, V7, P69, DOI 10.1038/ng0594-69; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOLT M, 1992, SCIENCE, V258, P67; KOBAYASHI H, IN PRESS GENES CHROM; LEBIANCSTRACESK.JM, 1994, GENOMICS, V19, P341; LICHTER JB, 1993, GENOMICS, V16, P320, DOI 10.1006/geno.1993.1192; LUKUO JM, 1994, HUM MOL GENET, V3, P99, DOI 10.1093/hmg/3.1.99; MONTGOMERY KT, 1993, GENOMICS, V17, P682, DOI 10.1006/geno.1993.1390; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MURRAY JC, 1994, SCIENCE, V263, P2049; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; RAIMONDI SC, 1986, BLOOD, V68, P69; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; STEPHENS JC, 1990, SCIENCE, V250, P237, DOI 10.1126/science.2218527; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TERRETT JA, 1994, NAT GENET, V6, P401, DOI 10.1038/ng0494-401; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSENBACH J, 1993, GENE, V135, P275, DOI 10.1016/0378-1119(93)90077-G	30	118	119	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			321	333						13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566099				2022-12-01	WOS:A1995TA34300005
J	LEVITAN, D; GREENWALD, I				LEVITAN, D; GREENWALD, I			FACILITATION OF LIN-12-MEDIATED SIGNALING BY SEL-12, A CAENORHABDITIS-ELEGANS S182 ALZHEIMERS-DISEASE GENE	NATURE			English	Article							SPECIFIES CELL FATES; C-ELEGANS; VULVAL INDUCTION; LIN-12; GLP-1; AUTONOMY; DECISION; PROTEIN; LET-60; LOCUS	THE lin-12 and glp-1 genes of Caenorhabditis elegans are members of the lin-12/Notch family of receptors for intercellular signals that specify cell fate(1,2). By screening for suppressors of a lin-12 gain-of-function mutation, we identified a new gene, sel-12, which appears to function in receiving cells to facilitate signalling mediated by lin-12 and glp-1. The sel-12 gene encodes a protein with multiple transmembrane domains, and is similar to S182, which has been implicated in early-onset familial Alzheimer's disease(3). The high degree of sequence conservation suggests that the function of the SEL-12 and S182 proteins may also be conserved.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Columbia University; Howard Hughes Medical Institute; Columbia University; Princeton University								ARTAVANISTSAKON.S, 1995, SCIENCE, V268, P225; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; COULSON A, 1988, NATURE, V235, P184; FERGUSON EL, 1985, NATURE, V110, P259; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SUNDARAM M, 1993, GENETICS, V135, P755; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341	29	639	675	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					351	354		10.1038/377351a0	http://dx.doi.org/10.1038/377351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566091				2022-12-01	WOS:A1995RX11100060
J	MOSS, SJ; GORRIE, GH; AMATO, A; SMART, TG				MOSS, SJ; GORRIE, GH; AMATO, A; SMART, TG			MODULATION OF GABA(A) RECEPTORS BY TYROSINE PHOSPHORYLATION	NATURE			English	Article							A RECEPTOR; MOLECULAR-BIOLOGY; TRANSFECTED CELLS; BETA-1-SUBUNIT; PHARMACOLOGY; POTENTIATION; SUBUNIT; KINASE	gamma-AMINOBUTYRIC acid type-A (GABA(A)) receptors are the major sites of fast synaptic inhibition in the brain, They are presumed to be pentameric heteroligomers assembled from four classes of subunits with multiple members: alpha (1-6), beta (1-3), gamma (1-3) and delta (1)(1-5). Here, GABA(A) receptors consisting of alpha 1, beta 1 and gamma 2L subunits, coexpressed in mammalian cells with the tyrosine kinase vSRC (the transforming gene product of the Rous sarcoma virus), were phosphorylated on tyrosine residues within the gamma 2L and beta 1 subunits. Tyrosine phosphorylation enhanced the whole-cell current induced by GABA. Site-specific mutagenesis of two tyrosine residues within the predicted intracellular domain of the gamma 2L subunit abolished tyrosine phosphorylation of this subunit and eliminated receptor modulation. A similar modulation of GABA(A) receptor function was observed in primary neuronal cultures. As GABA(A) receptors are critical in mediating fast synaptic inhibition, such a regulation by tyrosine kinases may therefore have profound effects on the control of neuronal excitation.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,LONDON WC1E 6BT,ENGLAND; UNIV LONDON,SCH PHARM,DEPT PHARMACOL,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London; University College London; University of London School of Pharmacy	MOSS, SJ (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,GORDON ST,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; EVANS GI, 1985, MOL CELL BIOL, V353, P769; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; HERBST R, 1991, J BIOL CHEM, V266, P19908; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MOSS SJ, 1993, NEUROCHEM RES, V18, P105, DOI 10.1007/BF00966929; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; NAYEEM N, 1994, J NEUROCHEM, V62, P815; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1987, NATURE, V326, P221; SMART TG, 1992, J PHYSIOL-LONDON, V447, P587, DOI 10.1113/jphysiol.1992.sp019020; SONGYANG Z, 1994, NATURE, V373, P536; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U	23	203	212	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					344	348		10.1038/377344a0	http://dx.doi.org/10.1038/377344a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566089				2022-12-01	WOS:A1995RX11100058
J	NIELSEN, FC; OSTERGAARD, L; NIELSEN, J; CHRISTIANSEN, J				NIELSEN, FC; OSTERGAARD, L; NIELSEN, J; CHRISTIANSEN, J			GROWTH-DEPENDENT TRANSLATION OF IGF-II MESSENGER-RNA BY A RAPAMYCIN-SENSITIVE PATHWAY	NATURE			English	Article							RIBOSOMAL PROTEIN-S6; INSULIN; KINASE; CELLS; DNA	INSULIN-LIKE growth factor (IGF)-II is important for fetal growth and development(1). The human IGF-II gene generates multiple mature transcripts with different 5' untranslated regions (5'UTRs) but identical coding regions and 3'UTRs(2). We have previously shown that a minor 4.8-kilobase messenger RNA was engaged in the synthesis of preproIGF-II, and a major 6.0-kb mRNA was untranslated and stored in a 100S ribonucleoprotein particle(3). Here we demonstrate that the 6.0-kb mRNA is selectively mobilized and translated in dispersed exponentially growing cells. Translational activation is prevented by rapamycin and mimicked by anisomycin, which suggests that translation of the 6.0-kb mRNA is regulated by the p70(S6k)/85(S6k) kinase signalling pathway. Therefore, the minor 4.8-kb mRNA generates a constitutive production of preproIGF-II, whereas the major 6.0-kb mRNA provides a post-transcriptionally regulated species.	UNIV COPENHAGEN,INST MOLEC BIOL,DK-1307 COPENHAGEN K,DENMARK; RIGSHOSP,DEPT CLIN BIOCHEM,DK-2100 COPENHAGEN 0,DENMARK	University of Copenhagen; Rigshospitalet; University of Copenhagen			Christiansen, Jan/L-3312-2014; Ostergaard, Lars/AAA-3020-2020; Nielsen, Finn Cilius/AAA-4926-2020	Christiansen, Jan/0000-0001-8624-4601; Ostergaard, Lars/0000-0003-2459-0511; Ostergaard, Lars/0000-0002-7619-605X; Nielsen, Jacob/0000-0001-9842-2276				AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; DILLING MB, 1994, CANCER RES, V54, P903; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1989, J BIOL CHEM, V264, P1293; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NEWELL S, 1994, MOL REPROD DEV, V39, P249, DOI 10.1002/mrd.1080390302; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; Nielsen Finn Cilius, 1992, Progress in Growth Factor Research, V4, P257, DOI 10.1016/0955-2235(92)90023-B; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0	29	155	156	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					358	362		10.1038/377358a0	http://dx.doi.org/10.1038/377358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566093				2022-12-01	WOS:A1995RX11100062
J	SAMAHA, RR; GREEN, R; NOLLER, HF				SAMAHA, RR; GREEN, R; NOLLER, HF			A BASE-PAIR BETWEEN TRANSFER-RNA AND 23S RIBOSOMAL-RNA IN THE PEPTIDYL TRANSFERASE CENTER OF THE RIBOSOME	NATURE			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; P-SITES; COMPLEX; IDENTIFICATION; NUCLEOTIDES; PROTEIN; END	Interaction of the conserved CCA terminus of tRNA with rRNA in the peptidyl transferase P site has been studied by in vitro genetics. A Watson-Crick G-C pair between G2252 in a conserved hairpin loop of 235 rRNA and C74 at the acceptor end of tRNA is required for proper functional interaction of the CCA end of tRNA with the ribosomal P site. These findings establish a direct role for 23S rRNA in protein synthesis.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, CTR MOLEC BIOL RNA, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz								AAGAARD C, 1991, BIOCHIMIE, V73, P1439, DOI 10.1016/0300-9084(91)90176-2; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BREITMEYER JB, 1976, J MOL BIOL, V101, P297, DOI 10.1016/0022-2836(76)90149-2; CANNON M, 1963, J MOL BIOL, V7, P360, DOI 10.1016/S0022-2836(63)80030-3; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DOUTHWAITE S, 1983, EUR J BIOCHEM, V131, P261, DOI 10.1111/j.1432-1033.1983.tb07258.x; Evnin L B, 1988, Ann N Y Acad Sci, V542, P61, DOI 10.1111/j.1749-6632.1988.tb25808.x; GRAJEVSKAJA RA, 1973, FEBS LETT, V33, P11, DOI 10.1016/0014-5793(73)80147-4; GREGORY ST, 1994, NUCLEIC ACIDS RES, V22, P279, DOI 10.1093/nar/22.3.279; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; KAJI H, 1966, J BIOL CHEM, V241, P1251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIEBERMAN KR, 1994, J BIOL CHEM, V269, P16163; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; Nierhaus K.H., 1990, RIBOSOMES PROTEIN SY, P161; NIERHAUS KH, 1974, P NATL ACAD SCI USA, V71, P4713, DOI 10.1073/pnas.71.12.4713; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1993, FASEB J, V7, P87, DOI 10.1096/fasebj.7.1.8422979; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; NOLLER HF, 1981, NUCLEIC ACIDS RES, V8, P2275; PEATTIE DA, 1981, P NATL ACAD SCI-BIOL, V78, P2273, DOI 10.1073/pnas.78.4.2273; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1993, GENE, V123, P75, DOI 10.1016/0378-1119(93)90542-B; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; SAMPSON JR, 1989, SCIENCE, V243, P1363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN S, 1988, METHOD ENZYMOL, V164, P481; TAPPRICH WE, 1986, P NATL ACAD SCI USA, V83, P556, DOI 10.1073/pnas.83.3.556; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	39	216	218	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					309	314		10.1038/377309a0	http://dx.doi.org/10.1038/377309a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566085				2022-12-01	WOS:A1995RX11100046
J	SHORT, N				SHORT, N			ON FIRST LOOKING INTO THE HUMAN GENOME - FOREWORD	NATURE			English	Editorial Material																			0	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377			S			1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TA343	7566095				2022-12-01	WOS:A1995TA34300001
J	TSIRKA, SE; GUALANDRIS, A; AMARAL, DG; STRICKLAND, S				TSIRKA, SE; GUALANDRIS, A; AMARAL, DG; STRICKLAND, S			EXCITOTOXIN-INDUCED NEURONAL DEGENERATION AND SEIZURE ARE MEDIATED BY TISSUE-PLASMINOGEN ACTIVATOR	NATURE			English	Article							BRAIN	NEURONAL degeneration in the hippocampus, a region of the brain important for acquisition of memory in humans, occurs in various pathological conditions, including Alzheimer's disease, brain ischaemia and epilepsy. When neuronal activity is stimulated in the adult rat and mouse hippocampus, tissue plasminogen activator (tPA), a serine protease that converts inactive plasminogen to the active protease plasmin, is transcriptionally induced(1,2). The activity of tPA in neural tissue is correlated with neurite outgrowth(3), regeneration(4) and migration(5), suggesting that it might be involved in neuronal plasticity. Here we show that tPA is produced primarily by microglia in the hippocampus. Using excitotoxins to induce neuronal cell loss, we demonstrate that tPA-deficient mice are resistant to neuronal degeneration. These mice are also less susceptible to pharmacologically induced seizures than wild-type mice. These findings identify a role for tPA in neuronal degeneration and seizure.	SUNY STONY BROOK,MED CTR,PROGRAM GENET,STONY BROOK,NY 11794; SUNY STONY BROOK,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	TSIRKA, SE (corresponding author), SUNY STONY BROOK,MED CTR,DEPT PHARMACOL,STONY BROOK,NY 11794, USA.		Tsirka, Stella/AAD-4018-2019	Gualandris, anna/0000-0002-2889-4080; Strickland, Sidney/0000-0002-3072-9244				ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; Jessell T., 1991, PRINCIPLES NEURAL SC; KINGSTON IB, 1995, NAT MED, V1, P138; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; SALLES FJ, 1990, EMBO J, V9, P2471, DOI 10.1002/j.1460-2075.1990.tb07425.x; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SMEYNE R, 1992, NEURON, V6, P13; STREIT WJ, 1993, J CHEM NEUROANAT, V6, P261, DOI 10.1016/0891-0618(93)90047-8; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x	17	574	592	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					340	344		10.1038/377340a0	http://dx.doi.org/10.1038/377340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566088				2022-12-01	WOS:A1995RX11100057
J	VAUGHAN, PS; AZIZ, F; VANWIJNEN, AJ; WU, SJ; HARADA, H; TANIGUCHI, T; SOPRANO, KJ; STEIN, JL; STEIN, GS				VAUGHAN, PS; AZIZ, F; VANWIJNEN, AJ; WU, SJ; HARADA, H; TANIGUCHI, T; SOPRANO, KJ; STEIN, JL; STEIN, GS			ACTIVATION OF A CELL-CYCLE-REGULATED HISTONE GENE BY THE ONCOGENIC TRANSCRIPTION FACTOR IRF-2	NATURE			English	Article							PROTEIN-DNA INTERACTIONS; FACTOR-I; MESSENGER-RNAS; EXPRESSION; PURIFICATION; PROMOTERS; INDUCTION; COMPLEX; GROWTH; BINDS	THE human histone H4 gene FO108 is regulated during the cell cycle with a peak in transcription during early S phase(1,2). The cell-cycle element (CCE) required for H4 histone activation is a sequence of 11 base pairs that binds a protein factor in electrophoretic mobility shift assays that has been designated histone nuclear factor M (HiNF-M)(2,3). Here we report the purification of HiNF-M, and show it to be a protein of relative molecular mass (M(r)) 48K that is identical to interferon (IFN) regulatory factor 2 (IRF-2), a negative transcriptional regulator of the IFN response(4). Recombinant IRF-2 (as well as the related protein IRF-1 (ref. 5)) binds the CCE specifically and activates transcription of this H4 histone gene, IRF-2 has been shown to have oncogenic potential(6), and our results demonstrate a link between IRF-2 and a gene that is functionally coupled to DNA replication and cell-cycle progression at the G1/S phase transition.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Tokyo	VAUGHAN, PS (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT CELL BIOL,CTR CANC,55 LAKE AVE N,WORCESTER,MA 01655, USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Ausubel F.M., 2002, SHORT PROTOCOLS MOL, V5th; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V56, P729; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PENA A, 1993, J BIOL CHEM, V268, P27277; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; SHAKOORI R, IN PRESS J CELL BIOC; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	29	167	170	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 28	1995	377	6547					362	365		10.1038/377362a0	http://dx.doi.org/10.1038/377362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566094				2022-12-01	WOS:A1995RX11100063
J	ZHENG, LX; FISHER, G; MILLER, RE; PESCHON, J; LYNCH, DH; LENARDO, MJ				ZHENG, LX; FISHER, G; MILLER, RE; PESCHON, J; LYNCH, DH; LENARDO, MJ			INDUCTION OF APOPTOSIS IN MATURE T-CELLS BY TUMOR-NECROSIS-FACTOR	NATURE			English	Article							FACTOR-ALPHA; MICE	T-CELL receptor-induced apoptosis regulates immune responses and can result from interactions between Fas (Apo1/CD95) and Fas ligand (FasL)(1-12). Mutations in the genes for Fas and FasL cause disorders resembling human autoimmune diseases in lpr and gld mice, respectively(13,14). However, peripheral T-cell deletion takes place in lpr mice, acid autoimmune syndromes occur in mouse strains without Fas or FasL defects(15,16). Here we show that tumour necrosis factor (TNF) can mediate mature T-cell receptor-induced apoptosis through the p75 TNF receptor. Blockage of both TNF and Fast is required to abrogate T-cell death and TNF mediates the death of most CD8(+) T cells, whereas FasL mediates the death of most CD4(+) T cells. Our results suggest that autoregulatory apoptosis of the mature T cells can occur by two distinct molecular mechanisms.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA; IMMUNEX RES & DEV CORP, DEPT IMMUNOBIOL, SEATTLE, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARIANI SM, 1994, EUR J IMMUNOL, V24, P3119, DOI 10.1002/eji.1830241231; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; RAZVI ES, 1995, AM J PATHOL, V147, P79; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCOTT DE, 1993, J IMMUNOL, V150, P664; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH MR, 1990, J IMMUNOL, V144, P162; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J	29	1025	1061	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 28	1995	377	6547					348	351		10.1038/377348a0	http://dx.doi.org/10.1038/377348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RX111	7566090				2022-12-01	WOS:A1995RX11100059
